Clinical Annotation ID	Evidence ID	Evidence Type	Evidence URL	PMID	Summary	Score
981755803	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
981755803	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
981755803	981755665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755665	21083385	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	981755678	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755678	22047557	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	982009991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982009991	23590265	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	2.25
981755803	1043737620	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1043737620	23757361	Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.	0.0
981755803	1043737636	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1043737636	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
981755803	1183629335	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629335	24066763	Genotype AA is associated with response to ivacaftor in women with Cystic Fibrosis.	0.25
981755803	1448267532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448267532	27745802	Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	1.5
981755803	1448423752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423752	27773592	Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	0.875
981755803	1449191908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191908	25682022	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	1449192031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192031	28651844	Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.	3.0
981755803	1449192055	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192055	28711222	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.25
981755803	1449192093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192093	25311995	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.0
981755803	1449192439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192439	28611235	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	1.5
981755803	1449192481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192481	26135562	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	1449192494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192494	25171465	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
981755803	1449192576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192576	25755212	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	1449192615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192615	26568242	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1449192709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192709	25473543	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
981755803	1449192721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192721	25145599	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1450043422	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450043422	23628510	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	3.0
981755803	1184512440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512440	25049054	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	1.5
981755803	981755746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755746	22942289	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	981755699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755699	19846789	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	981755787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755787	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755803	1043737597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737597	23757359	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
981755803	982006840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006840	23313410	Allele A is associated with response to ivacaftor in men with Cystic Fibrosis.	0.25
981755803	1446903789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903789	24461666	Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
981755803	1448099051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099051	27158673	Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	2.0
1449311190	1449311153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311153	29683944	Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.0
981204774	655386750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386750	15007373	Genotype AG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype AA.	-2.25
981204774	655385584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385584	17224915	Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG.	3.0
981204774	655386751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386751	15007373	Genotype GG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype AA.	-2.75
1449191690	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191690	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191690	1449191113	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191113	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191746	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191746	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191746	1449191063	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191063	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
981419532	981419513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419513	17376224	Allele G is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele C.	2.75
981419532	827776736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827776736	20347093	Allele G is associated with increased risk of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Hyperlipoproteinemia Type II as compared to allele C.	2.25
981419532	1183689650	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689650	23942138	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele G.	-1.75
1449566379	1449566369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449566369	29925376	Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.5
981419266	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
981419266	PA166264881	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166264881		Annotation of DPWG Guideline for phenytoin and HLA-B	100
981419266	PA166104860	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104860		Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B	100
981419266	981349390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349390	18637831	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	2.75
981419266	981859069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859069	20235791	HLA-B *15:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	3.0
981419266	981859108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859108	21216202	HLA-B *15:02:01 + *46:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	0.0
981419266	981859117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859117	22500513	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	0.25
981419266	1183680863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680863	23692434	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	-2.25
981419266	1183680889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680889	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	1.5
981419266	1184987970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987970	23551241	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin in children.	-0.25
981419266	1184988734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988734	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	1.25
981419266	1184988858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988858	22429379	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	0.25
981419266	1184989223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989223	25096692	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	2.5
981419266	1446902370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902370	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	2.25
981419266	1447948964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948964	26928377	HLA-B *15:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	-1.5
981419266	1447949133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949133	26927288	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	3.75
981419266	1448614858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614858	28391407	HLA-B *15:02:01 is not associated with likelihood of drug reaction with eosinophilia and systemic symptoms or Stevens-Johnson Syndrome when exposed to phenytoin as compared to HLA-B *07:02:01.	-2.0
981419266	1450806464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806464	30270535	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	3.5
981419266	1449566048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566048	28476759	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	-1.25
981419266	1184755407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755407	19018717	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	This annotation is not used for clinical annotation scoring. No patients had the allele.
981419266	1451271980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451271980	28476759	HLA-B *15:02:01 is associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.	3.5
981419266	1185003437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003437	25305458	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	This annotation is not used for clinical annotation scoring. Allele not found in the study population
981419266	1451783740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451783740	34175889	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.	-1.5
1451259580	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1451259580	PA166104982	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104982		Annotation of DPWG Guideline for amitriptyline and CYP2D6	100
1451259580	1448612606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448612606	28350251	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is associated with decreased likelihood of Constipation, dry mouth, Fatigue, Urinary Retention and Vision Disorders when treated with amitriptyline in people with Diabetic Neuropathies as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	0.125
1451259580	981476405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476405	18070221	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	3.5
1451259580	1183615533	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615533	21614669	CYP2D6 *4/*4 is associated with toxicity when exposed to amitriptyline.	0.25
1451259580	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451259580	1183617442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617442	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	2.0
1451259580	1183619031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619031	17008819	CYP2D6 *4/*4 is associated with side effects when treated with amitriptyline.	0.25
1451259580	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451265560	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1451265560	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1451265560	1183684386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684386	2293406	CYP2D6 poor metabolizers are associated with decreased dose of imipramine in people with Diabetic Neuropathies as compared to CYP2D6 normal metabolizer phenotype.	0.125
1451265560	1183617426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617426	18070221	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	2.5
1451265560	1446902201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902201	17667959	CYP2D6 *1/*1xN + *1/*2xN (assigned as ultra-metabolizer phenotype phenotype) are associated with increased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.5
1451265560	1446902225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902225	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	3.0
1451288200	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1451288200	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1451288200	1183682358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682358	22492761	CYP2D6 ultra-metabolizer phenotype is associated with increased risk of Death or Severe Respiratory Depression when treated with codeine in children with adenotonsillectomies for obstructive sleep apnea syndrome.	0.125
1451288200	1183684089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684089	22398969	CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain.	0.0
1451288200	1183617941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617941	12920424	CYP2D6 *1/*2xN is associated with increased risk of Drug Toxicity when treated with codeine, hydrocodone or oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.0
1451288200	1183618114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618114	18713907	CYP2D6 *1xN is associated with Respiratory Insufficiency when treated with codeine as compared to CYP2D6 *1/*1.	0.25
1451288200	1183623194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623194	15625333	CYP2D6 *1/*1xN is associated with Life-threatening opioid intoxication when treated with codeine as compared to CYP2D6 *1/*1.	0.25
1451288200	1183632396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632396	21743374	CYP2D6 *1/*2xN + *2/*2xN are associated with increased opioid related adverse events ( immediate pain relief from codeine but stopped taking it due to dizziness and constipation) when treated with codeine in women as compared to CYP2D6 *1/*1.	0.25
1451288200	1183680580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680580	9357099	CYP2D6 *1xN is associated with severity of abdominal pain when treated with codeine.	0.25
1451288200	1183682365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682365	22492761	CYP2D6 *1/*2xN is associated with risk of Death when treated with codeine in children with adenotonsillectomy for obstructive sleep apnea syndrome.	0.25
1451288200	1183623203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623203	18719619	CYP2D6 *2/*2xN is associated with increased risk of cns depression or Death when treated with codeine in infants as compared to CYP2D6 *1/*1xN.	2.25
1451282240	PA166181885	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166181885		Annotation of CPIC Guideline for atomoxetine and CYP2D6	100
1451282240	PA166104989	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104989		Annotation of DPWG Guideline for atomoxetine and CYP2D6	100
1451282240	1183688875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688875	22803597	CYP2D6 poor metabolizers are not associated with clinically significant change in QT(c) when exposed to atomoxetine in healthy individuals.	-0.75
1451282240	1446896699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446896699	25919121	CYP2D6 *3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.	2.5
1451285240	PA166176068	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176068		Annotation of CPIC Guideline for tamoxifen and CYP2D6	100
1451285240	PA166104966	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104966		Annotation of DPWG Guideline for tamoxifen and CYP2D6	100
1451285240	1183703991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703991	24329190	CYP2D6 poor metabolizer is associated with increased risk of Recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1 (assigned as normal metabolizer phenotype) .	0.0
1451285240	1444712493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712493	23100173	CYP2D6 normal metabolizers are not associated with event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	-0.75
1451285240	1444930785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930785	23842856	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1444932944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932944	25091503	CYP2D6 poor metabolizers are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.875
1451285240	1444932970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932970	25091503	CYP2D6 normal metabolizers are associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms.	1.125
1451285240	1444935131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935131	22395643	CYP2D6 poor metabolizers are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1444935762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935762	22395644	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-1.0
1451285240	1445402890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402890	22735900	CYP2D6 poor metabolizers are not associated with increased risk of Breast Neoplasms when treated with tamoxifen as compared to CYP2D6 normal metabolizers.	-0.875
1451285240	1445556295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556295	20454926	Genotype *1/*1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *3 + *4 + *5 + *10 + *41.	0.0
1451285240	1445556335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556335	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *4 + *10.	-0.5
1451285240	1445556346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556346	20454926	Genotype *1/*1 (assigned as normal metabolizers phenotype) are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *3 + *4 + *5 + *10 + *41.	-0.5
1451285240	1445556373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556373	20454926	CYP2D6 normal metabolizers are not associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype *4.	-0.375
1451285240	1445556396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556396	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556415	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556423	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556437	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556444	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556444	20454926	CYP2D6 normal metabolizers are not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-0.375
1451285240	1445556502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556502	23712329	Genotype *1/*1 (assigned as normal metabolizers phenotype) are associated with increased event-free survival and overall survival when treated with tamoxifen in women with Breast Neoplasms.	0.875
1451285240	1445556517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556517	23712329	CYP2D6 poor metabolizers are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.5
1451285240	1445556526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556526	23712329	CYP2D6 intermediate metabolizers are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	0.0
1451285240	1445556576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556576	23712329	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.5
1451285240	1445556583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556583	23712329	CYP2D6 poor metabolizers are not associated with decreased event-free survival or overall survival when treated with tamoxifen in women with Breast Neoplasms.	-0.5
1451285240	1445556597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445556597	23712329	Genotype *10/*10 (assigned as poor metabolizers phenotype) are not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes *1/*1 + *1/*10.	-0.4375
1451285240	1448260933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260933	26681084	CYP2D6 poor metabolizers are not associated with Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.125
1451285240	1448821366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821366	28730340	CYP2D6 poor metabolizer is not associated with likelihood of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.	-1.125
1451285240	1449717459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717459	30022682	CYP2D6 low activity is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 high activity.	1.375
1451285240	769146130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146130	16361630	Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	2.0
1451285240	769146179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146179	19809024	Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.	3.0
1451285240	769146129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146129	16361630	Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	2.0
1451285240	769146144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146144	17244352	Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.	0.0
1451285240	769146138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146138	16361630	Allele T is not associated with decreased overall survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.	-1.5
1451285240	827707602	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707602	21880792	CYP2D6 *1 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707600	21880792	CYP2D6 *3 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707609	21880792	CYP2D6 *6 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707615	21880792	CYP2D6 *41 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707613	21880792	CYP2D6 *17 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707607	21880792	CYP2D6 *5 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827813293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813293	21830868	CYP2D6 *4 is not associated with response to antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.75
1451285240	827707604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707604	21880792	CYP2D6 *4 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	827707611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707611	21880792	CYP2D6 *10 is not associated with decreased risk of Breast Neoplasms when treated with raloxifene or tamoxifen in women with high breast neoplasm risk.	-2.0
1451285240	1183630771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630771	24060820	CYP2D6 *3/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630816	24060820	CYP2D6 *3/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630822	24060820	CYP2D6 *3/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630834	24060820	CYP2D6 *4/*11 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630840	24060820	CYP2D6 *4/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630846	24060820	CYP2D6 *4/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630852	24060820	CYP2D6 *4/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630858	24060820	CYP2D6 *4/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630894	24060820	CYP2D6 *5/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630900	24060820	CYP2D6 *6/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1183630906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630906	24060820	CYP2D6 *6/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.5
1451285240	1444706217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706217	20309015	CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7 (assigned as poor metabolizers phenotype) are associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.	1.75
1451285240	1444708216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708216	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	3.5
1451285240	1444708249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708249	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	-2.0
1451285240	1444708269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708269	19809024	CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	3.0
1451285240	1444708297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708297	19809024	CYP2D6 *1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3 (assigned as heterozygous normal metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451285240	1444708449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708449	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.0
1451285240	1444708481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708481	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	2.5
1451285240	1444708528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708528	18024866	CYP2D6 *1/*4 + *1/*5 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444708545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708545	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.5
1451285240	1444708574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708574	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	2.0
1451285240	1444708609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708609	18024866	CYP2D6 *1/*4 + *1/*5 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444708626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708626	18024866	CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.	-1.5
1451285240	1444708801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708801	15632378	CYP2D6 *3 + *4 + *5 + *6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.75
1451285240	1444709086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709086	19809024	CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451285240	1444709154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709154	17244352	CYP2D6 *4/*4 is associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	2.5
1451285240	1444709176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709176	17244352	CYP2D6 *4 is not associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-2.0
1451285240	1444709377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709377	20849243	CYP2D6 *4/*4 is not associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	-1.75
1451285240	1444709399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709399	20849243	CYP2D6 *4/*4 is associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.	2.0
1451285240	1444709414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709414	16361630	CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	3.0
1451285240	1444709440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709440	16361630	CYP2D6 *4/*4 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	-1.5
1451285240	1444709457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709457	16361630	CYP2D6 *4/*4 is associated with decreased risk of Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.	0.0
1451285240	1444709474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709474	20124171	CYP2D6 *1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444709600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709600	22180457	CYP2D6 *4 + *5 + *10 + *14 + *21 + *36 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444709657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709657	22623212	CYP2D6 *4/*4 + *4/*5 + *4/*10 are associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*4.	3.5
1451285240	1444709772	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709772	18294285	CYP2D6 *10/*10 is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	2.75
1451285240	1444709809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709809	19189210	CYP2D6 *4 + *3 + *5 + *10 + *41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1 + *2 + *35.	-1.25
1451285240	1444709919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709919	19189210	CYP2D6 *4/*4 + *4/*41 + *1/*5 + *2/*5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.	1.75
1451285240	1444710214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710214	24682508	CYP2D6 *3 + *4 + *5 + *6 + *10 + *41 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444710290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710290	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	2.75
1451285240	1444710323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710323	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are not associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	-1.5
1451285240	1444710359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710359	18794105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.	-1.5
1451285240	1444710610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710610	19596663	CYP2D6 *10/*10 is not associated with event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.5
1451285240	1444710646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710646	19596663	CYP2D6 *10/*10 is not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-1.5
1451285240	1444710956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710956	20574415	CYP2D6 *1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *1/*36 + *1/*41 + *5/*5 + *5/*10 + *5/*21 + *10/*10 + *10/*21 + *21/*41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN.	-1.5
1451285240	1444711469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711469	21437611	CYP2D6 *1/*10 + *1/*41 + *1/*5 + *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-2.0
1451285240	1444711494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711494	21437611	CYP2D6 *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41 + *1/*5.	-1.5
1451285240	1444711544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711544	21437611	CYP2D6 *10/*10 + *10/*41 + *5/*10 + *5/*5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41 + *1/*5.	-1.5
1451285240	1444711617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711617	23167378	CYP2D6 *10/*5 + *10/*10 + *10/*41 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*36 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *10/*35.	-0.25
1451285240	1444711651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711651	23167378	CYP2D6 *10/*5 + *10/*10 + *10/*41 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*36 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *10/*35.	2.5
1451285240	1444711687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444711687	23167378	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	2.5
1451285240	1444712315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712315	16877740	CYP2D6 *4/*4 is associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.	2.5
1451285240	1444712361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712361	24125101	CYP2D6 *3/*4 + *4/*4 + *4/*6 + *6/*6 + *1/*4 + *1/*41 + *4/*41 + *1/*3 + *4/*10 + *3/*41 + *1/*6 + *1/*10 + *10/*10 + *10/*41 + *6/*41 are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444712505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712505	25211580	CYP2D6 *1/*4 + *1/*10 + *4/*10 + *10/*10 + *4/*4 are not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444712582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712582	21823108	CYP2D6 *4/*4 + *3/*4 + *4/*10 + *10/*10 are not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*1xN.	-1.5
1451285240	1444712614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712614	19156902	CYP2D6 *10/*10 is not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-1.5
1451285240	1444712651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712651	23226070	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.	1.5
1451285240	1444712664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712664	23226070	CYP2D6 *1/*1 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.	2.0
1451285240	1444712685	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712685	23226070	CYP2D6 *10/*10 is not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.25
1451285240	1444712890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712890	17115111	CYP2D6 *4/*4 + *1/*4 are associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.0
1451285240	1444712932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712932	17115111	CYP2D6 *4/*4 + *1/*4 are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444712957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712957	17115111	CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.5
1451285240	1444712986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712986	17115111	CYP2D6 *1/*4 is not associated with decreased event-free survival, overall survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1444713029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713029	20515869	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.	3.25
1451285240	1444713116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713116	20515869	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 (assigned as normal metabolizers phenotype) .	2.75
1451285240	1444713311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713311	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizers phenotype) .	2.0
1451285240	1444713343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713343	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizers phenotype) .	2.25
1451285240	1444713382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713382	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizers phenotype) .	2.0
1451285240	1444713399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713399	21860550	CYP2D6 *5/*10 (assigned as poor metabolizers phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizers phenotype) .	2.25
1451285240	1444713499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713499	23776391	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	1.5
1451285240	1444930474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930474	23476897	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.	-1.0
1451285240	1444930567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930567	18407954	CYP2D6 *10/*10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.125
1451285240	1444930651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930651	23842856	CYP2D6 *4 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444930760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930760	23842856	CYP2D6 *41 is not associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444930906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930906	21325141	CYP2D6 *4 is not associated with increased likelihood of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444932107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932107	25701109	CYP2D6 *10 is not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444932596	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932596	20809362	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizers phenotype) .	-2.0
1451285240	1444932651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932651	20809362	CYP2D6 *3 + *4 + *5 + *6 + *7 + *9 + *10 + *41 are not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN + *1/*35 + *2/*2.	-2.0
1451285240	1444932674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932674	20809362	CYP2D6 *3 + *4 + *5 + *6 + *7 + *9 + *10 + *41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN + *1/*35 + *2/*2.	2.75
1451285240	1444932743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444932743	20809362	CYP2D6 *4 + *5 + *10 + *41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	0.0
1451285240	1444933205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933205	23570465	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5 are associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1xN/*4 + *1/*1xN + *1/*1 + *1/*41 + *1/*10.	2.25
1451285240	1444933287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933287	23570465	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5 are not associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1xN/*4 + *1/*1xN + *1/*1 + *1/*41 + *1/*10.	-1.5
1451285240	1444933385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933385	21860550	CYP2D6 *5/*10 + *10/*10 + *1/*10 + *1/*5 are not associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.	-0.25
1451285240	1444933835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933835	23776391	CYP2D6 *10/*10 is not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-0.25
1451285240	1444933870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933870	23776391	CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizers phenotype) are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *5/*10 + *10/*14 (assigned as intermediate metabolizers phenotype) .	-1.0
1451285240	1444933926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933926	23213055	CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.75
1451285240	1444933959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933959	23213055	CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444933987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444933987	23213055	CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.75
1451285240	1444934738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934738	15987423	CYP2D6 *1/*4 + *4/*4 are associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	2.5
1451285240	1444934783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934783	15987423	CYP2D6 *1/*1 is not associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.	-1.5
1451285240	1444935174	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935174	22395643	CYP2D6 *4 is not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444935249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935249	22183189	CYP2D6 *10/*10 + *4/*10 + *5/*10 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	3.25
1451285240	1444935399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935399	19189212	CYP2D6 *4/*4 is associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.25
1451285240	1444935416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935416	19189212	CYP2D6 *1/*4 is not associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.25
1451285240	1444935873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935873	20731819	CYP2D6 *4 + *5 + *9 + *10 + *41 are not associated with overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1444936265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936265	15952058	CYP2D6 *4/*4 + *1/*4 are not associated with overall survival or progression-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-1.5
1451285240	1445400664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400664	24265036	CYP2D6 *3 + *4 + *6 + *14 + *41 are not associated with increased risk of Hot Flashes when treated with tamoxifen in women Breast Neoplasms as compared to CYP2D6 *1.	-2.0
1451285240	1445558113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558113	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	1.75
1451285240	1445558158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558158	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-1.0
1451285240	1445558282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445558282	24060820	CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizers phenotype) are not associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.	-1.0
1451285240	1444930579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930579	18407954	CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *1/*1.	3.0
1451226160	982009360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009360	23632726	Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1451226160	982009377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009377	23632726	Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1451226160	1451222720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222720	28320034	Genotypes AG + GG are not associated with severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AA.	-0.25
1451226166	1451222008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222008	27983768	Allele G is associated with decreased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele A.	0.0
1451226200	1451222205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222205	27983768	Allele A is associated with increased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in infants as compared to allele C.	0.0
1451226206	1451222205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222205	27983768	Allele A is associated with increased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in infants as compared to allele C.	0.0
1451226212	1451222240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222240	27983768	Allele A is associated with decreased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele G.	0.0
1451226220	1451222240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222240	27983768	Allele A is associated with decreased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele G.	0.0
1451340300	1451340224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340224	32498119	UGT1A3 *3 is associated with decreased concentrations of telmisartan in healthy individuals as compared to UGT1A3 *1/*1.	2.0
1451340300	1451340220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340220	32498119	UGT1A3 *2 is associated with decreased concentrations of telmisartan in healthy individuals as compared to UGT1A3 *1/*1.	2.0
1451340320	1451340242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340242	32498119	Allele C is associated with increased concentrations of telmisartan in healthy individuals as compared to allele G.	1.5
1450930839	1450930711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450930711	29666375	Allele A is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele G.	3.0
1451356840	1451356805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356805	32606912	Genotype TT is associated with increased dose of sufentanil in people with Pain, Postoperative as compared to genotypes CC + CT.	1.75
1451225360	982009360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009360	23632726	Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1451225360	982009377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009377	23632726	Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1450930464	1450827273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827273	28692418	Genotype TT is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes CC + CT.	2.25
1451290960	981240017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240017	22385882	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.75
1451290960	1185235790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235790	25115353	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	2.0
1451356520	1451226960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226960	30336686	Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	2.5
1451356520	1451228860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228860	29575099	Genotypes CC + CT are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype TT.	-1.75
1451356520	1451354800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354800	25932441	Genotypes CC + CT are associated with decreased response to simvastatin as compared to genotype TT.	0.0
1451356520	1451354923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354923	28482130	Allele C is associated with decreased response to simvastatin as compared to genotype TT.	2.5
1451356520	1448624730	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624730	28482130	Allele C is not associated with response to simvastatin as compared to allele T.	-1.75
1451356520	1451354953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354953	20207952	Genotypes CC + CT are not associated with decreased response to simvastatin as compared to genotype TT.	-1.75
1451356520	1451354962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354962	24668570	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.	-1.75
1451356520	1451355040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451355040	23100282	Genotypes CC + CT are associated with decreased response to simvastatin as compared to genotype TT.	3.0
1451356520	1451355120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451355120	24096969	Genotypes CC + CT are associated with decreased response to simvastatin.	2.5
1451356520	827922669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922669	22668755	Allele T is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele C.	-1.5
1451356520	1183681930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681930	23263738	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.	-1.75
1451356520	1184998473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998473	25379722	Genotypes CC + CT is associated with decreased response to simvastatin in people with Dyslipidaemia as compared to genotype TT.	2.0
655386913	1451285801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451285801	32897581	Genotypes CT + TT are not associated with risk of Hemorrhage when treated with clopidogrel as compared to genotype CC.	-2.0
655386913	827815453	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815453	22228204	Genotypes CT + TT are associated with increased risk of bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
655386913	1043818226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818226	23922007	Genotype CT is not associated with bleeding events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
655386913	699638709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638709	20083681	Allele T is associated with increased risk of bleeding when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	3.5
655386913	769146047	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146047	20801498	Allele T is associated with increased risk of bleeding events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.	2.5
655386913	1449165280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165280	29260275	Allele T is not associated with risk of Hemorrhage when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	-1.5
655386913	982022890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022890	22704413	CYP2C19 *17 is associated with increased risk of bleeding when treated with clopidogrel as compared to CYP2C19 *1.	2.5
655386913	1184349763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349763	24762860	CYP2C19 *17/*17 is associated with increased risk of bleeding events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.75
655386913	1184472078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472078	22123356	CYP2C19 *1/*17 + *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
655386913	1450370939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450370939	29536505	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2 + *2/*2 + *2/*17 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	2.0
655386913	1450806559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806559	30652301	CYP2C19 *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17.	2.25
655386913	1451285789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451285789	26790469	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	-1.75
655386913	1451285863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451285863	28255319	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	-1.75
655386913	1451285880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451285880	23364775	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	-2.0
655386913	1451342180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451342180	22552318	CYP2C19 *17 is not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	-1.0
655386913	1451342060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451342060	24762860	CYP2C19 *17 is not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1.	-2.0
1451356180	1451356100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356100	32555152	Genotype CT is associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype TT.	0.0
1451151506	1451149941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149941	32451486	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451356356	1451356320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451356320	32555608	Genotype AA is associated with increased likelihood of Pruritus when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	1.0
1451356386	1451356350	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356350	32555608	Genotype AA is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	2.25
1451225320	1451222008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222008	27983768	Allele G is associated with decreased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele A.	0.0
1451356380	1451356341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356341	32555608	Genotype AA is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	2.75
1451240740	769165283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769165283	21047201	Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.	2.75
1451240746	827695864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695864	21047201	Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.	2.75
1450815092	1450815015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815015	23241943	Allele G is associated with decreased response to risperidone in people with Schizophrenia as compared to allele A.	0.0
1451240880	1448994366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994366	28885988	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with dapsone.	2.0
1451240880	1448994391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994391	28885988	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with dapsone.	2.0
1451351160	1451351120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451351120	30700073	Genotype GG is associated with increased severity of Sleep Disorders due to opioids in people with Pain as compared to genotypes AA + AG.	2.0
1451277440	982015415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015415	17632216	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	2.5
1451277440	655388451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388451	20680028	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	2.5
1451277440	655388454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388454	19142101	Allele C is associated with increased risk of Metabolic Syndrome when treated with clozapine and risperidone in people with Schizophrenia as compared to allele G.	1.75
1451277440	1448255358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255358	27441116	Allele C is not associated with risk of Metabolic Syndrome when treated with amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone or ziprasidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to allele G.	-1.5
1451277440	1448997808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997808	25152019	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	1.625
1451244680	1448601968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601968	27967318	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.	2.0
1451351240	1451351220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351220	30969062	Genotype TT is associated with decreased response to fentanyl or remifentanil in children.	0.25
1451121880	655386332	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386332	19786980	Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.	2.5
1451121880	827816143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816143	21902499	Genotype GG is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AG.	2.25
1451121880	827817015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817015	22026922	Genotypes AG + GG are not associated with increased likelihood of Drug Toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	-1.25
1451121880	827826160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826160	22188361	Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.	-1.25
1451121880	1448568476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568476	27995989	Genotype GG is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.	-1.5
1451121880	1450374672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374672	30914949	Genotype AA is associated with increased risk of febrile neutropenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.	2.5
1451351260	1451351220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351220	30969062	Genotype TT is associated with decreased response to fentanyl or remifentanil in children.	0.25
1451350801	1451350780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451350780	32888428	HLA-B *55:01:01 is associated with increased risk of Drug Hypersensitivity due to penicillin g or penicillin v.	2.5
1451350944	1451350920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451350920	30166422	Genotype AA is associated with increased severity of Sleep Apnea Syndromes when treated with morphine in men as compared to genotype AG.	1.75
1451325840	1450936718	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936718	31002879	Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG.	2.0
1450375701	1450375663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375663	30924126	Allele C is associated with increased response to allopurinol.	0.0
1451357200	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451357200	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451357200	1451228540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451228540	29950617	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.	3.0
1451357200	1451356526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451356526	20347093	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.25
1451357200	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451357200	1183689628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689628	23708174	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.	-2.0
1451357200	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451357200	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451357200	1448821127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821127	28812116	Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.	3.25
1451244720	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451244720	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451244720	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1450810357	1450810107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810107	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1451244700	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451244700	827827170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827170	17015053	Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.	-0.125
1451244700	1450823509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823509	30989645	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.	2.0
1451241320	981934294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934294	22162992	NAT2 *5D/*5D + *5D/*6B + *5D/*7A + *6B/*6B + *6B/*7A (assigned as slow acetylator phenotype) is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to NAT2 *4/*4 + *4/*12A + *4/*13A + *12A/*12A + *13A/*13A + *4/*5D + *4/*6B + *5D/*12A + *5D/*13A + *6B/*12A + *6B/*13A (assigned as rapid acetylator phenotype) .	2.0
1450375047	1450374712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374712	30914949	Genotype CC is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CT + TT.	2.0
1450375047	1450374725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374725	30914949	Genotype CC is associated with increased risk of Pain due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CT + TT.	2.5
1451357763	1451357620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451357620	32701512	Allele G is associated with increased response to anastrozole in women with Breast Neoplasms as compared to allele A.	0.0
1451357759	1451356940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356940	32701512	Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele G.	0.0
1451357783	1451356971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356971	32701512	Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele G.	0.0
1451357790	1451356980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451356980	32701512	Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele C.	0.0
1451238460	1450932594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932594	30549211	Genotype AG is associated with decreased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG.	2.25
1451238460	1450932667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932667	30549211	Genotype AG is associated with increased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG.	-2.25
1451123780	1451123748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451123748	23275066	Allele del is associated with decreased catalytic activity of CES1 when assayed with 2-oxo-clopidogrel or clopidogrel as compared to allele A.	0.0
1448256712	1448256532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256532	22736425	Genotype AA is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.	1.75
1451328325	1043818338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818338	23903772	Genotypes AG + GG are associated with increased risk of Coronary Artery Disease when treated with hmg coa reductase inhibitors as compared to genotype AA.	3.0
1451328325	1043818343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818343	23903772	Genotypes AG + GG are associated with increased risk of Coronary Artery Disease when treated with hmg coa reductase inhibitors as compared to genotype AA.	1.5
1451328325	1449310862	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449310862	29703846	Allele G is associated with increased risk of Coronary Disease when treated with hmg coa reductase inhibitors as compared to allele A.	2.5
1451344820	1451340200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451340200	32562552	Genotypes GG + GT are associated with increased risk of Peripheral Nervous System Diseases when treated with taxanes in people with Neoplasms as compared to genotype TT.	0.0
1451353040	1445401050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401050	20615525	Allele T is associated with increased dose of warfarin as compared to allele C.	0.25
1451353040	1445401057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401057	15630486	Allele T is associated with increased dose of warfarin as compared to allele C.	0.25
1451353040	1445401065	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401065	19663669	Allele T is associated with increased dose of warfarin as compared to allele C.	0.25
1451353040	1447520668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520668	26513304	Allele T is associated with decreased response to warfarin as compared to allele C.	0.25
1451238365	1450823079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823079	25744370	Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.	3.5
1451328500	1444687074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444687074	23057546	Genotype AG is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotype GG.	-1.5
1451328500	1183689326	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689326	24192118	Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG.	2.0
1451328500	1447680222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680222	26244882	Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A.	2.0
1451328500	699638591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638591	19365401	Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.5
1451328500	1451243060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451243060	16909270	Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.375
1451237983	1450372692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372692	30874608	Genotype TT is associated with decreased response to antidepressants in people with Depression as compared to genotypes GG + GT.	2.5
1451238020	1450372675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372675	30874608	Genotype TT is associated with decreased response to paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.	2.5
1451238040	1450372715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372715	30874608	Genotype TT is associated with decreased response to escitalopram in people with Depression as compared to genotypes GG + GT.	2.75
1451336020	1451317820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451317820	33378980	Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	2.25
1451336026	1451317880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451317880	33378980	Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.	1.25
1451336041	1451335100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451335100	33378980	Allele G is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to allele A.	1.75
1451336047	1451335120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451335120	33378980	CYP3A5 *1/*1 is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.	1.75
1451336060	1451317900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451317900	33378980	Genotype CG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.	0.0
1451245960	1447951965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951965	22331829	Genotypes AG + GG are associated with decreased response to rosuvastatin as compared to genotype AA.	0.0
1451336074	1451335141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451335141	33378980	Genotype GG is associated with increased likelihood of Asthenia due to olanzapine in healthy individuals as compared to genotypes AA + AG.	1.75
1451336100	1451335149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451335149	33378980	Genotype CC is associated with increased likelihood of Arrhythmias, Cardiac due to olanzapine in healthy individuals as compared to genotypes CT + TT.	1.75
1451246040	981802588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802588	23459442	Genotype GG is associated with increased severity of withdrawal in people not taking nicotine in women Tobacco Use Disorder as compared to genotypes AA + AG.	1.5
1450377208	1450377146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377146	27488001	Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.	2.25
1451139080	1451138980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138980	25241292	CYP2C9 *3 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C9 *1/*1.	0.0
1451245600	1444695050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695050	18466100	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	3.5
1451245600	1444695080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695080	18466100	CYP2C19 *1/*2 + *1/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	3.0
1451245600	1444695105	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695105	18466100	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased resistance to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	2.0
1451245620	1444695287	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695287	25323806	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	1.0
1451352140	1451352120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352120	31269327	Genotype CC is associated with increased dose of opioids in people with Low Back Pain as compared to genotypes CT + TT.	2.5
1451352146	1451352126	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451352126	31269327	Allele G is associated with increased likelihood of Nausea due to opioids in people with Low Back Pain as compared to allele A.	2.5
1451253880	827815311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815311	19620853	Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.	1.75
1451253880	827824027	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824027	22188362	Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	2.5
1451253880	827824037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824037	22188362	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	2.5
1451253880	1447678341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678341	26555147	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	-1.0
1451253880	1447678444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678444	26314341	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	0.0
1451163868	1451163820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163820	16170755	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir or indinavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28.	2.25
1451163868	1451209120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209120	16609363	UGT1A1 *1/*28 + *28/*28 are not associated with risk of Hyperbilirubinemia when treated with indinavir in people with HIV Infections as compared to UGT1A1 *1/*1.	-1.25
1451163868	1451209180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209180	16609363	UGT1A1 *6/*28 is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV Infections as compared to UGT1A1 *1/*1.	2.75
1451228945	1448104103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448104103	27289271	CYP2B6 *6 is associated with increased severity of Pain when treated with methadone in men with Opioid-Related Disorders.	2.0
1451228940	1183702914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702914	17329992	CYP2B6 *6/*6 is associated with increased risk of prolonged QTc when treated with methadone as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1450934061	1450933234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933234	30713339	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	0.0
1450934169	1450934112	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934112	30611854	Allele T is associated with decreased inhibition of SCN4A with mexiletine as compared to allele A.	0.0
1450934181	1450934100	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934100	30611854	Allele T is associated with decreased inhibition of SCN4A with mexiletine as compared to allele G.	0.0
1451359886	1451089566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451089566	20216107	Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele A.	This annotation is not used for clinical annotation scoring. Association seen as part of haplotype.
1451359886	1451359880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451359880	33030089	Genotype GG is associated with increased response to propranolol in people with Temporomandibular joint-pain-dysfunction syndrome as compared to genotype AA.	0.0
1451351302	1451351280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351280	33127459	Genotype TT/TT is associated with increased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	1.75
1451244869	1449715221	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715221	23302985	Genotype AA is associated with decreased response to fentanyl in women with as compared to genotypes AG + GG.	0.0
1451244900	1450373815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373815	27027462	Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG.	2.5
1451244900	1450373834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373834	27027462	Genotype AA is associated with increased response to remifentanil in infants with Pain as compared to genotypes AG + GG.	2.5
1451359601	1451358800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451358800	32736537	Genotype TT is associated with decreased risk of Memory Disorders due to heroin in people with Heroin Dependence as compared to genotypes CC + CT.	3.0
1451244980	1451121600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451121600	31493434	Genotypes AA + AG are associated with increased response to oxycodone as compared to genotype GG.	2.0
1451245004	1450933130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933130	30704436	Genotype AG is associated with decreased dose of opioids in children as compared to genotype GG.	1.25
1451245004	1448818544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448818544	28745577	Genotype GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotypes AA + AG.	2.0
1451245004	1449173486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173486	25185591	Genotype GG is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.	2.0
1451245004	1449714130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449714130	21398039	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.	-2.5
1451245004	1451221008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451221008	27729204	Genotype GG is associated with increased dose of opioids in women with Breast Neoplasms and Pain, Postoperative as compared to genotypes AA + AG.	2.25
1451245004	1451350980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451350980	30211780	Genotypes AA + AG is associated with increased dose of opioids in people with Pain as compared to genotype GG.	-2.25
981204995	982046452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046452	22761669	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.0
981204995	827704209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827704209	21826087	Genotypes CT + TT are associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype CC.	2.75
981204995	827813099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813099	19620936	Allele T is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C.	2.75
981204995	827817088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817088	22026922	Genotype CC is associated with increased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	2.5
981204995	827817099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817099	22026922	Genotype CC is not associated with increased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	-1.5
981204995	827817125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817125	22026922	Genotype CC is not associated with increased overall survival when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	-1.25
981204995	827827919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827919	22188361	Genotypes CT + TT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-1.25
981204995	827828246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828246	22188361	Genotype CT is associated with increased likelihood of overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	2.0
981204995	1183491977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491977	23962907	Genotype CC is not associated with increased overall survival when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT.	-1.25
981204995	1183700722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700722	18347182	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	-1.25
981204995	1296599211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599211	24446315	Genotypes CT + TT is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-1.75
981204995	1296599255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599255	24446315	Genotypes CT + TT is not associated with overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-1.75
981204995	1444936058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936058	25592234	Genotypes CT + TT is associated with increased event-free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC.	3.25
981204995	1448568311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568311	27995989	Genotype CC is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.	-1.5
981204995	1449752404	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752404	29662106	Allele C is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.5
1451121940	1451551143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551143	32173978	Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele G.	3.5
1451121940	827832057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827832057	19620936	Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele A.	2.25
1451121940	1448568304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568304	27995989	Genotype GG is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.	-2.0
1451245081	1449173508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173508	23773341	Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G.	2.25
1451245081	1450373815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373815	27027462	Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG.	2.5
1451245081	1450373824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373824	27027462	Genotype GG is associated with decreased response to morphine in infants with Pain as compared to genotypes AA + AG.	2.0
1451245081	982043262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043262	23210659	Genotype AA is associated with increased numerical rating scale (NRS) score for pain during painful procedure when treated with morphine as compared to genotype GG.	-2.5
1451245081	1451407529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407529	31806881	Genotype AA is associated with decreased response to morphine in healthy individuals as compared to genotypes AG + GG.	-2.0
1451244920	1449713837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713837	28006928	Genotype AA is associated with decreased dose of sufentanil in children as compared to genotypes AG + GG.	1.5
1451244920	1451446281	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451446281	33977649	Allele A is not associated with dose of sufentanil as compared to allele G.	-1.5
1451245764	1448576467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448576467	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451245764	1449575788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449575788	29923122	NUDT15 *2 + *3 + *4 + *5 + *6 are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to NUDT15 *1.	3.5
1451245800	1451133189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451133189	32308129	NUDT15 *1/*2 + *1/*3 + *1/*6 + *2/*2 is associated with increased Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.75
1451254580	981483686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483686	23233662	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	1.0
1451254580	655387928	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387928	19901119	Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	1.75
1451254580	1451465086	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465086	21387541	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	0.0
1451254580	1184747694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747694	25098908	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.	1.0
1451254580	1449003329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003329	28525903	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.25
1451254580	1450045181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045181	29791011	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	-1.0
1451245925	981499270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981499270	19800676	Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG.	3.25
1451245925	769170806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170806	15500895	Genotype GG is associated with increased morning peak expiratory flow rate during treatment with regularly scheduled albuterol compared with placebo when treated with salbutamol in people with Asthma as compared to genotype AA.	2.25
1451245925	1448259816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259816	26071206	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	-1.75
1451245925	1451493920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493920	15687340	Genotype AA is associated with decreased response to salbutamol in healthy individuals as compared to genotypes AG + GG.	1.0
1451245925	1451564962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451564962	32986886	Allele A is not associated with response to salbutamol in people with Asthma as compared to allele G.	-1.0
1451237820	1449715394	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715394	29926893	CYP3A4 *36/*36 is associated with decreased concentrations of sufentanil in women with Pain as compared to CYP3A4 *1/*1 + *1/*36.	2.0
981237878	827812640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812640	21806385	Genotype CC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.	2.5
981237878	827812695	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812695	21806385	Genotype AC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	2.5
981237878	1448107604	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448107604	15761113	Allele C is associated with increased glucuronidation of valproic acid in HEK 293 cells..	0.0
981238234	827793233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793233	21449676	Allele T is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.	1.25
981238234	827793245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793245	21449676	Allele T is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele C.	1.25
981239568	981239489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239489	14765194	Allele C is associated with increased dose of warfarin as compared to allele A.	0.25
981239568	981239497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239497	18234403	Allele C is associated with increased dose of warfarin as compared to allele A.	0.0
1449718265	1449718012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718012	29507678	Genotype CC is associated with increased risk of Leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CT + TT.	2.25
1451245040	1450933135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933135	30704436	Genotypes AA + AG are associated with increased response to opioids in children as compared to genotype GG.	1.25
1451289620	1447519972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519972	19752777	Allele T is associated with risk of over-anticoagulation when treated with warfarin as compared to allele C.	2.75
1451257000	1184470380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470380	24658827	Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.	1.5
1451257000	1184471141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471141	24465960	Allele C is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	-2.0
1451257000	1184483156	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483156	24921414	Allele T is not associated with dose-adjusted trough concentration when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.0
1451257000	1185012370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012370	24061445	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451257000	1185023373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023373	25271728	Allele C is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	-1.5
1451257000	1444694133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694133	24739669	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	-1.25
1451257000	1451095020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451095020	28229376	Genotypes CT + TT is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-0.75
1451257000	1444934259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934259	26067485	Genotypes CT + TT is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451257000	1447520696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520696	26227094	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.25
1451257000	1448285592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285592	26829596	Genotypes CT + TT are not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-1.0
1451257000	1448573195	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573195	28094348	Genotype CC is not associated with metabolism of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.	-0.125
1451257000	1449162946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162946	29318894	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.	-1.5
1451257000	1449171398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171398	27966227	Genotype CC is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.	-0.125
1451257000	1449749631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749631	29878980	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451257000	1449750524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750524	30323313	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451330460	1451330363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451330363	12421483	CYP2D6 *10/*10 is associated with increased response to propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	1.5
1451354640	1451353806	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353806	32481444	Genotype GG is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype AG.	2.25
1449716213	1449716201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716201	29502940	Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.	0.0
1451354647	1451353817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353817	32481444	Genotype CT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.	2.25
1451354700	1451353812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353812	32481444	Genotype CT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.	2.75
1450813849	1450813816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813816	22048466	Genotype TT is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotypes CC + CT.	3.0
1451150004	1451149639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149639	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451338440	1450972220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450972220	32088688	Genotype GG is not associated with sustained virological response (svr) when treated with ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.	-1.25
1451338440	1451338240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451338240	24367041	Genotype GG is associated with decreased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.	1.5
1451338440	1451338260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451338260	29866411	Genotype GG is associated with decreased sustained virological response (svr) when treated with direct acting antivirals in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.	3.0
1451338440	1451338300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451338300	31260374	Genotype TT/TT is associated with increased likelihood of sustained virological response (svr) when treated with direct acting antivirals or sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1451150066	1451149675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149675	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451354560	1451353780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353780	32481444	Genotypes CT + TT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.	2.75
1451346385	827923820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827923820	19733552	Genotype CT is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	1.75
981201387	1451504420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451504420	22074251	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
981201387	608431578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431578	14647408	Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.5
981201387	769174305	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769174305	15797993	Allele A is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.	-0.0
981201387	1448617045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617045	28422153	Genotypes AA + AG are associated with decreased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.	0.0
1451329580	981844004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981844004	16636344	Genotype AA is not associated with dose of irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.25
1451329580	1447945228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945228	26862009	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with decreased dose of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*28 + *1/*6.	2.75
827836551	699638654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638654	16678543	Genotypes CG + GG are associated with increased pain relief when treated with ibuprofen as compared to genotype CC.	2.5
827836551	1451406248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406248	33812699	Genotypes CG + GG are not associated with response to ibuprofen in people with Pain, Postoperative as compared to genotype CC.	-1.5
1449576301	1449576291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576291	29097388	Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T.	0.0
1451337885	982046574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046574	18421452	Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1450936284	1450936021	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936021	30822619	Allele T is associated with decreased sulfation of acetaminophen as compared to allele A.	0.0
1450935813	1450935638	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935638	30745309	Allele T is associated with decreased expression of CYP2C9 protein as compared to allele C.	0.0
1450935813	1450935691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935691	30745309	Allele T is associated with decreased clearance of tolbutamide as compared to allele C.	1.5
1450935826	1450935649	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935649	30745309	Allele C is associated with decreased expression of CYP2C9 protein as compared to allele T.	0.0
1450935826	1450935701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935701	30745309	Allele C is associated with decreased clearance of tolbutamide as compared to allele T.	1.0
1451223506	1296599938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599938	24637499	Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	1.75
1451223506	1451504441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451504441	22074251	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
1451223506	1451506260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506260	23198157	Genotype AA is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-2.0
1451223506	1451506520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506520	24386571	Allele A is not associated with response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
1451223506	1446898351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898351	21644011	Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	1.75
1451223506	827698220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698220	21747412	Genotype GG is associated with increased event-free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	2.0
1451223506	608431574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431574	14647408	Allele A is associated with decreased likelihood of event-free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.0
1451223506	637879719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879719	17488658	Allele A is associated with decreased likelihood of event-free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG.	0.875
1451223506	608431599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431599	15781665	Allele A is associated with increased risk of Recurrence when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	3.0
1451223506	637879749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879749	17512587	Genotype AA is associated with increased overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-2.0
1451223506	769170744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170744	16462575	Allele A is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-0.25
1451337408	655385709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385709	19794412	Genotype TT is associated with increased response to sulfonamides, urea derivatives.	3.0
1451337408	1449310654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310654	29681852	Allele T is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele C.	-1.75
1451337408	1449310660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310660	29681852	Allele C is not associated with response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to allele A.	-1.75
1451337408	655385712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385712	19794412	Genotype CC is associated with increased response to sulfonamides, urea derivatives.	3.0
655384558	655387597	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655387597	18451141	Allele C is associated with increased expression of CYP1B1 in CEU and YRI cell lines.	0.0
655384558	655387598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387598	18451141	Allele C is associated with increased IC50 of daunorubicin as compared to allele G.	2.5
827847725	827827855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827855	21079520	Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	0.0
827847759	827820202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827820202	22249355	Genotype GG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + AG.	2.0
827848740	827783461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783461	21174621	Genotype AA is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.0
827848751	769164633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164633	9860300	Genotype GG is associated with increased spine Bone Mineral Density when treated with conjugated estrogens and medroxyprogesterone as compared to genotype AA.	2.5
981201549	769278134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769278134	18305461	Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype TT.	2.25
981201549	827700157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700157	20520601	Genotype CC is associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes CT + TT.	0.0
827848762	827788986	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827788986	15284535	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with tolbutamide.	0.0
827848365	1184746658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746658	25007187	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	769170671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170671	18458567	Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	751696635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751696635	12915598	Allele A is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
827848365	769171025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171025	16870553	Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-2.0
827848365	1184510298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510298	23488607	Genotypes AA + AG is associated with increased risk of hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	2.75
827848365	1451464465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451464465	19031955	Genotype AA is associated with increased risk of Neurotoxicity Syndromes and Toxic liver disease when treated with methotrexate in children with Osteosarcoma.	0.25
827848365	1451465191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465191	21534867	Genotypes AA + AG are associated with increased risk of Thrombocytopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.5
827848365	1447979303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979303	25110820	Genotypes AA + AG are associated with increased risk of Leukopenia or Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	3.25
827848365	637879736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879736	17488658	Genotype AA is associated with increased risk of Thrombocytopenia or Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.	2.75
827848365	827829042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829042	22143415	Genotype AA is associated with increased risk of toxicity when treated with methotrexate as compared to genotype GG.	0.5
827848365	769146371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146371	16501586	Genotype AA is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype GG.	This annotation is not used for clinical annotation scoring. Overlap of authors and likely overlap of cohort with PMID 11418485
827848365	637879745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879745	17512587	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	This annotation is not used for clinical annotation scoring. Overlap of authors and patient cohort with PMID 12453860
827848365	655387891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387891	19648163	Genotype AA is associated with increased risk of gastrointestinal toxicity, Leukopenia and Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	This annotation is not used for clinical annotation scoring. Author overlap with PMID 17488658
827848365	1451504586	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504586	22074251	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
827848365	1451511426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451511426	25177243	Genotypes AA + AG are associated with increased risk of Leukopenia or Thrombocytopenia due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	2.5
827848365	1451552860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451552860	32612964	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
827848365	1451553448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553448	32695297	Genotype AA is associated with increased risk of hematotoxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.75
827848365	1451634220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634220	34346513	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.25
827848365	1451635256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451635256	33841551	Allele A is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.25
827848365	1446898640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898640	21644011	Genotypes AA + AG is associated with increased Drug Toxicity when treated with methotrexate in children with as compared to genotype GG.	2.5
827848365	1447675071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675071	25778468	Genotype GG is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.	-2.25
827848365	1451547041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451547041	27104192	Allele A is not associated with risk of mucositis, nephrotoxicity or Toxic liver disease due to methotrexate in children with Osteosarcoma as compared to allele C.	-0.25
827848365	1451547222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451547222	27781293	Genotype AG is associated with increased risk of hematotoxicity due to methotrexate in people with primary central nervous system lymphoma as compared to genotype GG.	3.0
827848365	1451548500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548500	29911750	Genotype AG is associated with increased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
827848365	1451548770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548770	30684021	Genotypes AG + GG are associated with increased severity of Leukopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	-2.25
827848365	981475997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475997	23089671	Genotype AA is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	-0.5
827848365	637879769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879769	12453860	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotypes AG + GG.	1.75
827848365	637879722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879722	17488658	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.	3.25
827848365	637879773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879773	11418485	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	2.0
827848365	1184169119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169119	23648444	Genotypes AA + AG is associated with increased risk of Toxic liver disease when treated with methotrexate in children with Neoplasms as compared to genotype GG.	1.75
827848365	1184169137	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169137	23648444	Allele A is not associated with risk of Toxic liver disease when treated with methotrexate in people with Neoplasms as compared to allele G.	-1.0
827848365	1184510310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510310	23488607	Genotypes AA + AG is not associated with risk of non-hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	-1.25
827848365	1184514065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514065	24241962	Allele G is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele A.	-0.75
827848365	1448124321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124321	27399166	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.	-1.25
827848365	1448997017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997017	28696419	Genotype GG is associated with decreased risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes AA + AG.	1.5
1450935819	1450935643	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935643	30745309	Allele C is associated with decreased expression of CYP2C9 protein as compared to allele A.	0.0
1450935819	1450935696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935696	30745309	Allele C is associated with decreased clearance of tolbutamide as compared to allele A.	1.5
981201642	1450821627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821627	16130010	Allele TTAAAGTTA is associated with increased risk of Precursor Cell Lymphoblastic Leukemia-Lymphoma when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype del/del.	0.0
827848785	769245963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245963	19365399	Allele C is associated with increased antidepressant response when treated with escitalopram in people with Depressive Disorder as compared to allele G.	2.75
827863928	769174175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174175	20031608	Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.	2.75
827863928	769174182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174182	20031608	Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.	3.0
827863928	769174179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174179	20031608	Genotype AG is not associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.	-2.75
981201408	981501525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501525	20136638	Allele T is not associated with likelihood of subclinical acute rejection when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
981201408	981934462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934462	22960765	Allele T is not associated with increased risk of rejection or affect graft function by 1 year after transplantation when treated with Calcineurin inhibitors and mycophenolate mofetil in people with Organ Transplantation as compared to genotype CC.	-2.0
981201408	769262707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262707	21142914	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.5
981201408	827807997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807997	20679962	Allele T is associated with decreased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	2.75
981201408	827808010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808010	20679962	Allele T is associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	2.25
981201408	731714509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/731714509	17851563	Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with kidney transplant as compared to genotype CC.	2.0
981201424	769262707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262707	21142914	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.5
981201424	827808010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808010	20679962	Allele T is associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	2.25
981201443	699638662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638662	19650939	Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes CT + TT.	3.25
981201455	699639151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639151	21047205	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder.	0.0
981201455	608431344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431344	18408563	Allele C is associated with increased response to lithium in people with Bipolar Disorder as compared to allele T.	2.0
981201571	769245524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245524	21325291	Genotypes C/del + CC are associated with decreased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype del/del.	2.0
981201571	982033322	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033322	23651026	Genotype del/del is not associated with increased activity of CDA in whole blood from healthy volunteers as compared to genotypes C/del + CC.	-0.0
981201571	827803673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827803673	21521023	Genotypes C/del + del/del are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype CC.	1.75
981201571	827803759	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803759	21521023	Genotypes C/del + del/del are associated with increased expression of CDA in PBMCs.	0.0
981201571	827824412	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824412	18473752	Genotypes C/del + CC are associated with increased likelihood of grade III hand foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype del/del.	0.0
981201571	827829888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829888	22304580	Genotype del/del is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotypes C/del + CC.	0.0
981201571	827922327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922327	22379997	Genotype del/del is associated with increased risk of Drug Toxicity when treated with cytarabine in children with Lymphoma, T-Cell.	0.25
981201571	769245529	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769245529	21325291	Genotype del/del is associated with increased expression of CDA in CEPH cell lines.	0.0
981201584	769245524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245524	21325291	Genotypes C/del + CC are associated with decreased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype del/del.	2.0
981201584	827824412	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824412	18473752	Genotypes C/del + CC are associated with increased likelihood of grade III hand foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype del/del.	0.0
981201770	981344812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344812	21878834	Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.	2.75
981201770	981344820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344820	21878834	Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GT.	2.75
981201770	981344839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344839	21878834	Allele T is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.	-1.75
981201770	981477575	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477575	19890249	Allele G is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	-1.0
981201770	981862494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862494	17906856	Genotype GG is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.	1.25
981201770	655387664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387664	19890249	Allele G is associated with decreased dose-normalized Cmax and dose-normalized AUC0to12 h when treated with mycophenolate mofetil in people with kidney transplants as compared to allele T.	0.75
981201770	769262706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262706	21142914	Allele G is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	0.0
981201788	827922971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922971	15622315	Allele C is associated with increased plasma efavirenz exposure when treated with efavirenz in people with HIV Infections as compared to allele T.	2.0
981201788	827695641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695641	16267764	Genotypes CC + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype TT.	-1.25
981201797	827641958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827641958	11394901	Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.	2.25
981201797	827641986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641986	12844137	Allele C is associated with decreased metabolism of nicotine.	2.25
981201797	827698774	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827698774	21521021	Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.	0.0
981201805	827641958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827641958	11394901	Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.	2.25
981201805	827642007	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827642007	16041240	Allele C is associated with decreased metabolism of coumarin.	1.75
981201805	827698774	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827698774	21521021	Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.	0.0
981201827	769278040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769278040	12445030	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.0
981201827	827551899	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827551899	11779172	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.125
981201881	981483915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483915	16998491	Allele C is associated with HLA-B*5701 in healthy individuals.	0.0
981201854	827861853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827861853	21441248	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	0.0
981201854	981344426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344426	22680342	Allele C is associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele T.	2.0
981201854	827807701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807701	18281305	Genotype CT is associated with increased plasma concentration of nevirapine in people with HIV Infections as compared to genotype TT.	1.5
981201854	827848035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848035	22354160	Genotypes CC + CT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	-1.25
981201854	827848949	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848949	19228205	Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.	-1.5
981201854	1296598953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598953	24217698	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	2.0
981201854	1448108791	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108791	27195527	Allele C is associated with increased concentrations of nevirapine in women as compared to allele T.	2.5
981201637	1450821676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821676	17410198	Allele del is associated with increased risk of Toxic liver disease when exposed to methotrexate in people with Psoriasis.	2.0
981201637	1450821683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821683	16501586	Genotype del/del is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype TTAAAGTTA/TTAAAGTTA.	0.0
981201637	1450821731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821731	27992285	Genotype del/del is associated with decreased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes TTAAAGTTA/TTAAAGTTA + TTAAAGTTA/del.	-1.25
981201637	1450821738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821738	26616421	Genotype TTAAAGTTA/TTAAAGTTA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes TTAAAGTTA/del + del/del.	-3.25
981201637	1451161440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161440	27217051	Allele del is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele TTAAAGTTA.	0.0
1450935838	1450935676	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935676	30745309	Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.	0.0
1450935838	1450935734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935734	30745309	Allele T is associated with decreased clearance of mephenytoin as compared to allele C.	1.0
827848732	769171028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171028	16870553	Genotype AA is associated with decreased severity of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	2.5
827848732	1451634408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634408	34346513	Allele A is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
827864513	769169291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169291	18425130	Genotypes AT + TT are associated with decreased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Other data from the same paper used for scoring.
827864513	1451861385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451861385	19628119	Genotype AA is associated with decreased risk of Death when treated with Beta Blocking Agents in people with Heart Failure as compared to genotypes AT + TT.	-3.5
827864513	1451842640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451842640	22703928	Genotypes AT + TT are associated with decreased risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotype AA.	0.0
827864513	1451842800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451842800	22703928	Allele A is not associated with risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to allele T.	-2.0
827864513	1451839940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451839940	19628119	Genotype AA is not associated with risk of Death when treated with Beta Blocking Agents in people with Heart Failure as compared to genotypes AT + TT.	-2.0
827864513	1451868583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451868583	25638254	Genotype AT is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to genotype AA.	-1.5
827864513	1451863980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451863980	34541364	Genotypes AT + TT are associated with increased response to Beta Blocking Agents in people with Heart Failure as compared to genotype AA.	3.25
827864513	1451863440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451863440	30374408	Genotype AA is associated with decreased risk of Death or heart transplantation when treated with Beta Blocking Agents in people with Heart Failure as compared to genotype AT.	0.0
827864513	827864486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864486	18425130	Genotypes AA + AT are associated with response to Beta Blocking Agents in people with Heart Failure as compared to genotype TT.	2.5
981201888	827704013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827704013	15505641	Allele A is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.	0.375
981201888	769246515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769246515	17611010	Allele A is not associated with increased QT interval when treated with antipsychotics in people with Schizophrenia as compared to allele G.	-1.25
981202090	827923804	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827923804	18485328	Allele T is associated with decreased catalytic activity of CES1 when assayed with methylphenidate.	0.0
981202090	1448573551	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573551	28087982	Allele T is associated with decreased metabolism of methylphenidate in healthy individuals as compared to allele C.	1.5
981202103	827843599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827843599	22350108	Genotype CC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotypes CT + TT.	2.5
981202103	827924796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924796	18591461	Allele C is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to allele T.	2.0
981202240	1450821690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821690	21919605	Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.	3.5
981202334	699642251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642251	19005482	Genotypes GT + TT are associated with decreased risk of venoocclusive disease of the liver when treated with cyclophosphamide in people with HLA-identical hematopoietic stem cell transplantation as compared to genotype GG.	2.5
981202356	827811269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811269	20179710	Allele T is associated with decreased likelihood of dose reduction when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele G.	2.0
981202366	655387656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387656	15564880	Genotype AA is associated with decreased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + AG.	2.0
981202366	769170797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170797	19827168	Genotypes AA + AG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.75
981202440	981500830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500830	23296156	Allele C is not associated with survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele A.	-1.25
981202440	827843556	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827843556	22117530	Allele A is associated with increased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele C.	2.75
981202440	769171568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171568	17704420	Allele A is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to allele C.	0.25
981202440	1449154943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154943	28719596	Genotype AA is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AC + CC.	2.0
981202440	1449165380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165380	27897268	Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.	-0.5
981202440	1449752269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752269	30318772	Allele C is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele A.	-2.0
981202520	827924775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924775	18591455	Genotype AA is associated with decreased reduction in SBP when treated with hydrochlorothiazide in people with Hypertension.	0.0
981202520	1449754439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449754439	19635985	Allele A is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.5
981202551	827811311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811311	20179710	Genotype AA is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AG + GG.	0.0
981202551	1449576742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576742	29938344	Genotypes AA + AG are associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.	3.0
981202562	1446907582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907582	26456622	Allele A is associated with decreased risk of gastrointestinal toxicity and Leukopenia when exposed to cyclophosphamide in people with Lupus erythematosus as compared to allele G.	3.5
981202562	1446907621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907621	26456622	Allele A is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele G.	2.0
981202562	827828575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828575	20358205	Genotype GG is associated with increased risk of toxicity when treated with cyclophosphamide in women with Lupus Erythematosus, Systemic as compared to genotypes AA + AG.	1.25
981237704	978639863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639863	22838948	Allele G is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.25
981237704	769174419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174419	17855192	Genotype GG is associated with increased risk of Brain Diseases when treated with methotrexate.	0.0
981237704	769174400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174400	19159907	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.	1.75
981237704	769173710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173710	16013960	Allele G is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-1.25
981202646	699638567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638567	18180754	Genotypes AA + AG are associated with decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG.	1.5
981202674	827849062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849062	22391769	Allele A is associated with increased methylation at sites 1 and 2 in the COMT promoter when treated with antipsychotics in people with Schizophrenia as compared to allele G.	1.75
981204525	769258433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769258433	20634689	Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT.	2.25
981204525	827825848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825848	21343546	Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT.	2.0
981204525	769166427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166427	19307503	Genotype GG is associated with decreased progression free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	0.0
981204525	1449752421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752421	29662106	Allele G is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.5
981204864	1445296870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296870	25331073	Genotype GG is associated with decreased event-free survival and overall survival when treated with capecitabine, fluorouracil or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.	3.75
981204864	769261454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769261454	20385995	Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.	0.0
981204864	769166385	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769166385	20078613	Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.	2.5
981204864	1449718603	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718603	29845393	Genotypes GG + GT is not associated with event-free survival when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-1.5
981204874	1444930241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930241	26010901	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	-1.5
981204874	1447814266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814266	25950378	Allele A is not associated with likelihood of cessation when treated with Drugs used in nicotine dependence in people with Tobacco Use Disorder as compared to allele G.	-1.0
981204874	827921955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921955	22648373	Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.	2.0
981204874	1184168936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168936	24733007	Genotypes AA + AG is not associated with likelihood of abstinance when treated with nicotine in smokers as compared to genotype GG.	-2.0
981204874	1450928770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928770	29621993	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.	2.25
981204874	1450928777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928777	29621993	Allele A is not associated with response to bupropion, nicotine or varenicline in men with Tobacco Use Disorder as compared to genotype GG.	-1.75
981204874	827921971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921971	22648373	Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.	2.5
981204874	827921996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921996	22648373	Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.	2.5
981204874	1450822293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822293	26142345	Allele G is not associated with response to varenicline in people with Tobacco Use Disorder as compared to allele A.	-2.0
981204874	1450822299	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822299	26142345	Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.	3.25
981204874	1449156009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449156009	29196725	Allele A is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele G.	-1.75
981238057	769250973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250973	18377430	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.	1.25
981238092	827824085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824085	22188362	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	-1.5
981238092	827824096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824096	22188362	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	-1.5
981238092	769257721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257721	16753003	Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.	-1.0
981238092	769257727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257727	16753003	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.	0.0
981238092	769146001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146001	20417680	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	-1.5
981238092	769171324	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171324	19450124	Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.	2.25
981238092	769171331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171331	19450124	Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.	2.75
981238092	769171327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171327	19450124	Allele C is associated with protection from drug resistance when treated with antiepileptics in men with Epilepsy.	2.5
981238108	827807741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807741	18334914	Allele A is associated with increased serum concentrations digoxin as compared to allele C.	0.0
981238108	827925294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925294	12189368	Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.	1.0
981238562	1451506360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506360	23198157	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	0.0
981238562	1451547020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451547020	27104192	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.	-1.0
981238562	1451552740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552740	32612964	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.5
981238562	1451553477	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451553477	32695297	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-0.75
981238562	1451615140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615140	33501733	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.0
981238562	769171040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171040	12411325	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.0
981238562	769171073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171073	17264302	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-0.5
981238562	769174318	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769174318	15797993	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.	-0.0
981238562	769171138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171138	20335220	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.5
981238562	1184513986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513986	24241962	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.	-0.75
981238562	1296598928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598928	25303299	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-0.125
981238562	1445585706	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445585706	24597986	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	-1.0
981238562	1449003351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003351	28525903	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-1.25
981238562	1450045175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045175	29791011	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	-1.0
981238910	827892722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892722	16595597	Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.	2.5
981345277	982029700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029700	23314736	Genotype CC is associated with decreased risk of Peripheral Nervous System Diseases when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.	2.25
981345277	982029713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029713	23314736	Genotype CC is associated with later onset of sensory neuropathy when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.	0.75
981202046	1451673080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451673080	34476898	Allele G is associated with decreased metabolism of nicotine as compared to allele A.	0.0
981202046	769278059	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769278059	11779172	Allele G is associated with decreased metabolism of nicotine as compared to allele A.	0.125
981202046	769278041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769278041	12445030	Allele G is associated with decreased metabolism of nicotine as compared to allele A.	0.0
981345285	655386624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386624	19786980	Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CT + TT.	3.0
981345285	827828058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828058	22188361	Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.25
981345285	827828072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828072	22188361	Genotypes CT + TT are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-2.0
981345285	827828226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828226	22188361	Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	0.0
1448256098	1451447360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451447360	31792371	Genotype TT is associated with increased risk of adverse events when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.75
1448256098	1448256037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256037	27452984	Genotype TT is associated with increased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.75
981345311	769171454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171454	19374892	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.	This annotation is not used for clinical annotation scoring. drug drug interaction
1184654135	1184470840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470840	24858023	HLA-B *48:01:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	2.75
1184654135	1184746938	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746938	19002350	HLA-B *48:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol or carbamazepine in people with severe cutaneous adverse reactions.	0.25
1184654135	1184757402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184757402	23669020	HLA-B *48:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	-0.25
1184654135	1184989404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989404	21912425	HLA-B *48:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	-2.0
1447814482	1447520868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520868	25412950	Genotype AA is associated with increased response to desloratadine and mizolastine in people with Urticaria as compared to genotypes AG + GG.	2.0
1447943646	1447678959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678959	25730470	Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	2.0
1448100370	1184407264	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184407264	18605963	Genotype AG is associated with increased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype GG.	0.0
1448100382	1184407240	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184407240	18605963	Genotype AT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype AA.	0.0
1448100389	1447987701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987701	27092952	Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.	2.5
1448100396	981477824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477824	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	2.25
1448100404	1447988304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447988304	27096233	Genotypes AG + GG are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype AA.	2.25
1448100426	1447988330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447988330	27096233	Genotypes CC + CT are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype TT.	2.25
1448104131	1444706762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706762	21572301	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG.	2.25
1448104131	1444706772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706772	21572301	Genotype GG is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG.	-0.25
1448264442	1448264419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264419	27027531	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.25
1448573512	1448573220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448573220	28117133	CYP2C19 poor metabolizer genotype is associated with increased severity of Hypertension when exposed to 3,4-methylenedioxymethamphetamine in healthy individuals as compared to CYP2C19 intermediate metabolizer and normal metabolizer.	0.5
1448616845	1183681981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681981	23736036	Allele A is not associated with risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele C.	-1.5
1448616845	1184471998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471998	24167597	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AC.	-1.75
1448616845	1448616210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616210	28347776	Genotypes AC + CC are associated with decreased likelihood of hand-foot syndrome and Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	3.75
1448616870	1448616804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616804	28347776	Genotypes CC + CT are associated with decreased likelihood of Nausea and Vomiting when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	2.75
1448616910	1448616794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616794	28347776	Genotypes CT + TT are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1448624459	1448624236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624236	29100455	Allele G is associated with increased likelihood of Leukopenia and Neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.	2.5
1448624459	1448624256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624256	29100455	Allele G is not associated with likelihood of Leukopenia and Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to allele A.	-2.0
1449144358	1449144262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144262	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1449144370	1449144274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144274	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144376	1449144280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144280	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144382	1449144286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144286	29121268	Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144396	1448926344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448926344	28796378	Allele A is associated with increased response to fluorouracil, Platinum compounds or radiotherapy in people with Stomach Neoplasms as compared to allele C.	2.5
1449155607	1449155451	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155451	28696418	Genotypes CT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	3.0
981202230	1450821580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821580	19384296	Allele TTAAAGTTA is not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms.	-1.5
981202230	1450821641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821641	20714149	Genotypes TTAAAGTTA/del + del/del are associated with increased risk of Hyperammonemia when treated with fluorouracil in people with Pancreatic Neoplasms and Stomach Neoplasms.	0.25
981202230	1450821668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821668	28427087	Allele del is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele TTAAAGTTA.	-2.0
981202230	1451254600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451254600	32695278	Genotype TTA/TTA is associated with increased severity of Neurotoxicity Syndromes when treated with FOLFOX in people with Neoplasms as compared to genotypes TTA/TTAAAGTTA + TTAAAGTTA/TTAAAGTTA.	1.75
981202230	1450821594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821594	23736036	Genotype TTA/TTA is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1449155614	1449155414	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155414	28696418	Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	3.25
1449155625	1449155460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155460	28696418	Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA.	3.0
1449155631	1449155401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155401	28696418	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA.	3.75
1449155637	1449155387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155387	28696418	Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype CC.	3.75
1449155643	1449155370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155370	28696418	Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	2.75
1449155649	1449155430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155430	28696418	Genotypes AT + TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	3.25
1449156117	1448926169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926169	28819312	HLA-B *15:12 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449164603	1449164364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164364	28485375	Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.	2.5
1449192303	1183699587	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183699587	21976485	Genotype del/del is associated with increased transport of CFTR when treated with lumacaftor in human bronchial epithelial cells.	0.0
1449192303	1183699603	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699603	21825083	Genotype del/del is associated with increased change in sweat chloride when treated with lumacaftor in people with Cystic Fibrosis.	1.5
1449192303	1449192125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192125	26137539	Genotype del/del is associated with response to lumacaftor.	This annotation is not used for clinical annotation scoring. In vitro study
1449566691	1449566398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566398	29844858	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.75
1449566691	1449566516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566516	29844858	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	-1.0
1449575745	827845911	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845911	22248286	Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G.	-1.75
1449575745	1444666251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666251	25312789	Allele A is associated with increased dose of warfarin as compared to allele G.	2.0
1449575745	1449190785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190785	29432897	Allele A is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele G.	-1.75
1449575745	1449575721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575721	29875668	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	0.0
1449576622	1449576231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576231	29785580	Allele A is associated with increased likelihood of Rhabdomyolysis when treated with HMG CoA reductase inhibitors, other combinations in people with Cardiovascular Diseases as compared to allele G.	1.0
1449713649	1449713634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713634	30071039	Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	2.5
1449713660	1449713624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713624	30071039	Allele A is associated with increased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	2.5
1449713666	1449713612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713612	30071039	Allele C is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	3.0
1449713676	1449713618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713618	30071039	Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	2.5
981238437	827826832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826832	14707031	Allele C is associated with increased risk of acute gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib or diclofenac as compared to allele A.	2.25
981238437	827826844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826844	17681167	Allele C is associated with increased risk of gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib, diclofenac, ibuprofen, naproxen or piroxicam as compared to allele A.	1.25
1449191740	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191740	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191740	1449191083	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191083	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449713682	1449713604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713604	30071039	Allele G is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.	2.5
1450373589	982046272	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046272	23272163	Genotype GG is associated with decreased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	0.5
1450373589	1450933658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450933658	30713339	Allele A is not associated with risk of Drug Toxicity and cessation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.	-1.75
1450373589	1449179077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449179077	29427770	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	1.25
1450373589	1450373569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373569	30237583	Genotype GG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.	1.5
1450373595	1450373404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373404	30237583	Genotypes AA + AG is associated with increased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.	2.5
1450373604	1450373412	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373412	30237583	Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.	2.0
1450814557	1450814545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814545	22882391	Allele C is associated with decreased severity of Cocaine-Related Disorders due to cocaine as compared to allele A.	1.5
1450814659	1450814610	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814610	22947179	Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.75
1450814665	1450814619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814619	22947179	Genotype GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CG.	2.25
1450814822	1450814771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814771	23007012	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.	1.5
1450814923	981481498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481498	12610044	Allele G is not associated with efficacy of pioglitazone when treated with pioglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	-1.5
1450814923	1450814898	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814898	23147557	Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.75
1450815142	1450815058	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815058	23241943	Allele G is associated with increased response to quetiapine in people with Schizophrenia as compared to allele A.	0.0
1450815166	1450815030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815030	23241943	Allele C is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1451323336	1183684626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684626	19281600	CYP2D6 poor metabolizer phenotype is associated with decreased reduction in pain AUC when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.75
1451323336	1451153666	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153666	11207001	CYP2D6 poor metabolizer phenotype is associated with decreased response to oxycodone in women with Neoplasms and Pain as compared to CYP2D6 normal metabolizer phenotype.	0.125
1451323336	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451323336	1183617884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617884	20590588	CYP2D6 *4/*4 is associated with decreased pain tolerance in cold pressor test when treated with oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.25
1451323336	1183617893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617893	20590588	CYP2D6 *1/*2xN is associated with increased pain tolerance in cold pressor test when treated with oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.25
1451323336	1183617913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617913	16631290	CYP2D6 *4/*6 is associated with intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief) when treated with oxycodone and tramadol.	0.25
1451323336	1183617932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617932	8803381	CYP2D6 *4/*4 is associated with decreased response (pain relief) to oxycodone when treated with oxycodone as compared to CYP2D6 *1/*1.	0.25
1451323336	1183621807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621807	21735164	CYP2D6 *4/*4 + *3/*4 is not associated with oxycodone pharmacodynamics (pain intensities, nausea, tiredness and cognitive function) when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	-1.75
1451323336	1183621819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621819	21735164	CYP2D6 *4/*4 + *4/*6 is not associated with oxycodone pharmacodynamics (pain intensities, nausea, tiredness and cognitive function) when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	-1.75
1451323336	1183621840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621840	19719813	CYP2D6 *3/*4 + *4/*4 are not associated with the efficacy of ocycodone when treated with oxycodone as compared to CYP2D6 *1/*1.	-1.75
1451323336	1183681894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681894	17986163	CYP2D6 *4/*4 is associated with decreased response to hydromorphone, ketorolac, morphine, opioids or oxycodone in women.	0.25
1449004733	1448617058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617058	28422153	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.	0.0
1449004739	1448617000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617000	28422153	Genotypes GG + GT are associated with decreased overall survival and progression-free survival when treated with cisplatin and gemcitabine in people with Mesothelioma as compared to genotype TT.	0.0
1449004745	1448617035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617035	28422153	Genotypes AA + AC are associated with decreased overall survival and progression-free survival when treated with cisplatin and gemcitabine in people with Mesothelioma as compared to genotype CC.	0.0
1449005041	1449003493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003493	28673292	Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.	1.25
1449005041	1449003659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003659	28673292	Allele C is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele T.	-1.25
1449005047	1449003545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003545	28673292	Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.	0.0
1449005047	1449003637	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003637	28673292	Allele T is associated with decreased response to lumefantrine in women with Malaria and Pregnancy as compared to allele C.	1.75
1449645432	1449639804	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449639804	29705271	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1449645438	1449645263	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645263	29705271	Allele T is associated with decreased sulfation of morphine as compared to allele C.	0.0
1449645444	1449645267	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645267	29705271	Allele T is associated with decreased sulfation of tapentadol as compared to allele C.	0.0
1449645450	1449645271	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645271	29705271	Allele T is associated with decreased sulfation of o-desmethyltramadol as compared to allele C.	0.0
1449645456	1449645185	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645185	29705271	Allele G is associated with decreased sulfation of acetaminophen as compared to allele A.	0.0
1449645462	1449645279	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645279	29705271	Allele G is associated with decreased sulfation of tapentadol as compared to allele A.	0.0
1449645468	1449645283	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645283	29705271	Allele G is associated with decreased sulfation of o-desmethyltramadol as compared to allele A.	0.0
1449645474	1449645191	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645191	29705271	Allele G is associated with decreased sulfation of acetaminophen as compared to allele T.	0.0
1449645480	1449645287	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645287	29705271	Allele G is associated with decreased sulfation of morphine as compared to allele T.	0.0
1449645486	1449645291	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645291	29705271	Allele G is associated with decreased sulfation of tapentadol as compared to allele T.	0.0
1449645492	1449645295	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645295	29705271	Allele G is associated with decreased sulfation of o-desmethyltramadol as compared to allele T.	0.0
1449645498	1449645195	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645195	29705271	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1449645498	1449645199	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645199	29705271	Allele A is associated with increased sulfation of acetaminophen as compared to allele C.	0.0
1449645507	1449645318	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645318	29705271	Allele A is associated with increased sulfation of morphine as compared to allele C.	0.0
1449645513	1449645310	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645310	29705271	Allele T is associated with decreased sulfation of tapentadol as compared to allele C.	0.0
1449645513	1449645322	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645322	29705271	Allele A is associated with increased sulfation of tapentadol as compared to allele C.	0.0
1449645522	1449645314	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645314	29705271	Allele T is associated with decreased sulfation of o-desmethyltramadol as compared to allele C.	0.0
1449645522	1449645326	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645326	29705271	Allele A is associated with increased sulfation of o-desmethyltramadol as compared to allele C.	0.0
1449645531	1449645212	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645212	29705271	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1449645537	1449645330	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645330	29705271	Allele T is associated with decreased sulfation of morphine as compared to allele C.	0.0
1449718242	1449718142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718142	29507678	Genotype CC is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.	2.25
1449718248	1449718005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718005	29507678	Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.	2.75
1449718259	827811231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811231	20179710	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.	2.0
1449718259	1449718168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718168	29507678	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.	2.25
1451228960	1449266539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266539	17178267	CYP3A5 *3 is not associated with concentrations of methadone in people with Opioid-Related Disorders.	-1.0
1451228960	1449271538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271538	18460585	CYP3A5 *1/*3 is associated with decreased concentrations of methadone.	-0.125
1451228960	1451161660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161660	21589866	CYP3A5 *3/*3 is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP3A5 *1/*1 + *1/*3.	-1.0
1451228960	1451228740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228740	28723731	CYP3A5 *3/*3 is associated with increased concentrations of methadone as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451229400	1183702909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702909	16338275	CYP2C19 poor metabolizer is not associated with methadone plasma levels when treated with methadone as compared to CYP2C19 normal metabolizer.	-0.5
1451229400	1449266489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266489	17178267	CYP2C19 *2 + *3 are not associated with concentrations of methadone in people with Opioid-Related Disorders.	-1.0
1451229400	1451161695	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161695	21589866	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2C19 *1/*1.	-1.0
1451229400	1451228820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228820	28723731	CYP2C19 *1/*2 + *1/*3 are associated with increased concentrations of methadone as compared to CYP2C19 *1/*1.	1.25
1451229400	1451228826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228826	28723731	CYP2C19 *2/*2 is not associated with concentrations of methadone as compared to CYP2C19 *1/*1.	-0.75
1451323205	1449002826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002826	23783165	CYP2D6 normal metabolizer genotype is not associated with risk of cns depression in infants when treated with oxycodone in women.	-0.625
1451323205	1449002834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002834	23783165	CYP2D6 ultrarapid metabolizer genotype is not associated with risk of cns depression in infants when treated with oxycodone in women.	-0.625
1451323205	1449002847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002847	23783165	CYP2D6 poor metabolizer genotype is not associated with risk of cns depression in infants when treated with oxycodone in women.	-0.625
1451323205	1451405781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451405781	33799050	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with likelihood of Drug Toxicity when exposed to oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	-0.75
1451323205	1183617913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617913	16631290	CYP2D6 *4/*6 is associated with intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief) when treated with oxycodone and tramadol.	0.25
1451323205	1183617941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617941	12920424	CYP2D6 *1/*2xN is associated with increased risk of Drug Toxicity when treated with codeine, hydrocodone or oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.0
1451323205	1183621807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621807	21735164	CYP2D6 *4/*4 + *3/*4 is not associated with oxycodone pharmacodynamics (pain intensities, nausea, tiredness and cognitive function) when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	-1.75
1451323205	1183621819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621819	21735164	CYP2D6 *4/*4 + *4/*6 is not associated with oxycodone pharmacodynamics (pain intensities, nausea, tiredness and cognitive function) when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	-1.75
1451323205	1183617950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617950	20590588	CYP2D6 *1/*2xN is associated with increased side effects when treated with oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.25
1451352420	1451352260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451352260	31755291	Genotype AG is associated with increased likelihood of adverse events due to sufentanil in people with Pain, Postoperative as compared to genotype AA.	2.25
1451352420	1450932053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932053	30455395	Allele G is not associated with likelihood of adverse events due to sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele A.	-1.5
1451352420	1451134720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134720	31773688	Genotypes AG + GG are not associated with risk of adverse events due to oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA.	-1.25
1451229340	1183702904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702904	16338275	CYP2C9 poor metabolizer is not associated with methadone plasma levels when treated with methadone as compared to CYP2C9 normal metabolizer.	-0.5
1451229340	1449266467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266467	17178267	CYP2C9 *2 + *3 are not associated with concentrations of methadone in people with Opioid-Related Disorders.	-1.0
1451229340	1451161652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161652	21589866	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2C9 *1/*1 + *1/*2.	-1.0
1451229340	1451228747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228747	28723731	CYP2C9 *1/*2 + *1/*3 are associated with increased concentrations of methadone as compared to CYP2C9 *1/*1.	1.25
1451229340	1451228780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228780	28723731	CYP2C9 *2/*2 + *3/*3 are not associated with concentrations of methadone as compared to CYP2C9 *1/*1.	-0.75
1451358900	1451354947	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354947	20207952	Genotypes CC + CT are not associated with decreased response to rosuvastatin as compared to genotype TT.	-1.75
1451358900	1451357220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451357220	22331829	Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.	0.0
1451358900	1451164700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451164700	31857620	Genotypes CC + CT are associated with response to rosuvastatin as compared to genotype TT.	0.25
1451358900	827922656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922656	22668755	Allele T is not associated with LDL-C response when treated with rosuvastatin in people with Coronary Disease as compared to allele C.	-1.5
1451244740	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1451244740	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451244740	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451244740	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451244740	1451341160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451341160	19833260	SLCO1B1 *5 is not associated with increased risk of Drug Toxicity when treated with pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.	-1.5
1451253200	1184511241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511241	24014145	CYP2C19 poor metabolizers is not associated with response to escitalopram or venlafaxine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	-0.625
1451253200	1448624911	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624911	28480819	CYP2C19 poor metabolizer genotype is associated with increased response to venlafaxine in people with Depression.	0.0
1451253200	1184169426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169426	23545896	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	-1.5
1451350580	827828815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828815	17083032	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.	2.0
1451350580	827828723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828723	19400747	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.	-1.5
1451350580	1444667396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667396	25485598	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.	-1.25
1451254826	1451506220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506220	23198157	Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	-2.0
1451254826	655387954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387954	12411325	Allele T is associated with worse prognoses when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.0
1451254826	1447675044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675044	25778468	Genotype CC is associated with increased overall survival when treated with methotrexate in people with Osteosarcoma as compared to genotype TT.	1.75
1451254826	1448126131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448126131	27409003	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-2.25
1451254826	1449002970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002970	28525903	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.75
1451254820	655386401	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386401	12915598	Allele C is not associated with Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.25
1451254820	1451506340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451506340	23198157	Genotype CC is associated with decreased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	0.0
1451254820	1451547111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451547111	27104192	Genotypes CT + TT are associated with decreased risk of mucositis due to methotrexate in children with Osteosarcoma as compared to genotype CC.	2.0
1451254820	1451552820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451552820	32612964	Genotype TT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	0.0
1451254820	1451553487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553487	32695297	Genotype CT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.75
1451254820	827698259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698259	21747412	Genotype CC is associated with increased severity of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	-3.0
1451254820	769170747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170747	16462575	Allele C is associated with increased vomiting when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-0.25
1451254820	769171098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171098	17180579	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.5
1451254820	1184514077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514077	24241962	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.	-0.75
1451254820	1296598758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598758	25303299	Genotype TT is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.25
1451254820	1445585698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445585698	24597986	Genotype TT is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	-1.0
1451254820	1449003063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449003063	28525903	Genotypes CC + CT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.75
1449167568	1449166351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166351	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449005195	1449005185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005185	29054760	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
1449167086	1449167014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449167014	20032820	Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.	2.0
1449167086	1449167021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449167021	20032820	Allele G is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.	-1.5
1449167093	1449167052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449167052	20032820	Allele C is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele T.	2.0
1449167093	1449167060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449167060	20032820	Allele C is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele T.	-1.5
1449168307	1449168118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168118	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168314	1449168112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168112	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168621	1449168283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168283	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1450375674	1450375604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375604	30924126	Allele A is associated with increased response to allopurinol as compared to allele G.	0.0
1450375680	1450375544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375544	30924126	Allele G is associated with increased response to allopurinol as compared to allele A.	0.0
1450375686	1450375594	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375594	30924126	Allele G is associated with increased response to allopurinol as compared to allele A.	0.0
1450376133	1450376100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376100	24909733	Genotype TT is associated with increased dose of morphine in children with Pain, Postoperative as compared to genotypes CC + CT.	0.0
1450810451	1450810440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810440	16679777	Genotype GG is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AA + AG.	2.5
1450810451	1450811230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811230	15902904	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	2.25
1450044809	1450044757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450044757	29873816	Genotype GG is associated with decreased concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes AA + AG.	0.25
1450112772	1450045257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045257	29791011	Genotypes GG + GT are associated with decreased clearance of methotrexate in people with Osteosarcoma as compared to genotype TT.	0.0
1450112778	1450045157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045157	29791011	Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.	2.0
1450112789	1450045121	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045121	29791011	Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.	2.0
1450820971	1450820931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820931	24498031	Genotype GG is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotypes AA + AG.	0.0
1450928829	1450928764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928764	29621993	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.	2.25
1451397762	1451360203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451360203	33190395	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.	2.75
1449753234	1449753147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449753147	29955115	Genotype CT is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.	1.75
1451397780	1451360203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451360203	33190395	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.	2.75
1450806874	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1450806874	PA166104987	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104987		Annotation of DPWG Guideline for lansoprazole and CYP2C19	100
1450806874	1450806823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806823	9164419	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1450806874	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1450806874	982047056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047056	22076562	CYP2C19 *17/*17 is associated with increased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.25
1450806874	982047065	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047065	22076562	CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.75
1450806874	982047769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047769	23623526	CYP2C19 *2 + *3 + *8 + *9 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of lansoprazole in children with Asthma as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.25
1450806874	1183618547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618547	11929404	CYP2C19 *1/*1 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	1.5
1450806874	1183618564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618564	11929404	CYP2C19 *1/*2 + *1/*3 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	1.0
1450806874	1183618805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618805	12386647	CYP2C19 *1/*1 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.	1.75
1450806874	1183618830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618830	12386647	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.	1.25
1450806874	1183623395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623395	18241283	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.125
1450806874	1183629838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629838	22076562	CYP2C19 *1/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.	1.25
1450806874	1183629846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629846	22076562	CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*2.	1.25
1450806874	1450806845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806845	9272410	CYP2C19 *2/*2 + *2/*3 are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1450806874	1450809629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809629	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1451400040	1451406100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406100	33812699	CYP2C8 poor metabolizer and intermediate metabolizer genotypes are not associated with response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 normal metabolizer genotype.	-0.75
1451400040	1451399960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451399960	33205280	CYP2C8 *2/*3 + *3/*4 are associated with decreased response to ibuprofen in people with Pain, Postoperative as compared to CYP2C8 *1/*1.	0.0
981237959	769261451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261451	20385995	Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.	2.75
981237959	655388448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388448	18267032	Genotypes GG + GT are associated with increased risk of Recurrence when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.	3.0
981237959	769166392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166392	20078613	Genotypes GT + TT are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	0.0
981478131	981478047	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478047	22682551	Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.	3.0
981478131	981478059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478059	22682551	Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.	0.0
1449715584	1449715511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715511	28256933	Genotype TT is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes GG + GT.	0.0
1450376188	1450376171	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376171	22264780	Genotypes CT + TT is associated with increased risk of Diabetes Mellitus, Type 2 when treated with tacrolimus in people with heart transplantation or Kidney Transplantation as compared to genotype CC.	2.75
1450932697	1450932643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932643	30549211	Genotype CT is associated with decreased likelihood of Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes CC + TT.	2.75
1450934506	1450934431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934431	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934515	1450934449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934449	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934525	1450934437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934437	30723321	Allele A is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934678	1450934362	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934362	30723321	Allele G is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934761	1450934734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934734	30728528	Allele del is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele GGAGTC.	2.5
1450935844	1450935720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935720	30745309	Allele A is associated with decreased clearance of mephenytoin as compared to allele G.	1.0
1450936242	1450936105	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936105	30822619	Allele A is associated with decreased sulfation of tapentadol as compared to allele G.	0.0
1450936747	1450936711	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936711	31002879	Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype TT.	1.5
1451397860	1451360140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451360140	33190395	Genotype AG is associated with decreased response to gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.	3.25
981204641	1451356461	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451356461	32561311	Genotype GG is associated with decreased sensitivity to ethanol in iPS-derived neurons as compared to genotype AA.	0.0
981204641	827806034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827806034	21900886	Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.	1.5
981204641	769171525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171525	17339526	Allele G is associated with increased alcohol response, consumption, and preference when exposed to ethanol.	0.0
981204641	769171518	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171518	15608594	Allele G is associated with increased subjective feelings of intoxication, stimulation, sedation, and happiness when exposed to ethanol as compared to allele A.	0.5
981204641	1450811650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811650	18433502	Allele G is not associated with response to ethanol as compared to allele A.	-2.75
981204641	1450812611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812611	20141248	Genotypes AG + GG are associated with increased response to ethanol as compared to genotype AA.	3.0
981204641	1450812854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812854	20479755	Genotype AG is associated with increased response to ethanol in men as compared to genotype AA.	2.0
981204641	1450814947	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814947	23240711	Allele G is associated with increased response to ethanol in people with Alcoholism as compared to allele A.	2.75
981204641	1450820473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820473	23876228	Genotype AG is associated with increased response to ethanol in people with Alcoholism as compared to genotype AA.	0.25
981204641	1450822034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822034	25937240	Genotype AG is associated with increased response to ethanol in people with Alcoholism as compared to genotype AA.	1.25
981204641	1450823384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823384	26125586	Genotypes AG + GG are associated with increased response to ethanol in people with Alcoholism as compared to genotype AA.	0.0
981204641	1450824374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824374	28273335	Genotypes AG + GG are not associated with response to ethanol as compared to genotype AA.	-0.75
981204641	1450826531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826531	28376280	Allele G is not associated with response to ethanol in healthy individuals as compared to allele A.	-0.5
981204641	1449161170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161170	22551036	Allele A is not associated with response to ethanol in people with Alcoholism as compared to allele G.	-1.25
981204641	1450371982	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371982	29497164	Allele G is not associated with response to ethanol in healthy individuals as compared to allele A.	-1.5
981204941	769245627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245627	20647221	Genotype CC is associated with increased likelihood of any grade 3 adverse event when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes CG + GG.	2.25
981204941	1451254100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451254100	28347333	Genotype CC is associated with increased severity of Diarrhea or Drug Toxicity when treated with leucovorin and tegafur in people with Rectal Neoplasms as compared to genotypes CG + GG.	2.75
1450935832	1450935671	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935671	30745309	Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.	0.0
1450935832	1450935725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935725	30745309	Allele T is associated with decreased clearance of mephenytoin as compared to allele C.	1.0
1450935850	1450935745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935745	30745309	Allele G is associated with decreased clearance of mephenytoin as compared to allele A.	0.125
1450935917	1450935868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935868	30817003	Genotype AA is associated with increased risk of Drug Toxicity due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotypes AG + GG.	2.25
1450936195	1450936141	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936141	30822619	Allele T is associated with decreased sulfation of tapentadol as compared to allele C.	0.0
1450936260	1450936114	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936114	30822619	Allele C is associated with decreased sulfation of tapentadol as compared to allele A.	0.0
1450936296	1450936075	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936075	30822619	Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.	0.0
1450936563	1450936536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936536	30840592	Genotypes CC + CG are associated with increased risk of Leukopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.	2.0
1451397880	1451360140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451360140	33190395	Genotype AG is associated with decreased response to gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.	3.25
982031741	769164769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164769	17687269	Allele T is associated with increased AUC of valproic acid in healthy individuals no disease as compared to allele C.	0.0
982031741	1448634988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634988	23099353	Genotype CC is not associated with metabolism of valproic acid in children with Epilepsy.	-0.75
982031741	1449169100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169100	29243113	Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	1.0
982031741	1449169116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169116	29243113	Genotype CT is not associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	-0.75
982030998	982030940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030940	23556445	Genotype CC is associated with increased likelihood of responding to treatment when treated with hydroxyurea in people with Thalassemia.	2.0
982040494	982009519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982009519	23619509	Genotype TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.5
982040494	827815008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815008	21338649	Allele T is not associated with response to paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	-1.5
1043880476	981785354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785354	23407050	Allele C is associated with increased major cardiovascular events (MACE) rate when treated with Ace Inhibitors, Plain in people with Coronary Artery Disease as compared to allele A.	2.5
982032756	981954037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954037	21781277	Allele G is not associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	-1.75
982032756	699639163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639163	21047205	Genotype GG is associated with increased risk of sleep disturbances when treated with lithium in people with Bipolar Disorder.	0.25
982034111	1184511609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511609	25042728	Genotypes CG + GG is not associated with dose of acenocoumarol as compared to genotype CC.	-2.75
982034111	1444699610	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699610	25519826	Allele G is associated with decreased dose of acenocoumarol as compared to allele C.	2.5
982034111	1444708155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708155	24927344	Genotype CG is not associated with dose of acenocoumarol as compared to genotype CC.	-1.5
982034111	1449190777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190777	29432897	Allele G is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
982037571	981844064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844064	18004210	Genotypes CT + TT are not associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	-2.0
982037571	982033401	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033401	16645157	Genotypes CT + TT are associated with reduced GP IIb/IIIa activation and lower platelet activation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	1.75
982037571	982033457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033457	17697139	Allele C is not associated with clopidogrel responsiveness when treated with clopidogrel in healthy individuals as compared to allele T.	-0.25
982037571	982034297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034297	19576320	Genotypes CT + TT are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype CC.	-1.75
982037571	1183699721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699721	24262617	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-1.0
982037571	1184349602	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349602	24140730	Genotype CC is not associated with increased P2Y12 reaction unit(PRU) values when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotypes CT + TT.	-0.5
982037571	1450823997	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823997	26891871	CYP3A4 *1/*36 is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to CYP3A4 *1/*1.	-1.25
982037571	1448633769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633769	28135763	CYP3A4 *36 is not associated with response to clopidogrel as compared to CYP3A4 *1/*1.	-1.75
1451397872	1451360210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451360210	33190395	Genotype AG is associated with increased dose of gabapentin in people with neuropathic pain as compared to genotype GG.	2.25
1043858980	982035187	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035187	18417193	Genotypes CT + TT are associated with increased response to aspirin in men as compared to genotype CC.	1.75
1043858980	982048049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048049	17245331	Genotype CC is associated with increased risk of aspirin resistance when treated with aspirin in healthy individuals as compared to genotypes CT + TT.	2.0
1183617979	1183684630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684630	19281600	CYP2D6 poor metabolizer phenotype is associated with decreased plasma oxymorphone/oxycodone ratio when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.75
1183617979	1449003184	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003184	20590587	CYP2D6 poor metabolizer genotype is associated with increased exposure to oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.5
1183617979	1451153660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153660	11207001	CYP2D6 poor metabolizer phenotype is associated with increased concentrations of noroxycodone and oxycodone in women with Neoplasms and Pain as compared to CYP2D6 normal metabolizer phenotype.	0.0625
1183617979	1451405702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451405702	33799050	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased concentrations of noroxycodone or oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	1.0
1183617979	1451647381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647381	34480108	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	1.25
1183617979	1183621778	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621778	21735164	CYP2D6 *4/*4 + *3/*4 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	2.25
1183617979	1183621795	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621795	21735164	CYP2D6 *4/*4 + *4/*6 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.	2.25
1183617979	1183621831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621831	19719813	CYP2D6 *4/*4 + *3/*4 is associated with mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio when treated with oxycodone as compared to CYP2D6 *1/*1.	2.25
1183617979	1184473395	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473395	23555934	CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7 (assigned as poor metabolizer phenotype) is associated with decreased Mean oxymophone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .	2.0
1183617979	1451155460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155460	12422998	CYP2D6 *4 is associated with increased concentrations of oxycodone.	This annotation is not used for clinical annotation scoring.
1183617979	1451159180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159180	19755414	CYP2D6 *1/*1xN is associated with decreased exposure to oxycodone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41.	0.125
1043880659	769256246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769256246	21430602	Allele A is associated with increased risk of Oligospermia when treated with Alkylating Agents and cisplatin in people with childhood cancer as compared to genotype GG.	2.5
1043880680	827789595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827789595	18346175	Allele del is associated with increased risk of extrapyramidal symptoms when treated with antipsychotics as compared to genotype AA.	3.25
1127092670	655387809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387809	20360315	Allele A is associated with decreased improvement of depression symptoms when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotype GG.	0.0
1153928101	827814624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814624	21946896	Allele C is associated with worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative when treated with cyclophosphamide and doxorubicin in people with Breast Neoplasms as compared to allele T.	2.5
1153928101	1449576854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576854	29938344	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	-1.5
1183491157	982044075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044075	15284534	Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.	1.5
1183491278	981419580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419580	15900215	CYP3A5 *3/*3 is associated with increased serum creatine kinase levels (increased risk of myalgia and greater degree of muscle damage) when treated with atorvastatin as compared to CYP3A5 *1/*3.	1.75
1183491278	982044254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044254	18727922	CYP3A5 *3/*3 is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1A/*1A + *1A/*3.	1.75
1183491278	982048117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048117	17289397	CYP3A5 *1/*3 is not associated with lipid response when treated with atorvastatin or simvastatin as compared to CYP3A5 *3/*3.	-1.25
1183491278	982048088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048088	17289397	CYP3A5 *3 is not associated with likelihood of myopathy when treated with atorvastatin or simvastatin as compared to CYP3A5 *1.	-1.25
1183491380	982045481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045481	16002074	Genotype AA is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AT.	1.75
1183681866	981679623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981679623	23392654	Genotypes AA + AG are associated with increased risk of Myocardial Infarction when treated with aspirin as compared to genotype GG.	2.25
1183682421	1450815197	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815197	23332809	CYP2C19 *2/*2 is associated with decreased metabolism of venlafaxine.	0.125
1451397900	1447521257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521257	26599303	HLA-B *38:02:01 is not associated with risk of Agranulocytosis when treated with propylthiouracil in people with Graves Disease.	-0.5
1451397900	1447521290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521290	26151496	HLA-B *38:02:01 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.	3.5
1183614605	982036232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036232	16765146	Genotypes AA + AG are associated with increased response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	3.5
1183614605	982036265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036265	16765146	Genotypes AA + AG are not associated with response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.	-2.0
1183630286	827641630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641630	16875718	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.	1.5
1183631480	1183491726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491726	22725663	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.	1.5
1183693390	981859074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859074	20235791	HLA-B *13:01:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	2.5
1183693390	1184989197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989197	25096692	HLA-B *13:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.	-1.5
1183693390	1448614832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614832	28391407	HLA-B *13:01:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to HLA-B *07:02:01.	3.5
1183693390	1448614847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614847	28391407	HLA-B *13:01:01 is not associated with likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to HLA-B *07:02:01.	-1.5
1183693395	1183680923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680923	23692434	HLA-B *58:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.	2.5
1183697747	1183682339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682339	23417334	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotypes CT + TT.	1.25
1183697752	1183682332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682332	23417334	Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.	2.25
1183697752	1446898150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898150	25939711	Allele A is not associated with steady-state concentration of metformin in healthy individuals as compared to allele C.	-0.125
1183698846	982046735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046735	23127916	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	2.25
1183700503	981344223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344223	22907731	Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.	3.75
1183700536	827836688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827836688	20538124	Genotypes AA + AG are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype GG.	3.25
1183689114	1183688841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688841	23526481	CYP2D6 *2/*10 is associated with increased agitation and insomnia when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity.	0.25
1451397920	1183617434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617434	18070221	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	2.5
1183700383	1183700296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700296	24279851	Genotype AA is associated with increased risk of uncontrolled asthma when treated with corticosteroids in children with Asthma as compared to genotype GG.	2.75
1183700383	1447680633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680633	26774659	Allele A is not associated with response to corticosteroids in children with Asthma as compared to genotype GG.	-1.0
1183700522	769173723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173723	19861437	Genotypes CT + TT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1183701234	1183701152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701152	24236482	HLA-B *51:01:01 is associated with Stevens-Johnson Syndrome when treated with phenobarbital.	3.5
1183700891	1183700867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700867	24279859	Allele C is not associated with risk of addiction due to ethanol, heroin, methamphetamine and nicotine as compared to allele T.	-0.0
1183700891	1183700877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700877	24279859	Allele T is associated with increased risk of addiction due to methamphetamine as compared to allele C.	0.0
1183700891	1183700886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700886	24279859	Genotype TT is associated with increased risk of addiction due to heroin as compared to genotype CC.	0.5
1183700891	1450827088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827088	28692418	Allele T is not associated with risk of Heroin Dependence due to heroin as compared to allele C.	-2.0
1183700891	1447676654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676654	26401760	Genotype CC is associated with increased likelihood of Substance-Related Disorders of methamphetamine in men as compared to genotypes CT + TT.	1.0
1183700410	PA166127637	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127637		Annotation of CPIC Guideline for fluvoxamine and CYP2D6	100
1183700410	1183703205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703205	9174682	CYP2D6 poor metabolizer is associated with increased areas under the serum concentration-time curve when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703476	11791895	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703487	8823236	CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183700410	1183703504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703504	9517369	CYP2D6 poor metabolizer is not associated with differences in the area under the serum concentration-timecurv when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.	-0.0625
1183700410	1183700294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700294	20547595	CYP2D6 *10/*10 + *5/*10 are associated with increased fluvoxamine plasma concentrations when treated with fluvoxamine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183700410	1183700359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700359	18978520	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *5/*10 are not associated with differences in in the fluvoxamine plasma level at 100, 150, and 200 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.	-0.125
1183700410	1183703160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703160	12883230	CYP2D6 *1/*1 is not associated with differences in steady-state plasma concentrations of fluvoxamine and its demethylated metabolite fluvoxamino acid when treated with fluvoxamine in people with Depression as compared to CYP2D6 *10/*10 + *5/*10.	-0.125
1183700410	1183703194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703194	12610741	CYP2D6 *1/*1 is not associated with differences in plasma fluvoxamine concentration when treated with fluvoxamine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*10 + *10/*10.	-0.125
1183700410	1183703493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703493	10668847	CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased AUC, Cmax and half-life time of fluvoxamine when treated with fluvoxamine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	0.125
1183700410	1184137435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137435	18978520	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *5/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.	1.0
1183700410	1449577638	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577638	20118554	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are associated with increased steady-state concentration of fluvoxamine as compared to CYP2D6 *1/*1.	0.125
1183700410	1449577681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577681	20118554	CYP2D6 *1/*10 + *1/*5 + *10/*10 + *10/*14 + *5/*10 are not associated with increased concentrations of fluvoxamine as compared to CYP2D6 *1/*1.	-0.125
982029857	PA166176068	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176068		Annotation of CPIC Guideline for tamoxifen and CYP2D6	100
982029857	1444935629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935629	21430657	CYP2D6 poor metabolizers are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	1.25
982029857	1444935672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935672	21430657	CYP2D6 poor metabolizers are not associated with increased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizers.	-0.75
982029857	1449170911	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170911	29436156	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.	-0.0625
982029857	1444708801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708801	15632378	CYP2D6 *3 + *4 + *5 + *6 is not associated with concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.75
982029857	1444709550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444709550	20124171	CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	2.25
982029857	1444710685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710685	21480951	CYP2D6 *10 + *5 is not associated with concentrations of 4-hydroxytamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-2.25
982029857	1444710781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710781	21480951	CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	2.25
982029857	1444710805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710805	21480951	CYP2D6 *41 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.	-0.125
982029857	1444712023	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712023	16815318	CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *2xN/*4 + *1/*1xN + *2/*1xN + *1/*2xN.	2.0
982029857	1444712210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712210	16815318	CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10.	2.0
982029857	1444930474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930474	23476897	CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.	-1.0
982029857	1444930553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930553	18407954	CYP2D6 *10/*10 is associated with decreased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	1.0
982029857	1444930567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930567	18407954	CYP2D6 *10/*10 is not associated with decreased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.	-0.125
982029857	1444935054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935054	23922954	CYP2D6 *3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 + *1/*17 + *1/*41.	-1.0
982029857	1444936127	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936127	17761971	CYP2D6 *10/*10 + *5/*5 are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	2.0
982029857	1444936241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936241	17761971	CYP2D6 *10/*10 + *5/*5 are not associated with decreased concentrations of n-desmethyltamoxifen or tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.	-1.0
982029857	1445401203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401203	20565970	CYP2D6 *4/*4 + *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.	2.25
982029857	1448112207	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448112207	27109434	CYP2D6 *2 + *10 + *87 + *90 + *91 + *93 + *95 + *98 are associated with decreased clearance of tamoxifen as compared to CYP2D6 *1.	0.0
1451401800	981483693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483693	23233662	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	1.5
1451401800	655387918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387918	19901119	Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	1.75
1451401800	1451465080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465080	21387541	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	0.0
1451401800	1451615128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615128	33501733	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
1451401800	1450045187	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045187	29791011	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	-1.0
982030732	769163207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163207	21148426	Genotypes AA + AC are associated with decreased on-treatment platelet reactivity when treated with clopidogrel in people with cigarette smokers as compared to genotype CC.	3.0
982030732	1183699705	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699705	24262617	Allele C is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	-1.0
982030873	982030334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030334	23394390	Genotypes CC + CT are associated with increased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotype TT.	0.0
982031855	982031816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031816	23249876	Allele T is associated with increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to allele C.	3.0
982031855	982031826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031826	23249876	Allele T is associated with decreased chance of achieving 6 month abstinence in the placebo group as compared to allele C.	3.0
982031855	1444930247	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930247	26010901	Genotype TT is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes CC + CT.	-1.5
982031855	1444930299	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930299	26010901	Allele C is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele T.	-2.0
982032763	699639285	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639285	21047205	Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder.	0.0
982036328	982036309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036309	15121491	Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype del/del.	2.25
982046386	982046373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046373	23071495	Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes GGGGCGGGGCCG/del + del/del.	2.0
1123915607	827923321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923321	22495174	Allele T is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele C.	3.5
1451397981	827816346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816346	22192668	Genotypes AG + GG are not associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype AA.	-1.75
1451397981	1451094340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451094340	21599570	Allele G is associated with increased response to carvedilol in healthy individuals as compared to allele A.	2.5
1451398000	982045173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045173	20643254	Genotype GG is associated with increased dose of carvedilol in people with Heart Failure as compared to genotype CC.	2.25
1043880098	981477559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477559	19890249	Allele A is associated with decreased clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.	0.75
1043880098	981477567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477567	19890249	Allele A is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.	-1.0
1043880098	981862502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862502	17906856	Genotype AA is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.	1.25
1043880276	982036681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036681	16116691	Genotype del/del is associated with decreased reduction in D-dimer levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	1.5
1043880276	982036717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036717	16116691	Genotype del/del is associated with increased reduction in CRP levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.5
1043880276	982036728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036728	16116691	Genotype del/del is associated with decreased reduction in IL-6 levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	1.5
1043880293	827811278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811278	20179710	Allele T is associated with increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele C.	0.0
1043880323	827778916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778916	21435719	Genotype AG is associated with increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to genotype AA.	1.5
1043880402	769245704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245704	21270790	Allele G is associated with increased dose of warfarin.	2.75
1043880454	982037248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037248	12742999	Genotypes AG + GG are associated with decreased risk of cardiovascular events when treated with pravastatin in men with Coronary Artery Disease as compared to genotype AA.	2.25
1043880454	982037279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037279	12742999	Genotypes AG + GG are not associated with angiographic measurements, lipid or lipoprotein levels when treated with pravastatin in men with Coronary Artery Disease as compared to genotype AA.	-1.75
1043880644	827808068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808068	21832968	Genotypes GT + TT are associated with Cough when treated with Ace Inhibitors, Plain as compared to genotype GG.	3.25
1140655380	982046536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046536	19802823	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.	-1.0
1140655380	982048025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048025	21392722	Allele A is associated with increased likelihood of myalgia when treated with atorvastatin in people with Coronary Artery Disease as compared to allele G.	2.0
1152661500	982046445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046445	16321621	Allele C is associated with increased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia.	2.0
1152661500	982046554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046554	19802823	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.	-1.0
1183490952	982023681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023681	23467860	Genotypes GG + GT are associated with decreased risk of bleeding events when treated with Dabigatran in people with Atrial Fibrillation as compared to genotype TT.	3.0
1183490952	982023705	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023705	23467860	Genotypes GG + GT are associated with decreased adjusted trough concentrations when treated with Dabigatran in people with Atrial Fibrillation as compared to genotype TT.	0.0
1183490952	1448100931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100931	27261537	Genotype GG is associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype TT.	1.25
1183491359	982045474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045474	16002074	Genotype GG is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.	1.75
1183491403	1024113143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1024113143	18174457	Genotype GG is associated with decreased likelihood of fatal coronary disease or nonfatal myocardial infarction when treated with pravastatin in men as compared to genotypes CC + CG.	4.0
1183631470	1183631378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631378	23930676	Genotype AA is associated with increased reduction in total cholesterol and LDL-cholesterol when treated with simvastatin as compared to genotype GG.	1.75
1183630246	981417266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417266	17602053	Allele A is associated with decreased risk of neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele G.	2.5
1183630246	981417285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417285	17602053	Genotype GG is associated with increased likelihood of progression-free survival when treated with gemcitabine in women with Breast Neoplasms as compared to allele A.	0.0
1183630246	981793989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981793989	20665488	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	-1.5
1183630246	827817277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817277	22026922	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	-1.5
1183632170	827805848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805848	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1183632170	1448109346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109346	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.5
1451398106	981500777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500777	20709156	Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.	1.75
1183617832	981750780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750780	19590397	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	-1.75
1183617832	981940039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981940039	21688171	Genotype GG is associated with increased response at 4 weeks after the initiation of treatment when treated with paroxetine in people with Panic Disorder as compared to genotypes CC + CG.	2.0
1183617832	608178498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178498	18484082	Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.	2.5
1183617832	655386291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386291	19800133	Genotype CC is associated with increased likelihood of non-response when treated with paroxetine and sertraline in people with Panic Disorder as compared to genotypes CG + GG.	2.5
1183616718	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1183616718	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1183616718	1451152807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152807	9357098	CYP2D6 ultrarapid metabolizer phenotype is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0
1183616718	1451152848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152848	9357098	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0
1183616718	1451153620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153620	10850391	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.0625
1183616718	1451157860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157860	18334103	CYP2D6 ultrarapid metabolizer genotype is associated with increased exposure to morphine in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.5
1183616718	1451206040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206040	24747667	CYP2D6 poor metabolizers are associated with decreased metabolism of codeine.	0.875
1183616718	1451568920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451568920	33404848	CYP2D6 poor metabolizer phenotype is associated with decreased exposure to morphine in infants as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	1.25
1183616718	827641940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641940	19940985	Genotype TT is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to genotypes CC + CT.	0.125
1183616718	827566510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566510	16819548	CYP2D6 *1/*2xN (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566496	16819548	CYP2D6 *1xN/*10 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566502	16819548	CYP2D6 *1xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566506	16819548	CYP2D6 *2xN/*41 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	827566514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827566514	16819548	CYP2D6 *1xN/*1 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.	1.0
1183616718	982047720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047720	16920476	CYP2D6 *2/*2xN is associated with increased metabolism of codeine.	0.125
1183616718	982047744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047744	19692698	CYP2D6 *1xN is associated with increased metabolism of codeine.	0.125
1183616718	1183623185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623185	8823235	CYP2D6 *36 is associated with decreased codeine metabolism and morphine and glucuronides formation when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183616718	1183632349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632349	24077935	CYP2D6 *1/*10 + *10/*10 is associated with decreased plasma levels of morphine, M3G and M6G levels but not those of codeine when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183616718	1183632366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632366	19940985	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.	1.5
1183616718	1183678427	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678427	9415713	CYP2D6 *17 is associated with decreased activity of CYP2D6 when assayed with bufuralol or codeine as compared to CYP2D6 *1.	0.0
1183616718	1183678599	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678599	17470523	CYP2D6 *10 is associated with decreased clearance of codeine as compared to CYP2D6 *1.	0.0
1183616718	1183678609	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678609	17470523	CYP2D6 *17 is associated with decreased clearance of codeine as compared to CYP2D6 *1.	0.0
1183616718	1183680593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680593	19395173	CYP2D6 *4/*4 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680606	19395173	CYP2D6 *3/*4 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680612	19395173	CYP2D6 *4/*6 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680618	19395173	CYP2D6 *4/*41 is associated with decreased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680624	19395173	CYP2D6 *1/*1 + *1xN/*1xN is associated with increased metabolism of codeine in healthy individuals.	0.0
1183616718	1183680992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680992	9129563	CYP2D6 *1/*1 + *1/*4 is associated with increased plasma level of morphine when treated with codeine in healthy individuals as compared to CYP2D6 *3/*4 + *4/*4 + *5/*5.	1.0
1183616718	1183684566	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684566	12438554	CYP2D6 *10 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1183684576	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684576	12438554	CYP2D6 *2 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1183684584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684584	12438554	CYP2D6 *17 is associated with decreased clearance of codeine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183616718	1184756913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756913	11823760	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.	2.0
1183616718	1184756952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756952	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1183616718	1447963867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963867	19357842	CYP2D6 *17 is associated with decreased metabolism of codeine in people with Anemia, Sickle Cell.	1.25
1183616718	1451156680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156680	17872605	CYP2D6 *2/*2xN is associated with increased metabolism of codeine in women.	0.125
1183689931	1448613202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613202	28112181	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.25
1183689931	982031594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031594	23778326	Genotype AG is not associated with tacrolimus dose-adjusted blood concentration when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-1.0
1183689931	1184470301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470301	24658827	Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1183689931	1185023357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023357	25271728	Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.5
1183689931	1448112417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112417	27314545	Genotype AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype GG.	0.0
1183689931	1183684149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684149	24052064	Genotype AG is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.25
1183689931	1183684036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684036	21903774	Genotype GG is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	2.5
1183689931	1184753642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753642	25141896	Genotypes AA + AG is not associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	-0.75
1183689931	1449171296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171296	29160300	Allele A is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	0.0
1183689931	1184753631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753631	25141896	Genotypes AA + AG is associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.	1.25
1183689931	1449163578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163578	29318894	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	This annotation is not used for clinical annotation scoring. No direction given by the authors
1183689931	1451415506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415506	32843687	Allele A is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	1.75
1183689931	1451714346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451714346	33512723	Genotypes AA + AG are associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.5
1183689931	1184470941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470941	24522145	CYP3A4 *1/*1 is not associated with clearance of everolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*22 + *22/*22.	-1.0
1183689931	1185234460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234460	25287072	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.25
1183689931	1444706019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706019	25588704	CYP3A4 *1/*22 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.5
1183689931	1444934293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934293	26067485	CYP3A4 *22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation.	-1.5
1183689931	1448358561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358561	27653228	CYP3A4 *1/*1 are associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*22 + *22/*22.	1.0
1183689931	1448568158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568158	28044353	CYP3A4 *1/*22 + *22/*22 are not associated with metabolism of tacrolimus in children with liver transplantation as compared to CYP3A4 *1/*1.	-0.75
1183689931	1448602351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602351	28050888	CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1448603912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603912	28229376	CYP3A4 *1/*22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-0.75
1183689931	1448603998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603998	28229376	CYP3A4 *1/*1 is not associated with trough concentration of tacrolimus in children with Kidney Transplantation as compared to CYP3A4 *1/*22.	-0.75
1183689931	1448641138	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448641138	28342282	CYP3A4 *1/*22 is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A4 *1/*1.	-0.125
1183689931	1448994572	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994572	28704257	CYP3A4 *1/*22 (assigned as poor metabolizers phenotype) is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.25
1183689931	1449161538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161538	29256966	CYP3A4 *1/*20 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.	1.25
1183689931	1449161549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161549	29256966	CYP3A4 *1/*22 + *22/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.	1.25
1183689931	1451118280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118280	31513279	CYP3A4 *22 is associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1183699824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699824	23588314	CYP3A4 *22 is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	-1.0
1183689931	1451250880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451250880	24444408	CYP3A4 *1/*22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1183689931	1185234509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234509	25287072	CYP3A4 *1/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.75
1183689931	1448635420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635420	28603840	CYP3A4 *22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	-1.25
1183689931	1185234522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234522	25287072	CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.25
1183689931	1183698704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698704	23557867	CYP3A4 *1/*18 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.0
1183689931	1449165805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165805	28945481	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*18 + *18/*18.	2.25
1183689931	1447946656	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946656	26770526	CYP3A4 *18 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.	2.0
1183689931	1183689729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689729	24189425	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36.	2.25
1183689931	1183689778	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689778	24189425	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.75
1183689931	981843814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981843814	23459029	CYP3A4 *1/*36 + *36/*36 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.5
1183689931	1445584912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584912	26228923	CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.0
1183689931	1450928466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928466	31401678	CYP3A4 *36 is not associated with concentrations of tacrolimus in children with proteinuria as compared to CYP3A4 *1/*1.	-1.25
1183689931	1447520683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520683	26227094	CYP3A4 *36 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.25
1183689931	827812461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812461	21635144	CYP3A4 *1/*1 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*36 + *36/*36.	2.0
1183689931	1447679078	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679078	26521259	CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.	-0.125
1183684162	827920244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827920244	22584460	Allele T is associated with decreased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	2.75
1183689987	769250131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250131	15707415	Genotypes CC + CT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype TT.	2.25
1183693433	1183681634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681634	23315321	Genotype AA is associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotypes AC + CC.	1.75
1183689409	1444668324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668324	15695296	Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC.	2.25
1183689409	1444687098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444687098	23057546	Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CT + TT.	-2.5
1183689409	1444693768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693768	17673491	Genotype CC is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	-1.75
1183689409	1444693787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693787	17673491	Genotype CC is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.	2.25
1183689409	1183689377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689377	24192118	Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes CT + TT.	-2.0
1183689409	1445585209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445585209	25311255	Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	2.25
1183689409	1447680253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680253	26244882	Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele T.	-1.625
1451398120	981500777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500777	20709156	Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.	1.75
1183681792	1183681743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681743	24152261	HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.	4.0
1183681792	1184988608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988608	23604100	HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.	3.5
1183681792	1448994310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994310	28885988	HLA-B *13:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with dapsone.	4.0
1183681792	1448994375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994375	28885988	HLA-B *13:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with dapsone.	3.0
1183681792	1448994399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994399	28885988	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with dapsone.	4.0
1183681792	1449752292	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752292	29541744	HLA-B *13:01:01 is associated with increased risk of severe cutaneous adverse reactions due to dapsone.	0.0
1183681792	1449752371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752371	29512326	HLA-B *13:01:01 is associated with increased risk of Maculopapular Exanthema due to dapsone.	0.25
1183681792	1449752489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752489	29458119	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to dapsone in people with Skin Diseases.	3.5
982047840	981502489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502489	22824134	Genotype AA is associated with decreased risk of Drug Hypersensitivity when treated with sulfamethoxazole in people with HIV Infections as compared to genotypes AC + CC.	3.75
982047840	981502500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502500	22824134	Allele A is associated with decreased risk of Drug Hypersensitivity when treated with sulfamethoxazole in people with HIV Infections as compared to allele C.	2.5
982047910	982032850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032850	8538349	Genotype del/del is associated with increased resistance to atenolol and enalapril in people with Kidney Diseases as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-1.75
982047910	982033050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033050	8986921	Genotype del/del is associated with increased response to enalapril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.75
982047910	982033349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033349	9661139	Genotype del/del is associated with decreased response to enalapril in people with glomerular disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-0.25
982047910	982041046	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982041046	10880412	Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del are associated with increased response to enalapril in people with Arteriosclerosis as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	2.75
982047910	982043371	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043371	16020596	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to enalapril and losartan in men with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	-2.0
982047910	982047358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047358	12799093	Genotype del/del is associated with increased bone mineral density response when treated with enalapril in women with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.5
982047910	827815275	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815275	19319668	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased likelihood of Kidney Failure, Chronic when treated with enalapril in people with Glomerulonephritis, IGA as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	1.5
982047910	1451250000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451250000	25002132	Genotype del/del is associated with increased clinical benefit to enalapril or lisinopril in men with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.25
1183491026	827785845	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827785845	22027652	Allele A is associated with decreased transport of when exposed to calcein or lopinavir.	0.0
1183491026	769171166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171166	19842932	Allele A is associated with a higher accumulation of lopinavir in peripheral blood mononuclear cells when treated with lopinavir in people with HIV Infections as compared to genotype GG.	0.75
1183533945	981794201	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794201	18221820	Genotype CC is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.5
1183533945	981843786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843786	18221820	Genotype CC is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	-1.5
1183533950	981793872	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981793872	23149126	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	3.0
1183533950	981793920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981793920	23149126	Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.	3.5
1183533966	981475790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981475790	22538805	Genotype TT is associated with increased response to flunisolide in people with Asthma as compared to genotypes CC + CT.	3.0
1183556309	981483776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483776	22722500	Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.	2.25
1183604793	981475773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475773	22041458	Allele C is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.	0.0
1183612432	981502054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502054	22441531	Genotypes CG + GG are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
1183612432	981502673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502673	22441531	Genotypes CG + GG are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.5
1183612731	982037510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037510	17473847	Genotype GG is associated with increased response to captopril in women with Hypertension as compared to genotypes AA + AG.	2.5
1183612731	982037525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037525	17473847	Genotype GG is not associated with response to captopril in women with Hypertension as compared to genotypes AA + AG.	-2.0
1183614499	981502284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502284	23335901	Genotypes AA + AG are associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG.	2.0
1183614855	982032137	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982032137	23408116	Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.	0.0
1183615135	981478525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478525	22967772	Allele G is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele C.	2.25
1183615621	1183615597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615597	20079160	Genotypes GG + GT are associated with decreased response to benazepril in people with Hypertension as compared to genotype TT.	3.5
1183619864	981238985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981238985	19112496	Genotypes CT + TT are associated with increased risk of requiring a blood transfusion when treated with amodiaquine, pyrimethamine and sulfadoxine in children with Malaria as compared to genotype CC.	0.0
1183631404	1183491171	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491171	23886675	Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	2.0
1183697592	981483665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483665	23233662	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.5
1183697592	1451613242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451613242	33501733	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.25
1183697592	1183681703	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681703	23652803	Genotypes AA + AG are associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.75
1183697592	1449003438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003438	28525903	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	-1.25
1183679828	981802639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802639	23478653	Genotype AG is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA.	0.0
1183679848	827777175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827777175	20970119	Allele C is associated with increased response to nortriptyline in people with Depression as compared to allele T.	2.75
1183680570	827789036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827789036	21993426	Allele T is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.	2.25
1183697557	1183681952	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681952	23736036	Genotypes AG + GG are associated with increased risk of Diarrhea when treated with capecitabine in people with Neoplasms as compared to genotype AA.	2.5
1183697557	1183681957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681957	23736036	Genotypes AG + GG are associated with increased risk of Dehydration when treated with capecitabine in people with Neoplasms as compared to genotype AA.	2.0
1183697557	1183681961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681961	23736036	Allele A is not associated with risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele G.	-1.5
1451398140	827704840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704840	21362365	Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	2.0
1183679122	1183678990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183678990	23995691	Allele T is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors or simvastatin as compared to allele C.	1.75
1183681861	981679601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981679601	23392654	Allele A is associated with decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration when treated with aspirin and clopidogrel as compared to allele G.	0.0
1183681861	981679610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981679610	23392654	Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.	0.0
1183681861	981679617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981679617	23392654	Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.	2.25
1183689585	1183689490	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689490	24192121	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	0.0
1183689914	1183689638	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689638	9630826	CYP2D6 poor metabolizers are associated with decreased clearance of tolterodine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183689914	1183689751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689751	10190648	CYP2D6 poor metabolizer is associated with increased serum tolterodine concentrations when exposed to tolterodine in men as compared to CYP2D6 normal metabolizer.	0.0625
1183689914	1183689846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689846	21352267	CYP2D6 poor metabolizers are associated with increased AUC and C max of tolterodine and undetectable 5-HMT (active metabolite) when exposed to tolterodine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183689914	1183689806	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689806	10583026	CYP2D6 *3 + *4 are associated with decreased metabolism of tolterodine in women as compared to CYP2D6 *1/*1.	1.0
1183689914	1183689858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689858	20530222	CYP2D6 *10/*10 + *5/*10 is associated with increased tolterodine exposure and increased active metabolite (5-HM) concentrations when exposed to tolterodine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.	1.5
1183689914	1183689895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689895	20530222	CYP2D6 *4/*4 is associated with increased tolterodine exposure and unquantifiable active metabolite (5-HM) concentrations when exposed to tolterodine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183693443	1183681617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681617	23315321	Genotypes CG + GG are associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotype CC.	2.25
1183699226	1183699139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699139	22901187	Genotype AG is associated with decreased response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + GG.	2.0
1183700243	1183700211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700211	24024897	Genotype AA is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	1.75
1183700279	1183700269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700269	24024896	Genotypes GG + GT are associated with increased risk of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	3.0
1183700396	827828657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828657	19932356	Allele A is not associated with differences in improvement in morning peak expiratory flow (PEF) when treated with corticosteroids and salmeterol in people with Asthma as compared to allele G.	-1.25
1183700396	1183700310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700310	24279851	Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG.	3.5
1183700396	1447680618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680618	26774659	Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG.	1.5
1183700527	981417467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981417467	23007924	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
1183700527	827808153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827808153	20309874	Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele A.	3.0
1183698531	1183698527	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183698527	18784617	Allele A is associated with drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.	3.25
1451398160	827704848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827704848	21362365	Genotypes AA + AG are associated with decreased severity of toxicity when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	2.5
1183698868	981755152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755152	19390945	Genotypes GG + GT are not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype TT.	-1.5
1183698868	981794577	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794577	16636344	Genotypes GG + GT are not associated with Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	-1.25
1183698868	981794594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794594	16636344	Genotypes GG + GT are not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	-1.25
1183698868	827552123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827552123	15007088	Allele G is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele T.	2.25
1183698868	1449147633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449147633	29098099	Genotype GG is associated with Drug Toxicity when treated with irinotecan.	0.25
1183698868	1449559848	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449559848	29737521	Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele T.	0.0
1183698868	1184510901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510901	23963147	UGT1A1 *60 is not associated with Drug Toxicity when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	-0.25
1183491318	1039730449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1039730449	18528690	CYP3A4 *36/*36 is associated with increased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.	2.0
1183491318	1040387995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1040387995	18528690	CYP3A4 *1/*1 is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *36/*36.	2.5
1183491318	1040863313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1040863313	18528690	CYP3A4 *1/*1 is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*36.	2.0
982031026	981476245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476245	18215618	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.	2.75
982032567	982032521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032521	23651024	Genotypes AA + AG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	0.0
982032727	981750332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750332	20348464	Allele T is not associated with response to lithium in people with Bipolar Disorder as compared to allele C.	-1.5
982032727	827784977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784977	21781277	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
982032727	827784987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784987	21781277	Genotype TT is associated with increased response to lithium in people with Bipolar Disorder.	1.75
982037796	982037699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037699	18854995	Genotype GG is associated with increased percentage change in HDL-C levels when treated with simvastatin in people with Coronary Disease as compared to genotype AA.	2.25
1043859346	982037646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037646	21831410	CYP2B6 *5 is associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2B6 *1.	2.5
1043859380	827815159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815159	21052032	Allele G is associated with increased likelihood of remission when treated with desipramine in people with Depressive Disorder, Major as compared to allele A.	2.25
1043880205	982045692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045692	16103896	Genotype AG is associated with increased response to lovastatin as compared to genotype GG.	2.75
1043880308	981478356	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478356	23147717	Genotype GG is associated with decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to genotypes AA + AG.	2.0
1043880318	827778906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778906	21435719	Genotypes AC + CC are associated with increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to genotype AA.	2.0
1043880328	827778899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778899	21435719	Genotype AA is associated with increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to genotype AG.	1.5
1043880841	827815502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815502	22044939	Allele A is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.	1.75
1043880841	827815513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815513	22044939	Allele A is associated with increased progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034) when treated with bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	2.25
1043880433	982046202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046202	18435918	Genotype TT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	-1.25
1043880433	982046206	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982046206	18435918	Genotype TT is associated with decreased transcription of SCAP when treated with atorvastatin in PBMCs.	0.0
1183491162	982044124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044124	17192506	Genotype CC is associated with decreased clearance of simvastatin in healthy individuals as compared to genotype TT.	1.0
1183491162	982044142	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044142	17192506	Genotype CC is associated with decreased metabolism of simvastatin in healthy individuals as compared to genotype TT.	0.125
1183491162	982046480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046480	16321621	Allele C is not associated with response to simvastatin in people with Hypercholesterolemia as compared to allele T.	-1.25
1183491162	982046495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046495	16321621	Allele C is not associated with risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele T.	-2.0
1183491162	1184754859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754859	24598718	Genotype TT is associated with increased clearance of simvastatin as compared to genotypes CC + CT.	0.0
1183491162	982044075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044075	15284534	Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.	1.5
1183491162	981501901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501901	23252946	CYP3A5 *3/*3 is not associated with response to simvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1/*1.	-1.75
1183491162	982048117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048117	17289397	CYP3A5 *1/*3 is not associated with lipid response when treated with atorvastatin or simvastatin as compared to CYP3A5 *3/*3.	-1.25
1183491162	1446897010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897010	26164721	CYP3A5 *3 is not associated with concentrations of simvastatin or simvastatin acid in people with Hypercholesterolemia as compared to CYP3A5 *1.	-1.5
1183491162	982048088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048088	17289397	CYP3A5 *3 is not associated with likelihood of myopathy when treated with atorvastatin or simvastatin as compared to CYP3A5 *1.	-1.25
1451398180	1448602216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602216	25008867	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	2.5
982030222	1448261868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261868	26491254	NAT2 slow acetylator is associated with decreased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 rapid acetylator.	1.0
982030222	1451308040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451308040	33165168	NAT2 slow acetylator is associated with increased concentrations of isoniazid in healthy individuals as compared to NAT2 rapid acetylator.	0.0625
982030222	1450807565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807565	30779340	Genotype AA is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes AG + GG.	2.0
982030222	981240165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981240165	19891553	Genotype AA is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype GG.	1.75
982030222	981848260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981848260	15855489	NAT2 *4 is associated with increased clearance of isoniazid in healthy individuals.	0.125
982030222	981851586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851586	16182272	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	1.5
982030222	981851591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851591	16182272	NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	1.5
982030222	981939860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939860	21479500	NAT2 *4 is associated with increased metabolism of isoniazid in healthy individuals.	1.0
982030222	981939971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939971	21753138	NAT2 *4 is associated with increased metabolism of isoniazid in people with Tuberculosis.	0.125
982030222	1184233189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233189	24533708	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 + *13A/*13A (assigned as rapid acetylator phenotype) .	2.0
982030222	1184233225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233225	24533708	NAT2 *5B/*7B + *5B/*5B + *5B/*6A + *5B/*6J + *5B/*7G + *6A/*7B (assigned as slow acetylator phenotype) is associated with decreased clearance of isoniazid in children with Tuberculosis as compared to NAT2 *4/*5B + *4/*6A + *4/*5C + *4/*6O + *4/*7G + *5B/*12A + *6A/*13A (assigned as intermediate acetylator phenotype) .	1.5
982030222	981851608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981851608	16531626	NAT2 *5A/*5A + *5A/*6A + *5A/*7A + *6B/*6B + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Lupus Erythematosus, Systemic as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	0.125
982030222	1183702439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702439	24383060	NAT2 *5A/*5A + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.0
982030222	981344548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344548	18544910	NAT2 *6A/*6A + *6A/*7B + *7B/*7B (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5B + *4/*6A + *4/*7B.	2.0
982030222	981476160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981476160	21558457	NAT2 *5A + *6B + *7A + *14A is associated with decreased clearance of isoniazid in children with HIV Infections as compared to NAT2 *4 + *12A + *13A.	0.0
1183492035	827808741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808741	19530961	Genotypes AG + GG are associated with decreased reduction in LDLc when treated with atorvastatin, lovastatin or simvastatin in people with Hyperlipidemias as compared to genotype AA.	3.0
1183492035	1449311045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311045	29695967	Genotype AA is associated with response to atorvastatin, rosuvastatin and simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.	1.5
982030805	1444696308	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444696308	25704243	Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.	1.5
982030805	981477709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477709	23111421	Genotype CT is associated with increased levels of clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.	2.5
982030805	981802686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802686	23275066	Allele T is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel when exposed to clopidogrel as compared to allele C.	0.0
1043880802	1451354840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451354840	25379722	Genotypes CC + CT is associated with decreased response to pravastatin in people with Dyslipidaemia as compared to genotype TT.	1.5
1043880802	1451450560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451450560	22189199	Genotypes CC + CT are associated with decreased response to pravastatin as compared to genotype TT.	3.0
1043880802	1451256960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451256960	15548849	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.	1.75
1043880802	982043772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043772	17439540	Genotype CT is associated with decreased response to pravastatin in people with Coronary Stenosis as compared to genotype TT.	1.5
1043880802	982043181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043181	16722833	Genotype CT is associated with increased response to pravastatin in children with Transplantation as compared to genotype TT.	1.5
1043880802	982045915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045915	16103896	Genotype CC is not associated with response to pravastatin as compared to genotype TT.	-1.75
1043880802	827811014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811014	21851379	Genotypes CT + TT are not associated with the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin when treated with pravastatin in men with as compared to genotype CC.	-2.0
1043880802	827827144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827144	16678544	Allele C is not associated with the lipid-lowering efficacy of pravastatin when exposed to pravastatin in healthy individuals.	-0.25
1043880802	769171495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171495	18794729	Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.	0.5
1043880802	769171498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171498	18794729	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.	-0.0
1043880802	1451450620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451450620	16917677	SLCO1B1 *1/*15 is associated with decreased response to pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.	1.5
1043858965	982044541	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044541	19286758	Genotypes AC + CC are associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	1.75
1183562698	982038152	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982038152	19542315	Genotypes CC + CT are associated with increased response to dobutamine in healthy individuals as compared to genotype TT.	2.5
1183562698	982038292	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982038292	19542315	Genotypes CC + CT are not associated with response to dobutamine in healthy individuals as compared to genotype TT.	-0.25
1183603764	981478516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478516	22967772	Allele C is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele A.	2.25
1183607901	982044812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044812	20346718	Genotype CT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	2.25
1183607901	982044822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044822	20346718	Genotype TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	2.25
1183614761	981500932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500932	23073467	Genotype AA is associated with increased triglycerides when treated with sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	2.25
1183615261	981954198	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954198	22700043	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	2.5
1183615359	982047043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047043	22129793	Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG.	3.25
1183615367	982046815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046815	23127338	Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Lung Neoplasms as compared to genotype GG.	3.5
1183615367	982046831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046831	23127338	Genotypes AA + AG are not associated with response to carboplatin and cisplatin in people with Carcinoma, Small Cell as compared to genotype GG.	-1.5
1183615367	982046834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046834	23127338	Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.25
1183615424	982046897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046897	22480748	Genotype TT is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	1.75
1183615424	982046956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046956	22480748	Genotype TT is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.	-1.25
1183618924	981477511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477511	11311507	Genotypes AG + GG are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	2.25
1183618924	769169302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169302	18253134	Genotype AG is associated with increased likelihood of remission when treated with paroxetine in people with Depression as compared to genotypes AA + GG.	2.75
1183618924	769169308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169308	18253134	Genotype AG is associated with improved response when treated with paroxetine in people with Depression as compared to genotypes AA + GG.	2.75
1183618924	1183623358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623358	20075642	Genotype GG is not associated with increased risk of discontinuation syndrome due to paroxetine in people with Depressive Disorder, Major.	-1.25
1183629315	981476212	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476212	18215618	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	2.75
1183632145	827924765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924765	18591455	Genotype TT is associated with decreased reduction in SBP when treated with hydrochlorothiazide in people with Hypertension as compared to genotypes CC + CT.	2.5
1183632165	827698281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698281	21747410	Genotype AA is associated with increased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to genotypes AT + TT.	2.5
1183632165	1447681374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447681374	25321336	Genotypes AA + AT are associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype TT.	1.5
1451398187	1447677615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677615	25677447	Genotype GG is associated with increased overall survival when treated with capecitabine, epirubicin and platinum in people with Colorectal Neoplasms as compared to genotypes AA + AG.	2.75
1183679135	1183679021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183679021	23995691	Allele C is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors or simvastatin as compared to allele T.	3.5
1183689961	1183689833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689833	24189425	CYP3A4 *1/*36 + *36/*36 is associated with increased risk of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*1.	2.25
1183689961	1183689749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689749	24189425	CYP3A4 *1/*1 is not associated with risk of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*36 + *36/*36.	-1.75
1183533955	981477278	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477278	22541248	Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.	2.5
1183601914	982044407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044407	18285551	Genotypes AG + GG are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	2.25
1183601914	982044416	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044416	18285551	Genotypes GG + GT are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	2.25
1183602560	981475767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475767	22041458	Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele A.	0.0
1183614466	982034333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034333	15148588	Genotypes AG + GG are associated with decreased response to benazepril in people with Essential hypertension as compared to genotype AA.	3.0
1183614466	982034351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034351	15148588	Genotypes AG + GG are not associated with response to benazepril in people with Essential hypertension as compared to genotype AA.	-2.0
1183614600	982034045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034045	12065207	Genotype GG is associated with increased response to candesartan in people with Hypertension as compared to genotypes AA + AG.	2.5
1183615587	981755436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755436	23280790	Genotype TT is associated with increased risk of hemorrhagic transformation when treated with Enzymes in people with Stroke as compared to genotypes CC + CT.	4.0
1183617618	827921657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921657	22641028	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.	3.25
1183617644	769218927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769218927	21121774	Allele A is associated with increased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele G.	2.0
1183621972	1183621538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621538	14520122	CYP2C9 *3/*3 is associated with decreased metabolism of trimipramine in healthy individuals.	1.0
1183622527	1183622437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622437	23859573	Allele A is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.	1.5
1183622527	1183622483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622483	23859573	Allele A is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major as compared to allele G.	1.5
1183622527	1183622507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622507	23859573	Allele A is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele G.	1.5
1183622622	1183622456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622456	23859573	Allele T is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele C.	1.5
1183622622	1183622495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622495	23859573	Allele T is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major.	1.5
1183622622	1183622511	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622511	23859573	Allele T is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele C.	1.5
1183629310	981476225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476225	18215618	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	2.75
1183684153	827920282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827920282	22584460	Allele T is associated with decreased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	2.75
1183697540	1183697518	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697518	24143213	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	2.5
1183698808	982045346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045346	20877298	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.	1.75
1183698831	982035499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035499	16607077	Genotypes CC + CG are associated with increased response to fenofibrate in patients with a high risk of cardiovascular disease as compared to genotype GG.	1.5
1451398240	1444694818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694818	25545243	Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.	3.0
1183617724	981500777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500777	20709156	Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.	1.75
1183617724	655388442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388442	15565110	Genotype AA is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AG + GG.	2.75
1183617478	PA166104992	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104992		Annotation of DPWG Guideline for zuclopenthixol and CYP2D6	100
1183617478	1447682070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682070	26514968	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.0625
1183617478	1451430400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451430400	12107620	CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.	1.75
1183701210	827919462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919462	21545408	HLA-A *33:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1183701210	1184747209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747209	21301380	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
1183701210	1184755056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755056	15743917	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1183701210	1184756745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756745	21393610	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
1183701210	1184756788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756788	21393610	HLA-A *33:03 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.5
1183701210	1451721639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451721639	35187976	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	0.0
1183701210	1184467904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467904	21912425	HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	0.0
1183690410	1183689924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689924	7474246	CYP2D6 poor metabolizer is associated with increased plasma timolol concentration and excerice heart rate reduction when exposed to timolol in men as compared to CYP2D6 normal metabolizer.	0.75
1183690410	1183690112	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183690112	16315032	CYP2D6 *3/*3 + *3/*4 + *4/*4 + *5/*4 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	1.0
1183693382	1183693363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693363	22585284	CYP2C19 *1/*2 + *1/*3 (assigned as heterozygous normal metabolizer phenotype) is associated with decreased metabolism of icotinib in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183693382	1446898274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898274	25995169	CYP2C19 *2 + *3 are associated with clearance of icotinib in healthy individuals as compared to CYP2C19 *1.	0.125
1183698786	1183698757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698757	23557867	CYP3A4 *18/*18 is associated with increased metabolism of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*1 + *1/*18.	1.25
1183698818	981755389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755389	16609363	Genotype AG is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV as compared to genotype GG.	2.25
1183700230	1183700217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700217	24024897	Genotypes GT + TT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype GG.	1.5
1183700238	1183700223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700223	24024897	Genotypes CG + GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype CC.	1.75
1183700248	1183700205	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700205	24024897	Genotypes AC + CC is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.	1.75
1183700253	1183700190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700190	24024897	Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	2.75
1183700258	1183700199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700199	24024897	Genotype AT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.	2.25
1183700512	827863595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863595	22267851	Allele T is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele C.	0.0
1183700812	1183700770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700770	24279852	Allele C is associated with increased metabolism of debrisoquine in healthy individuals as compared to allele G.	1.75
1183701068	1450041941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450041941	19604081	Genotypes CC + CG is associated with decreased metabolism of thioridazine as compared to genotype GG.	1.25
1183700477	1183689186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689186	9399616	CYP2D6 poor metabolizers is not associated with oral clearance or elimination half-life of propranolol when treated with propranolol in healthy individuals as compared to CYP2D6 normal metabolizer.	-0.0625
1183700477	1183689191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689191	9399616	CYP2D6 poor metabolizer is not associated with response to propranolol (as measured by percentage reductions in exercise heart rate) when treated with propranolol in healthy individuals as compared to CYP2D6 normal metabolizer.	-0.125
1183700477	1183689178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689178	12728976	CYP2D6 *10 is not associated with beta-blockade effect of propranolol when treated with propranolol in healthy individuals as compared to CYP2D6 *1.	-0.25
1183700477	1183689169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689169	12728976	CYP2D6 *10 is associated with increased S-propranolol plasma concentration when treated with propranolol in healthy individuals as compared to CYP2D6 *1.	0.125
1451398300	981419822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419822	18511948	Genotype AA is associated with decreased likelihood of survival when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.	3.0
1451398340	1446898383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898383	23920449	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	1.5
1183700488	769168989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769168989	20195290	Genotype AA is associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype CC.	3.5
982047500	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
982047500	PA166104984	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104984		Annotation of DPWG Guideline for phenytoin and CYP2C9	100
982047500	PA166104860	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104860		Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B	100
982047500	769248925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248925	21068649	Allele T is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to genotype CC.	2.0
982047500	769250028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250028	16815679	Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.	1.5
982047500	769250082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250082	10901705	Allele T is not associated with decreased metabolism of phenytoin.	-0.5
982047500	769249039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249039	16220110	Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG.	2.0
982047500	769249041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249041	16220110	Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.	2.0
982047500	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
982047500	769249040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249040	16220110	Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC.	2.0
982047500	769250083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250083	10901705	Allele C is associated with decreased metabolism of phenytoin.	0.0
982047500	769248929	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248929	21068649	Allele C is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to allele A.	2.0
982047500	769250031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250031	16815679	Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA.	0.125
982047500	769249016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769249016	16220110	Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC.	2.0
982047500	981858971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858971	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*2.	2.0
982047500	981859014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859014	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *2/*2.	1.5
982047500	981859021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859021	10510154	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*3.	2.0
982047500	982046592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046592	21532277	CYP2C9 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	1.5
982047500	982046599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046599	21532277	CYP2C9 *1/*1 is associated with increased the intrinsic metabolic activity (V(max)/K(m)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	1.5
982047500	982046605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046605	9860067	CYP2C9 *1/*3 is associated with decreased the mean maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	0.0
982047500	982046623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046623	9333104	CYP2C9 *1/*1 is associated with increased the maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*3.	1.0
982047500	982046630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046630	11668218	CYP2C9 *1/*3 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	0.125
982047500	982046637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046637	11668218	CYP2C9 *1/*2 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	0.125
982047500	1448612922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612922	28302415	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	3.25
982047500	1448994156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994156	14659971	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	1.5
982047500	1449565307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565307	25597548	CYP2C9 *3 is associated with increased concentrations of phenytoin.	0.25
982047500	1449565369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565369	25998968	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in children.	0.25
982047500	1449565430	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565430	27163851	CYP2C9 *2 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565442	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565442	27163851	CYP2C9 *3 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565453	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565453	27163851	CYP2C9 *8 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565462	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565462	27163851	CYP2C9 *11 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565471	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565471	27163851	CYP2C9 *13 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565484	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565484	27163851	CYP2C9 *14 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565493	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565493	27163851	CYP2C9 *16 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565531	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565531	27163851	CYP2C9 *29 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	-0.0
982047500	1449565540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565540	27163851	CYP2C9 *31 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565549	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565549	27163851	CYP2C9 *33 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565576	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565576	27163851	CYP2C9 *37 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565594	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565594	27163851	CYP2C9 *39 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565621	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565621	27163851	CYP2C9 *42 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565630	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565630	27163851	CYP2C9 *43 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565648	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565648	27163851	CYP2C9 *45 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565695	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565695	27163851	CYP2C9 *50 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565715	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565715	27163851	CYP2C9 *52 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565742	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565742	27163851	CYP2C9 *55 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
982047500	1449565832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565832	27179628	CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	1.75
982047500	1449565846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449565846	27179628	CYP2C9 *1/*2 is not associated with concentrations of phenytoin in children with as compared to CYP2C9 *1/*1.	-0.75
982047500	1450969200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969200	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	2.5
982047500	1450969140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969140	31461080	CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	2.5
982047500	1450969293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450969293	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1.	2.25
982047500	981859049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859049	15385837	CYP2C9 *1/*3 is associated with increased steady state concentration per dosage when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	1.5
982047500	1445388514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445388514	26122019	CYP2C9 *1/*1 + *1/*2 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	-0.75
982030907	982030355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030355	23394390	Genotype CC is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.5
982030990	982030932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030932	23556445	Genotype CC is associated with increased likelihood of responding to treatment when treated with hydroxyurea in people with Thalassemia.	1.5
982031767	827696097	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827696097	21593735	Allele A is associated with increased activity of CYP1A2.	0.0
982031767	769218940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769218940	21121774	Allele A is associated with increased dose of paroxetine in people with Depressive Disorder, Major as compared to allele C.	2.0
982031767	769218958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769218958	21121774	Allele A is associated with increased risk of Fatigue when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.	2.5
982031864	982031835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031835	23249876	Allele A is associated with increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to allele G.	3.5
982031864	1450928798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928798	29621993	Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G.	-1.75
982032257	982032054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032054	23651024	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	0.0
982032396	982032363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032363	23651024	Genotypes CC + CT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT.	0.0
982036556	982031753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031753	22016816	Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.	1.5
982037368	982032965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032965	19106083	Allele C is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	-2.0
982037368	982034154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034154	19530321	Allele C is associated with less decrease in the platelet reactivity after 600 mg of clopidogrel when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	2.25
982037368	982034178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034178	15166949	Genotype CT is associated with decreased antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention when treated with clopidogrel in patients undergoing coronary stent implantation as compared to genotype TT.	1.5
982037368	982035715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035715	16458133	Genotype CT is not associated with differences in platelet inhibition when exposed to clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	-0.25
982037368	1184472141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472141	22028352	Genotypes CC + CT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.	3.25
982037368	1184989701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989701	23834376	Allele C is not associated with resistance to aspirin or clopidogrel as compared to allele T.	-1.0
1148480056	827824903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824903	22188361	Genotype CG is associated with increased risk of severe emesis when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	2.75
1148480056	827828178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828178	22188361	Genotype CG is not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-1.5
982037603	982032893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032893	17900275	Genotypes CT + TT are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype CC.	1.75
982037603	982033093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033093	19463375	Allele T is not associated with differences in platelet inhibition 7h after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-1.25
982037603	1448258628	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258628	25060201	Genotype CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	-0.25
982037603	981344476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344476	22990067	Genotype AC is not associated with high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	-1.75
982037603	982029017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029017	19934793	Genotypes AC + CC are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype AA.	1.75
982037603	982032830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032830	17900275	Genotypes AC + CC are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype AA.	1.75
982037603	982033064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033064	19463375	Allele C is associated with decreased platelet inhibition 7h after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	1.75
982037603	982037616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037616	21831410	Allele C is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele A.	-1.5
982037603	1448258637	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258637	25060201	Genotype AC is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	-1.25
982037603	1448115817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448115817	26526111	CYP2C9 *2 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1.	-1.5
982037603	1448115838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448115838	26526111	CYP2C9 *3 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1.	-1.5
982037603	1448276578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276578	27756942	CYP2C9 *1/*1 is not associated with likelihood of platelet aggregation when exposed to clopidogrel in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *2/*2.	-1.0
982037603	1448729670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448729670	28745576	CYP2C9 *2/*2 is associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C9 *1/*1.	0.0
982040423	982033024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033024	19106083	Allele A is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	-2.0
982040423	982033700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033700	15933261	Allele A is associated with increased risk of neurological events when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotype GG.	2.5
982040423	1446896521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896521	26362473	Genotype AA is not associated with decreased response to clopidogrel as compared to genotype GG.	-2.75
1451398281	982046368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046368	23071495	Genotype CC is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes CG + GG.	2.0
1451398281	827863984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863984	16844790	Genotype CC is associated with increased response when treated with bucindolol in people with Heart Failure as compared to genotype GG.	2.5
1451398293	1446898383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898383	23920449	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	1.5
1183607419	981794217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794217	18221820	Genotypes CT + TT are associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.5
1183607419	981843816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843816	18221820	Genotypes CT + TT are not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-1.5
1183607656	982044801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044801	20346718	Genotype CC is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	3.25
1183574175	1451747900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451747900	23183491	Genotype CC is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotypes CT + TT.	0.0
1156738774	1043859202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859202	19842935	Genotype TT is associated with increased exposure to drug when treated with simvastatin in healthy individuals as compared to genotypes GG + GT.	1.5
1183614504	981755456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755456	23280790	Genotype GG is associated with increased risk of Death when treated with Enzymes in people with Stroke as compared to genotypes AA + AG.	3.5
1183614802	981477269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477269	22541248	Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.	2.0
1183614989	981502148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502148	22926595	CYP2B6 *6/*6 is associated with increased metabolism of mirtazapine in people with Depression.	1.5
1043858656	827785887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785887	20921925	Genotype TT is associated with decreased aspirin-induced asthma when treated with aspirin in people with Asthma as compared to genotypes CC + CT.	1.75
1043859297	981239667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239667	22940005	Genotypes AG + GG are associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotype AA.	3.5
1043859386	981851530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851530	22210424	Allele C is associated with diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	3.0
1043859386	981851562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851562	22210424	Allele C is not associated with increased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	-2.0
1043859386	981851574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851574	22210424	Allele C is associated with increased risk of Proteinuria when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	2.5
1043880303	981478397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478397	23147717	Genotypes AA + AC are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.	1.75
1043880367	981502935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502935	23215885	Allele A is associated with a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans when treated with warfarin as compared to allele G.	2.25
1043880367	1447682722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682722	26745506	Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.	0.0
1143176298	982046440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046440	16321621	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.	2.0
1143176298	982046536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046536	19802823	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.	-1.0
1146391450	827699919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827699919	21788965	Genotypes AA + AG are associated with increased likelihood of glucocorticoid responsiveness when treated with corticosteroids in people with Crohn Disease as compared to genotype GG.	2.75
1148995043	982045496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045496	16103896	Genotype CC is associated with increased response to atorvastatin as compared to genotype AA.	3.5
1148995043	982046554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046554	19802823	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.	-1.0
1148995043	827862165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827862165	18851956	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele C.	2.5
1148995043	827862175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827862175	18851956	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele A.	2.5
1148995043	1447949684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949684	26932749	Genotypes AA + AC are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.	-2.5
1183491021	827785845	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827785845	22027652	Allele A is associated with decreased transport of when exposed to calcein or lopinavir.	0.0
1183532599	1043880045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880045	20064494	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	2.75
1183619312	981476274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476274	18215618	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	2.75
1183564259	982043089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043089	15188945	Genotype GT is associated with increased response to atenolol and irbesartan in men with Essential hypertension as compared to genotype GG.	2.25
1183564259	982043114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043114	15188945	Genotype GT is not associated with response to atenolol and irbesartan in men with Essential hypertension as compared to genotype GG.	-1.25
1183564259	982043126	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043126	15188945	Genotypes GT + TT are not associated with response to atenolol and irbesartan in women with Essential hypertension as compared to genotype GG.	-0.25
1183623069	1000539719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539719	23588304	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	3.75
1183623069	1184988222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988222	25141953	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	3.0
1183623069	1451128209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128209	31666714	Allele G is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.	-1.75
1183623069	1448432084	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448432084	27457817	Allele G is not associated with risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele A.	-1.5
1183623069	1448616356	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616356	28448657	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.	-1.5
1183629480	1183629398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629398	23859574	Genotype GG is associated with increased general adverse reactions when treated with risperidone in healthy individuals as compared to genotypes AA + AG.	1.75
1183631536	1183492303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183492303	23963862	Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes GG + GT.	2.5
1183631564	1183492275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183492275	23422377	Genotype TT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotypes GG + GT.	3.0
1183631564	1450928272	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928272	28696411	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	-1.75
1183631782	981848274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848274	23508266	Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T.	0.0
1183679813	827829070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829070	22310351	Allele T is associated with increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to allele C.	0.0
1451398307	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1451398314	1446898364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898364	23920449	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	1.25
1451398314	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1183492249	982045529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045529	16103896	Genotype CT is associated with increased response to atorvastatin as compared to genotype CC.	3.0
1183492249	1043859215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859215	20031582	Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.	3.0
1183492249	827807830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807830	20031551	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.	3.0
1183492249	1450972880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450972880	17289397	Genotype CT is associated with increased likelihood of lipid response when treated with atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin as compared to genotype CC.	0.0
1183492249	1450973800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450973800	19667110	Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC.	3.5
1183679833	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183679833	769176398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176398	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1183679833	1184473513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473513	23942539	Allele G is associated with increased risk of Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele A.	2.0
1183679833	1447945640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945640	26099996	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.75
1183679833	1448108454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108454	14635116	Genotype AG is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.0
1183679833	1448119107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119107	18299612	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
1183679833	1448120824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448120824	19473056	Genotype AG is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.5
1183679833	1448122765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122765	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1183679833	1448124027	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124027	23588312	Genotype AG is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype AA.	-0.0
1183679833	1448124372	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448124372	23942539	Genotypes AG + GG is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.0
1183679833	1448126296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126296	26794347	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele A.	-2.0
1183679833	1448262714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262714	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1183679833	1449162083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162083	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1183617651	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1183617651	PA166104982	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104982		Annotation of DPWG Guideline for amitriptyline and CYP2D6	100
1183617651	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183617651	1446901072	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901072	7159207	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183617651	1446901646	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901646	3571939	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in people with Depression as compared to CYP2D6 normal metabolizers.	0.0625
1183617651	827777562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777562	15205367	CYP2D6 *4 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	827777575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777575	15205367	CYP2D6 *10 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	827777570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777570	15205367	CYP2D6 *41 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	1.5
1183617651	1183615357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615357	17764479	CYP2D6 *4/*4 is associated with increased amitriptyline + nortriptyline plasma concentration in one CYP2D6 PM when treated with amitriptyline.	0.125
1183617651	1183615381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615381	17764479	CYP2D6 *4/*4 is associated with increased nortriptyline/(E)-10-OH-NT ratio when treated with amitriptyline as compared to CYP2D6 *1.	1.5
1183617651	1183615397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615397	17764479	CYP2D6 *4/*4 is associated with increased amitriptyline/(E)-10- OH-AT ratio when treated with amitriptyline as compared to CYP2D6 *1.	1.0
1183617651	1183617193	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617193	12172336	CYP2D6 *2/*5 + *1/*10 is not associated with differences in the ratio of nortriptyline and its metabolite when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	-0.5
1183617651	1183617206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617206	12172336	CYP2D6 *5/*10 + *10/*10 is associated with increased ratio of nortriptyline and its metabolite (NT/EHNT) when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	0.0
1183617651	1183623082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623082	16024198	CYP2D6 *4/*4 is associated with decreased clearance of amitriptyline in one suicide case.	0.25
1183617651	1446902725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902725	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	1.0
1183617651	1446903079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903079	20531370	CYP2D6 *3 + *4 + *5 + *6 are associated with increased concentrations of nortriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.0
1183617651	1446903324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903324	21614669	CYP2D6 *4/*4 is associated with increased concentrations of amitriptyline.	0.125
1183617651	1446903345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903345	16024198	CYP2D6 *4/*5 + *4/*4 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.	2.5
1183617651	1446903489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903489	17764479	CYP2D6 *4/*4 is not associated with metabolism of amitriptyline as compared to CYP2D6 normal metabolizers.	-0.125
1183617701	769218954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769218954	21121774	Genotype TT is associated with slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.0
1183617701	827695955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695955	21121774	Genotype TT is associated with slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.5
1183620959	1183685166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685166	22015451	G6PD deficiency is associated with Hemolysis when treated with methylene blue and rasburicase in people with Neoplasms.	0.125
1183620959	1183685184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685184	18561168	G6PD deficiency is associated with lack of response when treated with methylene blue in children with Hyperuricemia.	0.125
1183620959	1183685284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685284	16493607	G6PD deficiency is associated with Hemolysis when treated with methylene blue in men with Methemoglobinemia.	0.125
1183620959	1183685289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685289	15842651	G6PD deficiency is associated with Hemolysis when treated with methylene blue in men with Methemoglobinemia.	0.125
1183620959	1183685297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685297	11048840	G6PD deficiency is associated with Hyperbilirubinemia when exposed to methylene blue in infants.	0.125
1183620959	1183685302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685302	9590495	G6PD deficiency is associated with lack of response when treated with methylene blue in infants with Methemoglobinemia.	0.125
1183620959	1183685307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685307	17444323	G6PD deficiency is associated with lack of response when treated with methylene blue in women.	0.125
1183620959	1183685312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685312	15787927	G6PD deficiency is associated with Jaundice when treated with methylene blue in infants with Methemoglobinemia.	0.125
1183620959	1183685366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685366	15587250	G6PD deficiency is associated with lack of response when treated with methylene blue in men with Methemoglobinemia.	0.125
1183620959	1183685371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685371	11418378	G6PD deficiency is associated with lack of response when treated with methylene blue and vitamin c in men with Methemoglobinemia.	0.125
1183620959	1183685383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685383	11824767	G6PD deficiency is associated with Anemia, Hemolytic when treated with methylene blue in men with methemoglobinemia.	0.125
1183620959	1183685388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685388	9605379	G6PD deficiency is associated with Methemoglobinemia when treated with methylene blue in women undergoing a laparoscopy.	0.125
1183620959	1183685393	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685393	17026773	G6PD deficiency is associated with a reduction in hemoglobin value when treated with methylene blue in children with Malaria.	0.0
1183620959	1183704109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704109	15655011	G6PD deficiency is not associated with hemolysis when treated with chloroquine and methylene blue in healthy individuals.	-0.625
1183620959	1183704160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704160	16179085	G6PD deficiency is not associated with severe hemolysis when treated with chloroquine and methylene blue in children with Malaria.	-0.125
1183620959	1444713834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713834	26033222	G6PD deficiency is associated with Anemia, Hemolytic and Methemoglobinemia when treated with methylene blue and rasburicase.	0.125
1183620959	1183620647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620647	5091568	G6PD A-202A_376G is associated with a lack of response when treated with methylene blue in men with Methemoglobinemia.	0.25
1183620959	1183620675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620675	23135803	G6PD A- 202A_376G is associated with Hemolysis when treated with methylene blue in children with Malaria.	0.0
1183622263	1183616457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616457	23859572	Genotype TT is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CC + CT.	1.5
1183680531	827807933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807933	20809084	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.5
1451398287	1446898364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898364	23920449	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	1.25
1183632108	1183631253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183631253	23753411	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	0.0
1183693532	827829013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829013	22310352	Allele G is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	0.0
1183679853	827863553	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863553	22267851	Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G.	0.0
1183679858	981802626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802626	23478653	Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.	0.0
1183684144	827920238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827920238	22584460	Allele A is associated with decreased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.	2.75
1183684167	827920257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827920257	22584460	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.	2.75
1183693438	1183681629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681629	23315321	Genotype AA is associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotypes AC + CC.	1.75
1183693448	1183681625	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681625	23315321	Genotypes CC + CT are associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotype TT.	2.25
1183697388	1183697377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697377	22281720	CYP2D6 *10 + *5 are associated with decreased metabolism of lovastatin in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183679823	827805817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805817	21900104	Allele A is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1183679823	1448109278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109278	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.5
1451398347	1446898364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898364	23920449	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	1.25
1451398347	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1451398347	1446898605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898605	23799528	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	-1.0
1451403400	1451402260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402260	33589790	Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype TT.	2.0
1451403420	1451402345	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402345	33589790	Genotype AA are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AG + GG.	2.0
1183690892	1183680808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680808	23996099	Genotypes AA + AG are associated with increased resistance to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype GG.	2.25
1183697278	1183697248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697248	22294058	Genotypes AT + TT are associated with decreased metabolism of losartan in healthy individuals as compared to genotype AA.	1.25
1183697278	1185234889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234889	25303293	Genotype AA is associated with decreased metabolism of losartan in healthy individuals as compared to genotype TT.	1.5
1183680546	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183680546	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
1183680546	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183680546	981240127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240127	22626609	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
1183680546	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1183680546	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183680546	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183689079	PA166181885	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166181885		Annotation of CPIC Guideline for atomoxetine and CYP2D6	100
1183689079	PA166104989	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104989		Annotation of DPWG Guideline for atomoxetine and CYP2D6	100
1183689079	1447679997	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447679997	11854152	CYP2D6 poor metabolizers are associated with decreased clearance of atomoxetine in human microsomes.	0.0
1183689079	1447680051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680051	12485958	CYP2D6 poor metabolizers are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183689079	1183678529	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678529	17470523	CYP2D6 *10 is associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.	0.0
1183689079	1183678537	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678537	17470523	CYP2D6 *17 is associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.	0.0
1183689079	1183688850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688850	17224704	CYP2D6 *4/*5 is associated with increased atomoxetine and methylphenidateplasma concentration after overdose when exposed to atomoxetine and methylphenidate.	0.125
1183689079	1183688880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688880	21543662	CYP2D6 *10/*10 is associated with increased area under the plasma concentration-time curve values when treated with atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.	0.125
1183689079	1183688895	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688895	21543662	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.	1.5
1183689079	1447813900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813900	17610534	CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.	1.5
1183689079	1447814409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814409	26254792	CYP2D6 *10/*10 + *1/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.	2.25
1183689079	1447814438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814438	26254792	CYP2D6 *10/*10 + *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.	2.25
1183689079	1447943783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447943783	26660002	CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.	2.0
1183689079	1447943838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447943838	26660002	CYP2D6 *4/*4xN + *4/*4 are associated with decreased clearance of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29.	1.0
1183689079	1447943944	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447943944	26666748	CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 when assayed with atomoxetine in microsomes from insect cells Sf21 as compared to CYP2D6 *1.	0.0
982031330	827816749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816749	21961650	Allele G is associated with response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
982032721	981954215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954215	23315174	Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.	2.25
982036604	982031782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031782	22016816	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.	1.5
982036604	1449576787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576787	29938344	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	-1.5
982037753	982037581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037581	14625131	Genotype GG is associated with decreased response to simvastatin in men with Hyperlipidemias as compared to genotypes AA + AG.	1.75
982038273	827778142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778142	22006095	Genotypes AG + GG are associated with increased significantly better response (Hamilton Anxiety Scale (HAM-A)) at 6 months of treatment when treated with venlafaxine in people with Anxiety Disorders as compared to genotype AA.	2.0
982038273	827778150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778150	22006095	Genotypes AG + GG are associated with significantly better improvement (Clinical Global Impression of Improvement (CGI-I) score) at 6 months of treatment when treated with venlafaxine in people with Anxiety Disorders as compared to genotype AA.	2.5
982045124	981345172	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345172	21883387	Genotype AA is associated with decreased the time to achieve a first INR within the therapeutic range when exposed to fluindione in people with venous thromboembolism as compared to genotype GG.	3.25
982045124	981345181	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345181	21883387	Genotype AA is associated with decreased the time to achieve a first INR within the therapeutic range when exposed to fluindione in people with venous thromboembolism as compared to genotype AG.	2.75
1043858685	1043758875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043758875	19448967	Allele A is associated with Peptic Ulcer when treated with aspirin in people with Cardiovascular Diseases as compared to allele G.	1.5
1043858840	982038305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038305	20653674	Allele T is associated with decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to allele C.	2.75
1183697531	1183697523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697523	24143213	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	2.5
1183697570	1183681994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681994	24019753	Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes AA + GG.	1.0
1183697570	1183681999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681999	24019753	Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.	1.0
1183697670	1183697658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697658	23444281	UGT2B15 *2/*2 is associated with increased response to sipoglitazar as compared to UGT2B15 *1/*1 + *1/*2.	2.5
1183697670	1183689468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689468	22960998	UGT2B15 *2 is associated with decreased clearance of sipoglitazar in healthy individuals as compared to UGT2B15 *1.	1.75
1183698841	982046726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046726	23127916	Genotype TT is associated with decreased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	2.75
1183698841	1183703531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703531	22875622	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	2.0
1183698841	1183703560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703560	22875622	Genotype TT is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	-1.5
1183698841	1183703603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703603	22875622	Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	2.0
1183698841	1183703607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703607	22875622	Genotype TT is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.	-1.5
1043858632	981750815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750815	19590397	Allele T is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	-1.75
1043858632	982023021	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023021	23221997	Genotypes GT + TT are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	2.5
1043858632	982023044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023044	23221997	Allele T is not associated with remission rates when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	-1.5
1043858632	982028731	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028731	23733030	Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes GT + TT.	-1.0
1043858632	982028738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028738	23733030	Genotype GG is not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes GT + TT.	-1.0
1043858632	1451148543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451148543	31721892	Genotypes GT + TT are associated with decreased response to escitalopram in people with Depression as compared to genotype GG.	1.75
1183697623	981755270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755270	22840423	Genotype TT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	-1.75
1183697623	981755292	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755292	22840423	Genotype CT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	-1.75
1183697623	1183682066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682066	23559864	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	-1.5
1183697623	1183682073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682073	23559864	Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT.	3.0
1451398299	1446898383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898383	23920449	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	1.5
1451403428	1451402301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402301	33589790	Genotypes CT + TT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype CC.	2.0
1183697575	1451504503	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451504503	22074251	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.5
1183697575	1451506300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506300	23198157	Genotype GG is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.	2.0
1183697575	1451506467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506467	24386571	Genotype TT is associated with decreased response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.	2.5
1183697575	827698241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698241	21747412	Genotype TT is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.	-2.0
1183697575	608431575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431575	14647408	Allele T is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.0
1183697575	608431618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431618	15781665	Allele T is not associated with increased risk of relapse when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-2.0
1183697575	637879752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879752	17512587	Allele T is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-0.25
1183697575	769146384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146384	15569990	Genotype GG is associated with decreased risk of relapse when treated with methotrexate in people with allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia. as compared to genotype TT.	3.25
1183697575	769170965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170965	16019535	Allele G is not associated with increased risk of second malignancy when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-0.25
1183697575	1183681733	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681733	23652803	Genotype GG is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-2.25
1183697575	1184510357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510357	23488607	Genotype TT is not associated with survival when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GT.	-1.25
1043858882	827690514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827690514	15861036	Allele G is associated with increased risk of Fractures, Bone when treated with calcium.	2.25
1043859365	827815152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815152	21052032	Allele A is associated with increased likelihood of remission when treated with desipramine in people with Depressive Disorder, Major as compared to allele G.	2.25
1043873003	827917986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827917986	22547144	Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT.	2.5
1043880165	981848218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981848218	22417933	Genotype GG is not associated with response to venlafaxine in people with Anxiety Disorders as compared to genotypes AA + AG.	-1.5
1043880165	981848236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981848236	22417933	Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG.	2.0
1043880165	1448639101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448639101	28627776	Genotypes AG + GG is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to genotype AA.	-1.5
1043880165	982023623	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023623	23706899	Genotype GG is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.5
1043880649	827808087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808087	21832968	Genotypes AA + AT are associated with same protective properties against angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain in people with homozygous GG genotype for rs4343 as compared to genotype TT.	2.25
1127445681	769259039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769259039	19628728	Allele G is associated with increased metabolism of zidovudine as compared to allele A.	1.5
1131245975	769259090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769259090	16791115	Allele T is associated with increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment when treated with indinavir, lamivudine and zidovudine in people with HIV Infections as compared to genotype CC.	0.125
1183491298	981785488	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785488	23407047	Genotypes CT + TT are associated with decreased biochemical response, optimal cytoreduction, and sensitivity to the induction chemotherapy treatment when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.	0.75
1183491385	982045488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045488	16002074	Genotype GG is associated with decreased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AG.	0.0
1183533882	982045665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045665	16103896	Genotype GG is associated with increased response to pravastatin as compared to genotypes CC + CG.	2.75
1183533972	982044931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044931	20235788	Genotype GG is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes AA + AG.	3.25
1183533972	982044957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044957	20235788	Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AA + AG.	3.0
1183533972	982044983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044983	20235788	Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotype AA.	3.0
1183589777	982045404	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045404	20877298	Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.	1.75
1183614687	981848128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848128	22760553	Allele A is associated with increased general side-effect burden when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	0.0
1183614701	981502232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502232	22795047	Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	3.0
1183615383	982046742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046742	23127916	Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.	2.25
1183615450	982047143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047143	23175667	CYP2C19 *2/*2 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.	1.5
1183615450	982047169	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047169	23175667	CYP2C19 *2/*2 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.	-0.25
1183620032	1183619873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619873	15126005	G6PD A- 202A_376G/A- 202A_376G is associated with Anemia, Hemolytic when treated with glibenclamide in people with Diabetes Mellitus, Type 2.	0.25
1183620032	1183943963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183943963	21147013	G6PD A-202A_376G/A-202A_376G (assigned as deficiency phenotype) is associated with Hemolysis when treated with glibenclamide in women with Diabetes Mellitus, Type 2.	0.25
1183630271	827892902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892902	22516052	Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1183630271	1448616311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616311	28448657	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.	-1.5
1043859430	PA166105000	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105000		Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6	100
1043859430	PA166104994	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104994		Annotation of DPWG Guideline for doxepin and CYP2D6	100
1043859430	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1043859430	1446900301	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446900301	11037801	CYP2D6 poor metabolizers are associated with decreased metabolism of doxepin in human liver microsomes as compared to CYP2D6 normal metabolizers.	0.0
1043859430	982030079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030079	12360109	CYP2D6 *4/*4 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1043859430	982030087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030087	12360109	CYP2D6 *4/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1043859430	982030093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030093	12360109	CYP2D6 *3/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1043859430	982030125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030125	16007002	CYP2D6 *1/*1xN is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1043859430	1183617426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617426	18070221	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	2.5
1043859430	1183622800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622800	16007002	CYP2D6 *2xN/*1 is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183622848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622848	16007002	CYP2D6 *35/*1xN is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1183622858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622858	16007002	CYP2D6 *2xN/*35 is associated with decreased AUC of the sum of doxepin and N-desmethyldoxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1043859430	1446905682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905682	17721180	CYP2D6 *3/*4 is associated with decreased metabolism of doxepin.	0.125
1043859430	1446905879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905879	12360109	CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1043859430	1446905772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905772	16007002	CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.	2.0
1183631545	1183492307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183492307	23963862	Genotype AG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes AA + GG.	3.0
1183632160	827700678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700678	21808285	Allele A is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.	3.0
1183634192	827704966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704966	19659438	Genotype AC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	0.25
1183634192	1183634168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634168	24080498	Genotypes AC + CC are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype AA.	2.25
1183634192	1183703693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703693	24477223	Genotype AA is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	-0.75
1183634192	1184467517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467517	24729586	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele A.	2.25
1183634192	1451127220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451127220	31628422	Genotype AC is not associated with exposure to efavirenz in healthy individuals as compared to genotype AA.	-0.125
1183634192	1448994381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994381	28886044	Genotype AC is associated with increased concentrations of efavirenz in children with HIV Infections.	1.5
1183679775	769246509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769246509	17611010	Genotypes AC + CC are associated with increased QT interval when treated with chlorpromazine in people with Schizophrenia as compared to genotype AA.	1.5
1183679775	769246512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769246512	17611010	Genotypes AC + CC are associated with increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to genotype AA.	2.0
1183679799	981344110	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344110	22912756	Allele T is associated with increased risk of Diarrhea when treated with sorafenib in people with Neoplasms as compared to allele C.	1.75
1451398380	1446898364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898364	23920449	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	1.25
1451398380	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1451403440	1451402306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402306	33589790	Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype TT.	2.0
1183631507	981728486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981728486	23353631	Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.	2.25
1183631507	981732098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981732098	23353631	Allele G is not associated with response to hydrochlorothiazide in people with Hypertension as compared to allele A.	-1.75
1183631507	827924775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924775	18591455	Genotype AA is associated with decreased reduction in SBP when treated with hydrochlorothiazide in people with Hypertension.	0.0
1183631507	1183631485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183631485	21052022	Genotypes AG + GG are associated with increased response to Beta blocking agents, selective or diuretics in people with Hypertension as compared to genotype AA.	2.5
1183621261	PA166127636	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127636		Annotation of CPIC Guideline for paroxetine and CYP2D6	100
1183621261	PA166104976	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104976		Annotation of DPWG Guideline for paroxetine and CYP2D6	100
1183621261	1183695918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183695918	1531950	CYP2D6 poor metabolizers are associated with increased median AUC, plasma half-life and steady-state plasma concentrations of paroxetine when exposed to paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183621261	1184137305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137305	10434486	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in people with Depressive Disorder, Major.	1.0
1183621261	1184137318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137318	1531950	CYP2D6 poor metabolizers is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183621261	1184165939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165939	16319918	CYP2D6 poor metabolizers is associated with increased steady-state Cmax and AUC(0-24) and the lowest clearance when treated with paroxetine in children with Depressive Disorder, Major.	0.0625
1183621261	1184169696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169696	1531951	CYP2D6 poor metabolizers are associated with increased paroxetine plasma concentration when treated with paroxetine in people with Diabetic Neuropathies as compared to CYP2D6 normal metabolizers.	0.0625
1183621261	982047439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047439	16319918	CYP2D6 *1/*1 is associated with increased clearance of paroxetine in children with Depressive Disorder, Major.	0.0
1183621261	1183615301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615301	16669849	CYP2D6 *5 is associated with decreased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183621261	1183619689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619689	16319918	CYP2D6 *2/*2 is associated with increased clearance of paroxetine in children with Depressive Disorder, Major.	0.0
1183621261	1183620613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620613	14639062	CYP2D6 *3/*4 + *4/*4 + *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	1.5
1183621261	1183620621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620621	14639062	CYP2D6 *3/*4 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
1183621261	1183620631	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620631	14639062	CYP2D6 *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
1183621261	1183620639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620639	14639062	CYP2D6 *2/*2xN is associated with undetectable paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major.	1.5
1183621261	1183620645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620645	19743889	CYP2D6 *1/*4 + *1/*5 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.	1.75
1183621261	1183620663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620663	19743889	CYP2D6 *4/*4 + *3/*4 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.	1.75
1183621261	1183620727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620727	16633156	CYP2D6 *1/*2xN is associated with low or undetectable paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1183620762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620762	20174590	CYP2D6 *1/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
1183621261	1183620875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620875	20174590	CYP2D6 *4/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
1183621261	1183620950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620950	12173784	CYP2D6 *9/*2xN is associated with undetectable paroxetine plasma concentration when treated with paroxetine in healthy individuals.	0.125
1183621261	1183621057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621057	18641553	CYP2D6 *1/*1xN is associated with undetectable paroxetine serum concentration when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1183621076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621076	18641553	CYP2D6 *1/*1xN is associated with decreased paroxetine serum concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
1183621261	1183621104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621104	15349705	CYP2D6 *10/*10 + *1/*10 is not associated with differences in plasma paroxetine concentrations at administered dose above 10mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.25
1183621261	1183621118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621118	15349705	CYP2D6 *10/*10 + *1/*10 are associated with increased plasma paroxetine concentrations at administered dose of 10mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183621261	1183621133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621133	16423440	CYP2D6 *1/*10 + *1/*5 is associated with increased paroxetine plasma concentration at an administered dose of 30mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.25
1183621261	1183621153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621153	16423440	CYP2D6 *1/*10 + *1/*5 is not associated with differences in paroxetine plasma concentration when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.25
1183621261	1183701674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701674	10505591	CYP2D6 *1/*3 + *1/*4 + *1/*5 is associated with increased median paroxetine steady-state plasma concentration when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
1183621261	1183701701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701701	16534507	CYP2D6 *10 + *5 is not associated with differences in paroxetine daily dose, plasma concentrations or nausea when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1.	-0.75
1183621261	1184137325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137325	10824636	CYP2D6 *10/*10 is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1183621261	1184165575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165575	16633156	CYP2D6 *1/*2xN is associated with undetectable or low paroxetine serum concentrations when treated with paroxetine in people with Depressive Disorder, Major.	0.125
1183621261	1184169844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169844	17256449	CYP2D6 *1/*4 is associated with increased paroxetine serum concentrations (Cmin) when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*41.	1.0
1183621261	1184468801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468801	15544025	CYP2D6 *1/*5 is associated with increased plasma concentration when treated with paroxetine.	0.125
1183621261	1444712725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712725	25967538	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .	2.0
1183621261	1444712755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712755	25967538	CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizers phenotype) .	1.5
1183621261	1448108691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108691	27187662	CYP2D6 *10/*10 is not associated with metabolism of paroxetine as compared to CYP2D6 *10/*41 + *41/*41 + *1/*10 + *1/*41 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.	-1.0
1183621261	1449310381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310381	28933337	CYP2D6 *5/*10 + *10/*10 + *10/*14 are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10 + *2/*14.	0.125
1183621261	1183615266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615266	16669849	CYP2D6 *4/*5 is associated with decreased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183621261	1183615309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615309	16669849	CYP2D6 *2xN is associated with increased paroxetine Vm (maximal rate) when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 *1/*1.	0.0
1183679808	827863608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863608	22267851	Allele C is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele T.	0.0
1183684132	827920292	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827920292	22584460	Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT.	2.75
1451398387	1446898383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898383	23920449	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	1.5
1451398394	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1183689492	1183632031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632031	11901361	CYP2D6 *1/*3 + *1/*4 are associated with increased Weight gain when treated with olanzapine in men with Schizophrenia as compared to CYP2D6 *1/*1.	2.0
1183682148	1451415020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415020	32483200	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele C.	-0.75
1183682148	1183682134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682134	23263737	Genotype CC is associated with increased clearance of lamotrigine as compared to genotypes CT + TT.	1.25
1183682148	1447682974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682974	26790665	Genotypes CT + TT are associated with increased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype CC.	2.0
1183682148	1447983624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983624	27096250	Genotype TT is associated with decreased clearance of lamotrigine in people with Epilepsy as compared to genotypes CC + CT.	1.25
1183682148	1448098996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448098996	26213157	Genotype CC is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.	-1.0
1183693378	981349421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349421	16538176	HLA-B *40:01:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	3.0
1183693378	1183680916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680916	23692434	HLA-B *40:01:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
1183693378	1183702077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702077	24336023	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
1183693378	1184407446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407446	16981842	HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	-1.25
1183693378	1184468430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468430	24268988	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
1183693378	1451640980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451640980	34350628	HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
1043859063	982037675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037675	18542840	Genotypes CT + TT are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	3.5
1183491044	981851766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851766	23524664	Genotypes GT + TT are associated with increased mitotane plasma concentrations when treated with mitotane in people with Adrenocortical Carcinoma as compared to genotype GG.	2.0
1183491044	981857028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981857028	23524664	Genotypes GT + TT are associated with being a predictor of mitotane plasma concentrations of at least 14 g/ml after 3 months of treatment when treated with mitotane in people with Adrenocortical Carcinoma as compared to genotype GG.	1.5
1183594148	982045029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045029	20577119	Genotypes AA + AT are associated with decreased fasting glucose when treated with amlodipine, chlorthalidone or lisinopril in people with Hypertension as compared to genotype TT.	2.0
1183603970	981478496	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478496	22967772	Allele T is associated with increased Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C.	2.0
1183614807	982044923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044923	20235788	Genotype AA is associated with increased response to atenolol in people with Essential hypertension as compared to genotype CC.	3.25
1183614807	982044949	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044949	20235788	Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AC + CC.	3.0
1183614807	982044975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044975	20235788	Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotype CC.	3.0
1183615242	982033386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033386	9869506	Genotype del/del is not associated with response to lisinopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-0.25
1183615242	1183491887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491887	9726242	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to lisinopril in people with Diabetes Mellitus, Type 1 as compared to genotype del/del.	0.0
1183615268	982029670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029670	23314736	Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG.	2.75
1183615268	1448522390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448522390	20530282	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
1183615317	655387621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387621	18981587	Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	1.25
1183624570	1450808664	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808664	11434512	Genotypes *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased response to rabeprazole in people with Helicobacter Infections as compared to genotype *1/*1.	1.625
1183624570	1450809758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809758	11552922	CYP2C19 poor metabolizers are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 normal metabolizers.	-0.75
1183624570	1184754985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754985	24996380	CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to rabeprazole in healthy individuals as compared to CYP2C19 poor metabolizer.	1.0
1183624570	827807793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807793	19166419	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.0
1183624570	1183617400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617400	11012469	CYP2C19 *1/*1 is not associated with intragastric pH when treated with rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.25
1183624570	1183618318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618318	11380317	CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	2.0
1183624570	1183618624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618624	12121503	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183624570	1183619140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619140	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-1.5
1183624570	1183619151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619151	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183624570	1183619844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619844	14687173	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.	1.5
1183624570	1183620160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620160	15470328	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183624570	1183620682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620682	15903128	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624570	1183620712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620712	15903128	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624570	1183620725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620725	15903128	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals.	-0.25
1183624570	1183621271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621271	16863547	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.875
1183624570	1183621341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621341	16863547	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-1.0
1183624570	1183621354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621354	16863547	CYP2C19 *1/*2 + *1/*3 is not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.875
1183624570	1183621475	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621475	16911688	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	-1.5
1183624570	1183622310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622310	16937451	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	-0.375
1183624570	1183622326	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622326	16937451	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	-0.375
1183624570	1183622336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622336	16937451	CYP2C19 *1/*2 + *1/*3 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	-0.375
1183624570	1183622976	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622976	17725594	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	-0.25
1183624570	1183622993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622993	17725594	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux.	-0.25
1183624570	1183624342	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624342	19552744	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-0.25
1183624570	1183679160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679160	20633187	CYP2C19 *1/*1 is associated with decreased response to omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1183624570	1183679247	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679247	22324425	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2.	2.0
1183624570	1183679530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679530	23646118	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.0
1183624570	1183679601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679601	11446878	CYP2C19 *1/*1 is not associated with response to omeprazole or rabeprazole in people with Helicobacter Infections.	-1.5
1183624570	1183679621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679621	11785712	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.25
1183624570	1183680098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680098	20559522	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.5
1183624570	1183680124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680124	21054464	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.5
1183624570	1183680182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680182	21118735	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Helicobacter Infections.	-1.5
1183624570	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183624570	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183624570	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183624570	1183679880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679880	14638340	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183624570	1183679894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679894	14638340	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183624570	1183680006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680006	16815316	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183624570	1183680019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680019	16815316	CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183624570	1183621166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621166	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183624570	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183624570	1183621202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621202	16863547	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183624570	1183621191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621191	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183624570	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183624570	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183624570	1183620172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620172	15470328	CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	2.0
1183624570	1451253729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253729	15715938	CYP2C19 *1/*1 is not associated with response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	-1.0
1183624570	1451343200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343200	21083596	CYP2C19 *2 is not associated with response to rabeprazole in people with Heartburn as compared to CYP2C19 *1/*1.	-1.5
1183624570	1451343240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343240	16133961	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Peptic Ulcer as compared to CYP2C19 *1/*1.	-0.25
1183624570	1451343120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343120	16911680	CYP2C19 *1/*1 + *1/*2 are not associated with response to rabeprazole in people with Peptic Ulcer as compared to CYP2C19 *2/*2.	-1.25
1183624570	1451343500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343500	30038671	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	-1.5
1183624570	1451343340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343340	27282261	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Ulcer as compared to CYP2C19 *1.	-1.25
1183624570	1451344540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344540	12848631	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.25
1183624570	1451344548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344548	14695703	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183624570	1451344650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344650	20831535	CYP2C19 *2 + *3 are not associated with response to esomeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183624570	1451344640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344640	17439512	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1.	-1.75
1183624570	1451344680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344680	26075959	CYP2C19 *2 + *3 are not associated with response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183624570	1183623333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623333	17934830	CYP2C19 *1/*1 is not associated with response to rabeprazole in people with Ulcer.	-0.25
1183693527	981488663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981488663	21095016	Allele T is associated with increased prolactin when treated with olanzapine in women as compared to allele G.	1.75
1183697628	1183682248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682248	22875663	Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.	2.0
1183697633	1183682206	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682206	23384627	Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG.	2.75
1183698813	982036737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036737	16849011	Allele A is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to allele G.	1.0
1451403437	1451402312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402312	33589790	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.	2.0
1183689558	PA166104955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104955		Annotation of DPWG Guideline for hormonal contraceptives for systemic use and F5	100
1183689558	1183685452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685452	7968118	Genotypes CT + TT are associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	0.0
1183689558	1183689235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689235	12069454	Genotype CT is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	3.5
1183689558	1183689367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689367	15208046	Genotypes CT + TT is not associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	-1.75
1183689558	1183689500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689500	16769590	Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	1.75
1183689558	1448993770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993770	28750087	Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.	3.5
1183689558	1183689466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689466	15946211	Genotypes CT + TT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.	0.0
1183688999	1183688829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688829	16338280	CYP2C19 *2 + *3 is associated with decreased metabolism of diazepam as compared to CYP2C19 *1.	1.75
1183700483	827918002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827918002	22547144	Genotypes CC + CT are associated with decreased reduction in fasting IL-2 when treated with fenofibrate as compared to genotype TT.	2.5
1183700493	827774270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827774270	20585342	Genotype CC is associated with decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to genotypes CT + TT.	2.25
1183700857	1183700819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700819	24090479	Genotypes CT + TT are associated with decreased response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC.	2.75
1183701206	1183701145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701145	24236482	HLA-A *02:07:01 is associated with Stevens-Johnson Syndrome when treated with zonisamide.	3.0
1183701224	PA166105008	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105008		Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B	100
1183701224	981482109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482109	23132554	HLA-A *31:01:02 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.	1.75
1183701224	992282434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/992282434	23588310	HLA-A *31:01:02 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.	2.5
1183701224	993813998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/993813998	23588310	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.	2.5
1183701224	993944301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/993944301	23588310	HLA-A *31:01:02 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	-1.5
1183701224	1183702064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702064	24336023	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
1183701224	1184466701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466701	21149285	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.75
1183701224	1184466909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466909	21428769	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	2.75
1183701224	1184466916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466916	21428769	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	3.25
1183701224	1184466922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466922	21428769	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
1183701224	1184467913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467913	21917426	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	4.0
1183701224	1184467926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467926	21917426	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	4.0
1183701224	1184467950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467950	21917426	HLA-A *31:01:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
1183701224	1184468310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468310	22348435	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.0
1183701224	1184468437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468437	24268988	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	3.5
1183701224	1184468448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468448	24268988	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.75
1183701224	1184469161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469161	24322785	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	4.0
1183701224	1184469204	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469204	24322785	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-3.5
1183701224	1184469261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469261	24322785	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	2.0
1183701224	1184469272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469272	24322785	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.0
1183701224	1184988697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988697	24897291	HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.25
1183701224	1296598666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598666	22211527	HLA-A *31:01:02 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	2.5
1183701224	1444935634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935634	25495410	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	0.625
1183701224	1448525723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525723	27888155	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	3.75
1183701224	1448612304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448612304	28340402	HLA-A *31:01:02 is associated with Exanthema when treated with carbamazepine in people with Epilepsy.	0.25
1183701224	1449295707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449295707	29610831	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Erythema multiforme NOS, Hypersensitivity and Maculopapular Exanthema when treated with carbamazepine in people with Bipolar Disorder, Epilepsy, Neuralgia or Schizophrenia.	0.0
1183701224	1450376254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376254	29288229	HLA-A *31:01:02 is not associated with risk of Maculopapular Exanthema due to carbamazepine.	-1.5
1183701224	1450376262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376262	29288229	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema due to carbamazepine.	0.0
1451403454	1451402321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402321	33589790	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.	2.0
1451403500	1451402360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402360	33589790	Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes CT + TT.	2.0
1451403500	1184755237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755237	24086514	Allele T is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele C.	-0.75
981238570	827793071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793071	20194698	Genotype TT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.	2.5
981238570	827793083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793083	20194698	Genotype CT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.	3.0
982009415	982006188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006188	23613831	Genotypes AA + AG are associated with increased reduction in blood pressure when treated with calcium channel blockers or nitrendipine in people with Essential hypertension as compared to genotype GG.	2.75
1451403476	1451402440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402440	33589790	Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes CT + TT.	2.0
981239773	981240106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240106	22863269	Genotype GG is associated with lack of treatment response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.	2.0
981239773	981344120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344120	22345656	Genotype TT is not associated with virological response (early, end-of-treatment and sustained virological response) in HCV-5 infected chronic hepatitis C patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotypes GG + GT.	-0.25
981239773	981352170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352170	22438096	Genotype TT is associated with increased response (SVR) in HCV genotype 1 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981352176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352176	22438096	Genotype TT is not associated with increased response (SVR) in HCV genotype 2 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.25
981239773	981352194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352194	22438096	Genotype TT is associated with increased response (SVR) to interferon monotherapy in HCV genotype 1 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981352203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352203	22438096	Genotype TT is not associated with increased response (SVR) to interferon monotherapy in HCV genotype 2 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.75
981239773	981419788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419788	21374656	Genotype TT is associated with rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.75
981239773	981419798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419798	21374656	Genotype TT is not associated with sustained virological response (SVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.75
981239773	981419920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419920	21145807	Genotype TT is not associated with sustained virological response (SVR) rate in HCV genotype 3 patients when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.25
981239773	981419932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419932	21145807	Genotype TT is associated with faster viral elimination (early virologic response) at week 2 or week 4 of antiviral treatment in HCV genotype 3 patients when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	0.0
981239773	981419944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419944	21068134	Genotype TT is associated with sustained virological response (SVR) and changes in viral load after 4 weeks of treatment when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	981479632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479632	21503910	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	981479639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479639	21503910	Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	2.75
981239773	981479677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479677	21739446	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	981479690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479690	21739446	Genotype TT is not associated with resistance to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-0.5
981239773	981481540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481540	21048934	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	981481554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481554	21321200	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	2.25
981239773	981481560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481560	21321200	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	2.25
981239773	981481567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481567	21254157	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	981483529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483529	21360545	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.0
981239773	981483541	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483541	21112660	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.0
981239773	981483548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483548	21112660	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	981501236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501236	23133602	Allele T is associated with increased response (SVR and RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G.	2.75
981239773	981934519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934519	23142377	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	1.0
981239773	982031621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031621	21390311	Genotype TT is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	-1.75
981239773	769248378	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769248378	19749757	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	0.0
981239773	827815352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815352	21745312	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.75
981239773	1184136190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136190	24355007	Genotypes GG + GT are associated with increased risk of treatment failure when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.0
981239773	1184136365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136365	24308755	Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.25
981239773	1444668499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668499	24102823	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
981239773	1444668556	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668556	24768758	Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.5
981239773	1444705115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705115	22328925	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Hepatitis C, HIV Infections and HIV Infections as compared to genotypes GG + GT.	3.0
981239773	1444705133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705133	21466653	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	1.5
981239773	1444705147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705147	21466653	Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	1444705254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705254	20060832	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	0.0
981239773	1444705262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705262	20060832	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C.	0.0
981239773	1444705281	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705281	21911885	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1444705313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705313	20434452	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
981239773	1444705520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705520	21346780	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.5
981239773	1444705578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705578	19749758	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	0.0
981239773	1444705585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705585	19749758	Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	0.0
981239773	1444705593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705593	19749758	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	0.0
981239773	1444705817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705817	21987611	Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT.	2.25
981239773	1444706377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706377	21112657	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-1.75
981239773	1444706671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706671	22301466	Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1444706848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706848	21907615	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.75
981239773	1444707045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707045	21384511	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1444707052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707052	23730840	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT.	1.75
981239773	1444843486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843486	26075078	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1444843578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843578	23281610	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.	3.0
981239773	1444843741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843741	26003758	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1445296333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296333	24929144	Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.5
981239773	1445296808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296808	25278709	Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	3.0
981239773	1447676959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676959	25852275	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.	2.25
981239773	1447682270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682270	26825765	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G.	1.5
981239773	1447948073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948073	26699619	Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
981239773	1447948089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948089	26699619	Genotype TT is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	-2.0
981239773	1447951892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951892	26334898	Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.	2.0
981239773	1448995614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995614	21931540	Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T.	0.0
1451403467	1451402373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402373	33589790	Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AC + CC.	2.0
1450375074	1450374817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374817	30914949	Genotypes AC + CC are associated with decreased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype AA.	2.5
1450811417	1450811409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811409	17373729	Genotypes AA + AC are associated with increased risk of Heroin Dependence due to heroin as compared to genotype CC.	0.0
1156076089	1043859197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859197	19842935	Genotype TT is associated with increased exposure to drug when treated with fluvastatin in healthy individuals as compared to genotypes GG + GT.	1.5
1043880701	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1043880701	1451228580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228580	29950617	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.0
1043880701	1451358200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358200	31981411	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.	1.5
1043880701	1451358660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358660	27557342	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	1.75
1043880701	827827497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827497	17473846	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.	1.5
1043880701	1183631263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631263	23930675	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	2.25
1043880701	1184169599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169599	23876492	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.	2.0
1043880701	1444693880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693880	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.	0.0
1043880701	1451124180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124180	31857620	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.125
1043880701	1451141460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141460	32361904	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.	2.25
1043880701	1447989994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989994	25673568	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	0.125
1043880701	1449733005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449733005	16198652	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	1.5
1043880701	1451226461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226461	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1043880701	1184746588	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746588	16697742	SLCO1B1 *14 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746570	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746570	16697742	SLCO1B1 *9 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746579	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746579	16697742	SLCO1B1 *15 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	1184746561	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746561	16697742	SLCO1B1 *5 is associated with decreased uptake of rosuvastatin as compared to SLCO1B1 *1 + *37.	0.0
1043880701	982043808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043808	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1043880701	982043792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043792	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1043880701	982043801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043801	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1043880520	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1043880520	1451226263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226263	30549267	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.	1.0
1043880520	1451451120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451120	26744986	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.	1.75
1043880520	827827514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827514	19776292	SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.	1.75
1043880520	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1043880520	1451451060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451060	17047488	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1043880520	982043980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043980	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA on rs4149056.
1043880520	982043959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043959	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1043880520	982043998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043998	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1043880520	982044004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044004	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
982031013	827784973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784973	21781277	Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	0.0
982031125	981844204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981844204	23327575	Genotype AG is associated with decreased metabolism of erythromycin in people with Neoplasms as compared to genotype GG.	1.0
982032512	982032504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032504	23651024	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	0.0
982032657	982032649	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032649	23651024	Genotypes AG + GG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype AA.	0.0
982034831	982034492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034492	23746184	Genotype AG is associated with increased recurrence-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	2.5
982045698	1449164471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164471	23567489	Genotype TT is associated with increased response to somatropin recombinant in children with growth hormone deficiency as compared to genotypes CC + CT.	2.0
1043858887	769258956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769258956	21451505	Genotype TT is associated with increased metabolism of erythromycin as compared to genotypes CC + CT.	1.5
1043880077	981939812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939812	18444945	Genotypes AA + AG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.	2.5
1043880362	827808098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827808098	20716240	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.0
1043880467	769173254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173254	20136356	Allele G is associated with increased risk of adverse drug events when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	2.5
1043880567	827827522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827522	20175818	Genotypes AG + GG are associated with increased pitavastatin plasma concentrations (AUC) and Cmax when exposed to pitavastatin in healthy individuals as compared to genotype AA.	1.0
1043880654	827808093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808093	21832968	Genotypes CC + CT are associated with same protective properties against angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain in people with homozygous GG genotype for rs4343 as compared to genotype TT.	2.25
1043880792	982044907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044907	20235788	Genotype CC is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes CT + TT.	3.0
1043880792	982044965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044965	20235788	Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotype TT.	3.0
1043880792	1451107275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451107275	31090079	Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C.	-1.5
1043880828	769170891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170891	19500084	Allele G is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to allele A.	2.5
1050579065	982041062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982041062	15136504	Genotypes GT + TT are associated with response to pravastatin in men.	0.0
1156497684	699638724	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638724	20125119	Allele T is associated with decreased metabolism of clozapine as compared to allele A.	0.0
1183490994	982031893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031893	23778321	Genotype TT is associated with decreased baseline mean arterial blood pressure when treated with diuretics in people with Nephrosclerosis as compared to genotypes AA + AT.	2.5
1183491746	827925947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827925947	15199031	Genotype AT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype AA.	3.5
1183491746	699638675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638675	15199031	Genotype AT is associated with decreased reduction in LDL when treated with pravastatin as compared to genotype AA.	0.0
1183492181	827807830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807830	20031551	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.	3.0
1183492181	1450972880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450972880	17289397	Genotype CT is associated with increased likelihood of lipid response when treated with atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin as compared to genotype CC.	0.0
1183492181	1450973800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450973800	19667110	Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC.	3.5
982030283	981953993	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953993	22788240	GSTT1 null is not associated with likelihood of adverse reactions when treated with isoniazid and rifampin in people with Tuberculosis.	-1.25
982030283	981954111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954111	22012226	GSTT1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis.	-1.5
982030283	981954147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954147	20853551	GSTT1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
982030283	981954208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954208	22335459	GSTT1 null is not associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.75
982030283	981954218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954218	20036620	GSTT1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
982030283	981954243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954243	20036620	GSTT1 null is not associated with increased likelihood of Maculopapular Exanthema when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.75
982030283	981954269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954269	18397238	GSTT1 null is associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.25
982030283	981954293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954293	11595069	GSTT1 null is not associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.25
982030283	981954305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954305	21753138	GSTT1 null is not associated with likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis.	-1.5
982030283	981954318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954318	18544910	GSTT1 null is associated with decreased serum hydrazine concentrations when treated with isoniazid and rifampin in people with Tuberculosis.	1.5
982030283	982010116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010116	22845549	GSTT1 null is not associated with Drug Toxicity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to GSTT1 non-null.	-1.5
982030283	982010131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010131	22845549	GSTT1 null is not associated with severity of Drug Toxicity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.	-1.5
982030283	1447944394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944394	24637014	GSTT1 null is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.	3.25
982030308	981953987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953987	22788240	GSTM1 null is not associated with likelihood of adverse reactions when treated with isoniazid and rifampin in people with Tuberculosis.	-1.25
982030308	981954123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954123	22012226	GSTM1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis.	-1.5
982030308	981954131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954131	20853551	GSTM1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
982030308	981954158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954158	20819434	GSTM1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
982030308	981954164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954164	22335459	GSTM1 null is not associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.75
982030308	981954237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954237	20036620	GSTM1 null is not associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
982030308	981954256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954256	20036620	GSTM1 null is not associated with increased likelihood of Maculopapular Exanthema when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.75
982030308	981954262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954262	18397238	GSTM1 null is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.25
982030308	981954283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954283	11595069	GSTM1 null is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.25
982030308	981954299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954299	21753138	GSTM1 null is not associated with likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis.	-1.5
982030308	981954311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981954311	18544910	GSTM1 null is associated with increased serum hydrazine concentrations when treated with isoniazid and rifampin in people with Tuberculosis.	2.0
982030308	982010109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010109	22845549	GSTM1 null is not associated with Drug Toxicity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to GSTM1 non-null.	-1.5
982030308	982010123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010123	22845549	GSTM1 null is associated with decreased severity of Drug Toxicity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to GSTM1 non-null.	2.5
982030308	1447944380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944380	24637014	GSTM1 null is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.	3.25
982037307	981848070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981848070	16581111	Allele C is not associated with response to aspirin as compared to allele T.	-1.5
982037307	982035083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035083	16493486	Allele C is not associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype TT.	-1.5
982037307	982035242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035242	16675000	Genotype TT is associated with aspirin-depressed thrombin generation and prolonged bleeding time after aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotypes CC + CT.	1.5
982037307	982035414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035414	10459913	Genotypes CC + CT are associated with increased risk of the lack of aspirin effect when treated with aspirin in men as compared to genotype TT.	1.0
982037307	982035687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035687	16458133	Genotype CT is associated with decreased platelet inhibition by aspirin when exposed to aspirin in people with Coronary Artery Disease as compared to genotype TT.	2.0
982037307	982035849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035849	16153930	Genotype CT is associated with increased blood loss when exposed to aspirin in people with Coronary Artery Disease as compared to genotype TT.	-1.75
982037307	982035891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035891	15840736	Genotypes CC + CT are associated with increased risk of aspirin resistance when treated with aspirin in people with Acute coronary syndrome as compared to genotype TT.	0.0
982037307	982035901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035901	11723016	Genotypes CC + CT are associated with non-response when exposed to aspirin in healthy individuals as compared to genotype TT.	0.25
982037307	982036056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036056	11054089	Genotypes CC + CT are associated with shorter bleeding time when exposed to aspirin in healthy individuals as compared to genotype TT.	1.25
982037307	982036269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036269	10704169	Genotype CT is associated with increased sensitivity to aspirin when assayed with aspirin as compared to genotypes CC + TT.	-0.75
982037307	982036419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036419	17184645	Genotypes CC + CT are associated with less effective platelet inhibition by aspirin when treated with aspirin in patients after cardiopulmonary bypass as compared to genotype TT.	0.0
982037307	769173318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173318	20138334	Genotype TT is associated with increased risk of inadequate inhibition of platelet activity when treated with aspirin as compared to genotypes CC + CT.	-2.5
982037307	1184472141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472141	22028352	Genotypes CC + CT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.	-3.25
982037307	1184989701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989701	23834376	Allele C is not associated with resistance to aspirin or clopidogrel as compared to allele T.	-1.0
1142234402	982046436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046436	16321621	Genotype GG is not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.	-1.25
1142234402	982046536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046536	19802823	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.	-1.0
1142234402	982047314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047314	19891551	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.	1.75
1154959505	981934482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934482	22960765	Allele G is not associated with increased risk of rejection or affect graft function by 1 year after transplantation when treated with Calcineurin inhibitors and mycophenolate mofetil in people with Organ Transplantation as compared to genotype AA.	-2.0
1154959505	981934514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934514	20679962	Allele G is not associated with increased risk of side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.	-1.75
1154959505	981934555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934555	21996196	Genotype AG is not associated with increased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
1154959505	981935108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935108	21996196	Genotype AG is not associated with increased risk of serious infections when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
1154959505	981935256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935256	21996196	Genotype AG is not associated with increased risk of gastrointestinal side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
1154959505	981935513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935513	21996196	Genotype AG is not associated with increased risk of Neutropenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
1154959505	981936312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936312	21996196	Genotype AG is associated with decreased risk of Lymphopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	2.5
1154959505	981939796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939796	18444945	Genotypes AG + GG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	3.0
1154959505	769171119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171119	19770842	Allele G is associated with decreased response to mycophenolic acid as compared to genotype AA.	0.25
1154959505	827813013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813013	19617864	Allele G is associated with increased inosine monophosphate dehydrogenase activity when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	1.0
1150414901	982046429	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046429	16321621	Genotype CC is associated with decreased response to simvastatin in people with Hypercholesterolemia.	1.75
1150414901	982047303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047303	19891551	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.	1.75
1150414901	982047307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047307	19891551	Genotype AC is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.	1.75
982032442	982032418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032418	23651024	Genotype GG is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes GT + TT.	0.0
982034869	982034534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034534	23746184	Genotype AG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	3.5
982034869	982034468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034468	23746184	Genotype AA is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	2.5
1183618209	827696154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827696154	21562485	Allele del is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele A.	1.5
1451403484	1451402480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402480	33589790	Genotype TT is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CC + CT.	2.0
982030369	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
982030369	1451408520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408520	28686080	Allele A is associated with dose of warfarin as compared to allele G.	0.0
982030369	982030316	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030316	23755828	Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.	0.0
982030369	982030322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030322	23755828	Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.	0.0
982030369	1185235783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235783	25461246	Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.	2.75
982030369	1445296716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296716	26024874	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.5
982030369	1447952633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952633	26877068	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.0
1183616940	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1183616940	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1183616940	1183682179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682179	3769385	CYP2D6 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183616940	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183616940	1183684371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684371	7965806	CYP2D6 poor metabolizers is associated with increased mean area under the plasma concentration-time curve (AUC) of desipramine when treated with imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183616940	1183684376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684376	3533565	CYP2D6 poor metabolizers is associated with increased imipramine and desipramine plasma concentrations when treated with imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1183616940	1184470658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470658	2741190	CYP2D6 poor metabolizers are associated with increased plasma concentration of imipramine and desipramine when treated with imipramine.	0.0625
1183616940	1446905104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905104	3356084	CYP2D6 poor metabolizers are not associated with metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	-0.0625
1183616940	1183684359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684359	7965806	CYP2D6 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183616940	1183684336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684336	7640151	CYP2D6 *3/*4 + *4/*4 + *5/*5 are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	0.0
1183616940	1446900845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900845	9014200	CYP2D6 *3/*5 + *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*5 + *1/*3 + *1/*4.	0.0
1183616940	1446902165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902165	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	2.5
1183621866	PA166105001	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105001		Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6	100
1183621866	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1183621866	1446901896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901896	10774635	CYP2D6 poor metabolizers are associated with decreased metabolism of trimipramine in people with Schizophrenia as compared to CYP2D6 normal metabolizers.	0.0625
1183621866	1183621485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621485	14520122	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183621866	1446901759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901759	14520122	CYP2D6 *3 + *4 + *5 + *6 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1183621866	1446901830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901830	14646691	CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizers phenotype) are associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN + *1/*1.	1.5
1183621866	1446901857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901857	14646691	CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.	2.0
1183621726	PA166104969	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104969		Annotation of DPWG Guideline for flecainide and CYP2D6	100
1183621726	1448099915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099915	26195225	CYP2D6 normal metabolizer genotype is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	1.0
1183621726	1183621641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621641	22718623	CYP2D6 *10 is not associated with pharmacokinetics of flecainide in healthy Chinese subjects when exposed to flecainide in healthy individuals as compared to CYP2D6 *1.	-0.125
1183621726	1183621590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621590	22941032	CYP2D6 *4 + *5 + *10 + *21 + *36 are associated with increased age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias when treated with flecainide as compared to CYP2D6 *1.	2.0
1183621726	1183621673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621673	16944116	CYP2D6 *5/*36 + *10/*10 + *10/*36 + *21/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.	1.25
1183617103	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1183617103	PA166104954	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104954		Annotation of DPWG Guideline for imipramine and CYP2C19	100
1183617103	1183684364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684364	7965806	CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	1.0
1183617103	1183684391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684391	1988236	CYP2C19 poor metabolizers are associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446902332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902332	8835703	CYP2C19 poor metabolizers are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446902590	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902590	8835703	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1446905415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905415	1988236	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.75
1183617103	1183622249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622249	19884907	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to CYP2C19 *1/*1.	2.5
1183617103	1183622781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622781	9316174	CYP2C19 *2/*3 + *2/*2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
1183617103	1446902041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902041	17667959	CYP2C19 *2 is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.5
1183617103	1446902544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902544	9316174	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
982037811	982035215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035215	9420339	Genotype AG is associated with decreased severity of Coronary Artery Disease when treated with pravastatin in men with Coronary Artery Disease.	3.0
982037811	982035199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035199	9420339	Genotype GG is associated with decreased reduction in luminal diameter when treated with pravastatin in men with Coronary Artery Disease.	3.0
982037811	982035232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035232	9420339	Genotype AA is not associated with decreased reduction in luminal diameter when treated with pravastatin in men with Coronary Artery Disease.	-2.0
982037811	982035525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035525	15856070	Genotype AA is associated with increased risk of cardiovascular disease events when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotypes AG + GG.	0.0
982037811	982036409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036409	15856070	Genotype GG is not associated with increased change in lipid parameters when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotype AA.	-1.75
982037811	827822957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827822957	18957472	Allele A is associated with increased risk of Death when treated with pravastatin in men with Coronary Artery Disease as compared to allele G.	2.5
982040619	981936592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936592	18444945	Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.	2.5
1043858877	982030217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030217	23764426	Allele G is associated with increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele T.	0.0
1043858975	982048040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048040	17245331	Genotype AA is associated with increased risk of aspirin resistance when treated with aspirin in healthy individuals as compared to genotypes AG + GG.	2.0
1043858975	1184165658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165658	23688183	Genotype AA is associated with increased risk of high on-aspirin residual platelet reactivity when treated with aspirin in people with off-pump coronary artery bypass grafting as compared to genotypes AG + GG.	3.0
1043859494	827813714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813714	21614492	Allele C is associated with decreased Pain when treated with escitalopram in men with neuropathic pain as compared to allele G.	1.5
1043873013	827863600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863600	22267851	Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G.	0.0
1043880039	827816713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816713	20619611	Genotype GG is associated with decreased response to fluvoxamine in people with Depressive Disorder, Major as compared to allele A.	1.0
1043880426	982046088	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046088	16158080	Genotype TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	1.75
1157204541	827808147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827808147	20168265	Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.	0.0
982040676	981851510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851510	22210424	Allele T is associated with increased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	0.0
982040676	981851542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851542	22210424	Allele T is not associated with diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-2.0
982040676	981861475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861475	16198654	Allele T is not associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 1g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-0.75
982040676	981861485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861485	16198654	Allele T is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	1.5
1451403580	1451402501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402501	33589790	Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CG + GG.	2.0
1043880397	1183701274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701274	18574025	Allele A is associated with dose of warfarin.	2.5
1043880397	1184756122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756122	25126975	Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele A.	3.0
1043880397	982032947	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032947	18535201	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
1183491004	827566968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827566968	21479364	Genotype AA is associated with decreased overall survival when treated with cisplatin and etoposide in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	1.0
1183491004	1184348627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348627	24533712	Genotype AA is not associated with decreased overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	-1.25
1183491004	1444694818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694818	25545243	Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.	3.0
982046070	1183621746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621746	23712614	CYP2C8 *1/*2 + *2/*2 is associated with decreased M-III:pioglitazone AUC0-48 ratio and M-III:M-IV AUC0-48 ratio in healthy African-American volunteers when exposed to pioglitazone in healthy individuals as compared to CYP2C8 *1/*1.	1.75
982046070	1449713390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713390	22625877	CYP2C8 *1/*1 is associated with decreased clearance of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.	1.5
982046070	1449713428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713428	22625877	CYP2C8 *1/*1 is associated with increased concentrations of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.	1.5
982046070	1449713452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713452	22625877	CYP2C8 *1/*1 is not associated with concentrations of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.	-0.125
982046070	1449713480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713480	22625877	CYP2C8 *1/*1 is not associated with metabolism of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.	-0.125
982046070	1449713492	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713492	22625877	CYP2C8 *1/*1 is not associated with metabolism of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.	-0.125
1183618725	PA166104998	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104998		Annotation of CPIC Guideline for nortriptyline and CYP2D6	100
1183618725	PA166104961	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104961		Annotation of DPWG Guideline for nortriptyline and CYP2D6	100
1183618725	1183698887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698887	24257813	CYP2D6 poor metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1446900047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900047	4082245	CYP2D6 ultrarapid metabolizer phenotype is associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major.	0.0625
1183618725	1446901165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901165	6111662	CYP2D6 poor metabolizers are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major.	0.0625
1183618725	1447519878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519878	24257813	CYP2D6 intermediate metabolizers are associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1447519884	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519884	24257813	CYP2D6 ultrarapid metabolizer phenotype are associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.75
1183618725	1183618214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618214	9585799	CYP2D6 *4 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618225	9585799	CYP2D6 *3 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618233	9585799	CYP2D6 *5 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618241	9585799	CYP2D6 *1/*2xN is associated with increased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183618725	1183618249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618249	9585799	CYP2D6 *4/*4 is associated with decreased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183618725	1183618362	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618362	11682257	CYP2D6 *4 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618379	11682257	CYP2D6 *3 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618387	11682257	CYP2D6 *5/*10 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183618467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618467	10770451	CYP2D6 *10 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183618725	1183618505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618505	10770451	CYP2D6 *5 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183618725	1183624207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624207	8867869	CYP2D6 *1/*4 + *1/*5 is not associated with differences in nortriptyline concentrations when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	-0.125
1183618725	1183624218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624218	8867869	CYP2D6 *1/*4 + *1/*5 is associated with decreased concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1183618725	1183624247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624247	11673748	CYP2D6 *1/*1xN is associated with very low nortriptyline after 7 days of treatment when treated with nortriptyline.	0.125
1183618725	1183678562	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678562	17470523	CYP2D6 *10 is associated with decreased clearance of nortriptyline as compared to CYP2D6 *1.	0.0
1183618725	1183678570	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678570	17470523	CYP2D6 *17 is associated with decreased clearance of nortriptyline as compared to CYP2D6 *1.	0.0
1183618725	1184468489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468489	9797795	CYP2D6 *1/*10 is not associated with metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183618725	1184468498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468498	9797795	CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	2.0
1183618725	1184468532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468532	16778723	CYP2D6 *1/*10 is not associated with metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1183618725	1184468543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468543	16778723	CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.	0.125
1183618725	1184468865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468865	15483356	CYP2D6 *5/*10 is associated with increased plasma concentrations when treated with nortriptyline.	0.125
1183618725	1446901389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901389	8093319	CYP2D6 *2/*1xN is associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major.	0.125
1183618725	1446902725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902725	15590749	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	1.0
1183618725	1446903079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903079	20531370	CYP2D6 *3 + *4 + *5 + *6 are associated with increased concentrations of nortriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.0
1183618725	1446904319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904319	8093319	CYP2D6 *2/*1xN is associated with increased dose of nortriptyline in people with Depressive Disorder, Major.	0.125
1183618725	1446904458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904458	11682257	CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.	1.5
1183618725	1446904494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904494	9585799	CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.	2.0
1183618725	1446899759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899759	12814461	CYP2D6 *1/*10 is not associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1183621987	PA166105001	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105001		Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6	100
1183621987	1446901990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901990	10774635	CYP2C19 poor metabolizers are associated with decreased metabolism of trimipramine in people with Schizophrenia as compared to CYP2C19 normal metabolizers.	0.0625
1183621987	1183621560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621560	14520122	CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183621987	1446901738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901738	14520122	CYP2C19 *2 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183491364	981239800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239800	22926161	Genotypes AG + GG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA.	2.5
1183491364	981239809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239809	22926161	Genotypes AG + GG are associated with greater reduction in homocysteine when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA.	2.5
1043859020	982042944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042944	14700505	Genotypes CT + TT are associated with increased response to atenolol in people with Hypertension as compared to genotype CC.	2.0
1043859020	982042996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042996	14700505	Genotypes CT + TT are not associated with response to atenolol in people with Hypertension as compared to genotype CC.	-0.25
1043859046	982035107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035107	15608561	Genotype GG is associated with increased response to fenofibrate in people with Diabetes Mellitus as compared to genotypes CC + CG.	2.5
1183491055	1183491049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491049	20126830	Allele G is associated with 5% lower ADP-induced peak platelet aggregation in-vitro when exposed to cangrelor as compared to genotype AA.	0.5
1183491098	982043865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043865	15262185	Genotypes CC + CG are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype GG.	2.25
1183491098	981501315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501315	20592455	Genotype CG is not associated with increased response to atorvastatin in people with Coronary Artery Disease as compared to genotype GG.	-1.75
1183491098	981501333	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501333	20592455	Genotype CG is associated with increased risk of Coronary Artery Disease as compared to genotype GG.	1.75
1183491098	982045958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045958	16103896	Genotype GG is not associated with response to atorvastatin as compared to genotype CG.	-2.0
1183491262	827820471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820471	21247998	Genotype AA is associated with increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype when treated with ondansetron in people with Alcoholism as compared to allele C.	2.25
1183491310	982045166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045166	15650881	CYP3A4 *1/*4 is associated with increased response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*1.	2.0
1183630057	982022919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022919	11191886	GSTM1 null/null is associated with increased risk of severe cutaneous adverse reactions when treated with sulfamethoxazole / trimethoprim in people with Acquired Immunodeficiency Syndrome.	This annotation is not used for clinical annotation scoring. Association only significant in patients who are also NAT2 slow acetylators.
1183491390	1003775005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1003775005	17931083	Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to allele G.	2.0
1183491541	699638678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638678	15199031	Genotype GT is associated with decreased reduction in LDL when exposed to pravastatin as compared to genotype TT.	0.375
1183491541	827925965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827925965	15199031	Genotype GT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype TT.	3.5
1183491541	699639067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639067	16103896	Genotype GT is not associated with response to pravastatin as compared to genotype TT.	-1.75
1183491541	699638985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638985	18815589	Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.	3.5
1183491541	769152897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769152897	18261733	Allele G is not associated with response to pravastatin in people with Vascular Diseases as compared to allele T.	-2.0
1183602693	981475744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475744	22041458	Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele A.	0.0
1183604439	981475732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475732	22041458	Allele C is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.	0.0
1183614711	981475566	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981475566	21892778	Genotype AA is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotypes AC + CC.	2.0
1183614726	1183614656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614656	23859571	Genotypes AA + AG are associated with decreased risk of sadness when treated with efavirenz in people with HIV Infections as compared to genotype GG.	2.5
1183614860	982032270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032270	23408116	Genotypes CG + GG are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.	1.75
1183615140	982029662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029662	23314736	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.	2.25
1183615273	1448522397	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522397	20530282	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
1183615273	1449754461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449754461	21057378	Genotype GG is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	3.5
1183617783	769169322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169322	18253134	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with lack of remission and lack of response when treated with antidepressants in people with Depression.	1.5
1183617783	769169338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169338	18253134	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased risk of adverse drug reaction after the second switch in treatment when treated with antidepressants in people with Depression.	2.5
1183619037	1451288740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451288740	18070221	CYP2D6 *4/*4 is associated with decreased dose of Selective serotonin reuptake inhibitors in people with Depression as compared to CYP2D6 *1/*1.	2.5
1183622368	1183616471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616471	23859572	Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AC + CC.	1.5
1183622651	1183622460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622460	23859573	Allele C is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.	1.5
1183622651	1183622503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622503	23859573	Allele C is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major as compared to allele T.	1.5
1183622651	1183622515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622515	23859573	Allele C is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele T.	1.5
1183629305	981476266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476266	18215618	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	2.75
1183629305	1183689529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689529	24192121	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.	0.0
1183629475	1183629344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629344	23859574	Genotype AA is associated with increased neurological adverse reactions when treated with quetiapine in healthy individuals as compared to genotypes AG + GG.	0.0
1183629475	1183629349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629349	23859574	Genotype AA is associated with increased likelihood of sleepiness when treated with quetiapine in healthy individuals as compared to genotypes AG + GG.	1.75
1183533961	982043591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043591	19907160	Genotypes CT + TT are associated with increased response to amlodipine in women with Hypertension as compared to genotype CC.	2.25
1183533961	982043660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043660	19907160	Genotypes CT + TT are not associated with response to amlodipine in men with Hypertension as compared to genotype CC.	-1.25
1183533961	982043670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043670	19907160	Genotypes CT + TT are not associated with response to amlodipine in people with Hypertension as compared to genotype CC.	-1.5
1183533961	982043679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043679	19907160	Genotypes CT + TT are not associated with response to amlodipine in women with Hypertension as compared to genotype CC.	-1.25
1183615208	981794186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794186	18221820	Genotype del/del is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	2.5
1183615208	981794628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794628	16636344	Genotype del/del is not associated with Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	-1.25
1183615208	981794637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794637	16636344	Genotype del/del is not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	-1.25
1183615208	981843704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843704	18221820	Genotype del/del is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	-1.5
1183615208	1184468863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468863	16636344	Genotype del/del is not associated with response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	-1.25
1183619225	981501007	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501007	20016225	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.	-1.0
1183619225	981501099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501099	20016225	Allele T is associated with decreased likelihood of side effects when treated with fluoxetine in people with Depressive Disorder, Major as compared to allele C.	0.25
1183620242	1184137268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137268	12968986	CYP2D6 poor metabolizers is associated with increased risk of severe adverse effects when treated with citalopram in healthy individuals.	0.125
1183620242	1184169557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169557	23545896	CYP2D6 normal metabolizers are associated with decreased number of failed medication trails when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder.	1.25
1183620242	1183619358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619358	21192344	CYP2D6 *4 is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1.	-2.0
1183620242	1184169374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169374	23545896	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	-1.5
1451403608	1451402531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402531	33589790	Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype TT.	2.5
1451403621	1451402513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402513	33589790	Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes AG + GG.	2.0
1451403720	1451402600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402600	33589790	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.	2.0
1183533940	981794295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794295	18221820	Genotypes AA + AG are associated with increased Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.0
1183533940	981843835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843835	18221820	Genotypes AA + AG are not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-1.5
1183592332	981502079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502079	22441531	Genotypes CC + CT are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	3.0
1183592332	981502653	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502653	22441531	Genotypes CC + CT are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1183592332	981502663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502663	22441531	Genotypes CC + CT are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	-2.0
1183614766	981502687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502687	22441531	Genotypes AA + AG are associated with decreased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.0
1183615177	982036359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036359	17178265	Genotype CC is associated with increased metabolism of amlodipine in healthy individuals as compared to genotypes CT + TT.	1.5
1183615177	982036394	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036394	17178265	Genotype CC is not associated with clearance of amlodipine in healthy individuals as compared to genotypes CT + TT.	-0.125
1183615177	1451147629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147629	32331352	CYP3A5 *3 + *6 + *7 are associated with decreased clearance of amlodipine in healthy individuals as compared to CYP3A5 *1.	0.0
1183615400	982047196	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047196	23230131	Genotypes AG + GG are associated with increased clearance of gemcitabine as compared to genotype AA.	1.0
1183631460	1183491305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491305	23371894	Genotypes CT + TT are associated with decreased clearance of memantine in people with Dementia as compared to genotype CC.	2.0
1183631787	981344274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344274	22907730	Allele C is associated with decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele T.	0.0
1183632073	1183632042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632042	23753411	Allele A is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.	0.0
1183632190	655386281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386281	12684679	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.	1.75
1183679780	827863578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863578	22267851	Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G.	0.0
1183679818	827813533	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813533	21487324	Genotypes AA + AG are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype GG.	2.5
1183679843	827813569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813569	21487324	Genotypes AC + CC are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype AA.	2.5
1183679863	827863649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863649	22267851	Allele T is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele C.	0.0
1183680415	1183679914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679914	14638340	Genotype GG is not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotypes AA + AG.	-1.5
1183680415	1183680034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680034	16815316	Genotype AG is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG.	2.75
1183680415	1183680029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680029	16815316	Genotype AA is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG.	2.75
1183680415	1183680131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680131	21054464	Genotype AA is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	-1.5
1183680516	981848320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848320	23508266	Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.	0.0
1183680555	827922347	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922347	22525200	Allele T is associated with increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to allele A.	3.0
1183680560	981758541	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758541	23267855	Genotype AA is associated with decreased response to metformin when exposed to metformin in healthy individuals as compared to genotypes AG + GG.	2.25
1183680560	982026156	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026156	23652408	Genotype AA is not associated with glucose-lowering effect of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	-0.125
1183680560	827788923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827788923	21956618	Genotype AA is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotypes AG + GG.	2.5
1183680560	827788949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827788949	21956618	Allele A is associated with increased promoter activity in reporter assays and reduced binding to transcription repressor MZF-1 as compared to allele G.	0.0
1183680560	1448998629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998629	28834135	Allele A is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele G.	-0.25
1183680565	981758534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758534	23267855	Genotypes AA + AG are associated with increased renal and secretory clearance of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	1.0
1183680565	982026116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026116	23652408	Genotype AA is associated with increased renal clearance and secretion clearance of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	1.5
1183680565	982026139	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026139	23652408	Genotype AA is not associated with differences in the plasma metformin concentration versus time curve or the maximum metformin concentration when exposed to metformin in healthy individuals as compared to genotype GG.	-0.125
1183680565	982026156	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026156	23652408	Genotype AA is not associated with glucose-lowering effect of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	-0.125
1183680565	1183682344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682344	23417334	Genotype GG is not associated with increased clearance of metformin in healthy individuals as compared to genotypes AA + AG.	-0.75
1183680565	1446898166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898166	25939711	Allele A is not associated with steady-state concentration of metformin in healthy individuals as compared to allele G.	-0.125
1183680575	827811251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811251	20179710	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	3.0
1183680575	1448994998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994998	28036387	Allele A is not associated with likelihood of febrile neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.	-1.25
1183680665	1183680640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680640	24113216	Genotypes AA + AG are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.25
1183680665	1449183033	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449183033	29399716	Genotypes AG + GG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype AA.	-1.25
1451403600	1451402507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402507	33589790	Genotype GG is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes GT + TT.	2.0
1183680511	827923138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923138	22664479	Allele C is associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	0.0
1183680526	608177457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608177457	20877297	Allele T is associated with decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major.	2.5
1450377339	1450377081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377081	23041303	Genotypes CC + CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype TT.	2.0
1450814641	1450814589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814589	22947179	Genotype TT is associated with decreased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.75
1450814647	1450814583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814583	22947179	Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.25
1450822023	1450821174	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821174	25122903	Allele G is not associated with severity of Heroin Dependence due to heroin as compared to allele A.	-1.75
1450822023	1450822004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822004	25911999	Genotypes AG + GG are associated with increased severity of Heroin Dependence due to heroin in men as compared to genotype AA.	2.25
1451403680	1451402525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402525	33589790	Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype GG.	2.0
1451403687	1451402545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402545	33589790	Genotype TT is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CC + CT.	2.0
982031106	981844189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981844189	23327575	Genotype AG is associated with decreased metabolism of midazolam in people with Neoplasms as compared to genotype GG.	2.0
982031106	1447673991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447673991	26114223	CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	1.75
982031517	981501708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501708	23324805	Allele A is associated with poor response at 8 week of treatment when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	3.5
982031517	981501714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501714	23324805	Allele A is associated with poor response at 6 week of treatment when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	2.5
982032329	982032312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032312	23651024	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	0.0
982032477	982032460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032460	23651024	Genotype GG is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AG.	0.0
982032672	982032665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032665	23651024	Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	-1.5
982032672	769182369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182369	21358750	Genotype AA is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	2.25
982034400	827783411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783411	17700361	Allele C is associated with decreased risk of primary outcome (all cause mortality, nonfatal myocardial infarction or nonfatal stroke) when treated with verapamil in people with Hypertension as compared to allele G.	2.5
982034888	982034681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034681	10334805	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to acetylcholine or nitroprusside in healthy individuals as compared to allele del.	1.75
982045076	981848256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848256	23508266	Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.	0.0
1043858661	1043755428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043755428	19019667	Genotypes GG + GT are associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype TT.	2.25
1043858680	1043858459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858459	18534082	Genotypes AG + GG are associated with increased likelihood of atopy in patients with aspirin-intolerant chronic urticaria as compared to genotype AA.	2.25
1043858680	1043858468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858468	18595682	Genotype AA is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AG + GG.	2.25
1043858722	769171148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171148	18511696	Genotype CC is associated with increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to genotype AA.	0.0
1043858845	981345135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345135	22948895	Allele C is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele T.	2.0
1043873008	827832031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827832031	18484082	Genotype TT is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes GG + GT.	2.0
1043873023	981344210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344210	22907731	Allele C is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.	3.75
1043873028	769250167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250167	19855097	Genotype AG is associated with increased metabolism of phenytoin as compared to genotype GG.	0.0
1043873028	769250164	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769250164	19855097	Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.	0.0
1043873028	769250168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250168	19855097	Genotypes AA + AG are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GG.	2.0
1043880298	827811321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811321	20179710	Genotype AG is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA.	2.5
1043880298	1449576807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576807	29938344	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	-1.5
1043880723	769169922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169922	18347610	Allele G is associated with decreased likelihood of Parkinsonian Disorders when treated with antipsychotics in people with Schizophrenia as compared to allele C.	2.0
1043880750	827828530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828530	20631561	Allele A is associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	2.75
1043880750	1446898677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898677	23799528	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	-0.5
1043880900	827811004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811004	21928084	Genotypes AG + GG are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	-1.5
1043880900	769162956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162956	21178985	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.	2.5
1043880900	1184137782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137782	24595600	Genotype AA is associated with increased creatine kinase when treated with hmg coa reductase inhibitors as compared to genotype AG.	1.25
1043880900	1448821155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821155	28812116	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.	-1.75
1043880630	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1043880630	769171454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171454	19374892	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.	This annotation is not used for clinical annotation scoring. drug drug interaction
1043880630	981758554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758554	23361102	Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.	0.125
1043880630	827827481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827481	17473846	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.	1.0
1043880630	1184169609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169609	23876492	Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.	1.5
1043880630	1451226420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226420	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1043880630	1451352842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352842	28435225	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1043880630	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1043880630	1451533063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451533063	20040338	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	1.75
1043880630	1451165020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451165020	31594719	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1183490957	981786297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786297	23337848	Allele T is associated with increased dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction when exposed to dexmedetomidine in healthy individuals as compared to allele G.	1.5
1135389481	981851520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851520	22210424	Allele A is associated with increased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	0.0
1135389481	981851552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851552	22210424	Allele A is not associated with diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	-2.0
1135389481	981859270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859270	16198654	Allele A is not associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 1g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	-0.75
1135389481	981861450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861450	16198654	Allele A is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	1.5
1135389481	981861548	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861548	20565459	Genotypes AA + AT are not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.	-1.75
1135389481	1448107164	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107164	22765258	Genotype AA is not associated with metabolism of mycophenolic acid as compared to genotype TT.	-0.5
1451403740	1451402606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402606	33589790	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.	2.0
1043858794	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1043858794	PA166104956	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104956		Annotation of DPWG Guideline for clopidogrel and CYP2C19	100
1043858794	982028906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028906	19106084	Allele A is associated with decreased plasma exposure to the active metabolite of clopidogrel when exposed to clopidogrel in healthy individuals as compared to allele G.	2.0
1043858794	982032776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032776	17900275	Allele A is associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to allele G.	1.75
1043858794	982042060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042060	23809542	CYP2C19 *2 is associated with decreased clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	3.0
1043858794	982042087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042087	23809542	CYP2C19 *17 is not associated with clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	-2.0
1043858794	1183697338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697338	24214141	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased Cmax and AUC of thiol metabolite when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1043858794	1184348998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348998	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.	1.0
1043858794	1184349010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349010	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*17 + *17/*17.	0.125
1043858794	1184469857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469857	19429918	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	2.0
1043858794	1184472453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472453	22428615	CYP2C19 *2/*2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	0.125
1043858794	1184472493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472493	21716274	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	0.125
1043858794	1184516457	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516457	25001882	CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.	0.0
1043858794	1184989861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989861	25008027	CYP2C19 *1/*2 + *1/*8 + *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.0
1043858794	1444607027	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607027	25542807	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1043858794	1444704559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704559	24402637	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.25
1043858794	1446907223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907223	26426352	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.	2.0
1043858794	1447359923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447359923	26524713	CYP2C19 *1/*2 + *2/*17 + *2/*2 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.	0.0
1043858794	1448101486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101486	26071277	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.	2.5
1043858794	1448624865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624865	27981573	CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	0.0
1043858794	1450664694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664694	21689142	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	0.0
1183491792	982028478	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028478	18769620	Genotype GG is associated with increased risk of Death in people with Acute coronary syndrome as compared to genotypes CC + CG.	2.5
1183491792	982028484	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028484	18769620	Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Acute coronary syndrome as compared to genotypes CG + GG.	2.0
1183491822	981865016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981865016	19027114	Genotype CT is associated with increased response to simvastatin in people with Myocardial Ischemia as compared to genotype TT.	1.75
1183492023	981786394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786394	23324806	Allele C is associated with nonresponse to anti-EGFR-based treatment when treated with cetuximab and panitumumab in people with Adenocarcinoma as compared to genotype AA.	2.25
1183492023	1446905410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446905410	25183481	Genotypes AC + CC is associated with increased progression-free survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype AA.	2.0
1183492023	1446908428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908428	26162609	Genotype AC is associated with increased response to capecitabine, cetuximab and oxaliplatin in people with Rectal Neoplasms as compared to genotype AA.	2.0
1183492023	1446909124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446909124	25210463	Genotypes AC + CC is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype AA.	-1.0
1183492023	1447520309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520309	24727325	Genotypes AC + CC is not associated with increased event-free survival when treated with cetuximab in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1183492023	1449165394	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165394	27897268	Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.	-0.5
1183549413	982032288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032288	23408116	Genotypes CG + GG are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.	1.75
1183549413	1185235585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235585	24104197	Genotypes CG + GG is associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.	0.0
1183605282	981477298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477298	22541248	Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AC + CC.	2.0
1183607013	981502885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502885	22414228	Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	2.0
1183607142	981502876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502876	22414228	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.5
1183614716	1183614651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614651	23859571	Genotypes GT + TT are associated with increased risk of abnormal dreams when treated with efavirenz in people with HIV Infections as compared to genotype GG.	3.0
1183614816	982032105	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982032105	23408116	Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CT + TT.	0.0
1183614825	982032212	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032212	23408116	Genotypes CT + TT are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.	1.75
1183614830	982029986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029986	23277250	Genotype GG is associated with increased QTc interval when treated with iloperidone in people with Schizophrenia as compared to genotypes AA + AG.	1.0
1183614835	981475614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981475614	22426923	Genotypes AG + GG are associated with increased response to capecitabine and docetaxel in women with Breast Neoplasms as compared to genotype AA.	2.25
1183622348	1183616466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616466	23859572	Genotype CC is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CG + GG.	1.5
1183629489	1183629394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629394	23859574	Genotype AA is associated with increased likelihood of cardiovascular adverse reactions when treated with risperidone in healthy individuals as compared to genotypes AG + GG.	2.25
1183618159	1183682020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682020	19514130	CYP2D6 poor metabolizer genotype is associated with decreased dose of tramadol in people with Pain.	0.0
1183618159	1451155689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155689	16129989	CYP2D6 poor metabolizer phenotype is not associated with dose of amitriptyline or tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	-0.625
1183618159	1451205840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205840	22428763	CYP2D6 poor metabolizers and intermediate metabolizers are not associated with dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizers.	-0.75
1183618159	1183618035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618035	17361124	CYP2D6 *3/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618044	17361124	CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618052	17361124	CYP2D6 *4/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1183618159	1183618060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618060	14499440	CYP2D6 *4/*4 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618069	14499440	CYP2D6 *3/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618082	14499440	CYP2D6 *5/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618090	14499440	CYP2D6 *4/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1183618098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618098	14499440	CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1183618159	1446898032	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898032	25948472	CYP2D6 *10/*10 is associated with increased dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.	2.5
1183618159	1451157968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157968	18520597	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is not associated with dose of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .	-1.25
1183618159	1183960516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960516	16960721	CYP2D6 *10/*10 is associated with significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy when treated with tramadol as compared to CYP2D6 *1/*1 + *1/*10.	1.75
1183619154	1183618754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618754	22926595	CYP2D6 *3/*4 + *4/*6 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.	1.0
1183619154	1183618807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618807	19429471	CYP2D6 *4/*4 + *4/*6 is associated with increased dose/weight adjusted AUC for mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.75
1183619154	1183618967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618967	17329996	CYP2D6 *4/*4 is associated with decreased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183619154	1183618996	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618996	17329996	CYP2D6 *1/*1xN is associated with increased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619012	17329996	CYP2D6 *4/*4 is not associated with differences in desmethyl-mirtazapine parameters when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183619051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619051	15538128	CYP2D6 *4/*4 is associated with decreased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619060	15538128	CYP2D6 *1/*1xN is associated with increased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183619154	1183619088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619088	15538128	CYP2D6 *1/*1xN is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183619103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619103	15538128	CYP2D6 *4/*4 is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.	-0.25
1183619154	1183618857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618857	19071885	CYP2D6 *4 + *5 are associated with increased serum concentrations of S(+)-mirtazapine, mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine when treated with mirtazapine in people with Mental Disorders as compared to CYP2D6 *1/*1.	2.25
1183631061	PA166104988	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104988		Annotation of DPWG Guideline for haloperidol and CYP2D6	100
1183631061	1448993570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993570	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.125
1183631061	1447682070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682070	26514968	CYP2D6 poor metabolizer is not associated with concentrations of haloperidol, paliperidone or zuclopenthixol in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.0625
1183631061	1183622774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622774	14499311	CYP2D6 *10/*10 is not associated with decreased metabolism of haloperidol as compared to CYP2D6 *1/*1 + *1/*10.	-1.0
1183631061	1183623437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623437	12784098	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183623462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623462	12784098	CYP2D6 *2 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183623471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623471	12784098	CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	0.0
1183631061	1183624234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624234	11560558	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.5
1183631061	1183629618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629618	10942177	CYP2D6 *10 is not associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	-0.75
1183631061	1183629749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629749	10096261	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183629922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629922	11595402	CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183630106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630106	11595402	CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.25
1183631061	1183630925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630925	12746736	CYP2D6 *4/*4 is associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4.	1.0
1183631061	1447677736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677736	12960748	CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183631061	1447677749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677749	12960748	CYP2D6 *10/*10 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*10.	0.0
1183631061	1449189048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449189048	29472872	CYP2D6 *1xN is associated with extrapyramidal symptoms, hepatic cytolysis and Weight gain when exposed to haloperidol, levomepromazine and risperidone in children with Schizophrenia as compared to CYP2D6 *1.	0.0
1183631061	1183629904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183629904	9352580	CYP2D6 *5 + *10 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183631061	1183630934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183630934	12746736	CYP2D6 *1/*10 + *17/*17 are not associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1183631061	1183622259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622259	17667795	CYP2D6 *3 + *4 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.	1.5
1183631061	1183623024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623024	12919180	CYP2D6 *2 + *10 are not associated with increased metabolism of haloperidol as compared to CYP2D6 *1.	-1.0
982014094	PA166161954	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161954		Annotation of CPIC Guideline for ondansetron and CYP2D6	100
982014094	981954714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954714	12065557	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.	3.25
982014094	982006758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006758	15731591	CYP2D6 *1xN + *2xN are associated with decreased response to ondansetron in women as compared to CYP2D6 *1.	2.0
982014094	982006805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006805	15731591	CYP2D6 *1xN + *2xN are not associated with response to ondansetron in women as compared to CYP2D6 *5.	-1.5
982014094	981954745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954745	21840870	CYP2D6 *2/*2 + *2/*10 are not associated with response to ondansetron in people with Neoplasms.	-1.5
1183614682	981848117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848117	22760553	Allele T is associated with increased hearing and vision-related side-effects when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	0.0
1183614886	981483784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483784	22722500	Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.	2.25
1183615041	981502166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502166	22926595	CYP2B6 *6/*6 is associated with increased response to mirtazapine in people with Depression.	1.5
1183631422	982046569	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046569	22590580	Genotype CC is associated with increased clearance of l-tryptophan as compared to genotypes AA + AC.	1.5
1183680463	1448532221	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448532221	26730167	CYP2C19 normal metabolizer genotype is associated with decreased response to amoxicillin, clarithromycin and esomeprazole in people with Gastritis as compared to CYP2C19 poor metabolizer and intermediate metabolizer genotypes.	0.875
1183680463	1183620997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620997	16338278	CYP2C19 *1/*1 is not associated with likelihood of complete endoscopic healing when treated with esomeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *2/*2.	-1.5
1183680463	1183623689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623689	18637061	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.	-1.5
1183680463	1183624182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624182	19785625	CYP2C19 *1/*2 is not associated with response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	-0.25
1183680463	1183679229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679229	22324425	CYP2C19 *1/*1 is associated with decreased response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	2.5
1183680463	1183679483	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679483	23646118	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.	-0.75
1183680463	1183680154	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680154	21118735	CYP2C19 *1/*1 is not associated with response to esomeprazole in people with Helicobacter Infections.	-1.5
1183680463	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183680463	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183680463	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183680463	1183623652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623652	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183680463	1183623663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623663	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	2.25
1183680463	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183680463	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183680463	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183680463	1451344650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451344650	20831535	CYP2C19 *2 + *3 are not associated with response to esomeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183680463	1451346608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451346608	21632579	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183680463	1451346620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451346620	21512411	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183680463	1451346700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451346700	26809022	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183680463	1451346726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451346726	26847964	CYP2C19 *2 + *3 are not associated with response to esomeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	-1.5
1183680521	827923978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923978	15824464	Genotype CC is associated with increased reduction in mean blood pressure when treated with Thiazides, plain in people with Essential hypertension as compared to genotypes CT + TT.	2.25
1448640327	1448640203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640203	26792652	TPMT *3B is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms.	2.25
1448640327	1448640212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640212	26792652	TPMT *3C is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms.	2.25
1183533986	982043687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043687	19907160	Genotypes AG + GG are not associated with response to amlodipine in men with Hypertension as compared to genotype AA.	-2.25
1183533986	982043698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043698	19907160	Genotypes AG + GG are not associated with response to amlodipine in women with Hypertension as compared to genotype AA.	-2.25
1183533986	982043709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043709	19907160	Genotypes AG + GG are not associated with response to amlodipine in people with Hypertension as compared to genotype AA.	-1.5
1183533986	769169820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169820	19907160	Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA.	3.0
1183679117	1183678874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183678874	23995691	Allele A is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele G.	2.25
1183679117	1183679086	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183679086	23995691	Allele G is associated with increased expression of GATM when exposed to simvastatin as compared to allele A.	0.0
1183679117	1183679102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183679102	23995691	Allele A is not associated with increased creatine kinase level when treated with hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to allele G.	-2.0
1183679117	1447814662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814662	25863251	Allele A is not associated with decreased risk of Muscular Diseases when treated with hmg coa reductase inhibitors in people with Dyslipidaemia as compared to allele G.	-2.0
1183614676	982029901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029901	23277235	Genotypes CC + CT are associated with increased risk of Weight gain when treated with antipsychotics as compared to genotype TT.	2.0
1183614676	827829008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829008	22310352	Allele C is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele T.	0.0
1183614676	1446898383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898383	23920449	Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.	1.5
1183621997	PA166104943	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104943		Annotation of DPWG Guideline for risperidone and CYP2D6	100
1183621997	1183699383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699383	23609392	CYP2D6 ultrarapid metabolizer phenotype is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .	2.0
1183621997	1183904079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183904079	24232129	CYP2D6 intermediate metabolizers is not associated with serum concentration of 9-hydroxyrisperidone or sum of risperidone and 9-hydroxyrisperidone when treated with risperidone as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6.	-1.0
1183621997	1184748530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748530	25042870	CYP2D6 poor metabolizer are associated with decreased clearance of risperidone in healthy individuals.	0.625
1183621997	1184754471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754471	24643635	CYP2D6 ultrarapid metabolizer is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 poor metabolizers.	0.0
1183621997	1184754478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754478	24643635	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	0.0
1183621997	1447682043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682043	26514968	CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	1.0
1183621997	1448266372	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266372	26129906	CYP2D6 poor metabolizer genotype is associated with increased exposure to risperidone in people with Bipolar Disorder, Depression, Psychotic Disorders or Substance-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.	1.0
1183621997	1448530802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530802	24828442	CYP2D6 poor metabolizers are associated with decreased metabolism of risperidone in children as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.5
1183621997	1448993578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993578	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.125
1183621997	1451251823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451251823	24232129	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .	1.25
1183621997	1183619675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619675	10639689	CYP2D6 *1xN is associated with increased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	0.25
1183621997	1183619945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619945	11791898	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.75
1183621997	1183620411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620411	15260906	CYP2D6 *4 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183621997	1183620517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620517	17715206	CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	2.0
1183621997	1183620832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620832	16833023	CYP2D6 *10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1.	1.5
1183621997	1183621939	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621939	15729081	CYP2D6 *10 is not associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	-0.125
1183621997	1183699417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699417	23609392	CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.	2.0
1183621997	1296599629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599629	24589909	CYP2D6 *10 + *5 are associated with increased concentrations of risperidone in people with Schizophrenia.	1.75
1183621997	1447681693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681693	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*10 + *1/*41.	0.0
1183621997	1447681711	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681711	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *1/*5 + *10/*10 + *10/*41.	0.0
1183621997	1448530382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530382	26944100	CYP2D6 *5/*10 + *4/*10 + *10/*10 + *10/*41 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizers phenotype) .	1.75
1183621997	1448530486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530486	26944100	CYP2D6 *4/*10 + *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1183621997	1448530511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530511	26944100	CYP2D6 *10/*10 + *10/*41 + *1/*4 + *1/*5 are not associated with metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.	-0.125
1183621997	1448530601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530601	20814331	CYP2D6 *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1183621997	1448530620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530620	20332423	CYP2D6 *10/*10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1183621997	1447959180	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959180	26544071	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.	0.0
1183621997	1451099341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451099341	30870237	CYP2D6 *10 is not associated with concentrations of risperidone in people with Schizophrenia as compared to CYP2D6 *1 + *2.	-0.125
1183621997	1183702193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702193	24329187	CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	1.5
1183621997	1183619642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619642	10639689	CYP2D6 *4 + *5 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.0
1183621997	1183620333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620333	15089809	CYP2D6 *4 + *5 + *10 +*14 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.	1.75
1183621997	1447681725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681725	26780783	CYP2D6 *1/*1 is associated with decreased concentrations of risperidone in children with Autistic Disorder as compared to CYP2D6 *4/*10 + *5/*10.	0.0
982034197	1451554360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451554360	32800527	Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotypes AA + AG.	1.75
982034197	1451649100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451649100	34689504	Genotypes AG + GG are associated with increased dose of morphine in people with Liver Neoplasms and Pain as compared to genotype AA.	2.25
982034197	731462495	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/731462495	17156920	Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA.	2.0
982034197	1184753725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753725	25155931	Genotypes AG + GG is not associated with increased dose of morphine in infants as compared to genotype AA.	-0.25
982034197	1451159083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159083	19514130	Genotype G is not associated with dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to genotype A.	-1.75
982034197	1448612958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612958	28346387	Genotype AG is associated with increased dose of morphine in people with Neoplasms as compared to genotype AA.	2.25
982034197	1449162954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162954	24703092	Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotypes AA + AG.	0.25
982034197	1449172643	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172643	29474345	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	-1.75
982034197	1449182322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449182322	29259946	Allele G is not associated with dose of morphine in people with Pain as compared to allele A.	-1.5
982034197	1449188786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188786	23431434	Allele G is not associated with dose of morphine in women with Pain, Postoperative as compared to allele A.	-1.5
982034197	1449188852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188852	16879459	Genotype GG is associated with increased dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG.	2.0
982034197	1449188859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188859	16871067	Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.	1.75
982034197	1449239780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449239780	16580900	Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA.	-1.25
982034197	1449295820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295820	23686330	Genotype GG is not associated with dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG.	-1.5
982034197	1449295851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295851	26902643	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	-1.5
982034197	1450373388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373388	27649267	Genotypes AG + GG are associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.	3.0
982030757	981486960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981486960	21196316	Genotype TT is associated with increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to genotype GG.	1.75
982030887	982030363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030363	23394390	Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.5
982030900	982030375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030375	23394390	Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.5
982031241	982031201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031201	23651021	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	1.5
982031241	1444935225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935225	25493569	Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA.	2.25
982031241	1448111986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448111986	27180831	Allele G is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid.	-2.0
982032306	982032084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032084	23651024	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	0.0
982034899	982034681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034681	10334805	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to acetylcholine or nitroprusside in healthy individuals as compared to allele del.	1.75
982030381	982030327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030327	23394390	Genotype CC is associated with increased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	0.0
982030381	637880307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880307	19924111	Genotype CC is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder.	0.0
982030381	1184998157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998157	25303296	Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	1.5
982030381	1184998246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998246	25303296	Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	1.25
982044867	981862390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862390	23567490	Genotype AA is associated with decreased time-to-tumor recurrence when treated with fluorouracil in Colonic Neoplasms as compared to genotypes AG + GG.	3.25
982045137	981345659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345659	22296034	Genotypes CT + TT are associated with decreased difference in fasting plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.0
982045137	981345683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345683	22296034	Genotypes CT + TT are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.0
1043858698	982047778	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047778	15898979	Genotype GG is associated with increased risk of aspirin-intolerant asthma when treated with aspirin in people with Asthma as compared to genotypes AA + AG.	2.25
1043880066	981939805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939805	18444945	Genotype TT is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes GG + GT.	3.0
1043880082	981861494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861494	20565459	Genotype CC is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes CG + GG.	2.25
1043880082	981861509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861509	20565459	Genotype CC is associated with increased risk of Diarrhea when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes CG + GG.	2.5
1043880082	981861524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861524	20565459	Genotype CC is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil, sirolimus or tacrolimus in people with Kidney Transplantation as compared to genotypes CG + GG.	-1.25
1051394394	982042116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042116	15864113	Genotype TT is associated with increased response to atorvastatin in men with Hyperlipoproteinemia Type II.	2.25
1051394394	982042181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042181	15864113	Genotype TT is not associated with increased response to atorvastatin in women with Hyperlipoproteinemia Type II as compared to genotype GG.	-2.25
1139265477	982045854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045854	16103896	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.	-1.75
1139265477	982046536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046536	19802823	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.	-1.0
1139265477	982048014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048014	21392722	Genotype GG is associated with decreased response to atorvastatin in people with Coronary Artery Disease as compared to genotypes AA + AG.	2.0
1139265477	1450983990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450983990	19238649	Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.	1.0
1158793019	827922560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922560	22668755	Genotype AG is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotype GG.	2.0
1158793019	827922597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922597	22668755	Genotype AA is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotypes AG + GG.	2.5
1183491214	981501721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501721	23324807	Genotype CT is associated with decreased midazolam metabolic ratios by 45% when exposed to midazolam as compared to genotype CC.	2.0
1183491214	827813026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813026	19801957	Genotype TT is associated with increased metabolic ratio of midazolam when exposed to midazolam as compared to allele C.	2.5
1183491333	982045376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045376	15936011	Genotypes AA + AG are associated with increased reduction in DNA damage when treated with simvastatin in people with Hypercholesterolemia as compared to genotype GG.	2.25
1183491809	1043759532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043759532	18997459	Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome.	2.25
1183532521	827807823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807823	20031551	Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele G.	3.5
1183617623	769218933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769218933	21121774	Allele T is associated with increased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.	3.0
1183617685	769218919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769218919	21121774	Allele T is associated with decreased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.	2.5
1183617685	827695940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695940	21121774	Genotype CC is associated with increased slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.5
1183617685	827695947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695947	21121774	Genotype CC is associated with increased slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.0
1043880170	982035525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035525	15856070	Genotype AA is associated with increased risk of cardiovascular disease events when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotypes AG + GG.	0.0
1043880170	982036409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036409	15856070	Genotype GG is not associated with increased change in lipid parameters when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotype AA.	-1.75
1043880170	1005117719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1005117719	17931083	Allele G is not associated with response to simvastatin in people with Hypercholesterolemia as compared to allele A.	-1.5
1043858905	827814949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814949	21114608	Genotype CC is associated with increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	2.25
1043858905	827826067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827826067	17519421	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.5
982035703	982035636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035636	18030307	Genotype CC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.	1.75
982035703	982037919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037919	20072124	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.0
982035703	982044357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044357	16611750	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.25
982035703	1183704687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704687	24019055	Genotype AA is associated with increased dose of warfarin as compared to genotype AC.	2.5
982035703	1450980580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980580	18322281	Genotype CC is associated with decreased dose of warfarin as compared to genotype AA.	2.75
1183619004	PA166127639	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127639		Annotation of CPIC Guideline for sertraline and CYP2C19	100
1183619004	PA166104980	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104980		Annotation of DPWG Guideline for sertraline and CYP2C19	100
1183619004	1183617538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617538	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with sertraline in people with Depressive Disorder, Major.	0.125
1183619004	1183698918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698918	11452243	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased clearance of sertraline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer phenotype) .	1.0
1183619004	1183699890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699890	18677622	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 are associated with increased mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.25
1183619004	1183699907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699907	18677622	CYP2C19 *1/*17 + *17/*17 are not associated with differences in mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-0.75
1183619004	1447950096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447950096	26830411	CYP2C19 *2 + *17 are not associated with metabolism of sertraline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-2.0
1183619004	1450933318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933318	31649299	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1183619004	1450933348	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933348	31649299	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1183619004	1450933341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933341	31649299	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
982037423	PA166104968	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104968		Annotation of DPWG Guideline for venlafaxine and CYP2D6	100
982037423	1451252940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451252940	12544511	CYP2D6 poor metabolizer phenotype is associated with decreased clearance of venlafaxine as compared to CYP2D6 normal metabolizer phenotype.	0.75
982037423	769143878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143878	16958828	Allele T is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele C.	1.5
982037423	750192626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/750192626	16958828	Allele del is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele A.	1.5
982037423	982015108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015108	16642541	Genotypes CT + TT are associated with increased venlafaxine concentration per unit dose when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.	1.5
982037423	982029364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029364	20174590	CYP2D6 *1/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.0
982037423	982029371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029371	20174590	CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.	1.5
982037423	982029490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029490	10774634	CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.5
982037423	982029511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982029511	18214456	CYP2D6 *4/*4 is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
982037423	982029591	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029591	10877013	CYP2D6 *10/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
982037423	982029604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029604	10877013	CYP2D6 *1/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	1.5
982037423	982029627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029627	10233212	CYP2D6 *10/*10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
982037423	982029646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029646	10233212	CYP2D6 *5/*10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
982037423	1447950037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447950037	25510856	CYP2D6 *10/*10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.5
982037423	982029525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982029525	18214456	CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	1.0
982037423	1183617359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617359	16044105	CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 *1/*1.	1.25
982037423	1450815182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815182	23332809	CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine.	0.125
982037423	1183681035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681035	23357843	CYP2D6 *4/*5 is associated with decreased metabolism of venlafaxine in a person with depression.	0.125
1183619068	PA166104937	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104937		Annotation of DPWG Guideline for aripiprazole and CYP2D6	100
1183619068	1183906189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183906189	24232129	CYP2D6 intermediate metabolizers is not associated with serum concentration of dehydroaripiprazole when treated with aripiprazole as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6.	-1.0
1183619068	1447682087	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682087	26514968	CYP2D6 poor metabolizer is associated with decreased metabolism of aripiprazole in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer.	0.5
1183619068	1448993561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993561	25868121	CYP2D6 poor metabolizer genotype is associated with increased dose-adjusted trough concentrations of aripiprazole in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer genotype.	1.0
1183619068	1451251861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451251861	24232129	CYP2D6 intermediate metabolizer phenotype is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .	1.375
1183619068	1183618939	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618939	17965519	CYP2D6 *2 is not associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.	-0.375
1183619068	1183697499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697499	21739267	CYP2D6 *1/*1 + *1/*10 + *1/*21 + *1/*5 (assigned as normal metabolizer phenotype) are not associated with decreased metabolism of aripiprazole in healthy individuals also being given fluvoxamine as compared to CYP2D6 *10/*10 + *5/*10 (assigned as intermediate metabolizer phenotype) .	-0.125
1183619068	1183618626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618626	17828532	CYP2D6 *4 + *5 + *6 is associated with decreased metabolism of aripiprazole as compared to CYP2D6 *1.	1.25
1183619068	1183618864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618864	17965519	CYP2D6 *5 + *10 + *41 is associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.	1.5
1183619068	1183697486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697486	21739267	CYP2D6 *1/*1 + *1/*10 (assigned as normal metabolizer phenotype) are associated with decreased metabolism of aripiprazole in healthy individuals also being given paroxetine as compared to CYP2D6 *10/*10 + *10/*21 (assigned as intermediate metabolizer phenotype) .	This annotation is not used for clinical annotation scoring. Paroxetine is a strong CYP2D6 inhibitor
1183619068	1451548640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451548640	30604050	CYP2D6 *3 + *4 + *4xN + *5 + *6 + *10 + *41 are associated with increased concentrations of aripiprazole as compared to CYP2D6 *1 + *1xN.	1.75
1183620386	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1183620386	PA166104977	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104977		Annotation of DPWG Guideline for citalopram and CYP2C19	100
1183620386	1183701599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701599	8451774	CYP2C19 poor metabolizer is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2C19 normal metabolizer.	0.75
1183620386	1183701639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701639	8835706	CYP2C19 poor metabolizer is associated with increased plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	0.875
1183620386	1451715780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451715780	33608663	Genotype AG is associated with increased concentrations of citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.	2.0
1183620386	982029840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029840	20531370	Genotype TT is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to genotype CC.	1.75
1183620386	982029829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029829	20531370	Genotype AA is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to genotype GG.	1.75
1183620386	982046981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046981	11802100	CYP2C19 *1/*2 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-0.125
1183620386	1183619572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619572	12968986	CYP2C19 *2/*2 + *2/*3 are associated with increased AUC of the S-enantiomer of citalopram (no effect on R-CT) when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183620386	1183619684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619684	12975335	CYP2C19 *2/*2 + *2/*3 is associated with decreased oral clearance of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	0.5
1183620386	1183619708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619708	12975335	CYP2C19 *2/*2 + *2/*3 is associated with increased citalopram AUC and terminal elimination half-life when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.5
1183620386	1183619732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619732	16418702	CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1183620386	1183619883	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619883	16855453	CYP2C19 *2 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.25
1183620386	1183619898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619898	16855453	CYP2C19 *3 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1183620386	1183701537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701537	23981149	CYP2C19 *1/*2 is not associated with clearance of citalopram in healthy individuals as compared to CYP2C19 *1/*1.	-0.125
1183620386	1183847009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183847009	19840783	CYP2C19 *1/*2 + *2/*2 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183620386	1184137222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137222	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with plasma concentrations when treated with citalopram in people with Depressive Disorder, Major.	0.125
1183620386	1184137230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137230	20531370	CYP2C19 *2/*2 is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to CYP2C19 *1/*1.	1.75
1183620386	1184137250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137250	20531370	CYP2C19 *1/*17 is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to CYP2C19 *1/*1.	1.75
1183620386	1184748190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748190	25154506	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1183620386	1184748315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748315	25154506	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1183620386	1184748329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748329	25154506	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1183620386	1184748337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748337	25154506	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1183620386	1446908220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908220	26343256	CYP2C19 *2 is associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.0
1183620386	1446908239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908239	26343256	CYP2C19 *1/*17 is not associated with metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	-0.5
1183547855	982032160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982032160	23408116	Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.	0.0
1183603016	981475680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475680	22041458	Allele T is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele C.	0.0
1183614476	981477286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477286	22541248	Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.	2.0
1183615328	981786052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786052	16456808	Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with decreased risk of Asthenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.	1.75
1183619292	981476290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476290	18215618	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	2.75
1183619303	981476235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476235	18215618	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	2.75
1183619317	981476308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476308	18215618	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	2.75
1183632117	1183632046	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632046	23753411	Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	0.0
1183632180	613977025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977025	16538175	Allele T is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele C.	2.0
1183614850	982034642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034642	15554460	Genotypes AG + GG are not associated with response to benazepril in people with Essential hypertension.	-2.0
1183614850	982034671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034671	15554460	Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA.	2.75
1183614850	982034790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034790	15554460	Genotypes AG + GG are not associated with response to benazepril in people with Essential hypertension as compared to genotype AA.	-1.75
1183632195	827825824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825824	20707787	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron as compared to genotypes AG + GG.	2.5
1183632195	1446896454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446896454	25012726	Genotype GG is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.	2.0
1183620575	PA166104962	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104962		Annotation of DPWG Guideline for propafenone and CYP2D6	100
1183620575	1450417472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450417472	14653957	CYP2D6 *10/*10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.	1.0
1183620575	1451294540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451294540	33203295	CYP2D6 *1/*5 + *2/*36 + *5/*10 + *5/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	1.5
1183620575	1451330400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451330400	12421483	CYP2D6 *10/*10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.	1.0
981204549	827921297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921297	12371972	Genotype del/del is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in men with Essential hypertension as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	2.5
981204549	827921327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921327	12371972	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in women with Essential hypertension as compared to genotype del/del.	-2.5
981204549	827922461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922461	21269061	Genotype del/del is associated with increased reduction in systolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	3.0
981204851	655386706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386706	15077009	Genotypes AA + AG is associated with increased likelihood of cessation when treated with nicotine as compared to genotype GG.	2.5
981204851	1450812294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812294	18690117	Allele A is not associated with response to nicotine in healthy individuals as compared to allele G.	-1.5
981204851	655387313	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387313	15033882	Genotypes AA + AG is associated with increased likelihood of smoking cessation when treated with nicotine in people with female gender as compared to genotype GG.	3.5
981204851	769261561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261561	21540761	Allele A is associated with smoking cessation when treated with nicotine in people with Depression as compared to genotype GG.	This annotation is not used for clinical annotation scoring. depended on condition of depression
981237871	769180246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180246	18294295	Allele G is associated with increased risk of Leukopenia when treated with docetaxel as compared to allele A.	2.25
981237871	827784589	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784589	21995462	Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.	1.0
981237871	827784616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784616	21995462	Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.	1.0
981237930	655386332	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386332	19786980	Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.	2.5
981237930	827826160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826160	22188361	Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.	-1.25
981238415	981501216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501216	23029095	Genotype CC is associated with increased event free survival when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.	2.25
981238415	827813059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813059	19858780	Allele A is associated with response to methotrexate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	3.25
981238415	827813071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813071	19858780	Allele A is associated with gastrointestinal toxicities when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	3.0
981238415	827863280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863280	22450926	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.75
981238415	769173671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173671	19193698	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
981238415	769173660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173660	16947783	Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	2.0
981238415	1449164992	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164992	27217051	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.75
981238415	1449557945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557945	29743634	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.0
981238415	1449752227	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752227	29520081	Genotypes AA + AC is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	-2.0
1451288220	PA166104996	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104996		Annotation of CPIC Guideline for codeine and CYP2D6	100
1451288220	PA166104970	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104970		Annotation of DPWG Guideline for codeine and CYP2D6	100
1451288220	1450376074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376074	30784356	CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.25
1451288220	1451351660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351660	31141989	CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 poor metabolizers and intermediate metabolizers.	0.0
1451288220	1451404282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451404282	33750887	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to codeine in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.	0.0
1451288220	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451288220	982046905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046905	17517247	CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046919	17517247	CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046931	17517247	CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	982046937	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046937	17517247	CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.	1.75
1451288220	1183617920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617920	16631290	CYP2D6 *4/*6 is associated with intolerance to codeine ( significant side effects as well as no pain relief) when treated with codeine.	0.25
1451288220	1183632376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183632376	21743374	CYP2D6 *4/*4 + *4/*5 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 *1/*1.	0.25
1183615535	827807728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807728	18334914	Allele A is associated with increased serum concentrations of digoxin as compared to allele G.	0.0
1183629972	1183623887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623887	17228018	GSTM1 non-null is associated with increased risk of hearing impairment when treated with cisplatin in men with Testicular Neoplasms as compared to GSTM1 null.	2.5
1183629972	1183624668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624668	23274376	GSTM1 non-null is not associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms.	-1.25
1183680506	981848325	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848325	23508266	Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.	0.0
1449164857	1449160225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449160225	29198060	Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.	1.0
1449713231	1449713211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449713211	30013178	Allele G is associated with increased risk of drug-induced liver injury due to interferon beta-1a or interferon beta-1b in people with Multiple Sclerosis as compared to allele A.	3.5
1449752810	1449752709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752709	29233746	Allele T is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele C.	3.0
981204210	769171345	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171345	20386493	Genotype AG is associated with increased likelihood of CNS adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.0
981204210	827863316	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863316	22450926	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.75
981204210	769173649	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173649	16947783	Allele A is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	2.0
981204210	1448576417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576417	27992285	Genotypes AA + AG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.75
981204210	1449164980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164980	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.75
981204210	1449557898	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557898	29743634	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
981204210	1449752221	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752221	29520081	Genotypes AA + AG is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	-2.0
1183630118	1183623897	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623897	17228018	GSTT1 non-null is not associated with increased risk of severe hearing impairment when treated with cisplatin in men with Testicular Neoplasms as compared to GSTT1 null.	-2.0
1183630118	1183624616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624616	23274376	GSTT1 non-null is associated with increased risk of Deafness when treated with cisplatin in children with Neoplasms as compared to GSTT1 null.	2.75
1183630118	1447715709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447715709	26803611	GSTT1 non-null is not associated with response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTT1 null.	-1.75
1183630118	1447677900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677900	26571237	GSTT1 null/null is not associated with decreased likelihood of Death and Recurrence when exposed to cisplatin and radiotherapy in women with Uterine Cervical Neoplasms as compared to GSTT1 non-null/non-null.	-2.5
1183679838	827805837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805837	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1183679838	1448109164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109164	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-1.5
1183615480	827807126	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807126	21599570	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *6/*6.	0.0
1183615480	827807118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807118	21599570	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *4/*4.	0.0
1183615480	827807123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807123	21599570	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *5/*5.	0.0
1183615480	827807099	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807099	21599570	CYP2D6 *1/*1 is associated with increased clearance of carvedilol in healthy individuals as compared to CYP2D6 *3/*3.	0.0
1183615480	982036882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036882	16849011	CYP2D6 *10 is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.	1.0
1183615480	982036911	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036911	16849011	CYP2D6 *4 is not associated with metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.	-0.125
1183615480	982036924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036924	16849011	CYP2D6 *5 is not associated with metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.	-0.125
1183615480	982043452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043452	16595916	CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	2.25
1183615480	982044314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044314	17329852	CYP2D6 *1/*4 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.	1.5
1183615480	982044321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044321	17329852	CYP2D6 *1/*5 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.	1.5
1183615480	982044327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044327	17329852	CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.	1.5
981238550	981239981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239981	15692831	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T.	1.75
981238550	981501753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501753	23252947	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	1.0
981238550	1447678288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678288	26555147	Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	2.0
1450373520	1450373495	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373495	27649267	Allele A is associated with increased dose of morphine in women with Pain, Postoperative as compared to allele G.	3.0
1450373622	1450373552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373552	30237583	Genotype AA is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AG + GG.	1.5
1451404212	1451404160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451404160	33676726	Genotype CC is associated with decreased dose of rocuronium in women as compared to genotypes CT + TT.	This annotation is not used for clinical annotation scoring. Paper does not include an independent replication cohort.
1451404219	1451404202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451404202	33676726	Genotype CC is associated with decreased dose of rocuronium in women as compared to genotypes CT + TT.	This annotation is not used for clinical annotation scoring. Paper does not include an independent replication cohort.
981239532	981239462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239462	14765194	Allele A is associated with increased dose of warfarin as compared to allele C.	0.25
981239532	981239523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239523	18234403	Allele A is associated with increased dose of warfarin as compared to allele C.	0.0
981239556	981239471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239471	14765194	Allele C is associated with increased dose of warfarin as compared to allele T.	0.25
981239556	981239505	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239505	18234403	Allele C is associated with increased dose of warfarin as compared to allele T.	0.0
981204902	981481971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481971	20840187	Genotype AA is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to genotypes AG + GG.	2.5
981204902	981482015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482015	21418140	Allele A is associated with increased severity of smoking when exposed to nicotine in people with smoking as compared to allele G.	1.5
981204902	981482036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482036	21418140	Allele A is not associated with increased risk of smoking when exposed to nicotine as compared to allele G.	-0.75
981204902	981482237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482237	20886544	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.0
981204902	981754805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754805	19706762	Allele A is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	3.5
981204902	981862067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862067	19132693	Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.	3.0
981204902	982022898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022898	20485328	Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.	0.0
981204902	769178836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769178836	18618000	Allele A is associated with increased risk of Tobacco Use Disorder.	2.0
981204902	827921955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921955	22648373	Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.	2.0
981204902	1184168936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168936	24733007	Genotypes AA + AG is not associated with likelihood of abstinance when treated with nicotine in smokers as compared to genotype GG.	-2.0
981204902	1450813499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813499	22046326	Allele A is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele G.	-1.5
981204902	1450813513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813513	22046326	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-1.5
981204902	1450928745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450928745	29621993	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-2.0
981204902	1450930789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450930789	29666375	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine in men as compared to allele G.	-2.5
981204902	1448261745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261745	27355804	Allele A is associated with increased likelihood of Tobacco Use Disorder as compared to allele G.	2.5
981204902	1449155955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155955	29196725	Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.75
981204902	1451120367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120367	31402126	Allele A is not associated with likelihood of cessation of nicotine in people with Lung Neoplasms as compared to allele G.	-1.5
981204902	1451135740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135740	31796940	Allele A is not associated with likelihood of cessation of nicotine in people with Tobacco Use Disorder as compared to allele G.	-1.5
981204902	1450112824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450112824	30453884	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	3.0
981238501	PA166122806	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122806		Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B	100
981238501	PA166104984	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104984		Annotation of DPWG Guideline for phenytoin and CYP2C9	100
981238501	1451151749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151749	32457604	Allele T is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele C.	2.25
981238501	1451151730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151730	32457604	Allele C is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele A.	2.25
981238501	769250046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250046	19617466	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype CC.	0.0
981238501	769248937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248937	21068649	Allele T is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele C.	3.0
981238501	769259087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769259087	21537551	Allele T is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele C.	-1.0
981238501	1448614798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614798	28391407	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele C.	3.5
981238501	1448614807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614807	28391407	Allele T is not associated with drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele C.	-1.5
981238501	769259088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769259088	21537551	Allele C is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele A.	-1.0
981238501	769248932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769248932	21068649	Allele C is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele A.	3.0
981238501	769250049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250049	19617466	Genotype AC is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype AA.	0.0
981238501	827921686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921686	22641027	CYP2C9 *2/*2 is associated with Drug Toxicity when treated with diazepam and phenytoin in children with Epilepsy.	0.25
981238501	981858881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858881	20390258	CYP2C9 *1/*3 is associated with increased risk of phenytoin toxicity when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	3.25
981238501	981858886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858886	15024534	CYP2C9 *1/*3 is associated with increased likelihood of diphenylhydantoin-induced skin rash when exposed to phenytoin in neurological patients as compared to CYP2C9 *1/*1.	2.0
981238501	981859027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859027	11673755	CYP2C9 *3/*3 is associated with increased toxicity when treated with phenytoin.	0.0
981238501	981859041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859041	12707459	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	0.0
981238501	981859044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859044	21338443	CYP2C9 *1/*2 + *1/*3 is associated with increased adverse drug reactions when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	2.5
981238501	981859058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859058	19030785	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	0.0
981238501	981859061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859061	10774639	CYP2C9 *1/*3 is associated with increased toxicity when treated with phenytoin.	0.0
981238501	1184989037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989037	25096692	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	4.0
981238501	1184989132	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989132	25096692	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	3.75
981238501	1184989143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989143	25096692	CYP2C9 *3 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	3.5
981238501	1184989152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989152	25096692	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.	3.0
981238501	1447948974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948974	26928377	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin as compared to CYP2C9 *1.	2.5
981238501	1449565339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565339	25994870	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions due to phenytoin in children with Epilepsy.	3.25
981238501	1449565877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565877	27179628	CYP2C9 *1/*3 + *2/*3 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1 + *1/*2.	-1.25
981238501	1449565892	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565892	27179628	CYP2C9 *1/*2 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1.	-1.25
981238501	1450376288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376288	29288229	CYP2C9 *3 is not associated with risk of Maculopapular Exanthema due to phenytoin.	-2.0
981238501	1450806480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806480	30270535	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with phenytoin as compared to CYP2C9 *1/*1.	3.5
981238501	1450969260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450969260	31461080	CYP2C9 *1/*2 is not associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	-1.5
981238501	1450969282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450969282	31461080	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	3.25
981238501	1451117820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451117820	31646624	CYP2C9 *3 is associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C9 *1/*1.	4.0
981419263	PA166105008	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105008		Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B	100
981419263	PA166265162	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265162		Annotation of DPWG Guideline for carbamazepine and HLA-B	100
981419263	PA166104780	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104780		Annotation of FDA Label for carbamazepine and HLA-B	100
981419263	981349387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349387	18637831	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	2.75
981419263	981349402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349402	15057820	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	981349415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349415	16538176	HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	3.0
981419263	981482101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482101	23132554	HLA-B *15:02:01 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.	1.75
981419263	981859096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859096	17509004	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.	2.75
981419263	981859117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859117	22500513	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	0.25
981419263	994166507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/994166507	23588310	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	2.5
981419263	1183680856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680856	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1183702071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702071	24336023	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.75
981419263	1183702087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702087	24336023	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	1.75
981419263	1183702093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702093	24336023	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	1.375
981419263	1184407607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407607	19915237	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.5
981419263	1184412194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184412194	20345939	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1184421854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184421854	20833111	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.25
981419263	1184466792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466792	21204807	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184466803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466803	21244392	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184466880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466880	21397523	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1184466899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466899	21424386	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184466933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466933	21676164	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.	2.75
981419263	1184467933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467933	21917426	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
981419263	1184467942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467942	21917426	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	3.25
981419263	1184468042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468042	22053601	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	2.0
981419263	1184468294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468294	22348435	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1184468301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468301	22348435	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184468322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468322	23884208	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	1.0
981419263	1184468379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468379	24225276	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.	1.0
981419263	1184468423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468423	24268988	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
981419263	1184469071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469071	24496695	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	2.5
981419263	1184469086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469086	24394201	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.5
981419263	1184469104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469104	24399721	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1184469192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469192	24322785	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	4.0
981419263	1184469237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469237	24322785	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-3.5
981419263	1184987994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987994	23551241	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.	-1.25
981419263	1184988662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988662	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.75
981419263	1185003386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003386	25266342	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.625
981419263	1185003427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003427	25305458	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	1.5
981419263	1444707937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707937	25938071	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	2.75
981419263	1444707960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707960	25938071	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	1446895471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895471	26319500	HLA-B *15:02:01 is associated with Epidermal Necrolysis, Toxic when treated with carbamazepine.	0.25
981419263	1446902307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902307	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	3.0
981419263	1447959759	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959759	27020614	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine in children with schizencephaly.	0.25
981419263	1447980932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447980932	27096699	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.	2.75
981419263	1447983639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447983639	23712814	HLA-B *15:02:01 is associated with risk of Stevens-Johnson Syndrome when treated with carbamazepine in women with Epilepsy.	0.25
981419263	1448261069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261069	25355835	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	2.5
981419263	1448525687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525687	27888155	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.75
981419263	1448635647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635647	28570299	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine.	3.25
981419263	1449004794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004794	29053440	HLA-B *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.5
981419263	1449147028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449147028	29076187	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	0.25
981419263	1184755407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755407	19018717	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	This annotation is not used for clinical annotation scoring. No patients had the allele.
981419263	1451305960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451305960	33356553	HLA-B *15:02:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	2.75
981419263	981349408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349408	16415921	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	0.25
981419263	1451431060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451431060	33910375	HLA-B *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	-1.0
981419263	1451504120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504120	34553372	HLA-B *15:11:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	2.25
981419263	1451641160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641160	34350628	HLA-B *15:11:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
981419263	1451641227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641227	34350628	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.5
981419263	1451780623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451780623	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.	3.75
655387745	655387714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387714	16413245	Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.	2.0
981419487	981419430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419430	21795085	Allele T is associated with severe statin myopathy and unknown myopathy when exposed to hmg coa reductase inhibitors in people with drug-induced muscle diseases as compared to allele C.	0.0
981419550	769180491	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180491	21386754	Genotype AA is associated with decreased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype GG.	0.0
981478113	981478023	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478023	22682551	Allele T is associated with drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone, diuretics or sotalol as compared to allele C.	2.5
981478113	981478039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478039	22682551	Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.	2.5
981419257	PA166104997	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104997		Annotation of CPIC Guideline for abacavir and HLA-B	100
981419257	PA166104991	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104991		Annotation of DPWG Guideline for abacavir and HLA-B	100
981419257	PA166104833	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104833		Annotation of FDA Label for abacavir and HLA-B	100
981419257	981349371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349371	18256392	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.0
981419257	981349377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981349377	15247625	HLA-B *57:01:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.75
981419257	981475111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475111	11888582	HLA-B *57:01:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV.	3.5
981419257	981476261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476261	22197535	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.25
981419257	1444705964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705964	25877443	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	1.0
981419257	1444707690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707690	25934581	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.0
981419257	1444876870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444876870	15024131	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	3.0
981419257	1444877117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444877117	18184080	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.25
981419257	1444877145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444877145	19195327	HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	2.75
981419257	1448255629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255629	27403179	HLA-B *57:01:01 is associated with Drug Hypersensitivity when treated with abacavir in people with HIV.	2.0
981419257	1448260768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260768	27530904	HLA-B *57:01:01 is associated with risk of Drug Hypersensitivity when treated with abacavir in people with HIV.	0.25
981419260	PA166105003	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105003		Annotation of CPIC Guideline for allopurinol and HLA-B	100
981419260	827919454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919454	21545408	HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0.0
981419260	981345627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345627	21393610	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
981419260	981345632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345632	21301380	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
981419260	981345637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345637	19696695	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.75
981419260	981345642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345642	19018717	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	981345647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345647	18192896	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	3.0
981419260	981345654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345654	15743917	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	981419988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419988	22909208	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	3.5
981419260	981420004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420004	22909208	HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	2.75
981419260	1183682459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682459	23669020	HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682532	23600531	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682546	23280169	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.	0.25
981419260	1183682555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682555	22348415	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1183682626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682626	21906289	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	2.0
981419260	1183685075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685075	17587850	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.	0.25
981419260	1183685103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685103	22017528	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	3.5
981419260	1183685113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685113	19483528	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.	0.25
981419260	1183685121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685121	22901319	HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.	0.25
981419260	1184467886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467886	21912425	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1184470833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470833	24858023	HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	-1.75
981419260	1184748340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748340	25115449	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1184755884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755884	19002350	HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.	-0.25
981419260	1184756798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756798	21393610	HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.625
981419260	1184987721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987721	25257159	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.75
981419260	1184998111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998111	25327504	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.	1.5
981419260	1445362018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445362018	26104483	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1447672343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672343	26632391	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	1447676605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676605	26655481	HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	1.0
981419260	1447949095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949095	26937673	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.	0.25
981419260	1448255668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255668	26996548	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.75
981419260	1448256105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256105	27486401	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1448530471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530471	25899558	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol.	0.25
981419260	1448997619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997619	28857441	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	4.0
981419260	1449170079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170079	29392141	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.	3.75
981419260	1450342159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342159	30383575	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic when treated with allopurinol.	0.25
981419260	1451211440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211440	32433341	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.25
981419260	1446902249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902249	25566896	HLA-B *58:01 is associated with Drug Hypersensitivity and Exanthema when treated with allopurinol.	0.25
981419260	1448429006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448429006	27835909	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.0
981419260	1183685128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685128	21790926	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.	0.25
981419260	1448624570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624570	28509689	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	3.0
1449167328	1449166088	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166088	29382897	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449168072	1449167742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167742	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168079	1449167827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167827	29407288	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449167453	1449166147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166147	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
982029652	982025963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025963	23556448	Allele A is associated with increased likelihood of dependence with methamphetamine in men as compared to allele C.	3.0
982029652	982025982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025982	23556448	Genotype AA is not associated with increased likelihood of psychosis due to methamphetamine in men as compared to genotype CC.	-0.75
982029652	1451135422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135422	31789429	Allele A are associated with increased risk of methamphetamine dependence due to methamphetamine as compared to allele C.	3.0
982030862	982030340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030340	23394390	Genotype AA is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotype GG.	0.0
982030971	981848195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848195	20126830	Genotype TT is associated with 20% and 17% less inhibition of platelet aggregation with crangrelor (0.05 and 0.25 microM) in-vitro when exposed to cangrelor as compared to genotype GG.	0.5
982031308	699639199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639199	21047205	Allele C is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele T.	0.0
982031346	827816699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816699	21961650	Genotype GG is associated with increased response to lithium in people with Bipolar Disorder as compared to genotype AA.	2.5
982031374	981750318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750318	20348464	Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.	2.5
982031407	981419765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981419765	18408563	Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder as compared to genotypes CC + CT.	2.0
982031795	982029378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029378	21107304	Allele A is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele G.	3.0
982032228	982032025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032025	23651024	Genotype CC is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC.	0.0
982032638	982032576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032576	23651024	Genotypes AA + AC are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	0.0
982029578	981755237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755237	22840423	Genotype AA is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	-1.75
982029578	981755243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755243	22840423	Genotype AC is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	-1.75
982029578	982025943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982025943	23570466	Genotypes AC + CC are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype AA.	1.75
982029578	1184510438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510438	23842101	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele C.	-1.75
982030916	981754634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754634	20237460	Allele C is associated with increased severity of Anxiety Disorders in women with Anxiety Disorders as compared to allele T.	1.0
982030916	981754640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754640	20237460	Allele C is associated with decreased response to antidepressants, benzodiazepine derivatives, mirtazapine or Selective serotonin reuptake inhibitors in women Depressive Disorder, Major as compared to allele T.	2.0
982031034	981848029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848029	18485500	Genotype AA is associated with stronger aggreagtion when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	2.5
982031034	981848040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848040	18485500	Genotype AA is associated with increased risk of non-response when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	3.0
982031034	981848051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848051	18485500	Genotype AA is associated with increased risk of clopidogrel resistance when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	3.5
982031034	981848168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848168	15933261	Allele A is not associated with increased risk of neurological events when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to allele C.	-1.5
982031034	982033003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033003	19106083	Allele A is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	-2.0
982031034	1446896509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896509	26362473	Genotype AA is not associated with decreased response to clopidogrel as compared to genotype CC.	-2.75
982035482	982035100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035100	21179214	Allele T is associated with lower levels of transthyretin precuror when exposed to warfarin as compared to allele G.	2.25
982036238	982035840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035840	19740397	Genotype GG is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AG.	1.0
982037378	981239713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239713	22940005	Allele T is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele C.	-2.0
982037378	982032933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032933	15205592	Genotypes CT + TT are associated with increased collagen-induced platelet aggregation when treated with aspirin and clopidogrel in patients undergoing coronary stenting as compared to genotype CC.	0.5
982037378	982035092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035092	16493486	Allele T is not associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype CC.	-1.5
982037378	982035468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035468	16214444	Genotypes CT + TT are associated with increased platelet aggregation after stimuli with adenosine diphosphate, collagen, and epinephrine when treated with aspirin and clopidogrel in people with Coronary Disease as compared to genotype CC.	1.75
982037378	982036665	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036665	17157856	Genotypes CT + TT are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype CC.	2.25
982045674	1449164464	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164464	23567489	Genotype CC is associated with decreased response to somatropin recombinant in children with Turner Syndrome as compared to genotypes CT + TT.	2.0
1451406523	1451406380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406380	33812699	Genotypes AG + GG are associated with increased response to tramadol in people with Pain, Postoperative as compared to genotype AA.	2.5
982045082	981848268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848268	23508266	Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
982033279	827814765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814765	21148049	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.	-1.5
982033279	827814749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814749	21148049	Allele C is associated with decreased dose of acenocoumarol as compared to allele A.	0.0
982033279	981934149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934149	16815313	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	1.5
982033279	981934157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934157	16815313	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	1.5
982033279	981934182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934182	12414349	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.75
982033279	981934227	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934227	12414349	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981940067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940067	19018719	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	-1.25
982033279	981940074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940074	19018719	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981954438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954438	22629463	CYP2C9 *1 is not associated with increased dose of acenocoumarol as compared to CYP2C9 *2 + *3.	-1.5
982033279	982006745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006745	23159639	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.75
982033279	982006752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006752	23159639	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	-1.75
982033279	982010010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010010	22486182	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	2.5
982033279	982010082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010082	22486182	CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.	2.5
982033279	982010090	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010090	22486182	CYP2C9 *1/*2 is not associated with dose of acenocoumarol.	-1.5
982033279	982010097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010097	22486182	CYP2C9 *1/*3 is not associated with dose of acenocoumarol.	-1.5
982033279	982015075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015075	23473641	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.5
982033279	982015087	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015087	23473641	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	982031268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031268	23651023	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	982032876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032876	23651023	CYP2C9 *2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1183680067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680067	24108193	CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	2.5
982033279	1184511592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511592	25042728	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1.	-2.75
982033279	1184754650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754650	23774941	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	0.0
982033279	1184996788	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184996788	18781852	CYP2C9 *1/*2 + *2/*2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	0.0
982033279	1184996801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184996801	18781852	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	0.0
982033279	1444699553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699553	25519826	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	3.0
982033279	1444705544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705544	23481074	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1444705555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705555	23481074	CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1444705825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705825	24956252	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.	3.0
982033279	1444705930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705930	24530212	CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.	3.25
982033279	1444705951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705951	24530212	CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.	3.25
982033279	1444706944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706944	19277427	CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	1444706957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706957	19277427	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol.	-1.5
982033279	1444706981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706981	19225451	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	3.0
982033279	1444707113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707113	18021343	CYP2C9 *1/*3 + *2/*3 + *2/*2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.25
982033279	1444707144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707144	16699986	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.75
982033279	1444707400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707400	14521618	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.25
982033279	1444707419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707419	14521618	CYP2C9 *1/*2 is not associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.25
982033279	1444707494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707494	12123234	CYP2C9 *2 + *3 are not associated with dose of acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1444707507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707507	12010835	CYP2C9 *3 + *2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	2.0
982033279	1444707543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707543	11186138	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	1.5
982033279	1444707558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707558	11186138	CYP2C9 *1/*2 + *2/*2 are not associated with decreased dose of acenocoumarol.	-0.25
982033279	1447678179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678179	15116052	CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
982033279	1447678195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678195	15116052	CYP2C9 *2 is not associated with time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1447678231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678231	24956252	CYP2C9 *2 + *3 is not associated with decreased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-2.0
982033279	1447678809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678809	16815313	CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.5
982033279	1447678821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678821	16815313	CYP2C9 *2 is not associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
982033279	1447681848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681848	26781925	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.	1.75
982033279	1448255545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255545	27335128	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to CYP2C9 *1/*1.	2.5
982033279	1448259338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259338	22911785	CYP2C9 *2 + *3 is associated with dose of acenocoumarol.	2.5
982033279	1448259384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259384	25089947	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1/*1.	2.0
982033279	1449188252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188252	29479633	CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.	3.0
982033279	1449188274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188274	29479633	CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.	3.0
982033279	1450415269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415269	30983536	CYP2C9 *3/*3 is associated with decreased dose of acenocoumarol.	0.25
982033279	981934319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934319	15128048	CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.0
982033279	1043818082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818082	20020283	CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.	2.25
982033279	981420009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981420009	22920394	CYP2C9 *2 is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
982033279	981420013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981420013	22920394	CYP2C9 *3 is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
982032743	827793255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793255	21449676	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.	1.25
1043858606	981501007	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501007	20016225	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.	-1.0
1043858606	981861657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981861657	19236730	Genotype CC is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype TT.	3.0
1043858606	982009519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982009519	23619509	Genotype TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.5
1043858606	982028611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028611	23733030	Genotype CT is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + TT.	1.5
1043858606	827815008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815008	21338649	Allele T is not associated with response to paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	-1.5
1043858606	1184167136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184167136	22965830	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.75
1043858606	1449311464	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311464	29748862	Genotype CC is not associated with response to escitalopram in people with Depressive Disorder as compared to genotypes CT + TT.	-1.75
1043858642	982034963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034963	20513247	Allele G is associated with increased risk of aspirin-intolerant asthma when treated with aspirin in people with Asthma as compared to allele A.	2.5
1043858651	982047758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047758	20224667	Genotype TT is associated with increased risk of aspirin hypersensitivity when treated with aspirin in people with Asthma as compared to genotypes CC + CT.	2.75
1043858651	982047764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047764	20224667	Genotype TT is associated with increased decline in FEV 1 after aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes CC + CT.	2.75
1043858666	1043753792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043753792	19019667	Genotype TT is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes CC + CT.	3.25
1043858872	982030184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030184	23764426	Allele A is associated with decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele G.	0.0
1043859119	981501697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501697	23324805	Allele A is associated with poor response after 8 weeks of treatment when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.	0.0
1043858990	981239667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239667	22940005	Genotypes AG + GG are associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotype AA.	3.5
1043858990	982034978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034978	16493486	Allele G is associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype AA.	2.5
1183490999	827817479	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817479	21663814	Genotypes GT + TT are associated with increased risk of QTc prolongation when exposed to dolasetron or granisetron in people with surgery as part of anesthetic management as compared to genotype GG.	2.0
1043880357	827567338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567338	15883587	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.0
1155598159	655388374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388374	19474787	Genotype TT is associated with increased AUC of atorvastatin in people with no disease as compared to genotypes GG + GT.	1.5
982030399	982030345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982030345	23394390	Genotypes AA + AT are associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotype TT.	3.0
982045146	981345692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345692	22296034	Genotypes AA + AG are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	1.5
1043859269	982037840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037840	21831410	Genotypes AG + GG are associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype AA.	2.5
1043859462	982030117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030117	12360109	CYP2C9 *3/*3 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1043872998	827917994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827917994	22547144	Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT.	2.5
1043880214	1450043998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450043998	10190398	Genotypes A/del + AA are associated with increased response to pravastatin in men with Coronary Artery Disease.	2.0
1043880214	1450044004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450044004	10190398	Genotypes A/del + AA are associated with decreased likelihood of angioplasty when treated with pravastatin in men with Coronary Artery Disease.	2.5
1043880229	1450044086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450044086	21183746	Genotype AA is associated with increased risk of Stroke when treated with lisinopril in people with Hypertension.	3.0
1043880229	1450044109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450044109	21183746	Genotype del/del is associated with decreased risk of Stroke when treated with lisinopril in people with Hypertension.	3.0
1043880234	982036510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036510	10636265	Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	0.0
1043880234	982036494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036494	10636265	Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	3.25
1043880255	982036636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036636	12695469	Genotype del/del is associated with response to pravastatin in people with non-hypercholesterolaemic patients scheduled for angioplasty as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.75
1043880313	981478404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478404	23147717	Genotypes CT + TT are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.	1.75
1043880337	982033113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033113	20833655	Allele T is associated with decreased dose of warfarin as compared to allele G.	3.0
1043880409	982037022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037022	12436350	Genotype CC is associated with increased apolipoprotein A1 and C3 when treated with fluvastatin in people with Coronary Artery Disease.	3.0
1043880409	982037033	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037033	12436350	Allele C is not associated with disease progression or regression when treated with fluvastatin in people with Coronary Artery Disease as compared to allele del.	-1.5
1043880447	827808074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808074	21832968	Genotype AG is associated with Cough when treated with Ace Inhibitors, Plain as compared to genotypes AA + GG.	3.25
1043880669	827820442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820442	21029375	Genotype CC is associated with increased Euphoric and Energetic after amphetamine (10 mg) when exposed to amphetamine in healthy individuals as compared to genotypes CT + TT.	1.5
1043880823	982043900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043900	15262185	Genotype GG is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	2.75
1043880823	982045934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045934	16103896	Genotype GG is not associated with response to atorvastatin as compared to genotype TT.	-2.0
1043880823	827817793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817793	21128988	Genotype TT is associated with increased mean percentage reduction of triglycerides level when treated with atorvastatin in people with Hyperlipidemias as compared to genotypes GG + GT.	2.0
1043880823	1447949667	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949667	26932749	Genotype TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes GG + GT.	2.5
1043880872	827923304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923304	22495174	Allele A is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele G.	3.5
1043880818	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1043880818	PA166182843	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182843		Annotation of DPWG Guideline for atorvastatin and SLCO1B1	100
1043880818	1451151642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151642	32453264	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.	-1.5
1043880818	1451163185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163185	32128760	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.	3.0
1043880818	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1043880818	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1043880818	1451390498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390498	26376374	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-0.875
1043880818	1451390500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390500	30569848	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.5
1043880818	1451465304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465304	34114646	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-2.0
1043880818	1451479880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479880	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.375
1043880818	1451480162	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480162	33150478	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-1.0
1043880818	827810986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810986	21928084	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	-1.5
1043880818	769164520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164520	21243006	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.	-0.25
1043880818	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1043880818	1183699594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699594	24263182	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.	3.25
1043880818	1447689782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447689782	26086347	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.	2.5
1043880818	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1043880818	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1043880818	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1048764135	982037477	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037477	14515062	Genotypes AA + AG are associated with increased IL1B serum levels when treated with pravastatin in men as compared to genotype GG.	0.0
1048764135	982037505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037505	14515062	Genotype GG is associated with increased adenosine-stimulated myocardial flow when treated with pravastatin in men as compared to genotypes AA + AG.	0.5
1048764135	982037517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037517	14515062	Genotype GG is associated with increased coronary flow reserve when treated with pravastatin in men as compared to genotypes AA + AG.	1.0
1124035501	827923278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923278	22495174	Allele G is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele T.	3.5
1145963221	981345040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345040	22366774	Genotype CC is associated with increased change in forced expiratory volume in 1 s (FEV1) when treated with corticosteroids in people with Asthma as compared to genotypes CG + GG.	2.0
1147261601	827824887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824887	22188361	Genotype TT is associated with increased progression-free survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AT.	1.75
1155650524	699638728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638728	20125119	Allele A is associated with decreased metabolism of clozapine as compared to allele G.	0.0
1157877076	827779555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827779555	22015057	Genotype TT is associated with increased risk of dose reductions due to toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.	2.25
1157877076	1184511499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511499	24013576	Allele C is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele T.	-1.25
1183490967	982013727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982013727	23635803	Genotypes AA + AC are associated with increased likelihood of response when treated with disulfiram in people with Cocaine-Related Disorders.	2.25
1183490978	982011805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982011805	23635803	Genotypes AA + AG are associated with increased likelihood of response when treated with disulfiram in people with Cocaine-Related Disorders as compared to genotype GG.	2.25
1183491035	981239818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239818	22926161	Genotypes AA + AG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype GG.	2.5
1183491140	982044219	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044219	18727922	Genotype CC is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CT + TT.	1.75
1183491140	982045554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045554	16103896	Genotypes CC + CT are associated with increased response to atorvastatin as compared to genotype TT.	3.0
1183491140	982044075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044075	15284534	Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.	1.5
1043880192	982035504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035504	12663600	Genotype GG is associated with increased response to atorvastatin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	2.0
1043880192	982035525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035525	15856070	Genotype AA is associated with increased risk of cardiovascular disease events when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotypes AG + GG.	0.0
1043880192	982036409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036409	15856070	Genotype GG is not associated with increased change in lipid parameters when treated with atorvastatin, pravastatin or simvastatin in people with Hyperlipoproteinemia Type II as compared to genotype AA.	-1.75
1043880192	982045940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045940	16103896	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.	-2.0
1183491189	982044239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044239	18727922	Genotype TT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	1.75
1183491354	827785466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785466	20859245	Genotype AA is associated with motor side effects when treated with haloperidol in people with Schizophrenia as compared to genotypes AG + GG.	2.5
1183491617	699638688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638688	18332269	Genotype TT is associated with increased reduction of LDL cholesterol when treated with simvastatin as compared to genotypes GG + GT.	2.5
1183491617	699638985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638985	18815589	Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.	3.5
1183491741	699638684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638684	18332269	Genotype AA is associated with increased reduction of LDL cholesterol when treated with simvastatin.	2.5
1183491775	1043737365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043737365	18622257	Genotype GG is associated with decreased likelihood of Coronary Artery Disease and Myocardial Infarction when treated with pravastatin in people with Hypertension.	2.5
1183492030	981859218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859218	21747585	Genotype GG is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to genotype AA.	2.25
1183492030	981859232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859232	21747585	Allele G is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	2.25
1183492128	1450972760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450972760	30363031	Genotype CT is associated with increased response to fluvastatin as compared to genotype CC.	1.625
1183492128	1450972880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450972880	17289397	Genotype CT is associated with increased likelihood of lipid response when treated with atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin as compared to genotype CC.	0.0
1183492235	1043830807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043830807	19673941	Genotype TT is associated with increased HDL-cholesterol when treated with pravastatin in people with Coronary Disease as compared to genotype CC.	2.25
1183614547	1183614514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614514	21622719	Genotypes AA + AG are associated with decreased efficact as measured by lower pain relief to opioids when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to genotype GG.	0.0
1183614624	981500456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500456	22292851	Genotype TT is associated with increased risk of discontinuation when treated with carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	3.25
1183614624	981478948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478948	21561445	Allele C is not associated with response to carbamazepine or oxcarbazepine in people with Epilepsy as compared to allele T.	-2.0
1183614624	982023280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023280	22591328	Genotypes CC + CT are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype TT.	2.25
1183614624	1183611749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183611749	23859570	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	-2.0
1183614624	1184999651	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999651	25155934	Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	3.25
1183614578	981751120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981751120	19694741	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	0.0
1183614578	981859192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859192	21747585	Allele A is associated with non-response when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	2.25
1183614578	1183613417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183613417	23859570	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	-1.0
1183614578	1183614112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183614112	23859570	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	-2.0
1183614578	1184999842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999842	25155934	Genotype AA is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	-1.75
1183614591	1447678311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678311	26555147	Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	-1.0
1183614591	1447678320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678320	26555147	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	-1.0
1183614591	1447678461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678461	26555147	Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	-1.0
1183614591	982023314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023314	22591328	Genotype TT is associated with increased response to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	2.25
1183614591	1184999830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999830	25155934	Genotype CC is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype TT.	-1.75
1183614776	1447680428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680428	26774523	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.	-1.0
1183614776	769163595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163595	19371316	Genotypes AC + CC are not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	-0.75
1183614776	769163124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163124	19779319	Genotypes AC + CC are associated with increased plasma concentration (p=0.028) of efavirenz in people with HIV Infections as compared to genotype AA.	1.25
1183614776	769163296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163296	20860463	Genotype AC is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	-0.5
1183614776	1183614664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614664	23859571	Allele C is associated with risk of hyperhidrosis when treated with efavirenz in people with HIV Infections as compared to allele A.	2.5
1183614776	1184473333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473333	23172109	Allele A is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	-2.0
1154221922	655388082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388082	20130569	Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.	2.75
1154221922	827807905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807905	20679960	Allele T is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.	2.75
1154221922	1183631259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631259	23930675	Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.	2.75
1154221922	1448107497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107497	20207952	Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.	2.5
1183615573	1451493540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493540	11910301	Genotypes AG + GG are associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype AA.	1.5
1183615573	982036621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036621	15614026	Genotype GG is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.	2.0
1183615573	982043042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043042	14700505	Genotype GG is not associated with response to irbesartan in people with Hypertension as compared to genotypes AA + AG.	-0.375
1183615573	1183615155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615155	11593098	Genotype GG is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AA + AG.	-1.25
1183618199	827696135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827696135	21562485	Allele T is associated with higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele C.	1.5
982031323	981953956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953956	23021822	Genotype AA is associated with decreased response when treated with lithium in people with Bipolar Disorder as compared to genotypes AG + GG.	2.0
982031323	699639264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639264	21047205	Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	0.0
982031323	699639266	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639266	21047205	Allele G is not associated with response to lithium in people with Bipolar Disorder as compared to allele A.	-1.5
982032495	982032487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032487	23651024	Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes AC + CC.	0.0
982032734	981953963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953963	23021822	Genotype AA is not associated with decreased response when treated with lithium in people with Bipolar Disorder as compared to genotypes AG + GG.	-1.5
982032734	827784981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784981	21781277	Genotype GG is associated with increased response to lithium in people with Bipolar Disorder.	0.0
982032734	827784991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784991	21781277	Genotype GG is associated with increased response to lithium in people with Bipolar Disorder.	2.75
982047849	981501374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501374	22926616	Genotypes CC + CT are associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to genotype TT.	2.75
1043858637	1024892077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1024892077	21072201	Genotypes AA + AG are associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype GG.	3.5
1043858637	1026668916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1026668916	21072201	Genotype AA is associated with increased decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes AG + GG.	3.0
1043858675	982035039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035039	16493486	Genotype AG is associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype GG.	2.5
1043858703	982036762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036762	17157856	Genotypes AA + AG are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype GG.	2.25
1183590959	981502225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502225	22795047	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	2.5
1183614696	981502239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502239	22795047	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	3.0
1183614721	981481642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481642	22041458	Allele G is associated with increased general side-effects when treated with sertraline in people with Depressive Disorder, Major as compared to allele T.	0.0
1183616495	1183616447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616447	23859572	Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AG + GG.	1.5
1183616511	1183616453	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616453	23859572	Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AC + CC.	1.5
1183617565	827793267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793267	21449676	Allele A is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele T.	0.75
1183617765	769171479	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171479	10683861	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.	2.75
1183617765	1184511375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511375	16302021	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major.	-1.5
1183617765	1184513240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513240	17018806	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.	2.5
1183618859	769169298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169298	18253134	Genotype GG is associated with increased risk of adverse drug reaction when treated with paroxetine in people with Depression as compared to genotypes AA + AG.	2.75
1183618859	1183619264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619264	14514498	Genotype GG is associated with increased risk of discontinuations due to adverse events and greater severity of side effects when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.5
1183618859	1183960363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960363	17697394	Allele G is not associated with Nausea when treated with paroxetine in people with Depressive Disorder as compared to allele A.	-1.25
1448999816	1448112308	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448112308	27097346	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of amitriptyline as compared to CYP2D6 *1.	0.0
1043858615	982028786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028786	23733030	Genotype CC is not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-0.875
1043858615	982028793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028793	23733030	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.0
1043858615	982028800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028800	23733030	Genotypes CC + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	1.25
1043858892	769245708	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245708	21270790	Allele T is associated with increased dose of warfarin.	2.25
1043858892	1444608095	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444608095	25499099	Genotype AT is associated with increased dose of warfarin as compared to genotype AA.	1.75
1043858892	1444608101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444608101	25499099	Genotype AT is associated with increased clearance of warfarin as compared to genotype AA.	1.75
1043858892	1444608112	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444608112	25499099	Genotypes AT + TT is associated with increased expression of CYP2C9 as compared to genotype AA.	0.0
1183617854	PA166105000	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105000		Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6	100
1183617854	1446905865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905865	12360109	CYP2C19 *2/*2 is associated with decreased clearance of doxepin in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183616699	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1183616699	PA166184528	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184528		Annotation of DPWG Guideline for clomipramine and CYP2C19	100
1183616699	1446906755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446906755	8181196	CYP2C19 poor metabolizers are associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183616699	1183616535	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616535	11763000	CYP2C19 *2 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.75
1183616699	1183616544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616544	11763000	CYP2C19 *3 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.25
1183616699	1446903139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903139	20531370	CYP2C19 *2/*2 is associated with decreased metabolism of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183616699	1446903149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903149	20531370	CYP2C19 *17 + *2 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183616699	1448631821	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631821	28470111	CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.	0.0
1043859029	981475658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981475658	21940774	Genotype TT is associated with increased resistance to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.5
1043859029	981475667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475667	21940774	Genotype TT is associated with increased likelihood of early relapse when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	2.5
1043859029	981475714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475714	21940774	Genotype TT is associated with increased risk of Death when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	3.0
1043859029	981475723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475723	21940774	Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	2.5
1183545767	982015058	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015058	23119086	Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C.	3.5
1183556815	981954525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954525	21596874	Genotype CC is associated with decreased metabolism of ondansetron as compared to genotypes CT + TT.	2.25
1183563324	982045336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045336	20877298	Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.	2.75
1183620349	769255551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769255551	8562390	Allele A (assigned as deficiency phenotype) is associated with Hemolysis when treated with glibenclamide in people with Diabetes Mellitus.	0.25
1183622321	1183616462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616462	23859572	Genotype TT is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CC + CT.	1.5
1183622557	1183622452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622452	23859573	Allele G is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.	1.5
1183624306	827820232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827820232	22249355	Genotypes CC + CT are associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotype TT.	2.0
1183624313	827820224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827820224	22249355	Genotype CT is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes CC + TT.	2.0
1183624328	827820216	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827820216	22249355	Genotype AG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + GG.	2.0
1183624421	827793270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793270	21449676	Allele A is associated with decreased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine in people with Depression as compared to allele T.	2.25
1183630276	981502861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502861	20447721	Genotypes AA + AC are associated with decreased risk of Disease Progression when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.0
1451406840	1451406781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451406781	31813937	Genotype CT is associated with increased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.0
1451406840	1451406760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451406760	31813937	Genotype CC is associated with decreased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.0
1451406840	1448276248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276248	27558924	Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.	0.0
1183624646	1183846978	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183846978	10208643	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183624646	1183846985	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183846985	8941024	CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.	0.5
1183624646	1183620603	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620603	14639062	CYP2D6 *4/*4 is associated with increased fluoxetine plasma concentration when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	1.5
1183624646	1183623634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623634	16236141	CYP2D6 *1/*1xN is not associated with differences in Dose-normalized plasma levels of individual enantiomers and of the active moiety when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	-0.75
1183624646	1183623961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623961	14726986	CYP2D6 *4 + *6 is associated with increased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.75
1183624646	1183624055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624055	14726986	CYP2D6 *4 + *6 is not associated with increased differences in C/D plasma concentrations of norfluoxetine or active moiety when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.75
1183624646	1183624094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624094	14726986	CYP2D6 *1/*1xN is associated with decreased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.75
1183624646	1183624105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624105	14726986	CYP2D6 *1/*1xN is not associated with increased differences in C/D plasma concentrations of norfluoxetine or active moiety when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.75
1183624646	1183624148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624148	11386497	CYP2D6 *4/*4 is associated with significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.	1.0
1183624646	1183678545	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678545	17470523	CYP2D6 *10 is associated with decreased clearance of fluoxetine as compared to CYP2D6 *1.	0.0
1183624646	1183678553	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678553	17470523	CYP2D6 *17 is associated with decreased clearance of fluoxetine as compared to CYP2D6 *1.	0.0
1183624646	1183684592	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684592	12438554	CYP2D6 *10 is associated with decreased clearance of fluoxetine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183624646	1183684600	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183684600	12438554	CYP2D6 *17 is associated with decreased clearance of fluoxetine with CYP2D6 allelic isoenzyme purified from baculovirus-mediated insect cells as compared to CYP2D6 *1.	0.0
1183624646	1183689783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689783	10583026	CYP2D6 *3/*3 + *3/*4 + *4/*4 is associated with increased plasma concentrations of fluoxetine and decreased nor-fluoxetine concentrations when treated with fluoxetine in women with Depression as compared to CYP2D6 *1/*1.	0.125
1183624646	1184472154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472154	24663076	CYP2D6 *1/*1 (assigned as normal metabolizers phenotype) are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	1.75
1183624646	1184472165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472165	24663076	CYP2D6 *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6 are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .	1.5
1183624646	1451255600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451255600	16236141	CYP2D6 *1/*1 is not associated with metabolism of fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*4 + *1/*3 + *1/*5 + *1/*6.	-1.25
1183624646	1183623583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623583	16236141	CYP2D6 *1/*1xN is associated with increased S-norfluoxetine/S-fluoxetine ratios when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 *4/*4.	0.125
1183622099	PA166105002	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105002		Annotation of CPIC Guideline for desipramine and CYP2D6	100
1183622099	1183682189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682189	3769385	CYP2D6 poor metabolizers is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	1.0
1183622099	1183684001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684001	6488689	CYP2D6 poor metabolizers is associated with increased desipramine to hydroxy-desipramine ratio when treated with desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1183622099	1446900203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900203	3816019	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900238	3816019	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900251	3621781	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446900258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900258	3621781	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1446904957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904957	9049581	CYP2D6 poor metabolizers are associated with increased concentrations of desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1183622099	1446905111	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905111	3356084	CYP2D6 poor metabolizers are associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.75
1183622099	1448126229	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448126229	27440861	CYP2D6 poor metabolizers are associated with decreased clearance of desipramine in human liver microsomes as compared to CYP2D6 normal metabolizers.	0.0
1183622099	1183621911	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621911	10895986	CYP2D6 *10/*10 + *5/*10 is associated with increased steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	1.5
1183622099	1183621960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621960	10895986	CYP2D6 *10/*10 + *5/*10 is associated with increased desipramine/2-hydroxy-desipramine ratio when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1183622099	1183621995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621995	15115913	CYP2D6 *6/*9 is associated with increased elimination half-life and drug exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1183622099	1183622026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622026	15115913	CYP2D6 *1/*1 + *1/*2 is associated with decreased desipramine elimination half-life and total exposure when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*4 + *1/*41.	1.5
1183622099	1183622080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622080	1346258	CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4 + *3.	2.0
1183622099	1183622215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183622215	11417443	CYP2D6 *1/*2xN + *5/*2xN is associated with a trend towards increased clearance of desipramine when exposed to desipramine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
1183622099	1183623304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623304	1346258	CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4/*4 + *4/*5.	2.0
1183622099	1446902165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902165	17667959	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	2.5
1183621000	PA166119846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166119846		Annotation of CPIC Guideline for rasburicase and G6PD	100
1183621000	1183685142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685142	22190578	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Burkitt Lymphoma.	0.125
1183621000	1183685166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685166	22015451	G6PD deficiency is associated with Hemolysis when treated with methylene blue and rasburicase in people with Neoplasms.	0.125
1183621000	1183685176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685176	18561168	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Hyperuricemia.	0.125
1183621000	1183685188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685188	16204390	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Kidney Failure, Acute.	0.125
1183621000	1183685208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685208	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685218	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Neoplasms.	0.125
1183621000	1183685222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685222	9369411	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183685227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685227	12075750	G6PD deficiency is associated with Hemolysis when treated with rasburicase in people with Neoplasms.	0.0
1183621000	1183685232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685232	22573495	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685242	17387701	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Burkitt Lymphoma.	0.125
1183621000	1183685251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685251	12942574	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Neoplasms.	0.0
1183621000	1183685257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685257	23860572	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Leukemia, Lymphoid.	0.125
1183621000	1184169040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169040	24750455	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in women with Tumor Lysis Syndrome.	0.125
1183621000	1184515920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515920	25115783	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Leukemia.	0.125
1183621000	1444710866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710866	25988058	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase.	0.125
1183621000	1444713834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713834	26033222	G6PD deficiency is associated with Anemia, Hemolytic and Methemoglobinemia when treated with methylene blue and rasburicase.	0.125
1183621000	1448634792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634792	28370399	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Tumor Lysis Syndrome.	0.125
1183621000	1449161310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161310	29290749	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183620431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620431	20196170	G6PD A-202A_376G is associated with Hemolysis when exposed to rasburicase in men with Burkitt Lymphoma.	0.25
1183621000	1184515977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515977	23209099	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with Hemolysis and subsequent death when treated with rasburicase in children with Hyperuricemia.	0.25
1183621000	1184515983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515983	19654083	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with adverse reaction due to rasburicase in men with Neoplasms.	0.25
1183621000	1444699847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699847	23989394	G6PD A- 202A_376G (assigned as deficiency phenotype) is associated with Methemoglobinemia when treated with rasburicase in infants with Kidney Failure, Acute.	0.25
982036249	982036220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036220	19740397	Genotype CC is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AC.	1.0
1043858970	982035225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035225	12515735	Genotypes AA + AC are associated with increased inhibition of FXIII activation by aspirin when treated with aspirin in men as compared to genotype CC.	1.5
1043859274	982036762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982036762	17157856	Genotypes AA + AG are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype GG.	2.25
1043872993	1184511758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511758	23940523	Allele A is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	-1.0
1043872993	1184511789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511789	23940523	Allele A is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	0.0
1043872993	1448123636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123636	27248474	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	1.5
1043876904	827923681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923681	17258395	Genotype CC is associated with increased response when treated with fluoxetine in people with major depression and high anxiety as compared to allele A.	1.75
1043880438	982026177	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026177	23670235	Genotype AC is associated with decreased plasma predose concentration (Ctrough) when treated with ABT-751 in people with Neoplasms as compared to genotype CC.	1.5
1043880608	827783761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783761	22016628	Genotype GG is associated with increased reduction in LDL when treated with atorvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.	2.0
1043880608	1183681948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681948	23263738	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.	-1.75
1043880608	1446896327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896327	26334272	Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	2.0
1043880608	1447949678	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949678	26932749	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	2.0
1043880664	827820384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820384	21029375	Genotype TT is associated with decreased Stimulation and Euphoria scores after amphetamine when exposed to amphetamine in healthy individuals as compared to genotypes CC + CT.	1.0
1043880783	827639412	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827639412	21562465	Allele G is associated with decreased risk of Myocardial Infarction and Stroke when treated with atenolol and verapamil in people with Coronary Artery Disease and Hypertension as compared to allele A.	2.75
1043880812	827923950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923950	22555810	UGT1A3 *2 is associated with decreased total and the low-density lipoprotein cholesterol maximum percent decreases from baseline when exposed to atorvastatin in healthy individuals as compared to UGT1A3 *1.	1.5
1043880812	827923943	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923943	22555810	UGT1A3 *2/*2 is associated with increased atorvastatin lactonization when exposed to atorvastatin in healthy individuals as compared to UGT1A3 *1/*1.	1.5
1043880851	769162922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162922	21228734	Genotype GG is associated with earlier onset of bortezomib-induced peripheral neuropathy when treated with bortezomib, melphalan and prednisone in people with Multiple Myeloma as compared to genotypes AA + AG.	3.0
1043880851	769162927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162927	21228734	Genotype GG is not associated with earlier onset of bortezomib-induced peripheral neuropathy when treated with bortezomib and dexamethasone as compared to genotypes AA + AG.	-1.5
1143918642	827808052	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827808052	20436376	Allele A is associated with decreased affinity to losartan in COS-1 cells.	0.0
1183490962	827815061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815061	21104443	Allele G is associated with increased Bispectral Index and Ramsay Sedation Scores, indicating a longer period for falling asleep when exposed to dexmedetomidine as compared to genotype CC.	2.0
1183492244	1043859185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859185	19752398	Genotype CC is associated with increased reduction in LDL-C when treated with pravastatin in men as compared to genotypes CT + TT.	2.5
1183492244	1043859190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859190	19752398	Genotype CC is associated with decreased reduction in LDL-C when treated with pravastatin in women as compared to genotypes CT + TT.	3.0
1183533592	769173751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173751	20403997	Genotype AA is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors.	2.0
1183533592	769173799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173799	20403997	Genotype AA is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors as compared to genotype TT.	1.5
1183533592	769173774	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173774	20403997	Genotype TT is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors.	2.0
1183533981	982023290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023290	22591328	Genotypes AA + AG are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype GG.	2.75
1183603158	981475779	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475779	22041458	Allele A is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele G.	0.0
1183614509	982036653	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036653	15614026	Genotype GG is associated with increased response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.	2.0
1183614614	982045391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045391	20877298	Genotype del/del is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	2.25
1183614752	981939599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939599	23092981	Genotype TT is associated with increased response to antidepressants in people with Depression as compared to genotypes CC + CT.	2.5
1183614845	982036476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036476	17178264	Genotypes CG + GG are associated with increased response to enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.	2.0
1183614891	981475608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981475608	22120873	Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.	3.0
1183615150	982037006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037006	17261659	Genotype TT is associated with increased response to benazepril in people with Hypertension as compared to genotypes GG + GT.	3.5
1183615213	982034374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034374	15226090	Genotype AA is associated with increased response to benazepril in people with Hypertension as compared to genotypes AG + GG.	2.75
1183615213	982034384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034384	15226090	Genotype AA is not associated with response to benazepril in people with Hypertension as compared to genotypes AG + GG.	-1.75
1183615213	982043442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043442	16081343	Allele G is associated with decreased response to benazepril in people with Hypertension.	3.25
1183615410	982047187	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982047187	23230131	Genotypes AA + AG are associated with decreased catalytic activity of CDA when exposed to cytarabine as compared to genotype GG.	0.0
1183615415	982046877	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046877	22480748	Genotype TT is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	1.75
1183615415	982046951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046951	22480748	Genotype TT is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	-1.25
1183615415	1445585200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445585200	25311255	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.	2.25
982037557	981934482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934482	22960765	Allele G is not associated with increased risk of rejection or affect graft function by 1 year after transplantation when treated with Calcineurin inhibitors and mycophenolate mofetil in people with Organ Transplantation as compared to genotype AA.	-2.0
982037557	981934514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934514	20679962	Allele G is not associated with increased risk of side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.	-1.75
982037557	981934555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934555	21996196	Genotype AG is not associated with increased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
982037557	981935108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935108	21996196	Genotype AG is not associated with increased risk of serious infections when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
982037557	981935256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935256	21996196	Genotype AG is not associated with increased risk of gastrointestinal side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
982037557	981935513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981935513	21996196	Genotype AG is not associated with increased risk of Neutropenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	-1.5
982037557	981936312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936312	21996196	Genotype AG is associated with decreased risk of Lymphopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	2.5
982037557	981939796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939796	18444945	Genotypes AG + GG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	3.0
982037557	769171119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171119	19770842	Allele G is associated with decreased response to mycophenolic acid as compared to genotype AA.	0.25
982037557	827813013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813013	19617864	Allele G is associated with increased inosine monophosphate dehydrogenase activity when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.	1.0
1451406860	1451406781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451406781	31813937	Genotype CT is associated with increased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.0
1451406860	1451406760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451406760	31813937	Genotype CC is associated with decreased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.0
1451406860	1448276248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276248	27558924	Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.	0.0
1183617714	PA166105006	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105006		Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6	100
1183617714	827808349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808349	16044105	Genotype AA is associated with increased log metabolic ratio of amitriptyline/nortriptyline when treated with amitriptyline as compared to genotype GG.	1.75
1183617714	1183617143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617143	12172336	CYP2C19 *2/*2 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1183617161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617161	12172336	CYP2C19 *2/*3 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.0
1183617714	1183617173	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617173	12172336	CYP2C19 *1/*2 + *2/*2 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.0
1183617714	1183617183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617183	12172336	CYP2C19 *1/*3 + *2/*3 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.0
1183617714	1183617529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617529	15168101	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with amitriptyline in people with Depressive Disorder, Major.	0.125
1183617714	1183623160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623160	16024198	CYP2C19 *2/*2 + *1/*2 is associated with decreased metabolism of amitriptyline in postmortem toxicology cases as compared to CYP2C19 *1/*1.	2.0
1183617714	1446901519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901519	12012142	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.0
1183617714	1446901546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901546	12012142	CYP2C19 *2/*2 + *2/*3 are associated with decreased concentrations of nortriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.5
1183617714	1446901561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901561	12012142	CYP2C19 *2/*2 + *2/*3 are not associated with clearance of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	-0.125
1183617714	1446902626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902626	16044105	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.25
1183617714	1446902958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902958	20531370	CYP2C19 *17 + *2 are not associated with concentrations of nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183617714	1446902977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902977	20531370	CYP2C19 *17 is associated with increased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	0.0
1183617714	1446903003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903003	20531370	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1446903025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903025	20531370	CYP2C19 *2/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.5
1183617714	1446903873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903873	15590749	CYP2C19 *1/*2 + *2/*2 are associated with increased concentrations of amitriptyline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.0
1183617714	1446903892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903892	20531370	CYP2C19 *17 + *2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-1.0
1183617714	1446903928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903928	15205367	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	-0.125
1183617714	1448615842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615842	28296334	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased exposure to amitriptyline in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183617714	1450664831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664831	15205367	CYP2C19 *1/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	1.0
1183617714	1450664844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450664844	15205367	CYP2C19 *1/*2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	0.125
1183615582	1451493546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493546	11910301	Allele G is not associated with response to atenolol in people with Hypertrophy, Left Ventricular as compared to allele A.	-0.25
1183615582	982042952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042952	14700505	Genotypes AG + GG are associated with increased response to atenolol in people with Hypertension as compared to genotype AA.	2.0
1183615582	982042988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042988	14700505	Genotypes AG + GG are not associated with response to atenolol in people with Hypertension as compared to genotype AA.	-0.25
1183615582	1183615155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615155	11593098	Genotype GG is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AA + AG.	-1.25
982031045	981204837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981204837	22890915	Allele T is associated with increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors in men with Coronary Artery Disease as compared to allele G.	2.0
982031956	981477242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477242	22541248	Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.	3.0
982036595	982031760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031760	22016816	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.	1.5
982036595	1449576792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576792	29938344	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	-1.5
1183564845	982037714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037714	18594050	Genotype AA is associated with increased response to candesartan in people with Heart Failure as compared to genotype AC.	2.5
1183564845	982037728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037728	18594050	Genotype AC is associated with increased response to candesartan in people with Heart Failure as compared to genotype AA.	1.5
1183564845	982037742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037742	18594050	Genotype AC is not associated with response to candesartan in people with Heart Failure as compared to genotype AA.	-0.25
1183614481	982036630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036630	15614026	Genotype CC is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes CT + TT.	2.0
1183614486	982034981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034981	15564877	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	2.0
1183614486	982035028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035028	15564877	Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.	2.5
1183614486	982035057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035057	15564877	Genotype CC is not associated with response to dobutamine in healthy individuals as compared to genotypes CG + GG.	-0.25
1183614619	982042071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042071	11007831	Genotype del/del is associated with increased response to benazepril or perindopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.75
1183614619	982043310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043310	15788353	Genotype del/del is associated with increased response to benazepril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.5
1183614619	982043336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043336	15788353	Genotype del/del is not associated with response to benazepril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-1.5
1183614706	982044398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044398	18285551	Genotype TT is associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.	2.75
1183614771	981502697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502697	22441531	Genotypes AA + AG are associated with decreased response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.0
1183614840	981500906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500906	23073467	Genotypes AA + AG are associated with increased total cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.	2.25
1183614840	981500923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500923	23073467	Genotypes AA + AG are associated with increased low-density lipoprotein cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.	2.25
1183614881	981477306	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477306	22541248	Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.	3.0
1183614970	1450974113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450974113	12042669	Genotypes CT + TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	2.5
1183615145	981201252	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981201252	22868256	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.	0.0
1183615186	981755188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755188	19390945	Genotype CT is not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype TT.	-1.5
1183615186	981794175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794175	18221820	Genotypes CC + CT are associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	3.0
1183615186	981843865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843865	18221820	Genotypes CC + CT are not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	-1.5
1183543916	982034454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034454	15249972	Genotypes CC + CT are associated with increased risk of Hypertriglyceridemia when treated with fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	1.5
1183543916	982034477	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034477	15249972	Genotypes CC + CT are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	-1.5
1183543916	982034517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034517	15249972	Genotypes CC + CT are not associated with risk of Hypercholesterolemia when treated with fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.	-1.5
1183615288	981953971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981953971	22700043	Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.	2.5
1183615373	982047137	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047137	23175667	Genotype CC is associated with increased hospital stay when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	0.75
1183619322	981476298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476298	18215618	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	2.75
1183629403	1183623748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623748	18751689	CYP2C19 *1/*1 is associated with increased metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629403	1183624295	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624295	19785625	CYP2C19 *1/*1 is not associated with metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.125
1183629403	1183679273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679273	22324425	CYP2C19 *1/*2 is not associated with clearance of esomeprazole in healthy individuals as compared to CYP2C19 *1/*1.	-0.125
1183630065	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183630065	PA166104957	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104957		Annotation of DPWG Guideline for omeprazole and CYP2C19	100
1183630065	1450370714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370714	1505152	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0
1183630065	1450370721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370721	7648764	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450806689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806689	8675169	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.25
1183630065	1450806923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806923	9284848	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450806946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806946	9357389	CYP2C19 poor metabolizers are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	1450807902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807902	10626755	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	1450807931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807931	10671908	CYP2C19 poor metabolizers are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183630065	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183630065	655387718	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387718	16413245	Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.	2.5
1183630065	655387742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387742	18294333	Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.	1.5
1183630065	1183619889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619889	15447734	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1183619918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619918	15447734	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1183623395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623395	18241283	CYP2C19 *1/*1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.125
1183630065	1183623411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623411	18241283	CYP2C19 *1/*1 is not associated with metabolism of omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 *1/*17.	-0.125
1183630065	1183624136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624136	8747407	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183630065	1184471092	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184471092	24945780	CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with omeprazole in E. coli DH5alpha as compared to CYP2C19 *1.	0.0
1183630065	1184564759	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184564759	19661214	CYP2C19 *26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1184565887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184565887	19661214	CYP2C19 *26 is associated with decreased metabolism of mephenytoin and omeprazole as compared to CYP2C19 *1.	2.0
1183630065	1184566038	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184566038	19661214	CYP2C19 *26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1444696659	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696659	19661214	CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1444696670	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696670	19661214	CYP2C19 *10 is associated with decreased clearance of omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1447963286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963286	8747407	CYP2C19 *1/*2 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183630065	1447992028	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447992028	26153442	CYP2C19 *3 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1183630065	1448263323	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448263323	27578295	CYP2C19 *24 is associated with decreased clearance of mephenytoin and omeprazole in E.coli as compared to CYP2C19 *1.	0.0
1183630065	1449166259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166259	29377228	CYP2C19 *2 is associated with decreased clearance of omeprazole in infants with Gastroesophageal Reflux as compared to CYP2C19 *1 + *17.	1.75
1183630065	1450806712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806712	8681489	CYP2C19 *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *1/*1.	1.0
1183630065	1450806762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806762	8823231	CYP2C19 *1/*1 is not associated with metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.75
1183630065	1450806785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806785	9014204	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1183630065	1450807298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807298	9797796	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.0
1183630065	1450807307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807307	9797796	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 (assigned as normal metabolizers phenotype) .	2.0
1183630065	1450807373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807373	9829356	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with acid-related disorders as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2.	2.0
1183630065	1450807702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807702	10206083	CYP2C19 *2/*3 + *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	0.125
1183630065	1450807854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807854	10511062	CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.	2.0
1183630065	1450808537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808537	11046127	CYP2C19 *2/*2 are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	1.0
1183630065	1450809604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809604	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630065	1447680365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680365	26244421	CYP2C19 *9 is associated with decreased metabolism of omeprazole in healthy individuals.	0.0
1183624491	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183624491	PA166104958	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104958		Annotation of DPWG Guideline for pantoprazole and CYP2C19	100
1183624491	1450807008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807008	9433390	Genotypes *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to genotypes *1/*1 + *1/*2 + *1/*3.	0.75
1183624491	1450807240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807240	9578184	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.0625
1183624491	827789167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827789167	19785625	CYP2C19 *1/*2 is associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183624491	982047471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047471	18664620	CYP2C19 *2/*2 is associated with decreased clearance of pantoprazole in children as compared to CYP2C19 *1/*1.	1.0
1183624491	1447947227	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947227	20223877	CYP2C19 *1/*1 + *1/*17 is associated with increased metabolism of pantoprazole in children as compared to CYP2C19 *1/*2 + *2/*17.	1.5
1183624491	1447947314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947314	22418828	CYP2C19 *17 is associated with increased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1.	1.0
1183624491	1447947325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947325	22418828	CYP2C19 *1/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183624491	1447947333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947333	22418828	CYP2C19 *2/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183624491	1450808617	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808617	11240974	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1043858733	982035125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035125	19178400	Allele G is associated with decreased risk of acetylsalicylic acid-intolerant chronic urticaria when exposed to aspirin as compared to genotype AA.	2.25
1043859108	981794122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794122	18221820	Genotypes CC + CT are associated with increased dose of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.0
1043880059	981862415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862415	18946804	Allele T is associated with increased dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype del/del.	1.0
1043880059	981862425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862425	18946804	Allele T is associated with increased dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid-7-O-glucuronide when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype del/del.	1.5
1183554425	981502089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502089	22441531	Genotype CT is associated with decreased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1183554425	1183554747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183554747	22441531	Genotype CC is not associated with response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	-2.0
1183602849	981475738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475738	22041458	Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.	0.0
1183613866	981475750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475750	22041458	Allele T is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele C.	0.0
1183615435	982047130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047130	23175667	CYP2C19 *2/*2 is associated with increased hospital stay when treated with tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.	1.25
1183615199	1451154500	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451154500	24897286	Genotypes T/del + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype del/del.	0.0
1183615199	981794112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794112	18221820	Genotype TT is associated with increased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + del/del.	2.0
1183615199	981843937	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981843937	16636344	Genotype del/del is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.	2.25
1183630036	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183630036	PA166104957	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104957		Annotation of DPWG Guideline for omeprazole and CYP2C19	100
1183630036	1184754946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754946	24996380	CYP2C19 normal metabolizers is associated with decreased intragastric ph when exposed to omeprazole in healthy individuals as compared to CYP2C19 poor metabolizer and intermediate metabolizer genotypes.	0.75
1183630036	1183617218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617218	10982760	CYP2C19 *1/*2 is associated with increased intragastric pH when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.	2.0
1183630036	1183617232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617232	10982760	CYP2C19 *1/*2 is associated with increased meal-stimulated plasma gastrin concentrations when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.	2.0
1183630036	1183617444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617444	11240980	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183618651	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618651	12121503	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.25
1183630036	1183619427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619427	12809821	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183619521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619521	14653835	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183619532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619532	14653835	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183619942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619942	15447734	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	-0.25
1183630036	1183620822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620822	15932363	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Gastroesophageal Reflux.	-2.0
1183630036	1183620957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620957	15976989	CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183630036	1183621225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621225	16863547	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183630036	1183621319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621319	16863547	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183621329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621329	16863547	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.375
1183630036	1183622382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622382	17112810	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183622397	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622397	17112810	CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.5
1183630036	1183623283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623283	17934830	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183623301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623301	17934830	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	0.375
1183630036	1183623444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623444	18241283	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.25
1183630036	1183623842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623842	19166419	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183623852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623852	19166419	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183623865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623865	19166419	CYP2C19 *1/*2 + *1/*3 is not associated with response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183679160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679160	20633187	CYP2C19 *1/*1 is associated with decreased response to omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183679177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679177	21361732	CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183679211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183679211	21361732	CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with decreased intragastric ph when treated with omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183630036	1183679401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679401	23646118	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.625
1183630036	1183679411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679411	23646118	CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183630036	1183679423	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679423	23646118	CYP2C19 *1/*2 + *1/*3 is not associated with response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183679579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679579	10579481	CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183679601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679601	11446878	CYP2C19 *1/*1 is not associated with response to omeprazole or rabeprazole in people with Helicobacter Infections.	-1.5
1183630036	1183679613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679613	11785712	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.25
1183630036	1183680115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680115	21054464	CYP2C19 *1/*1 is not associated with response to omeprazole in people with Helicobacter Infections.	-1.5
1183630036	1450807430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807430	9867757	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1450807446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807446	9867757	CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	2.25
1183630036	1450807458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807458	9867757	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.	1.75
1183630036	1450807761	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807761	10340921	CYP2C19 *1/*2 + *1/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183630036	1450807773	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807773	10340921	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.5
1183630036	1450807784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450807784	10340921	CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	2.0
1183630036	1450808566	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808566	11069321	CYP2C19 *1/*2 + *1/*3 are associated with increased response to omeprazole in people with Esophagitis and Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	1.75
1183630036	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183630036	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630036	1183679880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679880	14638340	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183630036	1183679894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679894	14638340	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183630036	1183617822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617822	11240980	CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.75
1183630036	1183680006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680006	16815316	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183680019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680019	16815316	CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183630036	1183621166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621166	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183630036	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183621202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621202	16863547	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183630036	1183621191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621191	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183630036	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183630036	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183630036	1451343133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451343133	16911680	CYP2C19 *1/*1 + *1/*2 are not associated with response to omeprazole in people with Peptic Ulcer as compared to CYP2C19 *2/*2.	-1.25
1183630036	1183623314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623314	17934830	CYP2C19 *1/*2 + *1/*3 are not associated with response to omeprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.375
1183624499	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183624499	PA166104958	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104958		Annotation of DPWG Guideline for pantoprazole and CYP2C19	100
1183624499	827789173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827789173	19785625	CYP2C19 *1/*2 is associated with increased response to pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1183624499	1183620957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620957	15976989	CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183624499	1183621536	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621536	16912869	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.	2.5
1183624499	1183622885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622885	17645482	CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624499	1183622896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622896	17645482	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183624499	1183623682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623682	18637061	CYP2C19 *1/*1 is not associated with response to pantoprazole in people with Helicobacter Infections.	-1.5
1183624499	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183624499	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183624499	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183624499	1183623652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623652	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.25
1183624499	1183623663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623663	18637061	CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	2.25
1183629373	1450806633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450806633	7648764	CYP2C19 poor metabolizers are associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 normal metabolizers.	0.5
1183629373	1183618419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618419	11380317	CYP2C19 *2/*2 + *3/*3 is associated with decreased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	2.0
1183629373	1183620365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620365	15470328	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629373	1183622261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622261	16937451	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	1.0
1183629373	1183622290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622290	16937451	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	-0.25
1183629373	1183622300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622300	16937451	CYP2C19 *1/*2 + *1/*3 is not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.	-0.25
1183629373	1183622935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622935	17725594	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1183629373	1183622953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622953	17725594	CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.0
1183629373	1183622965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622965	17725594	CYP2C19 *1/*1 is not associated with metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	-0.125
1183629373	1183624311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624311	19552744	CYP2C19 *2/*2 + *2/*3 is associated with decreased clearance of rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1183629373	1183679290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679290	22324425	CYP2C19 *1/*2 is not associated with clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1.	-0.125
1183629373	1450809654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809654	11474773	CYP2C19 *1/*1 + *1/*2 + *1/*3 are not associated with metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.125
1183629373	1183620224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620224	15470328	CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	2.0
1183629373	1451253680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253680	15715938	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183629373	1451253733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253733	20838991	CYP2C19 *1/*1 is associated with increased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.	0.125
1183629373	1451253720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451253720	15715938	CYP2C19 *1/*2 + *1/*3 are not associated with metabolism of rabeprazole as compared to CYP2C19 *1/*1.	-0.125
1183629796	PA166219103	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219103		Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19	100
1183629796	PA166104987	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104987		Annotation of DPWG Guideline for lansoprazole and CYP2C19	100
1183629796	1184754961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754961	24996380	CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizers and intermediate metabolizers.	0.75
1183629796	1184754980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754980	24996380	CYP2C19 intermediate metabolizers is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizer.	0.75
1183629796	1184754990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754990	24996380	CYP2C19 intermediate metabolizers is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizers.	0.75
1183629796	1183617346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617346	11012469	CYP2C19 *1/*1 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183617370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617370	11012469	CYP2C19 *1/*2 + *1/*3 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183617444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617444	11240980	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183618465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618465	11929404	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183618478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618478	11929404	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*3 + *2/*2.	2.0
1183629796	1183618644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618644	12121503	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.25
1183629796	1183618781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618781	12386647	CYP2C19 *2/*2 + *2/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.75
1183629796	1183618795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618795	12386647	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.25
1183629796	1183619140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619140	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-1.5
1183629796	1183619151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619151	12544691	CYP2C19 *1/*1 is not associated with response to lansoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183619401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619401	12656699	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183619415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183619415	12656699	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183620883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620883	15963082	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629796	1183620899	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620899	15963082	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.0
1183629796	1183621246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621246	16863547	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.75
1183629796	1183621366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621366	16863547	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-0.875
1183629796	1183621387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621387	16863547	CYP2C19 *1/*2 + *1/*3 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-0.75
1183629796	1183622712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622712	17215846	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183622726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622726	17215846	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	-0.5
1183629796	1183622809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622809	17295875	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.25
1183629796	1183622820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622820	17295875	CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623444	18241283	CYP2C19 *1/*1 is not associated with response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2.	-0.25
1183629796	1183623799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623799	19166419	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623810	19166419	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.25
1183629796	1183623820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623820	19166419	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183624062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624062	19259653	CYP2C19 *1/*2 + *1/*3 is associated with decreased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.	2.5
1183629796	1183624077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624077	19259653	CYP2C19 *1/*1 is associated with increased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183679442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679442	23646118	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.625
1183629796	1183679456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679456	23646118	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.25
1183629796	1183679469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679469	23646118	CYP2C19 *1/*2 + *1/*3 is not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183679635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679635	12662378	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.25
1183629796	1183679931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679931	15710002	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183679942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679942	15710002	CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183679983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679983	15952098	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	3.0
1183629796	1183679996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679996	15952098	CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	3.0
1183629796	1183680085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680085	20559522	CYP2C19 *1/*1 is not associated with response to lansoprazole in people with Helicobacter Infections.	-1.5
1183629796	827807783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807783	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183623786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623786	19166419	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.75
1183629796	1183623774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183623774	19166419	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183679880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679880	14638340	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.5
1183629796	1183679894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679894	14638340	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183617822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617822	11240980	CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	2.75
1183629796	1183680006	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680006	16815316	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183680019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680019	16815316	CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.	2.75
1183629796	1183621166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621166	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.75
1183629796	1183679361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679361	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183621202	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621202	16863547	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.0
1183629796	1183621191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183621191	16863547	CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.	1.5
1183629796	1183679374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679374	23646118	CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.5
1183629796	1183679387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679387	23646118	CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	1.25
1183629796	1183622736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622736	17215846	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.5
1183629796	1183679954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183679954	15710002	CYP2C19 *1/*2 + *1/*3 are not associated with response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.	-1.25
982030948	981754567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754567	19641488	Allele C is associated with increased likelihood of suicidal ideation when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to allele T.	2.5
982040598	981851703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851703	23257377	Allele A is associated with higher platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment when treated with prasugrel in people with Acute coronary syndrome as compared to genotype GG.	2.0
982040598	981851716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851716	23257377	Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with prasugrel in people with Acute coronary syndrome as compared to genotype GG.	2.5
982040598	982032797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032797	17900275	Allele A is not associated with differences in exposure to the active metabolite of prasugrel when treated with prasugrel in healthy individuals as compared to allele G.	-0.75
982040598	982032807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032807	17900275	Allele A is not associated with differences in pharmacodynamic response when treated with prasugrel in healthy individuals as compared to allele G.	-1.25
982040717	981239721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239721	22940005	Allele T is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele C.	-2.0
982040717	1043747656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043747656	17559347	Genotype CT is associated with increased net decrease in AA-induced platelet aggregation after aspirin treatment when treated with aspirin in healthy individuals as compared to genotype CC.	1.5
982040717	1043749510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043749510	17559347	Genotype CT is not associated with differences in net change in ADP-induced platelet aggregation after aspirin treatment when treated with aspirin in healthy individuals as compared to genotype CC.	-0.375
982040717	827675784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827675784	15757620	Genotype CT is associated with increased risk of aspirin-resistant phenotype when treated with aspirin as compared to genotype TT.	2.75
1183631465	981501905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501905	23252946	Genotype GG is not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.	-1.75
1183631465	1183631410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631410	23930676	Genotype GG is associated with increased reduction in total cholesterol and LDL-cholesterol when treated with simvastatin as compared to genotype AA.	1.75
1183631554	1183492299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183492299	23963862	Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + CT.	3.0
1183631559	1183491895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491895	23963862	Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG.	3.0
1183632078	1183632007	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632007	23753411	Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	0.0
1183632091	1183632057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183632057	23753411	Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.	0.0
982047862	982032925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032925	8806248	Genotype del/del is associated with increased resistance to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.0
982047862	982033131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033131	9069453	Genotype del/del is associated with decreased response to captopril in healthy individuals as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.5
982047862	982033238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033238	9551410	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.75
982047862	982033375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033375	9869506	Genotype del/del is associated with decreased response to captopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	1.5
982047862	982042579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042579	12832683	Genotype del/del is associated with decreased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.0
982047862	982042629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042629	12832683	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.0
982047862	982044530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044530	19286758	Genotype del/del is associated with decreased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	2.25
982047862	1183491329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491329	20830509	Genotype del/del is associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	-1.5
1183632150	827700671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700671	21808285	Allele T is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele C.	2.0
1183632155	827700663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700663	21808285	Allele C is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.	2.5
1183632175	827814205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814205	22212732	Allele G is associated with increased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia as compared to allele A.	3.0
1451407200	1451407120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407120	31792367	SLC6A4 HTTLPR long form (L allele) is associated with increased likelihood of Sexual Dysfunctions, Psychological due to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.75
1183632140	827805692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805692	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1183632140	1448109451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109451	23441093	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	2.0
1183614735	981502071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502071	22441531	Genotypes AA + AC are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
1183614735	981502641	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502641	22441531	Genotypes AA + AC are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.5
1183614735	981502647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502647	22441531	Genotypes AA + AC are not associated with response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-1.5
1183614793	982044493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044493	20833658	Genotypes GGGGAGCTTTCCCAGAGACCC/del + del/del are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC.	2.25
1448636930	1448636722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636722	28727815	Allele G is associated with increased likelihood of Leukopenia when treated with everolimus in women with Breast Neoplasms as compared to allele A.	2.75
1448636930	1448636739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636739	28727815	Allele G is associated with decreased likelihood of Hyperglycemia when treated with everolimus in women with Breast Neoplasms as compared to allele A.	2.25
1451407348	1451407140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407140	31792367	Allele T is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	2.25
1451407321	1451407167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407167	31792367	Genotype AA is associated with increased likelihood of Sexual Dysfunctions, Psychological due to sertraline in people with Depressive Disorder, Major as compared to genotypes AG + GG.	0.0
1451407329	1451407152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407152	31792367	Genotype AA is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram in people with Depressive Disorder, Major as compared to genotypes AG + GG.	1.75
1451407341	1451407140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407140	31792367	Allele T is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	2.25
1448999385	1183678673	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678673	18838503	CYP2D6 *24 is associated with increased clearance of dextromethorphan as compared to CYP2D6 *1.	0.0
1448999385	1183678689	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678689	18838503	CYP2D6 *24 is associated with decreased clearance of codeine as compared to CYP2D6 *1.	0.0
1448999385	1448616567	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616567	24647041	CYP2D6 *22 + *23 + *24 + *27 + *33 + *49 are not associated with decreased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	-0.0
1448999559	1447943884	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447943884	26666748	CYP2D6 *89 + *98 are not associated with clearance of atomoxetine in microsomes from insect cells Sf21 as compared to CYP2D6 *1.	-0.0
1448999559	1447943934	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447943934	26666748	CYP2D6 *94 is associated with increased clearance of atomoxetine in microsomes from insect cells Sf21 as compared to CYP2D6 *1.	0.0
1448999559	1447943896	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447943896	26666748	CYP2D6 *90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10 are associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.	0.0
1449003934	1448996227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996227	27157822	Allele G is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A.	0.0
1449003956	981476071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476071	22341855	Genotypes AC + CC are associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotype AA.	2.25
1449003956	1449002772	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002772	29036176	Allele C is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.	-1.5
1449003995	1449003271	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449003271	29053759	Allele T is associated with decreased affinity to salbutamol as compared to allele C.	0.0
1449165479	981500878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500878	23296156	Genotype GG is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	1.75
1449165479	1449154934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154934	28719596	Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG.	2.0
1449165479	1449165374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165374	27897268	Allele G is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.	-0.5
1449165479	1449752258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752258	30318772	Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	3.5
1449157773	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449157773	1449157754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157754	28527222	Allele A is associated with Malignant Hyperthermia when treated with halothane and succinylcholine as compared to allele G.	0.25
1449157773	1449157786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157786	28326467	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449157843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157843	27663056	Allele A is associated with Rhabdomyolysis and Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160134	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160899	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160930	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160942	25960145	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160948	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160954	19346234	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449160960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160960	21455645	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1449157773	1449160966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160966	21965348	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449157773	1449161016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161016	24433488	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449752825	1449752736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752736	29233746	Allele A is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele G.	3.0
1451407962	1451407800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407800	31806881	Genotype CC is associated with increased response to butorphanol in healthy individuals as compared to genotypes CT + TT.	0.0
1450810236	1450823069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823069	25744370	Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	3.5
1450810236	1450810035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810035	16476706	Allele T is associated with increased risk of Alcoholism or Opioid-Related Disorders due to ethanol or opioids as compared to allele C.	3.25
1450931416	1450931119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931119	29667742	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	0.0
1451407981	1451407512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407512	31806881	Genotypes AG + GG are associated with increased response to morphine in healthy individuals as compared to genotype AA.	2.5
1451408000	981862194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862194	19094200	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	0.0
1451408000	1449295927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295927	26902643	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	-1.5
1449716056	1449716044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716044	30106258	Allele A is associated with increased dose of opioids in people with Pain, Postoperative as compared to allele G.	2.75
1449716178	1449716107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716107	24858579	Genotype AG is associated with decreased severity of Nausea or Vomiting due to fentanyl in people with Pain, Postoperative as compared to genotype AA.	2.25
1450810351	1450810107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810107	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1450810381	1450810080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810080	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1450811972	1450811735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811735	18433502	Allele A is associated with increased response to ethanol as compared to allele G.	3.25
1449191379	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191379	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191379	1449191088	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191088	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191385	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191385	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191385	1449191034	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191034	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191367	1449191208	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191208	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191401	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191401	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191401	1449191068	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191068	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449716207	1449716194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716194	29502940	Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.	0.0
1449191395	1449191217	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191217	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449270967	1449270711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270711	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449750773	1449750552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750552	27698403	Genotype CC is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AC.	2.75
1449750832	1449750780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750780	28696415	Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	3.0
1449750838	1449750812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750812	28696415	Genotype GG is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotype GT.	2.5
1449750843	1449750794	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750794	28696415	Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	3.0
1449191407	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191407	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191407	1449191078	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191078	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191413	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191413	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191413	1449191128	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191128	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191424	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191424	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191424	1449191044	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191044	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191430	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191430	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191430	1449191123	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191123	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449163934	827617207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827617207	20390257	Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC.	1.5
1449163934	827617217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827617217	17370067	Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC.	1.0
1449163934	769247726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769247726	10233211	Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC.	1.75
1449163934	1449163874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163874	29282363	Genotypes AA + AC is associated with increased metabolism of caffeine as compared to genotype CC.	1.375
1449169484	827812759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812759	21806385	Genotype TT is not associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes CC + CT.	-1.5
1449169484	1448261553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261553	27406852	Genotypes CC + CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.	1.5
1449169484	1449169125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169125	29243113	Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	1.0
1449169484	1449169135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169135	29243113	Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.	1.25
1449169546	1449165287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165287	29260275	Allele G is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	0.0
1449169601	1449169583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169583	29250329	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.	2.25
1449169675	1449169293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169293	29425227	Genotypes AC + CC is associated with increased risk of Colonic Neoplasms in people not taking aspirin as compared to genotype AA.	0.0
1451408008	1451407860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407860	31806881	Genotype CC is associated with decreased response to butorphanol in healthy individuals as compared to genotypes CT + TT.	2.0
1449564720	1447680951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680951	26237184	Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	3.25
1449566673	1449566347	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566347	29844858	Genotype AC is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	3.0
1449566673	1449566482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566482	29844858	Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	2.75
1449566679	1449566386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566386	29844858	Genotypes AG + GG is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.5
1449566685	1449566432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566432	29844858	Genotype AA is associated with decreased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1449566685	1449566506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566506	29844858	Genotype AA is associated with increased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	3.0
1450044803	1450044772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450044772	29873816	Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.	1.0
1450813484	1450813415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813415	22046326	Genotypes AA + AG is associated with decreased severity of Tobacco Use Disorder due to nicotine as compared to genotype GG.	2.5
1450928835	1450928764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928764	29621993	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.	2.25
1450929015	1450928984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928984	30031856	Genotype GG is associated with decreased response to opioids in people with Neoplasms and Pain as compared to genotypes AA + AG.	0.0
1450929025	1450928977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928977	30031856	Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.	2.0
1450929816	1184467499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467499	24624916	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.	2.5
1450929816	1451406403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406403	33812699	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.	-1.5
1451408023	1451407844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407844	31806881	Genotype GG is associated with decreased response to butorphanol in healthy individuals as compared to genotypes AA + AG.	2.0
1450929851	PA166161955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161955		Annotation of CPIC Guideline for tropisetron and CYP2D6	100
1450929851	981954714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954714	12065557	CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.	3.25
1450930536	1450930491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450930491	29650764	Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T.	2.25
1449000317	1448112207	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448112207	27109434	CYP2D6 *2 + *10 + *87 + *90 + *91 + *93 + *95 + *98 are associated with decreased clearance of tamoxifen as compared to CYP2D6 *1.	0.0
1449005372	1448637103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448637103	28694205	Genotype CC is associated with increased concentrations of low density lipoprotein in people with Bipolar Disorder, Depressive Disorder, Psychotic Disorders or schizoaffective disorder as compared to genotypes AA + AC.	2.25
1448821500	1448821487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821487	28462920	Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.	1.75
1449164681	1449164633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164633	28696414	Genotypes CT + TT is associated with decreased response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.25
1449171114	1449171059	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171059	28184434	Genotype CT is associated with increased concentrations of (S)-EDDP as compared to genotype CC.	1.75
1449171120	1449171049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171049	28184434	Genotype TT is associated with increased concentrations of methadone as compared to genotypes CC + CT.	1.75
1449192313	1449192131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192131	26137539	Genotype AA is associated with response to lumacaftor.	1.5
1449718300	1449717980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717980	29507678	Genotypes CG + GG are associated with increased risk of Anemia and Leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.	2.75
1450821128	1450821104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821104	25064769	Genotype CC is associated with decreased response to spironolactone in people with Hypertension as compared to genotypes CG + GG.	2.0
1450928486	1450928121	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928121	28696411	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1451408961	1451408080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408080	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	3.25
1451409020	1451408080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408080	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	3.25
1451409026	1451408080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408080	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	3.25
1448995134	1448995097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995097	28858994	Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.	1.5
1449157530	1449157484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157484	29193002	Genotypes AG + GG is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype AA.	3.0
1450820856	1450820823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820823	24360851	Genotypes AA + AG are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype GG.	1.75
1450820863	1450820844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820844	24360851	Genotypes CT + TT are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype CC.	1.75
1450820963	1450820923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820923	24498031	Genotypes AG + GG are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype AA.	0.0
1450821349	1450821167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821167	25122903	Genotype GG is associated with increased severity of Heroin Dependence due to heroin as compared to genotypes AA + AG.	2.75
1451409080	1451408106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408106	31806882	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	0.0
1451409080	1451408101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408101	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	2.25
1449167289	1449166070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166070	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167300	1449166076	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166076	29382897	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167317	1449166082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166082	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167339	1449166094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166094	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167350	1449166100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166100	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167361	1449166106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166106	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167409	1449166122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166122	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167420	1449166128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166128	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167431	1449166134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166134	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167442	1449166140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166140	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1451409101	1451408106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408106	31806882	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	0.0
1451409101	1451408101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408101	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	2.25
1449168364	1449167758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167758	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168371	1449167821	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167821	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168378	1449167770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167770	29407288	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168385	1449167791	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167791	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168392	1449167778	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167778	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168399	1449168100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168100	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168405	1449167869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167869	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168412	1449167839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167839	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168419	1449167845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167845	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168426	1449167875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167875	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168433	1449167863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167863	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168440	1449167857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167857	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168447	1449168125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168125	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1451409127	982048130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048130	17289397	CYP2D6 *1/*4 + *4/*4 is associated with increased response when treated with fluvastatin or simvastatin as compared to CYP2D6 *1/*1.	0.25
1451409120	1451408106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408106	31806882	Allele del is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele T.	0.0
1451409120	1451408101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408101	31806882	Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.	2.25
1451409120	982048130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048130	17289397	CYP2D6 *1/*4 + *4/*4 is associated with increased response when treated with fluvastatin or simvastatin as compared to CYP2D6 *1/*1.	-0.25
1451409133	1451408180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408180	31806882	Allele A is associated with decreased response to rosuvastatin as compared to allele G.	3.25
1451409141	1451408800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451408800	31806882	Allele G is associated with increased response to rosuvastatin as compared to allele A.	3.25
1449156112	1448926159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926159	28819312	HLA-B *15:01:01:01 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449004504	1449004397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004397	28814798	Allele C is not associated with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to allele T.	-1.75
1449004504	1448821284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821284	28814798	Genotype CC is associated with increased risk of Anemia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.	3.25
1449155833	1448925982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925982	28819312	HLA-B *51:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156127	1448926199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926199	28819312	HLA-B *15:25:01 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155838	1448925992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925992	28819312	HLA-B *51:02:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156144	1448926209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926209	28819312	HLA-B *15:27:01 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155843	1448926002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926002	28819312	HLA-B *54:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156149	1448926229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926229	28819312	HLA-B *15:32 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155848	1448926012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926012	28819312	HLA-B *55:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155853	1448926022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926022	28819312	HLA-B *55:02:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155858	1448926035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926035	28819312	HLA-B *56:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155863	1448926045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926045	28819312	HLA-B *56:06 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156029	1449155910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155910	29196725	Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele T.	2.75
1449156029	1449155990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155990	29196725	Allele A is associated with increased response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T.	2.25
1449156045	1449155949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155949	29196725	Allele G is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele C.	2.75
1449156061	1448926065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926065	28819312	HLA-B *78:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156066	1448926075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926075	28819312	HLA-B *13:02:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156071	1448926089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926089	28819312	HLA-B *38:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156089	1448926119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926119	28819312	HLA-B *39:05:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156094	1448926129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926129	28819312	HLA-B *39:06:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156099	1448926139	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926139	28819312	HLA-B *39:09 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156107	1448926149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926149	28819312	HLA-B *57:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156157	1448926239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926239	28819312	HLA-B *15:35 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156162	1448926249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926249	28819312	HLA-B *52:01:01:01 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156189	1448925873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925873	28819312	HLA-C *04:03 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156194	1448925883	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925883	28819312	HLA-C *04:06 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156199	1448925893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925893	28819312	HLA-C *04:07 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156204	1448925903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925903	28819312	HLA-C *05:01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156209	1448925913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925913	28819312	HLA-C *05:09:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156214	1448925923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925923	28819312	HLA-C *18:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156231	1448926279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926279	28819312	HLA-DRB1 *01:03 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156236	1448926289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926289	28819312	HLA-DRB1 *04:04:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156241	1448926299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926299	28819312	HLA-DRB1 *08:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156249	1448926309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926309	28819312	HLA-DRB1 *10:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1450377187	1450377173	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377173	27488001	Allele C is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele T.	2.25
1450810255	1450810059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810059	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele C.	2.75
1450930470	1450822444	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822444	22500942	Allele G is not associated with risk of Heroin Dependence due to heroin as compared to allele A.	-2.0
1450930470	1450827145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827145	28692418	Genotype AA is associated with decreased risk of Heroin Dependence due to heroin as compared to genotypes AG + GG.	3.0
1450934632	1450934470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934470	30723321	Allele G is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934693	1450934374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934374	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934717	1450934482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934482	30723321	Allele A is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450929867	PA166161955	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161955		Annotation of CPIC Guideline for tropisetron and CYP2D6	100
1450929867	981954738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954738	12065557	CYP2D6 *3/*3 is associated with decreased metabolism of tropisetron in people with Neoplasms.	1.5
1450929867	1447148415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447148415	12728290	CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1450929867	1447148428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447148428	12728290	CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1450929867	1447159547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447159547	12728290	CYP2D6 *1/*2xN (assigned as ultra-metabolizer genotype phenotype) is associated with increased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .	0.0
1449155310	1449155058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155058	28117434	Genotype GG is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.	2.5
1450807912	982025714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025714	16395295	Allele G is associated with decreased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele A.	3.0
1450807912	1450807870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807870	11927842	Genotype GG is not associated with risk of Tobacco Use Disorder when exposed to nicotine as compared to genotypes AA + AG.	-2.0
1450812417	1450812385	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812385	19205682	Genotype CG is associated with increased response to nimodipine in healthy individuals as compared to genotype CC.	1.5
1449270961	1449270739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270739	29593529	Allele G is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.	0.0
1450934684	1450934368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934368	30723321	Allele C is associated with increased response to migalastat in people with Fabry Disease.	0.0
1449154729	PA166179847	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166179847		Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	100
1449154729	1449154644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154644	29099344	Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	3.5
1449154729	1449154699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154699	29099333	Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	3.25
1449154729	1449192662	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192662	28930490	Genotype del/del is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	2.0
1450373854	1450373783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373783	27027462	Genotype TT is associated with decreased response to morphine or remifentanil in infants with Pain as compared to genotypes CC + CT.	2.5
1450373854	1450373797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373797	27027462	Genotype CC is associated with increased response to morphine in infants with Pain as compared to genotypes CT + TT.	2.5
1451409760	1451409712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409712	31959879	Genotype CT is associated with increased concentrations of cotinine glucuronide as compared to genotype TT.	1.25
1449168684	1449168179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168179	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449171162	1449171147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449171147	29459008	Genotype TT is associated with increased risk of Heroin Dependence due to heroin as compared to genotype CC.	2.5
1449171162	1449171154	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449171154	29459008	Genotype CT is not associated with risk of Heroin Dependence due to heroin as compared to genotype CC.	-2.0
1449271051	1449270746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270746	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1450928430	1450928129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928129	28696411	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1450928499	1450928135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928135	28696411	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1449171168	1449171141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449171141	29459008	Genotypes AC + CC are associated with decreased risk of Heroin Dependence due to heroin as compared to genotype AA.	3.0
1451409780	1451409700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409700	31959879	Genotype GT is associated with increased concentrations of nicotine as compared to genotype GG.	1.25
1450932674	1450932579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932579	30549211	Genotypes AA + AG are associated with increased likelihood of gastrointestinal toxicity when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype GG.	1.75
1450932674	1450932550	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932550	30549211	Genotype AA is associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.	1.75
1450932674	1450932572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932572	30549211	Genotype AA is associated with increased likelihood of Nausea when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.	-1.75
1450932674	1450932660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932660	30549211	Genotypes AG + GG are associated with increased likelihood of Nausea when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AA.	1.75
1450928528	981859157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981859157	22935916	Allele C is not associated with response to risperidone in people with Schizophrenia.	-1.5
1450928528	1450928150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928150	28696411	Allele T is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1450933017	1450932816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932816	30651574	Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AA + AG.	2.0
1449713738	1449713732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713732	30075559	Genotype GT is associated with decreased response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes GG + TT.	2.0
1449717941	1449717930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717930	30136624	Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.	3.0
1450813869	1450813743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813743	30806694	Allele T is associated with increased risk of Myelosuppression when treated with azathioprine, mercaptopurine or thioguanine in people with Inflammatory Bowel Diseases as compared to allele C.	0.0
1449732040	1183620382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620382	15089809	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.	-0.75
1449732040	1183699477	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699477	23609392	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.	-0.125
1449732040	1448266530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266530	26129906	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.	-1.5
1449732040	1449731979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449731979	29723928	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.	1.25
1451410200	1448636647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636647	28727815	Genotype AG is associated with increased concentrations of everolimus in women with Breast Neoplasms as compared to genotype GG.	1.0
1451410200	1451409980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409980	32015456	Genotype AG is not associated with trough concentration of everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to genotype GG.	-0.125
1451410200	1184470941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470941	24522145	CYP3A4 *1/*1 is not associated with clearance of everolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*22 + *22/*22.	-1.0
1450813881	1450813798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450813798	22048466	Genotypes CT + TT are associated with increased response to varenicline in people with Tobacco Use Disorder as compared to genotype CC.	2.75
1450813994	1450813963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450813963	22217949	Genotype GG is associated with increased response to modafinil in people with methamphetamine dependence as compared to genotypes AA + AG.	2.0
1449565066	1449557433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557433	29751792	Genotypes CT + TT are not associated with progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-1.75
1449565066	1449557451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557451	29751792	Genotypes CT + TT are associated with increased overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.75
1449565066	1449557574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557574	29751792	Allele C is not associated with risk of Neutropenia and Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.25
1451410221	1448428998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428998	26458301	Genotypes CC + CT is associated with decreased clearance of everolimus in people with heart transplantation as compared to genotype TT.	1.0
1451410221	1448636654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636654	28727815	Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC.	-0.125
1451410221	1451410001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451410001	32015456	Genotype CT is associated with decreased trough concentration of everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to genotype CC.	1.5
1451410221	1184470953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470953	24522145	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of cyclosporine or everolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.75
1451410221	1444698809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698809	24628014	CYP3A5 *1/*3 is not associated with dose-adjusted trough concentrations of everolimus in people with lung transplantation as compared to CYP3A5 *3/*3.	-0.75
1451410221	1449748025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748025	29547545	CYP3A5 *3/*3 is not associated with metabolism of everolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-0.5
1448820584	1448820472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820472	28685716	Genotypes CC + CT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype TT.	1.75
1448820584	1448820481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820481	28685716	Genotypes CC + CT are not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype TT.	-0.75
1448820590	1448820497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820497	28685716	Genotype CT is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CC + TT.	-0.75
1448820590	1448820506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820506	28685716	Genotypes CC + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CT.	2.25
1449157883	1449157859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157859	28290528	Genotype AA is associated with increased metabolism of nicotine as compared to genotypes AG + GG.	2.25
1449157883	1449157875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157875	28290528	Genotypes AG + GG is associated with decreased severity of Tobacco Use Disorder in people with Tobacco Use Disorder as compared to genotype AA.	2.0
1449296290	1449296280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449296280	29668752	Genotype AA is associated with increased likelihood of insomnia due to caffeine as compared to genotypes AC + CC.	0.25
1449296320	1449295802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295802	29650774	Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	0.0
1449296326	1449295782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295782	29650774	Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.	0.0
1449296332	1449295791	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295791	29650774	Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	0.0
1449565060	1449557406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557406	29751792	Genotypes GT + TT are associated with increased progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.25
1449565060	1449557416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557416	29751792	Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-1.75
1449565060	1449557554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557554	29751792	Genotypes GT + TT are associated with increased severity of Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.25
1449565060	1449557564	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557564	29751792	Allele G is not associated with severity of Neutropenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.25
1449565184	1449560285	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449560285	29737521	Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele A.	0.0
1449565184	1449560311	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449560311	29737521	Allele G is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele A.	0.0
1450824479	1450824458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824458	28273335	Genotypes CC + CT are associated with increased dose of ethanol as compared to genotype TT.	2.75
1449563861	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449563861	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1449563861	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1449004841	1451506620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506620	24386571	Allele C is not associated with response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.5
1449004841	1449002901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002901	28525903	Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	3.25
1449165169	1451615680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451615680	33794950	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.	-1.5
1449165169	769173272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173272	18381794	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.0
1449165169	1449164851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164851	27217051	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.75
1449165158	769173268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173268	18381794	Genotype AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.5
1449165158	1449164791	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164791	27217051	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.75
1450810228	1450810035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810035	16476706	Allele T is associated with increased risk of Alcoholism or Opioid-Related Disorders due to ethanol or opioids as compared to allele C.	3.25
1450810283	1450810069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810069	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele G.	3.25
1450810289	1450810069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810069	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele G.	3.25
1450810369	1450810168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810168	16476706	Allele A is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele G.	2.75
1450810393	1450810138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810138	16476706	Allele T is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele C.	2.25
1450934647	1450934488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934488	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450935242	981862049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862049	15289789	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1A.	2.5
1450935242	1183702768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702768	18694831	CYP2C8 *1/*3 is associated with increased R-ibuprofen metabolism when exposed to ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.	-1.0
1450935242	1183702784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702784	18694831	CYP2C8 *1/*3 is associated with decreased iNOS expression and fewer adverse events when exposed to ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.	1.5
1450935242	1447682570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682570	26122864	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals.	0.0
1450935242	1450935251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935251	19480553	CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.	0.125
1450935242	1450935268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935268	15606441	CYP2C8 *3 is associated with decreased metabolism of ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.	1.0
1449715596	1449715526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715526	28256933	Genotype CC is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AC.	2.25
1449715626	1449715613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449715613	16906017	Genotype GG is associated with decreased severity of Respiratory Insufficiency due to alfentanil in healthy individuals as compared to genotypes AA + AG.	2.0
1451410280	1451410120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410120	32015456	Allele C is associated with decreased likelihood of progression-free survival when treated with everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to allele T.	1.5
1449715423	1451838540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451838540	35799642	Genotype CC is associated with increased dose of sufentanil in women with Pain, Postoperative as compared to genotypes CT + TT.	1.5
1449715423	1451134880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134880	31773688	CYP3A4 *36/*36 is associated with decreased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	1.5
1449715423	1449716717	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716717	28121959	CYP3A4 *1/*36 + *36/*36 is associated with decreased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	0.0
1449715423	1449715407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715407	29926893	CYP3A4 *36/*36 is associated with decreased dose of sufentanil in women with Pain as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449715423	1451446260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451446260	33977649	CYP3A4 *36 is not associated with dose of sufentanil as compared to CYP3A4 *1.	-1.5
1450373489	1450373239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373239	30420869	Genotype CC is associated with decreased response to methadone in people with Heroin Dependence as compared to genotypes CT + TT.	0.0
1449003976	981476056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476056	22341855	Genotype GG is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AA + AG.	2.25
1449003976	1449002668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002668	29036176	Allele G is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.	-1.5
1449161127	1449161105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161105	28750137	Allele G is associated with decreased risk of Drug Hypersensitivity due to Antiinflammatory agents, non-steroids as compared to allele A.	2.0
1449161156	1449161149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161149	29239905	Genotypes GT + TT are associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype GG.	3.5
1449161162	1449161138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161138	29239905	Genotypes CT + TT are associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype CC.	3.5
1450374101	1450374079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374079	30908574	Genotype AA is associated with increased response to acetaminophen in healthy individuals as compared to genotypes AC + CC.	1.75
1450375059	1450374608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374608	30914949	Genotype TT is associated with increased risk of Anemia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CC + CT.	2.5
1450375734	1450375599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375599	30924126	Allele A is associated with decreased response to allopurinol as compared to allele G.	0.0
1450931447	1450931368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931368	29667742	Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.	0.0
1450931822	1450931764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931764	30281924	Genotypes AG + GG are associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype AA.	2.0
1450932389	1450932383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932383	30482948	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	0.0
1450932703	1450932651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932651	30549211	Genotype TT is associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes CC + CT.	2.25
1450932995	1450932798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932798	30651574	Genotype CC is associated with decreased response to deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	2.5
1451410900	1451410820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410820	32024945	HLA-C *12:03:01:01 is associated with increased risk of drug-induced liver injury due to infliximab.	1.75
1451410920	1451410780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410780	32024945	HLA-DQB1 *02:01:01 is associated with increased risk of drug-induced liver injury due to infliximab.	2.75
1451410860	1451410740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410740	32024945	HLA-B *39:01:01:01 is associated with increased risk of drug-induced liver injury due to infliximab.	2.75
1451410860	1451410845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410845	32024945	HLA-B *08:01:01 is associated with increased risk of drug-induced liver injury due to infliximab.	1.75
1451411000	1451410785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410785	32024945	HLA-DRB1 *03:01 is associated with increased risk of drug-induced liver injury due to infliximab.	2.25
1451411000	1451410840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410840	32024945	HLA-DRB1 *04:04:01 is associated with increased risk of drug-induced liver injury due to infliximab.	1.75
1451410960	1451410825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451410825	32024945	HLA-DPB1 *10:01 is associated with increased risk of drug-induced liver injury due to infliximab.	1.75
1450375710	1450375609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375609	30924126	Allele C is associated with decreased response to allopurinol as compared to allele T.	0.0
1450813988	1450813927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813927	22217949	Genotype CC is associated with decreased severity of methamphetamine dependence due to methamphetamine as compared to genotypes CT + TT.	1.5
1450929031	1450928995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928995	30031856	Genotype TT is associated with decreased response to opioids in people with Neoplasms and Pain as compared to genotypes CC + CT.	2.0
1450934049	1450933226	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933226	30713339	Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC.	3.75
1451412140	1451412055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451412055	32461665	Genotypes CG + GG are associated with decreased likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotype CC.	3.75
1449566697	1449566532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449566532	29844858	Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	2.75
1449753229	1449753164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449753164	29955115	Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype AA.	1.75
1450042856	1450042840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450042840	29315502	Allele A is associated with decreased exposure to atazanavir in women with HIV Infections as compared to allele C.	0.875
1450042856	1451111080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451111080	31562781	Allele A is associated with decreased exposure to atazanavir in women with HIV Infections as compared to allele C.	1.75
1450934175	1450934135	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934135	30611854	Allele T is associated with increased inhibition of SCN4A with flecainide as compared to allele A.	0.0
1450934494	1450934341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934341	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934533	1450934455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934455	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1449718271	1449718077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718077	29507678	Genotypes AA + AG is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.	2.75
1449718277	1449717968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717968	29507678	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.	2.75
1449718283	1449718019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718019	29507678	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.	2.25
1449718283	1449718219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718219	29507678	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.	3.25
1449718289	1449718119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718119	29507678	Genotypes AA + AG are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.	2.25
1449718289	1449718226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718226	29507678	Genotype AA is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.	3.25
1449718311	1449718095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718095	29507678	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AC + CC.	3.25
1449718317	1449717957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717957	29507678	Genotypes AG + GG are associated with increased risk of Anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype AA.	3.25
1449718323	1449718189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718189	29507678	Genotype TT is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.	3.25
1449718331	1449718175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718175	29507678	Genotypes CT + TT is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.	2.75
1449718337	1449718161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718161	29507678	Genotypes AA + AG is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.	2.25
1449718343	1449717995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717995	29507678	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.	2.75
1450374095	1450374073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374073	30908574	Genotypes AA + AG is associated with increased response to acetaminophen in healthy individuals as compared to genotype GG.	1.75
1450374917	1450374909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374909	26810137	Genotypes AA + AC is associated with increased adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	2.5
1450375041	1450374540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374540	30914949	Genotype GG is associated with increased risk of Infection due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AA + AG.	2.5
1450375041	1450374835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374835	30914949	Genotype GG is associated with increased risk of Nausea due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AA + AG.	2.5
1450375080	1450374672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374672	30914949	Genotype AA is associated with increased risk of febrile neutropenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.	2.5
1450375746	1450375583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375583	30924126	Allele G is associated with decreased response to allopurinol as compared to allele A.	0.0
1450376139	1450376124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376124	24909733	Genotype GG is associated with increased dose of morphine in children with Pain, Postoperative as compared to genotypes AA + AG.	0.0
1451411080	1451411060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451411060	32123296	Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.75
1451411080	1451411069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451411069	32123296	Genotype AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + GG.	3.25
1451412069	1451411969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451411969	32461665	Genotypes AA + AG is associated with increased likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotype GG.	2.75
1450934209	1450934161	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934161	30611854	Allele A is associated with increased inhibition of SCN4A with flecainide as compared to allele G.	0.0
1450934539	1450934461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934461	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934641	1450934476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934476	30723321	Allele G is associated with increased response to migalastat in people with Fabry Disease.	0.0
1451412100	1451412040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451412040	32461665	Genotype GG is associated with decreased likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotypes GT + TT.	2.25
1451411220	1451411160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451411160	32080354	Allele G is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain as compared to allele A.	3.0
1449576610	1449576244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576244	29785580	Allele A is associated with increased likelihood of Rhabdomyolysis when treated with HMG CoA reductase inhibitors, other combinations in people with Cardiovascular Diseases as compared to allele G.	1.0
1449576616	1449576256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576256	29785580	Allele G is associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.	1.0
1449717935	1449717924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717924	30136624	Genotype GG is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes AA + AG.	3.0
1451413082	1451413004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451413004	32504053	Allele T is associated with increased risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.	2.75
1449747595	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747595	1449733363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733363	12709367	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747595	1449747515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449747515	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1449747617	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747617	1449733380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733380	12883402	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747643	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449747643	1449733354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733354	12709367	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1449747643	1449733370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733370	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1451411286	1451411280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451411280	32461666	Genotypes CC + CT are associated with decreased exposure to voriconazole in healthy individuals as compared to genotype TT.	0.125
1450373514	1450373502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373502	27649267	Allele A is associated with decreased dose of morphine in women with Pain, Postoperative as compared to allele G.	2.5
1450373583	1450373576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373576	30237583	Genotype CC is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CT + TT.	1.5
1450373745	1450373711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373711	30889042	Allele A is associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to allele G.	2.25
1449170621	1449169809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169809	29177954	Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	1.5
1449170621	1449170492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170492	29177954	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.	-0.25
1449170621	1449170512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170512	29177954	Genotype CT is not associated with likelihood of overall survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.	-0.25
1449171464	1449171382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171382	27966227	CYP3A7 *1A/*1A is associated with decreased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A7 *1A/*1C + *1C/*1C.	1.0
1449171921	1449171673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449171673	28316087	Genotypes AA + AC is associated with increased risk of Nausea and Vomiting when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1449171933	1449163209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163209	29318894	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.	-1.5
1449171933	1449171668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171668	28316087	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1449171933	1449171720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171720	28316087	Genotypes CT + TT is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451413140	1451413004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451413004	32504053	Allele T is associated with increased risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.	2.75
1449171944	1449171705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171705	28316087	CYP2C8 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*1.	1.5
1449172004	982026067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026067	18769365	CYP2C8 *3 is associated with increased risk of Kidney Diseases when treated with Calcineurin inhibitors, cyclosporine or tacrolimus in people with liver transplantation as compared to CYP2C8 *1.	1.5
1449172004	982026075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026075	18769365	CYP2C8 *3 is associated with increased risk of Kidney Diseases when treated with tacrolimus in people with liver transplantation as compared to CYP2C8 *1.	1.0
1449172004	982029542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029542	23426640	CYP2C8 *3 is associated with increased risk of Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors when treated with Calcineurin inhibitors, cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1A.	2.5
1449172004	1449171901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449171901	28316087	CYP2C8 *1/*3 + *3/*3 is associated with increased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*1.	1.0
1449269612	1448635726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635726	28678049	Genotype TT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype GG.	1.5
1449269612	1449188612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188612	29457840	Genotypes GG + GT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype TT.	0.0
1449269830	1448635733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635733	28678049	Genotypes CC + CT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype TT.	1.0
1449269830	1449191972	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191972	29457840	Genotypes CT + TT is associated with increased clearance of apixaban in people with Atrial Fibrillation as compared to genotype CC.	0.0
1449269938	1449190924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190924	29432897	Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T.	2.75
1449269960	1183700215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700215	19297519	Allele T is associated with decreased metabolism of Vitamin K as compared to allele C.	0.125
1449269960	1449192202	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449192202	28521079	Genotypes CT + TT is associated with increased concentrations of Vitamin K as compared to genotype CC.	0.0
1451413120	1451413004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451413004	32504053	Allele T is associated with increased risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.	2.75
1451411555	1451411381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451411381	32448869	Genotypes CT + TT are associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.0
1449155302	1449155050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155050	28117434	Genotype TT is associated with increased progression-free survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	3.0
1449271045	1449270755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270755	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271349	1449271339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449271339	21070507	Genotype TT is associated with increased risk of Substance-Related Disorders due to cocaine, ethanol or nicotine in women as compared to genotypes CC + CT.	3.0
1449748187	827815078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815078	21458191	Allele G is not associated with LDL-C response and vascular event risk response to statin therapy when treated with simvastatin as compared to allele A.	-2.0
1449748187	1449748065	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748065	30304062	Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.	0.0
1449748187	1449748095	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748095	30304062	Genotype GG is associated with decreased response to atorvastatin, rosuvastatin or simvastatin in people with Hypercholesterolemia as compared to genotype AA.	0.0
1449748187	1449748103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748103	30304062	Genotype GG is associated with decreased response to atorvastatin or simvastatin in people with Hypercholesterolemia as compared to genotype AA.	3.0
1450808938	1450808851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808851	15475735	CYP2A6 low activity is associated with decreased risk of Tobacco Use Disorder due to nicotine.	1.5
1450808938	1450808863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808863	15475735	CYP2A6 intermediate activity is not associated with risk of Tobacco Use Disorder due to nicotine.	-1.0
1450808938	1450813230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813230	22046326	Genotypes AA + AT are associated with decreased risk of Tobacco Use Disorder due to nicotine as compared to genotype TT.	This annotation is not used for clinical annotation scoring. Score for this paper comes from another VA
1450808938	1450813125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813125	22046326	Allele A is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele C.	-1.5
1450808938	1450813108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813108	22046326	CYP2A6 *1/*1 is associated with decreased risk of Tobacco Use Disorder due to nicotine as compared to CYP2A6 *1/*12 + *12/*12.	2.5
1450811273	1450809868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450809868	15902904	Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.	0.0
1450812235	1450812153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812153	18518925	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	0.0
1450808951	1450808871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808871	15475735	CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.	1.625
1450808951	1448104272	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104272	16402128	CYP2A6 *1/*2 + *2/*2 is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to CYP2A6 *1/*1.	2.25
1450808951	827824787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824787	16452582	CYP2A6 *4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9 are associated with decreased daily cigarette consumption as compared to CYP2A6 *1/*1.	2.0
1450808951	827705104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827705104	15940289	CYP2A6 *46/*46 is associated with increased cigarettes per day due to nicotine as compared to CYP2A6 *1/*1.	1.75
1450812748	1450812627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812627	20231857	Genotype CC is associated with increased response to nicotine in women as compared to genotypes CT + TT.	1.5
1450812998	1450812948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812948	21658141	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele) are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.75
1449188526	1444707135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707135	17596133	Genotype AA is associated with decreased dose of acenocoumarol as compared to genotypes AG + GG.	0.0
1449188526	1449188291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188291	29479633	Allele G is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele A.	3.0
1449188545	1449188499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188499	29479633	Allele T is associated with decreased likelihood of Hemorrhage when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to allele C.	2.0
1449188673	1449188355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188355	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	2.25
1449188701	1449188382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188382	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	2.25
1449188707	1449188388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188388	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	2.25
1449188713	1449188394	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188394	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	1.75
1449188719	1449188406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188406	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele T.	2.25
1449188725	1449188412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188412	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	2.25
1449188731	1449188418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188418	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	2.25
1449188743	1449188430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188430	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.	2.25
655385392	1451589740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589740	31114289	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AC + CC.	2.25
655385392	982038217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038217	21176721	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.5
655385392	981858915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858915	23183958	Genotype GG is associated with increased dose of warfarin in children as compared to genotypes AA + AG.	2.0
655385392	982034232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034232	16270629	Allele A is associated with decreased dose of warfarin as compared to allele G.	0.0
655385392	982035655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035655	18030307	Allele A is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele G.	2.25
655385392	982043321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043321	16821005	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	1.5
655385392	982043330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043330	17031720	Genotype AG is associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.0
655385392	982043353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043353	18240904	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.0
655385392	982045597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045597	18855533	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	0.0
655385392	982045763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045763	19077919	Allele A is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to allele G.	2.5
655385392	982045796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045796	19077919	Genotype AG is associated with a lower risk of time to first INR greater than 3.5, but is not a significant factor in influencing the time to reach stable dose in Korean patients with MHVR when treated with warfarin as compared to genotype AA.	3.0
655385392	982045891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045891	19297219	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	2.75
655385392	982045909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045909	19297219	Allele A is associated with a more rapid attainment of target INR and higher frequency of dose adjustments when treated with warfarin as compared to allele G.	2.5
655385392	982047450	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047450	21273734	Genotype AA is associated with decreased dose of warfarin in children with Heart Diseases as compared to genotypes AG + GG.	1.5
655385392	827567313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567313	15883587	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	827642014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827642014	17329985	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	827647045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827647045	16611750	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.25
655385392	827654491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827654491	17111199	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	827661232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827661232	16432637	Allele A is associated with decreased dose of warfarin as compared to allele G.	3.0
655385392	827845768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845768	22248286	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.75
655385392	655388076	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388076	16676068	Allele A is associated with decreased dose of warfarin.	2.5
655385392	637879816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879816	20203262	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.0
655385392	769277894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277894	15358623	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	1183697705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697705	23990957	Genotypes AA + AG is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype GG.	2.25
655385392	1183699109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699109	19177029	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.75
655385392	1183701330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701330	17989110	Allele A is associated with decreased dose of warfarin as compared to allele G.	0.0
655385392	1183704872	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704872	24019055	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385392	1184169091	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169091	24728385	Genotype AA is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.	2.5
655385392	1184472429	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472429	20128861	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	1184483630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483630	23159229	Genotypes AA + AG is associated with decreased maintenance dose of warfarin when treated with warfarin as compared to genotype GG.	2.75
655385392	1184510021	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510021	22549502	Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	1184510186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510186	22075505	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.25
655385392	1184511615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511615	25026456	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	982037652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037652	17391071	Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.	2.5
655385392	1451130683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451130683	31653973	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.5
655385392	1448109658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109658	27121899	Allele A is associated with dose of warfarin as compared to allele G.	0.0
655385392	1448267909	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267909	20585834	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.25
655385392	1448267942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267942	26996562	Genotypes AG + GG are associated with increased dose of warfarin in people with Stroke as compared to genotype AA.	2.0
655385392	1448267977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267977	21981797	Genotype AA is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.	2.0
655385392	1448268060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268060	22534826	Genotypes AG + GG are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.	2.25
655385392	1448275994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448275994	21326313	Genotype GG is associated with increased dose of warfarin as compared to genotype AA.	3.0
655385392	1448276279	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276279	25989350	Allele A are associated with dose of warfarin in people with Stroke.	0.0
655385392	1448431482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431482	26223945	Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.	2.5
655385392	1448601916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601916	27938396	Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.	2.5
655385392	1449005156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005156	29054760	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1449005203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005203	28262345	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1449260063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449260063	27617219	Allele A is associated with decreased dose of warfarin as compared to allele G.	1.75
655385392	1446765916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765916	26257249	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	2.5
655385392	1447519665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519665	18466099	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.25
655385392	1447520081	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520081	26433837	Genotypes AG + GG are not associated with decreased dose of warfarin as compared to genotype AA.	-1.125
655385392	1447573633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447573633	19074728	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385392	827642001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827642001	17329985	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	2.0
655385462	981934267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934267	23095111	Genotype AG is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.25
655385462	769173251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173251	20136356	Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	2.5
655385462	1296667235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667235	25074866	Genotype GG is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.5
655385462	1451110260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451110260	31099054	Allele G is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.5
655385462	1444843110	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843110	26071279	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.	3.0
655385462	1448124312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124312	27399166	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.	-1.25
655385462	1449164801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164801	27217051	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.75
655385462	1451616980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451616980	33794950	Allele G is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.	-1.5
655385379	655387802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387802	17600820	Allele G is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.	2.5
655385388	655387870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387870	16522833	Genotypes AC + CC are associated with increased risk of Myocardial Infarction in people with increased coffee intake.	1.5
655385388	655387864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387864	16522833	Genotype AA is not associated with increased risk of Myocardial Infarction in people with increased coffee intake.	-1.5
655385404	655387083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387083	15453913	Genotype CC is associated with response to atenolol in people with Hypertension.	0.25
655385404	655387086	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387086	15453913	Genotype CT is associated with response to atenolol in people with Hypertension.	0.25
655385418	981419300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981419300	16876132	Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.	2.75
655385426	655387788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387788	17600820	Allele T is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.	2.0
655385466	622888380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/622888380	19176441	Allele A is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.0
655385471	637879601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879601	19684603	Allele C is associated with increased methotrexate polyglutamate accumulation when treated with methotrexate in people with B-hyperdiploid subtype of Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	1.5
655385475	637879608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879608	16439441	Allele G is associated with higher mean toxicity score when treated with methotrexate in people with Arthritis, Rheumatoid.	1.5
655385479	637879621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879621	17286537	Allele G is associated with decreased in the disease activity score when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	2.5
655385483	637879900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879900	20714340	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	2.25
655385491	637879906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879906	20714340	Allele G is associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	1.75
655385579	699638662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638662	19650939	Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes CT + TT.	3.25
655385579	769164961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164961	19704415	Allele C is associated with increased likelihood of response when treated with Antihypertensives in people with Pre-Eclampsia as compared to allele T.	2.5
655385604	981858866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858866	23492908	Allele A is not associated with olanzapine exposure when treated with olanzapine in people with Psychotic Disorders as compared to allele C.	-1.25
655385604	655385601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385601	19636338	Genotype AA is associated with decreased plasma concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C.	1.75
655385613	655385610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385610	19636338	Genotype AA is associated with increased risk of side effects when treated with olanzapine in people with psychiatric disorders as compared to allele G.	1.5
655385701	827695457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695457	16267764	Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.	2.25
655385701	655385696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385696	16267764	Genotype AA is associated with increased likelihood of favorable virologic responses when treated with efavirenz in people with HIV as compared to genotypes GG + GT.	2.25
655385701	655385693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385693	16267764	Genotype AA is associated with increased CD4 T cell count when treated with efavirenz in people with HIV Infections as compared to genotype GG.	0.0
655385701	655385690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385690	11809184	Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.	2.5
655385701	655387331	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387331	20662624	Allele A is not associated with decreased response to efavirenz in people with Acquired Immunodeficiency Syndrome.	-1.5
655385701	769163065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163065	20860463	Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	-0.5
655385701	769169899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169899	16912956	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.	2.25
655385701	1184168552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168552	23734829	Allele G is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele A.	-1.5
655385705	655387194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387194	19414708	Genotype GG is associated with increased response to antidepressants, desipramine and fluoxetine in people with Depressive Disorder, Major.	2.5
655385749	655385744	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655385744	19255940	Allele C is associated with decreased clearance of midazolam.	0.0
655385763	655385762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385762	20054294	Genotype TT is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	1.5
655385818	655388335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388335	11294926	Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G.	2.25
655385856	1444705420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705420	16467099	Genotypes AA + AT are associated with increased response to paclitaxel in women with Ovarian Neoplasms as compared to genotypes AC + CC.	1.75
655385856	1444705431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705431	18836089	Genotype CC is associated with decreased response to paclitaxel in women with Breast Neoplasms.	2.0
655385969	655385959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385959	16330681	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele A.	3.25
655385969	1447814301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814301	26799497	Allele A is not associated with likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele T.	-1.5
655385969	1447944547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944547	25823784	Genotypes AT + TT is associated with increased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype AA.	0.0
655385969	1448994921	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994921	28763429	Allele A is not associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele T.	-2.0
655385969	1449164397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164397	28485375	Genotype AA is associated with decreased risk of Drug Toxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.	2.5
655385973	655385891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385891	16330681	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.	2.25
655385977	981865161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865161	19448608	Genotypes AG + GG are associated with decreased risk of toxicity when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AA.	2.0
655385977	655385953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385953	16330681	Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.	3.25
655385977	1447814310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814310	26799497	Allele A is not associated with likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.	-1.5
655385977	1448994670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994670	28763429	Allele A is not associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele G.	-2.0
655385977	1449164421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164421	28485375	Genotype AA is associated with increased risk of cardiotoxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.	2.0
655385981	655385947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385947	16330681	Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	3.25
655385985	655385965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385965	16330681	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	2.25
655385985	1449164388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164388	28485375	Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.	3.0
655385985	1447944567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944567	25823784	Genotypes AA + AG is associated with increased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype GG.	0.0
655385989	655387520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387520	19952982	Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C.	2.0
655385993	655387523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387523	19952982	Allele G is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele A.	2.0
655385997	769143881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143881	17537913	Genotype AA is associated with decreased inhibitory concentration 50 when exposed to etoposide as compared to genotypes AG + GG.	1.75
655385814	982046771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046771	23697249	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.	-1.25
655385814	827705076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827705076	21799461	Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.	2.5
655385814	827824194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824194	22188362	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	-1.5
655385814	827824458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824458	22256867	Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.	-2.0
655385814	827824539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824539	22256867	Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.	-1.75
655385814	827844971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827844971	21449672	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.	-2.0
655385814	827921760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921760	22630058	Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.	-2.0
655385814	1184999713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999713	25155934	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	3.25
655385814	1184999741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999741	25155934	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	0.0
655385814	1296599297	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599297	24567120	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.	-1.5
655385422	655386715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386715	15492764	Genotype GG is associated with increased likelihood of smoking cessation when treated with bupropion in women as compared to genotypes AA + AG.	0.0
655385422	655386722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386722	17654295	Genotype GG is associated with increased likelihood of smoking cessation as compared to genotypes AA + AG.	2.5
655385422	655386727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386727	18058343	Genotype GG is associated with increased likelihood of smoking cessation when treated with bupropion as compared to genotypes AA + AG.	3.5
655385422	1446765784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765784	26153084	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.	-1.5
655385422	1449713140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713140	25881752	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.	-1.0
655385422	1449713146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713146	14570538	Allele A are not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele G.	-1.5
655385495	982025827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025827	18579277	Allele A is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele G.	-1.5
655385495	655387666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387666	19339912	Genotypes AA + AG are associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to genotype GG.	1.75
655385495	637879909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879909	15286066	Allele A is associated with increased prolactin level when treated with antipsychotics in people with Schizophrenia as compared to allele G.	2.0
655385674	982015415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015415	17632216	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	2.5
655385674	655388451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388451	20680028	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.	2.5
655385674	655388454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388454	19142101	Allele C is associated with increased risk of Metabolic Syndrome when treated with clozapine and risperidone in people with Schizophrenia as compared to allele G.	1.75
655385674	1448255358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255358	27441116	Allele C is not associated with risk of Metabolic Syndrome when treated with amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone or ziprasidone in people with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to allele G.	-1.5
655385674	1448997808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997808	25152019	Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.	1.625
655385400	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
655385400	981239905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239905	22871975	Allele C is not associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to allele T.	-1.5
655385400	1448257102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257102	27488389	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.75
655385400	981477999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477999	23132553	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.	1.5
655385400	981481812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481812	20833655	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	981481830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481830	20833655	Allele T is associated with increased dose of warfarin as compared to allele C.	2.25
655385400	981483967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483967	20653676	Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.	2.0
655385400	981489956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981489956	21084764	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	2.0
655385400	981500599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500599	21127708	Allele C is not associated with dose of warfarin in people with Myocardial Infarction as compared to allele T.	-1.5
655385400	981502925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502925	23215885	Allele T is associated with a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans when treated with warfarin as compared to allele C.	1.75
655385400	981502959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502959	23215885	Allele T is not associated with therapeutic warfarin dose requirement in African-Americans when treated with warfarin as compared to allele C.	-1.75
655385400	981754851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754851	23061746	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	2.0
655385400	982037942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037942	20072124	Allele T is not associated with decreased dose of warfarin as compared to allele C.	-1.5
655385400	982047993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047993	22130800	Genotype CC is not associated with dose of warfarin in children as compared to genotype TT.	-0.75
655385400	769246303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769246303	20442691	Genotype CC is associated with decreased dose of warfarin as compared to genotype CT.	2.0
655385400	827641885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641885	19300499	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	827813045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813045	19741565	Allele C is not associated with stable warfarin dose univariately when treated with warfarin as compared to allele T.	-1.75
655385400	827925134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925134	22528326	Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC.	2.5
655385400	978614465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614465	22676192	Allele T is associated with dose of warfarin.	0.0
655385400	655388324	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388324	20182420	Genotype CC is not associated with decreased required dose of warfarin as compared to genotypes CT + TT.	-0.5
655385400	699638607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638607	18250228	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	3.25
655385400	608431751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431751	19794411	Allele C is associated with dose of warfarin.	0.0
655385400	769182565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182565	21383771	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.5
655385400	827864558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864558	21228733	Allele C is not associated with decreased dose of warfarin as compared to allele T.	-0.5
655385400	1183697697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697697	23990957	Genotypes CC + CT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype TT.	2.25
655385400	1183700033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700033	19207028	Allele T is associated with increased dose of warfarin as compared to allele C.	2.5
655385400	1183700228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700228	19297519	Allele T is associated with increased dose of warfarin as compared to allele C.	2.0
655385400	1183701528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701528	20421126	Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele T.	2.5
655385400	1183704839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704839	24019055	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	3.0
655385400	1183934923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183934923	22010099	Genotype TT is associated with higher mean warfarin daily dose requirement when treated with warfarin in children as compared to genotypes CC + CT.	0.0
655385400	1184472389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472389	20128861	Allele T is not associated with dose of warfarin as compared to allele C.	-1.5
655385400	1184482772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482772	23949431	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	2.75
655385400	1184483813	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483813	23104259	Genotype TT is associated with increased dose of warfarin as compared to genotype CC.	2.25
655385400	1184510039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510039	22549502	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655385400	1184510136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510136	22192158	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	1.75
655385400	1184510155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510155	22172097	Genotype CT is associated with increased dose of warfarin as compared to genotype CC.	2.0
655385400	1184511577	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511577	25042728	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	2.0
655385400	1184511955	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511955	24029542	Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC.	1.0
655385400	1184654456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654456	24330000	Allele T is not associated with increased dose of warfarin in children with Heart Diseases as compared to allele C.	-1.5
655385400	1184748929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748929	25084205	Allele T is associated with increased dose of warfarin.	2.0
655385400	1184756280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756280	25126975	Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele T.	3.0
655385400	1185235744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235744	24601977	Allele C is not associated with dose of warfarin in children as compared to allele T.	-1.25
655385400	1444694633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694633	25594941	Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC.	-1.5
655385400	1445296694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296694	26024874	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	3.5
655385400	1446765933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765933	26257249	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.5
655385400	1447680563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680563	26739746	Allele T is associated with dose of warfarin as compared to allele C.	0.0
655385400	1447952609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952609	26877068	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	3.0
655385400	1447983837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983837	27073641	Allele T is associated with increased dose of warfarin as compared to allele C.	1.0
655385400	1448108296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108296	27262824	Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC.	-0.25
655385400	1448109663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109663	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
655385400	1448268037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268037	22534826	Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes CC + CT.	2.25
655385400	1448275984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448275984	21326313	Genotype CC is associated with decreased dose of warfarin as compared to genotype TT.	0.0
655385400	1448276458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276458	21725053	Allele T is associated with dose of warfarin.	0.0
655385400	1448431513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431513	26223945	Genotypes CC + CT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.	2.5
655385400	1448602262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602262	27938396	Genotypes CT + TT is not associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.	-1.5
655385400	1448615563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615563	28429387	Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	3.0
655385400	1448624178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624178	28550460	Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.	2.0
655385400	1448633907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633907	28620303	Allele T is associated with increased dose of warfarin as compared to allele C.	3.0
655385400	1449005167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005167	29054760	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655385400	1449005218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005218	28262345	Genotypes CC + CT are associated with decreased dose of warfarin as compared to genotype TT.	2.0
655385400	1449190771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190771	29432897	Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
655385400	1449191473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191473	29252193	Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.5
655385400	1449192000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192000	29201113	Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.5
655385400	1449251596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449251596	28049362	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
655385400	1449259246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449259246	27617219	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655385400	1449269209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269209	28973620	Allele T is associated with dose of warfarin as compared to allele C.	0.0
655385400	1449575733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575733	29875668	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
655385400	1450186421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450186421	30506689	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.	1.75
655385400	1450370810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370810	30821933	Allele T is not associated with dose of warfarin as compared to allele C.	-1.0
655385400	827783872	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783872	21174619	CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1.	2.25
655385400	1447682700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682700	26745506	CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.	2.25
655385400	1448276515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276515	26710337	CYP4F2 *3 is associated with dose of warfarin.	0.0
655385384	655388002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388002	18551043	Genotypes CT + TT are associated with decreased risk of Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype CC.	2.0
655386421	1451617101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451617101	33794950	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.	-1.5
655386421	981934259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934259	23095111	Allele C is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid.	-1.25
655386421	1296667227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667227	25074866	Genotype CC is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	2.0
655386421	1451110180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451110180	31099054	Genotype TT is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	2.5
655386421	1444698548	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698548	24350725	Genotypes CC + CT is associated with increased risk of gastrointestinal toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	3.5
655386421	1449164775	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164775	27217051	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.25
655386436	1451618330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451618330	33794950	Allele G is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.	-1.5
655386436	981934245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934245	23095111	Allele T is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid.	-1.25
655386436	827774243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827774243	21931346	Allele G is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.0
655386436	827813090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813090	19858780	Allele G is associated with increased likelihood of neurotoxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	3.0
655386436	655386428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386428	16572443	Allele G is associated with increased risk of side effects when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.5
655386436	769170681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170681	16439441	Allele T is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	2.5
655386436	769170689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170689	20514079	Allele G is associated with increased likelihood of elevated transaminases when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.25
655386436	1450968022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450968022	32024416	Allele G is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	0.0
655386436	1449164936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164936	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.75
655386002	748448812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748448812	17537913	Genotype GG is associated with increased sensitivity to etoposide when exposed to etoposide as compared to genotypes AA + AG.	1.25
655386028	655386021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386021	11503014	Genotype AA is associated with decreased plasma concentration of fexofenadine in healthy individuals as compared to genotypes AG + GG.	1.5
655386028	655386010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386010	11994059	Genotype AA is not associated with plasma concentration of fexofenadine in healthy individuals as compared to genotype GG.	-0.25
655386070	769173442	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769173442	19022938	Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.	0.0
655386070	769173407	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769173407	19022938	Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.	0.0
655386070	1448105610	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105610	19016765	Genotype GG is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype AG.	2.25
655386070	1448105620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105620	19016765	Genotype GG is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype AG.	1.75
655386070	1448105627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105627	19016765	Genotype GG is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype AG.	1.75
655386079	655385943	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385943	16330681	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.	2.25
655386083	699642282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642282	17559346	Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.	0.0
655386083	827811231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811231	20179710	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.	2.0
655386083	699642283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642283	17559346	Genotype CC is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.	1.75
655386088	1448105647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105647	19016765	Genotype CC is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype CT.	1.75
655386088	1448105654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105654	19016765	Genotype CC is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype CT.	0.0
655386088	1448105661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105661	19016765	Genotype CC is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype CT.	1.75
655386093	655388209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388209	20038957	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	2.0
655386099	699638963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638963	20038957	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386104	655388206	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388206	20038957	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	2.0
655386109	655388200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388200	20038957	Allele T is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	2.0
655386114	699638971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638971	20038957	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	1.5
655386114	699638968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638968	20038957	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	2.0
655386120	699638975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638975	20038957	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	2.0
655386126	655388257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388257	20038957	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	1.5
655386126	655388260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388260	20038957	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386131	655388254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388254	20038957	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386136	655388251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388251	20038957	Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	2.0
655386141	655388248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388248	20038957	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	2.0
655386146	655388245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388245	20038957	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	2.0
655386151	655388242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388242	20038957	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386156	655388239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388239	20038957	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	2.0
655386161	655388236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388236	20038957	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386166	655388213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388213	20038957	Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.	2.0
655386171	655388228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388228	20038957	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	2.0
655386171	655388232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388232	20038957	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	1.5
655386176	655388223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388223	20038957	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	2.0
655386181	655388203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388203	20038957	Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.	2.0
655386186	655388219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388219	20038957	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.	2.0
655386191	655388216	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388216	20038957	Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.	2.0
655386212	655386202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386202	19756153	Genotype TT is associated with increased frequency of rescue analgesic administration when treated with opioids in people with Pain as compared to genotypes CC + CT.	2.5
655386212	769173176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173176	20220551	Genotype TT is associated with increased dose of methadone in people with Substance-Related Disorders as compared to genotypes CC + CT.	1.25
655386212	769173180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173180	20220551	Genotype TT is associated with increased dose of opioids in people with Pain as compared to genotypes CC + CT.	0.0
655386310	699638956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638956	20157331	Allele C is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	0.25
655386315	699638960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638960	20157331	Genotype TT is associated with decreased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	0.25
655386320	655388313	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388313	20157331	Genotype AA is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	0.25
655386324	655388312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388312	20157331	Allele T is associated with increased clearance of docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.25
655386447	655386443	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386443	19636336	Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC.	3.25
655386550	655386547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386547	17976958	Allele A is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics in people with Schizophrenia.	2.25
655386585	1000539707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539707	23588304	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	3.75
655386585	1000539746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539746	23820299	Allele C is not associated with risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	-1.5
655386585	655386562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386562	19898482	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	0.0
655386585	1184988180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988180	25141953	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	3.25
655386585	1447676734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676734	25551397	Allele C is not associated with likelihood of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele T.	-1.0
655386585	1448616321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616321	28448657	Allele C is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.	-1.5
655386589	1000539725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539725	23588304	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	3.5
655386589	1000539750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539750	23820299	Allele T is not associated with risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	-1.5
655386589	655386573	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386573	19898482	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	0.0
655386589	1184988200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988200	25141953	Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.	3.25
655386589	1447677002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677002	25551397	Allele T is associated with increased likelihood of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.	0.0
655386589	1448616342	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616342	28448657	Allele T is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.	-1.5
655386589	1448624787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624787	28445188	Genotype CC is not associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to genotypes CT + TT.	-1.5
655386593	1000539696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539696	23588304	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	3.5
655386593	1000539737	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539737	23820299	Allele T is not associated with risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	-1.5
655386593	655386554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386554	19898482	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	3.5
655386593	1184987276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987276	24642735	Allele T is not associated with increased risk of Ototoxicity when treated with cisplatin in children as compared to allele A.	-1.25
655386593	1184987310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987310	25141953	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.	3.25
655386593	1451128181	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128181	31666714	Allele T is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.	-1.75
655386593	1447676709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676709	25551397	Allele T is not associated with likelihood of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele A.	-1.0
655386593	1448616335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616335	28448657	Allele T is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.	-1.5
655386593	1448624794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624794	28445188	Genotype AA is not associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to genotypes AT + TT.	-1.5
655386597	1000539713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539713	23588304	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	3.75
655386597	1000539742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539742	23820299	Allele T is not associated with risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	-1.5
655386597	655386568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386568	19898482	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	0.0
655386597	1184988190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988190	25141953	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	3.0
655386597	1447676721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676721	25551397	Allele T is not associated with likelihood of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.	-1.5
655386597	1448616328	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616328	28448657	Allele C is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.	-1.5
655386601	1000539731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539731	23588304	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children as compared to allele C.	3.5
655386601	1000539754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1000539754	23820299	Allele T is not associated with risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	-1.5
655386601	655386579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386579	19898482	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	3.5
655386601	1184987296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987296	24642735	Allele T is not associated with increased risk of Ototoxicity when treated with cisplatin in children as compared to allele C.	-1.25
655386601	1184988210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988210	25141953	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.	3.0
655386601	1447677013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677013	25551397	Allele T is not associated with likelihood of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.	-1.5
655386601	1448616349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616349	28448657	Allele C is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.	-1.5
655386601	1448624776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624776	28445188	Genotype CC is not associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to genotypes CT + TT.	-1.5
655386616	827813109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813109	19620936	Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T.	-2.75
655386616	827816865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816865	22026922	Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	2.5
655386616	827816886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816886	22026922	Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	3.0
655386616	769166392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166392	20078613	Genotypes GT + TT are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	0.0
655386616	1449752396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752396	29662106	Allele G is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.5
655386616	827704200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827704200	21826087	Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT.	-2.75
655386616	827793330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793330	21449681	Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT.	1.75
655386616	827827967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827967	22188361	Genotypes GG + GT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.5
655386616	655386609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386609	19434073	Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT.	2.25
655386616	637880131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880131	15213713	Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT.	2.5
655386649	655386478	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386478	19786980	Genotype CCT/CCT is associated with decreased risk of Thrombocytopenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	2.5
655386649	827824953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824953	22188361	Genotype CCT/CCT is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	-1.25
655386649	827824957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824957	22188361	Genotype CCT/CCT is not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	-1.5
655386649	655386482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386482	19786980	Genotype CCT/CCT is associated with decreased risk of Anemia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	3.0
655386649	655386485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386485	19786980	Genotype CCT/CCT is associated with decreased risk of Peripheral Nervous System Diseases when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.	0.0
655386665	613979640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613979640	19203783	Genotype CC is associated with increased progression-free survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + AC.	2.0
655386801	827824914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824914	22188361	Genotypes AA + AG are associated with increased likelihood of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	1.75
655386830	655386814	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386814	15814642	Genotype AA is associated with increased severity of Drug Toxicity when treated with cisplatin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	0.25
655386830	655386827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386827	17194903	Allele A is associated with increased severity of Neutropenia when treated with gemcitabine in people with Neoplasms as compared to allele G.	2.5
655386830	1184086208	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184086208	24361227	Allele G is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele A.	-1.25
655386852	655386848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386848	18794724	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	2.0
655386856	655386834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386834	18794724	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	2.0
655386869	769143853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143853	15739035	Genotype CC is associated with increased improvement in bone mineral density when treated with alendronate and raloxifene in people with Osteoporosis, Postmenopausal as compared to genotype TT.	2.0
655386869	769164322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164322	12608943	Genotype CC is associated with increased Bone Mineral Density when treated with alendronate in people with Osteoporosis as compared to genotype TT.	1.75
655386873	655386864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386864	19020788	Allele A is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to allele G.	2.75
655386888	655386877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386877	16257277	Genotype GG is associated with increased likelihood of resistance when treated with Bisphosphonates in people with Osteitis Deformans as compared to genotypes AA + AG.	3.0
655386244	655386223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386223	20017669	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.	2.0
655386244	769169899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169899	16912956	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.	2.25
655386244	769169877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169877	16912957	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections as compared to allele G.	2.0
655386612	655386605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386605	19434073	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T.	2.25
655386612	1448616370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616370	28448657	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.	-1.5
655386639	655386332	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386332	19786980	Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.	2.5
655386639	827816143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816143	21902499	Genotype GG is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AG.	2.25
655386639	827817015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817015	22026922	Genotypes AG + GG are not associated with increased likelihood of Drug Toxicity when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	-1.25
655386639	827826160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826160	22188361	Genotypes AG + GG are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AA.	-1.25
655386639	1448256744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256744	27498158	Genotypes AA + AG are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
655386639	1448522390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448522390	20530282	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
655386661	827816070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816070	21902499	Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC.	2.25
655386661	827826211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826211	22188361	Genotypes AA + AC are not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-1.25
655386661	655386628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386628	19786980	Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype AA.	3.0
655386657	982046469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046469	22761669	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-0.875
655386657	827641636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641636	16875718	Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.	1.5
655386657	827817158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817158	22026922	Genotypes CT + TT are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	2.5
655386657	827817165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817165	22026922	Genotypes CT + TT are not associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	-1.5
655386657	827828058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828058	22188361	Genotypes CC + CT are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.25
655386657	827828226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828226	22188361	Genotypes CT + TT are associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	0.0
655386657	769172568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172568	19362955	Genotype TT is associated with worse overall survival outcome when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
655386657	1184754301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754301	25025378	Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.	2.75
655386657	1184886873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886873	25232828	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele C.	-0.25
655386657	1296599089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599089	24446315	Genotypes CT + TT is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-2.25
655386657	1296599231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599231	24446315	Genotypes CT + TT is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-2.25
655386657	1444698493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698493	24224851	Genotypes CT + TT is associated with decreased response to Platinum compounds in people with Colorectal Neoplasms and Stomach Neoplasms as compared to genotype CC.	1.25
655386657	1448123553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123553	27248474	Genotypes CC + CT are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	1.75
655386657	1448263426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263426	27636246	Genotype TT is associated with decreased progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	1.125
655386657	1448522347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522347	20530282	Genotype CC is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	-2.0
655386657	1448617027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617027	28422153	Genotypes CT + TT are associated with decreased overall survival and progression-free survival when treated with cisplatin and gemcitabine in people with Mesothelioma as compared to genotype CC.	0.0
655386657	1448640030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640030	28743242	Genotypes CT + TT is associated with decreased response to platinum in people with Lung Neoplasms as compared to genotype CC.	1.75
655386657	1449752308	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752308	29662106	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.5
655386657	1449754452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449754452	21057378	Genotype CC is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.	3.5
655387949	981483656	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483656	23233662	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	1.5
655387949	655387946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387946	19901119	Allele C is associated with decreased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	2.75
655387949	1451463760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451463760	31870219	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-0.125
655387949	1451615120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615120	33501733	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.0
655387949	1183681696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681696	23652803	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.75
655387949	1184747687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747687	25098908	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.	1.5
655387949	1296666350	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666350	24712521	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.75
655387949	1449003337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003337	28525903	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-1.25
655387949	1450045245	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045245	29791011	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.	-1.0
655386969	655386965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386965	18539621	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	2.75
655386981	655386973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386973	18539621	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	2.75
655387942	1451634521	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634521	34346513	Allele C is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.25
655387942	655387935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387935	19901119	Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	2.75
655387942	1449003016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449003016	28525903	Genotype CC is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	-1.75
655386990	699642255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642255	19005482	Genotypes AG + GG are associated with increased risk of oral mucositis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype AA.	3.0
655386995	699642279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642279	19376514	Allele C is associated with decreased risk of Ovarian Failure, Premature when treated with cyclophosphamide in people with Breast Neoplasms as compared to genotype TT.	2.25
655386999	699642248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642248	19005482	Genotypes CT + TT are associated with increased risk of hemorrhagic cystitis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype CC.	2.5
655387004	655387574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387574	19696793	Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.	2.75
655387004	655387577	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387577	19696793	Allele T is associated with increased severity of Neutropenia when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.	2.25
655387004	655387580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387580	19696793	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.	2.75
655387009	699638540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638540	19671875	Genotypes GG + GT are associated with increased disease free survival when treated with cyclophosphamide, doxorubicin, fluorouracil and methotrexate in people with Breast Neoplasms as compared to genotype TT.	2.25
655387009	699638544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638544	19671875	Genotype TT is associated with increased disease free survival in people not taking cyclophosphamide in women with Breast Neoplasms as compared to genotypes GG + GT.	2.5
655387009	1449576797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576797	29938344	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	-1.5
655387014	699638537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638537	19671875	Genotype CC is associated with increased disease free survival in people not taking cyclophosphamide in women with Breast Neoplasms as compared to genotypes CT + TT.	3.0
655387023	982033328	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033328	23651026	Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AC + CC.	0.0
655387023	769245523	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769245523	21325291	Allele C is not associated with expression of CDA in CEPH cell lines.	-0.0
655387023	827803684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827803684	21521023	Genotypes AC + CC are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype AA.	1.75
655387023	827803765	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803765	21521023	Genotype CC is associated with increased expression of CDA in PBMCs.	0.0
655387023	827829894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829894	22304580	Genotype CC is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.	2.25
655387023	827922313	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922313	22379997	Genotype CC is associated with increased risk of Drug Toxicity when treated with cytarabine in children with Lymphoma, T-Cell.	0.25
655387023	827922320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827922320	22379997	Genotype CC is associated with decreased clearance of cytarabine in children Lymphoma, T-Cell.	0.25
655387023	699639373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639373	19458626	Genotype AA is associated with decreased risk of grade III/IV liver toxicity when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.	2.25
655387023	1184483119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483119	25003625	Genotype CC is associated with increased risk of toxicity when treated with cytarabine in children Burkitt Lymphoma.	0.25
655387027	982033310	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033310	23651026	Genotype CC is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes CT + TT.	0.0
655387027	769245516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245516	21325291	Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to allele C.	2.5
655387027	827803655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827803655	21521023	Genotypes CT + TT are associated with increased Drug Toxicity when exposed to cytarabine in healthy individuals as compared to genotype CC.	1.75
655387027	827803670	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803670	21521023	Genotype TT is associated with increased expression of CDA in PBMCs.	0.0
655387027	827829873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829873	22304580	Genotype TT is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype CC.	2.25
655387027	769245519	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769245519	21325291	Allele T is not associated with expression of CDA in CEPH cell lines.	-0.0
699639332	1296598746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598746	25303299	Genotype GG is not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.25
699639332	1451465020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465020	21387541	Genotype GG is associated with decreased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.	0.0
699639332	1451465184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465184	21534867	Genotypes GG + GT are associated with decreased risk of Skin Manifestations due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.0
699639332	1451475101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475101	21887680	Genotypes GT + TT are associated with increased risk of Anemia or Drug Toxicity when treated with methotrexate in people with Osteosarcoma.	2.5
699639332	1451504681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504681	22074251	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.5
699639332	1451511460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451511460	25177243	Allele G is not associated with risk of Anemia, Leukopenia, mucositis, Thrombocytopenia or Toxic liver disease due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to allele T.	-0.25
699639332	1451553481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553481	32695297	Genotype GT is associated with decreased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.25
699639332	1451634260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634260	34346513	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.25
699639332	1451635250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451635250	33841551	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.25
699639332	1447964581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964581	25065700	Genotypes GT + TT is associated with increased risk of mucositis when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.5
699639332	1451548803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548803	30684021	Genotypes GG + GT are associated with increased severity of Neutropenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.25
699639332	981476018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476018	23089671	Genotype GG is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.	-0.5
699639332	608431620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431620	15781665	Allele T is not associated with increased risk of toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-2.0
699639332	637879731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879731	17488658	Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GT + TT.	-3.0
699639332	769170699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170699	18368069	Genotype TT is associated with increased likelihood of red blood cell transfusions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.	1.75
699639332	769170997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170997	17323057	Genotype GG is associated with decreased risk of Myelosuppression when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.	2.25
699639332	769146374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146374	16501586	Genotype GG is associated with decreased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype TT.	2.0
699639332	769173704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173704	16013960	Allele T is not associated with decreased IQ when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-1.25
699639332	1184169884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169884	18987660	Allele G is not associated with likelihood of Drug Toxicity, Infection and Stomatitis when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.75
699639332	1184510305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510305	23488607	Genotypes GG + GT is not associated with risk of hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype TT.	-1.25
699639332	1184510316	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510316	23488607	Genotypes GG + GT is not associated with risk of non-hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype TT.	-1.25
699639332	1184514061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514061	24241962	Allele G is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.	-0.75
699639332	1448997035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997035	28696419	Genotype TT is not associated with risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes GG + GT.	-1.375
655387221	655387218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387218	19997080	Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT.	1.5
655387229	655387327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387327	19997080	Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.	1.5
655387237	655387233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387233	19997080	Genotypes CT + TT are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype CC.	1.5
655387257	655387253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387253	19873684	Allele A is associated with increased likelihood of Weight gain when treated with risperidone in children as compared to genotype GG.	1.75
655387257	827811992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811992	21510767	Allele G is not associated with increased likelihood of Obesity when treated with antipsychotics as compared to allele A.	-0.25
655387257	1446898502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898502	23799528	Allele G is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.	2.0
655387257	1447945041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945041	26880915	Genotype GG is associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AA + AG.	2.5
655387672	655387669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387669	19339912	Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T.	2.25
655387688	655387683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387683	10823405	Allele A is associated with increased prolactin concentrations when exposed to nemonapride in women with schizophrenia as compared to allele G.	1.5
655387767	655387719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387719	16413245	Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.	2.0
699639249	655387903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387903	20212519	Allele C is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele T.	2.0
655387821	655387811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387811	19902562	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	3.25
655387825	655387805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387805	19902562	Genotypes CT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	3.25
655387835	655387832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387832	18580170	Genotype AA is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype GG.	2.0
655387839	655387829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387829	18580170	Genotype GG is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype TT.	2.0
655387876	655387845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387845	19506579	Allele G is associated with increased risk of extrapyramidal symptoms when treated with risperidone in people with Bipolar Disorder or Schizophrenia as compared to allele A.	2.75
655388022	655388018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388018	12175731	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.	1.75
655388510	769250907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250907	18926547	Genotype GG is not associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype G/del.	-1.5
655388510	655388500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388500	16513877	Allele del is associated with increased time to respond when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype GG.	1.75
655388510	637879842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879842	15830237	Allele del is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G.	-1.5
655388510	655386540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386540	9858029	Genotype GG is associated with increased likelihood of Schizophrenia as compared to genotypes G/del + del/del.	1.25
655388510	655386544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386544	9858029	Allele G is not associated with response to antipsychotics in people with Schizophrenia as compared to allele del.	-1.75
655388510	637879832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879832	9918131	Allele del is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G.	-1.5
655388510	655387630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387630	17105675	Allele del is not associated with response to risperidone in people with Schizophrenia.	-0.5
655388510	769172782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769172782	15694263	Genotype GG is associated with increased response to chlorpromazine in people with Schizophrenia as compared to genotypes G/del + del/del.	2.0
655388510	769171560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171560	11505224	Genotype GG is associated with increased improvement in Anxiety-Depression symptoms when treated with bromperidol and nemonapride in people with Schizophrenia as compared to genotypes G/del + del/del.	1.5
655388510	769168983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769168983	20194480	Allele del is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG.	1.25
655388510	1449140243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449140243	28673279	Genotype G/del is associated with decreased response to aripiprazole in people with schizoaffective disorder.	0.25
699639328	655388360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388360	20212519	Allele G is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele C.	2.0
699639336	1447674471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674471	26616421	Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.5
699639336	1447981047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447981047	25618758	Genotype GT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	2.0
699639336	1448107993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107993	21931346	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.0
699639336	608431521	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431521	20863444	Allele G is associated with increased likelihood of clinical response when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	2.0
699639336	655386425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386425	16572443	Genotype TT is associated with increased response base on Disease Activity Score in 44 joints improvement at 6 months of treatment when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.	2.5
699639336	769170786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170786	19827168	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.25
699639336	769170664	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170664	20595278	Allele G is not associated with response to methotrexate in people with Arthritis, Juvenile Rheumatoid.	-0.0
699639336	769171245	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171245	18322994	Allele G is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid.	-1.25
699639336	1184467445	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467445	24624914	Genotype GT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	-1.75
699639336	1184467466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467466	24624914	Genotype TT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	-1.5
699639336	1184467472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467472	24624914	Genotype GT is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	-1.0
699639343	699639186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639186	21052031	Allele A is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele G.	2.5
699639347	699639147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639147	21052031	Allele C is associated with decreased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.	2.5
699639351	699639202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639202	21052031	Allele C is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.	2.0
699642190	699642186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699642186	18496129	Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.	3.0
769143802	699638681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638681	15121491	Genotypes AA + AG are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype GG.	2.25
769171387	769171384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171384	18540691	Genotype GG is associated with decreased risk of haematological toxicity when exposed to fluorouracil in people with Rectal Neoplasms as compared to genotype AA.	2.5
769171582	769171579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171579	18195729	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	2.5
655387245	655387241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387241	19997080	Allele A is associated with decreased response to risperidone in children with Autistic Disorder as compared to genotype GG.	1.5
655387938	655387918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387918	19901119	Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	1.75
655387938	655387922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387922	19901119	Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	2.25
655386985	1451411393	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451411393	32448869	Allele T is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
655386985	655386977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386977	18539621	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	3.25
655386961	1451411387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451411387	32448869	Allele T is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
655386961	655386955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386955	18539621	Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	2.75
655386945	655386935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386935	18408560	Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	2.5
655386945	655386940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655386940	18408560	Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	2.0
655386945	1448634968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634968	18408560	Allele T is not associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.	-1.75
655387053	827830124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830124	12966368	Genotypes CT + TT are not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotype CC.	-1.5
655387053	655388265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388265	20368718	Genotype CC is associated with decreased dose of cyclosporine as compared to genotypes CT + TT.	3.0
655387053	1183689883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689883	22886152	CYP3A5 *3 is associated with decreased dose of cyclosporine in people with Kidney Transplantation as compared to CYP3A5 *1.	1.75
655387798	655387790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387790	19916996	Genotype AA is associated with decreased oxazepam oral clearance when exposed to oxazepam as compared to genotype CC.	1.5
655387798	655387783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387783	15044558	Genotype AA is associated with decreased S-oxazepam glucuronidation in human liver microsomes when exposed to oxazepam as compared to genotype CC.	1.0
655387798	1449559875	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449559875	29737521	Allele A is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele C.	0.0
655387895	655387888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387888	19648163	Allele del is associated with increased risk of drug-induced liver injury when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-2.5
655387895	827698251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698251	21747412	Genotype TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TGGCGCGTCCCGCCCAGGT/del + del/del.	3.0
655387895	1451548720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548720	30684021	Genotype TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT is associated with increased severity of Leukopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TGGCGCGTCCCGCCCAGGT/del + del/del.	0.0
637879869	637879857	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/637879857	15284538	Allele A is associated with decreased clearance of methotrexate.	0.0
637879869	769173745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173745	16999998	Allele A is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.0
613976848	613976809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613976809	16538176	Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele T.	3.0
613977037	613977005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977005	16538175	Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele A.	2.25
613977064	605833570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/605833570	15790597	Allele A is associated with increased likelihood of nicotine dependence when exposed to nicotine as compared to allele G.	2.0
613979021	982044028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044028	20352314	Genotype GG is associated with increased response to carvedilol in people with Heart Failure as compared to genotypes CC + CG.	2.0
613979021	613978953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613978953	12835612	Genotype CC is associated with decreased likelihood of improved left ventricular ejection fraction when treated with carvedilol in people with Heart Failure as compared to genotypes CG + GG.	2.25
613979021	827807199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807199	21599570	Allele C is associated with increased reduction in resting blood pressure when treated with carvedilol in healthy individuals as compared to allele G.	2.5
613979021	613978984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978984	15861037	Allele G is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele C.	-1.5
613979403	655385715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385715	17361120	Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC.	3.0
618376538	613977087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977087	19290018	Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	2.0
618376538	1449155963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155963	29196725	Allele G is not associated with Tobacco Use Disorder when exposed to nicotine as compared to allele A.	-1.75
619523389	655385772	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385772	11997281	Allele A is associated with increased risk of Torsades de Pointes when treated with amiodarone as compared to allele G.	0.0
619523400	981793996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981793996	20665488	Genotype AA is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	2.0
619523400	981794002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794002	20665488	Genotype AA is associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	3.0
619523400	655388027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388027	17602053	Allele G is associated with decreased risk of Neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele A.	2.5
619523400	827817287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817287	22026922	Genotypes AA + AG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	-1.5
619523400	655388028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388028	17602053	Genotype AA is associated with increased likelihood of progression-free survival when treated with gemcitabine in women with Breast Neoplasms as compared to allele G.	0.0
619523400	1184086281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184086281	24361227	Genotype AA is not associated with increased likelihood of Neurotoxicity Syndromes when treated with gemcitabine and paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.	-1.25
619523400	1184175237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184175237	20226083	Genotype GG is associated with risk of Hematologic Diseases when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.25
619523400	1184175240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175240	20226083	Genotype AA is not associated with response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-1.25
619523414	655385916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385916	18215618	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.	3.25
619523414	827921673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921673	22641028	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.	3.25
619523414	1448276439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276439	26704739	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.	-1.25
619523422	655386253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386253	18215618	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	2.25
619523422	1448276512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276512	26704739	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.	-1.25
637879590	655386098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386098	18855526	Genotype CC is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes CT + TT.	0.0
637879590	982023728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023728	17361129	CYP2C8 *3 is associated with decreased metabolism of amodiaquine in vitro when treated with amodiaquine as compared to CYP2C8 *1A.	0.0
637879595	655386119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386119	18855526	Genotype TT is associated with decreased risk of side effects when treated with amodiaquine as compared to genotypes CC + CT.	0.0
637879595	982023728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023728	17361129	CYP2C8 *3 is associated with decreased metabolism of amodiaquine in vitro when treated with amodiaquine as compared to CYP2C8 *1A.	0.0
637879637	1448107984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107984	19129747	Genotypes AA + AC is associated with increased response to azathioprine in people with Lupus Erythematosus, Systemic as compared to genotype CC.	2.25
637879864	637879861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879861	18539621	Allele G is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	3.25
637879932	655386216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386216	18615156	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	2.25
637879937	655386219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386219	18615156	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	0.0
637879942	655386250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386250	18615156	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	0.0
637879947	655386347	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386347	18615156	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	2.25
637879952	655386350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386350	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	2.75
637879957	655386353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386353	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.	2.25
637879962	655386356	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386356	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	0.0
637879967	1448107943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107943	18615156	Allele A is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	0.0
637879631	981502205	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502205	20584552	Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T.	-1.25
637879631	655386196	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386196	15993855	Genotypes CC + CT are associated with increased risk of reduced response when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotype TT.	0.0
637879785	981754860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754860	23061746	Allele G is not associated with decreased dose of warfarin as compared to allele A.	-1.5
637879785	608431768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431768	19794411	Allele A is associated with decreased dose of warfarin.	2.25
637879785	827690618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827690618	21593757	Allele A is not associated with dose of warfarin.	-1.5
637879972	655386363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386363	18615156	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	2.75
637879977	655386373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386373	18615156	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	2.25
637879982	655386377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386377	18615156	Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	2.75
637879987	655386381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386381	18615156	Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	2.75
637879992	655386386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386386	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	2.75
637879997	655386391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386391	18615156	Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	0.0
613976757	981501779	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501779	23252947	Genotype GG is not associated with clearance of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	-0.75
613976757	827815322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815322	19620853	Allele G is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	1.75
613976757	827824071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824071	22188362	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	-1.5
613976757	613976745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613976745	15692831	Allele G is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	1.75
613976757	1444935567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935567	25495409	Genotypes AG + GG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype AA.	2.0
613976757	1447678268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678268	26555147	Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	2.0
613976757	1447678334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678334	26555147	Genotype GG is not associated with dose of carbamazepine in people with Epilepsy as compared to genotype AA.	-1.0
613978937	769248943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769248943	17001291	Genotypes CT + TT are associated with increased dose of phenytoin in people with Epilepsy as compared to genotype CC.	0.0
613978937	613978601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978601	15805193	Allele T is associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.	2.25
613979643	982035136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035136	15100686	Genotypes AC + CC are associated with increased risk of sensitivity to aspirin when exposed to aspirin as compared to genotype AA.	1.75
613979643	655385753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385753	19862937	Allele C is associated with increased risk of Urticaria when treated with aspirin.	2.75
613979643	769171398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171398	16433794	Allele C is associated with increased risk of Urticaria when treated with aspirin.	0.0
619523395	1448106156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106156	21151198	Allele T is associated with increased response to Bisphosphonates in people with Osteoporosis as compared to allele G.	2.5
619523395	655385769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385769	18687167	Genotype GG is associated with decreased response to Bisphosphonates in people with Osteoporosis, Postmenopausal as compared to genotypes GT + TT.	0.0
637879879	608431797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431797	20200517	Allele G is associated with increased dose of warfarin.	2.5
637879879	637879876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879876	20200517	Allele G is associated with increased dose of warfarin.	2.0
637879879	637879873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879873	20200517	Allele G is associated with increased dose of warfarin.	2.25
637879879	827864550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864550	21228733	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	0.0
637879879	1184757033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184757033	25126975	Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.	-2.0
637880014	613979632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613979632	19203783	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.	2.5
655384011	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
655384011	PA166182844	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182844		Annotation of DPWG Guideline for simvastatin and SLCO1B1	100
655384011	1451231960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451231960	29242847	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.	2.25
655384011	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
655384011	655386692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386692	18650507	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.	3.5
655384011	981420028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420028	18650507	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.	0.0
655384011	769164512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164512	21243006	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.	1.75
655384011	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
655384011	1183699615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699615	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	0.0
655384011	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
655384011	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
655384011	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
637880217	637880145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880145	17409936	Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.0
637880217	637880175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880175	17401013	Genotype GG is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.5
637880217	637880107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880107	15213713	Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.	2.5
637880217	637880188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880188	16707601	Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with oxaliplatin in people with Gastrointestinal Neoplasms as compared to genotypes AG + GG.	2.25
637880217	637880206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880206	20530282	Genotype AA is associated with increased risk of Neurotoxicity Syndromes and Neutropenia when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.	3.25
637880217	1448568462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568462	27995989	Genotype GG is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.	-1.5
637880226	637880121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880121	15213713	Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.	2.0
637880226	637880148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880148	17409936	Allele G is not associated with survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	-1.5
637880226	637880107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880107	15213713	Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.	2.5
637880226	1448568344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568344	27995989	Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG.	-1.5
637880243	655386396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386396	18652519	Genotypes GT + TT are associated with increased sensitivity when exposed to erlotinib as compared to genotype GG.	0.0
637880250	655386400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386400	18652519	Genotypes GT + TT are associated with decreased sensitivity when treated with topoisomerase I inhibitors as compared to genotype GG.	0.0
637880258	655386399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386399	18652519	Genotypes GT + TT are associated with decreased sensitivity when exposed to geldanamycin as compared to genotype GG.	0.0
637880263	655386403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386403	18652519	Genotypes GT + TT are associated with decreased sensitivity when exposed to Alkylating Agents as compared to genotype GG.	0.0
637880267	981475089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475089	17375033	Genotypes GT + TT are associated with increased response rate (RR) when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.25
637880267	655386406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386406	17375033	Genotypes GT + TT are associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.25
637880078	637880063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880063	17457342	Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.	2.0
637880078	1183624664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624664	23274376	Allele C is not associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms.	-1.25
637880078	1451128160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128160	31666714	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.	-1.75
637880471	655386747	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386747	12065748	Genotype TT is associated with decreased clearance of paclitaxel.	0.0
637880471	655386746	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386746	12065748	Genotype CT is associated with decreased clearance of paclitaxel.	0.0
637880534	655386909	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386909	12065748	Genotype CT is associated with decreased clearance of paclitaxel.	0.0
637880534	655386908	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386908	12065748	Genotype CC is associated with decreased clearance of paclitaxel.	0.0
637880563	655386925	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386925	12065748	Genotype TT is associated with decreased clearance of paclitaxel.	0.0
637880563	655386926	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655386926	12065748	Genotype CT is associated with decreased clearance of paclitaxel.	0.0
652472012	652351416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/652351416	20712529	Genotype AA is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes AG + GG.	2.5
652472012	1447964483	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964483	27021566	Genotypes AA + AG is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype GG.	3.0
652509715	652252614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/652252614	20712529	Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes AA + AT.	2.5
652509715	1447964381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964381	27021566	Genotypes AA + AT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.	3.0
652519736	652326097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/652326097	20712529	Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes CC + CT.	0.0
652519736	1447964466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964466	27021566	Genotypes CC + CT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.	3.0
652595205	655387557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387557	19863340	Genotype CC is associated with increased risk of cardiac damage when treated with anthracyclines and related substances in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	1.75
652882846	699642239	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/699642239	18551042	Allele A is associated with decreased expression of CBR3 in breast tissue.	0.0
652882846	699642230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642230	18551042	Allele G is associated with decreased severity of Neutropenia when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.	1.75
652882846	699642233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642233	18551042	Allele G is associated with decreased tumor response when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AA.	1.75
652882846	699639388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639388	18551042	Allele G is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.	2.25
655384474	613979632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613979632	19203783	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.	2.5
655384485	827843529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827843529	18349392	Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.	-1.5
655384485	827843536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827843536	16788380	Genotype AA is associated with decreased survival when treated with cetuximab in people with Colorectal Neoplasms.	1.5
655384485	827843546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827843546	22117530	Allele G is associated with decreased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele A.	2.0
655384510	699642404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642404	17548750	Allele A is associated with decreased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	3.0
655384510	699642415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642415	20643483	Genotype GG is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.0
655384529	699642395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699642395	19369910	Genotypes CT + TT are associated with increased response to clozapine in people with Schizophrenia as compared to genotype CC.	2.5
655384539	699638648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638648	17206635	Genotype AA is associated with increased risk of resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to genotypes AC + CC.	3.0
655384546	827814000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814000	21806386	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.5
655384546	655388180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388180	18717915	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.	2.0
655384546	1183689861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689861	22886152	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.	0.0
655384546	1444934313	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934313	26107754	Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.	2.25
637880221	613979636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613979636	19203783	Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes AG + GG.	2.5
637880221	637880145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880145	17409936	Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.0
637880221	637880206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880206	20530282	Genotype AA is associated with increased risk of Neurotoxicity Syndromes and Neutropenia when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.	3.25
637880425	981750801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750801	19590397	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	-1.75
637880425	637880371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880371	16642436	Genotype AA is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to genotype GG.	3.5
637880425	637880382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880382	19077664	Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.	3.0
637880425	637880298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880298	17671280	Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.	3.5
652779372	827807593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807593	22124095	Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.	2.75
652779372	655387546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387546	18457324	Allele G is associated with increased risk of Heart Failure when treated with anthracyclines and related substances as compared to allele A.	0.0
655384534	699642290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642290	19509150	Allele G is associated with decreased survival when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele A.	2.5
655384738	1451589825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589825	31114289	Allele A is not associated with dose of warfarin as compared to allele G.	-1.25
655384738	981500592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500592	21127708	Allele A is associated with increased dose of warfarin in people with Myocardial Infarction as compared to allele G.	0.0
655384738	982034189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034189	16270629	Allele A is associated with higher dose of warfarin when exposed to warfarin as compared to allele G.	0.0
655384738	982044373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044373	16611750	Allele A is not associated with increased dose of warfarin as compared to allele G.	-1.25
655384738	1184472420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472420	20128861	Allele A is not associated with dose of warfarin as compared to allele G.	-1.5
655384738	1450979360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450979360	25084205	Allele A is associated with increased dose of warfarin as compared to allele G.	2.0
655384738	1450981800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450981800	22676192	Allele A is associated with increased dose of warfarin as compared to allele G.	0.0
655384830	1451834452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451834452	15634941	CYP3A4 *17 is associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.	1.0
655384563	981500798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500798	20709156	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.	-1.0
655384563	982028827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028827	23733030	Genotype AA is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AC + CC.	-1.0
655384563	982028836	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028836	23733030	Genotypes AC + CC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	1.25
655384563	655388432	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388432	15565110	Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AA + AC.	2.75
655384563	827828566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828566	19676097	Allele A is not associated with clinical outcomes when treated with mirtazapine or paroxetine in people with Depression.	-1.5
655384563	655388405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388405	18597649	Genotypes AC + CC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	2.0
655384568	981500787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500787	20709156	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.	-1.0
655384568	982015355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015355	17467808	Allele T is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to allele C.	0.25
655384568	982028807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028807	23733030	Genotype CC is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	1.25
655384568	982028817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028817	23733030	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.0
655384568	655388402	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388402	18597649	Genotypes CT + TT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype CC.	2.0
655384568	827793233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793233	21449676	Allele T is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.	1.25
655384568	827793245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793245	21449676	Allele T is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele C.	1.25
655384568	827828556	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828556	19676097	Allele C is not associated with clinical outcomes when treated with mirtazapine or paroxetine in people with Depression as compared to allele T.	-1.5
655384568	655388437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388437	15565110	Genotype TT is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes CC + CT.	3.25
655384578	1448263634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263634	27574448	Genotype CC is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CT + TT.	2.5
655384578	1448263828	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263828	27574448	Genotype CC is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CT + TT.	0.0
655384578	1447954607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447954607	24704000	Genotype CC is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.	-1.25
655384578	1444935247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935247	25495407	Genotypes CC + CT is associated with increased risk of infusion related reaction when treated with docetaxel in women with Breast Neoplasms as compared to genotype TT.	2.25
655384578	1448107856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107856	18509327	Allele C is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele T.	0.0
655384582	655387623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387623	18781850	Genotype CC is associated with decreased LDL-C reduction when treated with fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AC.	3.0
655384592	655387863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387863	16890579	Allele C is associated with decreased metabolism of paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	0.0
655384602	655387128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387128	17588543	Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT.	1.75
655384607	655387127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387127	17588543	Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes CT + TT.	2.5
655384607	655387138	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387138	17588543	Genotype TT is associated with increased response to quetiapine and ziprasidone in people with Schizophrenia as compared to genotype CC.	0.0
655384607	655387131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387131	17588543	Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia.	2.5
655384616	699638678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638678	15199031	Genotype GT is associated with decreased reduction in LDL when exposed to pravastatin as compared to genotype TT.	0.375
655384616	827925965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827925965	15199031	Genotype GT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype TT.	3.5
655384616	699638688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638688	18332269	Genotype TT is associated with increased reduction of LDL cholesterol when treated with simvastatin as compared to genotypes GG + GT.	2.5
655384616	699639067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639067	16103896	Genotype GT is not associated with response to pravastatin as compared to genotype TT.	-1.75
655384616	699638985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638985	18815589	Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.	3.5
655384616	769152897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769152897	18261733	Allele G is not associated with response to pravastatin in people with Vascular Diseases as compared to allele T.	-2.0
655384616	699639070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639070	17563401	Allele T is not associated with response to fluvastatin in people with renal transplantation as compared to allele G.	-2.0
655384635	748897582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748897582	18816295	Allele A is associated with decreased UGT1A9 activity for propofol when exposed to propofol as compared to allele G.	0.0
655384645	747790540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/747790540	18187595	Genotype CC is associated with increased mean plasma AUC of repaglinide as compared to genotypes CT + TT.	1.5
655384645	1449311234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311234	29748863	Genotype CT is associated with increased concentrations of repaglinide in healthy individuals as compared to genotype TT.	1.5
655384670	699642389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642389	15809899	Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C.	1.75
655384670	699642392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642392	17700364	Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations in people with HIV Infections as compared to allele C.	0.0
655384679	699638652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638652	16678543	Genotype CC is associated with increased pain relief when treated with rofecoxib as compared to genotypes CG + GG.	2.5
655384694	769145994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769145994	12837457	Genotypes AG + GG are associated with decreased chance of response when treated with sildenafil in people with Erectile Dysfunction (male patients) as compared to genotype AA.	2.5
655384703	655387539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387539	18544707	Allele C is associated with increased beta cell function when treated with troglitazone in people with high risk for type 2 diabetes as compared to allele T.	3.0
655384724	769146304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146304	19578179	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.0
655384767	699642296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642296	18212314	Genotype GG is associated with decreased systolic blood pressure when treated with chlorthalidone in people with Hypertension.	0.0
655384767	699642297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642297	18212314	Allele G is associated with decreased major adverse cardiac events (mace) when treated with chlorthalidone in people with Hypertension as compared to genotype AA.	2.0
655384767	699642298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642298	18212314	Genotype AA is associated with decreased major adverse cardiac events (mace) when treated with amlodipine in people with Hypertension as compared to allele G.	0.0
655384772	981750780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750780	19590397	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	-1.75
655384772	981940039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981940039	21688171	Genotype GG is associated with increased response at 4 weeks after the initiation of treatment when treated with paroxetine in people with Panic Disorder as compared to genotypes CC + CG.	2.0
655384772	982028661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028661	23733030	Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + CG.	-1.0
655384772	982028667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028667	23733030	Genotype GG is not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + CG.	-1.0
655384772	608178498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178498	18484082	Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.	2.5
655384772	655386298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386298	18387740	Genotype GG is associated with decreased treatment response when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + CG.	2.25
655384772	655386295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386295	18047755	Allele G is associated with increased likelihood of response when treated with antidepressants.	0.25
655384772	655386291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386291	19800133	Genotype CC is associated with increased likelihood of non-response when treated with paroxetine and sertraline in people with Panic Disorder as compared to genotypes CG + GG.	2.5
655384781	769143811	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143811	18855529	Genotype GG is associated with decreased cardiac rehospitalization when treated with atenolol, Beta Blocking Agents, carvedilol or metoprolol in people with Acute coronary syndrome as compared to genotypes CC + CG.	2.5
655384794	655388464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388464	10904024	Allele T is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C.	2.75
655384794	655388472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388472	11699055	Allele T is not associated with increased risk of ACEI-related cough when treated with perindopril in people with Diabetes Mellitus, Type 2 as compared to allele C.	-1.5
655384794	655388475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388475	12522467	Genotypes CT + TT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC.	3.0
655384794	655388481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388481	19744011	Allele T is not associated with Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C.	-1.5
655384804	769146107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146107	18617639	Allele A is associated with increased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele G.	3.0
655384809	608178461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178461	19381165	Allele C is associated with decreased reduction in HbA1c levels when treated with metformin in people with Diabetes Mellitus.	2.0
655384809	769169367	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169367	19898263	Genotype AA is not associated with response to metformin in people with genetic variation at rs2289669.	-1.25
655384809	769169373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169373	19898263	Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.	2.25
655384809	769169370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169370	19898263	Genotype AC is associated with response to metformin in people with genetic variation at rs2289669.	0.0
655384813	608178465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178465	18794727	Genotype GG is associated with increased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	0.0
655384817	608178470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178470	18794727	Genotype GG is associated with decreased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype TT.	2.75
655384821	827831546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827831546	18854776	Genotype GG is associated with decreased repaglinide plasma concentration (AUC) and Cmax when exposed to repaglinide in healthy individuals as compared to genotype AA.	1.5
1184747247	1184747221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747221	21301380	HLA-A *02:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
1184747247	1184757230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184757230	23669020	HLA-A *02:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	-0.25
1184747247	1184764318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184764318	21912425	HLA-A *02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	-2.0
655384587	655388183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388183	16299241	Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele A.	-1.25
655384587	655387869	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/655387869	11668219	Allele A is associated with decreased clearance of paclitaxel.	0.0
655384597	699638940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638940	18594024	Genotype TT is associated with increased risk of Osteonecrosis of the jaw when treated with Bisphosphonates in people with Multiple Myeloma as compared to genotypes CC + CT.	0.0
655384597	827863672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863672	21151627	Genotypes CT + TT are not associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates in men with Prostatic Neoplasms as compared to genotype CC.	-1.25
655384611	827925947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827925947	15199031	Genotype AT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype AA.	3.5
655384611	699638675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638675	15199031	Genotype AT is associated with decreased reduction in LDL when treated with pravastatin as compared to genotype AA.	0.0
655384626	982043099	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043099	16722833	Genotype AG is associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.	1.5
655384626	769146445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146445	15226675	Genotype AG is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype GG.	-1.5
655384674	769143868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143868	16609067	Allele C is associated with increased complete response rate when treated with rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to allele A.	2.5
655384674	827825779	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825779	21900198	Genotype AA is associated with decreased progression free survival when treated with cyclophosphamide, doxorubicin, prednisolone, rituximab and vincristine in people with Lymphoma, B-Cell as compared to genotypes AC + CC.	0.0
655384674	769143871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143871	12975461	Genotype CC is associated with response rate when treated with rituximab in people with Lymphoma, Non-Hodgkin as compared to genotypes AA + AC.	0.0
655384674	769143864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769143864	19018870	Genotype AA is associated with decreased levels of IgG when treated with rituximab in people with non-Hodgkin's lymphoma and stem cell transplantation as compared to genotypes AC + CC.	0.5
655384799	1444668176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668176	12759288	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.0
655384799	1444668552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668552	18050183	Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG.	2.5
655384799	1444668728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668728	18713756	Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA.	3.25
655384799	699638591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638591	19365401	Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.5
655384799	1451243060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451243060	16909270	Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	1.375
655384799	1444668429	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668429	16720636	Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.25
655384799	1183703414	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703414	22760475	Genotypes AG + GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotype AA.	1.75
655384653	655387147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387147	17178266	Allele C is associated with increased metabolism of rosiglitazone in healthy individuals as compared to allele T.	1.5
655384653	1450935112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935112	23426382	CYP2C8 *1/*3 + *3/*3 are associated with decreased concentrations of rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to CYP2C8 *1/*1.	0.0
655384653	1450935194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935194	19129086	CYP2C8 *1/*3 is associated with decreased concentrations of rosiglitazone in healthy individuals as compared to CYP2C8 *1/*1.	1.5
655384653	1333193325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193325	17178266	CYP2C8 *3 is associated with increased metabolism of rosiglitazone in healthy individuals.	1.5
655384621	981502824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502824	20215968	Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin in people with prior vascular disease as compared to genotype AA.	2.0
655384621	769146469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146469	18222353	Genotypes AG + GG are associated with decreased risk of Myocardial Infarction when treated with pravastatin.	3.0
655384621	981482129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981482129	20886236	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.	3.5
655384621	981565085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981565085	18222353	Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin.	This annotation is not used for clinical annotation scoring. other VA from the same publication already counted in the scoring
655384621	981962878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981962878	20403483	Genotypes AG + GG are associated with increased response to pravastatin in people with Myocardial Infarction as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The study included patients from CARE study which already been published previously (PMID:18222353, 20886236) and used for scoring.
655384966	981478544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478544	22967772	Allele G is not associated with Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C.	-1.5
655384966	769261685	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261685	21121776	Allele G is associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.	1.5
655384966	769181734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769181734	19434072	Allele C is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele G.	2.0
655384966	1448998819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998819	17016522	Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.	0.0
655384966	1449001852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449001852	27217270	Genotype GG is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele C.	1.25
655385028	1451340124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340124	31869433	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	1.0
655385028	1451589737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589737	31114289	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385028	982035663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035663	18030307	Allele G is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.	2.25
655385028	982038182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038182	20203262	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.0
655385028	982043538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043538	16493479	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.25
655385028	982043645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043645	17456829	Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.75
655385028	982044365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044365	16611750	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.25
655385028	982046155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046155	19874474	Allele G is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
655385028	769160740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769160740	16270629	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
655385028	1183704889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704889	24019055	Genotype CC is associated with increased dose of warfarin as compared to genotypes CG + GG.	2.5
655385028	1450980643	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980643	18322281	Genotype GG is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385028	1447519677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519677	18466099	Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.	2.75
655384975	608431246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431246	17588543	Genotype TT is associated with increased response to olanzapine and perphenazine in people with Schizophrenia as compared to genotypes GG + GT.	2.0
655385012	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
655385012	PA166182841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182841		Annotation of DPWG Guideline for warfarin and VKORC1	100
655385012	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
655385012	1184748906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748906	25084205	Allele T is associated with decreased dose of warfarin.	2.0
655385012	1185235716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235716	24601977	Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.	2.25
655385012	1444666236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666236	25312789	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1444694721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694721	25594941	Genotype TT is associated with decreased dose of warfarin in people with as compared to genotype CT.	2.5
655385012	827864542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864542	20833980	Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.	1.75
655385012	1183689393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689393	22990331	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.0
655385012	981754840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754840	23061746	Allele T is associated with decreased dose of warfarin.	2.5
655385012	1183700756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700756	20375999	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	1449192273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192273	28049362	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.25
655385012	1451409502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409502	31902949	Genotypes CC + CT is associated with increased dose of warfarin in people with Heart Failure as compared to genotype TT.	2.0
655385012	1451589723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589723	31114289	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	982045983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045983	19582440	Allele T is associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to allele C.	2.5
655385012	982038234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038234	21176721	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.5
655385012	1445296652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296652	26024874	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	3.5
655385012	1445401042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445401042	20615525	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	0.0
655385012	1446847493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446847493	26219158	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	1447519319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519319	23602689	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	1447520009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520009	26445138	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1447520074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520074	26433837	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	1.375
655385012	1447586694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447586694	20386359	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	1447586762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447586762	20339978	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.25
655385012	1447680544	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680544	26739746	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	0.0
655385012	1447682688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682688	26745506	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	3.25
655385012	981483977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483977	20653676	Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to genotypes CC + CT.	2.5
655385012	981502435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502435	19875892	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	2.25
655385012	981505306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505306	21185752	Genotypes CT + TT are associated with lower warfarin dose requirement when treated with warfarin as compared to genotype CC.	2.0
655385012	982033139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033139	20833655	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	982035645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035645	18030307	Allele T is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.	2.25
655385012	982036670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036670	18542936	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	982036934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036934	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	982037894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037894	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	982040695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982040695	19135231	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.75
655385012	982043014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043014	17510308	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	2.25
655385012	982043949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043949	15947090	Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.	2.75
655385012	982044388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044388	16890578	Genotype TT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CT.	2.5
655385012	982045585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045585	18855533	Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.	0.0
655385012	982046164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046164	19874474	Allele T is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
655385012	982046752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046752	22010099	Genotype CC is associated with increased dose of warfarin in children as compared to genotypes CT + TT.	2.5
655385012	982047897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047897	22130800	Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.	2.25
655385012	608431774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431774	19794411	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.75
655385012	827567282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567282	15883587	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	827567361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567361	15888487	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.5
655385012	827601694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827601694	18305455	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	827603022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827603022	15930419	Allele T is associated with decreased dose of warfarin.	2.5
655385012	827664180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827664180	16580898	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	827783301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783301	22040439	Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation.	0.25
655385012	827783799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783799	21174619	Genotype CC is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to genotype TT.	2.75
655385012	827814719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814719	21148049	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655385012	827823796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823796	21110192	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	2.5
655385012	827826043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827826043	21747589	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	827925119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925119	22528326	Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.	2.5
655385012	978614455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614455	22676192	Allele T is associated with dose of warfarin.	0.0
655385012	637879838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637879838	20203262	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655385012	637880256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880256	18535201	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
655385012	637880237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880237	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	637880240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880240	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
655385012	637880249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880249	19228618	Allele T is associated with decreased dose of warfarin.	2.0
655385012	769277920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277920	17049586	Genotype TT is associated with decreased dose of warfarin as compared to genotype CT.	2.25
655385012	827864552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864552	21228733	Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1183697213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697213	22349464	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.75
655385012	1183697690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697690	23990957	Genotype TT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotypes CC + CT.	2.75
655385012	1183701155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701155	18574025	Allele T is associated with decreased dose of warfarin.	2.5
655385012	1183701305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701305	19679631	Allele C is associated with increased dose of warfarin as compared to allele T.	2.0
655385012	1183701524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701524	20421126	Allele T is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele C.	2.5
655385012	1183704858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704858	24019055	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	3.0
655385012	1184472424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472424	20128861	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
655385012	1184472851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472851	24474498	Genotype TT is associated with decreased dose of warfarin in children as compared to genotypes CC + CT.	2.25
655385012	1184473132	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473132	22158446	Genotype CC is associated with increased likelihood of having warfarin Dose greater than 7.5 mg/day when treated with warfarin as compared to genotypes CT + TT.	1.25
655385012	1184473580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473580	25001883	Allele T is associated with decreased dose of warfarin in children as compared to allele C.	1.75
655385012	1184482753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482753	23949431	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	1184483809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483809	23104259	Genotypes CC + CT is associated with increased dose of warfarin as compared to genotype TT.	2.75
655385012	1184509863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509863	22854539	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.0
655385012	1184509986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509986	22592842	Allele T is associated with decreased warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.	2.5
655385012	1184510015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510015	22571356	Genotypes CT + TT is associated with decreased stable warfarin dose when treated with warfarin as compared to genotype CC.	3.0
655385012	1184510103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510103	22274142	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1184510339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510339	21320153	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.75
655385012	1184511552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511552	25042728	Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
655385012	1184511950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511950	24029542	Genotype CC is associated with increased dose of warfarin in healthy individuals as compared to genotypes CT + TT.	1.5
655385012	1184654330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654330	24330000	Genotype CC is associated with increased dose of warfarin in children with Heart Diseases as compared to genotype TT.	1.5
655385012	982037339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037339	19745563	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.5
655385012	1451120169	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451120169	31395958	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.75
655385012	1448615516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615516	28429387	Genotype TT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.	3.0
655385012	1448624157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624157	28550460	Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.	2.5
655385012	1449165091	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165091	28382498	Allele C is associated with increased dose of warfarin as compared to allele T.	1.75
655385012	1449260681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449260681	27617219	Allele T is associated with decreased dose of warfarin as compared to allele C.	1.75
655385012	1449262642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449262642	29568565	Allele T is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	2.0
655385012	1449577174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577174	29781049	Genotype CT is associated with increased dose of warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.	2.5
655384834	655388190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388190	16299241	Allele T is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele C.	-0.75
655384834	608431735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431735	11668219	Allele T is associated with decreased metabolism of paclitaxel as compared to allele C.	1.5
655384838	608431745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431745	11668219	Allele C is associated with decreased metabolism of paclitaxel as compared to allele T.	1.5
655384842	608431006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431006	20212519	Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to genotype CC.	2.0
655384846	608178486	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178486	12082591	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.	1.75
655384850	608178490	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178490	17190370	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.	1.0
655384854	608178494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178494	19440701	Genotype CC is associated with decreased metabolism of indinavir in people with HIV Infections as compared to genotypes CT + TT.	1.0
655384862	608178504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178504	18484082	Genotype CC is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.5
655384866	608178665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178665	19369910	Genotype CT is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype CC.	0.0
655384878	608431051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431051	18521091	Genotype GG is associated with the highest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotypes GT + TT.	0.0
655384882	608431055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431055	18521091	Genotype GG is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotypes AA + AG.	0.0
655384886	608431059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431059	18521091	Genotype CC is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia.	0.0
655384890	608431067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431067	18521091	Genotype CT is associated with the lowest mean increased QT when treated with iloperidone in people with Schizophrenia as compared to genotype CC.	0.0
655384894	608178672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178672	19247217	Genotype GG is associated with increased risk of QTc prolongation when treated with verapamil.	0.0
655384898	608178676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608178676	19247217	Genotype GG is associated with increased risk of QTc prolongation when treated with verapamil as compared to genotype TT.	3.0
655384902	769235406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769235406	19581389	Allele A is not associated with metabolism of leflunomide in people with Arthritis as compared to genotype CC.	-0.75
655384902	608431071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431071	18496682	Genotype CC is associated with increased risk of toxicity when treated with leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	0.0
655384906	608431010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431010	19207032	Genotype CC is associated with increased likelihood of remission when treated with leflunomide in people with Arthritis, Rheumatoid as compared to genotype AA.	0.0
655384914	608431157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431157	18325643	Genotype CT is associated with decreased response to Measles vaccines as compared to genotype CC.	2.0
655384918	608431161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431161	17606663	Allele T is associated with increased likelihood of relapse of psychosis when exposed to methamphetamine.	2.25
655384922	608431166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431166	17555717	Allele C is associated with increased risk of Psychotic Disorders when exposed to methamphetamine.	2.75
655384926	608431170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431170	17555717	Allele A is associated with increased risk of Psychotic Disorders when exposed to methamphetamine.	0.0
655384930	608431175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431175	16293801	Genotype GG is associated with increased FEV1 response when treated with montelukast in people with Asthma as compared to genotypes AA + AG.	1.75
655384934	608431182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431182	16293801	Allele G is associated with increased risk of asthma exacerbations when treated with montelukast in people with Asthma as compared to allele A.	2.25
655384938	608431188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431188	16293801	Allele C is associated with decreased risk of asthma exacerbation when treated with montelukast in people with Asthma as compared to genotype AA.	2.25
655384942	608431206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431206	19193342	Allele T is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	2.0
655384946	608431210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431210	19193342	Genotype GG is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	2.5
655384950	608431018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431018	19494443	Allele A is associated with increased risk of treatment-resistance when treated with olanzapine and risperidone in people with Alzheimer Disease as compared to allele G.	0.0
655384954	981477941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477941	17702092	Allele C is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele G.	-1.5
655384954	1448998934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998934	20504252	Genotype GG is not associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CG.	-2.0
655384954	1448999487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999487	19997080	Genotype GG is associated with increased severity of Weight gain when treated with risperidone in children with Autistic Disorder as compared to allele C.	1.5
655384954	1449000725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449000725	26880915	Genotype CG are associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders.	2.0
655384954	1449001835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449001835	27217270	Genotype GG is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele C.	1.25
655384958	608431218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431218	19193342	Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	2.0
655384962	608431224	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431224	18320559	Genotype CC is associated with greater positive symptom improvement and positive symptom remission when treated with olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	1.75
655384979	608431255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431255	17588543	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes GT + TT.	0.0
655384983	608431299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431299	18681781	Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	2.5
655384987	608431318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431318	17344938	Genotype AG is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	2.25
655384987	608431315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431315	17344938	Genotype AA is associated with larger mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	2.25
655384991	608431327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431327	17344938	Genotype AG is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	2.25
655384991	608431322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431322	17344938	Genotype AA is associated with smaller mean changes in systolic and diastolic blood pressure when treated with nifedipine as compared to genotype GG.	2.25
655385041	982045832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045832	16103896	Genotype AA is not associated with response to pravastatin as compared to genotype GG.	-1.75
655385041	613977375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977375	15116054	Allele G is associated with decreased plasma AUC of pravastatin.	1.0
655385054	613979290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613979290	18855532	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	2.0
655385054	769168986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769168986	20194480	Allele A is not associated with response to antipsychotics in people with Schizophrenia as compared to allele G.	-1.0
655385054	1450928201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928201	28696411	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	-1.75
655385016	608431827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431827	18535201	Allele T is associated with decreased dose of warfarin.	0.0
655385033	613977311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613977311	17693647	Allele G is associated with response to trastuzumab.	2.25
655385037	613977365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613977365	19396436	Allele T is associated with increased response to pramipexole.	1.5
655385045	699638854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638854	17925385	Allele T is associated with decreased CYP3A4 acitvity when exposed to rifampin.	1.5
655385050	613979204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613979204	18204343	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	2.5
655385062	699638857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638857	18855532	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	2.0
655385062	1450928225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928225	28696411	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	-1.75
655385067	699638861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638861	18855532	Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	2.0
655385067	1450928233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928233	28696411	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	-1.75
655385072	699638917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638917	19451915	Allele G is associated with increased response to risperidone in people with Schizophrenia.	2.0
655385077	699638922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638922	19451915	Allele G is associated with increased response to risperidone in people with Schizophrenia.	2.0
655385082	655385847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385847	15809899	Allele T is associated with increased risk of Hypertriglyceridemia when treated with ritonavir in people with HIV Infections as compared to allele C.	1.75
655385082	769180703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180703	16417409	Genotypes CT + TT are associated with decreased severity of Hypertriglyceridemia when treated with protease inhibitors as compared to genotype CC.	2.5
655385087	769180706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180706	16417409	Genotypes CC + CT are associated with decreased severity of Hypertriglyceridemia when treated with protease inhibitors as compared to genotype TT.	2.5
655385092	769180711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180711	16417409	Genotypes CG + GG are associated with decreased Hypertriglyceridemia when treated with protease inhibitors as compared to genotype CC.	2.5
655385097	699639130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639130	18693052	Allele G is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.	2.75
655385110	699639154	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639154	18408560	Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.	2.5
655385110	699639165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639165	18408560	Allele G is not associated with decreased response to salbutamol in people with Asthma as compared to allele A.	-1.75
1451414840	1451412500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451412500	32015454	Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.	3.25
1451414840	827816100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816100	21902503	Genotypes AG + GG are associated with increased likelihood of neuropsychiatric adverse events when treated with oseltamivir in children with Influenza, Human as compared to genotype AA.	0.25
655384971	827811981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811981	21510767	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics as compared to allele C.	0.0
655384971	1448998799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998799	17016522	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	0.0
655384971	1449001844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449001844	27217270	Genotype CC is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele T.	1.5
655385004	608431753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431753	17909004	Allele T is associated with decreased metabolism of nicotine as compared to allele G.	1.0
655385004	769169917	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169917	18300939	Allele T is associated with decreased clearance of nicotine.	0.0
655385004	1183693407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183693407	24192532	Allele T is associated with decreased nicotine glucuronidation when exposed to nicotine as compared to genotype GG.	2.0
655385102	981499254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981499254	16772309	Genotype AA is associated with increased risk of asthma exacerbations when exposed to salmeterol in children with Asthma as compared to genotype GG.	2.25
655385102	981499270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981499270	19800676	Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG.	3.25
655385102	699639135	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639135	16322642	Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG.	2.25
655385102	1183700310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700310	24279851	Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG.	3.5
655385102	1184169941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169941	24681963	Genotype GG is not associated with influence on differential bronchodilator effects when treated with montelukast or salmeterol in people with Asthma as compared to genotype AA.	-1.25
655385102	1451341440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451341440	30425908	Allele G is associated with increased response to salmeterol in children Asthma as compared to allele A.	1.75
655385102	981499235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981499235	23126384	Genotype AA is associated with decreased response to salmeterol in children with Asthma.	This annotation is not used for clinical annotation scoring. The variant annotation is on treatment comparison rather than genotype comparison.
655385144	699639419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639419	18334920	Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol when exposed to talinolol as compared to allele G.	1.0
655385144	1448612424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612424	27825374	Allele A is not associated with clearance of talinolol in healthy individuals as compared to allele G.	-0.75
655385164	699642171	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642171	19076156	Allele T is associated with increased non-inducible thiotepa clearance and decreased tepa clearance when treated with thiotepa.	1.5
655385134	699639389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639389	17519421	Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	3.0
655385139	655385756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655385756	20054294	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.5
655385159	1451761040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451761040	33850298	Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.	3.0
655385159	699642165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642165	17597712	Genotype TT is associated with increased tenofovir renal clearance, and lower AUC when treated with tenofovir as compared to genotypes CC + CT.	-0.5
655385159	699642168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642168	18398970	Genotypes CC + CT are associated with increased intracellular tenofovir diphosphate (TFV-DP) concentrations when treated with tenofovir in people with HIV Infections as compared to genotype TT.	-1.0
655385159	1449004578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449004578	29061086	Genotype TT is associated with decreased clearance of tenofovir in people with HIV Infections as compared to genotypes CC + CT.	0.0
655385159	1444703303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703303	25801567	Genotypes CC + CT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype TT.	-1.0
655385149	699639424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639424	17713466	Genotype CC is associated with increased triglycerides in postmenopausal woman when treated with tamoxifen as compared to genotype TT.	1.25
655385154	699639427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639427	17713466	Genotype GG is associated with decreased in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women when treated with tamoxifen as compared to genotypes AA + AG.	1.0
655385307	751539632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751539632	11710708	Genotypes AA + AG are associated with increased risk of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.5
655385307	1451618382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451618382	33794950	Genotypes AA + AG are associated with increased likelihood of Drug Toxicity due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	2.0
655385307	981934235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934235	23095111	Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.25
655385307	827774221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827774221	21931346	Allele A is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
655385307	748441277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748441277	18381794	Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	1.5
655385307	608431516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431516	20863444	Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.0
655385307	769170642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170642	20472929	Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Arthritis, Psoriatic as compared to genotypes AG + GG.	2.75
655385307	769170659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170659	20595278	Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	2.75
655385307	769170688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170688	20514079	Allele A is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
655385307	1448592699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448592699	27992285	Allele A is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	1.25
655385307	1449164930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164930	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.75
655385307	1449270267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270267	29589488	Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.	0.5
655385168	699642174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699642174	18496129	Allele C is associated with increased response to mirtazapine and venlafaxine in people with Depression as compared to genotype TT.	2.5
655385178	699642198	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642198	16293801	Genotype CT is associated with increased changes in FEV1 when treated with montelukast in people with Asthma as compared to genotype CC.	2.25
655385195	699642204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699642204	19151602	Genotype AG is associated with decreased response to montelukast in people with Asthma as compared to genotype GG.	1.75
655385195	1183699264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699264	23970434	Allele A is not associated with clearance of montelukast in healthy individuals as compared to allele G.	-0.125
655385210	731577503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/731577503	18794727	Genotype TT is associated with decreased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.	2.75
655385257	747926545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/747926545	18256692	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	2.25
655385262	747943548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/747943548	18256692	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.	2.25
655385262	748020560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748020560	18256692	Genotype GG is associated with increased risk of toxicity when treated with methotrexate in people with Psoriasis as compared to genotypes AA + AG.	2.75
655385267	747980551	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/747980551	18256692	Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.	2.75
655385267	1449557891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557891	29743634	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.0
655385272	747991835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/747991835	18256692	Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.	2.75
655385277	748006197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/748006197	18256692	Genotypes AG + GG are associated with decreased risk of onset of toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.	2.75
655385286	748042563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/748042563	18256692	Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.	2.25
655385299	613977129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977129	15677700	Allele G is associated with severity of Arthritis, Rheumatoid when treated with methotrexate.	1.5
655385299	827863300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863300	22450926	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.75
655385299	769160719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769160719	15457444	Genotype GG is associated with decreased disease activity as assessed by the physician when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	2.0
655385299	769173655	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173655	16947783	Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.	2.0
655385299	769171251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171251	18322994	Allele C is not associated with response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	-1.25
655385299	769173663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173663	16947783	Allele G is associated with increased likelihood of any adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	0.0
655385299	1447814502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814502	26799664	Allele C is not associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.5
655385299	1447814515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814515	26799664	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	2.25
655385299	1448266196	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266196	27676277	Genotypes CC + CG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.5
655385299	1448266227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266227	27676277	Genotypes CG + GG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.0
655385299	1448432602	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448432602	27885916	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.	3.25
655385299	1449164986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164986	27217051	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.75
655385299	1449557927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557927	29743634	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
655385299	1449752233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752233	29520081	Genotypes CG + GG is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	-2.0
655385323	769181620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769181620	15457444	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.0
655385328	751755636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751755636	19176441	Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. when treated with methotrexate as compared to allele A.	2.75
655385333	751776639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751776639	19176441	Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance when treated with methotrexate as compared to allele A.	2.75
655385338	751884916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/751884916	19037197	Genotype del/del is associated with increased response to metoprolol.	2.25
655385338	751923645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751923645	19037197	Genotype del/del is associated with increased plasma concentrations of metoprolol when treated with metoprolol.	1.25
655385352	769181593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769181593	19037197	Allele T is associated with increased plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. when treated with metoprolol as compared to allele C.	2.25
655385115	699639185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639185	18408560	Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.	2.25
655385115	699639192	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639192	18408560	Allele G is not associated with decreased response to salbutamol in people with Asthma as compared to allele A.	-2.0
655385115	1448634953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634953	18408560	Allele G is not associated with decreased response to salbutamol in people with Asthma as compared to allele A.	-1.5
655385361	981479899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981479899	21740768	Genotype AG is associated with increased likelihood of smoking initiation when exposed to nicotine in men.	1.25
655385361	981479907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981479907	21740768	Genotype GG is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine in men.	2.25
655385361	613977160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977160	19290018	Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	2.0
655385369	655387073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387073	15453913	Genotype AG is associated with response to irbesartan in people with Hypertension.	2.0
655385369	655387074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387074	15453913	Genotype GG is associated with response to irbesartan in people with Hypertension.	2.0
655385120	699639201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639201	18408560	Allele A is associated with decreased response to salbutamol in people with Asthma as compared to allele T.	2.5
655385120	699639212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639212	18408560	Allele A is not associated with decreased response to salbutamol in people with Asthma as compared to allele T.	-1.75
655385120	1448634923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634923	18408560	Allele A is not associated with decreased response to salbutamol in people with Asthma as compared to allele T.	-1.5
655385223	981501502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501502	20136638	Allele T is associated with decreased likelihood of subclinical acute rejection when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele C.	1.25
655385223	981934430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934430	22960765	Allele T is not associated with increased risk of rejection or affect graft function by 1 year after transplantation when treated with Calcineurin inhibitors and mycophenolate mofetil in people with Organ Transplantation as compared to genotype CC.	-2.0
655385223	981934528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934528	20679962	Allele T is not associated with increased risk of side effects when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.75
655385223	769262708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262708	21142914	Allele T is not associated with increased risk of acute cellular rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.5
655385223	731672567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/731672567	17851563	Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Transplantation as compared to genotype CC.	2.5
655385125	699639234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639234	12576843	Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT.	3.0
655385205	981862203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862203	19094200	Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.	0.0
655385205	731493498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/731493498	17156920	Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA.	2.0
655385205	1184753733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753733	25155931	Genotype GG is not associated with increased dose of morphine in infants as compared to genotypes AA + AG.	-0.25
655385205	1451094980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451094980	31967515	Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A.	2.75
655385205	1448612967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612967	28346387	Allele G is not associated with dose of morphine in people with Neoplasms as compared to allele A.	-1.25
655385205	1449173347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173347	29474345	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele G.	-1.75
655385205	1449182349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449182349	29259946	Allele G is not associated with dose of morphine in people with Pain as compared to allele A.	-1.5
655385205	1449295811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295811	23686330	Genotype AA is associated with decreased dose of morphine in people with Pain, Postoperative as compared to genotypes AG + GG.	2.0
655385205	1449295921	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449295921	26902643	Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A.	-1.5
655385241	747435525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/747435525	18004207	Genotypes AG + GG are associated with increased cortisol response when treated with naloxone as compared to genotype AA.	1.5
655385241	747714537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/747714537	11751037	Allele G is associated with increased cortisol response when treated with naloxone as compared to genotype AA.	1.5
655385241	747661534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/747661534	12627468	Genotypes AG + GG are associated with increased peak cortisol response when treated with naloxone as compared to genotype AA.	1.5
655385241	1449188836	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188836	16123758	Genotypes AG + GG is associated with increased response to naloxone as compared to genotype AA.	0.75
1449575633	1444700050	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700050	24648345	Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.	0.0
1449575633	1449575572	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575572	29769267	Allele C is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.	0.0
1449716951	1451241020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451241020	30094551	CYP2A6 *1/*1 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *9/*9 (assigned as poor metabolizers and intermediate metabolizers phenotype) .	2.0
1449716951	827864375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864375	21975350	CYP2A6 *1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12 are associated with decreased clearance of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1/*1.	2.75
1449716951	827704864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704864	21494765	CYP2A6 *1/*46 + *1/*46 + *46/*46 are associated with increased clearance of letrozole in women as compared to CYP2A6 *1/*4 + *1/*9 + *46/*4 + *46/*7 + *46/*9 + *4/*7 + *4/*9 + *7/*9 + *9/*9.	0.125
1449575668	1449575534	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575534	29769267	Allele G is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.	0.0
1449575668	1449575609	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575609	29769267	Allele G is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.	0.0
1449575690	1449575509	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575509	29769267	Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.	0.0
1449575690	1449575604	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575604	29769267	Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele G.	0.0
1449575696	1449575598	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575598	29769267	Allele T is associated with increased expression of DPYD protein in 293FT cells as compared to allele A.	0.0
1449713004	1449712956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449712956	30020991	HLA-A *11:01:01 is associated with increased risk of adverse events due to levetiracetam in people with Epilepsy.	3.25
1449575656	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575656	1444700024	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700024	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1449575656	1449575546	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575546	29769267	Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.	0.0
1449575662	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575662	1448125721	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125721	24648345	Allele T is not associated with activity of DPYD when assayed with fluorouracil as compared to allele C.	-0.0
1449575662	1449575540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575540	29769267	Allele T is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.	0.0
1449748511	1449748447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748447	29615122	Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.	2.25
1450371713	1450371578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371578	30457672	Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.25
1450373100	1450372702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372702	30874608	Genotype TT is associated with decreased response to atomoxetine, desvenlafaxine, duloxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Depression as compared to genotypes GG + GT.	2.5
1450373100	1450372709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372709	30874608	Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors in people with Depression as compared to genotypes GG + GT.	2.25
1450373628	1450373432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373432	30237583	Genotypes AG + GG is associated with decreased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.	1.5
1450373634	1450373559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373559	30237583	Genotype TT is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.	1.5
1450375692	1450375552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375552	30924126	Allele T is associated with increased response to allopurinol.	0.0
981237695	827828664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828664	19400747	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.	-1.5
981237695	827828804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828804	17083032	Allele A is associated with decreased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele T.	2.0
981238459	769169612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169612	11408373	Allele C is associated with decreased clearance of losartan.	0.0
981238459	769169634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169634	11823761	Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A.	1.0
981237922	769250001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250001	16220110	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	1.5
981237950	827824994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824994	22188361	Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.	-2.0
981237950	655386344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386344	19786980	Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes AG + GG.	2.5
981204890	769173001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173001	1969501	Allele A is associated with increased risk of Alcoholism when exposed to ethanol.	1.25
981204890	1450824129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450824129	27447243	Allele A is not associated with risk of Alcoholism due to ethanol as compared to allele G.	-1.5
981204890	1449192973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192973	8033754	Genotypes AA + AG is associated with increased likelihood of Alcoholism and Substance-Related Disorders as compared to genotype GG.	3.0
981204890	1450807074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807074	10490697	Allele A is not associated with risk of Alcoholism due to ethanol as compared to allele G.	-1.5
981204890	769173005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173005	17989061	Allele A is associated with increased risk of Alcoholism when exposed to ethanol.	0.5
981204890	1451133260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451133260	31702801	Allele A is not associated with risk of Alcoholism due to ethanol as compared to allele G.	-1.0
981204890	1449166478	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449166478	11054774	Allele A is not associated with risk of Alcoholism due to ethanol as compared to allele G.	-1.25
981204890	1449166552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449166552	1839129	Allele A is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele G.	2.5
981204890	1449166594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449166594	1979357	Allele A is not associated with risk of Alcoholism when exposed to ethanol as compared to allele G.	-1.5
981344897	769180358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180358	21386754	Genotype CC is associated with increased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype TT.	3.5
981352141	769165047	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769165047	19112496	Genotypes CT + TT are associated with increased risk of requiring a blood transfusion when treated with artesunate, chlorproguanil and dapsone in children with Malaria as compared to genotype CC.	0.0
981352141	769176539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176539	19690618	Genotype CT is not associated with increased risk of unsafe hemoglobin decreases or requirement for a blood transfusion when treated with artesunate, chlorproguanil and dapsone in children with Malaria.	-2.0
981352141	769176533	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176533	19690618	Genotype TT is associated with increased risk of severe/ unsafe hemoglobin decreases when treated with artesunate, chlorproguanil and dapsone in children with Malaria as compared to genotype CC.	0.0
827830327	827784888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784888	21961091	Genotype AC is associated with increased likelihood of non-response when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.	3.0
827831021	982033310	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033310	23651026	Genotype CC is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes CT + TT.	0.0
827831021	827803670	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803670	21521023	Genotype TT is associated with increased expression of CDA in PBMCs.	0.0
827831021	769245519	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769245519	21325291	Allele T is not associated with expression of CDA in CEPH cell lines.	-0.0
827831021	699639370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639370	19458626	Genotype TT is associated with increased risk of Death when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.	2.25
827831021	699639367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639367	19458626	Genotype TT is associated with decreased 5 year survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.	2.25
827831123	827807448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807448	18309947	Genotype GG is associated with increased severity of Diarrhea when treated with erlotinib in people with Neoplasms as compared to genotypes GT + TT.	2.25
827831417	613979640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613979640	19203783	Genotype CC is associated with increased progression-free survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + AC.	2.0
827831417	982046448	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046448	22761669	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	-0.875
827831417	827922747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827922747	22329723	Allele A is not associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to allele C.	-1.5
827831417	827922757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922757	22329723	Genotypes AA + AC are not associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC.	-1.5
827831417	827922767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922767	22329723	Genotypes AA + AC are not associated with increased risk of Death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC.	-1.5
827831417	769172559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172559	19362955	Genotypes AA + AC are associated with increased overall survival when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	-3.0
827831417	1449752300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752300	29662106	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	2.5
827831435	827814005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814005	21806386	Genotype AT is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.5
827831435	655388177	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388177	18717915	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype CC.	2.5
827831435	1185012207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012207	25240575	Genotypes AC + CC is associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotypes AA + CT.	1.5
827831435	1185012234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012234	25240575	Genotypes AC + CC is associated with decreased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes AA + CT.	1.5
827832280	981476550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981476550	16815314	Genotype CC is associated with increased response to metoprolol in people with Essential hypertension as compared to genotypes CG + GG.	2.25
827832280	981477795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477795	17496726	Genotype CC is associated with increased response to metoprolol in people with Heart Failure as compared to genotypes CG + GG.	1.75
827832280	982045219	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045219	20643254	Genotypes CG + GG are not associated with response to carvedilol or metoprolol in people with Heart Failure as compared to genotype CC.	-1.25
827832280	982045253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045253	20643254	Genotypes CG + GG are not associated with dose of metoprolol in people with Heart Failure as compared to genotype CC.	-0.25
827832280	1043859504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859504	21311897	Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotypes CG + GG.	1.5
827832280	748396572	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/748396572	12844134	Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.	2.0
827832280	827567343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567343	14534524	Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotype GG.	1.5
827832280	827567370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567370	12921807	Allele C is not associated with increased response to metoprolol in people with Heart Failure as compared to allele G.	-1.75
827832280	827603889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827603889	15735607	Genotypes CG + GG are associated with increased likelihood of requiring more heart failure medication when treated with metoprolol in people with Heart Failure as compared to genotype CC.	2.25
827832280	827816261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816261	22192668	Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.	3.0
827832280	1451107261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451107261	31090079	Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G.	-1.75
827832280	1449004542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004542	29095089	Genotype CC is not associated with decreased heart rate when treated with metoprolol in people with as compared to genotypes CG + GG.	-1.75
1451415425	1451414860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451414860	32483200	Genotypes CT + TT are associated with increased dose of lamotrigine in people with Epilepsy as compared to genotype CC.	2.75
827847788	827793307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827793307	21449681	Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	1.75
827847788	769166391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166391	20078613	Genotype GG is associated with increased progression free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	0.0
827847788	1184886901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886901	25232828	Allele G is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.	-0.25
827847788	1444694879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694879	25545243	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	-1.5
827847788	1448263434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263434	27636246	Genotype GG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	1.75
827847788	1448522297	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522297	20530282	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
827847788	1448568344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568344	27995989	Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG.	-1.5
981188336	1451504521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451504521	22074251	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.5
981188336	769170720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170720	18368069	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-1.0
981188336	769171272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171272	12972956	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.0
981188336	608431580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431580	14647408	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.0
981188336	769171263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171263	11937185	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased progression free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	3.0
981188336	769171359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171359	12651279	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is not associated with increased risk of relapse when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.25
981188336	769170729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170729	15713801	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased risk of CNS relapse or hematologic relapse when treated with asparaginase, cytarabine, daunorubicin, etoposide, mercaptopurine, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.5
981188336	769174427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174427	16130010	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	This annotation is not used for clinical annotation scoring. Cohort overlap with PMID 11937185
827847738	827573981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827573981	21606946	Genotypes AA + AT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	3.25
827847744	827812125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827812125	21635146	Genotype TT is associated with increased likelihood of overall survival or progression-free survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.	2.5
827847744	827812110	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812110	21635146	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.	2.75
827847744	1451124640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124640	31611591	Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Liver Neoplasms as compared to genotypes GG + GT.	2.0
827847751	827815660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815660	21691274	Genotype CC is associated with increased Depression when treated with peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827847751	827815673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815673	21691274	Genotype CC is not associated with increased Depression when treated with peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.5
827847768	769164968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769164968	19859084	Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
827848563	827836674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827836674	20538124	Genotype GG is associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AG.	2.75
827848725	827815689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815689	21628669	Allele G is associated with increased kidney tubular dysfunction when exposed to tenofovir as compared to allele A.	2.5
827849079	1450936365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936365	16985250	Genotypes CT + TT are associated with increased likelihood of Endometrial Neoplasms when treated with conjugated estrogens as compared to genotype CC.	0.0
827849095	827826967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826967	21570397	Allele A is associated with increased likelihood of drug induced liver injury when treated with amoxicillin and clavulanate in people with Drug Toxicity as compared to allele T.	0.0
827848555	827805749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805749	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
827848555	1448109295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109295	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-1.5
981201399	1447673706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673706	26535588	Genotypes AA + AG are not associated with glomerular disease when exposed to tenofovir in people with HIV Infections as compared to genotype GG.	-2.0
981201399	1447682948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682948	26807589	Allele A is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele G.	-1.75
981201399	827828651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828651	19400747	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.	-1.5
981201399	827828798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828798	17083032	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.	2.0
981201399	1444667374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667374	25485598	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.	-1.25
827849109	769258178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769258178	21502966	Allele G is associated with increased anti-IFN-beta antibodies when treated with interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.	2.5
978639596	655387159	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387159	14534525	Allele C is associated with increased metabolism of repaglinide in healthy individuals as compared to allele T.	1.5
981188353	769164791	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164791	15761113	Allele G is associated with increased glucuronidation of valproic acid.	0.0
981188353	827812626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812626	21806385	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.	2.5
981188353	827812675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812675	21806385	Genotype AG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.	2.5
981188379	981785462	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785462	18538445	Genotype AA is not associated with increased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	-1.25
981188379	981793960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981793960	20665488	Genotype AA is associated with decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms.	-2.5
981188379	827641523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827641523	21625252	Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	1.75
981188379	1183634368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634368	22546611	Genotypes AC + CC are associated with increased risk of severe neutropenia due to gemcitabine in people with Neoplasms as compared to genotype AA.	-1.5
981188379	1183700709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700709	18347182	Genotype AA is associated with increased risk of toxicity due to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	1.75
981188379	1450373681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373681	30889042	Genotypes AC + CC are associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	2.75
981201333	637880031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880031	16788380	Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.	-0.25
981201333	827812838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827812838	22158333	Genotype GG is associated with increased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to genotypes AA + AG.	2.5
981201333	769170841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170841	18006781	Allele A is associated with cytotoxicity of egfr inhibitors.	0.0
981201333	1184510737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510737	23959273	Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-1.25
981201817	1447680436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680436	26774523	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CT.	-1.0
981201817	1447680725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680725	26779253	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	-1.0
981201817	769163503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163503	19371316	Genotype TT is not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections.	-0.75
981201817	827847979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827847979	22354160	Allele T is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele C.	-1.25
981201817	769163300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163300	20860463	Genotype CT is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	-0.5
981201817	769163136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163136	19779319	Genotypes CT + TT are not associated with increased plasma concentration (p=0.509) of efavirenz in people with HIV Infections as compared to genotype CC.	-0.75
981201817	1184473155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473155	24316028	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	1.25
981201817	1184473337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473337	23172109	Allele T is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	-2.0
981201864	981344509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344509	22990067	Genotypes AG + GG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	-1.75
981201864	981844074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844074	18004210	Genotypes AG + GG are not associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	-2.0
981201864	982029617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029617	23751603	Genotypes AG + GG are associated with increased platelet activation response to ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	2.25
981201864	982033197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033197	18577829	Genotypes AG + GG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	1.5
981201864	982034323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034323	19576320	Genotypes AG + GG are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype AA.	-1.75
981201864	699638704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638704	17803810	Allele G is associated with increased risk of Coronary Artery Disease as compared to allele A.	2.5
981201864	699638755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638755	16769602	Allele G is not associated with response to clopidogrel.	-1.5
981201864	699638765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638765	16581111	Allele G is not associated with response to clopidogrel as compared to allele A.	-1.5
981201864	699638805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638805	16181985	Genotypes AG + GG are not associated with response to clopidogrel as compared to genotype AA.	-1.5
981201864	699638814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638814	15795539	Allele G is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele A.	-1.75
981201864	699638721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699638721	16961627	Allele G is not associated with response to clopidogrel as compared to allele A.	-0.25
981201864	769169225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169225	16405973	Allele G is not associated with increased likelihood of Myocardial Infarction in people with Coronary Artery Disease as compared to allele A.	-1.0
981201864	769169222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169222	14662702	Allele G is associated with increased risk of Peripheral Vascular Diseases as compared to allele A.	1.5
981201864	769169273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169273	12912815	Allele G is associated with increased platelet aggregation.	1.25
981201864	827892728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892728	17337040	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	-2.0
981201864	1183699733	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699733	24262617	Allele G is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	-1.0
981201864	1448119331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119331	27380588	Allele G is not associated with platelet reactivity when treated with clopidogrel as compared to allele A.	-1.5
981201864	1448601657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601657	27566695	Genotype AA is associated with increased response to clopidogrel in people with Coronary Disease as compared to genotypes AG + GG.	2.0
981201864	1447986830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447986830	25730082	Genotypes AG + GG are associated with increased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.	2.0
981201895	827804313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827804313	21391884	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-0.5
981201895	827921768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921768	22630058	Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.	-2.0
981201895	769257578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257578	15857428	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-1.75
981201895	769257607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257607	16386926	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.	-1.5
981201895	769257621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257621	17521963	Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.	3.5
981201895	769257594	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257594	16542858	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.	-1.5
981201895	769257624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257624	12686700	Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.	-3.25
981201895	769257724	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257724	16753003	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.	0.0
981201895	769257735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257735	15452306	Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.	-2.0
981201895	769257755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257755	17125969	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.	-1.75
981201895	769257569	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257569	17306068	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-1.5
981201895	769171344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171344	19450124	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.	2.0
981201895	1183703357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703357	24300029	Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.	3.5
981201895	1183703365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703365	24300029	Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.	2.5
981201895	1444607282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607282	25458099	Allele G is not associated with resistance to antiepileptics in people with Epilepsy, Temporal Lobe as compared to allele A.	-1.5
981201895	769257584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257584	16004559	Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.	This annotation is not used for clinical annotation scoring. Association only seen as part of a haplotype.
981201937	608431741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431741	19794411	Allele T is not associated with dose of warfarin.	-1.0
981201937	827567352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567352	15883587	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.0
981201937	769168963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769168963	20694283	Allele T is not associated with dose of warfarin as compared to allele C.	-2.0
981201937	1184510620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510620	21195460	Genotype TT is associated with increased dose of warfarin as compared to genotype CC.	2.0
981201937	1184757043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184757043	25126975	Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele T.	-2.0
981201937	1444695613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695613	25681132	Genotypes CT + TT is not associated with dose of warfarin as compared to genotype CC.	-1.0
981201937	1444936331	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936331	26106580	Allele T is not associated with dose of warfarin as compared to genotype CC.	-1.0
981201937	1446765961	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765961	26257249	Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.	-1.5
981201937	1447677818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677818	26751406	Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.	-1.5
981201937	1448615525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615525	28429387	Genotypes CC + CT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype TT.	-3.0
981201937	1449246811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449246811	28049362	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
981202068	981239680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239680	22940005	Allele C is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele T.	-2.0
981202068	981478631	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478631	23150151	Allele T is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele C.	-2.0
981202068	981483583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483583	22723959	Allele T is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele C.	-1.25
981202068	981755512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755512	23418418	Genotypes CT + TT are associated with increased risk of cardiovascular events (composite of cardiac death, MI, stent thrombosis) in Korean patients after PCI when treated with clopidogrel as compared to genotype CC.	3.0
981202068	981755523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755523	23418418	Genotypes CT + TT are not associated with repeat revascularization when treated with clopidogrel as compared to genotype CC.	-2.0
981202068	981755532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755532	23418418	Genotypes CT + TT are not associated with clopidogrel on-treatment platelet reactivity (OPR) when treated with clopidogrel as compared to genotype CC.	-2.5
981202068	981755541	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755541	23418418	Genotypes CT + TT are associated with increased small-dense LDL levels when treated with clopidogrel as compared to genotype CC.	1.5
981202068	981794335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794335	21685174	Allele T is not associated with increased residual platelet aggregation when treated with clopidogrel in people with elective coronary stent placement as compared to allele C.	-2.0
981202068	981794345	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794345	21685174	Genotype TT is not associated with increased risk of cardiovascular events when treated with clopidogrel in people with elective coronary stent placement as compared to genotype CC.	-2.0
981202068	981794355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794355	21972404	Allele T is not associated with clopi-H4 formation or antiplatelet response after 300 or 900 mg clopidogrel loading dose when treated with clopidogrel in men with Myocardial Infarction as compared to allele C.	-1.5
981202068	981794365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794365	21972404	Genotype TT is not associated with increased risk of major cardiovascular events or occurrence of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	-1.75
981202068	981794421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794421	22520065	Genotype TT is not associated with biologigical response to clopidogrel when treated with clopidogrel as compared to allele C.	-1.0
981202068	981794431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794431	22520065	Genotype TT is not associated with increased risk of major cardiovascular events (MACE) when treated with clopidogrel as compared to allele C.	-1.0
981202068	981798663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981798663	22374717	Allele T is not associated with clopidogrel active metabolite formation and antiplatelet response after a single dose when treated with clopidogrel in healthy individuals as compared to allele C.	-0.25
981202068	981800640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981800640	22427735	Genotype TT is not associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-1.5
981202068	981802559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802559	22368149	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.	-2.0
981202068	981802814	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802814	23346768	Allele C is not associated with maximum platelet aggregation (MPA) or the anti-platelet effect of clopidogrel in Chinese stroke patients when treated with clopidogrel in people with Stroke as compared to allele T.	-1.5
981202068	981843527	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843527	21918510	Genotype TT is not associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype CC.	-2.0
981202068	981843579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843579	22624833	Allele T is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-2.0
981202068	981843623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843623	22624833	Genotype CC is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	-2.0
981202068	981843691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843691	22190063	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.	-2.0
981202068	769258865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769258865	21527445	Allele T is not associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-2.0
981202068	827714744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827714744	21918510	Genotype TT is not associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype CC.	-2.0
981202068	827784037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784037	21881565	Allele C is not associated with ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele T.	-2.0
981202068	827784078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784078	21881565	Allele C is not associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele T.	-2.0
981202068	827814062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814062	21806387	Allele C is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele T.	-1.5
981202068	827814135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814135	21819538	Genotype CC is associated with decreased on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI) when treated with clopidogrel in people with Myocardial Ischemia as compared to genotypes CT + TT.	2.25
981202068	827919665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919665	22462746	Genotype CC is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	-1.25
981202068	769164682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164682	21170047	Genotype TT is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	4.0
981202068	1183699744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699744	24262617	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	-1.0
981202068	1183703509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703509	22974728	Genotypes CT + TT is associated with increased ADP-induced platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	2.25
981202068	1183703525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703525	22974728	Genotypes CT + TT is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	2.75
981202068	1183705608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705608	24535487	Allele T is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele C.	-1.5
981202068	1184168874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168874	23726091	Genotypes CC + CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	-1.75
981202068	1184472145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472145	22028352	Genotypes CC + CT is not associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.	-1.75
981202068	1184472513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472513	22285300	Allele C is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele T.	-1.75
981202068	1184473150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473150	23993903	Genotypes CT + TT is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.	2.5
981202068	1184473186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473186	23993903	Genotypes CT + TT is not associated with ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.	-1.5
981202068	1184747724	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747724	24504666	Genotype TT is not associated with response to clopidogrel in people with Cardiovascular Diseases as compared to genotypes CC + CT.	-1.75
981202068	1184990053	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184990053	25329996	Allele T is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to allele C.	-1.5
981202261	827824467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824467	22256867	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	-2.0
981202261	827824547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824547	22256867	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.	-1.75
981202261	827845000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845000	21449672	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.	-2.0
981202261	827921753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921753	22630058	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	2.5
981202261	1184999857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999857	25155934	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	-1.75
827848548	655387580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387580	19696793	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.	2.75
978608464	699642245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642245	19005482	Allele A is associated with graft vs host disease when treated with cyclosporine and methotrexate in people with recipients of HLA-identical hematopoietic stem cell transplantation.	1.0
978608464	769146358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146358	16920564	Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	3.25
827923032	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
827923032	1184988306	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988306	20952418	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
827923032	1184988061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988061	20338069	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.75
827923032	1184233697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233697	24145522	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections.	0.0
827923032	1446905193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905193	25611810	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	1447680376	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680376	26774523	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.5
827923032	1447680746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680746	26779253	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	1448104256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104256	27299708	Genotype GG is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	1.5
827923032	1448107499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107499	26196596	Genotype GG is associated with increased dose of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	0.0
827923032	981478640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478640	22471906	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	981480729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981480729	22927450	Genotype TT is associated with increased exposure of efavirenz in women with HIV Infections as compared to genotypes GG + GT.	2.5
827923032	982046514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046514	23080225	Allele T is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele G.	2.5
827923032	827692937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827692937	20860463	Genotype TT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	827695744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695744	15864119	Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	827807674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807674	18281305	Allele T is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele G.	2.5
827923032	827811199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811199	20723261	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	827922951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922951	15622315	Allele T is associated with increased plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy when treated with efavirenz in people with HIV Infections as compared to allele G.	2.0
827923032	769162981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162981	20860463	Genotypes GT + TT are associated with increased PBMC-associated drug concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	769163543	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163543	16267764	Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.	2.75
827923032	769163473	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163473	19371316	Genotype TT is associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	769163086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163086	19779319	Genotype TT is associated with increased plasma concentration (p<0.001) of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	769162974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162974	15864119	Genotype TT is associated with increased intracellular PBMC exposure of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1183491412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491412	23254426	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1183491417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491417	23254426	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	2.0
827923032	1183491421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491421	23254426	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1183634127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634127	23970651	Genotype GT is associated with increased plasma level of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1183634159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634159	24080498	Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.25
827923032	1184233832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233832	24551111	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.5
827923032	1184349348	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349348	20625352	Genotypes GT + TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184471312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471312	19659438	Genotype TT (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG (assigned as normal metabolizer phenotype) .	1.5
827923032	1184471369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471369	19659438	Allele T (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele G (assigned as normal metabolizer phenotype) .	1.5
827923032	1184472014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472014	24551111	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	3.0
827923032	1184473116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473116	24316028	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1184473123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473123	24316028	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.25
827923032	1184473161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473161	24316028	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele G.	1.75
827923032	1184473237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473237	23399569	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184473241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473241	23399569	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GT.	1.25
827923032	1184473245	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473245	23399569	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1184473309	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473309	23172109	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1184473321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473321	23172109	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	2.0
827923032	1184511673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511673	20441246	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.	0.25
827923032	1184512470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512470	22057858	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	0.0
827923032	1184987905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987905	24956253	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.	0.0
827923032	1185234900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234900	25303294	Genotypes GT + TT is associated with concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1451122240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451122240	32209837	Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.	2.0
827923032	1451127146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451127146	31628422	Genotypes GT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype GG.	1.0
827923032	1451131980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451131980	32106141	Genotype TT is associated with decreased metabolism of efavirenz in women with HIV Infections as compared to genotype GG.	0.125
827923032	1444698851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698851	25669165	Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.	2.5
827923032	1448265859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448265859	27655857	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	1.0
827923032	1448633511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633511	28145050	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448636173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636173	28692529	Genotypes GT + TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923032	1448663995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448663995	28816644	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1448684688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448684688	28187506	Genotypes GT + TT are associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	1.0
827923032	1448821568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821568	28718515	Genotypes GT + TT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.5
827923032	1448993476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993476	24521642	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.75
827923032	1448993691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993691	25974723	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448993700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993700	19218571	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.75
827923032	1448994222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994222	22950382	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448994415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994415	28886044	Genotype TT is associated with increased concentrations of efavirenz in children with HIV Infections.	1.5
827923032	1448995933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995933	18728241	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	1.5
827923032	1448995941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995941	17918089	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.25
827923032	1448997108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997108	26831894	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	0.125
827923032	1448997129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997129	26107645	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997148	25889207	Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448997209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997209	25882300	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923032	1448997218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997218	25831219	Genotypes GT + TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997225	25501988	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	0.125
827923032	1448997232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997232	24831655	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1448997239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997239	24299220	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923032	1448997257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997257	22481606	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1448997449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997449	20841522	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.0
827923032	1448997462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997462	20720517	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.5
827923032	1448997483	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997483	19704172	Genotypes GT + TT are associated with increased concentrations of efavirenz as compared to genotype GG.	1.5
827923032	1448997489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997489	19531981	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.25
827923032	1448997496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997496	19433561	Genotypes GT + TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	0.125
827923032	1448997672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997672	19124658	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	1.5
827923032	1448997679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997679	18784455	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.0
827923032	1448997691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997691	18057928	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	0.0
827923032	1448997712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997712	17968817	Genotype GT is associated with increased concentrations of efavirenz in women HIV Infections as compared to genotype GG.	0.0
827923032	1448997743	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997743	17047492	Genotypes GT + TT are associated with increased exposure to efavirenz in people with HIV Infections as compared to genotype GG.	2.25
827923032	1448997777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997777	16495778	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	1.25
827923032	1448997797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997797	16392089	Genotype TT is associated with increased exposure to efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.0
827923032	1448998426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998426	15825040	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923032	1448998441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998441	15668854	Genotype TT is associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	0.125
827923032	1448998466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998466	16857630	Genotype GT is associated with increased concentrations of efavirenz in men with HIV Infections as compared to genotype GG.	0.125
827923032	1448998482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998482	18839779	Genotypes GT + TT are associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	0.125
827923032	1448998489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998489	19474465	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	1.75
827923032	1449156764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449156764	23763943	Genotype GT is associated with increased concentrations of efavirenz as compared to genotype GG.	0.125
827923032	1449275102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449275102	29624706	Genotype TT is associated with increased concentrations of efavirenz in people with Hepatitis B and HIV Infections as compared to genotypes GG + GT.	0.0625
827923042	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
827923042	827695756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695756	15864119	Genotype TT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.	2.75
827923042	827695768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695768	15864119	Genotype TT is associated with increased likelihood of Fatigue when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.	3.0
827923042	827811208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811208	20723261	Genotype TT is not associated with increased likelihood of Drug Toxicity when treated with efavirenz, lamivudine and stavudine in people with HIV Infections as compared to genotypes GG + GT.	-1.25
827923042	827922504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922504	21715435	Genotype TT is associated with early (< 3 months) termination of efavirenz therapy when treated with efavirenz as compared to genotypes GG + GT.	3.25
827923042	827922962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922962	15622315	Allele T is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele G.	2.0
827923042	1183614660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183614660	23859571	Allele T is associated with risk of central nervous system adverse side effects when treated with efavirenz in people with HIV Infections as compared to allele G.	2.5
827923042	1183634134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634134	23970651	Genotype GT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotype GG.	1.75
827923042	1183634227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634227	24080498	Genotypes GT + TT are not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.75
827923042	1184473278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473278	24517233	Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in men with HIV Infections.	2.5
827923042	1184987941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987941	24956253	Allele T is associated with increased likelihood of Disorders of Excessive Somnolence when treated with efavirenz in people with HIV Infections.	2.0
827923042	1448265875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265875	27655857	Allele T is not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele G.	-0.25
827923042	1448633500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633500	28145050	Genotypes GT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	0.0
827923042	1448636188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636188	28692529	Genotype TT is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-2.0
827923042	1448993680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993680	25974723	Genotype TT is not associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.5
827923042	1448993713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993713	19218571	Genotype TT is not associated with increased risk of Central Nervous System Diseases when treated with efavirenz or nevirapine in people with HIV Infections.	-1.5
827923042	1448994229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994229	22950382	Genotypes GT + TT are not associated with increased risk of Depression when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.25
827923042	1448997115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997115	26831894	Genotypes GT + TT are associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in children with HIV Infections as compared to genotype GG.	0.25
827923042	1448997441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997441	21633320	Genotype TT is associated with increased likelihood of Epilepsy, Absence when treated with efavirenz in children with HIV Infections as compared to genotype GG.	0.25
827923042	1448997475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997475	20441246	Genotype TT is associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	0.25
827923042	1448997704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997704	17968817	Genotype GT is associated with increased likelihood of Psychotic Disorders when treated with efavirenz in women HIV Infections as compared to genotype GG.	0.25
827923042	1448998433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998433	15668854	Genotype TT is associated with increased likelihood of Psychotic Disorders when treated with efavirenz in women with HIV Infections as compared to genotype GG.	0.25
827923042	1448998455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998455	16857630	Genotype GT is associated with Central Nervous System Diseases when treated with efavirenz in men with HIV Infections as compared to genotype GG.	0.25
827923042	1449156598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156598	28492729	Genotypes GT + TT are not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	-1.0
827923042	1449156613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156613	25889207	Allele T is not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele G.	-1.5
827923042	1449156651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156651	20720517	Genotypes GT + TT are associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.	2.0
827923042	1449156692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156692	17356468	Genotypes GT + TT are not associated with Drug Toxicity when treated with efavirenz in children with HIV Infections as compared to genotype GG.	-1.25
827923042	1449156706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156706	18503405	Genotype GT is associated with Sleep Disorders when treated with efavirenz as compared to genotype GG.	0.25
827923042	1449156714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156714	18655316	Allele T is associated with Status Epilepticus when treated with efavirenz as compared to allele G.	0.25
827923042	1449156757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156757	23763943	Genotype GT is associated with increased risk of Toxic liver disease when treated with efavirenz as compared to genotype GG.	0.25
827923042	1184168515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168515	23734829	CYP2B6 *1 is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV as compared to CYP2B6 *6.	-1.5
981201535	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201535	1449161585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161585	29239269	Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	-3.0
981201535	1447987449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987449	22490566	Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
981201535	981398678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981398678	19473056	Genotypes CC + CT are associated with decreased likelihood of Neutropenia when treated with fluorouracil in women with Neoplasms as compared to genotype TT.	-2.25
981201535	769169640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169640	19104657	Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.	2.75
981201535	827892931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892931	14635116	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	0.0
981201535	1447945605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945605	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201535	1447991474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991474	11156223	Allele C is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.25
981201535	1448119062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119062	18299612	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
981201535	1448122697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122697	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
981201535	1448123099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123099	20819423	Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	0.0
981201535	1448124184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124184	23736036	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201535	1448124647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124647	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-2.0
981201535	1448126260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126260	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele T.	-2.0
981201535	1448262663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262663	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201535	1449161605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161605	29239269	Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.	-2.5
981201535	1449162069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162069	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981201535	1449732006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732006	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
981201535	1450371940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371940	30723313	Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	-2.0
981201981	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201981	769169883	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169883	17848752	Genotype AG is associated with increased likelihood of Nausea and Vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	1.75
981201981	1451287140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451287140	17848752	Genotype AG is not associated with increased likelihood of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.25
981201981	1447676563	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676563	24434920	Allele G is associated with increased risk of hand-foot syndrome, Photophobia and Unspecified conjunctivitis when treated with fluorouracil in women with Rectal Neoplasms.	0.25
981201981	1447945354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945354	26846104	Genotypes AG + GG is associated with increased Infection, nephrotoxicity and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	2.0
981201981	981390734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981390734	19473056	Genotypes AG + GG are associated with decreased likelihood of overall gastrointestinal toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	2.0
981201981	827892796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892796	17121937	Genotypes AG + GG are not associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.75
981201981	827892947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892947	14635116	Genotype AG is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	-1.5
981201981	1450951020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951020	23481061	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Head and Neck Neoplasms as compared to allele A.	-0.25
981201981	1450951420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951420	27752409	Genotype AG is associated with increased risk of Cardiomyopathies when treated with fluorouracil in people with Rectal Neoplasms.	0.25
981201981	1450952670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952670	11156223	Allele G is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms.	0.25
981201981	1450953284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953284	20819423	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele A.	-1.0
981201981	1450954100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954100	18299612	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.25
981201981	1450954546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954546	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.5
981201981	1448126278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126278	26794347	Allele G is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele A.	-2.0
981201981	1448262652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262652	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201981	1449162062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162062	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
981201981	1449731947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731947	30114658	Genotypes AA + AG is associated with decreased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.0
981201981	1449732144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732144	29998006	Genotypes AA + AG is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms as compared to genotype GG.	-2.0
981202294	827861835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827861835	21441248	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	0.0
981202294	1448108757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108757	27195527	Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.	2.5
981202294	981240255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240255	22680342	Allele T is associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele G.	2.0
981202294	827784211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784211	21860339	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	0.0
981202294	827807692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807692	18281305	Allele T is associated with increased plasma concentration of nevirapine in people with HIV Infections as compared to allele G.	2.0
981202294	827823670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823670	22111602	Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	1.5
981202294	827848013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848013	22354160	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	0.0
981202294	827848956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848956	19228205	Genotype GT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.5
981202294	827848963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848963	19228205	Genotype TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.5
981202294	827849230	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827849230	21393201	Genotype TT is associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotypes GG + GT.	2.0
981202294	769163522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163522	15864119	Genotype TT is associated with increased plasma exposure of nevirapine in people with HIV Infections as compared to genotype GG.	1.75
981202294	1183491986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491986	23982262	Genotype TT is associated with increased nevirapine AUC0-6 h when treated with nevirapine in people with HIV Infections as compared to genotypes GG + GT.	0.125
981202294	1184349353	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349353	20625352	Genotypes GT + TT is not associated with metabolism of nevirapine in people with HIV Infections as compared to genotype GG.	-0.5
981202294	1296598965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598965	24217698	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	2.0
981202294	1448110402	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448110402	26348712	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	2.0
981202294	1448993707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993707	19218571	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	1.75
981202294	1449001754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449001754	28947469	Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	2.5
981202609	1451258120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451258120	24967362	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	3.0
981202609	769153041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769153041	20847201	Allele C is associated with decreased risk of Disease Activity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.5
981202609	769173673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769173673	19193698	Allele C is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	2.25
981202609	1448266203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266203	27676277	Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
981202609	1448589833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448589833	27992285	Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	1.625
981202714	769170910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170910	12623934	Allele T is associated with decreased absolute mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.25
981202714	1451341865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451341865	23863317	Genotypes GT + TT is associated with increased response to hydrochlorothiazide as compared to genotype GG.	1.0
981202714	827921263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921263	14553962	Allele T is not associated with response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.	-2.0
981202714	827923882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923882	9149697	Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG.	2.25
981202714	827923903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923903	10523341	Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.75
981202714	827923924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923924	11882573	Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.75
981202714	827924535	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924535	19057513	Allele T is associated with decreased reduction in ambulatory SBP when treated with hydrochlorothiazide in men with Hypertension as compared to allele G.	0.0
981202714	827924748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924748	18591455	Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.	3.0
1451415660	1450823574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823574	31108563	HLA-DRB1 *08:03:02 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations.	1.0
1451415660	1451415580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415580	32963330	HLA-DRB1 *08:03:02 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.	3.25
981755820	981478774	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478774	22383668	Genotype del/del is associated with lack of treatment response when treated with ivacaftor in people with Cystic Fibrosis.	0.0
981755820	1449154713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154713	29099333	Genotype CTT/del is associated with increased response to ivacaftor in people with Cystic Fibrosis.	-3.25
981755820	1449191199	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191199	23891399	Allele del is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
981755820	981755776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755776	22293084	Allele del is associated with decreased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755820	981755766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755766	22942289	Allele del is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755820	981755725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755725	21602569	Allele del is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755820	981755710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755710	19846789	Allele del is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
981755820	1447981017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447981017	26968770	Allele del is associated with increased response to ivacaftor in people with Cystic Fibrosis.	This annotation is not used for clinical annotation scoring.
981755820	1449192540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449192540	25148434	Allele del is not associated with protein stability of CFTR when treated with ivacaftor.	-0.0
981204695	1451351843	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451351843	31160146	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.	-0.25
981204695	1451353640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353640	32344532	Genotype AG is associated with increased response to naltrexone in men with hypersexuality state and Parkinson Disease.	0.25
981204695	827785851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785851	21946895	Allele G is not associated with treatment success on any of the outcome measures when treated with naltrexone in people with Alcoholism as compared to allele A.	-1.25
981204695	827805932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805932	21900886	Genotypes AG + GG are associated with increased blunting of alcohol craving when treated with naltrexone in healthy individuals as compared to genotype AA.	1.5
981204695	827806034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827806034	21900886	Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.	1.5
981204695	769171526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171526	18250251	Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.	2.5
981204695	1450811334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811334	16960700	Genotypes AG + GG are associated with decreased response to naltrexone in people with Tobacco Use Disorder as compared to genotype AA.	0.0
981204695	1450821424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821424	25410894	Genotypes AG + GG are not associated with response to naltrexone in people with Alcoholism as compared to genotype AA.	-0.75
981204695	1450928668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928668	29265379	Allele G is not associated with response to naltrexone as compared to allele A.	-1.25
981204695	1451113700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451113700	31206155	Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A.	-1.75
981204695	1451141783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141783	31961981	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.	-1.0
981204695	1451143900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451143900	32020635	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.	-1.25
981204695	1444697966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444697966	25715171	Allele G is not associated with response to naltrexone in people with Alcoholism and Depressive Disorder, Major.	-1.5
981204695	1444827662	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827662	25760804	Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A.	-1.5
981204695	1449161179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161179	22551036	Allele A is not associated with response to naltrexone in people with Alcoholism as compared to allele G.	-1.25
981204695	1449181636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449181636	22515274	Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.	1.375
981204695	1449188815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188815	24729984	Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.	2.5
981237907	827814638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814638	21628662	Genotype CC is associated with requirement for earlier dose reduction of ribavirin when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes AA + AC.	1.25
981237907	827815123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815123	21503919	Genotype CC is associated with cumulative reduction of ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	3.0
981237907	827815133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815133	21503919	Genotype CC is associated with decreased frequency of patients who received at least the recommended 80% of scheduled ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.5
1451415686	1451415607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415607	32963330	HLA-DQB1 *06:01:01 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.	2.75
1451415691	1451415621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415621	32963330	HLA-DQA1 *01:03:01:01 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.	2.75
1451415680	1451415601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415601	32963330	HLA-B *39:01:01:01 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.	3.0
1451416140	1451404786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451404786	33774263	Genotype AA is associated with increased risk of Apnea due to succinylcholine as compared to genotype GG.	0.25
1451416140	1451415720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415720	33024248	Genotype AA is associated with increased risk of Apnea when treated with succinylcholine.	0.25
981238370	978639846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639846	22838948	Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
981238370	769170716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170716	18368069	Genotype AG is associated with decreased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.	1.75
981238370	769174314	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769174314	15797993	Genotype AA is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.	0.0
1451416400	1451416180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451416180	33097827	Genotypes CC + CT is associated with increased response to antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype TT.	0.0
1451416400	982028673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028673	23733030	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.0
1451416400	982028679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028679	23733030	Genotype CC is not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.0
1451416400	1445296437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296437	25108775	Allele C is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	-1.0
1451416408	1451416260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451416260	33097827	Genotype CC is associated with increased risk of adverse events when treated with antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotypes CT + TT.	1.125
981237900	1448123009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123009	27386433	Allele C is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	-1.5
981237900	1449147143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147143	28834135	Allele A is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele C.	-0.25
981237900	1449564081	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449564081	29790415	Allele C is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	0.0
981237900	827864536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827864536	21186350	Allele C is associated with treatment success, achieving an HbA1c below 7% when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	0.0
981237900	978614975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614975	22751958	Allele C is not associated with increased response to metformin as compared to allele A.	-2.0
981237900	1183574189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183574189	22453232	Allele C is associated with increased treatment success when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	1.75
1451416422	1451416300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451416300	33097827	Genotypes AA + AG is associated with decreased risk of adverse events when treated with antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype GG.	1.5
1451416434	1451416321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451416321	33097827	Genotype GG is associated with increased response to antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype AA.	0.0
1451416434	982028703	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028703	23733030	Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	-1.0
1451416434	982028711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028711	23733030	Genotype GG is not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	-1.0
1451416434	637880422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880422	20453658	Allele A is associated with increased resistance when treated with antidepressants in people with Depressive Disorder, Major as compared to allele G.	0.0
1451416434	637880323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880323	19924111	Allele G is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to allele A.	2.25
1451416434	1445296428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296428	25108775	Genotypes AG + GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.	1.25
981238025	827811288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811288	20179710	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.	3.0
981238025	1449576782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576782	29938344	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	-1.5
981240029	981240002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240002	22385882	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.0
981240029	981240017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240017	22385882	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	1.75
981240029	827641446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641446	11318841	Allele T is not associated with decreased response to sulfonamides, urea derivatives.	-1.0
981240029	1184470119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470119	24442125	Allele C is not associated with risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	-0.5
981240029	1184470130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470130	24442125	Allele C is not associated with dose of glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	-1.5
981240029	1184470143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470143	24442125	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele T.	-1.5
981240029	1185235790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235790	25115353	Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.	2.0
1451416940	1451416846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451416846	33462346	UGT1A1 *28 is associated with increased risk of Thrombocytopenia when treated with FOLFIRINOX in people with Pancreatic Neoplasms as compared to UGT1A1 *1.	3.0
1451416946	1451416852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451416852	33462346	Genotype CC is associated with increased risk of Nausea when treated with gemcitabine and paclitaxel in people with Pancreatic Neoplasms as compared to genotypes AA + AC.	2.25
1451417123	1451417063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451417063	33589792	Genotypes AA + AG are associated with decreased concentrations of temozolomide in people with Glioma as compared to genotype GG.	1.25
1451418220	1183701619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701619	8451774	CYP2D6 poor metabolizer is associated with decreased demethylation clearance of desmethylcitalopram when treated with citalopram in healthy individuals as compared to CYP2D6 normal metabolizer.	0.75
1451418220	1183701655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701655	8835706	CYP2D6 poor metabolizer is associated with increased ratio of desmethylCIT/N-didesmethylCIT plasma when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.	0.0
1451418220	982046960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046960	11802100	CYP2D6 *1/*4 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	-0.125
1451418220	1183701546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701546	23981149	CYP2D6 *1/*10 + *10/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451418220	1183847020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183847020	19840783	CYP2D6 *1/*4 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451418260	1183624260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624260	14652703	CYP2D6 *1xN + *2xN are associated with decreased response to citalopram, mianserin, mirtazapine, nortriptyline, paroxetine or venlafaxine in people with Mood Disorders.	2.0
1451418260	1183921586	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183921586	22775532	CYP2D6 *1/*1xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	-0.25
1451418281	1183617434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617434	18070221	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	2.5
981239544	981239480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239480	14765194	Allele G is associated with increased dose of warfarin as compared to allele A.	0.25
981239544	981239514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239514	18234403	Allele G is associated with increased dose of warfarin as compared to allele A.	0.0
981202598	637880058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880058	18349392	Genotype AA is associated with decreased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotype GG.	3.0
981202598	827697915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827697915	21673069	Genotype GG is associated with increased likelihood of complete pathologic response when treated with cetuximab in people with Rectal Neoplasms as compared to genotype AA.	2.5
981202598	637880035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880035	16788380	Genotype AA is associated with increased survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	0.25
981202598	1184510753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510753	23959273	Genotype AA is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	-1.25
981202598	1449165351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165351	27897268	Allele G is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A.	-0.75
981202618	982047201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047201	22695756	Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.	-2.5
981202618	655386671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386671	17548664	Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG.	2.5
981202618	655386700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386700	18192898	Genotype GG is associated with increased likelihood of relapse when treated with nicotine.	3.0
981202618	655386691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386691	18192898	Genotype AG is associated with increased likelihood of relapse when treated with nicotine.	2.0
981202618	1447675314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675314	26555332	Genotype AA is associated with increased likelihood of cessation when treated with Drugs used in nicotine dependence in people with as compared to genotypes AG + GG.	0.0
981220481	769174403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174403	19159907	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in children with Osteosarcoma as compared to genotypes AG + GG.	2.25
981220481	982029634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029634	23314736	Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG.	2.75
981220481	769176384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176384	20819423	Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	-1.25
981220481	769176385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176385	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	1.75
981220481	1448568374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568374	27995989	Genotype AA is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.	-1.5
981475986	981475086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475086	17375033	Genotype (CA)16/(CA)16 is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes (CA)16/(CA)17 + (CA)17/(CA)17.	1.75
981475986	981475152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475152	19201048	Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased response rate (RR) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.	2.25
981475986	981475175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475175	19473722	Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased median survival time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.	1.75
981475986	981475186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475186	17597605	Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased better clinical response when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.	1.75
981202393	1451634560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634560	34346513	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	This annotation is not used for clinical annotation scoring. Variant not in HWE
981202393	981202405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981202405	18368069	Genotypes AG + GG are associated with increased likelihood of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	1.75
981345293	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
981345293	1451226263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226263	30549267	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.	1.0
981345293	1451451120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451120	26744986	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.	1.75
981345293	982042588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042588	15226675	Genotype CT is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype TT.	1.5
981345293	982043146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043146	16722833	Genotype CT is not associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.125
981345293	982043158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043158	16722833	Genotype CT is associated with increased metabolism of pravastatin in children with Transplantation as compared to genotype TT.	-1.0
981345293	827826991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826991	15116054	Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.	1.0
981345293	827827131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827131	16678544	Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.	1.0
981345293	827827157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827157	17015053	Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.	1.5
981345293	827827440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827440	17622941	Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.	1.5
981345293	769170865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170865	12811365	Allele C is associated with decreased metabolism of pravastatin in healthy individuals as compared to allele T.	0.125
981345293	827827514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827514	19776292	SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.	1.75
981345293	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
981345293	1451451060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451060	17047488	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
981345293	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
981345293	982043980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043980	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA on rs4149056.
981345293	982043959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043959	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
981345293	982043998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043998	17622941	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
981345293	982044004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044004	17622941	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. Duplicate scoring with VA on rs4149056.
1451264120	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264120	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264120	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451282340	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1451282340	1445296755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296755	25258374	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.	0.5
1451282340	769245468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245468	21392617	Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.	0.5
1451282340	769245459	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245459	21392617	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.	-1.5
1451282340	769245456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245456	21392617	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282340	769245465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769245465	21392617	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	1.75
1451282340	981844125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844125	22265638	Allele A is not associated with decreased platelet inhibition when treated with clopidogrel as compared to genotype GG.	-1.5
1451282340	1447986842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447986842	25730082	Genotypes AA + AG are associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	981344520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344520	22990067	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	-1.75
1451282340	982033044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033044	19463375	Genotype CC is associated with greater platelet inhibition 2 h after a 600-mg dose when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.	1.75
1451282340	982033119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033119	20492469	Genotypes CT + TT are associated with decreased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
1451282340	827815445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815445	22228204	Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
1451282340	827919816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919816	22462746	Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	2.25
1451282340	699638703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638703	20083681	Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	3.0
1451282340	1184469584	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469584	19496924	Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	3.0
1451282340	1184470013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470013	18781853	Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	-1.5
1451282340	1448258619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258619	25060201	Genotypes CT + TT are not associated with response to clopidogrel in people with Acute coronary syndrome.	-1.25
1451282340	981344388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344388	22990067	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981344408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344408	22990067	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	982033598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033598	18346178	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033614	18323861	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	2.0
1451282340	982034226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034226	19576320	Allele A is associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	2.75
1451282340	982034575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034575	21786436	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	2.5
1451282340	982034728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034728	18532997	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982035447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035447	21168310	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	1043765783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043765783	20650435	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	2.5
1451282340	1043818407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818407	20724801	Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.	3.0
1451282340	827919808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919808	22462746	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.25
1451282340	1448258608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258608	25060201	Genotype AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.25
1451282340	981344366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344366	22990067	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981344377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344377	22990067	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.25
1451282340	981801214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981801214	22427735	Allele A is associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	981802548	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802548	22427735	Allele A is associated with decreased platelet inhibition when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	981843471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843471	22624833	Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	3.5
1451282340	981844053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844053	18004210	Genotypes AA + AG are associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	3.0
1451282340	981844094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981844094	18004210	Genotypes AA + AG are associated with increased residual platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.5
1451282340	982029072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029072	19463375	Allele A is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	1.75
1451282340	982032787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032787	17900275	Allele A is associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to allele G.	1.75
1451282340	982033103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033103	20492469	Genotypes AA + AG are associated with increased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	982033160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033160	18577829	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	1.5
1451282340	982033431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033431	16772608	Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033484	18323861	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	2.0
1451282340	982033525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033525	18346178	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982033630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033630	18394438	Allele A is associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282340	982033674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033674	18482659	Genotypes AA + AG are associated with increased risk of high-on clopidogrel platelet reactivity when treated with clopidogrel in patients undergoing elective coronary stent placement as compared to genotype GG.	3.0
1451282340	982034249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034249	19576320	Allele A is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	-1.75
1451282340	982034526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034526	21786436	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	2.5
1451282340	982034621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034621	21426546	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.5
1451282340	982034718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034718	18532997	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	1.5
1451282340	982035424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035424	21168310	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	2.0
1451282340	982037635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037635	21831410	Allele A is associated with high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	2.5
1451282340	1029227540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1029227540	19531897	Genotypes AA + AG are associated with increased platelet reactivity when treated with clopidogrel in PCI-scheduled patients as compared to genotype GG.	1.5
1451282340	1043760981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043760981	19624462	Genotypes AA + AG are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel as compared to genotype GG.	2.5
1451282340	1043762214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043762214	20510210	Genotypes AA + AG are associated with increased risk of insufficient antiplatelet response to clopidogrel when treated with clopidogrel in patients undergoing elective coronary stent implantation as compared to genotype GG.	2.0
1451282340	1043765400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043765400	20650435	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	2.5
1451282340	827784087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784087	21881565	Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.	3.0
1451282340	827784103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784103	21881565	Allele A is associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele G.	0.0
1451282340	827787114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787114	22088980	Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	2.75
1451282340	827815433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815433	22228204	Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	827823391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823391	21628721	Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.	3.0
1451282340	827919768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919768	22462746	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.25
1451282340	1183702397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702397	24353446	Genotypes AA + AG is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.0
1451282340	1184470005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470005	18781853	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	1184470036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470036	19926050	Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	2.0
1451282340	1184472508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472508	22285300	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.25
1451282340	1444702829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702829	25860557	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282340	1448258595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258595	25060201	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282340	1449192147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192147	28806186	Genotype AG is associated with increased platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype AA.	2.5
1451282340	1450129827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450129827	30487649	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	0.0
1451282340	981478604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478604	23150151	CYP2C19 *2 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	3.0
1451282340	981478609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478609	23150151	CYP2C19 *3 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	3.0
1451282340	827814107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814107	21806387	CYP2C19 *17 is associated with decreased likelihood of platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	0.0
1451282340	981802868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802868	23470885	CYP2C19 *2 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	2.0
1451282340	981802889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802889	23470885	CYP2C19 *3 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	2.0
1451282340	982023647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023647	23692149	CYP2C19 *2 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	982023653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023653	23692149	CYP2C19 *3 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	982042094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042094	23809542	CYP2C19 *2 is associated with increased post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	3.5
1451282340	982042102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982042102	23809542	CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	-3.0
1451282340	982047473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047473	22955794	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	2.0
1451282340	982047486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047486	22955794	CYP2C19 *17 is not associated with increased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	-1.5
1451282340	1043818349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818349	21345843	CYP2C19 *2 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.5
1451282340	1043818357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818357	21345843	CYP2C19 *3 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.5
1451282340	1043818375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818375	21511217	CYP2C19 *2 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.25
1451282340	1043818382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818382	21511217	CYP2C19 *3 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	2.25
1451282340	1183491857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491857	23428009	CYP2C19 *1/*1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2 + *2/*2.	2.25
1451282340	1183631797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631797	24088578	CYP2C19 *2 is associated with increased On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.0
1451282340	1183631808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631808	24088578	CYP2C19 *3 is associated with increased on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.0
1451282340	1183681446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681446	24019397	CYP2C19 *1/*1 + *1/*17 + *2/*17 + *3/*17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.75
1451282340	1183681642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681642	24019752	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.	1.75
1451282340	1183689255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689255	23001453	CYP2C19 *2 + *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	3.0
1451282340	1183697283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697283	24214141	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1451282340	1183697317	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697317	24214141	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.75
1451282340	1183702381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702381	24353446	CYP2C19 *1/*2 + *2/*2 is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.0
1451282340	1183702492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702492	24336898	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of high platelet reactivity when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	3.0
1451282340	1183703514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703514	22974728	CYP2C19 *2 + *3 is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.25
1451282340	1183704618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704618	23517020	CYP2C19 *1/*2 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282340	1183704627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704627	23517020	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282340	1183704635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704635	23517020	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*2.	2.5
1451282340	1183705597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705597	24535487	CYP2C19 *2 + *3 are associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	2.5
1451282340	1183848900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848900	24576527	CYP2C19 *1/*17 + *1/*2 + *17/*17 + *2/*17 are not associated with platelet aggregation activity as measured by the VerifyNow P2Y12 test when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.0
1451282340	1184168830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168830	23726091	CYP2C19 *1/*2 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282340	1184168844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168844	23726091	CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	0.0
1451282340	1184168856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168856	23726091	CYP2C19 *1/*3 + *3/*3 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-2.75
1451282340	1184168878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168878	23726091	CYP2C19 *1/*17 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-1.75
1451282340	1184348910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348910	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.5
1451282340	1184348932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348932	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.75
1451282340	1184348998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348998	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.	1.0
1451282340	1184349010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349010	24782221	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*17 + *17/*17.	0.125
1451282340	1184349199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349199	24418943	CYP2C19 *1/*2 is associated with increased platelet aggregation with ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	1.25
1451282340	1184349853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349853	23895809	CYP2C19 *2 is associated with increased platelet reactivity by P2Y12 reaction units when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.	2.25
1451282340	1184469799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469799	21075428	CYP2C19 *1/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *1/*3.	-1.25
1451282340	1184469816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469816	21075428	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	3.0
1451282340	1184469836	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469836	21075428	CYP2C19 *2/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *2/*3.	-0.25
1451282340	1184469934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469934	19429918	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	1.5
1451282340	1184470291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470291	22045970	CYP2C19 *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.75
1451282340	1184472114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472114	22123356	CYP2C19 *1/*17 + *17/*17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282340	1184472347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472347	22390861	CYP2C19 *2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	3.5
1451282340	1184472379	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472379	22390861	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	-2.0
1451282340	1184473178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473178	23993903	CYP2C19 *2/*2 is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	2.0
1451282340	1184473190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473190	23993903	CYP2C19 *2/*2 + *1/*2 is associated with increased ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	2.5
1451282340	1184987641	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987641	24508947	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1184987661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987661	24508947	CYP2C19 *3 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1444607076	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607076	25542807	CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282340	1444667855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667855	24440142	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451282340	1444667887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667887	24440142	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451282340	1444701698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701698	25832119	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282340	1444701710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701710	25828136	CYP2C19 *2 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-0.25
1451282340	1444701722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701722	25828136	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1451282340	1444702906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702906	25850030	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.25
1451282340	1444704608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704608	24402637	CYP2C19 *1/*2 + *2/*2 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.75
1451282340	1444704692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704692	24856643	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.0
1451282340	1444706389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706389	25891840	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	3.0
1451282340	1444706434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706434	25897911	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.5
1451282340	1444706449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706449	25897911	CYP2C19 *2 + *3 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	-1.75
1451282340	1444936339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936339	25712182	CYP2C19 *2/*2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*2.	3.25
1451282340	1444936352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936352	25712182	CYP2C19 *17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	-1.75
1451282340	1445296396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296396	25115434	CYP2C19 *17/*17 + *1/*17 are associated with increased platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1451282340	1445296466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296466	25175362	CYP2C19 *1/*1 is associated with decreased platelet reactivity when treated with clopidogrel in people with as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	3.0
1451282340	1446899066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899066	26265231	CYP2C19 *2 + *4 are associated with decreased response to clopidogrel as compared to CYP2C19 *1 + *17.	3.0
1451282340	1448112663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112663	26526111	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	2.5
1451282340	1448115828	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448115828	26526111	CYP2C19 *17 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	-1.5
1451282340	1448119221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119221	27380588	CYP2C19 *2 + *3 are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.	3.5
1451282340	1448603367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603367	28255319	CYP2C19 *2 is associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448603378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603378	28255319	CYP2C19 *17 is associated with decreased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448631999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631999	28329746	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2.	2.75
1451282340	1448633723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633723	28135763	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448633744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633744	28135763	CYP2C19 *1/*17 is associated with increased platelet aggregation inhibition when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282340	1448633755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633755	28135763	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	-1.75
1451282340	1448633804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633804	28135763	CYP2C19 *17 is not associated with response to clopidogrel as compared to CYP2C19 *1/*1.	-1.75
1451282340	1448634286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634286	28604225	CYP2C19 *1/*1 is associated with decreased platelet aggregation when treated with aspirin and clopidogrel in people with Acute coronary syndrome and Myocardial Infarction as compared to CYP2C19 *1/*2 + *2/*2.	2.75
1451282340	1448634534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634534	28589365	CYP2C19 *1 + *17 are associated with decreased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *2.	3.0
1451282340	1449187738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187738	29397568	CYP2C19 *3 is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	3.0
1451282340	1449187754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187754	29397568	CYP2C19 *2 is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282340	1449296254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296254	29653637	CYP2C19 *2 is associated with decreased response to clopidogrel.	3.0
1451282340	1449712939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449712939	30020015	CYP2C19 *2 is associated with increased platelet aggregation when treated with aspirin and clopidogrel as compared to CYP2C19 *1 + *17.	2.0
1451282340	1450253685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450253685	30061570	CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.5
1451282340	1450370841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450370841	29536505	CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .	2.5
1451282340	1450664741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450664741	21689142	CYP2C19 *2/*2 + *2/*3 are associated with increased high on-treatment platelet reactivity when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	0.0
1451282340	1450664799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450664799	21806387	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	2.5
1451274140	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274140	982009671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009671	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype TT.	1.75
1451274140	1444699959	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444699959	24648345	Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.	0.0
1451274140	1447990735	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447990735	24107927	Genotype CT is associated with decreased activity of DPYD as compared to genotype TT.	0.0
1451274140	1448097582	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448097582	16361556	Allele C is associated with decreased activity of DPYD.	0.0
1451282440	PA166104948	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104948		Annotation of CPIC Guideline for clopidogrel and CYP2C19	100
1451282440	PA166104956	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104956		Annotation of DPWG Guideline for clopidogrel and CYP2C19	100
1451282440	1183699694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699694	24262617	CYP2C19 normal metabolizers are associated with decreased risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 poor metabolizers and intermediate metabolizers.	0.75
1451282440	1449140365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449140365	29102571	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.	1.25
1451282440	1451116983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451116983	31316169	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with percutaneous coronary intervention.	1.75
1451282440	1450112843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450112843	30487649	Genotypes AA + AG are not associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-1.5
1451282440	981843458	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843458	23364775	Allele T is associated with decreased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	2.5
1451282440	981843680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843680	22190063	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.	-2.0
1451282440	1043818226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818226	23922007	Genotype CT is not associated with bleeding events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	1043818236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818236	23922007	Genotype CT is not associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	1043818242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818242	23922007	Genotype CT is not associated with increased risk of cardiovascular events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	-2.0
1451282440	769146312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146312	20979470	Allele T is associated with decreased cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome.	2.5
1451282440	1184472133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472133	22028352	Genotypes CT + TT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype CC.	2.25
1451282440	1449310952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310952	29540324	Allele T is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele C.	2.5
1451282440	981352416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352416	19106083	Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA.	3.5
1451282440	982028948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028948	19106084	Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	3.0
1451282440	982032538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032538	20801498	Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	2.5
1451282440	981344417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344417	22990067	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282440	981352394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352394	19106083	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	982028939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028939	19106084	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	982032530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032530	20801498	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	982035455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035455	21168310	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	1.5
1451282440	981239613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239613	22940005	Genotype AA is associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotypes AG + GG.	3.5
1451282440	981344397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344397	22990067	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1451282440	981794408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794408	21972404	Allele A is associated with increased risk of major cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.25
1451282440	981802939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802939	23364775	Genotype AA is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282440	981802954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802954	23364775	Genotype AA is associated with increased risk of composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	2.5
1451282440	981843499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843499	21918510	Genotype AA is associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	981843514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843514	21918510	Genotype AA is associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.5
1451282440	981843601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843601	22624833	Genotype AA is associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	2.25
1451282440	981843612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843612	22624833	Genotype AG is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-2.0
1451282440	981843646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843646	22190063	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.	3.0
1451282440	982028928	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028928	19106084	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	982033160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033160	18577829	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	1.5
1451282440	982035437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035437	21168310	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	1.5
1451282440	1027543294	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1027543294	19108880	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	3.25
1451282440	1027950849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1027950849	19108880	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	3.25
1451282440	1028218721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1028218721	19193675	Genotypes AA + AG are associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype GG.	3.5
1451282440	1043763118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043763118	20845077	Genotypes AA + AG are associated with increased risk of cardiovascular events when treated with clopidogrel as compared to genotype GG.	1.75
1451282440	827814610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814610	21700758	Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.	2.5
1451282440	769258868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769258868	21527445	Genotype AA is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	3.0
1451282440	655388276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388276	19106083	Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	3.0
1451282440	769146008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146008	19106084	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	3.0
1451282440	769146034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146034	19706858	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.	2.5
1451282440	769146043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146043	20801498	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	769146308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146308	20979470	Allele A is not associated with cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	-2.0
1451282440	1184472125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472125	22028352	Genotypes AA + AG is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	3.25
1451282440	1449310942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310942	29540324	Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.	2.5
1451282440	1449732819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732819	30188374	Genotypes AA + AG are associated with increased major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.5
1451282440	981352424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352424	19106083	CYP2C19 *5 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.5
1451282440	981478613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478613	23150151	CYP2C19 *2 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	0.0
1451282440	981478617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478617	23150151	CYP2C19 *3 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	0.0
1451282440	981483636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483636	22723959	CYP2C19 *2 is associated with increased risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	2.25
1451282440	981483641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483641	22723959	CYP2C19 *3 is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	-1.25
1451282440	981500454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500454	22464343	CYP2C19 *2 is associated with increased risk of major adverse cardiovascular events and stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	2.0
1451282440	981755468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755468	23429358	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282440	981755473	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755473	23429358	CYP2C19 *1/*3 + *2/*3 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.5
1451282440	982023666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023666	23692149	CYP2C19 *2 is associated with increased risk of stent thrombosis (ST) after 1 year when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	982023672	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023672	23692149	CYP2C19 *3 is associated with increased risk of stent thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	1043858934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858934	19106083	CYP2C19 *4 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.5
1451282440	1043880481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880481	20801498	CYP2C19 *6 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880487	20801498	CYP2C19 *8 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880576	20801498	CYP2C19 *5 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.5
1451282440	1043880590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043880590	19106084	CYP2C19 *5 is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681283	24019397	CYP2C19 *2/*2 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681306	24019397	CYP2C19 *2/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	3.0
1451282440	1183681314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681314	24019397	CYP2C19 *1/*2 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-2.0
1451282440	1183681338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681338	24019397	CYP2C19 *1/*17 + *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	-2.0
1451282440	1183681384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681384	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	3.5
1451282440	1183681419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681419	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	-2.0
1451282440	1183681542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681542	24019397	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	3.0
1451282440	1183705616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705616	24535487	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	2.5
1451282440	1184348948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348948	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.75
1451282440	1184348964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348964	24821368	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282440	1184349625	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349625	24080325	CYP2C19 *2 + *3 are associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282440	1184349639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349639	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.5
1451282440	1184349649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349649	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.25
1451282440	1184349659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349659	24080325	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349669	24080325	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349679	24080325	CYP2C19 *2 + *3 are associated with increased risk of ischaemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.75
1451282440	1184349692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349692	24080325	CYP2C19 *2 + *3 are not associated with increased risk of Mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.0
1451282440	1184349702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349702	24762860	CYP2C19 *2 is associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	2.5
1451282440	1184349711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349711	24762860	CYP2C19 *2 is not associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-1.75
1451282440	1184349747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349747	24762860	CYP2C19 *2 is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	0.0
1451282440	1184349821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349821	24762860	CYP2C19 *9 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	-2.5
1451282440	1184467283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467283	23402725	CYP2C19 *2/*2 + *1/*2 is associated with increased likelihood of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.25
1451282440	1184987695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987695	24508947	CYP2C19 *3 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	3.0
1451282440	1184987748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987748	24996381	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	0.5
1451282440	1444701909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444701909	25828136	CYP2C19 *2 is associated with increased risk of when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.25
1451282440	1444702878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702878	25851472	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1444704450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704450	25877345	CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	1.25
1451282440	1444704497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704497	25877345	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282440	1444704529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704529	25877345	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are not associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	-0.5
1451282440	1444704559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704559	24402637	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.25
1451282440	1444706464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706464	25897911	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	3.0
1451282440	1444706496	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706496	25897911	CYP2C19 *2 + *3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	2.75
1451282440	1446899082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899082	26265231	CYP2C19 *2 + *4 are not associated with risk of Death, Ischemic Attack, Transient, Stroke or Thrombosis when treated with clopidogrel as compared to CYP2C19 *1 + *17.	-1.0
1451282440	1446899112	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899112	26265231	CYP2C19 *2 + *4 are associated with increased risk of Myocardial Infarction when treated with clopidogrel as compared to CYP2C19 *1 + *17.	2.0
1451282440	1446899985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446899985	26019129	CYP2C19 *2 is associated with increased likelihood of Stroke when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	0.0
1451282440	1447678787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678787	26757134	CYP2C19 *1/*2 + *2/*3 + *1/*3 + *2/*17 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.5
1451282440	1447949788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949788	26961113	CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	2.75
1451282440	1448101486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101486	26071277	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.	2.5
1451282440	1448257000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257000	27348249	CYP2C19 *2 + *3 are not associated with likelihood of Hemorrhage when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	-2.0
1451282440	1448602737	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602737	27368038	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	3.0
1451282440	1448603394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603394	28255319	CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	2.75
1451282440	1448617237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617237	27806998	CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.5
1451282440	1448617264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617264	27806998	CYP2C19 *2 + *3 + *8 are associated with increased risk of composite endpoints (stroke, myocardial infarction, or vascular death) when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	1.5
1451282440	1448617742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617742	27653892	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1448631945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631945	28377187	CYP2C19 *2 + *3 are not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	-2.0
1451282440	1448631958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631958	28329746	CYP2C19 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C19 *1/*1.	2.25
1451282440	1449187703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187703	29397568	CYP2C19 *3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	2.5
1451282440	1449187720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187720	29397568	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	-1.5
1451282440	1449751959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449751959	30191759	CYP2C19 *3/*17 is associated with Thrombosis when treated with aspirin and clopidogrel.	0.25
1451282440	1450370889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450370889	29536505	CYP2C19 *1/*1 (assigned as normal metabolizer phenotype phenotype) is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*2 + *2/*2 + *2/*17 + *17/*17 + *1/*17.	-1.5
1451282440	1448624845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624845	27981573	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2.	-1.75
1451282440	1444667802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667802	24440142	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1451282440	1444667831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667831	24440142	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.0
1451282840	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1451282840	PA166104977	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104977		Annotation of DPWG Guideline for citalopram and CYP2C19	100
1451282840	1183701647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701647	8835706	CYP2C19 poor metabolizers is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	-0.625
1451282840	1184748582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748582	25122046	CYP2C19 poor metabolizers is associated with increased risk of electrocardiogram qt prolonged when treated with citalopram as compared to CYP2C19 normal metabolizers.	0.0
1451282840	1449717838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449717838	30135031	CYP2C19 poor metabolizer phenotype is not associated with risk of adverse events due to citalopram or escitalopram in people with as compared to CYP2C19 normal metabolizer phenotype.	-0.5
1451282840	1451715793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451715793	33608663	Genotype AG is associated with increased likelihood of adverse events due to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.	2.5
1451282840	1183619342	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619342	21192344	CYP2C19 *4 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	0.0
1451282840	1183619350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619350	21192344	CYP2C19 *2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.5
1451282840	1450415299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450415299	30983508	CYP2C19 *1/*2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 *1/*1.	-1.5
1451282840	1183619955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619955	18382661	CYP2C19 *2 + *3 +*17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	-2.0
1451286040	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286040	1449732030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732030	30114658	Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	This annotation is not used for clinical annotation scoring. From the discussion section: "no associations with common variants remained statistically significant after correction"
1451286040	1447987436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987436	22490566	Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.	-1.75
1451286040	1450954760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954760	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.5
1451286040	827810898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810898	21498394	Genotypes CT + TT is associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.0
1451286040	1449162055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162055	29065426	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
1451286040	1447945619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945619	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286040	1448124677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124677	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451286040	1448124810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124810	24647007	Genotypes CT + TT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451286040	1448262721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262721	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286040	1448723954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448723954	28745575	Genotypes CC + CT is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	2.75
1451286040	1448994804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994804	28481884	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.	-1.5
1451286040	1450371918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371918	30723313	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286040	1450372243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372243	30858516	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
1451286320	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286320	1447987416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987416	22490566	Genotypes CC + CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
1451286320	1447945633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945633	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451286320	1450954700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954700	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.5
1451286320	1451147880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451147880	32378051	Allele C is associated with increased risk of Diarrhea due to capecitabine in women with Breast Neoplasms as compared to allele T.	2.0
1451286320	1448123245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123245	21498394	Genotypes CC + CT are not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-3.0
1451286320	1448124670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124670	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	-2.0
1451286320	1448124831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124831	24647007	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451286320	1448125094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125094	25677447	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms or gastroesophageal cancer as compared to genotype TT.	-1.5
1451286320	1448262704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262704	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286320	1448994783	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994783	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451286320	1449162048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162048	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451286320	1449732013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732013	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451286326	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451286326	1447945626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945626	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286326	1450953025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953025	26603945	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele C.	-1.0
1451286326	1450954660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954660	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451286326	1448123237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123237	21498394	Genotypes CT + TT is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-3.0
1451286326	1448124239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124239	23736036	Genotype CT is associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.0
1451286326	1448124661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124661	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451286326	1448124838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124838	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451286326	1448262697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262697	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286326	1448568402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568402	27995989	Genotype CT is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype CC.	-1.5
1451286326	1448994776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994776	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451286326	1449161763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161763	28427087	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CT + TT.	-2.0
1451286326	1449162040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162040	29065426	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	-2.0
1451286326	1449732020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732020	30114658	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.5
1451287240	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287240	1448994618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994618	28481884	Allele G is associated with decreased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele A.	2.0
1451287240	1450953284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953284	20819423	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele A.	-1.0
1451287240	1450954546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954546	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.5
1451287240	1450961080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450961080	21498394	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-3.0
1451287240	1448124639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124639	24590654	Allele G is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A.	-2.0
1451287240	1448124875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124875	24647007	Genotypes AG + GG are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-2.0
1451287240	1448125079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125079	25677447	Genotypes AG + GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1451287240	1448125087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125087	25677447	Genotypes AG + GG is associated with increased risk of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.	1.75
1451287240	1448262652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262652	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287240	1449162062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162062	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1451287240	1449731947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731947	30114658	Genotypes AA + AG is associated with decreased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.0
1451287240	1449732144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732144	29998006	Genotypes AA + AG is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms as compared to genotype GG.	-2.0
1451287360	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287360	1449161585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161585	29239269	Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.0
1451287360	1447987449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987449	22490566	Genotype CT is not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
1451287360	769169640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169640	19104657	Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.	2.75
1451287360	827810914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810914	21498394	Genotypes CC + CT are associated with increased severity of Diarrhea and hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	0.0
1451287360	1444698729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698729	25782327	Genotype CT is associated with increased severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	2.25
1451287360	1447945605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945605	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451287360	1448122697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122697	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451287360	1448123099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123099	20819423	Allele T is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	0.0
1451287360	1448124184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124184	23736036	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1451287360	1448124647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124647	24590654	Allele C is not associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-2.0
1451287360	1448124868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124868	24647007	Genotypes CC + CT are not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451287360	1448125103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125103	25677447	Genotypes CC + CT are not associated with risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms and gastroesophageal cancer as compared to genotype TT.	-1.5
1451287360	1448262663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262663	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287360	1448994748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994748	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451287360	1449161605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161605	29239269	Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.	-2.5
1451287360	1449162069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162069	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451287360	1449732006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732006	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1451287360	1450371940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371940	30723313	Genotypes CC + CT is not associated with risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	-2.0
1451287440	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451287440	769176398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176398	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1451287440	1444698773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698773	25782327	Genotype AG is associated with increased severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.	2.25
1451287440	1447945640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945640	26099996	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.	-1.75
1451287440	1448122765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122765	19530960	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451287440	1448123338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123338	21498394	Genotype AG is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-1.5
1451287440	1448125175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125175	25677447	Genotype AG is associated with increased severity of Stomatitis when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.	1.75
1451287440	1448262714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262714	24923815	Allele G is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451287440	1448994790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994790	28481884	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele A.	-1.5
1451287440	1449162083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162083	29065426	Genotypes AG + GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	-2.0
1451290840	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451290840	1444703361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703361	25624441	Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.5
1451290840	1447682392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682392	26405151	Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1451290840	1447682626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682626	26033531	Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1451290840	1447682735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682735	26076924	Genotype CT is associated with decreased dose of azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	2.5
1451290840	1447682776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682776	26503813	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.75
1451290840	1447989193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989193	27095468	Genotypes CT + TT is associated with decreased dose of azathioprine or mercaptopurine.	0.25
1451290840	1447989974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989974	27193222	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.5
1451290840	1448260651	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260651	27577869	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.0
1451290840	1449575844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575844	29923122	Genotype TT is associated with decreased dose of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.	2.5
1451290840	1449749328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749328	28418010	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.75
1451290840	1449750266	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750266	29720126	Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	0.0
1451290840	1447945037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945037	26878724	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .	1.625
1451290840	1448576430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576430	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451290840	1448624581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624581	28445187	NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.25
1451290840	1448624596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624596	28445187	NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451290840	1448635204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635204	28659275	NUDT15 *1/*2 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	0.25
1451290840	1449750346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750346	29967377	NUDT15 *1/*3 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 + *1/*5 + *1/*6 + *1/*2.	0.0
1451290840	1449750363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750363	29967377	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.	0.0
1451329460	981742607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981742607	19390945	Genotype AA is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.	2.5
1451329460	981743951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981743951	19390945	Genotype AG is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.	3.0
1451329460	981747378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981747378	19299905	Genotypes AA + AG are associated with increased severity of Neutropenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.	2.0
1451329460	981794141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794141	18221820	Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1451329460	981794502	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794502	16636344	Genotype AA is associated with increased Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	1.75
1451329460	1445584988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445584988	26229432	Genotypes AA + AG is associated with increased risk of Neutropenia when treated with irinotecan in people with biliary tract neoplasms and Pancreatic Neoplasms as compared to genotype GG.	1.5
1451329460	1447814363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814363	26830078	Genotype AG is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	1.5
1451329460	1448617804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617804	28367249	Allele A is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to allele G.	2.0
1451329460	1448617936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617936	28502040	Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG.	3.5
1451329460	1184483416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483416	24308720	UGT1A1 *6 is not associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	-1.0
1451329460	1184483429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483429	24308720	UGT1A1 *6 + *28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	1.0
1451329460	1184483547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483547	24448639	UGT1A1 *1/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451329460	1184483574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483574	24448639	UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451329460	1184483688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483688	24519753	UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*6.	1.75
1451329460	1184483699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483699	24519753	UGT1A1 *1/*6 + *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451329460	1184483709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483709	24519753	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28 + *1/*1.	1.25
1451329460	1185235290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235290	25285015	UGT1A1 *6 is not associated with risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451329460	1448422676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422676	26857783	UGT1A1 *6 + *28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.	2.5
1451329460	1448422855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422855	27385990	UGT1A1 *1/*28 + *6/*28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	1.0
1451329460	1451210158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210158	26229432	UGT1A1 *28/*28 + *6/*6 + *1/*6 + *1/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451329460	1448820825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448820825	28585035	UGT1A1 *1/*6 + *6/*6 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451332611	PA166105002	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105002		Annotation of CPIC Guideline for desipramine and CYP2D6	100
1451332611	1183684281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684281	9049581	CYP2D6 poor metabolizer are associated with increased risk of Hypotension, Orthostatic and sedation when treated with desipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.125
1451332611	1183684295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684295	8422746	CYP2D6 poor metabolizers are associated with cardiotoxicity when treated with desipramine in people with.	0.125
1451332611	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451288269	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451288269	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451288269	1451313980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451313980	33410339	Genotype CT is not associated with increased likelihood of Drug Toxicity or treatment modification when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	-2.0
1451288269	827823468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823468	19530960	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	2.0
1451288269	1448123285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123285	21498394	Genotypes CT + TT are associated with increased likelihood of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.0
1451288269	1448124454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124454	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1451288269	1448124654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124654	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1451288269	1448124852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124852	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-3.0
1451288269	1448255378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255378	26603945	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451288269	1448262687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262687	24923815	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451288269	1448568395	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568395	27995989	Genotype CC is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.	-1.5
1451288269	1448994769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994769	28481884	Allele C is not associated with risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	-1.5
1451288269	1450373074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373074	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1451289700	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451289700	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451289700	1450964880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964880	31745289	Allele C is associated with decreased activity of DPYD as compared to allele G.	0.0
1451289700	1448261538	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448261538	27544765	Genotype CC is associated with decreased activity of DPYD.	0.0
1451289700	1448267561	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267561	25410891	Allele C is associated with decreased activity of DPYD.	0.0
1451289700	1448605284	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605284	28295243	Genotype CG is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype GG.	0.0
1451420300	1183688850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183688850	17224704	CYP2D6 *4/*5 is associated with increased atomoxetine and methylphenidateplasma concentration after overdose when exposed to atomoxetine and methylphenidate.	0.125
1451265780	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1451265780	PA166104964	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104964		Annotation of DPWG Guideline for clomipramine and CYP2D6	100
1451265780	1183683989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683989	2741190	CYP2D6 poor metabolizers are associated with side effects when treated with clomipramine.	0.125
1451265780	981476405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476405	18070221	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	3.5
1451265780	982030065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030065	16871470	CYP2D6 *4/*6 is associated with increased risk of Drug Toxicity when treated with clomipramine and quetiapine in people with Depressive Disorder, Major.	0.25
1451265780	1183616659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616659	15252821	CYP2D6 *1/*4 is associated with increased risk of side effects when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2.	0.25
1451265780	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451265780	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451285360	PA166104998	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104998		Annotation of CPIC Guideline for nortriptyline and CYP2D6	100
1451285360	PA166104961	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104961		Annotation of DPWG Guideline for nortriptyline and CYP2D6	100
1451285360	1183683958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683958	6111662	CYP2D6 poor metabolizers are associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major.	0.125
1451285360	1444702163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702163	25761838	CYP2D6 poor metabolizers are not associated with increased risk of Drug Toxicity when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	-0.875
1451285360	1183615499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615499	15483356	CYP2D6 *5/*10 is associated with increased Constipation, Dizziness and dry mouth when treated with nortriptyline.	0.25
1451285360	1183615525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615525	22389859	CYP2D6 *10/*10 is associated with violent psychosis when treated with nortriptyline.	0.125
1451285360	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451285360	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451282740	PA166127638	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166127638		Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19	100
1451282740	PA166104975	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104975		Annotation of DPWG Guideline for escitalopram and CYP2C19	100
1451282740	1183698879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698879	24257813	CYP2C19 poor metabolizers are associated with decreased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	0.75
1451282740	1183698912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698912	24257813	CYP2C19 ultrarapid metabolizer phenotype is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.	0.75
1451282740	1184137275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137275	19404631	CYP2C19 poor metabolizers is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizers.	1.0
1451282740	655387725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387725	17625515	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	2.5
1451282740	655387729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387729	17625515	Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.	2.5
1451282740	655387735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387735	17625515	Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.	2.5
1451282740	655387732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387732	17625515	Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.	2.5
1451282740	1183618316	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183618316	18654768	CYP2C19 *17/*17 is associated with increased clearance of escitalopram in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1451282740	1183619481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619481	20350136	CYP2C19 *2/*2 + *2/*3 is associated with increased S-CIT serum concentrations when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*2.	1.25
1451282740	1183619732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619732	16418702	CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.75
1451282740	1183619741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619741	17625515	CYP2C19 *2 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619754	17625515	CYP2C19 *3 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619762	17625515	CYP2C19 *17/*17 is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.	2.5
1451282740	1183619790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619790	21926427	CYP2C19 *2/*2 + *2/*3 are associated with increased mean escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.0
1451282740	1183619821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619821	21926427	CYP2C19 *17/*17 is associated with decreased mean logarithm escitalopram concentration and higher mean metabolic ratio when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	2.0
1451282740	1183699996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699996	19841156	CYP2C19 *1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased clearance of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	2.0
1451282740	1183700031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700031	19773541	CYP2C19 *2/*2 is associated with increased relative dose-adjusted serum concentrations of escitalopram and lower relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite when treated with escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1.	0.125
1451282740	1183700043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700043	19773541	CYP2C19 *17/*17 is associated with lower relative dose-adjusted serum concentrations of escitalopram and higher relative dose-adjusted serum concentrations of N-desmethyl S-citalopram and propionic acid metabolite when treated with escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1.	0.125
1451282740	1183700055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700055	19404631	CYP2C19 *2/*2 + *2/*4 (assigned as poor metabolizer phenotype) is associated with increased area under the time-plasma concentration curve (AUC(0-24)) when treated with escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1451282740	1184137240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137240	21926427	CYP2C19 *1/*17 is associated with decreased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	1.5
1451282740	1184748190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748190	25154506	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282740	1184748315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748315	25154506	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1451282740	1184748329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748329	25154506	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.25
1451282740	1184748337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748337	25154506	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	1.0
1451282740	1449163468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163468	29325448	CYP2C19 *2 + *3 + *4 are associated with increased exposure to escitalopram as compared to CYP2C19 *1/*1.	2.5
1451282740	1449163487	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163487	29325448	CYP2C19 *1/*17 + *17/*17 are associated with decreased exposure to escitalopram as compared to CYP2C19 *1/*1.	2.5
981202790	827923960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923960	11926892	Genotypes GT + TT are associated with decreased likelihood of Myocardial Infarction when treated with diuretics in people with Hypertension.	3.75
981202790	827924164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924164	17189961	Allele G is not associated with risk of Myocardial Infarction when treated with diuretics in people with Hypertension as compared to allele T.	-2.0
981204258	769169025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169025	16950614	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.	1.5
981204258	1451638940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451638940	34280009	Allele C is not associated with severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele A.	-1.25
981204258	1451726349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451726349	33649523	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with paclitaxel in people with Neoplasms as compared to genotype AA.	-1.5
981204258	769169021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169021	16950614	Genotype GG is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to genotypes AA + AG.	This annotation is not used for clinical annotation scoring. Already have a VA from this paper on the same CA
981203854	769166534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166534	21047202	Genotype CC is associated with increased risk of Hyperlipidemias when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.25
981204026	827863237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863237	22450926	Allele T is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	0.0
981204116	769180585	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180585	21289623	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AC + CC.	1.75
981204116	1448573382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573382	28135009	Genotype AA is not associated with response to tacrolimus in people with Colitis, Ulcerative.	-1.25
981204433	769169480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169480	18408561	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.	2.0
981204444	655388038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388038	11434506	Genotype GG is associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG.	1.5
981204444	1184468576	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184468576	12914549	Allele A is not associated with transport of rhodamine 123 CD56+ NK cells and CD4+ T-helper cells as compared to allele G.	-0.0
981204466	827817217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827817217	22026922	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	-1.5
981204466	769262755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262755	21142915	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	1.75
981237713	827807299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807299	21605004	Genotype AA is not associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.5
981237713	769174400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174400	19159907	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.	1.75
981237713	1449752326	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752326	29662106	Genotypes AA + AG is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
981238041	769169476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169476	18408561	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.	2.5
981203697	982046754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046754	23697249	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.	-1.25
981203697	827824453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824453	22256867	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	-2.0
981203697	827824530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824530	22256867	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.	-1.75
981203697	827921746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921746	22630058	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	2.5
981203697	1296599283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599283	24567120	Genotypes CT + TT is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.	-1.5
981203697	1448426774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426774	27816260	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.	1.5
981203790	827699004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827699004	20526235	Genotype CT is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	3.25
981203790	769179627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769179627	17495880	Allele T is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	2.25
981203790	1184515722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515722	21677300	Allele T is associated with increased risk of tacrolimus nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	2.0
981203790	1184515775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515775	22369694	Allele C is not associated with tacrolimus-induced toxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele T.	-1.5
981203790	1184515778	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515778	19644155	Genotype CT is not associated with increased likelihood of nephrotoxicity when treated with tacrolimus in children with Kidney Transplantation as compared to genotype CC.	-0.25
981203790	1184515793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515793	19067682	Genotype CC is not associated with risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.25
981203790	1185023296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185023296	25201288	Genotypes CT + TT is not associated with risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-0.875
981203790	1185023309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185023309	25201288	Genotypes CT + TT is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203790	1448597123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448597123	27977332	Genotype CC is not associated with nephrotoxicity or transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-2.0
981203790	1449645590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449645590	29991328	Genotype CC is not associated with nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.5
981203790	1184515747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515747	23574377	CYP3A5 *1/*3 + *3/*3 is associated with nephrotoxicity when treated with tacrolimus in men with Kidney Transplantation.	-0.25
981203790	1447946869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946869	26856709	CYP3A5 *1 is not associated with risk of nephrotoxicity or Neurotoxicity Syndromes when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3.	-0.25
981203790	1448358389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448358389	27717793	CYP3A5 *1/*1 + *1/*3 are associated with increased risk of Drug Toxicity and nephrotoxicity when treated with tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	2.0
981203790	1448427648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427648	27217047	CYP3A5 *3/*3 is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-1.5
981203790	1449747898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449747898	29539600	CYP3A5 *3/*3 is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-2.0
981203886	827823764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823764	22111602	Genotype CC is associated with increased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.	0.375
981203886	827848827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827848827	21824325	Allele C is not associated with increased risk of toxicity when treated with nevirapine in people with HIV Infections as compared to allele T.	-1.25
981203886	827848927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827848927	19228205	Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.	-1.5
981203886	655386238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386238	20017669	Genotypes CC + CT is associated with increased plasma alanine aminotransferase level when treated with nevirapine in people with HIV Infections as compared to genotype TT.	1.0
981203954	769163146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163146	19779319	Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	1.25
981203954	769163066	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163066	20860463	Allele C is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to allele T.	-0.5
981203954	1183634176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634176	24080498	Genotypes CT + TT are not associated with plasma concentration of efavirenz in people with HIV Infections as compared to genotype CC.	-1.25
981203954	1184473341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473341	23172109	Allele T is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.	-2.0
981203954	1447680448	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680448	26774523	Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	-1.0
981204345	981859149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859149	21747585	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	-1.75
981204345	981954829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954829	18812236	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	-1.75
981204345	769257724	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257724	16753003	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.	0.0
981204345	769146005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146005	20417680	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	-1.75
981204345	1447678493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678493	26555147	Genotype GG is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	-1.5
981204912	1444844075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444844075	26014925	Genotype AA is not associated with risk of Drug Toxicity when treated with cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate in women Breast Neoplasms as compared to genotype GG.	-1.5
981204912	1447989228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447989228	18299612	Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype GG.	2.5
981204912	981785378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785378	23407049	Allele A is not associated with increased risk of grade 3-4 overall toxicity, febrile neutropenia or hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	-1.5
981204912	982029634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029634	23314736	Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG.	2.75
981204912	769245648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245648	20638924	Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.	2.0
981204912	827811335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811335	19384296	Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	2.5
981204912	769176384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176384	20819423	Genotype AA is not associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	-1.25
981204912	769176385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176385	20819423	Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	1.75
981204912	1183681940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681940	23736036	Allele A is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele G.	-1.75
981204912	1184471976	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471976	24167597	Genotype AA is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AG + GG.	-1.75
981204912	1448431771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448431771	27864592	Genotype AA is not associated with event-free survival when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes AG + GG.	-1.5
981204912	1448522567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448522567	27557140	Genotypes AA + AG is not associated with risk of Drug Toxicity when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotype GG.	-1.25
981204912	1448568374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568374	27995989	Genotype AA is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.	-1.5
981204912	1449147499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449147499	29134491	Genotypes AA + AG is associated with increased risk of Diarrhea, mucositis and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.5
981204912	1449161941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161941	27738344	Allele A is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer as compared to allele G.	-1.5
981204912	1449165581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165581	26967565	Allele A is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele G.	-1.75
981238288	827695494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695494	16267764	Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele C.	0.0
981238288	827695550	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695550	16267764	Genotypes AT + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	-0.75
981238288	769163063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163063	20860463	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.	-0.5
981238288	1184349397	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349397	20625352	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.	-0.5
981238288	1447680392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680392	26774523	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.	1.5
981202806	978639529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639529	21692745	Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.	3.5
981204044	PA166104938	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104938		Annotation of DPWG Guideline for acenocoumarol and VKORC1	100
981204044	1184754659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754659	23774941	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	0.0
981204044	1444699595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699595	25519826	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.5
981204044	1444705565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705565	23481074	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.0
981204044	1444705842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705842	24956252	Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	3.0
981204044	1444706967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706967	19277427	Genotype TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	1444707179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707179	16611310	Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	981502435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502435	19875892	Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.	2.25
981204044	981859299	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981859299	22486182	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.25
981204044	981940056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981940056	19018719	Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.	2.25
981204044	981954427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954427	22629463	Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.	1.5
981204044	982006724	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006724	23159639	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	3.25
981204044	982006735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982006735	23159639	Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.	3.25
981204044	982010028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010028	22486182	Genotype TT is not associated with dose of acenocoumarol as compared to genotype CT.	-1.25
981204044	982010039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010039	22486182	Genotype CC is associated with increased dose of acenocoumarol as compared to genotype CT.	0.0
981204044	982015093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015093	23473641	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	2.5
981204044	982031288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031288	23651023	Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	982031298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031298	23651023	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.5
981204044	827814729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814729	21148049	Allele T is associated with decreased dose of acenocoumarol as compared to allele C.	2.5
981204044	1183680104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680104	24108193	Genotype TT is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotype CC.	2.5
981204044	1184511557	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511557	25042728	Genotypes CT + TT is associated with decreased dose of acenocoumarol as compared to genotype CC.	2.75
981204044	1448255537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255537	27335128	Genotypes CT + TT are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to genotype CC.	2.0
981204044	1448259259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259259	21636598	Allele T is associated with dose of acenocoumarol or phenprocoumon.	0.0
981204044	1448259324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259324	22911785	Allele T is associated with dose of acenocoumarol.	2.5
981204044	1448259376	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259376	25089947	Genotype CC is associated with increased dose of acenocoumarol in people with Atrial Fibrillation or venous thromboembolism as compared to genotypes CT + TT.	2.0
981475450	1447673749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673749	15737014	Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.	0.25
981475450	981417754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417754	21233402	Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	3.0
981475450	981417766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417766	18596266	Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	2.5
981475450	981475241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475241	18093943	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475253	17085664	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475286	20129249	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475298	19381876	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475337	21430269	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
981475450	981475352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475352	22215752	Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
981475450	981475378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475378	21248300	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.0
981475450	981475801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475801	21921847	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.	0.25
1451286020	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451286020	1449732030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732030	30114658	Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	This annotation is not used for clinical annotation scoring. From the discussion section: "no associations with common variants remained statistically significant after correction"
1451286020	1447987436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987436	22490566	Genotype CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype CC.	-1.75
1451286020	1450952660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952660	11156223	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to genotype CC.	0.25
1451286020	1450953980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953980	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-2.0
1451286020	1450954760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954760	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.5
1451286020	981394398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981394398	19473056	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286020	1449162055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162055	29065426	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
1451286020	1447945384	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945384	26846104	Genotype CC is not associated with Drug Toxicity when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	-1.5
1451286020	1447945619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945619	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
1451286020	1447949996	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949996	26794347	Allele T is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms or Colorectal Neoplasms as compared to allele C.	3.5
1451286020	1448262721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262721	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
1451286020	1448997530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997530	28614820	Genotype TT is associated with Drug Toxicity when treated with fluorouracil.	0.25
1451286020	1450371918	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371918	30723313	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451286020	1450372243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372243	30858516	Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
1451214480	PA166124619	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166124619		Annotation of CPIC Guideline for tacrolimus and CYP3A5	100
1451214480	PA166104983	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104983		Annotation of DPWG Guideline for tacrolimus and CYP3A5	100
1451214480	1448994558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994558	28704257	CYP3A5 poor metabolizers are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 intermediate metabolizers.	1.125
1451214480	981858976	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858976	23073468	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	981858994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858994	23073468	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	982047178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047178	23175667	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	-1.0
1451214480	982047183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047183	23175667	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.25
1451214480	827698515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698515	21206424	Genotypes CT + TT are associated with decreased trough concentrations when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	827698684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698684	20818834	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.25
1451214480	827812467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812467	21635144	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	827813909	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813909	21806386	Allele C is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele T.	2.5
1451214480	769172716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172716	15521904	Allele C is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation.	-0.75
1451214480	769174170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769174170	19865079	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1183533891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533891	23459029	Genotype TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183533896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533896	23459029	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183533912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533912	22706623	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.	1.5
1451214480	1183684051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684051	21903774	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1183690054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690054	23073208	Genotypes CT + TT is associated with increased metabolism of tacrolimus in healthy individuals as compared to genotype CC.	1.0
1451214480	1183697938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697938	21094796	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.25
1451214480	1183698005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698005	23149441	Genotype CC is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.0
1451214480	1183698721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698721	23557867	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.0
1451214480	1183700136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700136	24024898	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184470313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470313	24658827	Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184514498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514498	22889968	Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184514504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514504	22469198	Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.5
1451214480	1184514507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514507	23633119	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184514513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514513	21480817	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.75
1451214480	1184514516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514516	21072155	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1184514519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514519	21436775	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.25
1451214480	1184514528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514528	23278282	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514534	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514534	21094797	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514537	21677300	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514540	15502717	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184514543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514543	16906020	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514546	17192769	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514555	20415563	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1184514561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514561	15729180	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514567	17635182	Genotype CC is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.25
1451214480	1184514570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514570	17032130	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1184514573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514573	18334918	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	3.0
1451214480	1184514579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514579	18589174	Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514582	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514582	19067682	Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184514585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514585	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184514588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514588	21273673	Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.	1.5
1451214480	1184514591	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514591	16146556	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184514594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514594	16249748	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184514665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514665	21839244	Allele T is not associated with metabolism of tacrolimus in people with heart transplantation as compared to allele C.	-0.125
1451214480	1184514668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514668	24231473	Genotypes CT + TT is not associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	-0.25
1451214480	1184514696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514696	16424824	Genotype CT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.	1.0
1451214480	1184514835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514835	15919447	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515001	21671989	Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.	0.0
1451214480	1184515004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515004	21102498	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with HSCT as compared to genotype CC.	1.0
1451214480	1184515016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515016	23580812	Genotype CC is associated with decreased metabolism of tacrolimus in Kidney Transplantation.	0.125
1451214480	1184515019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515019	17430486	Genotypes CT + TT are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515022	18334918	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515026	19067682	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184515029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515029	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515035	16146556	Genotype CC is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1451214480	1184515163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515163	24024898	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1184515181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515181	17192769	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184515224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515224	24118301	Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.0
1451214480	1184515270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515270	16753004	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515288	21366650	Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1184515373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515373	18443548	Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184515446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515446	20415563	Genotype CC is associated with increased PBMC concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.25
1451214480	1184515460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515460	20393454	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184515480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515480	16906020	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1184515781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515781	21544031	Genotype CC is not associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	-2.0
1451214480	1184998169	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998169	21698374	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1184998356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998356	21922127	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1184998389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998389	22369694	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1184998516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998516	23364483	Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1185023279	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023279	25201288	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
1451214480	1185023332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023332	25271728	Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1451214480	1296599155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599155	25303300	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1451214480	1444666410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666410	25487141	Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1444693964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693964	22786571	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	0.75
1451214480	1444694094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694094	24739669	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	1.75
1451214480	1444694110	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694110	24739669	Genotypes CT + TT is not associated with concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	-0.75
1451214480	1444694176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694176	24435759	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1444694209	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694209	25279405	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1451214480	1444694255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694255	25565672	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with hemopoietic stem cell transplant as compared to genotype CC.	2.0
1451214480	1444694284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694284	25594874	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
1451214480	1448597114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448597114	27977332	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
1451214480	1448603528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603528	28246425	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.	1.25
1451214480	1449575706	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449575706	29804290	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	0.125
1451214480	1449747826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747826	29454235	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.75
1451214480	1448112425	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112425	27314545	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.	1.75
1451214480	1448106854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106854	17495880	Allele C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	1.0
1451214480	1451415515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415515	32843687	Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451214480	1451714340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451714340	33512723	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1451214480	1183693321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693321	22660440	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1183699973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699973	23305195	CYP3A5 *1/*1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1183699984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699984	23305195	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1183954989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183954989	18429967	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1183959875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959875	20383212	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of tacrolimus in children with hemopoietic stem cell transplant as compared to CYP3A5 *3/*3.	-0.25
1451214480	1184085726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184085726	24126681	CYP3A5 *3/*3 is associated with increased tacrolimus plasma trough levels and severely diminished tacrolimus clearance when treated with tacrolimus as compared to CYP3A5 *1/*1.	0.125
1451214480	1184470264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470264	24625991	CYP3A5 *3/*3 is associated with increased likelihood of achieving target concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1184470680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470680	24875272	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.25
1451214480	1184470726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470726	24656015	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1184470790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470790	24655974	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
1451214480	1184470893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470893	24528196	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
1451214480	1184470932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470932	24522145	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1184470999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470999	24465960	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
1451214480	1184471077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471077	24465960	CYP3A5 *3/*3 is not associated with likelihood of achieving target concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-1.0
1451214480	1184471246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471246	24444408	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	2.5
1451214480	1184471300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471300	24444408	CYP3A5 *3/*3 is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	2.5
1451214480	1184471417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471417	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1451214480	1184514654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514654	23990505	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1184515038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515038	19545678	CYP3A5 *1/*3 + *3/*3 is associated with increased blood concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.25
1451214480	1184515044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515044	21930396	CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentrations of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1184515084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515084	21528942	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.125
1451214480	1184515125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515125	22210422	CYP3A5 *1/*1 + *1/*3 is not associated with blood concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1451214480	1184515192	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515192	22339449	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with lung transplantation as compared to CYP3A5 *3/*3.	0.0
1451214480	1184515210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515210	24238261	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1184515311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515311	21528942	CYP3A5 *1/*1 + *1/*3 is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.125
1451214480	1185023177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023177	24383873	CYP3A5 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.5
1451214480	1444706282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706282	25894154	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1444934203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934203	25846845	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.75
1451214480	1445164647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164647	26177012	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
1451214480	1445584925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584925	26228923	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447520652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520652	26227094	CYP3A5 *1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447520795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520795	26543771	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447673635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447673635	26114223	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1447674165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674165	26635230	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1447674267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674267	26622455	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447674595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674595	26325438	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1447674691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674691	26615671	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.75
1451214480	1447946634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946634	26770526	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1447947435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947435	26915847	CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1447947447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947447	26915847	CYP3A5 *1/*1 is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	-0.375
1451214480	1447949204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949204	25673014	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1448267244	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267244	26667830	CYP3A5 *3 + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.	0.0
1451214480	1448285615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285615	26990259	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1448285727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285727	27110018	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1448525595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448525595	27885697	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1448530624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530624	28030534	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
1451214480	1448569672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569672	28094348	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1448602336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602336	28050888	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	0.0
1451214480	1448640944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640944	26924289	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1451214480	1448819453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819453	28540692	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1451214480	1448820606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820606	28736028	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1449004146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449004146	29043387	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	2.75
1451214480	1449165818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165818	28945481	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.25
1451214480	1449170380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170380	27138785	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
1451214480	1449170428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170428	29162334	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	1.0
1451214480	1449171352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171352	27966227	CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1449183240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449183240	29441922	CYP3A5 *1 is not associated with metabolism of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	-0.75
1451214480	1449748012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748012	29547545	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.5
1451214480	1449748260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748260	29603629	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1449748829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748829	29691732	CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	2.25
1451214480	1449748903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748903	29731062	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
1451214480	1449749340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749340	29733390	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
1451214480	1449749618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749618	29878980	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1449750499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750499	30251062	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1451214480	1450372838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372838	30260084	CYP3A5 *1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	0.75
1451214480	1450372870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372870	29229354	CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
1451214480	1450377052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450377052	30730287	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3 + *1/*1.	1.0
1451214480	1450415351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415351	30983501	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.25
1451214480	1451118200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118200	31513279	CYP3A5 *3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	2.25
1451214480	1183699846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699846	23588314	CYP3A5 *6 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183699837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699837	23588314	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183699855	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699855	23588314	CYP3A5 *7 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1184515509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515509	23588314	CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.	2.0
1451214480	1183945249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183945249	16501005	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in human liver microsomes as compared to CYP3A5 *3/*3.	This annotation is not used for clinical annotation scoring.
1451214480	1184515204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515204	24089074	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
981203618	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981203618	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
981203618	982006241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006241	23603345	Allele A is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
981203618	827824687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824687	17700593	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	2.25
981203618	827892780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892780	17121937	Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
981203618	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
981203618	1184471966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471966	24167597	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	3.25
981203618	1444607104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607104	25381393	Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	4.0
981203618	1449731731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731731	30114658	Genotype AT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	4.0
981203618	1447945538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945538	26099996	Genotype AT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.0
981203618	1447950006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447950006	26794347	Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele T.	4.0
981203618	1447959064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959064	24923815	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
981203618	1447988411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988411	19795123	Allele A is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
981203618	1447991448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991448	11156223	Allele A is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.25
981203618	1447991648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991648	19104657	Allele A is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.0
981203618	1448118919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448118919	18299612	Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil.	3.0
981203618	1448123106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123106	20819423	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	-1.25
981203618	1448123303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123303	21498394	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	3.0
981203618	1448124229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124229	23736036	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
981203618	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
981203618	1449161738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161738	28427087	Genotype TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AA + AT.	-2.0
981203618	1449162090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162090	29065426	Genotype AT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981203618	1449716974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716974	27122156	Genotype AT is associated with risk of Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
981203618	1450372255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372255	30858516	Genotypes AA + AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.25
981203618	1450373060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373060	30485432	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	0.25
981345382	1451320594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451320594	31242253	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.	1.75
981345382	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
981345382	769162953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162953	21178985	Allele C is associated with increased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.	3.0
981345382	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
981345382	1450929840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450929840	31220337	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.	2.0
981345382	1450957388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957388	31967516	Genotype CC is associated with increased likelihood of discontinuation when treated with hmg coa reductase inhibitors in people with Acute coronary syndrome and Myocardial Infarction as compared to genotype TT.	3.5
981345382	1448531979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531979	27595674	Allele T is not associated with increased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors in people with familial hypercholesterolemia as compared to allele C.	-1.75
981345382	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
981345382	1449576182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576182	29785580	Genotypes CC + CT are not associated with likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.	-0.75
981345382	1449576215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576215	29785580	Genotypes CC + CT are associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.	1.0
981420042	PA166104789	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104789		Annotation of FDA Label for gefitinib and EGFR	100
981420042	1446908230	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908230	26490356	Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	1.75
981420042	1446908159	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908159	26490356	Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
981420042	981417211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417211	20022809	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.0
981420042	981417228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417228	20573926	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417247	20573926	Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.0
981420042	981417256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417256	20573926	Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417279	21900837	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	2.5
981420042	981417296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417296	19692680	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.	3.25
981420042	981417305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417305	19692680	Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.	3.0
981420042	981419226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419226	22760226	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419236	22760226	Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419322	20038723	Allele G is associated with increased response rates when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	0.0
981420042	981419331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419331	20038723	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.	3.0
981420042	981419441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419441	16204011	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.25
981420042	981419460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419460	17047654	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.0
981420042	981419469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419469	17047654	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	1.5
981420042	981419477	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419477	17473659	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419589	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419589	17106442	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419598	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419598	17106442	Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	1.5
981420042	981419607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419607	16956694	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419616	16956694	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419624	16956694	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	3.0
981420042	981419634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419634	15897572	Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.	2.25
981420042	981419643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419643	15897572	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.	2.25
981420042	981419653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419653	16203769	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419668	17317677	Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
981420042	981419710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419710	17387341	Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419719	17387341	Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419727	17192902	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419736	17192902	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.75
981420042	981419746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419746	16865253	Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.0
981420042	981419755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419755	16865253	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.	1.5
981420042	981419803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419803	16115929	Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981419813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419813	17285735	Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475192	17429313	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475201	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475201	17429313	Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.	2.25
981420042	981475368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475368	22215752	Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
981420042	981477340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477340	22370314	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.25
981420042	981477349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477349	22370314	Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.75
981420042	981477357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477357	22370314	Allele G is not associated with Overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-1.25
981420042	981477365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477365	22370314	Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	2.0
981420042	981477373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477373	22370314	Allele G is not associated with progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-0.25
981420042	981477381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477381	22370314	Allele G is not associated with overall survival (OS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.	-0.25
981420042	827926134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827926134	15118073	Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	0.0
981203518	769278124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769278124	18305461	Genotype TT is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype CC.	2.0
981203518	827783588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783588	12825092	Genotype TT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.	0.75
981203518	827783690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783690	22012471	Genotype TT is not associated with anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.	-0.5
981203518	769278090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769278090	20520601	Genotype TT is associated with increased Anxiety Disorders when exposed to caffeine.	2.75
981203532	982033316	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033316	23651026	Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AG + GG.	0.0
981203532	769245521	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769245521	21325291	Allele G is not associated with expression of CDA in CEPH cell lines.	-0.0
981203532	827803662	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803662	21521023	Genotype GG is associated with increased expression of CDA in PBMCs.	0.0
981203532	827803666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827803666	21521023	Genotypes AG + GG are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype AA.	1.75
981203532	827829878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829878	22304580	Genotype GG is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.	2.25
1451141900	PA166228121	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228121		Annotation of CPIC Guideline for hydrocodone and CYP2D6	100
1451141900	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451141900	1451141860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141860	31969823	CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.	0.25
981203578	827793137	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827793137	21332319	Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	2.25
981203578	608431045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431045	20029384	Allele T is not associated with response to clozapine in people with Schizophrenia as compared to allele C.	-1.0
981203641	769164789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164789	15761113	Allele G is associated with increased glucuronidation of valproic acid.	0.0
981203641	827812612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812612	21806385	Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GT + TT.	2.5
981203641	827812655	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812655	21806385	Genotype GT is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype TT.	2.5
981203709	699642389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642389	15809899	Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C.	1.75
981203709	699642392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642392	17700364	Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations in people with HIV Infections as compared to allele C.	0.0
981204080	827849283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849283	21810746	Allele T is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele C.	3.25
981204090	827808476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808476	22124095	Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.	2.25
981204107	827690365	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827690365	17495879	Allele G is associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C.	1.0
981204107	827690372	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827690372	17495879	Allele G is associated with decreased risk of Coronary Disease when treated with aspirin as compared to allele C.	0.75
1451241420	1447944425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944425	26616266	NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with isoniazid in people with Tuberculosis as compared to NAT2 intermediate and rapid acetylators.	1.75
1451241420	1451308025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451308025	33165168	NAT2 slow acetylator is associated with increased adverse events when treated with isoniazid in healthy individuals as compared to NAT2 rapid acetylator.	0.125
1451241420	1448994962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994962	28799976	NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.	1.625
1451241420	981344330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344330	19686464	Genotype CT is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women with Tuberculosis.	0.25
1451241420	981240117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240117	19891553	Allele A is associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.5
1451241420	981861770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861770	11595069	Allele A is not associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele G.	-1.25
1451241420	981939788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939788	19891553	Allele A is not associated with risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
1451241420	1449002647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002647	29036176	Allele A is not associated with risk of drug-induced liver injury when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele G.	-2.5
1451241420	981862352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862352	19761367	NAT2 *4/*4 is not associated with likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis.	-1.5
1451241420	981936611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936611	22506592	NAT2 *6A/*7B is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981939951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939951	21753138	NAT2 *5B is not associated with likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis.	-1.5
1451241420	981952688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981952688	21856096	NAT2 *4 is associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.	2.25
1451241420	1183702608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702608	23875638	NAT2 *4 (assigned as rapid acetylator phenotype) is associated with decreased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.0
1451241420	1447962939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447962939	18330759	NAT2 *6A is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.25
1451241420	1451241480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451241480	18421452	NAT2 *5A/*5A + *5A/*6A + *5A/*7A + *6A/*6A + *7A/*7A are associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.25
1451241420	981344312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344312	17950035	NAT2 *5B/*7B + *6A/*6A + *6A/*7B + *7B/*7B are associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981476263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476263	20392357	NAT2 *5D + *6B + *7A are associated with increased risk of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.5
1451241420	981934211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934211	21261721	NAT2 *6B/*7A is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1451241420	981862026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862026	16677176	NAT2 *7A + *6B + *5A (assigned as slow acetylator phenotype) is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis.	-1.5
1451241420	1451435599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451435599	33135175	NAT2 *6B + *7A (assigned as slow acetylator phenotype) are associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis.	1.75
1451241420	981862092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862092	16770646	NAT2 *4/*5A + *4/*6B + *4/*7A + *4/*14A + *5A/*5A + *5A/*6B + *5A/*7A + *6B/*6B + *6B/*7A is not associated with increased likelihood of Toxic liver disease when treated with isoniazid and pyridoxal phosphate in people with Tuberculosis as compared to NAT2 *4/*4.	-1.25
1451241420	1183702528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702528	24188272	NAT2 *5D/*7A + *6B/*7A (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5D + *4/*7A.	2.25
1451241420	981934428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934428	22020825	NAT2 *6B + *7A (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934449	22020825	NAT2 *5A (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	This annotation is not used for clinical annotation scoring. Ambiguous genotyping for identification of *5 allele
1451241420	981934405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934405	22283902	NAT2 *6B + *7A + *5A (assigned as slow acetylator phenotype) is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	-1.5
1451241420	981934399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934399	21047300	NAT2 *5A + *6B + *7A (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	2.0
1451241420	1451797500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451797500	24888881	NAT2 *5A/*5A + *5A/*6B + *5A/*7A + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with increased risk of drug-induced liver injury when exposed to isoniazid as compared to NAT2 *4/*4 + *4/*5A + *4/*6B + *4/*7A (assigned as rapid acetylator phenotype) .	2.5
1451241420	981861818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861818	11915035	NAT2 *6B/*6B + *6B/*7A (assigned as slow acetylator phenotype) are associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.	2.5
1451241420	981861841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861841	12668988	NAT2 *5A + *6B + *7A (assigned as slow acetylator phenotype) are associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4 (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934205	21261721	NAT2 *5A/*7A is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	This annotation is not used for clinical annotation scoring. This paper also has other haplotypes contributing to same CA
1451241420	981934195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934195	21261721	NAT2 *5A/*4 is associated with decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	-2.5
1451241420	1183702632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702632	23394127	NAT2 *5D/*5D + *5D/*6B + *5D/*7A + *6B/*6B + *6B/*7A (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.	2.75
1451241420	981862142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862142	18023090	NAT2 *6A is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.	2.75
1451241420	981862039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862039	16246623	NAT2 *5B/*7B + *6A/*6A + *6A/*7B (assigned as slow acetylator phenotype) is associated with increased risk of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*12A (assigned as rapid acetylator phenotype) .	2.0
1451241420	981953978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981953978	22788240	NAT2 *5B + *5G + *6A + *6B + *5C + *17 + *5D + *7B + *6E + *6D + *6C + *14B + *5J + *5E + *5A + *14A is associated with increased likelihood of adverse reactions when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4 + *12A + *13A +*11A + *12C + *12B (assigned as rapid acetylator phenotype) .	2.75
1451241420	981934348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934348	22012226	NAT2 *5A + *5B + *6A + *7B +*14B +*5C (assigned as slow acetylator phenotype) is associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis as compared to NAT2 *4 + *12A + *13A.	1.5
1451241420	981851624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851624	23190413	NAT2 *5D + *6B + *7A + *14A (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
981204286	827807645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807645	18334915	Genotype GG is associated with decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes AA + AG.	1.75
981204286	827814015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814015	21806386	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.5
981204286	827830252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830252	12966368	Allele G is not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to allele A.	-1.5
981204286	1444705991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705991	25536375	Genotype GG is associated with decreased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.	1.5
981204306	769250209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250209	17529887	Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.	3.0
981204306	769146005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146005	20417680	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	-1.75
981204306	1451151740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451151740	32457604	Allele G is not associated with resistance to phenytoin in people with Epilepsy as compared to allele A.	-1.25
981204317	769250004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769250004	16220110	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	1.5
981204317	613978575	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978575	15805193	Allele A is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele G.	-1.0
981204361	981239689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239689	22940005	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.	-2.0
981204361	981344455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344455	22990067	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.75
981204361	981478621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478621	23150151	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.	-2.0
981204361	981483607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483607	22723959	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.	-1.25
981204361	981802700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802700	23056288	Genotypes AA + AG are associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	0.75
981204361	981802737	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802737	23056288	Genotype AA is associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	1.0
981204361	981802753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802753	23056288	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-0.5
981204361	981802786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802786	23056288	Genotypes AA + AG are not associated with increased risk of major adverse cardiovascular events (MACE) (more than one year) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-0.5
981204361	981802821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802821	23056288	Genotypes AA + AG are associated with increased risk of major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	1.0
981204361	981802835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802835	23056288	Genotypes AA + AG are not associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-1.0
981204361	981802847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802847	23056288	Genotypes AA + AG are not associated with increased risk of ischemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-0.5
981204361	981802858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802858	23056288	Genotypes AA + AG are not associated with all-cause mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-1.0
981204361	981802899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802899	23056288	Genotypes AA + AG are not associated with stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-0.5
981204361	981802910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802910	23056288	Genotype AA is associated with decreased bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	1.0
981204361	981802921	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802921	23364775	Allele A is not associated with increased risk of myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	-2.0
981204361	981843548	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843548	21918510	Genotypes AA + AG are associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	0.0
981204361	981843559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843559	22624833	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	-2.0
981204361	981843667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843667	22190063	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.	2.5
981204361	982032630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032630	20801498	Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.	2.5
981204361	982037849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037849	21831410	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	-1.5
981204361	1043766070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043766070	20650435	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.	-2.0
981204361	827814073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814073	21806387	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.	-1.5
981204361	655386894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386894	20801494	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.	3.0
981204361	655388271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388271	19106083	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	3.0
981204361	769169793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169793	17112805	Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.	1.25
981204361	1183699700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699700	24262617	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	-1.0
981204361	1183705612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705612	24535487	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.	-1.5
981204361	1184168867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168867	23726091	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.75
981204361	1184349841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349841	24762860	Allele A is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	-2.5
981204361	1184470351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470351	22045970	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.	-2.25
981204361	1184472517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472517	22285300	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	-1.75
981204361	1185234754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234754	25430046	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.	1.0
981204361	1185234764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185234764	25430046	Genotype AA is not associated with platelet aggregation when treated with clopidogrel as compared to genotypes AG + GG.	-0.25
981204361	1444607043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607043	25542807	Genotypes AA + AG are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.25
981204361	1444607054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607054	25542807	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
981204361	1444607066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607066	25542807	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
981204361	1444702924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702924	25850030	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.	2.25
981204361	1446896476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896476	26362473	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.	2.75
981204361	1449002186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002186	28914344	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.	-0.75
981204361	1184472137	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472137	22028352	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.	2.75
1451231100	PA166211021	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166211021		Annotation of DPWG Guideline for siponimod and CYP2C9	100
1451231100	PA166182738	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166182738		Annotation of FDA Label for siponimod and CYP2C9	100
1451231100	1451230861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230861	30088221	CYP2C9 *2/*3 + *3/*3 are associated with increased concentrations of siponimod in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1451231100	1451230840	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451230840	29273968	CYP2C9 *3/*3 + *2/*2 are associated with decreased metabolism of siponimod as compared to CYP2C9 *1/*1.	0.0
981204455	827923082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923082	18576903	Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.	1.5
981204455	655385617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385617	15778422	Allele A is not associated with pharmacokinetics of dicloxacillin.	-0.125
981203918	827922979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922979	15622315	Allele C is associated with decreased plasma efavirenz exposure when treated with efavirenz in people with HIV as compared to allele T.	2.0
981203918	1183703705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703705	24477223	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	-0.75
981203918	1184349374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349374	20625352	Genotype TT is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.	-0.5
981203918	1447680831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680831	26779253	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	-1.0
981203918	1448108161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108161	16267764	Genotypes CC + CT are not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT.	-1.25
981203918	1448108212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108212	20860463	Allele C is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	-0.5
981204137	827804302	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827804302	21391884	Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-0.5
981204137	769257609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257609	16386926	Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-1.5
981204137	769257752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257752	17125969	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele C.	-1.75
981204137	769257727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257727	16753003	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.	0.0
981204403	982034583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034583	23746184	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.	-1.5
981204403	827892730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892730	21332314	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.	2.75
981204403	827892734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892734	21332314	Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.	2.0
981204403	827892732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892732	21332314	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.	-1.75
981204403	1448519749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448519749	20530282	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
981204414	769262752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262752	21142915	Genotype GG is associated with decreased risk of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.	1.75
981204414	769245657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245657	20638924	Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.	-1.0
981204414	1448519742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448519742	20530282	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	-2.0
981204975	769171000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171000	17323057	Genotype AG is not associated with increased likelihood of Myelosuppression when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-1.25
981204975	978639856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639856	22838948	Allele A is not associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
981204975	769170674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170674	18458567	Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.0
981203808	827698623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827698623	21076384	Genotypes CT + TT are associated with increased likelihood of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203808	1183697981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697981	23149441	Genotype CC is not associated with risk of acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.5
981203808	1184515519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515519	19067682	Genotype TT is associated with increased risk of acute rejection when treated with tacrolimus in Kidney Transplantation as compared to genotypes CC + CT.	3.0
981203808	1184515525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515525	18443548	Genotype CT is associated with increased risk of acute rejection when treated with tacrolimus in Kidney Transplantation as compared to genotype CC.	1.5
981203808	1184515528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515528	17430486	Genotype CT is associated with increased risk of acute rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.5
981203808	1184515561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515561	16906020	Genotypes CT + TT is not associated with likelihood of acute rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-0.25
981203808	1184515564	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515564	18334918	Genotypes CT + TT is not associated with increased likelihood of biopsy-proven acute rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-1.5
981203808	1184515567	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515567	19125240	Genotypes CT + TT is not associated with increased risk of subclinical acute rejection when treated with tacrolimus in Kidney Transplantation as compared to genotype CC.	-1.25
981203808	1184998415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998415	22310591	Allele T is not associated with risk of Infection or transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
981203808	1185023288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185023288	25201288	Genotypes CT + TT is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
981203808	1444693896	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444693896	22786571	Genotype CC is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-1.0
981203808	1444694013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444694013	21886016	Genotypes CT + TT is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203808	1448597123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448597123	27977332	Genotype CC is not associated with nephrotoxicity or transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	-2.0
981203808	1184470744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470744	24656015	CYP3A5 *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.25
981203808	1184515531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515531	19343327	CYP3A5 *3/*3 is associated with decreased risk of allograft rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.25
981203808	1184515537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515537	19545678	CYP3A5 *1/*1 is associated with increased risk of acute rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	2.25
981203808	1444706295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706295	25894154	CYP3A5 *1/*1 is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	0.25
981203808	1445164660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445164660	26177012	CYP3A5 *1/*1 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	-0.25
981203808	1447674180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674180	26635230	CYP3A5 *1/*1 + *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.5
981203808	1447674608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674608	26325438	CYP3A5 *1/*3 + *3/*3 is associated with decreased risk of transplant rejection when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1.	3.5
981203808	1448255810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255810	26518946	CYP3A5 *1/*3 + *3/*3 are not associated with risk of delayed graft function, Drug Toxicity, Infection and transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	-1.25
981203808	1448427628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427628	27217047	CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Graft vs Host Disease when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.	1.5
981203808	1448530701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530701	28030534	CYP3A5 *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.25
981203808	1448604356	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448604356	28157649	CYP3A5 *1/*1 + *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.5
981203808	1449004108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004108	29043387	CYP3A5 *1/*1 + *1/*3 are associated with increased likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
981203808	1449004120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004120	29043387	CYP3A5 *1/*1 + *1/*3 are not associated with likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.75
981203808	1449172248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172248	29375701	CYP3A5 *1/*1 + *1/*3 is not associated with response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.25
981203808	1449183090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449183090	29161757	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	2.0
981203808	1449183251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449183251	29441922	CYP3A5 *1 is not associated with risk of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	-1.25
981203808	1449748185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748185	29550576	CYP3A5 *1/*1 + *1/*3 is not associated with response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.25
981203808	1449748725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449748725	29689130	CYP3A5 *1/*1 + *1/*3 is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.75
981203808	1449749486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749486	29735966	CYP3A5 *3/*3 is not associated with response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-1.5
981203808	1449749638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749638	29878980	CYP3A5 *1/*1 + *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.5
981203808	1450361683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450361683	30489455	CYP3A5 *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.5
981203936	769250136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250136	16815317	Genotype CC is associated with decreased metabolism of sirolimus in people with Transplantation as compared to genotypes CT + TT.	1.0
981203936	1447520795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520795	26543771	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
981203936	1448567727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567727	23974086	CYP3A5 *1/*3 is not associated with metabolism of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.0
981203936	1448567850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567850	17941052	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
981203936	1448567934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567934	22094953	CYP3A5 *1 is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	-0.75
981203936	1448603056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603056	28245187	CYP3A5 *1/*3 is associated with decreased concentrations of sirolimus as compared to CYP3A5 *3/*3.	1.5
981204372	982033553	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033553	11697464	Genotype GG is associated with increased steady-state level of digoxin as compared to genotypes AA + AG.	0.0
981204372	982037228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037228	17404720	Genotype AA is associated with decreased clearance of digoxin in healthy individuals as compared to genotypes AG + GG.	1.0
981204372	982042172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042172	12425480	Genotype AG is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.	-1.0
981204372	982042511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982042511	12425480	Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.	-1.0
981204372	982044204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044204	17652833	Genotype GG is not associated with clearance of digoxin in people with Heart Failure as compared to genotypes AA + AG.	-0.75
981204372	982044781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044781	18810246	Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.	1.5
981204372	827807733	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807733	18334914	Allele A is associated with increased serum concentrations of digoxin as compared to allele G.	0.0
981204372	827925284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925284	12189368	Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.	1.0
981204372	769170859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170859	10716719	Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.	1.5
1451241700	982046274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046274	23837476	Genotypes CT + TT are associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.	2.5
1451241700	982046278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046278	23837476	Genotypes CT + TT are associated with increased time to reach stable dose of tacrolimus in children with Transplantation as compared to genotype CC.	2.0
1451241700	1183491645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491645	23900887	Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241700	1183533905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533905	21359536	Allele C is associated with decreased dose of tacrolimus in people with liver transplantation as compared to allele T.	1.75
1451241700	1184512384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512384	22422348	Genotype TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	0.0
1451241700	1184514968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514968	16628701	Genotype CC is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.5
1451241700	1446899553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899553	26271661	Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1451241700	1184514988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514988	19289993	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451241700	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241700	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
981204272	827922851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827922851	22527101	Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.	-1.5
981204272	655387906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387906	18836089	Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.	1.75
981204272	1447954657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447954657	24704000	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.	-1.25
981204272	1451726355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451726355	33649523	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.	0.0
981203545	827816268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816268	21902500	Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	2.75
981203545	769169148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169148	19373123	Genotypes AA + AG are associated with increased dose of methadone in people with treatment for heroin addiction as compared to genotype GG.	-2.0
981203719	PA166124619	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166124619		Annotation of CPIC Guideline for tacrolimus and CYP3A5	100
981203719	PA166104983	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104983		Annotation of DPWG Guideline for tacrolimus and CYP3A5	100
981203719	981858954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858954	23073468	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	827699040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827699040	19258929	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.25
981203719	827813802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813802	21770725	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	827830139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830139	12966368	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	2.25
981203719	769166529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166529	21047202	Genotype TT is associated with risk of being underdosed when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1183532526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183532526	22871995	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1183533900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533900	23837477	Genotype CC is associated with decreased dose of tacrolimus in children with Transplantation as compared to genotypes CT + TT.	2.25
981203719	1183533922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533922	21711429	Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1183684248	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684248	24120259	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1183684255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684255	24120259	Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1183684260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684260	24120259	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.25
981203719	1184468834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468834	21047202	Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	2.25
981203719	1184514549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514549	12694072	Genotype CT is associated with increased dose of tacrolimus in children with heart transplantation as compared to genotype CC.	1.25
981203719	1184514552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514552	14578760	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1184514558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514558	15167702	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
981203719	1184514564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514564	15808586	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.5
981203719	1184514687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514687	23991193	Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	1.75
981203719	1184514784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514784	21047202	Genotype TT is associated with higher stable dose levels of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.	0.0
981203719	1184514793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514793	22101623	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	1184514796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514796	21851254	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
981203719	1184514802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514802	22469198	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.5
981203719	1184514808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514808	23146466	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514811	24024898	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514817	21480817	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.75
981203719	1184514826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514826	21671989	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	0.0
981203719	1184514829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514829	21566507	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514832	21677300	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
981203719	1184514838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514838	16753004	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514850	16146556	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
981203719	1184514853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514853	16249748	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1184514859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514859	17430486	Genotypes CT + TT are associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.0
981203719	1184514862	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514862	18334918	Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514865	19067682	Genotype TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184514868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514868	19125240	Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.	2.25
981203719	1184514871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514871	21273673	Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1184514874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514874	21331500	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	3.0
981203719	1184998300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998300	22304537	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.5
981203719	1184998312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998312	22704849	Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	2.75
981203719	1184998369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998369	21922127	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
981203719	1184998398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998398	22369694	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	1184998408	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998408	22310591	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
981203719	1185011784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185011784	25310192	Genotype CC is associated with decreased dose of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.	2.75
981203719	1444694034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694034	24739669	Genotypes CT + TT is associated with increased dose of tacrolimus in people with heart transplantation as compared to genotype CC.	2.25
981203719	1444694293	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694293	25594874	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	0.0
981203719	1448597107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448597107	27977332	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	2.5
981203719	1449147673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147673	29113387	Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1449732574	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732574	29393157	Genotype CC is associated with decreased dose of tacrolimus in people with Colitis, Ulcerative as compared to genotypes CT + TT.	2.0
981203719	827698530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698530	21206424	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
981203719	827785547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827785547	20818295	Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.	1.5
981203719	1183697996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697996	23149441	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
981203719	827784291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784291	21886016	Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
981203719	1183697400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697400	22183771	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1183959864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959864	20383212	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to CYP3A5 *3/*3.	-0.25
981203719	1184470735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470735	24656015	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184470804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470804	24655974	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	3.0
981203719	1184470883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470883	24528196	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1184471318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471318	24444408	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	3.0
981203719	1184471382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471382	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184471393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471393	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1184471403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471403	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.	1.75
981203719	1184514597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514597	19343327	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1184514634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514634	23146479	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.	2.75
981203719	1184514878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514878	19343327	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1184514887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514887	19545678	CYP3A5 *1/*3 + *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	2.25
981203719	1184514893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514893	20041908	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1184514901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514901	21528942	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1184514907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514907	21930396	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1184514921	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514921	23666583	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1184514927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514927	24089074	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
981203719	1184514946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514946	24033383	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	2.0
981203719	1184989793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989793	25322286	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1445164685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164685	26177012	CYP3A5 *3/*3 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	-0.25
981203719	1445297499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297499	25817604	CYP3A5 *3/*3 is not associated with dose of tacrolimus in people with Arthritis, Rheumatoid as compared to CYP3A5 *1/*1 + *1/*3.	-1.25
981203719	1447520665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520665	26227094	CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1447520826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520826	26543771	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1447673635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447673635	26114223	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.	1.75
981203719	1447946747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946747	26823971	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1447946767	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946767	26823971	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981203719	1447947417	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947417	26915847	CYP3A5 *1/*1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.	2.0
981203719	1448255771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255771	26518946	CYP3A5 *1/*3 + *3/*3 are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	1.75
981203719	1448267453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267453	26714287	CYP3A5 *3 is not associated with dose of tacrolimus in people with Kidney Transplantation.	-1.5
981203719	1448267466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267466	26990694	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.5
981203719	1448285878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285878	27225724	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
981203719	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
981203719	1448423892	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423892	26450467	CYP3A5 *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1448427616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448427616	27217047	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1448530690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530690	28030534	CYP3A5 *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1448640957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640957	26924289	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
981203719	1448819466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819466	28540692	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.75
981203719	1448819488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448819488	28605053	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	3.0
981203719	1449170393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170393	27138785	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.5
981203719	1449171185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171185	29162334	CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.	2.0
981203719	1449172013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172013	28401703	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.25
981203719	1449172236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449172236	29375701	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with Autoimmune Diseases as compared to CYP3A5 *3/*3.	-0.125
981203719	1449183103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449183103	29161757	CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.	2.5
981203719	1449747633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747633	29535109	CYP3A5 *1/*3 is not associated with dose of tacrolimus in children with henoch-schonlein purpura nephritis as compared to CYP3A5 *3/*3.	-0.125
981203719	1449747930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747930	29539600	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.5
981203719	1449748855	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748855	29691732	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.	1.25
981203719	1449748938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748938	29731062	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	1.0
981203719	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
981203719	1449750413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750413	29920880	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.	0.75
981203719	1450373276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373276	30704156	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Arthritis, Rheumatoid or Colitis, Ulcerative as compared to CYP3A5 *3/*3.	1.5
981203719	1448276612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276612	27266721	CYP3A5 *3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation.	0.0
981203719	1447674199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674199	26635230	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.0
981203719	1451554440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451554440	32848803	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.75
981345350	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
981345350	1451228580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228580	29950617	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.0
981345350	1451358200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358200	31981411	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.	1.5
981345350	1451358660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358660	27557342	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	1.75
981345350	827827497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827497	17473846	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.	1.5
981345350	1183631263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631263	23930675	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.	2.25
981345350	1184169599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169599	23876492	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.	2.0
981345350	1444693880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693880	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.	0.0
981345350	1451124180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124180	31857620	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.	0.125
981345350	1451141460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141460	32361904	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.	2.25
981345350	1447989994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989994	25673568	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.	0.125
981345350	1449733005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449733005	16198652	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.	1.5
981345350	1451226461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226461	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
981345350	982043808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043808	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
981345350	982043792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043792	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
981345350	982043801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043801	17568401	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1451244800	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1451244800	1451163180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451163180	32128760	Allele C is associated with increased exposure to atorvastatin as compared to allele T.	0.0
1451244800	1451164960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451164960	31594719	Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	1.5
1451244800	1451230062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230062	29442027	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	2.0
1451244800	769171454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171454	19374892	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.	This annotation is not used for clinical annotation scoring. drug drug interaction
1451244800	1451352820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352820	29039339	Genotypes CC + CT are associated with increased concentrations of atorvastatin as compared to genotype TT.	1.25
1451244800	1451352866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352866	26857559	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	1.75
1451244800	1451352940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352940	26373210	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.	0.125
1451244800	981758554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758554	23361102	Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.	0.125
1451244800	827827481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827481	17473846	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.	1.0
1451244800	1184169609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169609	23876492	Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.	1.5
1451244800	1447990018	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447990018	25673568	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.	0.125
1451244800	1451226420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226420	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1451244800	1451448741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451448741	33805706	SLCO1B1 *1/*5 + *5/*5 are associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	2.0
1451244800	1451352842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352842	28435225	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.0
1451244800	1184989258	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989258	15970799	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1451244800	1184989241	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184989241	15970799	SLCO1B1 *5 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.	0.0
1451244800	1451533063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451533063	20040338	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	1.75
1451244800	1451165020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451165020	31594719	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA
1451244800	1451905600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905600	35034348	SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.	2.5
1451241780	1184470178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470178	24351870	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241780	1184514719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514719	16421475	Genotypes CT + TT is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	0.75
1451241780	1184514722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514722	16628701	Genotypes CT + TT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.	1.0
1451241780	1184514725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514725	17568575	Genotypes CT + TT is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1184514748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514748	19384171	Genotypes CT + TT is associated with decreased concentration-to-adjusted dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1184515243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515243	17015051	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	1.75
1451241780	1184515246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515246	17875118	Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.25
1451241780	1184753650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753650	25141896	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	2.75
1451241780	1184754595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754595	24820765	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.25
1451241780	1444706064	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706064	25712187	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1448112500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112500	26518936	Genotype CC is associated with increased steady-state concentration of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1448569538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569538	28084894	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.5
1451241780	1448820454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820454	28685716	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1451241780	1449165670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165670	28941036	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1451241780	1184998363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998363	21922127	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	1.25
1451241780	1446899545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899545	26271661	Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1451241780	1184469270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469270	24911663	CYP3A5 *1/*3 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241780	1184470918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470918	24526611	CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451241780	1184471447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471447	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451241780	1184514760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514760	22210422	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1451241780	1184514766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514766	19289993	CYP3A5 *1/*3 is associated with decreased dose-adjusted trough levels of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1451241780	1184515125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515125	22210422	CYP3A5 *1/*1 + *1/*3 is not associated with blood concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1451241780	1448423903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423903	26450467	CYP3A5 *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	0.5
1451241780	1448568122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568122	28044353	CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.25
1451241780	1447679054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679054	26521259	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1451243216	1184514962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514962	22309416	Genotype CT are not associated with dose of tacrolimus in people with liver transplantation as compared to genotype CC.	-1.25
1451243216	1184998539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998539	23738951	Genotypes CT + TT is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.	1.5
1451243216	1185011784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185011784	25310192	Genotype CC is associated with decreased dose of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.	2.75
1451243216	1444694003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694003	21886016	Genotypes CT + TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.	1.125
1451243216	1184514971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514971	19289993	CYP3A5 *1/*1 + *1/*3 is not associated with dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.25
1451243216	1447946859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946859	26856709	CYP3A5 *1/*1 is not associated with dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.125
1451243216	1448308356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308356	27320564	CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451243216	1449748555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748555	29621122	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1451243216	1449749543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749543	29855074	CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1451254525	981477722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477722	23111421	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype CC.	3.0
1451254525	981477735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477735	23111421	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.	2.25
1451254525	1444696319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444696319	25704243	Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.	1.5
1451261620	1451234500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451234500	16175507	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.	1.75
1451261620	1451234800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451234800	20625347	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain in men as compared to allele C.	3.5
1451261620	1451260720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451260720	21898657	Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.	3.0
1451263877	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263877	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263877	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263877	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263877	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263966	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263966	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263966	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263966	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263966	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263966	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451263973	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263973	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263973	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263973	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263973	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263973	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451263980	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263980	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263980	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263980	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263980	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451263986	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451263986	1184510886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510886	9199552	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to allele C.	0.0
1451263986	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263986	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451263986	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263986	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451263986	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451264020	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264020	1184510886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510886	9199552	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to allele C.	0.0
1451264020	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451264020	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1451264020	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451264020	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451264020	1444697679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697679	11260227	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to caffeine or halothane as compared to allele C.	0.0
1451264060	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264060	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264060	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451264081	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264081	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264081	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451264087	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264087	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264087	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451264128	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264128	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264128	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451264140	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1451264140	1449564995	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449564995	22547813	Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.	0.0
1451264140	1447954410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954410	19825159	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1451274200	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274200	1450960041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960041	9865912	Genotype AC is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451274200	1448124993	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124993	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.	0.0
1451274045	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451274045	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451274045	827825073	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827825073	16115930	Genotype AT is associated with decreased catalytic activity of DPYD in peripheral blood mononuclear cells.	0.0
1451274045	827892661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892661	17064846	Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	2.75
1451274045	1450964760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964760	31745289	Allele A is associated with decreased activity of DPYD as compared to allele T.	0.0
1451274045	1444700055	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700055	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.	0.0
1451274045	1447814319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814319	26804652	Genotype AT is associated with increased exposure to fluorouracil in women with Colonic Neoplasms.	0.25
1451274045	1448109745	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448109745	26265035	Genotype AT is associated with decreased activity of DPYD.	0.0
1451274045	1448109863	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448109863	26804652	Allele A is associated with decreased activity of DPYD.	0.0
1451274045	1448124032	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124032	23588312	Genotype AT is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype TT.	-0.0
1451274045	1448126052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448126052	26216193	Genotype AT is not associated with metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.	-1.0
1451274045	1448255178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255178	11988088	Genotype AT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.0
1451274045	1448267635	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267635	25410891	Allele A is not associated with activity of DPYD.	-0.0
1451274045	1448605290	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605290	28295243	Genotype AT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype TT.	0.0
1451274090	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274090	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274090	1450932303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932303	31486738	Genotype AT is associated with increased severity of Drug Toxicity and Death when treated with capecitabine.	0.25
1451274090	982006241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006241	23603345	Allele A is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.75
1451274090	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451274090	1184000471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000471	24590654	Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	4.0
1451274090	1184471966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471966	24167597	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	3.25
1451274090	1449731731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731731	30114658	Genotype AT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	4.0
1451274090	1447945538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945538	26099996	Genotype AT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.0
1451274090	1447959064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959064	24923815	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
1451274090	1447988411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988411	19795123	Allele A is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274090	1447991648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991648	19104657	Allele A is associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.0
1451274090	1448123106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123106	20819423	Allele A is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms.	-1.25
1451274090	1448123303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123303	21498394	Genotype AT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	3.0
1451274090	1448124229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124229	23736036	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451274090	1448124799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124799	24647007	Genotype AT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.	-3.0
1451274090	1448125409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125409	25677447	Genotype AT is associated with increased severity of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype TT.	1.75
1451274090	1448255009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255009	21077799	Genotype AT is associated with risk of Death, Drug Toxicity and Ectropion when treated with capecitabine in people with Rectal Neoplasms.	0.25
1451274090	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451274090	1448568497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568497	27995989	Genotype AT is associated with increased risk of hand-foot syndrome when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype TT.	2.5
1451274090	1448605513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448605513	27454530	Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype TT.	2.5
1451274090	1448994811	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994811	28481884	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.	2.5
1451274090	1449161738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161738	28427087	Genotype TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AA + AT.	-2.0
1451274090	1449162090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162090	29065426	Genotype AT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
1451274090	1449716901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716901	29889674	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine in men with Colonic Neoplasms.	0.25
1451274090	1449732118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732118	29846282	Genotype AT is associated with Drug Toxicity when treated with capecitabine in men with Colonic Neoplasms.	0.25
1451274090	1449732196	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732196	29998006	Genotype AT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
1451274090	1450371932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371932	30723313	Genotypes AA + AT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	2.5
1451274090	1450372255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372255	30858516	Genotypes AA + AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	3.25
1451274090	1450373060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373060	30485432	Genotype AT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.	0.25
1451274984	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274984	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274984	769176388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176388	20819423	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
1451274984	1450950682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950682	19104657	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1451274984	981352330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352330	17000685	Genotype CT is associated with Death when treated with capecitabine in women with Breast Neoplasms.	0.25
1451274984	981352355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352355	20507294	Genotype CT is associated with Death and Drug Toxicity when treated with capecitabine in women with Breast Neoplasms.	0.25
1451274984	982006233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006233	23603345	Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
1451274984	982010242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010242	23585145	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274984	827810882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810882	21498394	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	3.5
1451274984	827823452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823452	19530960	Genotype CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
1451274984	769166460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166460	17203168	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	0.25
1451274984	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451274984	1184000475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000475	24590654	Allele T is not associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-3.5
1451274984	1184471962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471962	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1451274984	1450951380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951380	27454530	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC.	2.5
1451274984	1450951410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951410	27864592	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotype CC.	0.0
1451274984	1450951460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951460	28950804	Genotype TT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC.	0.25
1451274984	1450951504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951504	31382864	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Colonic Neoplasms.	0.25
1451274984	1450951600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951600	27738344	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.25
1451274984	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
1451274984	1450956264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450956264	23736036	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1451274984	1447959056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959056	24923815	Allele T is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
1451274984	1447988460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988460	19795123	Allele T is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
1451274984	1448124202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124202	23736036	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451274984	1448124817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124817	24647007	Genotype CT is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1451274984	1448994797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994797	28481884	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.	2.5
1451274984	1449162076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162076	29065426	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	0.0
1451274984	1449731693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731693	30114658	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	4.0
1451274984	1449732176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732176	29998006	Genotype CT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
1451274984	1450371900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371900	30723313	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
1451274984	1450373052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373052	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1451275020	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451275020	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451275020	1450950160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450950160	9323575	Genotypes CT + TT are associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	827824632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824632	18600527	Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	1.0
1451275020	827825063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825063	16151913	Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.125
1451275020	827827351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827351	10071185	Genotype TT is associated with Purine-Pyrimidine Metabolism, Inborn Errors.	0.125
1451275020	827892647	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827892647	17064846	Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.75
1451275020	1450945160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450945160	9472650	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450945204	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450945204	9472650	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450949680	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450949680	11895907	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450950020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950020	11988088	Genotype CT is associated with increased likelihood of Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.0
1451275020	1450950560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450950560	11953843	Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.0
1451275020	1450950647	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450950647	11953843	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951280	9470816	Genotype TT is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.0
1451275020	1450951440	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951440	28929491	Genotype CT is associated with decreased enzyme activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951521	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951521	8698850	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450951541	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951541	26804652	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450952584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952584	10803677	Genotype CT is not associated with decreased activity of DPYD.	-0.0
1451275020	1450953420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953420	16361556	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1451275020	1450955720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955720	20803296	Genotype CT is associated with decreased activity of DPYD.	0.0
1451275020	1450960760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960760	9439663	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1451275020	1450964980	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450964980	31745289	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1451275020	1445400130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445400130	26216193	Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.	2.0
1451275020	1447987751	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987751	23328581	Genotype TT is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype CC.	0.0
1451275020	1448267629	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267629	25410891	Allele T is not associated with activity of DPYD.	-0.0
1451275020	1448605295	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605295	28295243	Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC.	0.0
1451275020	1449165541	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449165541	26967565	Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC.	0.0
1451276160	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451276160	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451276160	1447959040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959040	24923815	Allele C is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Article designed about c.11295923C>G as additional risk variant and not to detect association with toxicity and c.1679T>G In the conclusion the authors state: "....c.11295923C>G DPYD variant as a predictive marker of earlyonset FP toxicity in a realworld clinical setting. We estimate that fewer than 50 patients need to be screened prior to therapy for this variant and for c.1905+1G>A, c.1679T>G and c.2846A>T in order to prevent one case of severe FP toxicity."
1451276160	1447945597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945597	26099996	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population Only two patients carried the varian and both had toxicities.
1451276160	1447991202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991202	19530960	Genotype AC is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population. Only 1 heterozygote variant carrier, which experienced grade 0-2 toxicity
1451276160	1450372235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372235	30858516	Genotypes AC + CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. c.1679T>G was present in 2 of the cases group, but were absent in the controls group. 2 patients developed Grade >=3 toxicity. Non-significance likely due to sample size.
1451276160	1448124824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124824	24647007	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Low number of subjects carried the variant, 1 out of 142 cases and 0 out of 330 control in Arm A and 1 out of 192 cases and 1 out of 340 controls in Arm B. Article mentioned also "Most patients with severe myelosuppression carried a rare DPYD allele: *2A, 2846T>A, *13 or A551T", with *13 being rs55886062.
1451276160	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1451276160	1448123368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123368	21498394	Genotype AC is not associated with likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	-1.5
1451276160	1448124253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124253	23736036	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1451276160	1449161870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161870	28427087	Genotype AA is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AC + CC.	-2.0
1451276160	1450373067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373067	30485432	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	0.25
1451275220	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451275220	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1451275220	982009679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009679	23588312	Genotype AC is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype AA.	1.75
1451275220	1450949780	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450949780	11895907	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1450950400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950400	11988088	Genotype AC is associated with increased severity of Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype AA.	0.0
1451275220	1450953540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953540	16361556	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1450965000	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450965000	31745289	Allele C is associated with decreased activity of DPYD as compared to allele A.	0.0
1451275220	1450952540	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952540	10803677	Genotype AC is associated with decreased activity of DPYD as compared to genotype AA.	0.0
1451275220	1447987724	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987724	23328581	Genotype CC is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype AA.	0.0
1451275220	1448267612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267612	25410891	Allele C is not associated with activity of DPYD.	-0.0
1451275220	1448605300	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448605300	28295243	Genotype AC is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype AA.	0.0
1451274165	PA166109594	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166109594		Annotation of CPIC Guideline for capecitabine and DPYD	100
1451274165	PA166104963	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104963		Annotation of DPWG Guideline for capecitabine and DPYD	100
1451274165	1183681878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681878	23736036	Genotype CG is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.	-1.75
1451274165	1184471970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471970	24167597	Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1451274165	1444698794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698794	25782327	Genotype CG is not associated with severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	-1.25
1451274165	1447954949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954949	24923815	Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	3.75
1451274165	1449161752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161752	28427087	Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.	-2.0
1451274165	1449162097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162097	29065426	Genotype CG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype GG.	-2.0
1451428340	1043859096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859096	15592325	CYP2D6 *9 + *29 + *45 + *46 + *17 + *10 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	2.0
981419540	981419504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419504	17376224	Allele A is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele G.	2.25
981238323	827704813	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704813	20568049	Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	1.5
981238323	827704840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704840	21362365	Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.	2.0
981238323	827824994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824994	22188361	Genotype AA is not associated with increased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes AG + GG.	-2.0
981238323	655386344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386344	19786980	Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes AG + GG.	2.5
981238323	1449576756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576756	29938344	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	-1.5
1451428500	1447959180	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959180	26544071	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.	0.0
1451430540	1447959407	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959407	26406933	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of venlafaxine as compared to CYP2D6 *1.	0.0
1451592476	1451592449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451592449	33476460	Genotypes CT + TT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype CC.	3.25
1451431120	1448612735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448612735	28358139	HLA-B *15:21 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine as compared to HLA-B *07:02:01.	1.5
1451431120	1449004817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004817	29053440	HLA-B *15:21 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	0.25
1451431120	1451407660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451407660	31896765	HLA-B *15:21 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy, Mood Disorders or neuropathic pain.	2.0
1451431120	1451431020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451431020	33910375	HLA-B *15:21 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	This annotation is not used for clinical annotation scoring. This looks to be duplicate of PMID: 31896765
1451431120	1451641220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641220	34350628	HLA-B *15:21 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	0.0
1451435940	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451435940	1444699253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699253	14681830	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele C.	0.0
1451435940	1444699277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699277	17085680	Allele T is associated with Ototoxicity when treated with streptomycin as compared to allele C.	0.25
1451435940	1449732321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732321	29876232	Allele T is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele C.	0.25
1451435940	1444699259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699259	16380089	Allele T is associated with Ototoxicity when treated with gentamicin, micronomicin or streptomycin as compared to allele C.	0.25
1451435940	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451592484	1451592467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451592467	33476460	Genotypes CC + CT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype TT.	3.25
1451435945	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451435945	1444699296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699296	17698299	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1451435945	1449732321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732321	29876232	Allele T is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele C.	0.25
1451435945	1444699283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699283	17434445	Allele T is associated with Ototoxicity when treated with gentamicin as compared to allele C.	0.25
1451435945	1444699290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699290	17698030	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1451435945	1444699271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699271	20416460	Allele T is not associated with Ototoxicity when treated with gentamicin as compared to allele C.	-0.25
1451435945	1444699259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699259	16380089	Allele T is associated with Ototoxicity when treated with gentamicin, micronomicin or streptomycin as compared to allele C.	0.25
1451435945	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451435945	1451440104	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451440104	25474306	Allele T is associated with decreased activity of MT-RNR1 when exposed to gentamicin.	0.0
1451436100	1444699259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699259	16380089	Allele T is associated with Ototoxicity when treated with gentamicin, micronomicin or streptomycin as compared to allele C.	0.25
1451436121	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436121	1447964718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964718	18830133	Allele T is associated with increased risk of Ototoxicity when treated with tobramycin in people with Cystic Fibrosis as compared to allele C.	0.25
981238397	769171080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171080	17264302	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	3.0
1451436133	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436133	1444699717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699717	15841390	Allele C is associated with Ototoxicity when treated with gentamicin in children as compared to allele T.	0.25
1451436133	1444699702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699702	15555598	Allele C is associated with Ototoxicity when treated with gentamicin as compared to allele T.	0.25
1451436133	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436133	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451436138	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436138	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436138	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451436180	1451434720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451434720	7550368	Allele CCCCCCC is associated with increased risk of Ototoxicity due to aminoglycoside antibacterials.	0.25
1451434860	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434860	1444697353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697353	19818876	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin in children with as compared to allele A.	0.0
1451434860	1444697282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697282	18820594	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434860	1449732298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732298	29805548	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.0
1451434860	1444697639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697639	25155176	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin in infants as compared to allele A.	3.0
1451434860	1444697089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697089	11857751	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434860	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697250	17637808	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697293	19376484	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434860	1444697449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697449	20416460	Allele G is associated with Ototoxicity when treated with gentamicin in infants as compared to allele A.	0.25
1451434860	1444697463	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697463	21495045	Allele G is not associated with Ototoxicity when treated with gentamicin in infants as compared to allele A.	-0.25
1451434860	1444697495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697495	22475488	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1451434860	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434860	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434860	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434860	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434860	1451437709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437709	17723226	Allele G is associated with increased risk of Ototoxicity due to gentamicin.	0.25
1451434860	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1451434860	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434860	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434860	1451440094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440094	24252789	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin.	0.25
1451434860	1451440143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440143	26497601	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin.	0.25
1451434860	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1451436226	1451434780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451434780	7550368	Allele C is associated with increased risk of Ototoxicity due to aminoglycoside antibacterials.	0.25
1451436209	1451434764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451434764	7550368	Allele C is associated with increased risk of Ototoxicity due to aminoglycoside antibacterials.	0.25
1451599320	769171557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171557	18784617	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	2.25
1451599320	1184999851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999851	25155934	Genotype GG is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype AA.	-1.75
1449004210	1448640683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640683	28775293	Genotypes CT + TT are associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	3.5
1449004220	1449001996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449001996	28763744	Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A.	2.0
1449004239	1448821242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821242	28814798	Genotype AA is associated with increased risk of Dermatitis when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AC + CC.	2.75
1449004245	1448821271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821271	28814798	Genotype CC is associated with increased risk of Dermatitis when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.	2.75
1449004487	1448821299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821299	28814798	Genotype CC is associated with decreased risk of Myelosuppression when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AC.	3.25
1449004487	1449004378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004378	28814798	Allele C is not associated with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia and Thrombocytopenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to allele A.	-1.75
1449004522	1448821255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821255	28814798	Genotypes AA + AG are associated with increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotype GG.	3.25
1449004522	1449004423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004423	28814798	Allele A is not associated with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to allele G.	-1.75
1449004528	1448821210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821210	28814798	Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotype AA.	2.75
1449004528	1449004439	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004439	28814798	Allele G is not associated with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to allele A.	-1.75
1449004567	1448998341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998341	28837897	Genotype GG is associated with increased concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.	1.5
1449004567	1448998389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998389	28837897	Allele A is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele G.	2.5
1449140063	1448639878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448639878	28676933	Allele T is associated with decreased likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to allele C.	2.5
1449140063	1449140029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449140029	28676933	Genotype TT is associated with decreased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT.	1.0
1449140273	1448926366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448926366	28796378	Allele T is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	3.5
1449144292	1449144194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144194	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144298	1449144201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144201	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144304	1449144207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144207	29121268	Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1449004229	1448821318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821318	28753467	Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T.	2.5
1449004229	981859205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859205	21747585	Allele C is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	-1.75
1449004229	1183612568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183612568	23859570	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	-1.0
1449004229	1183612769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183612769	23859570	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	-2.0
1449004229	1184999830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999830	25155934	Genotype CC is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype TT.	-1.75
1449144310	1449144213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144213	29121268	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1449144316	1449144219	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144219	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449005066	1451439540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451439540	29043387	Genotype CT is associated with increased likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with as compared to genotype TT.	3.25
1451599327	769171557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171557	18784617	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	2.25
1449144322	1449144225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144225	29121268	Allele C is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144328	1449144231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144231	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144334	1449144238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144238	29121268	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1449144340	1449144244	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144244	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449144346	1449144250	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144250	29121268	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1449144352	1449144256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144256	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.	0.0
1449564190	1449564143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449564143	29871907	Allele C is associated with increased risk of Hypertension due to bevacizumab in people with Colorectal Neoplasms as compared to allele A.	0.0
1449564196	1449564133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449564133	29871907	Allele G is associated with increased risk of Hypertension due to bevacizumab in people with Colorectal Neoplasms as compared to allele A.	0.0
1449564202	1449564166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449564166	29871907	Allele A is associated with increased risk of Hypertension due to bevacizumab in people with Colorectal Neoplasms as compared to allele C.	0.0
1451599340	769171557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171557	18784617	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	2.25
1451599340	1184999851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184999851	25155934	Genotype GG is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype AA.	-1.75
1451434900	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434900	1444696947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696947	9039999	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.0
1451434900	1444697015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697015	9391883	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697127	12920080	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697353	19818876	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin in children with as compared to allele A.	0.0
1451434900	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434900	1444697120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697120	12031626	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697145	14755216	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697179	16168391	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele A.	0.25
1451434900	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434900	1444697212	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697212	16631122	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697250	17637808	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697293	19376484	Allele G is associated with Ototoxicity when treated with gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434900	1444696916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696916	7689389	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434900	1444697037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697037	9779807	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697046	9831149	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1444697075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697075	9950117	Allele G is associated with Ototoxicity when treated with streptomycin as compared to allele A.	0.25
1451434900	1446897414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897414	11174059	Allele G is associated with Ototoxicity when treated with isepamicin or streptomycin as compared to allele A.	0.25
1451434900	1451436280	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436280	8687424	Allele G is associated with decreased activity of MT-RNR1 when exposed to streptomycin in HeLa cells.	0.0
1451434900	1451436622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436622	11870684	Allele G is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451434900	1451437464	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437464	12054632	Allele G is not associated with activity of MT-RNR1 when exposed to streptomycin in cybrids.	-0.0
1451434900	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434900	1451437675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437675	16935512	Allele G is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451434900	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1451434900	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434900	1451437874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437874	19835846	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1451434900	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434900	1451440086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440086	23256547	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1451434900	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1449564208	1449564175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449564175	29871907	Allele C is associated with increased risk of Hypertension due to bevacizumab in people with Colorectal Neoplasms as compared to allele T.	0.0
1450112801	1450045127	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045127	29791011	Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.	2.0
1451599347	769171557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171557	18784617	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	2.25
1451599354	769171557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171557	18784617	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	2.25
1449190656	1184466781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466781	21169036	HLA-B *15:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	2.25
1449190656	1184468150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468150	22818943	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	-1.75
1449190656	1184468220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468220	23829937	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine.	-2.0
1449190656	1184988711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988711	24897291	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine.	-0.5
1449190656	1184988858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988858	22429379	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	0.25
1449190656	1448264250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264250	27666425	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	-2.0
1451436481	1451436467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436467	10326749	Allele CCCCCCC is associated with increased risk of Ototoxicity due to dihydrostreptomycin or streptomycin.	0.25
1451436481	1451436638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436638	12037390	Allele CCCCCCC is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451436481	1451437920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437920	20171168	Allele CCCCCCC is not associated with risk of Ototoxicity when treated with amikacin, kanamycin or streptomycin.	-0.25
1450932687	1450932629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932629	30549211	Genotype AA is associated with increased likelihood of Vomiting when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.	-2.25
1450932687	1450932557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932557	30549211	Genotypes AA + GG are associated with increased likelihood of adverse events or Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG.	2.75
1451436473	1451436467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436467	10326749	Allele CCCCCCC is associated with increased risk of Ototoxicity due to dihydrostreptomycin or streptomycin.	0.25
1451434880	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434880	1444696940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696940	8414970	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.0
1451434880	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697155	15708009	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697188	16375862	Allele G is associated with Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1451434880	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434880	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434880	1451437476	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437476	12127547	Allele G is associated with increased affinity to MT-RNR1 of kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434880	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434880	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434880	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1451434880	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1451434905	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434905	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434905	1451437460	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437460	12054632	Allele G is associated with decreased activity of MT-RNR1 when exposed to neomycin or paromomycin in cybrids.	0.0
1451434905	1451437476	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437476	12127547	Allele G is associated with increased affinity to MT-RNR1 of kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434905	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1451434920	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434920	1444697442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697442	20353758	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or streptomycin as compared to allele A.	0.25
1451434920	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434920	1444697006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697006	9164619	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin, kanamycin, neomycin or streptomycin as compared to allele A.	0.25
1451434920	1448256010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256010	27427311	Allele G is associated with risk of Ototoxicity when treated with amikacin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434920	1451436542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451436542	10661905	Allele G is associated with increased risk of Ototoxicity when treated with amikacin.	0.25
1451434930	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451434930	1447964710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964710	18830133	Allele G is associated with increased risk of Ototoxicity when treated with tobramycin in people with Cystic Fibrosis as compared to allele A.	0.25
1451434930	1451433420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451433420	24703164	Allele G is not associated with Ototoxicity when treated with tobramycin in children with Cystic Fibrosis as compared to allele A.	-0.25
1451434930	1444697622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697622	24703164	Allele G is associated with Ototoxicity when treated with amikacin, gentamicin or tobramycin in children with Cystic Fibrosis as compared to allele A.	0.25
1451434930	1451436400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451436400	9315872	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, hygromycin b, kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434930	1451437476	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437476	12127547	Allele G is associated with increased affinity to MT-RNR1 of kanamycin, neomycin, paromomycin or tobramycin.	0.0
1451434930	1451437860	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451437860	19687236	Allele G is associated with increased affinity to MT-RNR1 of gentamicin, kanamycin, neomycin, paromomycin, streptomycin or tobramycin.	0.0
1448635968	1448635943	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635943	28688202	HLA-DRB3 *01:01:02:01 is associated with increased likelihood of heparin-induced thrombocytopenia when treated with heparin.	3.75
1449163928	827696091	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827696091	21593735	Allele A is associated with decreased activity of CYP1A2.	0.0
1449163928	769246583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769246583	10101295	Genotypes AA + AG are associated with decreased metabolism of caffeine as compared to genotype GG.	1.0
1449163928	1449163901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163901	29282363	Allele A is not associated with metabolism of caffeine as compared to allele G.	-0.75
1449162866	1449162769	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162769	24709712	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.	1.0
1449162866	1450375434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375434	17265061	Allele A is associated with increased concentrations of tramadol in healthy individuals as compared to allele G.	0.25
1449162899	1449162764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162764	24709712	Genotype AA is associated with increased exposure to tramadol as compared to genotype CC.	1.0
1449162899	1450375453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375453	17265061	Allele A is not associated with clearance of o-desmethyltramadol or tramadol in healthy individuals as compared to allele T.	-0.5
1449162912	1449162758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162758	24709712	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.	1.0
1449163252	1449162823	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162823	29282361	Genotype CC is associated with increased risk of Osteonecrosis when treated with corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	3.0
1449163252	1449162880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449162880	29282361	Genotype CC is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes CT + TT.	0.0
1449163306	1449162793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162793	29282361	Genotype AA is associated with increased risk of Osteonecrosis when treated with corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.	3.75
1449163306	1449162875	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449162875	29282361	Genotype AA is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes AC + CC.	0.0
1449164609	1449164371	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164371	28485375	Genotype AT is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.	2.5
1449164746	1449164715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164715	28762371	Genotypes AA + AG is associated with decreased risk of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.	3.0
1449164752	1449164702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164702	28762371	Genotypes CG + GG is associated with increased risk of conjunctival hemorrhage when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	2.5
1449164863	1449160237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449160237	29198060	Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.	1.0
1449164869	1449160218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449160218	29198060	Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.	1.0
1449165034	769171352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171352	20386493	Genotype TT is associated with decreased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.5
1449165034	1449164833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164833	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.75
1449188737	1449188424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188424	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	2.25
1449271360	827807210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807210	17724700	Genotypes CC + CT is associated with decreased metabolism of morphine in people with Anemia, Sickle Cell as compared to genotype TT.	1.0
1449188570	655388486	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388486	11692083	Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.	0.0
1449188570	982031251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031251	23651023	CYP2C9 *2 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449188570	982031260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031260	23651023	CYP2C9 *3 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449188570	1184996740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184996740	18781852	CYP2C9 *1/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.0
1449188570	1184996754	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184996754	18781852	CYP2C9 *1/*2 + *2/*2 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.0
1449188570	1444705857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705857	24956252	CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444705909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705909	24919870	CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444706561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706561	22252093	CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444706597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706597	22252093	CYP2C9 *1/*2 + *2/*2 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444707009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707009	19225451	CYP2C9 *2/*2 + *2/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.5
1449188570	1444707293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707293	15128048	CYP2C9 *1/*2 + *2/*2 + *2/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.5
1449188570	1444707332	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707332	15116052	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1444707358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707358	15116052	CYP2C9 *1/*2 + *2/*2 are not associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.5
1449188570	1444707371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707371	14614357	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.25
1449188570	1444707455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707455	12634980	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	0.0
1449188570	1444707467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707467	12414349	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.75
1449188570	1444707520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707520	11692083	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	0.25
1449188570	1444708161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708161	24911077	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	2.75
1449188570	1447678839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678839	16815313	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.	3.0
1449188570	1449188485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188485	29479633	CYP2C9 *3 is associated with increased likelihood of Blood Coagulation Disorders when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.	1.5
1449169595	1449169568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169568	29250329	Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.	1.75
1449169668	1449169287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169287	29425227	Genotypes AG + GG is associated with increased risk of Colonic Neoplasms in people not taking aspirin as compared to genotype AA.	0.0
1449170060	1449169878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169878	29238301	HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.	2.75
1449170060	1184468267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468267	23830818	HLA-A *33:03 is associated with decreased risk of Maculopapular Exanthema when treated with lamotrigine.	1.75
1449170150	1449170097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170097	29392141	Genotypes AG + GG are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype AA.	3.75
1449752771	1449752641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752641	29925895	Genotypes CC + CG is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.	3.5
1450813825	1450813810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813810	22048466	Genotypes CT + TT are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype CC.	3.0
1450415170	PA166104995	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104995		Annotation of DPWG Guideline for metoprolol and CYP2D6	100
1450415170	1450415150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415150	31107373	CYP2D6 poor metabolizers are associated with decreased dose of metoprolol.	1.0
1450415170	1449717747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717747	28181117	CYP2D6 *4 is associated with decreased dose of metoprolol in people with Heart Failure.	2.0
1450814653	1450814595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814595	22947179	Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.75
1450928460	1450928092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928092	28696411	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1450928473	1450928104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928104	28696411	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1450928522	1450928113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928113	28696411	Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.	0.0
1450822470	1450822385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822385	22500942	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.	3.0
1449000354	1446899382	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446899382	24647041	CYP2D6 *2 + *9 + *25 + *26 + *28 + *32 + *43 + *45 + *70 are associated with decreased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1449000354	1446899430	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446899430	24647041	CYP2D6 *53 is associated with increased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1449000354	1447959237	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959237	24647041	CYP2D6 *7 + *12 + *114 + *31 + *36 + *37 + *40 + *47 + *51 + *52 + *54 + *55 + *57 + *62 + *63 + *64 + *65 + *71 + *72 + *75 are associated with decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1449000354	1447959334	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959334	24647041	CYP2D6 *10 + *14 + *17 + *18 + *29 + *30 + *35 + *46 + *50 + *61 are associated with decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1449000354	1448616567	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616567	24647041	CYP2D6 *22 + *23 + *24 + *27 + *33 + *49 are not associated with decreased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	-0.0
1449000354	1448616608	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616608	24647041	CYP2D6 *39 + *48 are associated with decreased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1450822778	1450822752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822752	23318993	Allele G is associated with increased risk of Heart Arrest or Respiratory Insufficiency due to antidepressants, antipsychotics, benzodiazepine derivatives, opioids or Sympathomimetics Overdose as compared to allele A.	2.0
1450822829	1450820886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820886	24447405	Genotype CC is associated with increased likelihood of cessation of nicotine in men with Tobacco Use Disorder as compared to genotypes CT + TT.	1.25
1450823316	1450821968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821968	25891233	Allele A is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to allele G.	2.75
1450823707	1450823635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823635	26320194	Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	1.75
1450928608	769171148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171148	18511696	Genotype CC is associated with increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to genotype AA.	0.0
1450928608	1183616476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616476	23859572	Genotype AA is not associated with percentage inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotype AC.	-0.25
1450928608	1450928579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928579	28820077	Genotypes AC + CC are associated with decreased response to aspirin or prasugrel as compared to genotype AA.	1.75
1449000657	1448112281	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448112281	26968424	CYP2D6 *2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98 are associated with decreased clearance of methadone as compared to CYP2D6 *1.	0.0
1449000657	1449192891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192891	17725248	CYP2D6 *9 + *10 + *41 are not associated with clearance of methadone in people with Opioid-Related Disorders and Pain as compared to CYP2D6 *1 + *2 + *33.	-0.75
1450812333	1450812289	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812289	18690117	Allele A is not associated with response to nicotine in women as compared to allele G.	-1.5
1450812333	1450812316	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812316	18690117	Allele A is associated with increased response to nicotine in men as compared to allele G.	2.5
1448636924	1448636706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636706	28727815	Allele A is associated with decreased likelihood of discontinuation when treated with everolimus in women with Breast Neoplasms as compared to allele G.	1.75
1450812912	1450812886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812886	21039637	Genotype TT is associated with increased severity of Alcoholism due to ethanol as compared to genotypes AA + AT.	1.75
1450820979	1450820941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820941	24498031	Genotype CC is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotypes CT + TT.	0.0
1449565072	1449557511	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557511	29751792	Allele C is not associated with overall survival or progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.25
1449565072	1449557822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557822	29751792	Allele T is not associated with severity of Neutropenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	-1.25
1449565072	1449557843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449557843	29751792	Genotype CC is associated with increased severity of Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CT.	2.75
1449748502	1449748454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748454	29615122	Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.	2.25
1450810266	1450823059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823059	25744370	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	3.5
1450810266	1450810059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810059	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele C.	2.75
1450822281	1450822272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822272	26092968	Genotype AG is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype AA.	2.75
1450822281	1450823864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823864	26449981	Allele G is not associated with craving of nicotine in children as compared to allele A.	-2.0
1450823109	1450822845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822845	25744370	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.5
1450823322	1450822161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822161	26042510	Genotype AA is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to genotypes AG + GG.	0.0
1451437666	1451437660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437660	16782057	Allele G is associated with increased risk of Ototoxicity when treated with streptomycin.	0.25
1451437721	1451437683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437683	18261986	Allele G is associated with increased risk of Ototoxicity when treated with gentamicin.	0.25
1450814529	1450814517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814517	22798433	Allele A is associated with increased dose of ethanol in children as compared to allele G.	2.0
1450814671	1450814625	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814625	22947179	Genotype TT is associated with decreased response to bupropion in people with Depressive Disorder, Major as compared to genotype CT.	2.25
1450814929	1450814910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814910	23147557	Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	2.25
1450931522	1450931477	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931477	30132178	Genotype GG is associated with increased risk of Alcoholism due to ethanol in men as compared to genotypes CC + CG.	3.5
1450936205	1450936080	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936080	30822619	Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.	0.0
1449269473	1449269459	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269459	29502154	Genotype CT is not associated with response to oxycodone in people with Neoplasms and Pain as compared to genotype CC.	-1.25
1449269473	1449269466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269466	29502154	Genotype TT is associated with decreased response to oxycodone in people with Neoplasms and Pain as compared to genotype CC.	1.75
1449269910	1444607225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607225	25521356	Genotype TT is not associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	-2.0
1449269910	1448108311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108311	27262824	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to allele C.	-0.25
1449269910	1444697545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697545	25769357	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.	3.5
1449269910	1444705902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705902	24919870	Genotypes CT + TT is associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to genotype CC.	3.0
1449269910	1444707678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707678	23423913	Genotype TT is associated with increased likelihood of Hemorrhage when treated with phenprocoumon as compared to genotype CC.	0.0
1449269910	1447222942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222942	18574025	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1447223015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223015	18690342	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-1.5
1449269910	1447519301	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519301	23602689	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.5
1449269910	1447519358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519358	21148049	Allele T is not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to allele C.	-1.5
1449269910	1447519399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519399	25244877	Allele T is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	0.0
1449269910	1447520016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520016	26445138	Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.0
1449269910	1447680512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680512	26777610	Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	2.5
1449269910	982044609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044609	18950464	Genotype TT is not associated with risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.	-1.25
1449269910	978616289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978616289	22571356	Genotype TT is associated with increased likelihood of Hemorrhage when treated with warfarin as compared to genotype CC.	3.0
1449269910	1184472922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472922	24474498	Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to genotype CC.	0.0
1449269910	1184473637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473637	25001883	Genotype CT is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to genotype CC.	2.75
1449269910	1184483191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483191	23932037	Genotypes CT + TT is not associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to genotype CC.	-1.0
1449269910	1184483278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483278	23774101	Genotype TT is not associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.	-1.5
1449269910	1184483882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483882	23104259	Allele T is not associated with increased risk of all, major and minor hemorrhage as well as over anticoagulation when treated with warfarin as compared to allele C.	-1.75
1449269910	1184509978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509978	22592842	Allele T is not associated with increased risk of bleeding events during the 6-year follow up in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.	-1.5
1449269910	1448257297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257297	27488176	Allele T is not associated with risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1448262987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262987	27581200	Allele T is not associated with increased risk of Hemorrhage when treated with warfarin as compared to allele C.	-2.0
1449269910	1448602391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602391	28033245	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	2.0
1449269910	1449005252	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449005252	28689179	Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to genotype CC.	3.0
1449269910	1449190889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190889	29432897	Allele T is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	2.75
1449269910	1449269120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449269120	29577257	Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to genotype CC.	3.5
1145231686	982043213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043213	16722833	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.	-0.125
1145231686	1043818325	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818325	19667110	Genotype CC is associated with increased percent reduction in LDL-cholesterol when treated with pravastatin in people with Acute coronary syndrome.	2.5
1451605911	827829013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829013	22310352	Allele G is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to allele A.	0.0
1451605946	1184348813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348813	24624910	Allele T is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.	This annotation is not used for clinical annotation scoring. Association only found when both rs2268639 and rs13429709 genotypes are considered.
1450377214	1450377157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377157	27488001	Allele G is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele A.	2.25
1451606000	1448604092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604092	28210634	Allele A is associated with decreased response to warfarin in women with Thrombosis as compared to allele G.	0.25
1449271027	1449270634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270634	29593529	Allele G is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271033	1449270725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270725	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271057	1449270643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270643	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271063	1449270618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270618	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449271069	1449270824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270824	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1451439812	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451439812	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1449165230	769178727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769178727	17609683	Allele C is associated with increased bioavailability (AUC, CL & AUC/CL ratio) when exposed to metformin.	2.0
1449165230	1448631741	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631741	27859023	Allele T is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	-1.0
1449165230	1448998564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998564	28834135	Allele T is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele C.	-0.25
1449165230	1448999777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448999777	28380657	Genotype TT is associated with decreased exposure to metformin in healthy individuals as compared to genotype CC.	1.0
1449165230	1449165120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165120	29352482	Allele T is associated with increased exposure to metformin in healthy individuals as compared to allele C.	1.5
1451436140	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1451436140	1444699662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699662	11079536	Allele C is associated with Ototoxicity when treated with streptomycin as compared to allele T.	0.25
1451436140	1444843889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843889	16875663	Allele C is associated with increased risk of Ototoxicity when treated with gentamicin, kanamycin or streptomycin as compared to allele T.	0.25
1451436140	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1449165794	1449165643	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165643	28941036	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	1.0
1448636814	1448636751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636751	28727815	Allele T is associated with decreased likelihood of pneumonitis when treated with everolimus in women with Breast Neoplasms as compared to allele C.	2.25
1448636814	1448636824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636824	28727815	Genotypes CT + TT are associated with increased likelihood of progression-free survival when treated with everolimus in women with Breast Neoplasms as compared to genotype CC.	2.75
1448636842	1448636767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636767	28727815	Allele A is associated with increased likelihood of Lymphopenia when treated with everolimus in women with Breast Neoplasms as compared to allele C.	2.25
1448636848	1448636758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636758	28727815	Allele A is associated with increased likelihood of mucositis when treated with everolimus in women with Breast Neoplasms as compared to allele G.	2.25
1450822790	1450821815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821815	25500252	Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.	2.0
1450822790	1449166485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449166485	11054774	Allele A is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele G.	-1.25
1450932989	1450932810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932810	30651574	Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.	2.5
1451608148	982043175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043175	23116553	Genotype GG is associated with decreased absolute leucocyte and neutrophil counts on day 15 when treated with doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.	1.5
1449164352	1449164327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164327	28440343	CYP3A4 *1/*22 is associated with increased concentrations of sildenafil in people with Heart Failure as compared to CYP3A4 *1/*1.	1.75
1449189236	1449189206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449189206	29523524	Allele G is associated with increased severity of Hyperglycemia when treated with chlorothiazide or hydrochlorothiazide in people with Hypertension as compared to allele T.	1.625
1451440020	1451440000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440000	22030963	Allele C is associated with increased risk of Ototoxicity when treated with kanamycin or streptomycin.	0.25
1451440041	1451440000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440000	22030963	Allele C is associated with increased risk of Ototoxicity when treated with kanamycin or streptomycin.	0.25
1450374881	1450374871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374871	23771192	Genotype AA is associated with increased adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AC + CC.	2.0
1450375024	1450374797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374797	30914949	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.	2.5
1450375035	1450374223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374223	30914949	Genotype CT is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT.	2.5
1449157113	1449157093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157093	29206869	TPMT *1/*3A + *1/*3C are associated with increased concentrations of thioguanine in people with Crohn Disease as compared to TPMT *1/*1.	2.0
1449556772	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1449556772	1446896983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896983	26164721	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.	2.5
1449556772	1451249860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451249860	17108811	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.	1.5
1449556772	1184754854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754854	24598718	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.	0.0
1449556772	1447983120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983120	25446771	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	0.5
1449556772	1451352480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352480	26774055	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	1.5
1449556772	1451352500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352500	25673568	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.	0.125
1449556772	1446907580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907580	26367500	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	2.0
1449556772	1448612369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612369	28350522	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.	1.0
1449556772	1449556752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449556752	29469964	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.	1.5
1449188679	1449188362	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188362	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.	2.25
1449557359	1449557344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557344	29706892	Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT.	1.75
1449166824	1449166810	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449166810	29344738	Allele T is associated with increased sensitivity to caffeine and chlorocresol in HEK 293 cells and myotubes as compared to allele C.	0.0
1449270865	1449270697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270697	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449564951	981240002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240002	22385882	Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	2.0
1449564951	827641446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641446	11318841	Allele T is not associated with decreased response to sulfonamides, urea derivatives.	-1.0
1449564951	1449310639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310639	29681852	Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.	2.25
1449270871	1449270845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270845	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449270877	1449270650	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270650	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449270889	1449270683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270683	29593529	Allele C is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.	0.0
1449270895	1449270780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270780	29593529	Allele C is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.	0.0
1449270901	1449270852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270852	29593529	Allele A is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270907	1449270787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270787	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270925	1449270794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270794	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270931	1449270611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270611	29593529	Allele C is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.	0.0
1449270937	1449270831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270831	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270943	1449270838	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270838	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449270949	1449270808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270808	29593529	Allele G is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.	0.0
1449270955	1449270601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270601	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449270973	1449270801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270801	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270979	1449270718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270718	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449564957	1184470146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470146	24442125	Allele C is not associated with decreased hemoglobin levels when exposed to glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to allele A.	-1.5
1449564957	1449310630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449310630	29681852	Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.	2.25
1449564963	1185235100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235100	18780301	Genotype TT is not associated with response to donepezil in people with Alzheimer Disease as compared to genotypes CC + CT.	-1.5
1449564963	1185235587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235587	17047484	Genotype CC is not associated with response to donepezil in people with Alzheimer Disease as compared to genotypes CT + TT.	-1.0
1449564963	1449311576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311576	27567841	Allele T is associated with increased response to donepezil in women with Alzheimer Disease as compared to allele C.	3.0
1449564963	1449311211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449311211	27911294	Allele T is associated with increased likelihood of cognitive dysfunction when treated with donepezil in people with Alzheimer Disease as compared to allele C.	0.0
1450928454	1450928098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928098	28696411	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1449003717	1448994861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994861	28437488	Genotype CT is associated with increased concentrations of oseltamivir in healthy individuals as compared to genotype TT.	0.125
1449003723	1448994870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994870	28829817	Allele T is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	0.0
1449003729	1448994901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994901	28829817	Allele A is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	0.0
1449003741	1448994886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994886	28829817	Allele A is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.	0.0
1451553602	1451465067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465067	21387541	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-1.0
1451553602	1451511100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511100	24718721	Allele T is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
1451553602	1451553460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451553460	32695297	Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.75
1451553602	1451614940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451614940	33501733	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
1451553602	1184513990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513990	24241962	Allele G is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.	-0.75
1451553602	1296598942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598942	25303299	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-0.125
1451553602	1449188622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188622	27566582	Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.	1.25
1450928505	1450928144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928144	28696411	Allele G is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1451615421	1451615012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615012	33501733	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.0
1451615421	1184175525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175525	24404132	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.0
1451615421	1184468945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468945	23222202	Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Leukemia, B-Cell, Acute as compared to genotype AA.	1.5
1451615421	1450045085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045085	29791011	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.	-1.0
1450928534	981859133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981859133	22935916	Allele A is not associated with response to risperidone in people with Schizophrenia.	-1.5
1450928534	1450928156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928156	28696411	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1450373610	1450373545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373545	30237583	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.	1.5
1450373616	1450373419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373419	30237583	Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.	2.0
1450377181	1450377092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377092	27488001	Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain or Tuberculous meningitis NOS as compared to allele C.	2.25
1450377193	1450377135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377135	27488001	Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele C.	2.25
1449752982	827826001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826001	15914676	Allele T is associated with decreased the K(m) for the nucleoside phosphonate analogs of adefovir dipivoxil, cidofovir or tenofovir as compared to allele C.	0.0
1449752982	1449752974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752974	26287941	Allele T is not associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to allele C.	-1.75
1449752982	1449752993	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449752993	15864112	Allele T is not associated with uptake of aminohippurate or methotrexate as compared to allele C.	-0.0
1449753021	1449753008	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449753008	15864112	Allele T is associated with decreased uptake of adefovir dipivoxil as compared to allele C.	0.0
1449753021	1449753015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449753015	15864112	Allele T is not associated with clearance of adefovir dipivoxil as compared to allele C.	-0.0
1449753021	1449753035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449753035	25717246	Allele T is not associated with increased risk of nephrotoxicity when treated with adefovir dipivoxil in people with Hepatitis B as compared to allele C.	-1.25
1450823344	1450822141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822141	26042510	Genotype AA is associated with increased dose of nicotine as compared to genotypes AG + GG.	0.0
1450931422	1450931208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931208	29667742	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	0.0
1450931428	1450931226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931226	29667742	Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.	0.0
1450931440	1450931144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931144	29667742	Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele T.	0.0
1450931815	1450931709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931709	30281924	Genotype AC is associated with increased response to fentanyl in healthy individuals as compared to genotype CC.	0.125
1450931828	1450931770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931770	30281924	Genotype AG is associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype GG.	2.0
1450823773	1450813194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813194	22046326	Allele G is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele A.	-1.5
1450823773	1450822097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822097	26042510	Genotypes AG + GG are not associated with risk of Tobacco Use Disorder due to nicotine as compared to genotype AA.	-1.5
1450823773	1450823738	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823738	26392368	Allele G is associated with decreased risk of Tobacco Use Disorder due to nicotine as compared to allele A.	0.0
1450823773	1449161426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161426	16387451	Allele G is not associated with increased risk of Alcoholism, Cocaine-Related Disorders, Opioid-Related Disorders or Tobacco Use Disorder when exposed to cocaine, ethanol, nicotine or opioids as compared to allele A.	-1.0
1450823785	1450809995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450809995	16476706	Allele G is not associated with risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	-2.0
1450823785	1450823751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823751	26392368	Allele G is associated with decreased risk of Cocaine-Related Disorders due to cocaine as compared to allele A.	0.0
1450823785	1449161426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161426	16387451	Allele G is not associated with increased risk of Alcoholism, Cocaine-Related Disorders, Opioid-Related Disorders or Tobacco Use Disorder when exposed to cocaine, ethanol, nicotine or opioids as compared to allele A.	-1.0
1450823785	1449190380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190380	23454283	Allele G is not associated with likelihood of Cocaine-Related Disorders or Heroin Dependence due to cocaine or heroin as compared to allele A.	-2.0
1449157600	1449157510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157510	29193002	Genotypes AA + AG are associated with decreased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype GG.	2.5
1450377220	1450377165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377165	27488001	Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.	2.25
1450826907	827847855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827847855	19605407	Genotypes AG + GG are associated with increased risk of Pain when treated with alfentanil in people with Extracorporeal shock wave lithotripsy (ESWL) as compared to genotype AA.	1.75
1450826907	1449715608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715608	16906017	Genotypes AG + GG are associated with decreased response to alfentanil in healthy individuals as compared to genotype AA.	0.25
1450826913	827847851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827847851	19605407	Genotypes AG + GG are associated with increased plasma concentration when treated with alfentanil in people with Pain as compared to genotype AA.	1.25
1450826913	1449715602	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715602	16906017	Allele G is not associated with concentrations of alfentanil in healthy individuals as compared to allele A.	-0.125
1450826993	1449271593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271593	22230405	Genotype AG is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotype AA.	2.5
1450933062	1450933039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933039	30653751	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotypes AG + GG.	2.5
1450933116	1450933081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450933081	30696812	Genotype AT is associated with increased risk of Tobacco Use Disorder due to nicotine in people with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	1.75
1451615920	1451615840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451615840	34390503	Allele C is associated with increased risk of osteonecrosis of jaw caused by drug when treated with Bisphosphonates in people with Neoplasms as compared to allele T.	3.5
1451615920	1451615832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451615832	34390503	Allele C is associated with increased risk of osteonecrosis of jaw caused by drug when treated with Bisphosphonates in people with Osteoporosis as compared to allele T.	2.0
1449140229	1449140035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449140035	28676933	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	1.5
1449645366	1449645220	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645220	29705271	Allele C is associated with decreased sulfation of morphine as compared to allele T.	0.0
1449645372	1449645224	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645224	29705271	Allele C is associated with decreased sulfation of tapentadol as compared to allele T.	0.0
1449645378	1449645233	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645233	29705271	Allele C is associated with decreased sulfation of o-desmethyltramadol as compared to allele T.	0.0
1449645386	1449645177	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645177	29705271	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1449645392	1449645237	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645237	29705271	Allele T is associated with decreased sulfation of morphine as compared to allele C.	0.0
1450813534	1450813399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813399	22046326	Genotype CG is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype CC.	0.0
1450813554	1450813423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813423	22046326	Genotype CC is associated with decreased severity of Tobacco Use Disorder due to nicotine as compared to genotypes AA + AC.	2.5
1451447387	1451447380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451447380	28627804	Genotypes AA + AG are associated with decreased response to rosuvastatin in healthy individuals as compared to genotype GG.	1.5
1449168058	1449167728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167728	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168065	1449167736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167736	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168321	1449168106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168106	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168628	1449168295	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168295	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168635	1449168301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168301	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168642	1449168205	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168205	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449169490	1449169145	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169145	29243113	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.	1.5
1449169490	1449169153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169153	29243113	Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype GT.	0.0
1449271393	1449271386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449271386	29593529	Allele A is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1451447440	1451447393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451447393	31792371	Genotypes CT + TT is associated with decreased response to azathioprine in children with Irritable Bowel Syndrome as compared to genotype CC.	2.25
1449004548	1447944945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944945	25823783	Allele C is associated with increased dose of oxcarbazepine in people with Epilepsy as compared to allele T.	0.0
1449004548	1448998365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998365	28837897	Genotype CC is not associated with concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes CT + TT.	-1.0
1449004548	1448998405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998405	28837897	Allele C is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele T.	2.0
1449752787	1449752655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752655	29925895	Genotypes CC + CG is associated with increased progression-free survival when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	2.5
1449156122	1448926179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926179	28819312	HLA-B *15:24 is associated with decreased risk of dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449155828	1448925972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925972	28819312	HLA-B *39:10:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156084	1448926109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926109	28819312	HLA-B *39:01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449747881	1184468829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468829	21047202	Allele G is associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele A.	2.25
1449747881	1449747832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747832	29454235	Genotype AA is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	1.75
1450810387	1450810080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810080	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1450810387	1451137700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451137700	31853823	Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.	2.75
1449156076	1184407542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407542	19104471	HLA-B *38:02:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.	-1.75
1449156076	1448926099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926099	28819312	HLA-B *38:02:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449168086	1449167833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167833	29407288	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168670	1449168161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168161	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168677	1449168167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168167	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449269868	982044565	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044565	18950464	Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.	1.25
1449269868	1449190810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190810	29432897	Allele T is not associated with likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-2.25
1449269868	982044597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044597	18950464	Genotypes AC + CC are not associated with risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype AA.	-0.25
1449269868	827814788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814788	21148049	Allele C is not associated with bleeding events when treated with acenocoumarol or warfarin.	-1.5
1449269868	1449190803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190803	29432897	Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele A.	3.25
1449269868	1449269136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449269136	29577257	Allele C is associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to allele A.	3.5
1449269868	1444703983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444703983	25858232	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin in people with Alcoholism as compared to CYP2C9 *1.	0.0
1449269868	1444706532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706532	23113310	CYP2C9 *1/*2 + *3/*3 + *2/*3 + *1/*3 + *2/*2 are not associated with increased risk of Hemorrhage when treated with acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	-1.25
1449269868	1444707161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707161	16699986	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.75
1449269868	1444707240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707240	15213846	CYP2C9 *1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	2.0
1449269868	1444707430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707430	12876643	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with acenocoumarol and indomethacin as compared to CYP2C9 *1/*1.	0.25
1449269868	1444707481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707481	12414349	CYP2C9 *1/*3 + *3/*3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.	-1.75
1449269868	1447519366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519366	21148049	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	-1.5
1449269868	1448602404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602404	28033245	CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1449269868	1448602417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602417	28033245	CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1451448900	1448576430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576430	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451448900	1449750363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750363	29967377	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.	0.0
1450810247	1450810059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810059	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele C.	2.75
1450810295	1450823034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823034	25744370	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.	3.5
1450810295	1450810069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810069	16476706	Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele G.	3.25
1450810345	1450810099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810099	16476706	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	2.5
1449169795	1449169755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449169755	29178257	Genotypes CT + TT are associated with decreased response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.	2.5
1449170055	1449169831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169831	29238301	HLA-A *02:07:01 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	2.25
1449170068	1184998217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998217	25327504	HLA-B *44:03:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.	0.25
1449170068	1447672353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672353	26632391	HLA-B *44:03:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	0.25
1449170068	1449169896	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169896	29238301	HLA-B *44:03:01 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.	2.25
1449170133	1449170115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170115	29392141	Genotypes AA + AG are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype GG.	3.75
1448999588	1447955020	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447955020	26937172	CYP2D6 *89 + *90 + *94 is not associated with clearance of dapoxetine as compared to CYP2D6 *1.	-0.0
1448999588	1447954971	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447954971	26937172	CYP2D6 *2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98 is associated with decreased clearance of dapoxetine as compared to CYP2D6 *1.	0.0
1449189242	1449189225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449189225	29523524	Allele A is associated with increased severity of Hyperglycemia when treated with chlorothiazide or hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1449577050	1449576749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576749	29938344	Genotype CTGGTGAGGAGAGAACC/del is associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.	3.0
1449752561	1449752315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752315	29662106	Genotype CC is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.0
1449752602	1449752337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752337	29662106	Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	2.0
1450376443	1450180215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450180215	29230023	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	1.625
1450376443	1450376358	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376358	23083021	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.0
1450376443	1450376384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376384	20929549	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.0
1450376443	1450376406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376406	22591463	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.25
1450376443	1450376455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376455	29374517	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	0.0
1450376443	1450376471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376471	29374517	Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	0.0
1450376443	1450376533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376533	23609393	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.	-1.5
1450376443	1450376573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376573	28871191	Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1451621726	1449003298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449003298	28525903	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	-1.75
1451621726	1184746717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746717	25007187	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1451621726	1451633770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451633770	34346513	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.75
1450376745	981478829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478829	23131881	Allele A is not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to allele G.	-1.5
1450376745	1184510536	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510536	23856854	Genotypes AA + AG is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype GG.	-1.75
1450376745	1450180302	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450180302	29230023	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	1.25
1450376745	1450374932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374932	18214865	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.0
1450376745	1450374939	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374939	18703939	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	2.0
1450376745	1450374950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374950	22149470	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-0.25
1450376745	1450376375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376375	19858760	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.75
1450376745	1450376626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376626	28871191	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1450376745	1450376659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376659	21550019	Genotypes AA + AG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	-2.0
1450376745	1450376668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376668	24035255	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.0
1450376745	1450376686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376686	22024001	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.25
1450376745	1450376695	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376695	24763183	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	2.5
1450376745	1450376712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376712	27482244	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1450376745	1450376738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376738	18580877	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1449157951	1449157937	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157937	29160302	Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.	1.25
1449157957	1449157889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157889	29160302	Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.	2.25
1449157963	1449004981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449004981	29099735	Genotype TT is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to genotypes CC + CT.	0.125
1449157963	1449157896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157896	29160302	Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.	2.25
1449170460	1449170340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170340	29177570	Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.	3.0
1449270486	1449270476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449270476	27911795	Allele A is associated with decreased dose of ethanol as compared to allele G.	0.0
1449270883	1449270690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270690	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449140263	1448820113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448820113	28783044	Allele T is associated with increased likelihood of Hyponatremia when treated with Thiazides, plain in people with Hypertension as compared to allele C.	2.5
1449140279	1448926357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448926357	28796378	Allele G is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.	3.5
1449752818	1449752631	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752631	29233746	Allele A is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele G.	3.0
1450813566	1450813361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813361	22046326	CYP2B6 *1/*4 + *4/*4 is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to CYP2B6 *1/*1.	2.5
1451448820	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451448820	PA166184613	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184613		Annotation of DPWG Guideline for mercaptopurine and NUDT15	100
1451448820	1448576467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448576467	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1451448820	1451133189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451133189	32308129	NUDT15 *1/*2 + *1/*3 + *1/*6 + *2/*2 is associated with increased Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.75
1451448820	1449575788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449575788	29923122	NUDT15 *2 + *3 + *4 + *5 + *6 are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to NUDT15 *1.	3.5
1451621742	619523386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/619523386	19093297	Genotype AG is associated with increased risk of non-response when treated with methotrexate in people with Arthritis, Rheumatoid.	1.5
1451621742	1451110160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451110160	31099054	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.5
1451621742	1444843105	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843105	26071279	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.0
1451621742	1448589644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448589644	27992285	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	1.375
1451621742	1449270232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449270232	29589488	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.	-0.5
1451621742	1449557881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557881	29743634	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
1451621742	1450415126	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415126	30983549	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	0.75
1450814813	PA166262261	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262261		Annotation of CPIC Guideline for pitavastatin and SLCO1B1	100
1450814813	1451674520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674520	23556337	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.	1.0
1450814813	1450814783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814783	23007012	SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.	2.0
1450814813	1451226403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226403	30528195	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	0.125
1450814813	1451451080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451080	18408565	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1450814813	1451674400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674400	17460607	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.	1.5
1449310234	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310234	1449160978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160978	12059893	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1449310234	1449160998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160998	16163667	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1449310234	1449161004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161004	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1449310234	1449161022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161022	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1449310249	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310249	1449160887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160887	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1449310265	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449310265	1449160893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160893	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
827863843	827777782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777782	21991891	Genotype GG is associated with increased likelihood of poor response when treated with glucocorticoids in people with Asthma as compared to genotype AA.	0.0
827864159	827864047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864047	19119263	Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.	3.25
827864159	827864069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864069	19119263	Genotype CC is not associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype TT.	-1.5
827864179	769278055	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769278055	9827545	Genotype TT is associated with decreased metabolism of coumarin as compared to genotypes AA + AT.	0.125
827864179	769278048	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769278048	9409631	Genotype TT is associated with decreased metabolism of coumarin as compared to genotype AT.	0.125
827864301	827783397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783397	17700361	Genotypes CT + TT are associated with earlier achievement of blood pressure control when treated with verapamil in people with Hypertension as compared to genotype CC.	2.5
827864301	827864262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827864262	18854753	Genotypes CT + TT are associated with decreased blood pressure in men as compared to genotype CC.	2.5
827864301	827864280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827864280	18496125	Genotypes CT + TT are associated with decreased risk of Hypertension as compared to genotype CC.	1.5
1450930548	1450930479	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450930479	29650764	Allele G is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele T.	2.75
1450930554	1450930485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450930485	29650764	Allele A is associated with increased response to atenolol in people with Hypertension as compared to allele G.	2.25
1450930560	1450930512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450930512	29650764	Genotype GG is associated with decreased dose of atenolol in people with Hypertension as compared to genotypes AA + AG.	2.75
1450930827	1450930699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450930699	29666375	Allele T is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele C.	3.0
1450936741	1450936672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936672	31002879	Genotype CT is associated with decreased concentrations of ethanol in healthy individuals as compared to genotype CC.	2.0
1450929786	1450826600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826600	28388599	Genotype AA is not associated with response to fentanyl in children as compared to genotypes AG + GG.	-1.25
1450929786	1449716341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716341	22277678	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.	0.0
827864250	827863788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863788	15128701	Genotype TT is associated with increased percent change in FEV when treated with corticosteroids in people with Asthma as compared to genotypes CC + CT.	2.75
827864250	827863834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863834	18539200	Genotypes CT + TT are not associated with mean annual change in FEV when treated with beclomethasone, budesonide or fluticasone propionate in people with Asthma as compared to genotype CC.	-1.25
827864250	827863877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863877	19210659	Genotype TT is not associated with mean change in FEV when treated with fluticasone/salmeterol in people with Pulmonary Disease, Chronic Obstructive as compared to genotype CC.	-1.25
827864250	827921704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921704	22641026	Allele T is associated with increased response to glucocorticoids in people with Asthma as compared to allele C.	2.5
827864250	1183703313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703313	22370858	Allele T is associated with increased response to fluticasone propionate in people with Asthma as compared to allele C.	1.75
827864250	1448258330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258330	27523435	Allele T is not associated with response to corticosteroids in people with Asthma as compared to allele C.	-1.0
827862764	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
827862764	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
827862764	1446904199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904199	26339796	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	4.0
827862764	981483523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483523	20964522	Genotypes CT + TT are associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	0.0
827862764	1444843642	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843642	26032235	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.5
827862764	1444706410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706410	23712427	Genotype TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	This annotation is not used for clinical annotation scoring. Direction of association changes depending on the type of analysis carried out.
827862764	1448594952	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448594952	28186161	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.75
827862764	981848148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848148	23383658	Genotype CC is associated with higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	0.0
827862764	981240111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240111	22863269	Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	981344129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344129	22345656	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotypes CT + TT.	-0.25
827862764	981352182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352182	22438096	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.75
827862764	981352188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352188	22438096	Genotype CC is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.25
827862764	981419782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419782	21374656	Genotype CC is associated with rapid virological response (rvr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	981419793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419793	21374656	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.75
827862764	981419910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419910	21145807	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.25
827862764	981419925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419925	21145807	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	981419938	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419938	21068134	Genotype CC is associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981478958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478958	21606533	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	2.25
827862764	981478966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478966	21606533	Genotypes CC + CT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.	2.0
827862764	981478976	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478976	21505315	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	981481472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481472	20804372	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981481534	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481534	20931559	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	981481546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481546	21447862	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.25
827862764	981483535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483535	21157362	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	981501267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501267	20176026	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	981501273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501273	20176026	Allele C is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele T.	-1.25
827862764	981501391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501391	20389235	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.5
827862764	981934499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934499	23142377	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	1.0
827862764	982031571	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031571	21390311	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	1444705303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705303	21911885	Genotype CC is associated with decreased severity of Hepatitis C when treated with peginterferon alfa-2b and ribavirin as compared to genotypes CT + TT.	0.0
827862764	769251002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769251002	19684573	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	0.0
827862764	827789030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827789030	21993426	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.75
827862764	827813726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813726	21726252	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.	1.0
827862764	827820480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820480	21254158	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	2.5
827862764	827864105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827864105	21951981	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1183888950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888950	24117654	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1183888954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888954	23321318	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	-2.0
827862764	1184136155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136155	23291588	Genotype CC is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.5
827862764	1184136375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136375	24308755	Genotype CC is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.25
827862764	1184136394	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136394	24072198	Genotype TT is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype CC.	3.5
827862764	1184985914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184985914	24748394	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.75
827862764	1444668491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668491	24102823	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1444668546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668546	24768758	Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.5
827862764	1444698141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698141	25705565	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotype TT.	0.25
827862764	1444705048	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705048	22368681	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	1444705100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705100	22328925	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.	3.0
827862764	1444705124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705124	21466653	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	1444705141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705141	21466653	Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
827862764	1444705288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705288	21911885	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.5
827862764	1444705484	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705484	21346780	Genotypes CT + TT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
827862764	1444705756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705756	20621700	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	2.75
827862764	1444705763	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705763	20621700	Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	3.25
827862764	1444705777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705777	20621700	Genotypes CC + CT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	-1.75
827862764	1444705790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705790	20621700	Genotypes CC + CT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.	-1.75
827862764	1444705804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705804	21987611	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
827862764	1444706036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706036	20728570	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.25
827862764	1444706170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706170	21537116	Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.	2.75
827862764	1444706370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706370	21112657	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.25
827862764	1444706626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706626	24073221	Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	3.0
827862764	1444706715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706715	20578254	Genotype CC is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-3.0
827862764	1444706722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706722	20399780	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.5
827862764	1444706780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706780	21572301	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes CT + TT.	3.0
827862764	1444706841	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706841	21907615	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CT.	2.25
827862764	1444843627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843627	26098993	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1444843635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843635	26098993	Genotype CC is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.25
827862764	1445296829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296829	25278709	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	-1.5
827862764	1447676759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676759	26284539	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C, Chronic as compared to genotypes CT + TT.	1.5
827862764	1447676885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676885	25958342	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.0
827862764	1447947784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947784	26902034	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1447948064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948064	26699619	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1447948081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948081	26699619	Genotype CC is not associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-2.0
827862764	1450934072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934072	31803800	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448107024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107024	23490377	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	3.0
827862764	1448107049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107049	23383658	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.25
827862764	1448265190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265190	27514956	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.0
827862764	1448266019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266019	25918016	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes CT + TT.	1.25
827862764	1448266117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266117	27714501	Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448428352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428352	27833958	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
827862764	1448530766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448530766	27498543	Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.75
827862764	1448602915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602915	26911666	Genotypes CT + TT are associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.0
827862764	1448636081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636081	28703131	Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
827862764	1448996449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996449	28261910	Allele T is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	2.0
827862764	1448998952	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998952	28739427	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1448999231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999231	28739427	Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1448999241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999241	28739427	Genotype CC is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
827862764	1450342908	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342908	30450628	Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
1451634907	769171236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171236	18322994	Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.	0.0
1451634914	1448266150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266150	27676277	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.5
1451634940	769174421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769174421	17611986	Genotype GG is associated with increased likelihood of methotrexate-induced nodulosis when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	1.75
1449310001	1183631267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183631267	23753411	Genotype CG is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to genotype CC.	0.0
1449310013	827825891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825891	22293537	Allele G is associated with increased risk of Leukopenia when treated with gemcitabine in people with Neoplasms as compared to allele A.	0.0
1449716392	1449716303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716303	22277678	Genotypes CC + CT are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype TT.	0.0
1449716392	1449716323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716323	22277678	Genotypes AC + CC are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype AA.	0.0
1449716764	1450826590	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826590	28388599	Allele G is not associated with dose of fentanyl in children as compared to allele A.	-1.25
1449716764	1449716295	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716295	22277678	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.	2.25
1449716764	1449716734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716734	29601950	Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.	2.0
1449748823	1449748653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449748653	29689130	Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	3.25
1449309975	1184349930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349930	18616518	Genotype AC is not associated with likelihood of adverse effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.	-1.5
1449309975	1184467210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467210	16431304	Genotypes AC + CC is not associated with risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype AA.	-2.25
1449309975	1448266637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266637	26674571	Genotype CC is associated with increased likelihood of Drug Toxicity when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotypes AA + AC.	0.0
1449309975	1448268147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268147	18662289	Genotypes AC + CC is associated with increased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	2.5
1449309937	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449309937	1449310291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449310291	11389482	Allele GAG is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to allele del.	0.25
1449309937	1449275168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275168	27857962	Allele del is associated with increased risk of Malignant Hyperthermia when treated with isoflurane or sevoflurane in children as compared to allele GAG.	0.25
1451635027	769171268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171268	12972956	Genotype AA is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	2.5
1451635034	1451474660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451474660	21887680	Genotypes AG + GG are associated with increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.	0.0
1450375716	1450375648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375648	30924126	Allele C is associated with increased response to allopurinol as compared to allele T.	0.0
1450375722	1450375589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375589	30924126	Allele T is associated with decreased response to allopurinol as compared to allele C.	0.0
1450375728	1450375622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375622	30924126	Allele T is associated with decreased response to allopurinol as compared to allele C.	0.0
1450822476	1450822376	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822376	22500942	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	3.0
1450823115	1450822853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822853	25744370	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.5
1450823333	1450822133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822133	26042510	Genotype AA is associated with increased dose of ethanol as compared to genotype AG.	4.0
1450823350	1450822152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822152	26042510	Genotype AA is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AG + GG.	0.0
1450823626	1450823595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823595	26202629	Allele C is associated with decreased risk of Substance-Related Disorders due to amphetamine, cannabinoids, cocaine or opioids as compared to allele A.	2.5
1450823791	1450823744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823744	26392368	Allele G is associated with decreased risk of Marijuana Abuse due to cannabinoids as compared to allele A.	0.0
1449004876	1449002928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002928	28525903	Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	2.75
1449005017	1449003535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003535	28673292	Allele A is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele del.	0.0
1449005017	1449003673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003673	28673292	Allele A is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele del.	-1.25
1449005031	1449003524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003524	28673292	Allele T is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele C.	1.25
1449005031	1449003666	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003666	28673292	Allele T is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele C.	-1.25
1449005382	1448637116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448637116	28694205	Genotypes AG + GG is associated with decreased concentrations of glucose in people with Bipolar Disorder, Depressive Disorder, Psychotic Disorders and schizoaffective disorder as compared to genotype AA.	2.25
1449005393	1448639423	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448639423	28614221	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	2.5
1449005393	1448639434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448639434	28614221	Genotype GG is associated with decreased likelihood of adverse events when exposed to sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.	1.5
1449004807	1449003049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449003049	28525903	Genotypes CT + TT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-1.75
1449004807	1449003343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003343	28525903	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.75
1449004807	1449003454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003454	28525903	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-1.75
1449575639	1449575566	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575566	29769267	Allele C is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele T.	0.0
1184000346	1183960884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960884	1669155	G6PD deficiency is associated with Anemia, Hemolytic when treated with nitrofurantoin in women.	0.125
1184000346	1183960890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960890	12659	G6PD deficiency is associated with Hemolysis when treated with nitrofurantoin in men with pyuria.	0.125
1184000346	1183960904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960904	5897424	G6PD deficiency is associated with Hemolysis when treated with nitrofurantoin in women with Pregnancy.	0.125
1184000380	1183964664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183964664	6410650	G6PD deficiency is associated with Anemia, Hemolytic when treated with phenazopyridine in men with renal impairment.	0.125
1184000380	1183969900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183969900	6125724	G6PD deficiency is associated with Anemia, Hemolytic when treated with phenazopyridine in men with Hematuria.	0.125
1183702975	1451643580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451643580	34380995	Genotype GG is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes GT + TT.	2.25
1183702975	1451679100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451679100	34910759	Allele T is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	-2.0
1183702975	827816234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816234	21902500	Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	3.25
1183702975	1183698962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698962	21790905	Genotypes GG + GT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT.	1.75
1183702975	1444695465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695465	25556837	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele T.	-1.25
1183702975	1450374150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374150	30907440	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele T.	-1.25
1183702959	1183697777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697777	23433505	Genotypes CC + CT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype TT.	3.25
1183702964	1183697782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697782	23433505	Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype CC.	3.25
1183704353	637879564	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637879564	20921970	Allele A is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to allele G.	3.0
1183945178	1183944086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944086	11755554	CYP1A2 high activity phenotype is associated with increased risk of Abortion, Spontaneous when exposed to caffeine in women with Pregnancy as compared to CYP1A2 low activity phenotype.	1.125
1183945178	1183944699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944699	11755554	CYP1A2 low activity phenotype is associated with increased intake of caffeine in women with Pregnancy as compared to CYP1A2 high activity phenotype.	1.0
1183945178	827698457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698457	17370067	CYP1A2 *1F/*1F is associated with increased metabolism of caffeine in people with Tobacco Use Disorder.	1.0
1183945178	1183944884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944884	15849225	CYP1A2 *1F/*1F is associated with increased likelihood of Abortion, Spontaneous when exposed to caffeine in women as compared to CYP1A2 *1A/*1A + *1A/*1F.	2.0
1183704339	827704156	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827704156	21826085	Genotypes CT + TT are associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype CC.	3.0
1183703010	1183699101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699101	23371966	Genotype GG is associated with increased glucuronidation of anastrozole in human liver microsomes as compared to genotypes AA + AG.	1.75
1183704233	981794238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794238	20665488	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	-1.5
1183704233	981794250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794250	20665488	Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	2.5
1183704404	981939609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981939609	23555300	Genotypes AA + AG are associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype GG.	0.0
1183704404	1448263877	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263877	27564082	Genotype AG is associated with increased response to etanercept in people with Psoriasis as compared to genotype GG.	2.0
1184136804	1184136781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136781	19204908	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased risk of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.0
1184136804	1184513523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513523	17414739	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of side effects when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	0.0
1184136804	1184513538	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513538	17414739	SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) is associated with increased risk of side effects when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	0.0
1184136899	1184136868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136868	23859574	SLC6A4 HTTLPR long form (L allele) is associated with increased risk of Dizziness when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.5
1184136899	1184136884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136884	22212732	SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with decreased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia.	This annotation is not used for clinical annotation scoring. no comparison allele
1184136899	1184136878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136878	22212732	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased likelihood of Weight gain when treated with risperidone in people with Schizophrenia.	This annotation is not used for clinical annotation scoring. no comparison allele
1184169936	1184169915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169915	24667440	Allele G is associated with decreased improvement in [DELTA]DAS28 (Disease Activity Score) when treated with infliximab in people with Arthritis, Rheumatoid as compared to allele A.	0.0
1184169936	1184169928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169928	24667440	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A.	2.0
1184169936	1447944531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944531	25823785	Allele A is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.	2.25
1183704302	827862340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827862340	21118971	Genotypes AG + GG are associated with increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to genotype AA.	0.0
1183960795	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960795	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960795	1449191776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191776	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960795	1183960702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960702	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183682436	1183682419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682419	23052413	Allele T is associated with increased response to flecainide in people with Myotonia as compared to allele C.	0.25
1183682436	1450934108	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934108	30611854	Allele T is associated with decreased inhibition of SCN4A with mexiletine as compared to allele C.	0.0
1183682436	1450934157	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934157	30611854	Allele T is not associated with inhibition of SCN4A with flecainide as compared to allele C.	-0.0
1183704272	827784584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784584	21995462	Allele A is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.	1.0
1183704272	827784609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784609	21995462	Allele A is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.	1.0
1183704316	981349362	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981349362	23007311	Genotypes AA + AC are associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotype CC.	2.25
1184136848	1184136826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136826	20212518	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with attenuated response to escitalopram among patients with major depression, who reported a stressful life event when treated with escitalopram.	2.25
1184136848	1184136840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136840	19272758	SLC6A4 HTTLPR short form (S allele) is not associated with response rate or mean change of depressive symptoms when treated with escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-1.5
1184136848	1184483616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483616	19567893	SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.25
1184136848	1184483645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483645	19567893	SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in men with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.5
1184136848	1184483660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483660	19567893	SLC6A4 HTTLPR long form (L allele) is not associated with increased response to escitalopram in women with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	-1.75
1184136848	1184500010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184500010	19375170	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.5
1184136848	1184509891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509891	23095326	SLC6A4 HTTLPR short form (S allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	-2.5
1184136848	1184509900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509900	23095326	SLC6A4 HTTLPR short form (S allele) is not associated with remission when treated with escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-1.5
1184136848	1184511121	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511121	24014145	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	1.5
1184136856	1184136755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136755	21247998	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron in people with Alcoholism as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.25
1183944118	1183705572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705572	23530079	G6PD deficiency is not associated with Hemolysis when treated with mefloquine in G6PD deficient mice.	-0.25
1183944118	1183705681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705681	11757641	G6PD deficiency is not associated with acute lung injury when treated with mefloquine in men with Malaria, Falciparum.	-0.125
1183944118	1183705686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705686	9753421	G6PD deficiency is associated with pulmonary toxicity when treated with mefloquine.	0.125
1183944118	1183848947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848947	10772204	G6PD deficiency is not associated with Hemolysis when treated with mefloquine and pyrimethamine in women with Malaria, Falciparum.	-0.0
1183944118	1183848955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848955	3301042	G6PD deficiency is not associated with Hemolysis when treated with mefloquine in children with Malaria, Falciparum.	-0.125
1183944118	1183848978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848978	2858743	G6PD deficiency is not associated with Hemolysis when treated with mefloquine in men with Malaria.	-0.125
1183944118	1183944101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944101	6345013	G6PD deficiency is not associated with Hemolysis when treated with mefloquine in men with Malaria, Falciparum.	-0.125
1183944118	1183705440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705440	24101478	G6PD A- 202A_376G (assigned as deficiency phenotype) is not associated with increased loss of human red blood cells when treated with mefloquine in huRBC NOD/SCID mice.	-0.25
1451635167	1449164948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164948	27217051	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.75
1451635167	1449270291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270291	29589488	Allele G is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.	0.5
1183704311	769250171	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250171	19855097	Genotypes GT/del + del/del are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GTGT.	2.0
1183704311	769250160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769250160	19855097	Allele del is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.	0.0
1184348731	1184348687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348687	24533712	Genotype CT is associated with increased risk of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	3.0
1184348731	1184348691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348691	24533712	Genotype CC is not associated with increased risk of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.25
1184472737	1184233031	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233031	23894347	Allele C is associated with increased risk of musculoskeletal pain when exposed to anastrozole and letrozole in women with early breast cancer as compared to allele T.	2.75
1184472746	1184233037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233037	23894347	Allele A is associated with increased risk of musculoskeletal pain when exposed to anastrozole and letrozole in women with early breast cancer as compared to allele G.	2.75
1184516188	1184516082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516082	1247492	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with decreased survival of red blood cells when exposed to sulfadoxine in healthy individuals.	0.0
1183702981	1451643586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451643586	34380995	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	1.75
1183702981	827816315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816315	21902500	Genotype GG is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype AA.	-1.75
1183702981	1183698967	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698967	21790905	Genotypes AA + AG are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	2.25
1183702981	1444695457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695457	25556837	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	-1.25
1184472649	1184137941	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184137941	24475091	CYP2A6 *15 + *21 + *22 are associated with decreased enzyme activity of CYP2A6 when treated with methoxsalen in E. coli membrane fractions from cells expressing human CYP2A6 *15, *21 or *22.	0.0
1184661207	981477999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477999	23132553	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.	1.5
1184661207	982015200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015200	23510058	Genotype TT is associated with increased dose of phenprocoumon as compared to genotypes CC + CT.	2.5
1184661207	982046672	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046672	21110013	Genotype CC is not associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	-1.25
1184661207	827807881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807881	21063236	Allele T is associated with increased dose of phenprocoumon maintenance dosage by 1.5 mg/week as compared to allele C.	2.0
1183705788	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705788	1447635152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635152	17081152	Allele C is associated with Malignant Hyperthermia as compared to allele T.	0.0
1183705788	1447681227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447681227	10097181	Genotype CT is associated with Malignant Hyperthermia and Myopathy, Central Core as compared to genotype TT.	0.0
1183705788	1447961009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961009	25989378	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele T.	0.25
1183960800	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960800	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960800	1449191818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191818	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960800	1451160403	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451160403	27160424	Allele A is associated with increased activity of CFTR when exposed to ivacaftor.	0.0
1183960800	1183960706	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960706	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183960766	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960766	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960766	1449190712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190712	28947035	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.5
1183960766	1449191837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191837	25266159	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960766	1449192458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192458	26474553	Allele C is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960766	1183960690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960690	22293084	Allele C is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183960775	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960775	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960775	1449191843	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191843	25266159	Allele G is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960775	1449192465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192465	26474553	Allele G is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960775	1183960694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960694	22293084	Allele G is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1183960785	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960785	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960785	1449191825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191825	25266159	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960785	1183960710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960710	22293084	Allele C is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184136380	1444665886	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665886	25393304	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1444706391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706391	23712427	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.	0.0
1184136380	1444707026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707026	24205831	Genotype TT/TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.75
1184136380	1444707037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707037	24205831	Genotype TT/TT is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	-1.5
1184136380	1444843653	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843653	26032235	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	2.5
1184136380	1444843660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843660	26032235	Genotype TT/TT is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	-1.5
1184136380	1444843667	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843667	25548683	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	2.5
1184136380	1444843675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843675	25548683	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes G/TT + GG.	0.25
1184136380	1448594944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448594944	28186161	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1445205151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445205151	26186989	Genotypes G/TT + TT/TT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	2.5
1184136380	1447682460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682460	26670100	Allele TT is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.	3.25
1184136380	1184136144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136144	23291588	Genotype TT/TT is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.5
1184136380	1184136180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136180	24690180	Genotype TT/TT is associated with increased response (SVR rate) to HCV triple therapy (telaprevir (TVR), peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1184136185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136185	24355007	Genotypes G/TT + GG are associated with increased risk of treatment failure in Japanese patients with with chronic genotype 1 HCV infection when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.	2.0
1184136380	1184136349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136349	24362944	Genotype TT/TT is associated with increased likelihood of achieving SVR in older patients with genotype 1b chronic hepatitis C when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1184136380	1184136358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136358	24308755	Genotype TT/TT is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.25
1184136380	1184136385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136385	24072198	Genotype GG is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype TT/TT.	3.5
1184136380	1184168705	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168705	24748394	Genotype TT/TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.	3.75
1184136380	1448123213	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123213	27180197	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C.	1.75
1184136380	1448264419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264419	27027531	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.25
1184136380	1448264449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264449	26820907	Genotype TT/TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.5
1184136380	1448427450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427450	27810523	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.0
1184136380	1448427467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427467	27810523	Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	1.75
1184136380	1448602991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602991	26916827	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.0
1184136380	1448636905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636905	28732143	Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis B as compared to genotypes G/TT + GG.	2.0
1184136380	1448996483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996483	28261910	Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.	2.0
1184136380	1448998994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998994	28739427	Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	3.0
1184136380	1448999052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999052	28739427	Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.5
1184136380	1448999280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448999280	28739427	Genotype TT/TT is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.	2.75
1183704321	981345128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345128	22948895	Allele A is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele C.	2.0
1183704372	827922445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922445	21993215	Genotypes GG + GT are associated with decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to genotype TT.	3.0
1184233161	1184226554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184226554	24059494	Genotype TT is associated with increased response to enalapril in people with Hypertension as compared to genotypes CC + CT.	2.75
1184233180	1184174500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174500	24444405	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased use of antidepressants, antiepileptics, Beta Blocking Agents or calcium channel blockers in people with Migraine with Aura as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	1.0
1184233180	1184174505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174505	24444405	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased use of antidepressants, antiepileptics, Beta Blocking Agents or calcium channel blockers in people with chronic migraine as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	1.0
1184233180	1184174509	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174509	24444405	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with use of antidepressants, antiepileptics, Beta Blocking Agents or calcium channel blockers in people with Migraine without Aura as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	-0.75
1184348713	1184280279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184280279	24533712	Genotype CT is associated with decreased likelihood of complete response when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + TT.	2.25
1184348718	1184305446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184305446	24533712	Genotype CT is associated with decreased progression-free survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	2.25
1184514202	1184514092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514092	24974847	Allele C is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele A.	1.75
1183888959	981483879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483879	21246582	Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.25
1183888959	827814618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814618	21628662	Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT.	2.25
1183888959	1183888942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888942	24117654	Genotype TT is associated with higher rate of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
1183888959	1184136354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136354	24362944	Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.0
1183888959	1444665876	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665876	25393304	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	3.25
1183888959	1444704847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704847	20648473	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT.	2.25
1183960805	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960805	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960805	1449191790	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191790	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960805	1183960682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960682	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184348872	1184348813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348813	24624910	Allele T is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.	This annotation is not used for clinical annotation scoring. Association only found when both rs2268639 and rs13429709 genotypes are considered.
1183704297	827813338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813338	22186618	Allele T is associated with decreased dose of atorvastatin and simvastatin.	3.0
1184348774	1184348667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348667	24533712	Genotype CC is associated with increased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	2.5
1184348774	1184348671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348671	24533712	Genotype CT is not associated with increased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-0.625
1184348859	1184348786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348786	24624910	Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype TT.	0.75
1184348859	1184348818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348818	24624910	Allele C is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.	1.25
1184473019	1448635009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635009	23099353	UGT1A6 *1a is associated with decreased dose of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.	2.75
1184473019	1448635034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635034	23099353	UGT1A6 *1a is associated with metabolism of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.	1.75
1184511154	1447989951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989951	26952092	CYP2D6 poor metabolizer is associated with decreased metabolism of donepezil in people with Alzheimer Disease as compared to CYP2D6 normal metabolizer.	0.5
1184511154	1184510970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510970	24433464	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) is associated with decreased clearance of donepezil in people with Alzheimer Disease.	2.0
1184511154	1184511033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511033	24433464	CYP2D6 *1/*1xN + *1xN/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of donepezil in people with Alzheimer Disease.	1.0
1184511154	1184511101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511101	24433464	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) is associated with increased likelihood of adverse events when treated with donepezil in people with Alzheimer Disease.	0.0
1184512128	1184512121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512121	24141364	Allele A is associated with increased likelihood of relapse when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	3.0
1184512128	1184512133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512133	24141364	Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	3.0
1183704277	827805855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805855	21900104	Allele G is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.	0.0
1183704277	1448109010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109010	23441093	Allele G is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.	-1.25
1183704367	1448109061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109061	23441093	Allele G is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele T.	-1.25
1183704367	827805762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805762	21900104	Allele G is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele T.	0.0
1183960318	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960318	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960318	982009662	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982009662	23027855	Allele A is associated with increased activity of CFTR when treated with ivacaftor in CFBEo- cells.	0.0
1183960318	1183960311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960311	24081349	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960318	1449191831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191831	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960318	1449192774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192774	28371569	Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.	0.25
1183960318	1183960686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960686	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184642788	1184642765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184642765	4386139	G6PD deficiency is associated with Hemolysis when treated with sulfasalazine in men with Colitis, Ulcerative.	0.125
1183703005	1183699105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699105	23371966	Genotype CC is associated with increased glucuronidation of anastrozole in human liver microsomes as compared to genotypes CT + TT.	0.0
1183704399	981344236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344236	22907731	Allele A is associated with decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele T.	3.25
1183704414	827823281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823281	18854779	Genotype CTGGTGAGGAGAGAACC/del is associated with increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.	2.5
1183704419	827807375	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807375	18347181	Genotype GG is associated with decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.	2.0
1184348703	1184348683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348683	24533712	Genotype CT is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	3.0
1184348708	1184348695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348695	24533712	Genotype CT is associated with increased risk of nephrotoxicity grades 1-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	2.75
1184348708	1184348699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348699	24533712	Genotype CC is not associated with increased risk of nephrotoxicity grades 1-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.	-1.25
1183704267	827805732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805732	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1183704267	1448109084	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109084	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-1.25
1183888969	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183888969	PA166104867	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104867		Annotation of FDA Label for telaprevir and IFNL3	100
1183888969	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183888969	981483885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483885	21246582	Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.25
1183888969	1183888950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888950	24117654	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183888969	1183888954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183888954	23321318	Genotype CC is not associated with sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	-2.0
1183888969	1444665865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665865	25393304	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.75
1183888969	1444704894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704894	20648473	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.25
1183888969	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1183888969	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183888969	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1184134160	1183960596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960596	21642870	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	2.0
1184134160	1184086216	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184086216	24361227	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	-1.25
1184134170	981793975	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981793975	20665488	Genotype TT is associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.	2.5
1184514449	1184212264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184212264	24498053	Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele A.	2.5
1184514458	1184216813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184216813	24498053	Allele A is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele G.	2.5
1184514464	1184221725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184221725	24498053	Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C.	2.5
1184514469	1184222339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184222339	24498053	Allele A is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele G.	2.5
1184514474	1184222805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184222805	24498053	Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C.	2.5
1184514253	1184514187	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514187	24974847	Allele A is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.	1.75
1184514260	1184514194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514194	24974847	Allele G is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.	1.75
1184563800	1184516316	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516316	16388034	G6PD deficiency is not associated with Hemolysis when exposed to sulfamethoxazole and trimethoprim in men with Pneumonia.	-0.125
1184563800	1184516710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516710	751223	G6PD deficiency is not associated with risk of Hemolysis when treated with sulfamethoxazole and trimethoprim in children with Typhoid Fever.	-0.125
1184563800	1184538689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184538689	46571	G6PD deficiency is not associated with Hemolysis when treated with sulfamethoxazole and trimethoprim in infants.	-0.125
1184563800	1184547156	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184547156	4120538	G6PD deficiency is not associated with Hemolysis due to sulfamethoxazole and trimethoprim in people with Infection.	-0.625
1184563800	1184550607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184550607	4116253	G6PD deficiency is associated with Hemolysis when treated with sulfamethoxazole and trimethoprim in women with Typhoid Fever.	0.125
1184563800	1184516286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516286	20065266	G6PD deficiency is associated with Anemia, Hemolytic when treated with sulfamethoxazole / trimethoprim in healthy individuals.	0.125
1184563800	1184516265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516265	20732351	G6PD deficiency is associated with Anemia, Hemolytic when treated with sulfamethoxazole / trimethoprim in people with HIV Infections.	0.125
1184563800	1184516651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516651	3495027	G6PD deficiency is not associated with Anemia, Hemolytic when treated with sulfamethoxazole / trimethoprim in people with Sepsis.	-0.125
1184563800	1184516312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516312	18349424	G6PD deficiency is associated with Hemolysis when treated with sulfamethoxazole / trimethoprim in men with HIV Infections.	0.125
1184563800	1184545202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184545202	4818663	G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is associated with Hemolysis when treated with sulfamethoxazole and trimethoprim.	0.25
1184473080	1451463720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451463720	31870219	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.0
1184473080	1451615018	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615018	33501733	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.0
1184473080	981474970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981474970	23069858	Genotypes CT + TT are associated with increased clearance of methotrexate in people with Lymphoma as compared to genotype CC.	1.5
1184473080	1184175504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175504	24404132	Allele T is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.5
1184473080	1184514000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514000	24241962	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.	-0.75
1184473080	1450045079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450045079	29791011	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.	-1.0
1184473109	1451463781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451463781	31870219	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	1.5
1184473109	1451463801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451463801	31870219	Genotypes CT + TT are not associated with risk of Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	-0.25
1184473109	1451634340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634340	34346513	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.25
1184473109	1184175472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184175472	24404132	Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	3.5
1184473109	1184514073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514073	24241962	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.	-0.75
1184472550	1184137763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137763	24595600	Genotype AA is associated with increased creatine kinase when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.	0.75
1183960780	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960780	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960780	1449191796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191796	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960780	1183960698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960698	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184472555	1184137773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137773	24595600	Genotype AA is associated with increased creatine kinase when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.	1.75
1451635460	1451635420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451635420	33953123	Genotype CC is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotypes CT + TT.	2.25
1183702969	1183697770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697770	23433505	Genotypes AG + GG is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype AA.	3.25
1183848120	1183848019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848019	24521109	Genotype CT is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype CC.	0.25
1183703760	1183703753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703753	24470002	Genotype AA is associated with increased risk of Cardiomyopathies when exposed to anthracyclines and related substances in children with Neoplasms as compared to genotype GG.	3.5
1183704248	827923203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923203	22664479	Allele C is associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	0.0
1183689217	PA166161537	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166161537		Annotation of CPIC Guideline for voriconazole and CYP2C19	100
1183689217	PA166104990	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104990		Annotation of DPWG Guideline for voriconazole and CYP2C19	100
1183689217	1183685147	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685147	15179414	CYP2C19 poor metabolizer genotype is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 normal metabolizer genotype.	0.0625
1183689217	1444714094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444714094	25558073	Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizers phenotype) are associated with increased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizers phenotype) .	0.0625
1183689217	1444714180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444714180	25239277	Genotypes *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.75
1183689217	1444827885	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827885	25558073	Genotypes *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.0625
1183689217	1444827890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444827890	25558073	Genotypes *1/*2 + *1/*3 + *2/*17 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of Drug Toxicity when exposed to voriconazole as compared to CYP2C19 normal metabolizer.	0.125
1183689217	1444827896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827896	25239277	Genotypes *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .	0.75
1183689217	1448123512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123512	27388292	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizers.	0.6875
1183689217	1449146934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146934	28923870	CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.	1.125
1183689217	1449146940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146940	28923870	CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.	0.625
1183689217	1449732409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732409	29393850	Genotypes *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of voriconazole in people with Mycoses.	0.75
1183689217	1449732418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732418	29393850	Genotypes *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) are not associated with metabolism of voriconazole in people with Mycoses.	-0.0625
1183689217	981565071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981565071	23215888	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in men with Granulomatous Disease, Chronic.	0.125
1183689217	982048012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048012	23588332	CYP2C19 *2 + *3 are associated with increased trough concentration of voriconazole in children as compared to CYP2C19 *1 + *17.	1.5
1183689217	1183685442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685442	19033450	CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2.	1.5
1183689217	1183848503	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848503	20669013	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1183689217	1183848916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848916	18982321	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183689217	1183848923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183848923	18982321	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1183849008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849008	18982321	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .	2.0
1183689217	1183849398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849398	19299322	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.0
1183689217	1183849453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849453	21192313	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.	2.0
1183689217	1183944019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944019	24554646	CYP2C19 *1/*1 + *1/*17 are associated with increased metabolism of voriconazole.	0.0
1183689217	1183944026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944026	24554646	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of voriconazole.	0.0
1183689217	1184468739	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468739	21383338	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748470	25084200	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748497	25084200	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is not associated with dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	-0.25
1183689217	1184748512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748512	25084200	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184748535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748535	25084200	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1184753704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753704	25155930	CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of voriconazole in men with Hepatitis C, Lymphoma and Shock, Septic.	0.125
1183689217	1444713552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713552	26024717	CYP2C19 *2/*2 + *1/*2 + *1/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.75
1183689217	1444827924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827924	16890574	CYP2C19 *2/*2 is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183689217	1444827950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827950	24475354	CYP2C19 *2/*2 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3.	-1.0
1183689217	1444827966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827966	24475354	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) is associated with increased trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1444827994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827994	24403552	CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.75
1183689217	1444828143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828143	22122271	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer genotype phenotype) is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828153	23400848	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.	0.125
1183689217	1444828163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828163	25120580	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828173	25986028	CYP2C19 *17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole.	0.125
1183689217	1444828207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828207	21615537	CYP2C19 *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with increased concentrations of voriconazole.	0.125
1183689217	1444841988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444841988	24475354	CYP2C19 *1/*1 + *1/*17 is associated with decreased trough concentration of voriconazole in people with Hematologic Diseases as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3.	2.0
1183689217	1444842336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842336	19033450	CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.5
1183689217	1444842443	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842443	20002085	CYP2C19 *1/*1 (assigned as poor metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.0
1183689217	1444842618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842618	21507170	CYP2C19 *1/*2 is associated with increased concentrations of voriconazole.	0.125
1183689217	1445297704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297704	25999694	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	0.0
1183689217	1445556721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556721	26239729	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole as compared to CYP2C19 *1/*1.	0.125
1183689217	1445556737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556737	26239729	CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to CYP2C19 *1/*1.	1.0
1183689217	1445584831	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445584831	25451051	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in children as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	0.125
1183689217	1446897275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897275	25239277	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) .	1.5
1183689217	1447672688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447672688	26239045	CYP2C19 *1/*2 + *1/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1183689217	1447672698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447672698	26239045	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1183689217	1447680755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680755	26775563	CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447680776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680776	26775563	CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447681020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681020	26775563	CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447681039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681039	26775563	CYP2C19 *1/*2 + *2/*2 is not associated with dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	-0.125
1183689217	1447681077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681077	26775563	CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	1.5
1183689217	1447681119	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681119	26775563	CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1447944033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944033	26861072	CYP2C19 *1/*1 is not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2.	-1.0
1183689217	1447944137	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944137	26861072	CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*3 + *2/*3.	1.5
1183689217	1447944149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944149	26861072	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1183689217	1447944162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944162	26861072	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	-1.0
1183689217	1447962788	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447962788	27056297	CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in infants with Severe Combined Immunodeficiency.	0.125
1183689217	1448112553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112553	16003289	CYP2C19 *1/*1 is associated with increased clearance of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.	1.0
1183689217	1448123702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123702	19933691	CYP2C19 *1/*2 is not associated with clearance of voriconazole in people with hematopoietic stem cell transplantation as compared to CYP2C19 *1/*1.	-0.125
1183689217	1448123818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123818	21831685	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3 are not associated with trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	-0.125
1183689217	1448525969	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448525969	27937048	CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	1.75
1183689217	1448604929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604929	28306618	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.	2.25
1183689217	1448604948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604948	28306618	CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.	2.25
1183689217	1448616451	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616451	27432796	CYP2C19 *1 + *17 are associated with decreased exposure to voriconazole in healthy individuals as compared to CYP2C19 *2 + *3.	0.125
1183689217	1448616465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616465	27432796	CYP2C19 *2 + *3 are associated with increased exposure to voriconazole in healthy individuals as compared to CYP2C19 *1 + *17.	0.125
1183689217	1448820856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820856	28604474	CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*17.	1.75
1183689217	1449146891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146891	29026840	CYP2C19 *1/*2 is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*17.	1.5
1183689217	1449161276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449161276	29285995	CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses.	0.125
1183689217	1449275114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449275114	29607533	CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.	2.25
1183689217	1449732457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732457	28834922	CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.25
1183689217	1450372517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372517	30653146	CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.	2.0
1183689217	1450372533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450372533	30653146	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.	2.5
1183863775	1183849255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849255	24590773	Genotype AA is associated with a significantly higher odds of Musculoskeletal adverse events (MSAEs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.	3.5
1183863775	1183849260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849260	24590773	Genotype AA is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.	3.0
1183863780	1183849268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849268	24590773	Genotype TT is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1184472751	982033335	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982033335	23651026	Genotype CC is not associated with increased activity of CDA in whole blood from healthy volunteers as compared to genotypes CT + TT.	-0.0
1184472751	827803772	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827803772	21521023	Genotype TT is associated with increased expression of CDA in PBMCs.	0.0
1184472751	978639905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639905	22838949	Genotypes CC + CT are associated with increased elimination clearance of dFdU and formation clearance of dFdCTP when treated with gemcitabine in people with Neoplasms as compared to genotype TT.	1.5
1184472751	1184174878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174878	24300978	Genotype TT is associated with decreased metabolism of gemcitabine as compared to genotypes CC + CT.	1.0
1184472751	1184175377	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184175377	17885621	Genotype CC is not associated with enzyme activity of CDA as compared to genotypes CT + TT.	-0.0
1184472841	769169283	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169283	17341693	Allele T is associated with decreased catalytic activity of CYP4F2.	0.0
1184472841	1184472303	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472303	24138531	Allele T is associated with decreased formation of CYP4F2 protein.	0.0
1184472841	1184472336	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472336	20861217	Allele T is associated with decreased enzyme activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2.	0.0
1184472841	1184472814	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472814	24759732	Allele T is associated with increased steady-state level of vitamin e as compared to allele C.	0.0
1184472841	1184472821	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472821	24759732	Allele T is associated with increased steady-state level of vitamin e as compared to allele C.	0.0
1184472890	1184175124	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175124	15564883	Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	2.5
1184472890	1184472881	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472881	15564883	Allele T is associated with increased expression of DCK as compared to allele C.	0.0
1183704243	827924360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827924360	22725681	Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.25
1183848125	1183705666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705666	24535487	Genotypes AC + CC are associated with increased on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.	2.0
1183960790	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1183960790	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1183960790	1449191784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191784	25266159	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1183960790	1183960714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960714	22293084	Allele A is associated with increased response to ivacaftor.	This annotation is not used for clinical annotation scoring.
1184233166	1451140186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451140186	5026380	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.	0.75
1184233166	1451141481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141481	2231320	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.	1.0
1184233166	1451141845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141845	1136859	NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.	0.75
1184233166	1451141965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141965	318493	NAT2 slow acetylator is associated with increased response to hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.75
1184233166	1184174568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174568	24444407	NAT2 *4/*14A + *4/*5D + *4/*6B + *4/*7A + *5D/*12A + *5D/*13A + *6B/*12A + *6B/*13A (assigned as intermediate acetylator phenotype) is not associated with response to hydralazine in people with resistant hypertension.	-0.25
1184233166	1184174521	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174521	24444407	NAT2 *5D/*14A + *5D/*5D + *5D/*6B + *5D/*7A + *6B/*14A + *6B/*6B + *7A/*6B (assigned as slow acetylator phenotype) is associated with increased response to hydralazine in people with resistant hypertension.	1.5
1184233166	1184174554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174554	24444407	NAT2 *12A/*12A + *13A/*13A + *4/*12A + *4/*13A + *4/*4 (assigned as rapid acetylator phenotype) is not associated with response to hydralazine in people with resistant hypertension.	This annotation is not used for clinical annotation scoring. Fast and intermediate acetylators are in separate VAs so in order to not count twice zeroing this one.
1183680699	1183680670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680670	24121523	TPMT *1/*2 + *1/*3A + *1/*3C are associated with increased risk of transplant rejection when treated with azathioprine in heart transplantation as compared to TPMT *1/*1.	2.25
1183680699	1183680687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680687	24121523	TPMT *1/*2 + *1/*3A + *1/*3C are associated with increased risk of transplant rejection when treated with azathioprine in heart transplantation as compared to TPMT *1/*1.	2.75
1184513736	1184513697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513697	23926243	Allele A is associated with decreased response to escitalopram in people with Depressive Disorder, Major as compared to allele G.	3.25
1184513736	1184513712	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513712	23926243	Genotypes AA + AG is associated with increased dose of escitalopram in people with Depressive Disorder, Major as compared to genotype GG.	2.5
1184654253	1184471209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471209	24858023	HLA-DRB1 *14:01:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	2.75
1184648909	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1184648909	PA166104952	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104952		Annotation of DPWG Guideline for mercaptopurine and TPMT	100
1184648909	1184174063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174063	20136357	TPMT poor metabolizer phenotype is associated with increased risk of myelotoxicity when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1184648909	1184174068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174068	20136357	TPMT intermediate metabolizer phenotype is associated with increased risk of mild leukopenia when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1184648909	1184233739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233739	20308917	TPMT intermediate metabolizer phenotype is associated with decreased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT poor metabolizer phenotype.	1.0
1184648909	1184348822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348822	1960624	TPMT poor metabolizer phenotype is associated with increased severity of hematological toxic effects when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1184648909	1184407184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407184	16543290	TPMT intermediate metabolizers is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184427832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184427832	8257179	TPMT poor metabolizer phenotype is associated with increased severity of myelosuppression when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1184648909	1444704973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704973	25347948	TPMT intermediate metabolizer phenotype is not associated with increased severity of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	-0.875
1184648909	1184407197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407197	16543290	TPMT intermediate metabolizers is not associated with increased likelihood of specific adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.	-0.625
1184648909	981239095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239095	22846425	Allele C is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	3.0
1184648909	1451106020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451106020	32265697	Allele C is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	2.5
1184648909	1449749281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749281	28418010	Genotype CT is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.25
1184648909	978639710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639710	22838948	TPMT *12 is associated with increased severity of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1.	2.25
1184648909	1184134111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134111	16202677	TPMT *1/*2 + *1/*3A is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1184648909	1184134311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134311	10376773	TPMT *1/*3A is associated with hepatic toxicity when treated with azathioprine, mercaptopurine or purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184134359	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134359	17164697	TPMT *1/*2 + *1/*3A + *3A/*3B is associated with increased risk of leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1184648909	1184169661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169661	17617792	TPMT *1/*3A is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169687	17617792	TPMT *1/*3C is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169693	17617792	TPMT *3A/*3C is associated with increased risk of neutropenia and infections when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184169875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169875	18987660	TPMT *1/*3A is associated with increased likelihood of Drug Toxicity, Infection and Stomatitis when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.75
1184648909	1184233729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233729	20308917	TPMT *1/*3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.75
1184648909	1184278692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184278692	11337943	TPMT *1/*3C is associated with increased risk of severe leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	1.5
1184648909	1184348445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348445	12142782	TPMT *1/*3A is associated with myelotoxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184348606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348606	10354134	TPMT *3A/*3A is associated with severe hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184349368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349368	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of overall ADRs when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184349431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349431	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1184648909	1184349446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349446	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is not associated with increased likelihood of hepatotoxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.0
1184648909	1184349470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349470	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is not associated with increased likelihood of pancreatitis when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.0
1184648909	1184467021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467021	9510461	TPMT *3A/*3C is associated with severe pancytopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184467028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467028	9510461	TPMT *3A/*3A is associated with severe pancytopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1184518693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184518693	21319286	TPMT *1/*3A + *1/*3C + *3A/*3A are associated with increased likelihood of tolerance of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	1.5
1184648909	1184642842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184642842	7862671	TPMT *2 is associated with increased risk of Drug Toxicity when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1184648909	1448256046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256046	27452984	TPMT *1/*3A is associated with increased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.25
1184648909	1448261284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261284	27604507	TPMT *1/*3C is not associated with risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to TPMT *1/*1.	-1.75
1184648909	1448268166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268166	18662289	TPMT *3A + *3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1184648909	1448576485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448576485	28146264	TPMT *1/*2 + *1/*3A are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1184648909	1449161615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161615	29210335	TPMT *6 is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.5
1184648909	1449161632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161632	29210335	TPMT *3C is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-2.5
1184648909	1355779542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1355779542	25441457	TPMT *1/*3A is associated with Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1184648909	1358207197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1358207197	25441457	TPMT *1/*3C is associated with Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1184648909	1351431664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1351431664	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 are associated with increased risk of Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1184648909	1184133979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184133979	20175817	TPMT *2 + *3A + *3B + *3C is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.25
1184648909	1184233422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233422	18188716	TPMT *1/*2 + *1/*3A + *1/*3C is associated with increased likelihood of hematological toxicity when treated with mercaptopurine or purine analogues in people with Leukemia as compared to TPMT *1/*1.	0.25
1184746746	1184516685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516685	16917910	TPMT *1/*20 + *1/*21 + *1/*22 are associated with decreased enzyme activity of TPMT when assayed with thioguanine.	0.0
1184746746	1333193250	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1333193250	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34 are associated with decreased activity of TPMT when treated with mercaptopurine or thioguanine as compared to TPMT *1/*1.	0.0
1184746746	1444672801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444672801	25564374	TPMT *1/*32 is associated with increased concentrations of thioguanine.	0.0
1184746746	1184517715	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184517715	19945438	TPMT *1/*27 is associated with decreased enzyme activity of TPMT when assayed with thioguanine.	0.0
1184746746	1184467144	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184467144	18708949	TPMT *2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30 are associated with decreased enzyme activity of TPMT when assayed with thioguanine in COS-7 cells as compared to TPMT *1.	0.0
1184653758	1184517724	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184517724	20881512	TPMT *31 is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine.	0.0
1184653758	1184518489	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184518489	24710034	TPMT *1/*37 is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine.	0.0
1184653758	1184518948	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184518948	23252716	TPMT *1/*32 is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine.	0.0
1184653758	1333193250	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1333193250	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34 are associated with decreased activity of TPMT when treated with mercaptopurine or thioguanine as compared to TPMT *1/*1.	0.0
1184653758	1451293440	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451293440	33118454	TPMT *21 is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1.	0.0
1184653758	1184174783	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184174783	18602085	TPMT *1/*9 + *1/*21 + *1/*24 + *1/*25 are associated with decreased activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.	0.0
1184653758	1184518969	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184518969	23252716	TPMT *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34 are associated with decreased enzyme activity of TPMT when assayed with mercaptopurine.	0.0
1183704287	827811244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811244	20179710	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	2.0
1184472708	1184085972	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184085972	24361227	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.	0.0
1184513893	769173696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173696	1415224	Allele A is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele G.	0.0
1184513893	1184989090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989090	12881446	Allele A is associated with increased risk of postanesthesia apnea when exposed to mivacurium and succinylcholine as compared to allele G.	0.0
1184516153	1183704191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704191	10793824	G6PD deficiency is not associated with increased reductions in glutathione levels when treated with aspirin as compared to G6PD non-deficient.	-0.0
1184516153	1184516141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516141	2502894	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham is associated with Anemia, Hemolytic when exposed to aspirin in children with Arthritis.	0.25
1184513880	1184511438	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511438	15731589	Allele T is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele C.	0.0
1184513880	1184511665	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511665	21637541	Allele T is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele C.	0.0
1184513880	1184511989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511989	12724618	Allele T is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele C.	2.0
1184513880	1184514272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514272	22053728	Allele T is associated with postanesthesia apnea when exposed to succinylcholine in men with as compared to allele C.	0.0
1184513880	1184514302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514302	21029050	Allele T is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	0.0
1184513880	1184989060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989060	12881446	Allele T is associated with increased risk of postanesthesia apnea when exposed to mivacurium and succinylcholine as compared to allele C.	0.0
1184513880	1451405500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451405500	33774263	Genotype CT is associated with increased risk of Apnea due to succinylcholine as compared to genotype CC.	0.25
1184513880	1451415761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415761	33024248	Allele T is associated with increased risk of Apnea when treated with succinylcholine.	0.25
1184513863	769171537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171537	2915989	Allele C is associated with decreased affinity of atypical cholinesterase for choline esters.	0.0
1184513863	1184511427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511427	15731589	Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	0.0
1184513863	1184511652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511652	21637541	Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	0.0
1184513863	1184511984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511984	12724618	Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	2.0
1184513863	1184514090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514090	21228368	Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	0.0
1184513863	1184514258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514258	22053728	Allele C is associated with postanesthesia apnea when exposed to succinylcholine in men with as compared to allele T.	0.0
1184513863	1184514305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514305	21029050	Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T.	0.0
1184513863	1184989067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989067	12881446	Allele T is associated with increased risk of postanesthesia apnea when exposed to mivacurium and succinylcholine as compared to allele C.	0.0
1184513863	1451415744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451415744	33024248	Allele C is associated with increased risk of Apnea when treated with succinylcholine.	0.25
1184513863	1451404880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451404880	33774263	Genotypes CC + CT are associated with increased risk of Apnea due to succinylcholine as compared to genotype TT.	0.25
1183863785	1183849264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849264	24590773	Genotype TT is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes CC + CT.	3.0
1183863785	1448106702	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448106702	20048079	Genotype CT is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole as compared to genotype CC.	0.0
1183863989	1183863885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863885	24595012	Allele C is associated with increased risk of toxicity when treated with capecitabine in people with Neoplasms as compared to allele T.	2.75
1184472900	1184175095	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184175095	15564883	Allele G is associated with increased expression of DCK as compared to allele C.	0.0
1184472900	1184175118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175118	15564883	Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	2.5
1184514240	1184514173	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514173	24974847	Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.	0.0
1450821418	1450812426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812426	19240053	Genotype AG is not associated with dose of ethanol in people with Alcoholism and Stress as compared to genotype AA.	-1.25
1450821418	1450814114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814114	22260295	Allele G is not associated with dose of ethanol as compared to allele A.	-1.75
1450821418	1450814162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814162	22436571	Allele G is associated with increased dose of ethanol in children as compared to allele A.	2.0
1450821418	1450814522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814522	22798433	Allele G is associated with increased dose of ethanol in children as compared to allele A.	2.5
1450821418	1450820267	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820267	23729673	Allele G is not associated with dose of ethanol as compared to allele A.	-2.0
1450821418	1450820613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820613	24134200	Genotypes AG + GG are not associated with dose of ethanol in children as compared to genotype AA.	-2.0
1450821418	1450821413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821413	25215437	Genotype AA is associated with increased dose of ethanol in children as compared to genotypes AG + GG.	2.5
1450821418	1450821902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821902	25836994	Genotypes AG + GG are associated with increased exposure to ethanol in healthy individuals as compared to genotype AA.	1.0
1450821418	1450821908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821908	25836994	Genotypes AG + GG are not associated with exposure to ethanol in healthy individuals as compared to genotype AA.	-0.5
1450821418	1450822078	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822078	26042510	Genotypes AG + GG are associated with decreased dose of ethanol in women as compared to genotype AA.	2.25
1450821418	1450824016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824016	27046326	Genotypes AG + GG are associated with increased exposure to ethanol as compared to genotype AA.	0.75
1450821418	1450824453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824453	28273335	Genotypes AG + GG are not associated with dose of ethanol as compared to genotype AA.	-1.75
1450821418	1450826488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826488	28376280	Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA.	2.5
1450821418	1450928634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928634	28992386	Allele G is not associated with dose of ethanol as compared to allele A.	-0.5
1450821418	1450928686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928686	29265379	Genotypes AG + GG are associated with decreased dose of ethanol as compared to genotype AA.	0.75
1184514209	1184514159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514159	24974847	Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele G.	1.75
1184514217	1184514166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514166	24974847	Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.	1.75
1184514248	1184514180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514180	24974847	Allele G is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele A.	0.0
1184514050	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1184514050	1451237500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451237500	31024313	Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.	3.0
1184514050	1184514014	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514014	25108385	Genotype TT is associated with increased severity of Leukopenia when treated with azathioprine in people with Crohn Disease as compared to genotype CC.	3.25
1184514050	1184514055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514055	25108385	Allele T is associated with increased risk of Leukopenia when treated with azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	3.0
1184514050	1450934743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934743	30728528	Allele T is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele C.	2.5
1184514050	1447682680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682680	26076924	Allele T is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	3.5
1184514050	1447682810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682810	26590936	Genotypes CT + TT is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	3.5
1184514050	1447682869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682869	26735160	Genotypes CT + TT is associated with Alopecia and Leukopenia when treated with azathioprine in children with Crohn Disease as compared to genotype CC.	0.0
1184514050	1448124075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124075	27416873	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with azathioprine in people with Colitis, Ulcerative, Crohn Disease or Hepatitis, Autoimmune as compared to genotype CC.	2.25
1184514050	1448261270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261270	27604507	Genotypes CT + TT are associated with increased risk of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to genotype CC.	3.75
1184514050	1448276309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276309	27558924	Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.	2.75
1184514050	1448531616	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531616	28088792	Allele T is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	1.75
1184514050	1449575757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449575757	29923122	Allele T is associated with increased likelihood of Alopecia, Digestive system anomalies NOS and Leukopenia when exposed to azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.	4.0
1184514050	1449749352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749352	30048756	Allele T is associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Behcet Syndrome, Hepatitis, Autoimmune, Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	0.0
1184514050	1449750314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750314	30101994	Genotype TT is associated with Agranulocytosis, Alopecia, febrile neutropenia, Leukopenia, Neutropenia, Thrombocytopenia and Toxic liver disease when treated with azathioprine in people with Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Pemphigus, Polyarteritis nodosa NOS or Vasculitis.	0.25
1184514050	1449750334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750334	30035323	Genotype TT is associated with Infection and Pancytopenia when treated with azathioprine in women with Pemphigus.	0.25
1184514050	1449750643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750643	29867468	Allele T is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to allele C.	3.25
1184514050	1449750655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750655	29867468	Genotypes CT + TT is associated with increased likelihood of Neutropenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to genotype CC.	2.75
1184514050	1449750718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750718	29704867	Genotype TT is associated with Neutropenia when treated with azathioprine in women with Arthritis, Rheumatoid and Pemphigus.	0.25
1184514050	1449750757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750757	29702976	Genotype TT is associated with Leukopenia when treated with azathioprine in women with Sjogren's Syndrome.	0.25
1451636580	981239072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239072	22846425	Allele T is associated with increased GI toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.5
1184136773	1183849451	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849451	10867985	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased clomipramine-induced prolactin release when exposed to clomipramine in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	1.5
1183704330	827836680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827836680	20538124	Genotype GG is associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AG.	2.25
1184472764	978639883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978639883	22838949	Genotype TT is associated with decreased clearance of gemcitabine in people with Neoplasms as compared to genotypes CC + CT.	1.0
1184472764	1184174881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174881	24300978	Genotype TT is associated with decreased clearance of gemcitabine as compared to genotypes CC + CT.	1.0
1184568404	1184555333	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184555333	4574753	G6PD deficiency is not associated with Anemia when treated with pyrimethamine, sulfadoxine, sulfametopyrazine or trimethoprim in men with Malaria.	-0.625
1184568404	1184516094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516094	1247492	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with decreased survival of red blood cells when exposed to sulfametopyrazine in healthy individuals.	0.0
1184513898	769173693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173693	1415224	Allele A is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele C.	0.0
1184513898	1184989096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989096	12881446	Allele A is associated with increased risk of postanesthesia apnea when exposed to mivacurium and succinylcholine as compared to allele C.	0.0
1184513898	1451405620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451405620	33774263	Genotype AC is associated with increased risk of Apnea due to succinylcholine.	0.25
1451637000	1451636760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636760	34061827	Allele A is associated with increased risk of adverse events when treated with aspirin as compared to allele G.	0.0
1183704262	827829082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829082	22310351	Allele T is associated with increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to allele C.	0.0
1184233711	827695530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695530	16267764	Genotype AA is not associated with increased likelihood of plasma exposure of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	-0.75
1184233711	827704671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704671	12545140	Genotype AA is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	0.25
1184233711	827704679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827704679	12545140	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	0.25
1184233711	769163065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163065	20860463	Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	-0.5
1184233711	1184349427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349427	20625352	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	-0.5
1184233711	1451129601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451129601	31628422	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.	-0.125
1184233711	1447680386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680386	26774523	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	2.0
1184233711	1448821786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821786	28718515	Genotypes AA + AG are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	-0.125
1184233711	1448994461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994461	28886044	Allele A is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele G.	-0.25
1184233711	1448997469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997469	20720517	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	1.0
1184233711	1184233704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184233704	24145522	Genotype GG is not associated with clearance of efavirenz in children with HIV Infections.	-0.75
1184133889	769163058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163058	20860463	Genotypes CC + CT are associated with increased accumulation of drug in PBMCs of efavirenz in people with HIV Infections as compared to genotype TT.	1.0
1184133889	1183944307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944307	24497997	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	1.75
1184133889	1451129611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451129611	31628422	Allele C is not associated with exposure to efavirenz in healthy individuals as compared to allele T.	-0.125
1184133889	1448994467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994467	28886044	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.	-0.25
1184133889	1185234940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234940	25303294	Allele C is associated with concentrations of efavirenz in people with HIV Infections as compared to allele T.	1.75
1184133889	1447984401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984401	27045425	Genotypes CC + CT is associated with increased trough concentration of efavirenz in people with HIV Infections and Tuberculosis as compared to genotype TT.	0.0
1184134274	827807553	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807553	17898703	Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.	2.5
1184348745	827812946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827812946	22158331	Genotype GG is associated with decreased survival when treated with platinum in women with Ovarian Neoplasms as compared to genotypes CC + CG.	1.75
1184348745	827812955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827812955	22158331	Genotype GG is associated with increased survival when treated with platinum in women with Ovarian Neoplasms as compared to genotypes CC + CG.	2.0
1184349177	1183849063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849063	15812265	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	1.75
1184349177	1183849101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849101	15812265	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine.	-1.5
1184349177	1183849112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849112	21688171	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele).	-0.25
1184349177	1183849125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849125	19259652	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele).	-1.5
1184349177	1183849138	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849138	19606452	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) are not associated with response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	-1.25
1184349177	1183849157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849157	18330458	SLC6A4 HTTLPR short form (S allele) is associated with positive correlation of paroxetine concentration with improvement in HAMD scores at week 2 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	-1.75
1184349177	1183849183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849183	17914325	SLC6A4 HTTLPR short form (S allele) is associated with being overrepresented in non-responder group when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	0.0
1184349177	1183944116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944116	17853254	SLC6A4 HTTLPR short form (S allele) is associated with increased presentation in the non-reponder group when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	2.5
1184349177	1183944176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944176	17853254	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with a trend of better treatment response (lower HAMD-17 score) starting at week 4 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	0.0
1184349177	1183944189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944189	15274037	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine or paroxetine in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	2.0
1184349177	1183944211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944211	11027924	SLC6A4 HTTLPR short form (S allele) is associated with increased time to improve (based on mean reductions from baseline in HRSD) when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	-1.5
1184349177	1183944224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944224	11027924	SLC6A4 HTTLPR short form (S allele) is not associated with response to nortriptyline or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-1.25
1184349177	1183944237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944237	10683861	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major.	-2.0
1184349177	1183944245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944245	10683861	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased improvement based on change of HAM-D score after antidepressant medication when treated with fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	2.0
1184349177	1183959898	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959898	10653220	SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.25
1184349177	1183959936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183959936	16874005	SLC6A4 HTTLPR long form (L allele) is associated with increased improvement based on HAM-D score percentage reduction when treated with fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.25
1184349177	1183959964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959964	16874005	SLC6A4 HTTLPR long form (L allele) is not associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	-0.25
1184349177	1183960116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960116	19800133	SLC6A4 HTTLPR long form (L allele) is not associated with differences in response when treated with paroxetine or sertraline in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184349177	1184483970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483970	20640435	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.75
1184349177	1184508133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184508133	16034444	SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in women with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.0
1184349177	1184511256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511256	16822601	SLC6A4 HTTLPR long form (L allele) is not associated with response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184349177	1184512692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512692	19468717	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	2.25
1184349177	1451254722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451254722	19468717	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.75
1184349177	1183959953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959953	16874005	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	This annotation is not used for clinical annotation scoring. since only associated if not drugs are pooled together for analysis
1184349177	1183849204	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849204	15520364	SLC6A4 HTTLPR short form (S allele) is not associated with differences at any time point for either the HDRS-17 or the GDS (depression rating scales) when treated with mirtazapine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-1.5
1184349177	1183849217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849217	15520364	SLC6A4 HTTLPR short form (S allele) is associated with decreased response when measured by the Geriatric Depression Scale at day 7 and day 28 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	2.0
1184472721	981794208	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794208	20665488	Genotype GG is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	0.0
1184472721	1184086271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184086271	24361227	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.	0.0
1184472796	1184472791	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472791	24300978	Genotype CC is associated with increased formation of gemcitabine triphosphate ditriethylamine.	0.0
1450826545	1450826481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826481	28376280	Allele del is associated with increased exposure to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.	2.5
1184348736	1184348675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348675	24533712	Genotype AG is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	2.5
1184348736	1184348679	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348679	24533712	Genotype AA is not associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	-2.75
1184661194	982010069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010069	22486182	Genotypes CT + TT are not associated with dose of acenocoumarol as compared to genotype CC.	-1.5
1184661194	981477999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477999	23132553	Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.	1.5
1184661194	981954447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954447	22629463	Genotype CC is not associated with decreased dose of acenocoumarol as compared to genotypes CT + TT.	-1.5
1184661194	982010017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982010017	22486182	Genotype TT is associated with increased dose of acenocoumarol as compared to genotype CT.	2.0
1184661194	982015210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015210	23510058	Genotype TT is not associated with increased dose of acenocoumarol as compared to genotypes CC + CT.	-1.75
1184661194	655388274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388274	19270263	Genotype CC is associated with decreased dosage requirement when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes CT + TT.	1.75
1184661194	1184511581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511581	25042728	Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC.	2.75
1184661194	1444699605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699605	25519826	Allele T is associated with increased dose of acenocoumarol as compared to allele C.	2.0
1184661194	1444705851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705851	24956252	Genotypes CT + TT are associated with increased dose of acenocoumarol as compared to genotype CC.	3.0
1184661194	1444706936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706936	19578179	Allele T is associated with increased dose of acenocoumarol as compared to allele C.	0.0
1184661194	1444708148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708148	24927344	Genotypes CT + TT is not associated with dose of acenocoumarol as compared to genotype CC.	-1.5
1184661194	1448259328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259328	22911785	Allele T is associated with dose of acenocoumarol.	2.5
1184661194	1449188284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188284	29479633	Allele T is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele C.	2.5
1184661194	1449190771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190771	29432897	Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
1184661194	1450186421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450186421	30506689	Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.	1.75
1450826763	1450822083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450822083	26042510	Genotypes AG + GG are not associated with dose of nicotine as compared to genotype AA.	-2.0
1450826763	1450826625	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826625	28548579	Genotypes AG + GG are not associated with exposure to nicotine in people with Bipolar Disorder or Schizophrenia as compared to genotype AA.	-0.75
1450826763	1450826727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826727	28548579	Genotypes AG + GG are associated with increased exposure to nicotine in people with Schizophrenia as compared to genotype AA.	1.0
1450826763	1450826733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826733	28548579	Genotypes AG + GG are not associated with exposure to nicotine in people with Bipolar Disorder as compared to genotype AA.	-0.5
1450826857	1451676300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676300	34871222	Genotype GG is associated with decreased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.	2.25
1450826857	1451676380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676380	34871222	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.	-1.25
1450826857	1450826840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450826840	28591085	Genotype AA is associated with increased likelihood of Pruritus due to morphine in women with Pain, Postoperative as compared to genotypes AG + GG.	2.75
1450826857	1450826827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450826827	28591085	Genotypes AG + GG are not associated with likelihood of Postoperative Nausea and Vomiting due to morphine in women with Pain, Postoperative as compared to genotype AA.	-1.25
1450826857	1445296778	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296778	25266679	Genotype AA is associated with increased risk of Respiratory Insufficiency when treated with morphine in children as compared to genotypes AG + GG.	2.25
1450826857	1449173395	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449173395	29474345	Allele G is not associated with likelihood of adverse events due to morphine in people with Pain, Postoperative as compared to allele A.	-1.75
1450826857	1449188761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188761	23431434	Allele G is not associated with likelihood of Dizziness, Nausea, Pruritus or Vomiting when treated with morphine in women with Pain, Postoperative as compared to allele A.	-1.5
1450826857	1449238250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449238250	16580900	Genotypes AG + GG are not associated with likelihood of Nausea or Vomiting due to morphine in people with Pain, Postoperative as compared to genotype AA.	-1.25
1183705764	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705764	1447673490	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673490	9334205	Allele A is associated with increased sensitivity to caffeine or halothane as compared to allele G.	0.0
1183705764	1447674728	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674728	9497245	Genotype AG is associated with sensitivity to caffeine or halothane in muscle as compared to genotype GG.	0.0
1183705764	1447952306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952306	8012359	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1445124435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124435	21455645	Genotype AG are associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1184510534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510534	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705764	1444697974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697974	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1445296836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296836	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705764	1445400815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400815	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447644623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644623	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447672272	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672272	16732084	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447672423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672423	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype AA.	0.0
1183705764	1447672565	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672565	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705764	1447673948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673948	12411788	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype GG.	0.25
1183705764	1447674225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674225	10051009	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447675255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675255	12151923	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447675304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675304	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447675406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675406	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447675632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675632	8828983	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447944085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944085	9543323	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705764	1447944096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944096	9543323	Genotype AG is associated with increased creatine kinase as compared to genotype GG.	0.0
1183705764	1447952011	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952011	8902717	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.0
1183705764	1447952297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952297	9106529	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to genotype GG.	0.25
1183705764	1447952360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952360	8825043	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype GG.	0.25
1183705764	1447952470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952470	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447952476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952476	16163667	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705764	1447960676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960676	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1447987336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987336	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705764	1449157608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157608	29101530	Allele A is associated with risk of Malignant Hyperthermia when treated with sevoflurane as compared to allele G.	0.25
1183705764	1449160111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160111	25268394	Allele A is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele G.	0.25
1183705773	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705773	1444667782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667782	16284304	Genotype AC is associated with Malignant Hyperthermia when exposed to caffeine or isoflurane as compared to genotype AA.	2.0
1183705773	1447522117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522117	19020143	Genotype AC is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to genotype AA.	0.0
1183705773	1447952235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952235	7829078	Genotype AC is associated with increased risk of Malignant Hyperthermia as compared to genotype AA.	0.25
1183705773	1447952485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952485	16163667	Genotype AC is associated with increased risk of Malignant Hyperthermia as compared to genotype AA.	0.25
1183705817	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705817	1447674814	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674814	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705817	1445297016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297016	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705817	1445297398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297398	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705817	1447645310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645310	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705817	1447672858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672858	11668625	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705817	1447673872	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673872	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705817	1447674260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674260	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705817	1447674312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674312	10051009	Allele T is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to allele C.	0.0
1183705817	1447944287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944287	9450902	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.25
1183705817	1447952558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952558	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705822	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705822	1184511833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511833	10888602	Allele T is associated with risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705822	1447675399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675399	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705822	1447675494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675494	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705822	1447952564	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952564	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705822	1447960630	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960630	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705822	1447987628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987628	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705827	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705827	1447521586	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447521586	22415532	Allele A is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.	0.0
1183705827	1447521594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521594	22415532	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele G.	0.25
1183705827	1447672311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672311	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705827	1447672593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672593	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705827	1447952283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952283	9450902	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1183705827	1447960758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960758	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705827	1447961050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961050	14985404	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane as compared to allele G.	0.0
1183705827	1447987608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987608	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183704257	827863590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863590	22267851	Allele T is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele A.	0.0
1183704282	1183633736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633736	21636554	Genotypes AA + AG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
1183704292	981802634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802634	23478653	Genotypes AG + GG are associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA.	0.0
1183704390	827700711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700711	21808284	Genotype AA is associated with increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to genotype GG.	3.25
1183705010	1451261580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451261580	32838647	Allele T is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to allele C.	-1.75
1183705010	1184467305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467305	24492364	Genotype CT is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1183705010	1184467298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467298	24492364	Genotypes CC + CT are associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1183705010	981478661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478661	22471906	Genotypes CC + CT are associated with decreased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	1.75
1183705010	1183699582	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699582	24293076	Genotypes CC + CT are associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1183705010	1183703687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703687	24477223	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	1.75
1183705354	1183705324	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705324	417891	G6PD A-202A_376G is associated with Hemolysis when treated with dimercaprol in children with Lead Poisoning, Nervous System, Childhood.	0.25
1450826788	1450826776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450826776	28550509	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	2.25
1450931434	1450931399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931399	29667742	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	0.0
1450931453	1450931377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931377	29667742	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	0.0
1450931583	1450931573	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931573	30221791	Genotype CC is associated with increased likelihood of Nausea and Vomiting due to citalopram in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.25
1450929804	1448612973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612973	28346387	Allele A is not associated with dose of morphine in people with Neoplasms as compared to allele G.	-1.25
1450929804	1449163018	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163018	24703092	Allele A is not associated with dose of morphine in women with Pain, Postoperative as compared to allele G.	-0.25
1450929804	1449173229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173229	29474345	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele G.	-1.75
1450929804	1449243739	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449243739	16580900	Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA.	-1.25
1450929804	1183681975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681975	19514130	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	3.25
1183863836	1183863801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863801	24557078	Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele C.	0.0
1183863836	1183863806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863806	24557078	Genotype TT is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to genotype CC.	0.0
1183863836	1445296945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296945	26180834	Genotype TT is associated with increased discontinuation of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	3.25
1183863836	1449154881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154881	29117017	Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.	3.0
1450823887	1450814119	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814119	22260295	Genotypes AA + AG are associated with increased smoking due to nicotine in children as compared to genotype GG.	-2.75
1450823887	1450814128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814128	22260295	Genotypes AG + GG is associated with increased smoking due to nicotine in children as compared to genotype AA.	2.75
1450823887	1450823878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823878	26558451	Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG.	1.25
1183705307	1184516100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516100	20127091	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with Anemia, Hemolytic when treated with ciprofloxacin in women with Colorectal Neoplasms.	0.25
1450822836	1450811453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811453	17978999	Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC.	2.75
1450823583	1444930282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930282	26010901	Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G.	3.0
1450823583	1448107584	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107584	23358500	Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.	1.25
1450823583	827823510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823510	21764527	Genotype GG is associated with increased functional MRI reactivity to smoking images due to nicotine in women with nicotine dependence as compared to genotypes AA + AG.	0.5
1450934702	1450934380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934380	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934702	1450934386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934386	30723321	Allele C is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934767	1450934743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934743	30728528	Allele T is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele C.	2.5
1450934767	1449750314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750314	30101994	Genotype TT is associated with Agranulocytosis, Alopecia, febrile neutropenia, Leukopenia, Neutropenia, Thrombocytopenia and Toxic liver disease when treated with azathioprine in people with Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Pemphigus, Polyarteritis nodosa NOS or Vasculitis.	0.25
1450934767	1449750334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750334	30035323	Genotype TT is associated with Infection and Pancytopenia when treated with azathioprine in women with Pemphigus.	0.25
1183704238	827805686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805686	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1183704238	1448109482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109482	23441093	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	2.0
1450935288	1450367891	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450367891	30562214	CYP2C8 *1/*3 is associated with decreased dose of ibuprofen.	2.75
1449157419	1449157411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157411	29236941	Genotypes AA + AG is associated with increased likelihood of Death in people with Alcoholism as compared to genotype GG.	2.75
1449157547	1449157470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157470	29193002	Genotypes AA + AC are associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype CC.	3.0
1449157547	1449170124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170124	29392141	Genotypes AA + AC are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype CC.	3.75
1451637008	1451636766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636766	34061827	Allele T is associated with increased risk of adverse events when treated with cephalexin as compared to allele G.	0.0
1451434925	1446897414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897414	11174059	Allele G is associated with Ototoxicity when treated with isepamicin or streptomycin as compared to allele A.	0.25
1451475700	1451474460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451474460	21887680	Genotypes AA + AG is associated with increased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.	2.0
1183703019	1183699298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699298	23609393	Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	3.0
1183703019	1184510528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510528	23856854	Genotype CC is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CG + GG.	-1.75
1183703019	1447983413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983413	27091191	Allele G is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to allele C.	0.0
1183703019	1450180291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450180291	29230023	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	1.375
1183703019	1450376527	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376527	23609393	Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.	-1.5
1183703019	1450376587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376587	28871191	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	-1.5
1183703019	1450376675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376675	22024001	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG.	-2.75
1183703019	1450376719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376719	27482244	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	-1.5
1183703019	1450376730	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376730	27482244	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity.	-2.0
1183703019	1450376755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376755	17283289	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	2.0
1183703019	1450376762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376762	17283289	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	-1.5
1183703019	1450376776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376776	18200436	Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	1.75
1183703019	1450376787	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376787	19150055	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG.	3.0
1183703019	1450376798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376798	21103886	Genotypes CG + GG are not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	-1.5
1183705698	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705698	1447673611	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673611	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1183705698	1447674761	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674761	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705698	981419447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419447	1774074	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.0
1183705698	1184510571	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510571	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705698	1444697819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697819	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1445124440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124440	21455645	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1445297022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297022	20681998	Allele T is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele C.	0.25
1183705698	1445400825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400825	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1446900676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900676	25658027	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447626893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447626893	18502356	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447635001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635001	17081152	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447649391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447649391	14500992	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447651288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447651288	12237752	Allele T is associated with Malignant Hyperthermia when exposed to sevoflurane and succinylcholine as compared to allele C.	0.0
1183705698	1447672415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672415	12059893	Genotypes CT + TT are associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447672484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672484	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447672514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672514	24195946	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447672572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672572	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447672846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672846	11668625	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447673042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673042	11553045	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447673095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673095	11493496	Genotypes CT + TT are associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447673643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673643	12434264	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447673651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673651	12434264	Genotype TT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447673826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673826	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447673922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673922	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.25
1183705698	1447673940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673940	12411788	Genotypes CT + TT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705698	1447673982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673982	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447674291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674291	10051009	Allele T is associated with increased risk of Malignant Hyperthermia and multi-core congenital myopathy as compared to allele C.	0.0
1183705698	1447674357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674357	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447674400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674400	11448278	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to genotype CC.	0.25
1183705698	1447675262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675262	12151923	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447675366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675366	17710899	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447675373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675373	9389851	Genotypes CT + TT are associated with increased risk of Malignant Hyperthermia when exposed to enflurane, halothane, isoflurane or succinylcholine as compared to genotype CC.	0.0
1183705698	1447675432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675432	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia, Myopathy, Central Core and Rhabdomyolysis as compared to genotype CC.	0.0
1183705698	1447675649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675649	8602662	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447675654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675654	7586638	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705698	1447675666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675666	7751854	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447944035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944035	10352931	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447948514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948514	17667581	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.0
1183705698	1447951935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447951935	9520251	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447951942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447951942	9520251	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447952206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952206	7762556	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705698	1447952426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952426	7633940	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447952494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952494	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705698	1447952704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952704	26951757	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to allele C.	0.0
1183705698	1447952756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952756	1510267	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to genotype CC.	0.25
1183705698	1447960695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960695	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1447960905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960905	7547049	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine or volatile anesthetics as compared to allele C.	0.0
1183705698	1447960967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960967	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1447961035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961035	14985404	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele C.	0.0
1183705698	1447961271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961271	19191333	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705698	1447987407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987407	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705698	1449158220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449158220	27646467	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.25
1183705698	1449160118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160118	25268394	Allele T is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele C.	0.25
1183705698	1449160141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160141	27382027	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.25
1183705759	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705759	1447673466	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673466	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1183705759	1447674721	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674721	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705759	1444667790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667790	17122579	Genotype CT is associated with Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	2.5
1183705759	1444697806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697806	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1444697935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697935	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1444698070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698070	23159934	Allele T is associated with increased response to halothane as compared to allele C.	1.5
1183705759	1445124430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124430	21455645	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1445400784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400784	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447644283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644283	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447653270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447653270	16732084	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447672403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672403	12059893	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447672529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672529	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447672779	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672779	8220423	Allele T is associated with increased risk of Myopathy, Central Core and Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447673813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673813	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447673984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673984	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to genotype CC.	0.25
1183705759	1447674167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674167	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447674310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674310	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447675026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675026	12151923	Allele T is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to allele C.	0.0
1183705759	1447675781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675781	7889656	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447947748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947748	21965348	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.0
1183705759	1447949930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949930	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447952044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952044	8592342	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705759	1447960578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960578	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705759	1447960912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960912	7547049	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine or volatile anesthetics as compared to allele C.	0.0
1183705759	1447960955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960955	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705759	1447987298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987298	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705807	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705807	1447674808	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674808	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705807	1184510583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510583	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1183705807	1444697837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697837	15448513	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1444698000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698000	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1445400684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400684	12220451	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447521869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521869	19919814	Allele T is associated with Malignant Hyperthermia and multi-core congenital myopathy as compared to allele C.	0.0
1183705807	1447634887	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634887	17081152	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447644820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644820	15731587	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447672437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672437	12059893	Genotype CT is associated with Malignant Hyperthermia as compared to genotype CC.	0.0
1183705807	1447672498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672498	25735680	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447672579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672579	18564801	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705807	1447673805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673805	10484775	Genotype CG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705807	1447673851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673851	16835904	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674091	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447674246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674246	12208234	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674371	11575529	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447674570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674570	9497245	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane and succinylcholine as compared to genotype CC.	0.0
1183705807	1447675422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675422	25960145	Genotype CT is associated with increased risk of Malignant Hyperthermia, Myopathy, Central Core and Rhabdomyolysis as compared to genotype CC.	0.0
1183705807	1447948638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948638	16244001	Genotype CG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype CC.	0.0
1183705807	1447952512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952512	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1183705807	1447960682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960682	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1447960985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960985	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1183705807	1447987507	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987507	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705807	1449160096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160096	25268394	Allele T is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele C.	0.25
1183705812	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705812	1184510587	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510587	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705812	1444697856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697856	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1444698005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698005	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1445124455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124455	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1445297009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297009	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1445400843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400843	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447521525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521525	23628358	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447629867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447629867	18502356	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype GG.	0.0
1183705812	1447634830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634830	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447636459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447636459	16732128	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447645250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645250	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447672435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672435	10793526	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447672455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672455	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447672504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672504	25735680	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447672586	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672586	18564801	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447672852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672852	11668625	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447673858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673858	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447674051	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674051	10484775	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447674253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674253	12208234	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447674378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674378	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447675269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675269	12151923	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447675467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675467	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia and Rhabdomyolysis as compared to genotype GG.	0.0
1183705812	1447947731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947731	21965348	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705812	1447949853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949853	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1447952530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952530	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447952792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952792	10700782	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705812	1447960466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960466	18945287	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447960643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960643	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1447987523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987523	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705812	1449157794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157794	28326467	Allele A is associated with risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449157801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157801	28063098	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449158213	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449158213	27646467	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1183705812	1449160088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160088	26994242	Allele A is associated with Malignant Hyperthermia and Rhabdomyolysis as compared to allele G.	0.25
1183705812	1449160104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160104	25268394	Allele A is associated with increased risk of Death and Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to allele G.	0.25
1183705812	1449160127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160127	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1451475720	1451474540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451474540	21887680	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.	2.0
1451637100	1451636780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636780	34061827	Allele G is associated with decreased risk of adverse events when treated with codeine as compared to allele C.	0.0
1450936169	1450936028	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936028	30822619	Allele T is associated with increased sulfation of acetaminophen as compared to allele C.	0.0
1450936177	1450936136	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936136	30822619	Allele G is associated with increased sulfation of tapentadol as compared to allele A.	0.0
1450936189	1450936045	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936045	30822619	Allele G is associated with increased sulfation of acetaminophen as compared to allele A.	0.0
1450936217	1450935979	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935979	30822619	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1450936272	1450936070	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936070	30822619	Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele A.	0.0
1450936302	1450936124	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936124	30822619	Allele A is associated with decreased sulfation of tapentadol as compared to allele G.	0.0
1450936308	1450936148	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936148	30822619	Allele G is associated with decreased sulfation of tapentadol as compared to allele T.	0.0
1183705226	1183704091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704091	79931	G6PD deficiency is associated with severe hemolytic anemia when treated with chloroquine.	0.0
1183705226	1183704109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704109	15655011	G6PD deficiency is not associated with hemolysis when treated with chloroquine and methylene blue in healthy individuals.	-0.625
1183705226	1183704160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704160	16179085	G6PD deficiency is not associated with severe hemolysis when treated with chloroquine and methylene blue in children with Malaria.	-0.125
1183705226	1183705568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705568	23530079	G6PD deficiency is not associated with Hemolysis when treated with chloroquine in G6PD deficient mice.	-0.25
1183705226	1183705452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705452	24101478	G6PD A- 202A_376G (assigned as deficiency phenotype) is not associated with increased loss of human red blood cells when treated with chloroquine in huRBC NOD/SCID mice.	-0.25
1183705226	1184516045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184516045	1247492	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is not associated with decreased survival of red blood cells when exposed to chloroquine in healthy individuals.	-0.0
1451637140	1451636801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636801	34061827	Allele T is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele C.	0.0
1183705783	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705783	1447681102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447681102	11063719	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype AA.	0.0
1183704358	827811238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811238	20179710	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	2.0
1183704358	1449718070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718070	29507678	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.	2.25
1183705086	1183704178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704178	10793824	G6PD deficiency is associated with increased reductions in glutathione levels when treated with chloramphenicol as compared to G6PD non-deficient.	0.5
1183705086	1183704206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704206	4644297	G6PD deficiency is associated with Anemia, Hemolytic when treated with chloramphenicol in children with Typhoid Fever.	0.0
1183705086	1183704213	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704213	5559437	G6PD deficiency is associated with Hemolysis when treated with chloramphenicol in children with Typhoid Fever.	0.125
1183705086	1183704218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704218	5345938	G6PD deficiency is associated with Anemia, Hemolytic when treated with chloramphenicol in children with Typhoid Fever.	0.125
1183705086	1183704223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704223	6021320	G6PD deficiency is associated with Hemolysis when treated with chloramphenicol and sulfanilamide in children with Typhoid Fever.	0.125
1184233486	1184233373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233373	24533707	Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA.	2.0
1184233504	1184233392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233392	24533707	Genotypes CC + CT is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype TT.	2.0
1184233517	1184233400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233400	24533707	Genotypes CG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype CC.	2.0
1451637147	1451636801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636801	34061827	Allele T is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele C.	0.0
1184233524	1184233408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233408	24533707	Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA.	1.5
1451475800	1451474580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451474580	21887680	Genotypes AG + GG is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.	2.0
1451475800	1451474747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451474747	21887680	Genotypes AG + GG are associated with decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma.	0.0
1183703748	1451589728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589728	31114289	Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.	2.25
1183703748	981239887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239887	22871975	Genotype AC is associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to genotype CC.	This annotation is not used for clinical annotation scoring. Cohort overlap with PMID 17110455
1183703748	1184510128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510128	22266406	Allele A is associated with increased dose of warfarin as compared to allele C.	2.0
1183703748	981862284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862284	23571513	Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.	2.0
1183703748	1184472416	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472416	20128861	Allele A is not associated with dose of warfarin as compared to allele C.	-1.5
1183703748	1448105757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105757	17110455	Allele A is associated with increased dose of warfarin as compared to allele C.	2.5
1451475820	1451474620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451474620	21887680	GSTT1 null is associated with decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to GSTT1 non-null.	0.0
1449162249	1183702539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702539	19207018	Genotype CC is associated with slower analgesic onset in European Americans undergoing oral surgery when treated with ketorolac as compared to genotypes CT + TT.	2.5
1449164763	1449164694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164694	28762371	Genotypes CT + TT is associated with increased risk of conjunctival hemorrhage when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	3.0
1449164769	1449164727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164727	28762371	Genotype CT is associated with decreased risk of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	2.5
1449192406	1449192335	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192335	27334259	Allele T is associated with response to ivacaftor / lumacaftor.	0.25
1449182358	1449182301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449182301	29259946	Allele A is associated with decreased dose of morphine in people with Pain as compared to allele C.	2.5
1449191373	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191373	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191373	1449191093	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191093	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1451463900	1451463808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451463808	31870219	Genotypes CC + CT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	1.5
1451637160	1451636801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636801	34061827	Allele T is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele C.	0.0
1451637200	1451636820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636820	34061827	Allele A is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele G.	0.0
1451476060	1451474660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451474660	21887680	Genotypes AG + GG are associated with increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.	0.0
1183705778	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705778	1444697990	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697990	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1445124445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124445	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1445400837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400837	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447644750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644750	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447673835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673835	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447674232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674232	12208234	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447674497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674497	9497245	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1183705778	1447949860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949860	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705778	1447952723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952723	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1183705778	1447952967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952967	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705778	1447960606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960606	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705778	1447987466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987466	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183702417	769250992	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250992	19684573	Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.	3.5
1183704409	827703956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827703956	17688403	Genotype TT is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CC + CT.	0.0
1183705797	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705797	1447674786	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674786	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705797	1445400831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400831	12124989	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705797	1447674039	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674039	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1183705797	1447674469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674469	9497245	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype CC.	0.0
1183705802	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1183705802	1447674795	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674795	9497245	Genotype AG is associated with sensitivity to caffeine or halothane in muscle.	0.0
1183705802	1184510579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510579	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1183705802	1444697633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697633	25466363	Allele A is associated with increased risk of Malignant Hyperthermia, Brain Edema and Brain Ischemia as compared to allele G.	0.25
1183705802	1444697831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697831	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1444697995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697995	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1445124450	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124450	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1445198675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445198675	12411786	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705802	1445297032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297032	20681998	Allele A is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele G.	0.25
1183705802	1447672429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672429	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447672492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672492	25735680	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447672839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672839	11668625	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447674045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674045	10484775	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447674364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674364	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1447674556	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674556	9497245	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.0
1183705802	1447675343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675343	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1183705802	1447948701	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948701	16244001	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype GG.	0.0
1183705802	1447948711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948711	12709367	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447952506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952506	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype GG.	0.25
1183705802	1447960725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960725	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1183705802	1447960979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960979	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1183705802	1447961278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961278	19191333	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1183705802	1447987489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987489	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1451464245	827698232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698232	21747412	Genotype TT is associated with increased dose of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.	0.0
1451464245	1449311094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311094	29683944	Genotype TT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.	-0.25
1183703000	1183699133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699133	23860526	Genotype CC is associated with decreased progression-free survival when treated with cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG.	2.0
1184654143	1450935681	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935681	30745309	Allele A is associated with decreased expression of CYP2C19 protein as compared to allele G.	0.0
1184654143	1450935739	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935739	30745309	Allele A is associated with decreased clearance of mephenytoin as compared to allele G.	1.0
1184654143	1183622363	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183622363	9732415	CYP2C19 *6 is associated with decreased catalytic activity of CYP2C19 when assayed with mephenytoin in cells as compared to CYP2C19 *1.	0.0
1184654143	1184471100	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184471100	24945780	CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with mephenytoin in E. coli DH5alpha as compared to CYP2C19 *1.	0.0
1184654143	1184516500	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516500	25001882	CYP2C19 *23 is associated with increased clearance of mephenytoin in cos-7 cell as compared to CYP2C19 *1.	0.0
1184654143	1184516618	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516618	25001882	CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.	0.0
1184654143	1184516634	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516634	25001882	CYP2C19 *11 + *13 + *15 + *18 + *28 are not associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.	-0.0
1184654143	1184516772	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516772	25001882	CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased clearance of mephenytoin in cos-7 cells as compared to CYP2C19 *1.	0.0
1184654143	1184516795	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516795	25001882	CYP2C19 *11 + *13 + *15 + *18 + *28 are not associated with decreased clearance of mephenytoin in cos-7 cells as compared to CYP2C19 *1.	-0.0
1184654143	1184516842	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516842	25001882	CYP2C19 *23 is associated with increased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.	0.0
1184654143	1184564759	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184564759	19661214	CYP2C19 *26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1184654143	1184565887	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184565887	19661214	CYP2C19 *26 is associated with decreased metabolism of mephenytoin and omeprazole as compared to CYP2C19 *1.	2.0
1184654143	1184566038	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184566038	19661214	CYP2C19 *26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 *1.	0.0
1184654143	1184642951	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184642951	17455109	CYP2C19 *18 is not associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in yeast microsomes heterologously expressing as compared to CYP2C19 *1.	-0.0
1184654143	1184642956	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184642956	17455109	CYP2C19 *19 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in yeast microsomes heterologously expressing CYP2C19*19 as compared to CYP2C19 *1.	0.0
1184654143	1184653723	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653723	12464799	CYP2C19 *9 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	0.0
1184654143	1184653730	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653730	12464799	CYP2C19 *10 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	0.0
1184654143	1184653737	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653737	12464799	CYP2C19 *11 is not associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	-0.0
1184654143	1184653744	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653744	12464799	CYP2C19 *13 is not associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	-0.0
1184654143	1184653794	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653794	12464799	CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	0.0
1184654143	1184653810	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184653810	12464799	CYP2C19 *9 is not associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.	-0.0
1184654143	1444695697	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444695697	25001882	CYP2C19 *5 + *6 + *8 + *9 + *16 + *22 + *24 are associated with decreased catalytic activity of CYP2C19 when assayed with clopidogrel or mephenytoin in COS-7 cells as compared to CYP2C19 *1.	0.0
1184654143	1444696445	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696445	21325430	CYP2C19 *8 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696459	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696459	21325430	CYP2C19 *9 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696474	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696474	21325430	CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696485	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696485	21325430	CYP2C19 *16 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696495	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696495	21325430	CYP2C19 *18 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696505	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696505	21325430	CYP2C19 *19 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696515	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696515	21325430	CYP2C19 *13 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696525	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696525	21325430	CYP2C19 *11 + *14 + *15 is not associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	-0.0
1184654143	1444696557	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696557	21325430	CYP2C19 *9 + *10 + *16 are associated with decreased clearance of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	0.0
1184654143	1444696579	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696579	21325430	CYP2C19 *11 + *13 + *14 + *15 + *18 are not associated with decreased clearance of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.	-0.0
1184654143	1444696659	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696659	19661214	CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1184654143	1444696732	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444696732	10411572	CYP2C19 *8 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or tolbutamide as compared to CYP2C19 *1.	0.0
1184654214	827919472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919472	21545408	HLA-C *08:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1184654214	1184471226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471226	24858023	HLA-C *08:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	2.75
1184654214	1184989516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989516	21912425	HLA-C *08:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	-2.0
1184654247	1184471196	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471196	24858023	HLA-DRB1 *09:01:02 is associated with increased risk of Drug Hypersensitivity when exposed to allopurinol in people with Hematologic Neoplasms.	2.75
1183703784	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183703784	1183703775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703775	24037119	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
1183703784	1447954574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954574	24388031	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in women with Colonic Neoplasms.	0.25
1184654139	827919467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919467	21545408	HLA-C *03:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1184654139	1184747194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747194	21301380	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
1184654139	1184755032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755032	15743917	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1184654139	1184756728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756728	21393610	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
1184654139	1184756770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756770	21393610	HLA-C *03:02 is associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	3.25
1184654139	1184467894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467894	21912425	HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1451637155	1451636847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636847	34061827	Allele G is associated with increased risk of adverse events when treated with meperidine as compared to allele T.	0.0
1184755902	1184755882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755882	8554938	CYP2D6 *5/*13 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.	0.125
1184755902	1184756714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756714	20473659	CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.	0.125
1184755902	1184819093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184819093	18797858	CYP2D6 *4/*69 is associated with decreased metabolism of dextromethorphan in healthy individuals.	0.125
1184755902	1184989053	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989053	23394389	CYP2D6 *5/*100 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.	0.125
1184755902	1184989087	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989087	23394389	CYP2D6 *2/*101 is associated with decreased metabolism of dextromethorphan in healthy individuals.	0.125
1444668236	1184466671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466671	24853734	Allele G is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele A.	1.25
1444668236	1184466667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466667	24853734	Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	2.75
1444673084	982046731	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046731	23127916	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	2.75
1444673142	1184512008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512008	24038027	Genotypes AG + GG is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype AA.	2.75
1444673156	1183699550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699550	24048425	Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	1.75
1444673156	1183699556	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699556	24048425	Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.	-1.25
1444673156	1448426950	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426950	27044681	Genotypes AC + CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	2.75
1444695653	827825987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825987	10411572	CYP2C19 *7 is associated with poor metabolizer phenotype when treated with mephenytoin.	0.0
1444695653	1183622033	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622033	8988068	CYP2C19 *1/*1 is associated with increased metabolism of mephenytoin in healthy individuals.	0.125
1444695653	1183622039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622039	8988068	CYP2C19 *1/*2 is associated with increased metabolism of mephenytoin in healthy individuals.	0.125
1444695653	1183622057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622057	8988068	CYP2C19 *1/*3 is associated with increased metabolism of mephenytoin in healthy individuals.	0.125
1444695653	1183622066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622066	8988068	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin in healthy individuals.	0.125
1444695653	1183622172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622172	9103550	CYP2C19 *2/*2 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1183622207	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622207	9103550	CYP2C19 *3/*3 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1183622217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622217	9103550	CYP2C19 *2/*5 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1183622346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183622346	9732415	CYP2C19 *2/*6 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1183622363	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183622363	9732415	CYP2C19 *6 is associated with decreased catalytic activity of CYP2C19 when assayed with mephenytoin in cells as compared to CYP2C19 *1.	0.0
1444695653	1183624136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624136	8747407	CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.5
1444695653	1444695646	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695646	10411572	CYP2C19 *2/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of mephenytoin.	0.0
1444695653	1444696719	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444696719	10411572	CYP2C19 *2/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of mephenytoin.	0.125
1444695653	1447963286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963286	8747407	CYP2C19 *1/*2 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.	2.0
1444695653	1447963315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963315	8195181	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.5
1444695653	1447963349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963349	8988068	CYP2C19 *2/*2 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1447963360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963360	8988068	CYP2C19 *3/*3 is associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1444695653	1447963391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963391	7969038	CYP2C19 *2 + *3 are associated with decreased metabolism of mephenytoin in healthy individuals.	0.125
1444695653	1444703814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703814	10022751	CYP2C19 *5 is associated with decreased metabolism of mephenytoin or tolbutamide.	0.0
1444700509	769169111	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169111	18981009	Genotype GT is associated with decreased metabolism of imatinib in people with Neoplasms as compared to genotype GG.	1.0
1444700509	1183701985	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701985	24322003	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.	0.0
1444700522	1183701980	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701980	24322003	Allele T is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele C.	0.0
1444700796	827784189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784189	21860339	Genotype AA is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.	0.0
1444700881	1183690824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183690824	20925579	Genotypes AA + AG are associated with increased risk of Bradycardia when treated with timolol in people with Glaucoma, Open-Angle as compared to genotype GG.	2.0
1444703123	981785340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785340	23407050	Allele del is associated with increased major cardiovascular events (MACE) rate when treated with Ace Inhibitors, Plain in people with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	3.0
1444703123	637880435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880435	19752885	Allele del is associated with increased mortality when treated with Ace Inhibitors, Plain, Beta Blocking Agents, calcium channel blockers, digoxin or diuretics in people with Heart Failure as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	2.75
1444703131	655388504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388504	16513877	Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT.	2.25
1444703146	982047944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047944	19138248	Genotypes AA + AG are associated with increased risk of aspirin-intolerant chronic urticaria when exposed to aspirin as compared to genotype GG.	2.5
1444703154	827820348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827820348	21159314	Allele T is associated with increased frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4) when treated with interferons and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	2.0
1445401118	1444934680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934680	25026457	Genotypes AA + AC is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype CC.	2.25
1445401125	1444934692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934692	25026457	Genotypes AG + GG is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype AA.	1.75
1445401897	1448266728	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266728	26421491	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.	-0.5
1445401897	1444935523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935523	25495409	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	2.0
1444673149	1183699530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699530	24048425	Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	1.75
1444673149	1183699535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699535	24048425	Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.	-1.25
1444673149	1448426957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426957	27044681	Allele A is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele G.	-1.25
1444703571	1183863864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863864	24583629	Allele C is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	0.0
1444703571	1449558010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449558010	29743634	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.0
1451476200	1451475080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475080	21887680	Genotypes AA + AG are associated with increased risk of Anemia when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.	1.5
1451476200	1451504704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504704	22074251	Genotypes AA + AG are associated with decreased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	3.0
1451476200	1451511500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451511500	25177243	Allele A is not associated with risk of Anemia, Leukopenia, mucositis, Thrombocytopenia or Toxic liver disease due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to allele G.	-0.25
1451476200	1451634399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634399	34346513	Allele A is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
1451493592	1451493500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493500	11910301	Genotype AG is associated with increased response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype GG.	2.25
1451493592	1183615160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615160	11593098	Genotype GG is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotype AG.	-1.25
1445401317	1444935157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935157	25493568	Genotypes GT + TT is associated with increased risk of Respiratory Insufficiency when treated with opioids in children as compared to genotype GG.	2.0
1445401317	1448603101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603101	27977335	Genotype TT is associated with increased likelihood of Respiratory Insufficiency when treated with morphine in children with Kyphosis and Scoliosis as compared to genotypes GG + GT.	0.0
1445401317	1448603248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603248	25558980	Genotypes GT + TT is not associated with risk of Respiratory Insufficiency when treated with morphine in children as compared to genotype GG.	-2.0
1445737062	699638540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638540	19671875	Genotypes GG + GT are associated with increased disease free survival when treated with cyclophosphamide, doxorubicin, fluorouracil and methotrexate in people with Breast Neoplasms as compared to genotype TT.	2.25
1445737062	699638544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638544	19671875	Genotype TT is associated with increased disease free survival in people not taking cyclophosphamide in women with Breast Neoplasms as compared to genotypes GG + GT.	2.5
1445737062	1444694895	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694895	25545243	Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms.	-1.5
1446898857	981501434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501434	20107430	Genotypes CT + TT are associated with increased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype CC.	0.0
1446898857	1446898478	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898478	23799528	Allele T is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	2.0
1446899151	982046005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046005	19582440	Allele T is not associated with warfarin dose in Japanese patients when treated with warfarin as compared to allele C.	-1.5
1446899151	982043519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043519	17049586	Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.	1.75
1446899151	978614496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614496	22676192	Allele T is associated with dose of warfarin.	0.0
1446899151	1184482814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482814	23941071	Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.	2.75
1446899151	1184510043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510043	22549502	Allele C is not associated with dose of warfarin as compared to allele T.	-1.5
1446899151	1184757038	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184757038	25126975	Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele T.	-2.0
1446899151	1444694650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694650	25594941	Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC.	-1.5
1446899151	1444694656	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694656	25594941	Genotypes CT + TT are not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype CC.	-1.5
1446899151	1444695604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695604	25681132	Genotypes CT + TT is not associated with decreased dose of warfarin as compared to genotype CC.	-1.0
1446899151	1444936324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936324	26106580	Allele T is not associated with dose of warfarin as compared to genotype CC.	-1.0
1446899151	1446765956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765956	26257249	Genotype CC is not associated with dose of warfarin as compared to genotypes CT + TT.	-1.5
1446899151	1448108305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448108305	27262824	Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC.	-0.25
1446899151	1448275978	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448275978	21326313	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	2.5
1446899151	1448615355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615355	28429387	Genotypes CC + CT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype TT.	-3.0
1446899151	1449250920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449250920	28049362	Allele T is not associated with dose of warfarin as compared to allele C.	-1.75
1185000205	1184515775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515775	22369694	Allele C is not associated with tacrolimus-induced toxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele T.	-1.5
1185000205	1184515816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515816	20030680	Genotype CT is associated with increased risk of Neurotoxicity Syndromes when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to genotype CC.	0.625
1185000205	1447946869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946869	26856709	CYP3A5 *1 is not associated with risk of nephrotoxicity or Neurotoxicity Syndromes when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3.	-0.25
1444666950	1184407457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407457	16981842	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	-1.25
1444666950	1184468002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468002	21917426	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.25
1444666950	1184469027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469027	24268988	HLA-B *51:01:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	3.5
1444666950	1184469038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469038	24268988	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.75
1444666950	1296598788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598788	22211527	HLA-B *51:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	2.0
1444673025	769169291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169291	18425130	Genotypes AT + TT are associated with decreased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Other data from the same paper used for scoring.
1444673025	1183615612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183615612	21127457	Genotypes AT + TT are associated with decreased risk of adverse cardiovascular outcomes when treated with atenolol, hydrochlorothiazide, trandolapril and verapamil in people with Hypertension and Coronary Artery Disease as compared to genotype AA.	1.5
1444673072	982046870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046870	22480748	Genotype CC is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.	2.25
1444673072	982046888	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046888	22480748	Genotype CC is associated with increased response to infliximab in people with Arthritis, Psoriatic as compared to genotypes CG + GG.	1.5
1444673072	982046944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046944	22480748	Genotype CC is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CG + GG.	-1.25
1444673072	982046966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046966	22480748	Genotype CC is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.	2.25
1444700822	1444672903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444672903	25602530	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to genotype AA.	2.5
1444700830	1043818421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818421	17496729	Genotype GG is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AA + AG.	1.5
1444703178	827815479	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815479	22158445	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele C.	2.25
1444703187	1183690153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183690153	16315032	Genotype AA is associated with increased systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol when exposed to timolol in healthy individuals as compared to genotypes AG + GG.	1.0
1444703195	1444702840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702840	25860557	Genotype GG is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	0.0
1444703840	827779573	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827779573	22015057	Genotype CT is associated with reduced progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.	2.75
1444703848	827779584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827779584	22015057	Genotype AC is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.	2.25
1444704055	1184997918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997918	25356900	Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	0.0
1444704067	981858853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858853	23492908	Allele T is associated with 25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.	2.25
1444704074	981858860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981858860	23492908	Allele T is associated with 29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.	2.25
1444704134	1183681021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681021	24128935	Allele A is associated with increased risk of diabetes when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.	2.5
1444704141	982031703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031703	23778325	Allele T is associated with increased risk of gastrointestinal toxicities when treated with celecoxib in people with Colorectal Neoplasms as compared to allele C.	2.5
1444930850	1444930731	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930731	24907224	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	0.0
1444930850	1444930780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930780	24602923	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C as compared to genotypes CT + TT.	0.0
1444930850	1448530812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530812	28072888	Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.0
1445401179	1444934910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934910	25111199	Genotype AA is associated with decreased progression-free survival when treated with cyclophosphamide and docetaxel in people with Prostatic Neoplasms as compared to genotypes AG + GG.	2.0
1445401310	1451128174	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128174	31666714	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.	-1.75
1445401310	1444935115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935115	25410892	Genotypes CC + CT is associated with decreased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to genotype TT.	1.75
1445117525	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445117525	1444974972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444974972	18212565	Allele T is associated with increased likelihood of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.25
1445401008	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445401008	1447674037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674037	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445401008	1447952570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952570	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445401008	1449565015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565015	15201141	Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1445401008	1449565023	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565023	15201141	Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.	0.0
1451637183	1451636820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636820	34061827	Allele A is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele G.	0.0
1444666938	1296598769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598769	22211527	HLA-A *02:01 is associated with decreased risk of Drug Toxicity when treated with carbamazepine.	-2.0
1444666938	1450968771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450968771	32055583	HLA-A *02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or valproic acid in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	0.25
1444666938	1451640620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451640620	34350628	HLA-A *02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
1444666938	1184468229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468229	23830818	HLA-A *02:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	1.75
1444666938	1184467956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467956	21917426	HLA-A *02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.25
1184986744	1184755355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755355	24086514	Allele A is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to allele G.	1.75
1184986770	1184755349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755349	24086514	Genotype CC is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype CT.	2.25
1445722592	1444694834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694834	25545243	Genotype CC is associated with increased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotypes CT + TT.	2.0
1450371701	1450371553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371553	30457672	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AC + CC.	2.25
1450375740	1450375658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375658	30924126	Allele T is associated with decreased response to allopurinol as compared to allele C.	0.0
1450375758	1450375653	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375653	30924126	Allele A is associated with increased response to allopurinol as compared to allele G.	0.0
1450375752	1447982567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447982567	26810134	Genotypes CT + TT are not associated with response to allopurinol in people with Gout as compared to genotype CC.	-1.5
1450375752	1450375616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375616	30924126	Allele T is associated with decreased response to allopurinol as compared to allele C.	0.0
1451637220	1451636820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636820	34061827	Allele A is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele G.	0.0
1444667234	1185002388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002388	25372392	Allele A is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele T.	0.0
1444667256	1185002399	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002399	25372392	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	0.0
1444667263	1185002405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002405	25372392	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	0.0
1444700354	769170818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170818	11586955	Genotype AA is associated with increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol in healthy individuals as compared to genotype GG.	1.0
1444700362	1444699432	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699432	25751398	Genotype CC is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CT + TT.	3.5
1444700371	1444699419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699419	25751398	Genotype TT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	0.0
1444700382	1444699407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699407	25751398	Genotype TT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.	0.0
1444700597	827815531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815531	22134350	Allele C is associated with decreased likelihood of Nausea when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele T.	3.0
1444700605	982031688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031688	23778325	Allele A is associated with increased risk of Adenoma when treated with celecoxib in people with Colorectal Neoplasms as compared to allele G.	2.5
1444700838	1183701942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701942	24305170	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.	2.5
1444700845	1183701955	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701955	24305170	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.	2.5
1444700853	1183701959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701959	24305170	Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.	2.5
1444701017	827863573	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827863573	22267851	Allele T is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele C.	0.0
1444701024	827783711	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783711	22064666	Genotypes CC + CT are associated with increased response to sildenafil in men with Erectile Dysfunction as compared to genotype TT.	2.25
1444705158	769169519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169519	18347611	Genotypes CC + CT are associated with decreased risk of Myocardial Infarction when treated with Ace Inhibitors, Plain in people with Hypertension as compared to genotype TT.	0.0
1444705166	981502459	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502459	19846067	Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	0.0
1445400945	1445296275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296275	24827774	Genotype GG is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes GT + TT.	2.5
1445401205	1448612694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612694	28367681	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	2.5
1445401205	1449005428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005428	28836054	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.	-1.25
1445401205	1445296596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296596	25245580	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	1.25
1445401218	1450821698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821698	25246386	Genotype TTAAAGTTA/TTAAAGTTA is associated with decreased progression-free survival when treated with pemetrexed in people with Mesothelioma as compared to genotypes TTAAAGTTA/del + del/del.	2.25
1445401247	1444934944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934944	25279974	Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.	2.0
1445402144	1445297161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297161	25582575	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	3.0
1445402163	1444935858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935858	25587129	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	1.75
1445402175	1444935875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935875	25587129	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AT + TT.	2.25
1445402182	1444935867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935867	25587129	Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	1.75
1445585748	1444699618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699618	25519826	Allele T is associated with increased dose of acenocoumarol as compared to allele C.	2.0
1451476309	1451475364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475364	21887680	Genotypes AT + TT are associated with increased risk of Leukopenia when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.	2.0
1451637280	1451636820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636820	34061827	Allele A is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele G.	0.0
1184754040	1447992050	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447992050	26153442	CYP2C19 *29 + *30 + *31 + *33 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.	0.0
1184754040	1448263335	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448263335	27578295	CYP2C19 *23 is associated with decreased clearance of omeprazole in E. coli as compared to CYP2C19 *1.	0.0
1184987460	1184755465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755465	25096645	Allele G is associated with increased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele A.	2.0
1444608441	1184510544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510544	23856854	Genotypes CT + TT is associated with increased intolerability of methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.	1.75
1444700740	1183847599	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183847599	19724244	Allele T is associated with increased risk of suicidal ideation when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	0.0
1444700748	827825897	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825897	22293537	Allele C is associated with increased risk of Leukopenia when treated with gemcitabine in people with Neoplasms as compared to allele T.	0.0
1444703339	1043818416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818416	17496729	Allele G is associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to allele C.	1.0
1444703346	1184349208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349208	24418943	Genotype CT is associated with increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotypes CC + TT.	0.75
1444703346	1444936362	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936362	25712182	Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	2.75
1444703380	827813040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813040	19741565	Genotype GG is associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype AA.	2.25
1444703380	1184472404	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472404	20128861	Allele A is not associated with dose of warfarin as compared to allele G.	-1.5
1444703380	1448567673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567673	28079798	Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.	2.0
1444703380	1448633875	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448633875	28620303	Allele A is associated with decreased expression of CYP4F12 as compared to allele G.	0.0
1444703380	1448633880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448633880	28620303	Allele A is associated with increased expression of CYP4F2 as compared to allele G.	0.0
1444703393	1184755051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755051	24577123	Genotypes AA + AG is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype GG.	2.0
1444703784	982026124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026124	23652408	Genotype TT is associated with increased renal clearance and secretion clearance of metformin when exposed to metformin in healthy individuals as compared to genotype CC.	1.5
1444703784	982026134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026134	23652408	Genotype TT is not associated with differences in the plasma metformin concentration versus time curve or the maximum metformin concentration when exposed to metformin in healthy individuals as compared to genotype CC.	-0.125
1444703784	982026163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026163	23652408	Genotype TT is not associated with glucose-lowering effect of metformin when exposed to metformin in healthy individuals as compared to genotype CC.	-0.125
1444703791	982026129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026129	23652408	Genotype AA is associated with increased renal clearance and secretion clearance of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	0.375
1444703791	982026146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026146	23652408	Genotype AA is not associated with differences in the plasma metformin concentration versus time curve or the maximum metformin concentration when exposed to metformin in healthy individuals as compared to genotype GG.	-0.125
1444703791	982026151	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026151	23652408	Genotype AA is not associated with glucose-lowering effect of metformin when exposed to metformin in healthy individuals as compared to genotype GG.	-0.125
1444703869	827922604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922604	22668755	Genotype AG is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotype GG.	2.0
1444703869	827922611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922611	22668755	Genotype AA is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotypes AG + GG.	2.0
1444703884	769235624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769235624	21278619	Genotype AA is associated with decreased serum bicarbonate levels when treated with topiramate and zonisamide as compared to genotype GG.	0.0
1444703906	1444699815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699815	25805645	Genotype ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA is associated with increased response to levodopa in people with Parkinson Disease as compared to genotypes ACATACACACTCAGACACACATACCATGCA/del + del/del.	2.75
1444703906	1444699877	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699877	25805645	Genotype ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA is associated with increased response to levodopa and methylphenidate in people with Parkinson Disease as compared to genotypes ACATACACACTCAGACACACATACCATGCA/del + del/del.	1.5
1444703250	1183703727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703727	24384557	Allele A is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele G.	-0.5
1444703250	1183703735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703735	24384557	Genotype GG is associated with increased concentration-to-dose ratios when treated with carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	2.5
1444703250	1448998381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998381	28837897	Genotype GG is not associated with concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.	-1.0
1444703250	1448998411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998411	28837897	Allele A is not associated with response to oxcarbazepine in people with Epilepsy as compared to allele G.	-1.5
1444703578	1183863870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863870	24583629	Allele T is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	0.0
1444703578	1449557987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557987	29743634	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.25
1451476360	1451475476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475476	21887680	Genotype AA is associated with decreased risk of mucositis when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to genotype GG.	2.0
1444703619	981500653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500653	23222202	Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Leukemia, B-Cell, Acute as compared to genotype AA.	2.5
1296666989	1296666974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666974	25493567	Allele A is associated with increased response to simvastatin as compared to allele G.	3.0
1445400792	1445296128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296128	24311107	Genotype AA is associated with increased bone density when treated with atorvastatin in people with Coronary Disease as compared to genotypes AG + GG.	1.75
1445400792	1448106204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106204	21151198	Allele A is associated with increased response to Bisphosphonates in people with Osteoporosis as compared to allele G.	2.5
1445400917	1444700343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444700343	24724887	Genotypes CT + TT is associated with increased response to naltrexone in men with Alcoholism as compared to genotype CC.	2.25
1445594343	1444703731	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703731	25695618	Allele C is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele T.	0.0
1445594352	1444703568	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703568	25695618	Allele A is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.	0.0
1445594359	1444703691	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703691	25695618	Allele G is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele A.	0.0
1446902898	1446902837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902837	26425837	Genotypes AA + AC is associated with increased response to atenolol in people with Hypertension as compared to genotype CC.	2.5
1446902898	1446902873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902873	26425837	Genotypes AA + AC is associated with increased response to bisoprolol in people with Hypertension as compared to genotype CC.	0.0
1446902905	1446902845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902845	26425837	Genotypes AA + AC is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.	2.5
1446902912	1446902855	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902855	26425837	Genotypes AA + AG are associated with increased response to atenolol in people with Hypertension as compared to genotype GG.	2.5
1446902920	1446902864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902864	26425837	Genotypes GG + GT are associated with increased response to atenolol in people with Hypertension as compared to genotype TT.	2.5
1446902927	1446902880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902880	26425837	Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.	1.75
1446905759	1445296106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296106	24311107	Genotype TT is associated with increased bone density when treated with atorvastatin in people with Coronary Disease as compared to genotypes GG + GT.	1.75
1446906439	769262749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262749	21142915	Genotype CC is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1446906446	1184988544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988544	24819158	Genotype TT is associated with increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.	2.25
1451493693	1183615168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615168	11593098	Genotype AA is not associated with response to atenolol or irbesartan in people with Hypertension as compared to genotypes AC + CC.	-1.25
1451493693	1451493580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493580	11910301	Genotype AC is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype AA.	1.5
1451493693	827815067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815067	21346624	Genotypes AC + CC are associated with increased blood pressure response when treated with irbesartan in people with Hypertension as compared to genotype AA.	2.5
1445400910	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400910	1447673436	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673436	9334205	Allele C is associated with increased sensitivity to caffeine or halothane as compared to allele T.	0.0
1445400910	1447674665	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674665	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1445400910	1445296822	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296822	20681998	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele T.	0.25
1445400910	1447674897	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674897	9066328	Genotypes CC + CT are associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype TT.	0.0
1445400910	1447675104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675104	17710899	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype TT.	0.25
1445400910	1447952457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952457	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype TT.	0.25
1446905691	981481580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481580	21274861	Allele A is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	2.5
1446905691	981483866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483866	21246582	Genotype CC is associated with increased risk of anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	1.75
1446905691	827815086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815086	21503919	Genotype CC is associated with decreased hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.0
1446905691	1444704997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704997	23707372	Genotype CC is associated with increased severity of Anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes AA + AC.	3.25
1446905691	1444706733	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706733	20173735	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	0.0
1446905691	1444706744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706744	20637204	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.	0.0
1446905691	1444707065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707065	23730840	Genotype AC is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CC.	1.75
1446905691	1444707727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707727	20547162	Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.	3.25
1446905691	1445297932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297932	26071337	Genotypes AA + AC is associated with decreased risk of Anemia when treated with peginterferon alfa-2b, protease inhibitors and ribavirin in people with Hepatitis C as compared to genotype CC.	2.5
1446905691	1446905487	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446905487	26441325	Genotype CC is associated with increased risk of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AA + AC.	2.5
1446905691	1447682514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682514	26670100	Allele C is not associated with increased risk of Anemia when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with as compared to allele A.	-1.75
1446905691	1448532142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532142	26438033	Genotype CC is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AA + AC.	1.75
1446905691	1448602968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602968	26916827	Genotype CC is associated with increased risk of Anemia when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.5
1446905691	1448428382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428382	27833958	Genotype CC is associated with increased likelihood of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	2.0
1446905703	981481593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481593	21274861	Allele C is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	2.5
1446905703	1444707735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707735	20547162	Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	3.25
1446905703	1446905501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446905501	26441325	Genotype AA is associated with increased risk of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AC + CC.	2.5
1446905703	1447682522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682522	26670100	Allele A is not associated with increased risk of Anemia when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with as compared to allele C.	-1.75
1446905703	1448255902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255902	20173735	Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with as compared to allele A.	0.0
1446905703	1448532157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532157	26438033	Genotype AA is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AC + CC.	1.5
1445400880	1444934374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934374	24704384	Genotypes AA + AG is associated with decreased risk of gastrointestinal toxicity when treated with melphalan in people with Multiple Myeloma as compared to genotype GG.	3.0
1445401156	1444934874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934874	25069475	Genotype TT is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes GG + GT.	2.0
1445402111	1444699493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699493	25560469	Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AA + AG.	2.5
1445400887	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400887	1445124465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124465	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400887	1445297250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297250	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400887	1445297422	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297422	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400887	1447522099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522099	19191329	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400887	1447673046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673046	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400887	1447675954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675954	21455645	Genotype AG is associated with risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400887	1447947721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947721	23736090	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to desflurane as compared to genotype GG.	0.0
1445400887	1447960689	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960689	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1444694385	769169088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169088	19752882	Genotype CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1444694562	982046845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046845	21359536	Genotype TT is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes GG + GT.	0.0
1444694574	982046879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046879	21359536	Genotype AA is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	0.0
1445296897	1445117476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445117476	25994031	CYP2C9 *1/*59 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.25
1445400873	1444700279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444700279	24684492	Genotype GG is associated with increased overall survival when treated with daunorubicin in people with Leukemia, Myeloid, Acute as compared to genotypes GT + TT.	2.0
1449753224	1449753155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449753155	29955115	Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype GG.	1.75
1450375053	1450374563	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374563	30914949	Genotypes GG + GT are associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT.	3.0
1445400894	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400894	1445124420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445124420	25256590	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1445296975	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296975	20681998	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1445400849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400849	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447634953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634953	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447672297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672297	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447672461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672461	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1445400894	1447672539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672539	19513315	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to enflurane and succinylcholine as compared to allele G.	0.25
1445400894	1447673865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673865	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447673900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673900	15108991	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447675323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675323	17710899	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447675740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675740	8220422	Genotype AG is associated with increased risk of Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1445400894	1447947742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947742	21965348	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400894	1447952537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952537	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400894	1447960614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960614	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400894	1447960991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960991	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400894	1447987537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987537	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445401168	1451416269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451416269	33097827	Genotypes AA + AG is associated with increased response to antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype GG.	-1.5
1445401168	982028685	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028685	23733030	Genotypes AA + AG are not associated with remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotype GG.	-1.0
1445401168	982028694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028694	23733030	Genotypes AA + AG are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype GG.	-1.0
1445401168	1445296421	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296421	25108775	Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	1.5
1449747575	1449733389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733389	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1451476500	1451475467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475467	21887680	Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.	1.5
1451476500	1296598772	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598772	25303299	Genotypes GT + TT are not associated with risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-1.25
1451476500	1451553532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553532	32695297	Allele T is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
1451476500	1451634708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451634708	34346513	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.25
1451637320	1451636900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636900	34061827	Allele C is associated with increased risk of adverse events when treated with meperidine as compared to allele A.	0.0
1445400156	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400156	1184510652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510652	24361844	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.	0.0
1445400156	1449160880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160880	19648156	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160905	15210166	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160912	12123492	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160919	23558838	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1445400156	1449160936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160936	25256590	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1444673177	1184512107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512107	24061601	Genotype del/del is associated with decreased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA.	2.25
1444679942	1184513720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513720	24126707	Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.	3.5
1444679942	1184513727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513727	24126707	Allele A is not associated with response to buprenorphine or methadone in men with Opioid-Related Disorders as compared to allele C.	-1.75
1444679942	1449157166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157166	23612435	Allele C is not associated with response to buprenorphine in people with Opioid-Related Disorders as compared to allele A.	-0.25
1444680131	1184513771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513771	24126708	Genotypes AG + GG is associated with decreased risk of Dyskinesias when treated with levodopa in people with Parkinson Disease as compared to genotype AA.	2.5
1444680131	1184513776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513776	24126708	Genotypes AG + GG is associated with decreased risk of Hallucinations when treated with levodopa in people with Parkinson Disease as compared to genotype AA.	2.0
1444680138	1184513812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513812	24148610	Genotypes AA + AG is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype GG.	3.25
1444703768	1183630647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630647	20826553	Genotype TT is associated with improved response (marginally significant) when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to genotypes CC + CT.	0.0
1444703768	1183630656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630656	20826553	Genotype TT is associated with improvements in neurovegetative symptoms when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes CC + CT.	2.75
1444703777	1444697710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697710	25713999	Genotypes AC + CC is associated with decreased risk of Anemia when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype AA.	3.0
1444704025	769169833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169833	17015050	Allele G is associated with increased metabolism of nicotine in people with Tobacco Use Disorder as compared to allele A.	2.5
1444704032	982031712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031712	23778325	Allele C is associated with increased risk of cardiovascular toxicity and symptoms when treated with celecoxib in people with Colorectal Neoplasms as compared to allele A.	2.5
1444704040	827785639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785639	21280267	Allele T is associated with decreased area under the plasma concentration-time curve when treated with fexofenadine in healthy individuals as compared to genotype CC.	1.0
1444704048	1184755040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755040	24577123	Genotypes CT + TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotype CC.	2.75
1446766000	1444694062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694062	25615449	Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.	2.25
1446899476	1446899416	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899416	25919042	Genotype CT is associated with decreased metabolism of enalapril in healthy individuals as compared to genotype CC.	1.5
1444673170	1184512095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512095	24061601	Genotype AA is associated with increased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype CC.	2.25
1444673170	1447813745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813745	26100253	Allele C is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele A.	-3.0
1444680101	1184513638	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513638	24126707	Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.	2.75
1444680101	1184513732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513732	24126707	Allele A is not associated with response to buprenorphine or methadone in men with Opioid-Related Disorders as compared to allele G.	-1.75
1444680101	1449157174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157174	23612435	Allele G is not associated with response to buprenorphine in people with Opioid-Related Disorders as compared to allele A.	-1.75
1451648366	1451647580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647580	34488071	Allele G is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele A.	0.0
1451648374	1451647569	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647569	34488071	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.	0.0
1445400172	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400172	1185234581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185234581	10823104	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane as compared to allele C.	0.0
1445400172	1185235523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235523	22030266	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine in people with Myopathy, Central Core as compared to allele C.	0.25
1445400172	1445117584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445117584	25086907	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400172	1449160984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160984	12059893	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1445400172	1449160992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160992	14985404	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to as compared to allele C.	0.0
1445400172	1449161010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161010	24433488	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1451716760	1184137288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184137288	21192344	CYP2C19 poor metabolizers is associated with increased likelihood of remission if tolerant to citalopram treatment when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	1.25
1451716760	1449717828	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717828	30135031	CYP2C19 poor metabolizer phenotype is associated with increased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.	0.875
1451716760	1451715786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451715786	33608663	Genotype AG is associated with decreased response to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.	2.5
1451716760	1183619369	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619369	21192344	CYP2C19 *2 is not associated with remission when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	-2.0
1451716760	1183619378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619378	21192344	CYP2C19 *17 is associated with decreased remission (reported as trend of association) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	0.0
1451716760	1184169426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169426	23545896	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	-1.5
1451716760	1448423400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423400	27804107	CYP2C19 *17/*17 is associated with decreased response to citalopram in people with Obsessive-Compulsive Disorder.	0.25
1451716760	1183619955	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619955	18382661	CYP2C19 *2 + *3 +*17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	-2.0
1451476520	1451475480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475480	21887680	Genotypes AA + AG are associated with decreased risk of Anemia or mucositis when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to genotype GG.	2.5
1447676595	PA166265341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265341		Annotation of DPWG Guideline for lamotrigine and HLA-B	100
1447676595	981859078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859078	20235791	HLA-B *15:02:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in Epilepsy.	-1.25
1447676595	1183680871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680871	23692434	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	-0.25
1447676595	1183680901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680901	23692434	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	1.25
1447676595	1184466675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466675	21071176	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine.	-0.25
1447676595	1184466819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466819	21306565	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine in people with Epilepsy.	-1.5
1447676595	1184988720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988720	24897291	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	1.25
1447676595	1446902388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902388	25647819	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine or valproic acid in people with Epilepsy.	-0.25
1447676595	1447676580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676580	25428396	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	1.5
1447676595	1449169849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169849	29238301	HLA-B *15:02:01 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.	3.25
1447676595	1451780623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451780623	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.	3.75
1451637387	1451636940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451636940	34061827	Allele A is associated with increased risk of adverse events when treated with simvastatin as compared to allele T.	0.0
1447521350	1447521232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521232	26599303	HLA-B *38:02:01 is associated with increased risk of Agranulocytosis when treated with carbimazole or methimazole in people with Graves Disease.	2.75
1447521350	1447521290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521290	26151496	HLA-B *38:02:01 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.	3.5
1451648382	1451647563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647563	34488071	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.	0.0
1451648420	1451647610	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647610	34488071	Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.	0.0
1451678080	1451676300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676300	34871222	Genotype GG is associated with decreased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.	2.25
1451678080	1451676380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676380	34871222	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.	-1.25
1451678080	1451134720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134720	31773688	Genotypes AG + GG are not associated with risk of adverse events due to oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA.	-1.25
1451678080	1451159129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451159129	19514130	Genotype G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to genotype A.	-1.75
1446896644	1446896603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896603	24595507	Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	2.5
1446897502	1444929667	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444929667	26083242	Allele T is associated with increased response to montelukast in people with Asthma as compared to allele G.	0.0
1446897509	1444929615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444929615	26083242	Allele A is associated with increased response to montelukast in people with Asthma as compared to allele G.	0.0
1446897520	1444929392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444929392	26083242	Genotype AA is associated with increased response to montelukast in people with Asthma as compared to genotype GG.	0.0
1446897526	1444929661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444929661	26083242	Allele T is associated with increased response to montelukast in people with Asthma as compared to allele G.	0.0
1446897533	1445402255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402255	26218592	Genotype CC is associated with increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.	2.25
1446897533	1445402279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402279	26218592	Genotype CC is associated with increased likelihood of Bone Diseases, Metabolic and Osteoporosis when treated with anastrozole or letrozole in women with Breast Neoplasms and Aromatase inhibitor-associated musculoskeletal syndrome as compared to genotypes CG + GG.	2.0
1446897540	1445402239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402239	26218592	Genotype CC is associated with increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.	2.25
1446897540	1445402270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445402270	26218592	Genotype CC is associated with increased likelihood of Bone Diseases, Metabolic and Osteoporosis when treated with anastrozole or letrozole in women with Breast Neoplasms and Aromatase inhibitor-associated musculoskeletal syndrome as compared to genotypes CG + GG.	2.0
1446897675	1184511503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511503	24013576	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	-1.25
1446897675	1446738922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446738922	26244574	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	2.25
1446897675	1446743057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446743057	26244574	Genotypes AA + AG are associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.	2.75
1446897710	1446748136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446748136	26244574	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.	3.25
1446897710	1448530569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530569	24874929	Genotypes AA + AT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.	1.75
1183632200	827825805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825805	20707787	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron.	2.5
1183632200	1446896527	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446896527	25012726	Genotype CC is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.	2.0
1451476540	1451475656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475656	21887680	Genotypes AG + GG are associated with increased risk of cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.	3.0
1451648440	1451647605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647605	34488071	Allele A is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.	0.0
1446899209	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1446899209	1183617426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183617426	18070221	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	2.5
1446899303	1444698157	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698157	25702819	CYP2B6 *6 is associated with decreased clearance of ketamine in people with Neoplasms and Pain as compared to CYP2B6 *1.	2.0
1446899616	1446899545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899545	26271661	Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1446899616	1446899553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899553	26271661	Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.75
1446899616	1448358522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358522	27653228	CYP3A5 *1/*1 + *1/*3 are not associated with dose-adjusted trough concentrations of cyclosporine in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1446899680	1446767195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446767195	25987655	Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	3.0
1446899688	1446767183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446767183	25987655	Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	3.0
1446899688	1446767204	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446767204	25987655	Allele T is associated with increased expression of NFATC2 as compared to allele A.	0.0
1446899949	1446897086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897086	26194361	Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.	3.0
1451476581	1451475680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475680	21887680	Genotypes GG + GT are associated with increased risk of nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype TT.	1.5
1451504280	1451504240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504240	33774263	Genotypes C/del + CC are associated with increased risk of Apnea due to succinylcholine as compared to genotype del/del.	0.25
1444704928	827921929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921929	22566498	Genotype GG is associated with decreased response to hydrochlorothiazide in people with essential hypertension as compared to genotype AA.	0.0
1444608250	1184169185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169185	23601795	CYP1A2 *1F/*1F is associated with increased risk of Seizures when treated with clozapine in people with Schizophrenia as compared to CYP1A2 *1A/*1A + *1A/*1F.	2.5
1444608250	1449146653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449146653	21481946	CYP1A2 *1C is associated with increased severity of Confusion, Drug Toxicity, Headache, Muscle Rigidity, sedation and Tachycardia when treated with clozapine in men with Schizophrenia.	0.25
1444607408	1183703542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703542	22875622	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	-1.5
1444607408	1183703573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703573	22875622	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	-1.5
1444607408	1183703589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703589	22875622	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.	2.5
1444607408	1445296591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296591	25245580	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	1.25
1444607408	1448612701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612701	28367681	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.	3.0
1444607408	1449005441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005441	28836054	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.	-1.25
1444607408	1448125824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448125824	27426203	Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.	This annotation is not used for clinical annotation scoring. Heterozygote has the strongest effect on phenotype.
1444607420	1183703910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703910	23537502	Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.25
1444607420	1183704054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704054	23537502	Allele A is not associated with response to antidepressants in people with Mental Disorders as compared to allele G.	-1.75
1444607466	1183703835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703835	23559402	CYP2C9 *1/*3 + *2/*3 + *3/*6 is associated with increased likelihood of Hypotension when exposed to olanzapine in healthy individuals as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.	2.25
1444607666	655386226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386226	20017669	Genotypes CT + TT is associated with increased plasma alanine aminotransferase level when treated with nevirapine in people with HIV Infections as compared to genotype CC.	1.5
1444607666	982047696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047696	23774940	Allele T is not associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele C.	-1.5
1444608238	1184169027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169027	23952191	Genotype CC is associated with increased severity of social withdrawal when treated with dextroamphetamine or methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.	2.25
1444608238	1184169032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169032	23952191	Genotype CC is associated with increased severity of Nausea when treated with dextroamphetamine or methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.	0.0
1444608238	1184169036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169036	23952191	Genotype CC is associated with increased severity of social withdrawal when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.	2.25
1444666615	1296667199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667199	25069034	Genotypes CCGG/CCGG + CCGG/del is associated with decreased overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype del/del.	3.0
1444666622	1296667158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667158	25069034	Genotype GG is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	2.5
1444666629	1296667150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667150	25069034	Genotypes CT + TT is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.0
1444666629	1448256843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256843	27498158	Genotypes CC + CT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1444668457	1184997439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997439	25350695	Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.	1.25
1444668468	1184997409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997409	25350695	Allele A is associated with increased response to hmg coa reductase inhibitors as compared to allele G.	1.25
1444673108	982023127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023127	23386248	Allele C is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to allele T.	2.5
1444673108	827677375	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827677375	12181437	Allele C is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	0.0
1444673115	982023140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023140	23386248	Allele A is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to allele G.	2.5
1444686816	1184470183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470183	24351870	Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG.	1.75
1444686824	1184747648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747648	24394199	Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.	2.5
1444686836	1184471130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471130	24465960	Genotype AA is associated with increased likelihood of achieving target concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	2.0
1444700688	1184513802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513802	22445761	Allele A is associated with increased risk of sexsual dysfunction when treated with fluvoxamine, milnacipran or paroxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1444704921	981501834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501834	23252947	Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.	1.5
1444704936	827921925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827921925	22566498	Genotype GG is associated with increased response to candesartan in people with Essential hypertension as compared to genotype AA.	0.0
1444704943	827696192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827696192	21633340	Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.	2.0
1444843382	1444843349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843349	26086825	Genotypes AT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	2.5
1444843389	1444843357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843357	26086825	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	3.0
1444843402	1444843366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843366	26086825	Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	2.5
1447673027	1184483624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483624	23159229	Genotype AG is associated with decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotypes AA + GG.	2.25
1447673027	1447519183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519183	19297219	Allele A is associated with decreased time in therapeutic range when treated with warfarin as compared to allele G.	2.5
1447681808	1447677275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677275	26463708	Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.	1.25
1447681808	1447677307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677307	26463708	Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.	1.5
1444686803	1184747603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747603	24338217	Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.	1.75
1444686803	1448522360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522360	20530282	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.	-2.0
1444668444	1043818329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818329	23903772	Genotypes AG + GG are associated with poorer reduction in low-density lipoprotein cholesterol (LDLc) when treated with hmg coa reductase inhibitors as compared to genotype AA.	3.0
1444668444	1043818334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818334	23903772	Genotypes AG + GG are associated with poorer reduction in low-density lipoprotein cholesterol (LDLc) when treated with hmg coa reductase inhibitors as compared to genotype AA.	1.5
1444668444	1184997420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997420	25350695	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.	1.25
1444668444	1447986186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447986186	27045730	Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.	1.0
1447673659	1447672868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672868	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447673659	1447522091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522091	19191329	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1447673659	1447961237	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961237	19191333	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1444930642	1444870968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444870968	25734178	Genotype CC is associated with increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to genotypes CT + TT.	2.25
1444930642	1448532296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532296	28100007	Genotype TT is associated with increased likelihood of Recurrence when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
1451678101	1451159122	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451159122	19514130	Allele A is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	-1.75
1451678101	1451676340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676340	34871222	Genotype GG is associated with increased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.	2.75
1451678101	1451676409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676409	34871222	Genotypes AA + AG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype GG.	-1.25
1447672998	1447222981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222981	18574025	Allele T is not associated with time to therapeutic inr when treated with warfarin as compared to allele C.	-2.0
1447672998	1447223148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223148	22571356	Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.	3.0
1447672998	1447520283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520283	19794411	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	2.75
1447672998	1447586687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586687	20386359	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	0.0
1447672998	1447586712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586712	21318593	Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.	3.5
1447672998	1447586784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586784	20339978	Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.	2.25
1447672998	1447586823	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586823	23279643	Allele T is not associated with time to therapeutic inr when treated with warfarin in children as compared to allele C.	-1.25
1447672998	1184472895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472895	24474498	Genotype TT is associated with shorter time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to genotypes CC + CT.	1.75
1447672998	1184510004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510004	22571356	Genotypes CT + TT is associated with decreased time to therapeutic INR>=2 when treated with warfarin as compared to genotype CC.	3.0
1447672998	1450980720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980720	18322281	Genotypes CT + TT is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.	3.75
1447672998	1449165055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165055	28382498	Allele T is not associated with international normalized ratio variability (inr-var) when treated with warfarin as compared to allele C.	-1.25
1447672998	1449190958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190958	29432897	Allele T is associated with increased time to therapeutic inr when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	2.25
1447673015	1447222974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222974	18574025	Allele T is associated with decreased time in therapeutic range when treated with warfarin as compared to allele C.	0.0
1447673015	1447223056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223056	18690342	Allele T is not associated with time in therapeutic range when treated with warfarin as compared to allele C.	-1.5
1447673015	1447521498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521498	22130800	Allele T is not associated with time in therapeutic range when treated with warfarin in children as compared to allele C.	-1.25
1447673015	1184473602	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473602	25001883	Allele T is associated with increased propertion of the first 6 months' treatment time spent within the target INR range (PTIR) when treated with warfarin in children as compared to allele C.	2.25
1447673015	1184510000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510000	22592842	Genotypes CT + TT is associated with increased number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to genotype CC.	2.0
1447673015	1450980720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980720	18322281	Genotypes CT + TT is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.	3.75
1447673015	1451122100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451122100	31720756	Genotype TT is associated with increased time in therapeutic range when treated with warfarin as compared to genotypes CC + CT.	2.25
1447673015	1448257403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257403	27511999	Allele T is not associated with time in therapeutic range when treated with warfarin as compared to allele C.	-1.5
1447673015	1449170748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170748	29396738	Allele T is associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to allele C.	3.0
1447673669	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673669	1447672449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672449	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1447673669	1447952524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952524	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1451476547	1451475649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475649	21887680	Genotypes AG + GG are associated with increased risk of Leukopenia when treated with doxorubicin in people with Osteosarcoma as compared to genotype AA.	2.0
1451465324	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451465324	1451465284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465284	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.	3.5
1451718264	1451718240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451718240	33649522	Allele C is associated with increased risk of Neoplasms when treated with hmg coa reductase inhibitors in women as compared to allele A.	3.0
1444607730	1184136664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136664	23364847	Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotypes CT + TT.	2.0
1444667334	1185002474	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002474	25372392	Allele C is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele T.	0.0
1444667346	1185002481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002481	25372392	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	0.0
1444700474	1183701997	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701997	24322003	Allele T is associated with increased sensitivity to dasatinib or imatinib in K562 cells as compared to allele C.	0.0
1444700488	1183701994	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701994	24322003	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.	0.0
1444700495	1183701991	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701991	24322003	Allele C is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele G.	0.0
1444700502	1183701988	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183701988	24322003	Allele G is associated with increased sensitivity to dasatinib, imatinib or nilotinib in K562 cells as compared to allele A.	0.0
1444703936	1184483111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483111	25000516	Genotype GG is associated with increased risk of induction failure when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	3.0
1444703951	1184173747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173747	24743543	Genotype TT is associated with increased risk of Cough when treated with enalapril in people with Hypertension as compared to genotypes GG + GT.	2.75
1444703951	1184173752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173752	24743543	Genotype TT is associated with increased risk of Cough when treated with enalapril in women with Hypertension as compared to genotypes GG + GT.	2.75
1444703976	769235619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769235619	21278619	Genotype TT is associated with decreased serum bicarbonate levels when treated with topiramate and zonisamide as compared to genotype CT.	0.0
1444704795	981491222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981491222	21086123	Allele C is associated with decreased risk of asthma when treated with aspirin as compared to allele T.	0.0
1444704810	982015298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015298	17233643	Allele T is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele C.	1.5
1444706854	981502120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502120	21107309	Allele C is associated with increased response to olanzapine in people with Schizophrenia as compared to allele T.	0.0
1444706861	982015513	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015513	17503482	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	0.0
1444706876	981488640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981488640	21095016	Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	1.75
1444706883	982015543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015543	17503482	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	0.0
1444706890	769173468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173468	20375926	Genotype CC is associated with increased risk of body weight gain when treated with clozapine, olanzapine or risperidone in people with Schizophrenia.	3.25
1445400939	1444700702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444700702	24725652	Genotype GG is associated with increased Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotype GT.	1.5
1445401413	1444936816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936816	25778466	Genotypes AG + GG is associated with decreased concentrations of bilirubin in people with Colorectal Neoplasms as compared to genotype AA.	2.0
1445401420	1444936844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936844	25778466	Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.	3.75
1445401439	1445379985	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445379985	26122019	Genotypes AT + TT is associated with increased dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.	1.25
1447678472	1447677158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677158	12629505	Genotypes *10B + *41 + *5 + *14 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of tardive dyskinesia when treated with antipsychotics in men with Schizophrenia as compared to genotypes *1 + *2 (assigned as normal metabolizers phenotype) .	0.0
1447678472	1447677849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677849	16478753	CYP2D6 poor metabolizer is not associated with increased severity of extrapyramidal symptoms when treated with antipsychotics in people with Schizophrenia.	-0.75
1447678472	1447677977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677977	9201806	Genotypes *4/*4 + *4/*5 + *4/*6 + *5/*5 (assigned as poor metabolizers phenotype) are associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.0
1447678472	1447678012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678012	9068770	Genotypes *3 + *4 + *5 (assigned as poor metabolizers phenotype) are not associated with risk of Dystonia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.625
1447678472	1447678258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678258	20877299	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased risk of Parkinsonian Disorders and tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 normal metabolizers.	0.875
1447678472	1447677248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677248	15861039	CYP2D6 *10 is not associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-0.875
1447678472	1447677261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677261	15861039	CYP2D6 *2 is not associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-0.875
1447678472	1447677408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677408	15861039	CYP2D6 *3 + *4 + *5 + *6 + *7 + *14 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	1.5
1447678472	1447677436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677436	10579557	CYP2D6 *2 is not associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-1.25
1447678472	1447677554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677554	11214775	CYP2D6 *3 + *4 + *5 + *6 is not associated with risk of Dystonia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-1.5
1447678472	1447677716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677716	12960748	CYP2D6 *2 is not associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-1.5
1447678472	1447677726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677726	12960748	CYP2D6 *10 is not associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	-1.5
1447678472	1447677931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677931	15118351	CYP2D6 *1/*10 + *10/*10 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in men with Schizophrenia as compared to CYP2D6 *1/*1.	3.5
1447678472	1447678049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678049	9713905	CYP2D6 *1/*4 + *1/*5 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1/*1.	2.0
1447678472	1447678152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678152	9713906	CYP2D6 *10 is associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.	1.75
1447678614	1447676694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676694	26323598	Genotypes GG + GT are associated with increased Weight gain when treated with antipsychotics in people with Schizophrenia as compared to genotype TT.	0.0
1447679509	1184469152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469152	24842074	GSTM1 non-null is associated with decreased survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 null.	0.0
1447679509	1184469163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469163	24842074	GSTM1 non-null/non-null is associated with decreased survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 null.	0.0
1447679509	1447677820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447677820	26571237	GSTM1 null/null is associated with decreased likelihood of Death and Recurrence when exposed to cisplatin and radiotherapy in women with Uterine Cervical Neoplasms as compared to GSTM1 non-null/non-null.	3.5
1447679509	1447711105	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447711105	26803611	GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null.	3.25
1447679509	1448263407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263407	27636246	GSTM1 null is not associated with response to oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 non-null.	-1.0
1447679509	1448522322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522322	20530282	GSTM1 null/null is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 non-null/non-null + non-null/null.	-2.0
1447679509	1448568334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568334	27995989	GSTM1 null is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to GSTM1 non-null.	-1.5
1444703702	1184467070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467070	19361869	Allele G is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.	-1.75
1444703702	1184467092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467092	19361869	Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1444703739	1184467070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467070	19361869	Allele G is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.	-1.75
1444703739	1184467075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467075	19361869	Allele G is associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1445400924	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400924	1447961043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961043	14985404	Allele A is not associated with risk of Malignant Hyperthermia as compared to allele G.	This annotation is not used for clinical annotation scoring. The variant is designated as MHS causative by EMHG group. IVCT test for the subject was negative. However, MH may still develop in connection with indicated drugs, so evidence is not counted as conflicting finding in CA.
1445400924	1444698017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698017	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400924	1447635058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447635058	17081152	Allele A is associated with Malignant Hyperthermia and Myopathy, Central Core as compared to allele G.	0.0
1445400924	1447673794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673794	17226826	Allele A is associated with increased risk of Myopathy, Central Core as compared to allele G.	0.0
1445400924	1447961003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961003	25989378	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1451476564	1451475669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475669	21887680	Genotypes AA + AG are associated with increased risk of nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.	0.0
1451504300	1451404424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451404424	33774263	Genotype AA is associated with increased risk of Apnea due to succinylcholine as compared to genotype CC.	0.25
1444704784	981345491	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345491	22949529	Genotype TT is associated with increased risk of adverse cardiovascular outcomes when treated with atenolol or verapamil in people with hypertension and coronory artery disease as compared to allele C.	0.0
1446904283	1446904186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446904186	26339796	Genotypes CT + TT are associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype CC.	2.75
1446904972	1446901050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901050	26403473	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.	0.25
1446905018	1446901061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901061	26403473	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.	0.25
1446906399	769169522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169522	18004211	Allele A is associated with oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to allele G.	2.25
1446906412	1183688940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688940	24192120	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype AA.	2.25
1446906421	827815735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815735	21902501	Allele T is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele C.	3.0
1446906421	827815810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815810	21902501	Allele T is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele C.	1.5
1446907957	1446907707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907707	26456622	Allele C is associated with metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	2.0
1446908002	1446907610	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907610	26456622	Allele C is associated with decreased risk of gastrointestinal toxicity and Leukopenia when exposed to cyclophosphamide in people with Lupus erythematosus as compared to allele T.	3.5
1446908002	1446907636	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907636	26456622	Allele C is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	2.0
1447680028	1447678770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678770	26633805	Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.	3.25
1447680035	1447678879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678879	26633805	Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG.	3.25
1447680045	1447678780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678780	26633805	Genotype CT is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.25
1447680068	1447677393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677393	26463708	Allele A is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	1.5
1447681831	1447677286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677286	26463708	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	1.5
1447681831	1447677450	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677450	26463708	Allele T is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	1.25
1447682293	1447677364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677364	26463708	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele A.	1.5
1446905231	1451127180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451127180	31628422	Genotypes CT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype CC.	0.125
1446905231	1451291500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451291500	24831655	Allele T is not associated with concentrations of efavirenz in people with HIV Infections as compared to allele C.	-0.75
1446905231	1446905219	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905219	25611810	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	1.5
1446905231	1447680740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680740	26779253	Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	-2.0
1446905231	982046523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046523	23080225	Allele T is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele C.	2.5
1451496100	1184521141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184521141	990860	G6PD deficiency is associated with Hemolysis when treated with sulfamethoxazole.	0.125
1451496100	1184653994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184653994	5061461	G6PD deficiency is associated with Hemolysis when treated with sulfamethoxazole in men.	0.125
1451496100	1184544617	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184544617	4818663	G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like (assigned as deficiency phenotype) is associated with Hemolysis when treated with sulfamethoxazole.	0.25
1451743169	1451743160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451743160	34158603	Genotypes CC + CT are associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	4.0
1451504307	1451404506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451404506	33774263	Genotype AC is associated with increased risk of Apnea due to succinylcholine as compared to genotype AA.	0.25
1451723589	1451147640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147640	32331352	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	0.0
1444666110	1184511336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511336	24013576	Genotype TT is associated with increased risk of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	1.75
1444666110	1184511340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511340	24013576	Genotype TT is not associated with risk of Anemia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	-1.25
1444666110	1446728788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446728788	26244574	Genotype TT is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.	2.25
1444666110	1448530302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530302	26914831	Allele T is associated with increased severity of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	2.5
1444666589	1296667136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296667136	25069034	Genotypes AG + GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.25
1444666601	1296667190	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296667190	25069034	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.25
1444666608	1296667143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296667143	25069034	Genotype TT is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	2.25
1444666667	1296667092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667092	24980784	Genotypes AA + AG is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
1444673184	1184512111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512111	24061601	Genotype GG is associated with increased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype del/del.	2.25
1444700625	1183693412	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183693412	24192532	Genotypes AG + GG is associated with increased glucuronidation of nicotine when exposed to nicotine as compared to genotype AA.	1.5
1444700639	1043818429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818429	17496729	Genotypes AG + GG are associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype AA.	1.5
1444700647	1444667472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667472	25485598	Genotype CT is associated with decreased creatinine clearance when treated with tenofovir in people with HIV Infections as compared to genotype CC.	0.25
1444704081	1184505152	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184505152	23510446	Genotypes GT + TT is associated with increased response to citalopram in children with Depressive Disorder as compared to genotype GG.	0.0
1445402209	1444936314	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936314	25685741	Genotype CC is associated with decreased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to genotypes AA + AC.	2.0
1446897159	1446897054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897054	25560300	Genotype AA is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.	3.0
1451504376	1451405632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451405632	33774263	Genotype CT is associated with increased risk of Apnea due to succinylcholine.	0.25
1446906343	827695790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695790	20860462	Genotypes CT + TT are associated with decreased heart rate when treated with Beta Blocking Agents as compared to genotype CC.	2.0
1446906343	827695798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695798	20860462	Genotypes CT + TT are associated with decreased heart rate when treated with Beta Blocking Agents as compared to genotype CC.	1.5
1446906350	769262461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262461	21121812	Allele T is associated with good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to allele C.	1.375
1444607641	1184136027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136027	23510626	Genotype GG is associated with increased risk of Nausea when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
1444607641	1184136032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136032	23510626	Genotype CG is not associated with risk of Nausea when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	-2.0
1444607641	1184136036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184136036	23510626	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
1444607641	1184136041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184136041	23510626	Genotype CG is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-2.0
1444666543	1333193025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193025	25348619	Genotype TT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.	1.25
1444666543	1449559870	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449559870	29737521	Allele T is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele C.	0.0
1444607648	982047688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047688	23774940	Allele C is not associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele G.	-1.5
1444607648	655386234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386234	20017669	Genotypes CC + CG is associated with increased plasma alanine aminotransferase level when treated with nevirapine in people with HIV Infections as compared to genotype GG.	1.5
1444608053	1184168562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168562	24215845	Genotype AA is associated with increased progression-free survival when treated with doxorubicin in people with Sarcoma as compared to genotypes AG + GG.	1.5
1444666550	1333193055	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193055	25348619	Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.	1.25
1444667461	1185003238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003238	25372592	Allele A is associated with decreased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.	3.0
1444700815	981785409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785409	23407048	Genotype AA is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype GG.	3.25
1444700815	1447982636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982636	27104815	Genotype AA is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis as compared to genotypes AG + GG.	3.25
1444706209	982045547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045547	16103896	Genotypes AC + CC are associated with increased response to atorvastatin as compared to genotype AA.	3.0
1444706830	978614573	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978614573	22776887	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele G.	3.5
1444930908	1444930897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930897	25080450	Genotype CC is associated with increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	0.0
1445401260	1444934938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934938	25279974	Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.	2.0
1445401267	1445296851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296851	25311385	Genotypes CC + CT is associated with increased risk of Respiratory Insufficiency when treated with morphine in children as compared to genotype TT.	2.75
1446906328	981501871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501871	23252947	Allele T is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele G.	1.25
1446906335	769169383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169383	17898344	Allele G is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression.	3.0
1446906363	769250900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250900	18926547	Genotype GG is associated with decreased response to aripiprazole in people with Schizophrenia as compared to genotype AA.	2.0
1446906370	1183491430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491430	23254426	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	-1.0
1446906370	1184473233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473233	23399569	Genotype CC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	1.25
1446906391	981237838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237838	22838950	Genotype TT is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.	2.25
1447813539	1447682959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682959	26807589	Allele G is associated with increased likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele A.	2.25
1447813554	827787870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787870	21961651	CYP2C19 *17 is not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	-1.5
1447813554	827813279	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813279	21830868	CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	2.75
1447813554	827813298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813298	21830868	CYP2C19 *17 is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	2.25
1447813554	827788756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827788756	21961651	CYP2C19 *17 is not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	-1.25
1447813554	1444710250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710250	24682508	CYP2C19 *17 are not associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1.	-1.25
1447813554	1444710925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444710925	21480951	CYP2C19 *2 + *3 + *17 is not associated with concentrations of 4-hydroxytamoxifen, endoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	-1.0
1447813554	1444712632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444712632	19156902	CYP2C19 *2/*2 + *2/*3 + *3/*3 is not associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1.	-1.5
1447813554	1444930867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444930867	23842856	CYP2C19 *2/*2 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1 + *1/*2.	0.0
1447813554	1447741578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447741578	26799162	CYP2C19 *2 is associated with decreased metabolism of tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.	2.0
1447813554	1447964385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964385	21047200	CYP2C19 *1/*2 is associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1.	2.0
1447813708	1447813645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813645	26806518	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	1.25
1447813720	1447813659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813659	26806518	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.	1.25
1447813855	1447519851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519851	26536870	Genotype CC is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotype AC.	2.5
1447813873	1447519817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519817	26536870	Genotypes CT + TT are associated with decreased bone density when treated with exemestane or letrozole in women with Breast Neoplasms as compared to genotype CC.	2.5
1447813873	1447519836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519836	26536870	Genotype TT is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1447813969	1447521075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521075	24980946	Genotype AA is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele G.	2.25
1447813969	769166388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769166388	20078613	Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.	2.0
1447813969	1449147078	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147078	29134491	Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.0
1447814178	1447814134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814134	26830973	Genotypes CG + GG are associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.	2.75
1447814397	1447519830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519830	26536870	Genotype TT is associated with decreased bone density when treated with exemestane or letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1447814397	1447519857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519857	26536870	Genotype TT is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1447814403	1447680419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680419	26774523	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	0.0
1447814424	1447678987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678987	25730470	Allele G is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	2.0
1447814450	1447521040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521040	24980946	Genotype CC is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele T.	2.25
1444607611	1183847028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183847028	24302953	Genotype AA is associated with decreased response and remission rate when treated with escitalopram in people with Depressive Disorder as compared to genotypes AG + GG.	1.75
1451504360	1451404566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451404566	33774263	Genotype CG is associated with increased risk of Apnea due to succinylcholine as compared to genotype CC.	0.25
1451504368	1451405580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451405580	33774263	Genotype AT is associated with increased risk of Apnea due to succinylcholine.	0.25
1444666533	1451726240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451726240	33649523	CYP3A4 *1/*22 is associated with increased likelihood of Exanthema when treated with paclitaxel in people with Neoplasms as compared to CYP3A4 *1/*1.	0.0
1444666533	1333193089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1333193089	25398452	CYP3A4 *1/*8 + *1/*20 are associated with increased risk of Peripheral Nervous System Diseases and treatment modification when treated with paclitaxel in people with Breast Neoplasms and Ovarian Neoplasms as compared to CYP3A4 *1/*1.	3.0
1447943620	1447676797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676797	26729753	Allele del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to allele C.	0.0
1447943626	1447676797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676797	26729753	Allele del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to allele C.	0.0
1444686850	1184747818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747818	24589908	Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	1.75
1444686850	1184747824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747824	24589908	Genotype CC is associated with decreased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.	1.75
1444686850	1184747830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747830	24589908	Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.	2.25
1444686857	1184483902	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483902	24897286	Genotype AA is associated with increased clearance of SN-38 in human liver microsomes as compared to genotypes AC + CC.	0.0
1444686868	1185002754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002754	25411163	Genotype AG is associated with increased response to pazopanib in people with Carcinoma, Renal Cell as compared to genotype AA.	2.5
1444686868	1185002764	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1185002764	25411163	Allele G is associated with decreased steady-state level of KDR as compared to allele A.	0.0
1444686880	1184483747	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483747	24897286	Genotypes CT + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype CC.	0.0
1444686880	1184483780	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483780	24897286	Genotypes CT + TT is associated with increased formation of UGT1A9 in human liver microsomes as compared to genotype CC.	0.0
1444686880	1184483784	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483784	24897286	Genotype TT is associated with increased formation of UGT1A1 in human liver microsomes as compared to genotype CC.	0.0
1444687039	1296666759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666759	24776844	Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes AC + CC.	3.5
1444700788	981851758	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981851758	23257377	Allele T is associated with increased risk of bleeding complications when treated with prasugrel in people with Acute coronary syndrome as compared to genotype CC.	2.5
1447813701	1447813633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813633	26806518	Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.	1.25
1447814153	1447814104	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814104	26830973	Genotypes CT + TT are associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.	2.25
1447814153	1447814126	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814126	26830973	Genotypes CT + TT are associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.	1.75
1447814165	1447814118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814118	26830973	Genotypes AA + AG are associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.	1.75
1447814185	1447814142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447814142	26830973	Genotypes AA + AG are associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.	2.25
1447814385	1447813620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447813620	25583994	Genotype AA is associated with decreased risk of major adverse cardiac events (mace) when treated with dalcetrapib in people with Acute coronary syndrome as compared to genotype GG.	0.0
1447814385	1448125943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448125943	27418594	Genotype AA is associated with increased response to dalcetrapib in people with as compared to genotype GG.	3.0
1447943597	1447676729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676729	26664259	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.	1.75
1447943597	1447680300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680300	26757307	Genotype GG is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + AG.	-1.25
1447943608	1447676729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676729	26664259	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.	1.75
1447943614	1447676797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676797	26729753	Allele del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to allele C.	0.0
1447943700	1447680274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680274	26757307	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.	2.0
1447943721	1447813735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813735	25563748	Genotypes AA + AC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotype CC.	1.75
1447943760	1447681671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681671	26788534	Allele G is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele A.	1.625
1447943772	1447676810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676810	26729753	Allele T is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.	0.0
1447944813	1447944175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944175	25616159	Allele G is associated with decreased response to corticosteroids in children with Asthma as compared to allele A.	1.5
1444686843	827815579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815579	22108237	Allele G is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele A.	2.25
1444686843	1184471061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471061	24465960	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	2.5
1444686843	1450928480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928480	31401678	Genotypes AA + AG are not associated with concentrations of tacrolimus in children with proteinuria as compared to genotype GG.	-1.25
1444686843	1448613208	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613208	28112181	Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	2.25
1444686843	1449163570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163570	29318894	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	3.0
1444686843	1449747816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747816	29454235	Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	1.75
1447749024	981502935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502935	23215885	Allele A is associated with a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans when treated with warfarin as compared to allele G.	2.25
1447749024	981502947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502947	23215885	Allele A is not associated with therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in African-Americans when treated with warfarin as compared to allele G.	-1.75
1447749024	1446765943	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765943	26257249	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.	-2.5
1447749024	1447521710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521710	21923605	Allele G is not associated with increased time to achieve stable dose when treated with warfarin as compared to allele A.	-1.25
1447749024	1447682722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682722	26745506	Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.	0.0
1449157278	1451676184	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451676184	32920647	Genotype CC is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.	0.0
1449157278	1451676000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451676000	32920647	Genotypes CT + TT are associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to genotype CC.	2.25
1449157278	1449157145	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157145	23612435	Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.	2.5
1449157278	1449157205	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157205	23612435	Allele C is not associated with response to buprenorphine in people with Opioid-Related Disorders as compared to allele T.	-1.75
1449157278	1449753059	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449753059	30368523	Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.	2.75
1447672622	827807404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807404	18322281	CYP2C9 *2 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672622	827807407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807407	18322281	CYP2C9 *3 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672622	1184472906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472906	24474498	CYP2C9 *2 is not associated with time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1447672622	1447222988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222988	18574025	CYP2C9 *2 + *3 are not associated with time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672622	1447223155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223155	22571356	CYP2C9 *2 + *3 are not associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	-3.0
1447672622	1447519191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519191	19297219	CYP2C9 *2 + *3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672622	1447519724	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519724	18466099	CYP2C9 *2 + *3 + *5 + *6 + *11 are not associated with time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672622	1447520219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520219	17226852	CYP2C9 *1/*2 + *1/*3 are associated with decreased time to therapeutic inr when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.	1.5
1447672622	1447520291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520291	19794411	CYP2C9 *2 + *3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	2.75
1447672622	1447572957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447572957	19074728	CYP2C9 *2 + *3 are not associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672622	1447586660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586660	20386359	CYP2C9 *2 + *3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672622	1447586700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586700	21318593	CYP2C9 *3 is associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672622	1447586768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586768	20339978	CYP2C9 *1/*2 + *1/*3 + *2/*3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	2.25
1447672622	1447586791	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586791	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672622	1447586810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586810	23279643	CYP2C9 *2 + *3 are not associated with time to therapeutic inr when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1445594491	1444703675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703675	25695618	Allele T is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele A.	0.0
1445594498	1444703605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703605	25695618	Allele A is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele T.	0.0
1445594505	1444703599	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703599	25695618	Allele T is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele A.	0.0
1446897166	1446897042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897042	25560300	Genotype AG is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + GG.	3.0
1446897184	1446897033	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897033	25560300	Genotypes AA + AG is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype GG.	3.0
1446899372	1448612847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612847	28322941	Genotype GT is associated with increased exposure to sulfasalazine in healthy individuals as compared to genotype GG.	0.375
1446899372	981501360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501360	18167504	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	1.0
1446899372	1444843284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843284	25872459	Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.	0.125
1447672600	827807404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807404	18322281	CYP2C9 *2 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	827807407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807407	18322281	CYP2C9 *3 is not associated with time to the first INR within the therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	982044562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044562	18322281	CYP2C9 *2 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.	2.25
1447672600	982044576	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044576	18322281	CYP2C9 *3 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.	2.25
1447672600	982045771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045771	19077919	CYP2C9 *1/*3 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	982045784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045784	19077919	CYP2C9 *1/*13 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	982045790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045790	19077919	CYP2C9 *1/*14 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672600	1183700166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700166	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672600	1184472906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472906	24474498	CYP2C9 *2 is not associated with time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1447672600	1447148336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447148336	17955230	CYP2C9 *2 + *3 are not associated with decreased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672600	1447223063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223063	18690342	CYP2C9 *2 + *3 are associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672600	1447521135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521135	17324110	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	1447521743	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521743	23279643	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1447672600	1447521763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521763	25504915	CYP2C9 *2 + *3 are not associated with time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	-1.75
1447672600	1449170693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170693	29396738	CYP2C9 *2 + *3 are associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1.	3.0
1447673759	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673759	1447640254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447640254	19685112	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele C.	0.25
1447673759	1447641258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447641258	19685112	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447644525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644525	16621918	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447645111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645111	16621918	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447673056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673056	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673759	1447952930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952930	16732084	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447673759	1449157821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157821	27918309	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to rocuronium and sevoflurane as compared to allele C.	0.25
1447673778	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673778	1447521640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521640	21282829	Allele A is associated with Malignant Hyperthermia and Myopathy, Central Core.	0.0
1447673778	1447645202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645202	16621918	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447673778	1447649057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447649057	16732084	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447673778	1447673076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673076	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447673778	1447673879	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673879	16835904	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447673778	1447675488	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675488	25960145	Genotype AG is associated with increased risk of Cryptorchidism and Malignant Hyperthermia as compared to genotype GG.	0.0
1447673778	1447675503	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675503	25960145	Genotype AG is associated with increased risk of king denborough syndrome, Malignant Hyperthermia and Myopathy, Central Core as compared to genotype GG.	0.0
1447673778	1447960872	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960872	17483490	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1447673787	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447673787	1447522105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447522105	19191329	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.0
1447673787	1447672329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672329	18306019	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447672379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672379	11928716	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447673084	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673084	16917943	Allele G is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447673787	1447675440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675440	16732084	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447675871	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447675871	1446900666	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900666	25658027	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447675871	1447673172	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673172	16163667	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1447675871	1447987304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987304	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1447676001	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447676001	1447672796	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672796	8220423	Allele G is associated with increased risk of Myopathy, Central Core as compared to allele C.	0.0
1447676077	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447676077	1445297310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297310	24433488	Allele C is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	0.0
1447676077	1447961097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961097	14641996	Genotype CG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1447672640	1184483642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483642	23159229	CYP2C9 *1/*3 + *3/*3 is associated with decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672640	1447148349	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447148349	17955230	CYP2C9 *2 + *3 are associated with decreased time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672640	1447222950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447222950	18574025	CYP2C9 *2 + *3 are not associated with time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672640	1447223042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223042	18690342	CYP2C9 *2 + *3 are not associated with time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672640	1447520043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520043	26469104	CYP2C9 *2 + *3 are associated with decreased time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
1447672640	1447520248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520248	17226852	CYP2C9 *1/*2 + *1/*3 are not associated with time in therapeutic range when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.	-0.25
1447672640	1447521470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521470	10961881	CYP2C9 *2 + *3 are not associated with time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672640	1447521484	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521484	22130800	CYP2C9 *2 + *3 are not associated with time in therapeutic range when treated with warfarin in children as compared to CYP2C9 *1/*1.	-1.25
1451725560	1451725540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451725540	32112986	CYP3A4 low activity is associated with increased risk of adverse events when treated with alprazolam in men with Alcoholism and Anxiety Disorders as compared to CYP3A4 high activity.	1.25
1451725560	1451725460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451725460	32112986	Genotype AG is associated with increased risk of adverse events when treated with alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.	0.0
1444666290	1184749219	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184749219	19183167	Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG.	2.25
1444667758	1444666368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666368	25487141	Genotypes GG + GT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	2.0
1444667758	1448603543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603543	28246425	Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.	1.25
1444667758	1448603612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448603612	28246425	Genotypes GG + GT is associated with increased expression of IL18 mRNA as compared to genotype TT.	0.0
1444686760	1184514207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514207	24165757	Genotypes CT + TT is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to genotype CC.	1.5
1444686760	1184514230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514230	24165757	CYP2C9 *2 + *3 is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to CYP2C9 *1/*1.	1.5
1444686789	1184514346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514346	24293093	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	1.5
1444686789	1184514351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514351	24293093	Genotype GG is associated with increased risk of side effects when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes GT + TT.	2.5
1444686789	1184514375	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514375	24293093	Genotypes GG + TT is associated with increased resistance to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GT.	2.5
1444703803	981239923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239923	22735389	Allele GTAAGTTG is associated with gastrointestinal side effects when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele del.	3.0
1444706869	981488671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981488671	21095016	Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	1.75
1447676781	1447676770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676770	26264253	Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT.	2.5
1447681869	1447677354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677354	26463708	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	1.5
1447681876	1447677374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677374	26463708	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	1.5
1447681883	1447677238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677238	26463708	Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.	1.25
1451649020	1451648933	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451648933	34680127	Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.	2.5
1447945787	1447678899	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678899	26773420	CYP2B6 *6 is associated with decreased clearance of cyclophosphamide in children with Lymphoma, B-Cell as compared to CYP2B6 *1/*1.	2.0
1447945800	1446904875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446904875	24599932	Allele C is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.	2.5
1447945850	1446907932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907932	25637052	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.	3.5
1447945887	769171565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171565	19005160	Allele A is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to allele C.	1.5
1447945887	1447944960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944960	25823782	Genotype CC is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	-1.0
1447945958	1446908047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908047	25385345	Genotypes CT + TT are associated with increased resistance to Antihypertensives in people with Coronary Artery Disease or Hypertension as compared to genotype CC.	1.75
1447945958	1446908090	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446908090	25385345	Genotypes CT + TT are associated with decreased expression of ATP2B1 as compared to genotype CC.	0.0
1447945967	1446895571	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446895571	25209194	Genotypes AG + GG is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype AA.	3.5
1447945967	1446908024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446908024	25096017	Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.	1.75
1447945978	1446908000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908000	25096017	Genotype TT is associated with increased risk of Memory Disorders when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AT.	2.25
1447945985	1447674758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674758	24633560	Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.	1.75
1447945992	1447674771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674771	24633560	Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CC + CT.	1.75
1447945999	1043859238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859238	20031582	Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.	3.0
1447945999	1447674959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674959	26408409	Genotypes CT + TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.	2.5
1447946011	827920004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827920004	22594510	Genotype TT is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	2.5
1447946011	1183699670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699670	23204795	Genotypes GT + TT are associated with increased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	1.75
1447946061	981417433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417433	20860460	CYP2E1 *1A/*1A is not associated with Hepatitis, Toxic when treated with Drugs For Treatment Of Tuberculosis.	-1.25
1447946061	981476079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476079	18713495	CYP2E1 *1A/*1A is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.	1.5
1447946061	981476493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476493	16770646	CYP2E1 *1A/*1A is associated with increased likelihood of Toxic liver disease when treated with isoniazid and pyridoxal phosphate in people with Tuberculosis.	2.25
1447946061	981476514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476514	16677176	CYP2E1 *5B is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis.	-1.5
1447946061	1447944368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944368	24637014	CYP2E1 *1A/*5B is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to CYP2E1 *1A/*1A.	2.75
1447946088	1447520929	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520929	25514903	Allele T is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele C.	1.75
1447946088	1447520958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520958	25514903	Allele T is associated with increased severity of Alcoholism when exposed to ethanol in people with Alcoholism as compared to allele C.	1.0
1447946098	1446905073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905073	21111021	Allele T is associated with decreased response to Hepatitis vaccines as compared to allele C.	2.25
1447946107	1446905079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905079	21111021	Allele C is associated with increased response to Hepatitis vaccines as compared to allele T.	2.25
1449156223	1184468090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468090	23328091	HLA-DRB1 *01:02:01 is associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV.	2.0
1449156223	1448926269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926269	28819312	HLA-DRB1 *01:02:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449192991	1449192973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192973	8033754	Genotypes AA + AG is associated with increased likelihood of Alcoholism and Substance-Related Disorders as compared to genotype GG.	3.0
1444667668	769169412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169412	17467803	Genotype CC is associated with increased response to latanoprost as compared to genotypes CT + TT.	1.75
1444667668	1444666097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666097	25339146	Allele T is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to allele C.	0.0
1451648980	1451648927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451648927	34680127	Allele C is associated with increased response to naltrexone in men with Alcoholism as compared to allele T.	2.5
1451726525	1447954657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447954657	24704000	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.	-1.25
1451726525	1451726355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451726355	33649523	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.	0.0
1444667680	1444666116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666116	25339146	Allele A is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to allele C.	0.0
1444667680	1448112064	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112064	27336732	Genotype CC is associated with increased response to latanoprost in people with Glaucoma or Ocular Hypertension as compared to genotypes AA + AC.	1.75
1444667704	1296666869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666869	25339146	Genotype AG is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype AA.	0.0
1444667733	1296666927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666927	25339146	Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC.	2.75
1444686893	1184747986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747986	24951635	Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.	2.0
1445400992	1444934586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934586	24958282	Genotype AA is associated with increased response to docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes AG + GG.	2.5
1445401001	1444934576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934576	24958282	Genotype CC is associated with decreased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.	2.0
1447681902	1447677221	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677221	26463708	Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.	1.5
1447682300	1447677231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677231	26463708	Allele G is associated with increased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	1.25
1447943640	1447678959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678959	25730470	Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	2.0
1447943653	1447678959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678959	25730470	Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	2.0
1447943673	1447520644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520644	25306451	Genotype TT is associated with increased response to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes CC + CT.	2.25
1447943685	1447680321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680321	26712426	Genotype TT is associated with decreased response to telmisartan in people with Essential hypertension as compared to genotypes CC + CT.	2.0
1447943693	1447520509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520509	25025989	Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT.	1.25
1447943713	1447521252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521252	26595166	Genotype GG is associated with increased exposure to silibinin in healthy individuals as compared to genotype AA.	1.5
1447943753	1447680234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680234	26757307	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.	2.0
1447944755	1447676920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676920	25679126	Allele C is associated with increased response to amisulpride in people with Schizophrenia as compared to allele T.	2.0
1447944806	1447944114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944114	25616159	Allele G is associated with decreased response to corticosteroids in children with Asthma as compared to allele C.	1.5
1447944819	1447681357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681357	25710119	Genotypes CC + CT are associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to genotype TT.	1.5
1447944855	1447681665	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681665	26788534	Allele C is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele G.	1.625
1447943739	769163062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163062	20860463	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.	-0.5
1447943739	1451129589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451129589	31628422	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.	-0.125
1447943739	1447680398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680398	26774523	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	0.0
1444686796	1184514481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514481	24307847	Genotype CC is associated with decreased response to Corticosteroids For Systemic Use in people with Asthma as compared to genotypes CT + TT.	1.5
1444686796	1184514486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514486	24307847	Genotype CC is associated with decreased response to corticosteroids in children with Asthma as compared to genotypes CT + TT.	1.75
1444704267	1444704155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704155	25815774	Genotype CC is associated with decreased progression-free survival when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CT.	0.0
1444704267	1444704172	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704172	25815774	Genotype CC is not associated with decreased overall survival or progression-free survival when treated with capecitabine and irinotecan in people with Colorectal Neoplasms as compared to genotype CT.	-1.75
1444704373	981240140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981240140	17537913	Genotype AA is associated with increased resistance to etoposide as compared to genotypes AG + GG.	1.0
1444704385	1183681025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681025	24128935	Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele A.	2.5
1444704392	981344530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344530	22954510	Allele A is associated with increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone in people with Alcoholism as compared to genotype GG.	1.5
1444704400	982025681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982025681	21280081	Genotype GG is associated with increased response to entacapone in people with Parkinson Disease as compared to genotype AA.	1.5
1447944882	1447681685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681685	26788534	Allele A is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele C.	1.375
1444704366	1184483234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483234	24978393	Genotypes CC + CT is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype TT.	1.75
1444704366	1448526070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448526070	27958380	Genotype CC is not associated with response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	-2.25
1451648958	1451648921	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451648921	34680127	Allele A is associated with decreased response to naltrexone in men with Alcoholism as compared to allele G.	2.5
1185000052	1184515235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515235	18408564	Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.25
1185000052	1447946869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946869	26856709	CYP3A5 *1 is not associated with risk of nephrotoxicity or Neurotoxicity Syndromes when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3.	-0.25
1444667661	1296666368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666368	25327507	Allele G is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele A.	3.0
1444686907	1185012200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012200	25240575	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.	1.0
1444686907	1185012251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012251	25240575	Genotypes AG + GG is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype AA.	1.5
1444686914	1185023364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023364	25271728	Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.0
1444686914	1449749395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749395	29733390	Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-0.75
1444686921	1296666859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666859	24776844	Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.	3.0
1444686927	1296666866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666866	24776844	Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.	2.75
1445401274	1448531882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531882	28063968	Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A.	-0.125
1445401274	1444934961	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934961	25340733	Genotypes AA + AG is associated with decreased concentrations of morphine in infants as compared to genotype GG.	1.0
1184999911	1183491630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491630	23900887	Genotypes CT + TT are associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	1.75
1184999911	1183533917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183533917	23894093	Genotype CT is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	-0.125
1184999911	1183684103	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684103	23107770	Genotype TT is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes CC + CT.	2.5
1184999911	1184470178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470178	24351870	Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1184999911	1184514710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184514710	22309416	Genotype CT are not associated with clearance of tacrolimus in people with liver transplantation as compared to genotype CC.	-0.75
1184999911	1184514713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514713	19384171	Genotype TT is not associated with concentration-to-adjusted dose ratio of tacrolimus in people with liver transplantation as compared to genotypes CC + CT.	-1.25
1184999911	1184515235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515235	18408564	Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.25
1184999911	1184753658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753658	25141896	Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	2.75
1184999911	1184754595	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754595	24820765	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.25
1184999911	1184998180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998180	21698374	Genotypes CT + TT are not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.	-0.25
1184999911	1184998546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998546	23738951	Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.	0.125
1184999911	1448569538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448569538	28084894	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.5
1184999911	1448820435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820435	28685716	Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.	2.25
1184999911	1449165670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165670	28941036	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.0
1184999911	1449747826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747826	29454235	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	1.75
1184999911	1184469290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469290	24911663	CYP3A5 *1/*1 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1184999911	1184470237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470237	24378577	CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	0.75
1184999911	1184471437	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471437	24438215	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1184514699	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514699	22210422	CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1184514728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514728	19289993	CYP3A5 *1/*1 + *1/*3 is not associated with dose-adjusted trough levels of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.125
1184999911	1184515131	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515131	19289993	CYP3A5 *1/*1 + *1/*3 are not associated with trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1184999911	1184515148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515148	19289993	CYP3A5 *1/*1 + *1/*3 are not associated with trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	-0.75
1184999911	1444706133	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706133	25869250	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1184999911	1447674129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674129	26634478	CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1184999911	1447946834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946834	26856709	CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1447946849	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946849	26856709	CYP3A5 *1/*1 is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1448358509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358509	27653228	CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.0
1184999911	1449749518	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749518	29855074	CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1184999911	1449749531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749531	29855074	CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.	0.75
1184999911	1447679054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679054	26521259	CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	1.5
1444700589	769171126	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171126	19047159	Allele A is associated with increased frequency of relapse when treated with tamoxifen in people with Breast Neoplasms as compared to allele G.	1.75
1445401281	1445296930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296930	25348617	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	2.5
1448573506	1448573444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573444	28117133	Genotype TT is associated with increased concentrations of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to genotype GG.	0.75
1448602689	1448602676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602676	28217400	Genotypes AG + GG is associated with increased severity of Hyperglycemia when treated with atenolol in people with Hypertension as compared to genotype AA.	3.0
1448602859	1448602813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602813	28139840	Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele del.	3.0
1448602865	1448602825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602825	28139840	Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele A.	3.0
1448602871	1448602832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602832	28139840	Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele T.	2.5
1448602877	1448602842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602842	28139840	Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele A.	2.5
1448602883	1448602852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602852	28139840	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele C.	2.5
1444687046	1296666792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666792	24776844	Genotypes AA + AT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease and Inflammatory Bowel Diseases as compared to genotype TT.	2.75
1445401142	1444934735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934735	25048416	Genotypes AA + AG is associated with increased diastolic blood pressure and systolic blood pressure when treated with antipsychotics in children as compared to genotype GG.	2.0
1445401149	1444934745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444934745	25048416	Genotypes AA + AG is associated with increased concentrations of glucose in children as compared to genotype GG.	2.0
1445585156	1445585092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445585092	25239468	Genotype AA is associated with increased concentrations of daptomycin as compared to genotypes AG + GG.	1.5
1445585156	1445585099	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445585099	25239468	Genotype AA is associated with decreased clearance of daptomycin as compared to genotypes AG + GG.	1.0
1451678087	1449173463	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449173463	29474345	Allele A is not associated with likelihood of adverse events due to morphine in people with Pain, Postoperative as compared to allele G.	-1.75
1451678087	1451676340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676340	34871222	Genotype GG is associated with increased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.	2.75
1451678087	1451676409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451676409	34871222	Genotypes AA + AG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype GG.	-1.25
1451638880	1451638800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451638800	34246203	CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.	3.0
1451649200	1451649160	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451649160	34728519	Genotypes AA + AC are associated with decreased metabolism of naltrexone as compared to genotype CC.	0.0
1451649186	1451649180	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451649180	34728519	Genotypes CT + TT are associated with decreased metabolism of naltrexone as compared to genotype CC.	0.0
1451679740	1451679529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451679529	34983973	Genotype TT is associated with increased concentrations of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	2.25
1451504901	1296598845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598845	25303299	Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1451504901	1451463740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451463740	31870219	Allele A is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-0.125
1451504901	1451465029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465029	21387541	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	-1.0
1451504901	1451504580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451504580	22074251	Genotypes AA + AG are associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1451504901	1451511420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511420	25177243	Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.	1.5
1451504901	1451552723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552723	32612964	Genotypes AG + GG are associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	-2.0
1451504901	1451553338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451553338	32695297	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.25
1451504901	1451615152	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615152	33501733	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.0
1451504901	1446898629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898629	21644011	Genotypes AA + AG is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.0
1451504901	1448109930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109930	17180579	Genotype AA is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	1.0
1451504901	1451511171	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511171	24908438	Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	0.0
1451504901	1451548506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451548506	29911750	Allele A is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-0.125
1451504901	1184513981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513981	24241962	Allele A is associated with increased risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele G.	2.25
1444668597	1444668581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668581	25367448	Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotype TT.	2.0
1444694373	981754621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754621	19713311	Allele T is associated with increased likelihood of Diabetes Mellitus when treated with cyclosporine, sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele C.	3.0
1444694373	1450376146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376146	21857094	Genotypes CT + TT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-1.5
1444694373	1450377097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377097	23041303	Genotype CT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype CC.	-1.5
1444695339	982047492	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047492	15533655	CYP2C19 *1/*1 is associated with metabolism of clobazam in children as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	1.5
1444695339	1444694964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694964	12451290	CYP2C19 *1/*2 + *2/*2 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	0.125
1444695339	1444694988	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694988	14729419	CYP2C19 *1/*2 is associated with metabolism of clobazam in people with Epilepsy.	0.125
1444695339	1444695013	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695013	15483195	CYP2C19 *1/*2 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	1.0
1444695339	1444695041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695041	18466100	CYP2C19 *1/*1 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	1.0
1444695339	1444695194	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695194	23666564	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	2.0
1444695339	1444695230	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695230	24345815	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.	0.0
1444695339	1444695268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695268	25323806	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.	1.0
1446897191	1183621249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621249	16633140	Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.	2.0
1446897191	1446897062	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897062	25560300	Genotypes CT + TT is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype CC.	3.0
1446903007	1446902609	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902609	25752520	Genotype TT is associated with decreased dose of codeine in women as compared to genotype CC.	2.25
1451720996	1451720780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720780	33788417	Genotypes AG + GG are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	1.75
1448601910	1448601802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601802	28068779	Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.75
1448602210	1448602188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602188	28025020	Genotypes CC + TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT.	2.25
1451649500	1451649297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451649297	34843875	Allele T is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to allele C.	0.0
1451649540	1451649440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451649440	34843875	Allele T is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele C.	0.0
1448603309	1451677642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451677642	34871222	Genotypes AA + AC are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype CC.	-1.25
1448603309	1448594361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448594361	27977335	Genotype AA is associated with increased likelihood of Respiratory Insufficiency when treated with morphine in children with Kyphosis and Scoliosis as compared to genotypes AC + CC.	2.25
1448603309	1448603175	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603175	25558980	Genotypes AA + AC is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC.	3.5
1448603309	1448603242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603242	25558980	Genotypes AA + AC is not associated with risk of Respiratory Insufficiency when treated with morphine in children as compared to genotype CC.	-2.0
1451679780	1451679523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451679523	34983973	Genotype TT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	2.75
1451721004	1451720846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720846	33788417	Genotypes AG + GG are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	0.0
1451721021	1451720863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720863	33788417	Genotypes AA + AC are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	0.0
1451737460	1451737080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451737080	34158603	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.	3.5
1444668402	1184997431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997431	25350695	Allele C is associated with increased response to hmg coa reductase inhibitors as compared to allele T.	1.25
1444700896	1183699255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699255	24240480	Genotype CC is associated with decreased metabolism of quetiapine in healthy individuals as compared to genotypes CT + TT.	1.5
1451721013	1451720836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720836	33788417	Genotypes CC + CT are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	0.0
1446897696	1446746409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446746409	26244574	Allele A is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell.	2.25
1446897696	1448431579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448431579	27564227	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.	2.75
1451638961	1448634673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634673	28447211	Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.	0.0
1451638961	1451638920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451638920	34280009	Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.	2.25
1451720980	1451720794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720794	33788417	Genotypes CT + TT are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	0.0
1451748166	1444694056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694056	25615449	Genotype CC is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CT + TT.	2.75
1184987404	1184985653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184985653	25148458	Allele G is associated with increased risk of Fractures, Bone when exposed to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	0.0
1184988860	1184988627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988627	25290263	Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T.	2.0
1184997066	1184468132	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468132	23360626	HLA-B *38:01:01 is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.	3.0
1184997072	1184468210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468210	23829937	HLA-B *38:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine.	3.0
1451748840	1351431664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1351431664	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 are associated with increased risk of Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1184998947	1184998709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998709	25155932	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.	0.0
1184998975	1184998684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998684	25155932	Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.	2.5
1184998975	1451143980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451143980	32090339	Allele T is associated with decreased clearance of morphine in children as compared to allele C.	1.25
1184997092	1184349257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349257	12873589	HLA-B *44:02:01:01 is associated with increased response to interferon alfa-2a, recombinant and ribavirin in people with Hepatitis C.	2.5
1451720988	1451720828	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720828	33788417	Genotypes CC + CT are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	0.0
1451726789	827922791	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922791	22527101	CYP2C8 *1/*3 + *3/*3 is associated with increased severity of neuropathy when treated with paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1/*1.	0.0
1451726789	982046703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046703	21327421	CYP2C8 *3 is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms.	-1.5
1451726789	1184167002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184167002	24706167	CYP2C8 *2 + *3 + *4 (assigned as poor metabolizer phenotype) is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to CYP2C8 normal metabolizer.	2.25
1451726789	1444844058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444844058	26115084	CYP2C8 *1/*3 is not associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel as compared to CYP2C8 *1/*1.	-1.75
1451726789	1446904129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446904129	24599932	CYP2C8 *4 is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1.	2.5
1451726789	1446904161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446904161	24599932	CYP2C8 *3 is not associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1.	-2.5
1451726789	1448110479	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448110479	25504632	CYP2C8 *3/*3 is associated with Toxic liver disease when treated with paclitaxel, pazopanib and simvastatin.	0.0
1451726789	1451726424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451726424	33649523	CYP2C8 *3 + *4 are associated with increased likelihood of Drug Toxicity when treated with paclitaxel in people with Neoplasms as compared to CYP2C8 *1.	0.0
1451737500	1451737148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451737148	34158603	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	3.5
1296598910	1296598796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598796	25461249	Allele A is associated with increased dose of phenprocoumon as compared to allele G.	2.0
1451721028	1451720870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451720870	33788417	Genotypes CC + CT are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	0.0
1444666308	1184749254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184749254	19331489	Genotypes AA + AC is associated with increased concentrations of topiramate in people with Alcohol-Related Disorders as compared to genotype CC.	1.0
1444666308	1184749261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184749261	19331489	Genotypes AA + AC is associated with decreased response to topiramate in people with Alcohol-Related Disorders as compared to genotype CC.	1.5
1444673163	1184470386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470386	24658827	Allele T is not associated with increased metabolism of cyclosporine in people with Kidney Transplantation as compared to allele C.	-0.75
1444673163	1185023114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023114	24061445	Genotype TT is associated with decreased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CC + CT.	2.0
1444673163	1449165693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165693	29135906	Allele T is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to allele C.	1.5
1444686935	1296666803	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666803	24776844	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes CC + CT.	3.5
1444686942	1296666743	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666743	24776844	Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotypes AA + AT.	2.75
1444686958	1296666780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666780	24776844	Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype CC.	2.75
1444694504	769180562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180562	21355884	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with cadaveric kidney graft as compared to genotype AA.	2.0
1444694544	982046804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046804	21359536	Genotype TT is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotype CT.	2.25
1444703639	827785915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785915	20827233	Allele A is associated with increased risk of non-response to methotrexate when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.	1.5
1444703668	1183699214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699214	24225399	Genotypes CT + TT is associated with decreased risk of Neutropenia when treated with gemcitabine as compared to genotype CC.	2.5
1444713220	1185001474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001474	11266078	HLA-DRB3 *02:02:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.	2.0
1444713245	1185001680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001680	17339877	HLA-B *44:03:01 is associated with increased risk of Toxic liver disease when treated with ticlopidine.	3.25
1444828083	1447946819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946819	26906307	G6PD deficiency is associated with Anemia, Hemolytic when treated with pegloticase in people with Gout.	0.125
1444828083	1444828021	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444828021	25224415	G6PD A- 202A_376G is associated with Hemolysis and Methemoglobinemia when exposed to pegloticase in people with Gout.	0.25
1445616165	1444703756	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703756	25695618	Allele C is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele T.	0.0
1445619121	1444703722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703722	25695618	Allele G is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele T.	0.0
1445619585	1444703625	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703625	25695618	Allele G is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele A.	0.0
1448573300	1448573185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573185	28135054	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	3.25
1444694511	982046912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046912	21359536	Genotype CC is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.	-2.25
1444694511	827813827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813827	21770725	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.75
1444694511	827813837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813837	21770725	Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.75
1444694511	769172714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172714	15521904	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.	-0.75
1444694511	1183491673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491673	23900887	Genotype CC is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.	-1.25
1444694511	1183491680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491680	23900887	Genotype CC is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.	-1.25
1444694511	1183693340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693340	22660440	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation.	-1.75
1444694511	1183697419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697419	22183771	Genotype CC is associated with increased dose of tacrolimus in people with Kidney Transplantation.	2.0
1444694511	1183959847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959847	18429967	Genotypes CC + CT is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + AT.	-1.0
1444694511	1183959859	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183959859	19376366	Genotypes AC + CT is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.0
1444694511	1183960177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960177	20383212	Allele A is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele C.	-0.25
1444694511	1183960204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960204	20383212	Allele A is not associated with clearance of tacrolimus in children with hemopoietic stem cell transplant as compared to allele C.	-0.25
1444694511	1184468811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468811	21047202	Genotype AT is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
1444694511	1184470912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470912	24528196	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation.	1.5
1444694511	1184753676	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184753676	25141896	Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.	1.75
1444694511	1185012354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012354	25310192	Genotype TT is not associated with concentrations of tacrolimus in children with liver transplantation.	-1.25
1444694511	1185023199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023199	24383873	Genotype CC is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation.	-0.125
1444694511	1448423959	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423959	26450467	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele C.	-0.125
1444694511	1448573370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573370	28135009	Genotype AA is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative.	-0.75
1444694511	1448820619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820619	28736028	Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.	1.0
1444694511	1449165839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165839	28945481	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
1444694511	1449171419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171419	27966227	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation.	-0.125
1444694511	1447520859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520859	26543771	Allele C is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele A.	-1.0
1444694511	1447946352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946352	26705892	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.	1.75
1444694511	1447946585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946585	26705892	Genotypes AC + CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	1.75
1444703649	1183863878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863878	24583629	Allele C is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	0.0
1444703649	1449558022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449558022	29743634	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.0
1444666386	982047669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047669	23774940	Allele C is associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele T.	3.0
1444666386	1296598592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598592	25147095	Genotypes CC + CT is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV Infections as compared to genotype TT.	4.0
1444666386	1448635501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635501	28689274	Allele C is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele T.	2.5
1444666386	1449155757	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155757	28819312	Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and dress syndrome when treated with nevirapine in people with HIV Infections as compared to allele T.	0.0
1296599132	1184746676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746676	25007187	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1296599132	1296598800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598800	25303299	Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.75
1296599132	1296598882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598882	25303299	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1296599132	1444843110	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444843110	26071279	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.	3.0
1296599132	1445297179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297179	25582575	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	2.5
1296599132	1448124312	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124312	27399166	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.	-1.25
1296599132	1449003004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003004	28525903	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.75
1296599132	1449003305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449003305	28525903	Genotypes AA + AG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-1.75
1296599132	1449003393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003393	28525903	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-1.25
1296599132	1451475460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451475460	21887680	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.	-2.0
1296599132	1451553526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553526	32695297	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.25
1296599132	1451633800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451633800	34346513	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.75
1451748940	1333193294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193294	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1451748940	1351431664	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1351431664	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 are associated with increased risk of Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1448573615	769180588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180588	21289623	Genotype AA is not associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.	-1.75
1448573615	1448573312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573312	28135009	Genotypes AG + GG are associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	2.75
1448601692	1448601675	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601675	27566695	Genotype GG is associated with decreased response to clopidogrel in people with Coronary Disease as compared to genotypes AA + AG.	2.0
1448603297	1448603159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603159	25558980	Genotypes CT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC.	3.0
1448603303	1448603169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603169	25558980	Genotypes AA + AG is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.	3.0
1448604082	1448604066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604066	28209466	Genotype del/del is not associated with response to cavosonstat in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	-1.0
1448604082	1448604071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448604071	28209466	Genotype del/del is associated with response to cavosonstat in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	1.75
1448604316	1448604276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448604276	26503818	Allele C is associated with increased risk of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to allele T.	0.0
1448594289	1448592786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448592786	28154789	Genotypes AA + AG is associated with decreased clearance of propofol as compared to genotype GG.	1.75
1448594289	827783818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783818	22006347	CYP2B6 *6 is not associated with metabolism of propofol.	-1.0
1448594289	827783823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783823	22006347	CYP2B6 *4 is not associated with metabolism of propofol.	-1.0
1448594289	827783832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783832	22006347	CYP2B6 *7 is not associated with metabolism of propofol.	-1.0
1451737520	1451737140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451737140	34158603	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.	3.5
1451748948	1333193294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193294	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1184989970	1183960116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183960116	19800133	SLC6A4 HTTLPR long form (L allele) is not associated with differences in response when treated with paroxetine or sertraline in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184989970	1184483446	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483446	12955294	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-2.5
1184989970	1184483570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483570	18452396	SLC6A4 HTTLPR long form (L allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.25
1184989970	1184509540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509540	21962566	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with posttraumatic stress disorder as compared to SLC6A4 HTTLPR short form (S allele).	-2.75
1184989970	1184509867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509867	19825907	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	0.0
1184989970	1184509880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509880	22885912	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	2.25
1184989970	1184513231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513231	17018806	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	2.5
1184989970	1449718352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449718352	16580768	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	-0.25
1444607496	1451147565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147565	32331352	Allele C is not associated with metabolism of ambrisentan, aripiprazole, atorvastatin, donepezil or olanzapine in healthy individuals as compared to allele T.	-1.25
1444607496	1183703789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703789	23559402	CYP3A5 *1/*1 + *1/*3 is associated with increased area under the curve when exposed to olanzapine in healthy individuals as compared to CYP3A5 *3/*3.	1.25
1444607496	1451335424	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451335424	33378980	CYP3A5 *3 is not associated with exposure to olanzapine in healthy individuals as compared to CYP3A5 *1.	-0.75
1184755574	1184755477	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184755477	1844820	CYP2D6 *9 is associated with decreased metabolism of bufuralol or sparteine in liver cells.	0.0
1184755574	1184755514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755514	8101460	CYP2D6 *1/*9 (assigned as normal metabolizers phenotype) is not associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1184755574	1184755565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755565	8101460	CYP2D6 *5/*9 (assigned as normal metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.	0.125
1184755574	1184756755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756755	9918137	CYP2D6 *4/*38 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine.	0.125
1184756108	1184756094	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756094	8807669	CYP2D6 *4/*15 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or dextromethorphan in healthy individuals.	0.125
1184986481	981785367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785367	22388796	Genotypes AA + AG are associated with increased risk of delayed graft function when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.	2.5
1184986481	981785387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785387	22388796	Genotypes AA + AG are associated with decreased renal function (lower creatinine clearance) at 3 months of follow-up when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.	2.5
1184986481	827815680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815680	21902502	Genotypes AA + AG are associated with decreased clearance of cyclosporine in people with Kidney Transplantation as compared to genotype GG.	1.5
1184986481	1184470287	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470287	24658827	Allele A is associated with decreased metabolism of cyclosporine in people with Kidney Transplantation as compared to allele G.	1.75
1184986481	1184470962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470962	24522145	CYP3A4 *1/*1 is associated with increased clearance of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*22 + *22/*22.	2.25
1184986481	1448358573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358573	27653228	CYP3A4 *1/*1 are not associated with dose-adjusted trough concentrations of cyclosporine in people with liver transplantation as compared to CYP3A4 *1/*22 + *22/*22.	-1.0
1184986481	1449165678	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165678	29135906	CYP3A4 *22 is not associated with concentrations of cyclosporine in children with Kidney Transplantation.	-0.125
1184986481	1449004049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004049	29043387	CYP3A4 *1/*22 is not associated with likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-1.75
1184986481	1449004075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004075	29043387	CYP3A4 *1/*22 is not associated with likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-1.75
1184986491	1184470358	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470358	24658827	Allele G is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.	1.5
1184989950	1183944237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944237	10683861	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major.	-2.0
1184989950	1183944245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183944245	10683861	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased improvement based on change of HAM-D score after antidepressant medication when treated with fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-2.0
1184989950	1184483970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483970	20640435	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.75
1184989950	1184484028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184484028	12476327	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	2.5
1184989950	1184509880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509880	22885912	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-2.25
1184989950	1184511344	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511344	16302021	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	3.0
1184989950	1184512692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512692	19468717	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	2.25
1184989950	1184513231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513231	17018806	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	-2.5
1184989950	1448285579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285579	27439447	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	3.0
1184989950	1448285601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285601	27439447	SLC6A4 L allele-rs25531T/L allele-rs25531T is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531C/L allele-rs25531T.	-1.5
1184989950	1451254722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451254722	19468717	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.75
1184989960	1184509821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509821	14573314	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of Sleep Initiation and Maintenance Disorders when treated with fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	1.5
1184989960	1184509830	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184509830	14573314	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of Psychomotor Agitation when treated with fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).	2.0
1184990000	1183849246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849246	15520364	SLC6A4 HTTLPR long form (L allele) is associated with increased risk of side effects when treated with mirtazapine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.0
1296598634	1185235133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235133	25303297	HLA-B *39:01:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.	2.5
1296598640	1185235152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235152	25303297	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.	3.0
1296598646	1185235161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185235161	25303297	HLA-B *15:05:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.	0.0
1444607348	1183703891	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183703891	23508821	Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.	0.0
1444607366	1183703906	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183703906	23508821	Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.	0.0
1444607373	1183703880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703880	23508821	Genotype CC is associated with increased lumbar bone loss when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes CT + TT.	2.0
1444607379	1184483601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483601	18452396	Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9.	-1.25
1444607379	1184513240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184513240	17018806	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.	2.5
1444607507	1183703824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703824	23559402	TPMT *1/*3A + *1/*3C is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to TPMT *1/*1.	2.25
1444607526	1184169902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169902	23559402	UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to UGT1A1 *1/*1.	2.75
1444607634	981239914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239914	22735389	Allele A is associated with gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	3.0
1444607634	827826357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827826357	17111267	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	1.5
1444607674	981750780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750780	19590397	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	-1.75
1444607674	1184511361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511361	16302021	Genotype CC is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to allele G.	3.0
1444607851	1184166127	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184166127	23584701	Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes AT + TT.	1.75
1444607863	1184173768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173768	24681964	Genotype CC is associated with decreased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CT.	3.0
1444672766	1183689248	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689248	12069454	Genotype AG is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype GG.	3.5
1444672766	1183689382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689382	15208046	Genotypes AA + AG is not associated with risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to genotype GG.	-1.75
1444672766	1183689524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689524	16769590	Genotypes AA + AG is not associated with risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype GG.	-1.75
1444672766	1448993802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993802	28750087	Allele A is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele G.	3.5
1444672774	982044485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044485	20833658	Genotypes CT + TT are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype CC.	2.75
1444672774	982034073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034073	12844135	Genotypes CT + TT are associated with increased response to clonidine in healthy individuals as compared to genotype CC.	2.5
1444672774	982034360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034360	12844135	Genotypes CT + TT are not associated with response to clonidine in healthy individuals as compared to genotype CC.	-0.25
1451649631	1451649590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451649590	34864618	Allele T is associated with increased risk of Peptic Ulcer due to aspirin as compared to allele A.	3.0
1451737560	1451737200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451737200	34158603	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele T.	3.5
1451749040	1333193294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193294	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.5
1184753786	1043858738	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858738	18641915	SLCO1B1 *15 is associated with decreased clearance of olmesartan in healthy individuals as compared to SLCO1B1 *37.	1.0
1184754281	1184653974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184653974	15499191	CYP2C19 *2/*16 is associated with decreased metabolism of methylphenobarbital as compared to CYP2C19 *1/*1.	0.125
1184986321	1184821109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184821109	24223824	Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.	1.75
1184986321	1184838013	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184838013	24223824	Allele T is associated with decreased expression of BCL2L11 mRNA as compared to allele C.	0.0
1184986585	1184754406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754406	24852429	Allele A is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele G.	2.5
1184986763	1184755344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755344	24086514	Genotype GG is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype AG.	1.75
1184986763	1450821004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821004	24950410	Genotype AA is associated with decreased risk of Opioid-Related Disorders due to tramadol as compared to genotypes AG + GG.	3.0
1184987048	1184986931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986931	24116192	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.	1.5
1184989940	1184472392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472392	14624186	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of non-remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	3.0
1184989940	1184472450	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472450	14624186	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184989940	1184483970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483970	20640435	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.75
1184989940	1184484056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184484056	23973251	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184989940	1184484076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184484076	23973251	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	1.5
1184989940	1184503573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184503573	23510446	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram in children with Depressive Disorder as compared to SLC6A4 HTTLPR short form (S allele).	0.0
1184989940	1184512692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512692	19468717	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	2.25
1184989940	1184513643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513643	18618621	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	2.5
1184989940	1184513661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513661	18618621	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is not associated with remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.5
1184989940	1451254722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451254722	19468717	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	-1.75
1444700423	1451128195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128195	31666714	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.	-1.75
1444700423	1444700411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444700411	25823781	Allele A is associated with decreased risk of Ototoxicity when treated with cisplatin as compared to allele C.	2.25
1444700423	1448432036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448432036	27457817	Allele A is associated with decreased risk of Ototoxicity when treated with cisplatin in people with Neoplasms.	2.0
1444700423	1448616363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616363	28448657	Allele C is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.	-1.5
1444700445	1444700430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444700430	25775161	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in people with HIV as compared to allele G.	2.5
1444700767	1184483225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483225	24978393	Genotype AA is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype AG.	1.75
1444700767	1448526046	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448526046	27958380	Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.75
1444700888	981500646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500646	23222202	Genotypes GG + GT are associated with decreased risk of toxicity when exposed to methotrexate in children with Leukemia, B-Cell, Acute as compared to genotype TT.	2.5
1444700888	1184468949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468949	23222202	Genotypes GG + GT are associated with decreased plasma level when exposed to methotrexate in children with Leukemia, B-Cell, Acute as compared to genotype TT.	1.5
1444703107	1183699205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699205	24225399	Genotypes AA + AG is associated with decreased risk of toxicity when treated with gemcitabine as compared to genotype GG.	2.0
1444706112	1444706053	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706053	25712187	Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype GG.	1.0
1444706112	1448603535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603535	28246425	Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.	1.25
1444706112	1448603604	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448603604	28246425	Genotypes CC + CG is associated with increased expression of IL18 mRNA as compared to genotype GG.	0.0
1444706787	981954851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954851	18989660	Allele A is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to allele G.	2.25
1444706794	699642407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699642407	17548750	Allele T is associated with increased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	3.0
1444706810	978614583	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978614583	22776887	Allele T is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele C.	0.0
1444706818	978614592	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978614592	22776887	Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele T.	0.0
1444703100	1183863874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863874	24583629	Allele T is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	0.0
1444703100	1449558016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449558016	29743634	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.0
1444709147	981954249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954249	23315174	Genotype AA is not associated with response to lithium in people with Bipolar Disorder as compared to genotypes AG + GG.	-1.75
1444709147	699639271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/699639271	21047205	Genotype AA is associated with increased response to lithium in people with Bipolar Disorder.	0.0
1451737600	1451737280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451737280	34158603	Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	3.5
1184986174	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1184986174	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1184986174	1183681878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681878	23736036	Genotype CG is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.	-1.75
1184986174	1184471970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471970	24167597	Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1184986174	1447676529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676529	26658227	Allele C is not associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele G.	-2.0
1184986174	1447954949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954949	24923815	Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	3.75
1184986174	1447988987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988987	20803296	Allele C is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele G.	2.0
1184986174	1448126287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126287	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele G.	-2.0
1184986174	1448997537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997537	28614820	Genotype CG is associated with Drug Toxicity when treated with fluorouracil.	0.25
1184986174	1449161752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161752	28427087	Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.	-2.0
1184986174	1449162097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162097	29065426	Genotype CG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype GG.	-2.0
1185000238	1184515869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184515869	24033383	CYP3A5 *3/*3 is associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1185000238	1448358439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448358439	27717793	CYP3A5 *1/*1 + *1/*3 are not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	-0.25
1185000238	1448573323	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573323	28135009	CYP3A5 *1/*1 is not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.	-1.25
1444607295	1183697790	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697790	21790903	Allele C is associated with decreased risk of Cocaine-Related Disorders when exposed to cocaine as compared to allele T.	1.5
1444607295	1183697802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697802	21790903	Genotype TT is not associated with risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotypes CC + CT.	-0.5
1444607302	1183697797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697797	21790903	Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG.	1.5
1444607302	1183697807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697807	21790903	Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG.	1.0
1444607737	1184135106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184135106	23240771	Genotype TT is associated with increased Vmax of ethanol in healthy individuals as compared to genotypes CC + CT.	1.5
1444607744	827777953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827777953	21989078	Genotype GAT/del is associated with decreased trough metformin steady-state concentration when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.	1.75
1444607751	827827977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827977	22188361	Genotypes AA + AG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.	-1.5
1444607751	1184137425	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184137425	22821704	Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.5
1444607751	1296599123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599123	24446315	Genotypes AA + AG is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-1.75
1444607751	1296599220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599220	24446315	Genotypes AA + AG is not associated with overall survival or progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-1.75
1444607751	1448123619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123619	27248474	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	1.5
1444607751	1448640016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448640016	28743242	Allele G is associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to allele A.	1.5
1444607751	1449752434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752434	29662106	Allele A is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	-1.5
1444607979	827815524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815524	22134350	Allele C is associated with decreased overall survival probability when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele A.	2.5
1444607979	1184086286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184086286	24361227	Allele A is not associated with increased likelihood of Neurotoxicity Syndromes when treated with gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	-1.25
1444607979	1448617019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617019	28422153	Genotypes AC + CC are associated with decreased overall survival and progression-free survival when treated with cisplatin and gemcitabine in people with Mesothelioma as compared to genotype AA.	0.0
1444608491	1184510648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510648	23959273	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	1.75
1444665939	1184510631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510631	23959273	Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.	2.25
1444667912	1444608518	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444608518	25372290	Genotypes AA + AG are associated with decreased likelihood of Drug Toxicity when exposed to valproic acid in people with Epilepsy as compared to genotype GG.	1.5
1444686969	1296666811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666811	24776844	Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative or Inflammatory Bowel Diseases as compared to genotype CC.	3.25
1444686969	1449155420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155420	28696418	Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	3.25
1444686976	1296666774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666774	24776844	Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.	3.5
1444686983	1296666832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666832	24776844	Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.	2.25
1444686990	1296666880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666880	24776844	Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.	3.0
1444686997	1296666850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666850	24776844	Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype CC.	3.0
1444687004	1296666874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666874	24776844	Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype TT.	4.0
1444687025	1296666768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666768	24776844	Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype GG.	3.75
1444687032	1296666820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666820	24776844	Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.	2.5
1444700760	1184513755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513755	23377640	Allele T is associated with increased improvement over the first 2 weeks when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	0.0
1444700760	1184513760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513760	23377640	Allele T is not associated with improvement over the first 2 weeks when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G.	-1.5
1444700999	1183690869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690869	22706620	Genotype TT is associated with decreased response to enalapril in people with Hypertension as compared to genotypes CC + CT.	2.0
1444701007	655388475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388475	12522467	Genotypes CT + TT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC.	3.0
1444704818	1183684081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684081	22398969	Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.	2.5
1444705191	981865038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865038	19388002	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.	0.0
1444705198	769164370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769164370	21107318	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.	3.5
1444705206	982015348	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015348	17467808	Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	3.0
1444705222	981480012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981480012	23158458	Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC.	2.0
1444705229	981502454	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502454	19846067	Allele C is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	0.0
1444706124	981483674	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483674	23233662	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.0
1445556297	655387202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387202	12439223	Genotype CT is associated with increased likelihood of smoking cessation when treated with bupropion in people with female gender as compared to genotype CC.	2.75
1445556297	655387206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387206	12439223	Genotype TT is associated with increased likelihood of smoking cessation when treated with bupropion in people with female gender as compared to genotype CC.	2.75
1445556297	1446765760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765760	26153084	Allele T is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele C.	-1.5
1184999957	982046287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046287	23837476	Genotypes CT + TT are not associated with rate of acute rejection when treated with tacrolimus in children with Transplantation as compared to genotype CC.	-2.0
1184999957	1183491697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491697	23900887	Genotype CC is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	-1.25
1184999957	1184469318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469318	24911663	CYP3A5 *1 is associated with increased risk of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	2.75
1184999957	1184471762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471762	24438215	CYP3A5 *1/*1 + *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	-1.25
1184999957	1449748545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449748545	29621122	CYP3A5 *1/*1 + *1/*3 is not associated with risk of transplant rejection when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	-1.5
1444705214	981477870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477870	18618621	Allele C is not associated with response to citalopram in people with Depression as compared to allele T.	-2.0
1444705214	981501261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501261	19996755	Allele C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to allele T.	1.5
1444705214	1184484066	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184484066	23973251	Allele C is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.	-1.5
1444672826	1183620980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620980	15976989	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	2.25
1444672826	1448603519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603519	27611887	Allele A (assigned as poor metabolizer genotype phenotype) is not associated with response to pantoprazole in people with Helicobacter Infections as compared to allele G.	-1.5
1444672826	1451414440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451414440	20376628	Genotypes AG + GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotype AA.	-1.5
1444672826	1451414561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451414561	18823430	Genotype GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotypes AA + AG.	-1.5
1444704833	1450823255	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823255	25794200	Genotypes AA + AG are not associated with dose of opioids in people with Pain as compared to genotype GG.	-1.0
1444704833	1449002556	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002556	28379874	Genotype GG is not associated with dose of opioids in people with Pain, Postoperative as compared to genotypes AA + AG.	-1.0
1444704833	1449171488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171488	24034787	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.	1.5
1444704833	1449713816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713816	23803057	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.	2.0
1444704833	1449714698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449714698	21398039	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.	-2.0
1444704833	1183681975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681975	19514130	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	3.25
1445421156	1451293140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451293140	33124517	Genotype GT is associated with decreased dose-adjusted trough concentrations of bupropion and hydroxybupropion in men with Depressive Disorder, Major.	0.125
1445421156	981786189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786189	23344581	CYP2B6 *6 is associated with decreased hydroxybupropion concentrations and hydroxybupropion/bupropion ratio when exposed to bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	981786255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981786255	23344581	CYP2B6 *18 is associated with decreased hydroxybupropion concentrations when exposed to bupropion in healthy individuals.	1.0
1445421156	1043880685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880685	14515060	CYP2B6 *4 is associated with increased clearance of bupropion in healthy individuals.	1.5
1445421156	1445403153	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445403153	23149928	CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.	1.5
1445421156	1445403174	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445403174	23149928	CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.	2.5
1445421156	1445556633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445556633	15083067	CYP2B6 *6 is associated with decreased metabolism of bupropion.	1.5
1445421156	1447521014	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521014	26580670	CYP2B6 *6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	1447963480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963480	15722458	CYP2B6 *1/*22 is associated with increased metabolism of bupropion as compared to CYP2B6 *1/*1.	2.25
1445421156	1448257502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257502	27528039	CYP2B6 *6 is associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2B6 *1.	0.125
1445421156	1448257516	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257516	27528039	CYP2B6 *6 is associated with increased steady-state concentration of bupropion in women with Pregnancy as compared to CYP2B6 *1.	0.125
1445421156	1449157219	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449157219	28181240	CYP2B6 *1/*30 is associated with decreased activity of CYP2B6 when exposed to bupropion as compared to CYP2B6 *1/*1.	0.0
1445421156	1449564017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449564017	29756345	CYP2B6 *6/*6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1445421156	1449564030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449564030	29756345	CYP2B6 *1/*4 + *4/*6 are associated with increased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	0.0
1445421156	1450820343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820343	23840296	CYP2B6 *1/*6 + *6/*6 are associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.	1.5
1445421156	1451350020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451350020	25565674	CYP2B6 *6/*6 is associated with decreased concentrations of hydroxybupropion as compared to CYP2B6 *1/*1 + *1/*6.	1.75
1444608367	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444608367	1184510147	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510147	15841390	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials in children as compared to allele A.	0.25
1444608367	1444696929	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696929	8285309	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444696981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696981	9111378	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697028	9490575	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697082	10633132	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697167	15917167	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697205	16458854	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697262	17999439	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697273	18790089	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697435	20111055	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697456	21162657	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697475	21504270	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697482	21725156	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697673	25744662	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	0.25
1444608367	1444697690	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697690	25515069	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.	1.5
1444608367	1444697282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697282	18820594	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1449732298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732298	29805548	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.0
1444608367	1444697089	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697089	11857751	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1444697136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697136	14699607	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin as compared to allele A.	0.25
1444608367	1444697179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697179	16168391	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele A.	0.25
1444608367	1444697228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697228	16955413	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1444608367	1444697241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697241	17341440	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin as compared to allele A.	0.25
1444608367	1444697495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697495	22475488	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele A.	0.25
1444608367	1451437580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437580	16152638	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1444608367	1451437800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437800	18386806	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin or streptomycin.	0.25
1444608367	1451437874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451437874	19835846	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1444608367	1451438424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438424	21205314	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1444608367	1451439920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451439920	21777984	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials.	0.0
1444608367	1451440060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440060	22879993	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials.	0.25
1444608367	1451440086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440086	23256547	Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials or streptomycin.	0.25
1444608367	1184510153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510153	20100600	Allele G is associated with Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin in children as compared to allele A.	0.25
1444706154	981483700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483700	23233662	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	1.5
1444668808	1183615560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615560	11593098	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to irbesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.0
1444668808	1451493552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493552	11910301	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to allele del.	-1.25
1184749280	1184749094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184749094	25084203	Allele A is associated with increased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	3.0
1184764189	1184746653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746653	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	0.0
1184764189	1184746667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746667	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.	0.0
1184986454	1184407356	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407356	24322967	Allele A is associated with increased risk of Stevens-Johnson Syndrome when exposed to nevirapine in women with Acquired Immunodeficiency Syndrome as compared to allele C.	3.0
1184986454	1448635524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635524	28689274	Allele A is not associated with likelihood of Toxic liver disease, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele C.	-1.5
1184986756	1184755338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755338	24086514	Genotype AG is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype GG.	1.75
1184987411	1184985784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184985784	25187485	CYP2C19 *2 is associated with increased exposure to bupropion in healthy individuals as compared to CYP2C19 *1.	1.0
1184987411	1184985811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184985811	25187485	CYP2C19 *17 is not associated with exposure to bupropion in healthy individuals as compared to CYP2C19 *1.	-0.125
1444666705	1296666360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666360	24712521	Genotype GG is associated with increased risk of Agranulocytosis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.	2.75
1444666731	1296599021	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599021	24422887	Genotypes AA + AG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype GG.	3.25
1444666738	1296598832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598832	23809733	Allele A is associated with increased response to citalopram in people with Depression as compared to allele G.	2.5
1444667578	1185003232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003232	25372592	Allele C is associated with decreased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.	3.0
1184997925	1184997889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997889	25356900	Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.	0.0
1184997925	1449164073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164073	29298995	Allele C is not associated with dose of warfarin as compared to allele T.	-2.0
1444666717	1451463726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451463726	31870219	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	-0.125
1444666717	1296666342	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666342	24712521	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	1.25
1184749370	827923379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923379	21327909	SLCO1B1 *37/*37 is associated with decreased repaglinide exposure (decreased AUC and increased clearance) when exposed to repaglinide in healthy individuals as compared to SLCO1B1 *15/*1 + *5/*1.	1.0
1184749370	827923369	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923369	21327909	SLCO1B1 *37/*37 is associated with decreased repaglinide exposure (decreased AUC and increased clearance) when exposed to repaglinide in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*37.	1.0
1184749160	1184749124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184749124	25084203	Allele T is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	3.0
1444704914	769170930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170930	12969965	Genotype GG is associated with increased metabolism of etoposide in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	2.0
1444710680	1444710575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710575	22249484	HLA-DQB1 *06:02:01 is associated with Narcolepsy when exposed to Influenza vaccines.	0.25
1444710680	1444710588	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710588	21102981	HLA-DQB1 *06:02:01 is associated with Narcolepsy when treated with Influenza vaccines.	0.25
1444710680	1444710601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710601	23486871	HLA-DQB1 *06:02:01 is associated with Narcolepsy when exposed to Influenza vaccines in children.	0.25
1444710680	1444710628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710628	25264897	HLA-DQB1 *06:02:01 is not associated with Narcolepsy when exposed to Influenza vaccines.	-0.25
1183697617	978639836	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639836	22838948	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.0
1183697617	655385912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385912	17410198	Allele CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC is associated with increased risk of Drug Toxicity when exposed to methotrexate in people with Psoriasis.	2.75
1183697617	1183681719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681719	23652803	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased risk of Stomatitis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.75
1183697617	769171001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171001	17323057	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is not associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.25
1183697617	1451504740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451504740	22074251	Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 are associated with decreased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	3.5
1183697617	1451532860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451532860	25177243	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with risk of Anemia, Leukopenia, mucositis, Thrombocytopenia or Toxic liver disease due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-0.25
1183697617	1451552840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451552840	32612964	Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 are associated with increased risk of Vomiting due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	0.0
1451640205	1451640200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451640200	34302059	Allele A is associated with decreased response to naltrexone in people with Alcoholism as compared to allele G.	0.0
1184756886	1184756608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756608	21545408	HLA-DQB1 *02:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.	0.0
1184747857	1184747838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747838	25171759	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.	2.5
1184986985	1184986856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986856	24116192	Allele G is associated with increased likelihood of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.	1.5
1184986992	1184986866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986866	24116192	Allele C is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele G.	1.5
1184987008	1184986888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986888	24116192	Allele T is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele C.	1.0
1184987030	1184986912	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986912	24116192	Allele C is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele T.	2.0
1184987041	1184986923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986923	24116192	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.	1.5
1185000225	1184998415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998415	22310591	Allele T is not associated with risk of Infection or transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
1185000225	1184470717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470717	24656015	CYP3A5 *1/*3 is associated with increased risk of Virus Diseases when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	3.0
1185000225	1184470753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470753	24625991	CYP3A5 *1/*1 + *1/*3 is not associated with risk of adverse events when treated with tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.25
1185000225	1184471736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471736	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Infection when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.75
1185000225	1184515856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515856	22210422	CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Infection when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.	2.25
1185000225	1448255810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255810	26518946	CYP3A5 *1/*3 + *3/*3 are not associated with risk of delayed graft function, Drug Toxicity, Infection and transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.	-1.25
1444608377	1184510180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510180	23142150	Genotypes CT + TT is associated with increased response to escitalopram in people with Depression as compared to genotype CC.	1.5
1444665984	1184510663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510663	23959273	Genotypes GT + TT is associated with increased survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype GG.	2.25
1444666032	1184510854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510854	23963147	UGT1A7 *3 is associated with increased likelihood of Vomiting when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	1.5
1444666038	1184510846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510846	23963147	UGT1A6 *2a is associated with increased likelihood of Vomiting when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	1.5
1444667902	1444666816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444666816	25405601	Genotype GT is associated with increased response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.	2.75
1444703473	827785745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827785745	21934637	Genotype TT is associated with increased clearance of vardenafil in men as compared to genotypes CC + CT.	1.0
1444703502	1020826129	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1020826129	18727619	Genotypes AT + TT are associated with increased risk of aspirin intolerance when exposed to aspirin in people with Asthma as compared to genotype AA.	2.75
1444703509	1023293827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1023293827	21461252	Genotypes CT + TT are associated with increased risk of Aspirin-Exacerbated Respiratory Disease when exposed to aspirin in people with Asthma as compared to genotype CC.	2.25
1444703985	1183848080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848080	22796099	Allele G is associated with early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele A.	0.0
1444704005	1183633851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633851	24040476	Genotype GG is associated with decreased HAMD scores when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.0
1444704012	827639426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827639426	21562465	Allele T is associated with increased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele C.	2.25
1444704419	1444712539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444712539	26004431	Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	2.0
1444704419	1447980961	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980961	26977146	Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.	1.25
1444704419	1448105842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448105842	22882994	Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.	2.0
1444704419	1448631766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631766	27859023	Allele A is not associated with response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.	-1.0
1444704419	1448998602	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998602	28834135	Allele A is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele G.	-0.25
1444705236	981480002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981480002	23158458	Genotype AA is associated with decreased risk of heart palpitations when treated with citalopram in people with Depression as compared to genotype GG.	2.5
1444705243	981502448	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502448	19846067	Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	0.0
1445556405	1445117531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445117531	21038416	Allele A is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele C.	4.0
1444704426	827805756	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805756	21900104	Allele C is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.	0.0
1444704426	1448109246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109246	23441093	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.	-1.5
1185003565	827825747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827825747	21109570	Genotype CC is associated with increased response to trastuzumab in women with Breast Neoplasms as compared to genotypes AA + AC.	0.25
1185003565	1185003533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185003533	18347005	Genotype CC is associated with increased response to trastuzumab in people with Breast Neoplasms as compared to genotypes AA + AC.	1.75
1185003565	1185003541	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003541	18347005	Genotype CC is associated with increased progression-free survival when treated with trastuzumab in women Breast Neoplasms as compared to genotypes AA + AC.	2.25
1451683665	1451683380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451683380	33649516	Genotype CC is associated with increased response to abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG.	2.25
1184986201	1184471936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471936	24167597	Genotypes AA + AG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	2.75
1184986201	1184471953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471953	24167597	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	2.75
1184986298	1184755719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755719	25127363	Allele C is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Neoplasms as compared to allele A.	0.0
1184986567	1184754606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754606	24820765	Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	2.25
1184986578	1184754389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754389	24852429	Allele G is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele T.	3.0
1184986654	1184754529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754529	23807564	Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT.	1.5
1184997025	1184468190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468190	22818943	HLA-B *27:09 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.0
1184997034	1184482747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184482747	24911354	HLA-B *35:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.25
1184997034	1185002091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002091	21505298	HLA-B *35:01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.	2.5
1184997034	1444697741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697741	25714001	HLA-B *35:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with nevirapine.	1.0
1184997043	1184407526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407526	19104471	HLA-B *35:05:01 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV.	3.25
1184997043	1185012163	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185012163	25361850	HLA-B *35:05:01 is associated with Exanthema when treated with lamivudine, nevirapine and stavudine in people with HIV.	3.5
1185000097	699639378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639378	20216337	Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.	3.0
1444706911	981479695	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479695	21519338	Genotype AA is associated with increased clearance of olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	2.5
1444706911	981479851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479851	21519338	Allele A is not associated with clearance of olanzapine in people with Schizophrenia as compared to allele G.	-1.0
1444706911	1183864130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183864130	24595013	Genotype AA is not associated with differences in dose-adjusted trough serum olanzapine concentrations when treated with olanzapine in people with Mental Disorders as compared to genotypes AG + GG.	-1.25
1184986386	769182562	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182562	21383771	Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.	2.5
1184986386	1183704846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704846	24019055	Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.	2.5
1184986386	1444699635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699635	25519826	Allele A is not associated with increased dose of acenocoumarol as compared to allele G.	-1.5
1184986386	1449577793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577793	17015052	Allele G is associated with dose of warfarin as compared to allele A.	0.0
1184986386	1449577814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449577814	29986700	Allele A is associated with dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism, Stroke and Venous Thrombosis as compared to allele G.	0.0
1444699749	1184473890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473890	24911354	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.25
1444699749	1185001827	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001827	18301070	HLA-DRB1 *01:01:01 is associated with increased risk of Exanthema when treated with efavirenz or nevirapine in people with HIV.	1.5
1444699749	1185002083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002083	21505298	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.	3.25
1444699749	1444697871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697871	25714001	HLA-DRB1 *01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.	1.0
1444699749	1444697890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697890	25714001	HLA-DRB1 *01:01:01 is associated with increased risk of Toxic liver disease when treated with nevirapine.	1.0
1444699749	1444699767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699767	15627041	HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1444699749	1448926259	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926259	28819312	HLA-DRB1 *01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1451640212	1451640186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451640186	34302059	Allele G is associated with decreased response to acamprosate in people with Alcoholism as compared to allele A.	0.0
1184986540	1184470034	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470034	24442125	CYP2C9 *2 + *3 is associated with increased risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to CYP2C9 *1.	1.5
1184997106	1184468197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468197	22818943	HLA-B *48:04 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.0
1184997213	1184988810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988810	19321411	HLA-B *15:18:01/*40:01:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in children with Seizures.	0.25
1184997213	1184988821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988821	22013310	HLA-B *15:18:01/*40:01:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in women with Seizures.	0.25
1444607697	982025918	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982025918	23188068	Genotypes CG + GG are associated with decreased clearance of docetaxel as compared to genotype CC.	0.0
1444607697	982025924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025924	23188068	Genotype CC is not associated with Neutropenia when treated with docetaxel in people with Neoplasms as compared to genotypes CG + GG.	-1.25
1444607697	769180240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180240	18294295	Allele G is associated with increased risk of Leukopenia when treated with docetaxel.	2.25
1444607704	1184136603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184136603	24036429	Genotype GG is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.	2.25
1444607704	1184136618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184136618	24036429	Genotype GG is not associated with response to deferiprone in people with beta-Thalassemia as compared to genotype TT.	-1.75
1444607704	1184136622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136622	24036429	Genotype GG is associated with increased risk of Drug Toxicity when treated with deferiprone in people with beta-Thalassemia as compared to genotype TT.	3.5
1444607704	1184136627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136627	24036429	Genotype GG is associated with increased risk of Drug Toxicity when treated with deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.	3.0
1444607716	655386383	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386383	14600574	Allele A is not associated with phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations when treated with ritonavir in people with HIV Infections as compared to allele C.	-0.0
1444607716	1184748358	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748358	24997317	Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.	2.0
1444607723	1184136638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136638	23703421	Genotypes AG + GG is associated with increased risk of Constipation when treated with hydrocodone in women with Pregnancy as compared to genotype AA.	2.0
1444607723	1184136643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136643	23703421	Genotypes AG + GG is associated with increased risk of dry mouth when treated with hydrocodone in women with Pregnancy as compared to genotype AA.	2.0
1444607723	1184136647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136647	23703421	Genotypes AG + GG is associated with increased risk of Respiratory Insufficiency when treated with hydrocodone in women with Pregnancy as compared to genotype AA.	2.0
1444607723	1184136651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136651	23703421	Genotypes AG + GG is associated with increased risk of side effects when treated with hydrocodone in women with Pregnancy as compared to genotype AA.	2.0
1444607768	1183703093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703093	16205777	Genotypes CC + CT are associated with increased risk of gastrointestinal side effects when treated with fluvoxamine in people with Depressive Disorder as compared to genotype TT.	2.75
1444607768	1183959993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959993	16874005	Genotype CC is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to genotypes CT + TT.	2.5
1444607768	1183960004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960004	16874005	Allele C is not associated with response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	-1.25
1444607775	1184165209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184165209	23709418	Genotype GG is associated with increased risk of Fatigue when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	2.25
1444607782	981344801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344801	21878834	Allele T is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.75
1444607782	981344858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344858	21878834	Allele T is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.	-1.75
1444607782	769262681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262681	21142914	Allele C is associated with decreased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.	3.0
1444607782	769262677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262677	21142914	Genotype TT is associated with increased risk of adverse drug reaction when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.	2.5
1444607870	1184166178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184166178	23323945	GSTM1 non-null/non-null is associated with increased response to bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null.	2.0
1444607870	1184166210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184166210	23323945	GSTM1 non-null/non-null is associated with decreased risk of Drug Toxicity when treated with bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null.	2.5
1444607960	1184166980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184166980	23645042	Genotype GG is associated with increased response to rituximab in people with Lupus Erythematosus, Systemic as compared to genotype GT.	2.25
1444607960	1184166985	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184166985	23645042	Genotype GG is associated with increased response to rituximab in people with Autoimmune Diseases as compared to genotype GT.	2.5
1444607966	827825859	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825859	22293537	Allele A is associated with increased risk of Leukopenia when treated with gemcitabine in people with Neoplasms as compared to allele C.	0.0
1444665946	1184510644	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510644	23959273	Genotype AA is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.	2.25
1444665946	1184510669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510669	23959273	Genotypes AA + AG is associated with increased overall survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype GG.	2.25
1444665964	1184510640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510640	23959273	Genotype AA is associated with decreased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.	2.25
1444665964	1184510654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510654	23959273	Genotype AA is associated with decreased survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.	3.25
1444666756	1296666686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666686	24752311	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	2.75
1444666756	1296666726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666726	24752311	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	2.5
1444666763	1296666377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666377	24732178	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.	2.0
1444666763	769166424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166424	19307503	Genotype AA is associated with increased progression-free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.0
1444666770	1296666459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666459	24732178	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.	2.5
1444666777	1296666448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666448	24732178	Allele A is associated with decreased risk of Drug Toxicity when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to allele G.	3.0
1444666789	1296666475	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296666475	24732178	Genotypes CT + TT is associated with decreased response to pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype CC.	2.5
1444666796	769246593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769246593	19841321	Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.	2.0
1444666796	1296666403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666403	24732178	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.	2.0
1444666803	1296666389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666389	24732178	Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.	2.0
1444666818	1296666397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296666397	24732178	Genotype TT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotypes CC + CT.	2.5
1444703086	1183685564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685564	19387424	Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	3.0
1444703230	1184472195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472195	24663076	Allele C is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.	-1.75
1444703230	1184472218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472218	24663076	Allele A is associated with increased response to fluoxetine in children with Depressive Disorder as compared to allele C.	1.75
1444712823	1185002015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002015	21245432	HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.	3.0
1444712823	1185003165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003165	24687830	HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.	3.5
1444712832	1445297635	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297635	25987243	HLA-DRB1 *07:01:01:01 is associated with increased risk of drug-induced liver injury when treated with lapatinib.	0.0
1444712832	1448820942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448820942	28786423	HLA-DRB1 *07:01:01:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in people with Breast Neoplasms.	4.0
1444712832	1185003155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003155	24687830	HLA-DRB1 *07:01:01:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.	3.5
1445624605	1444932166	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444932166	25920679	Allele G is associated with decreased expression of SLC22A3 as compared to allele C.	0.0
1445624605	1444932172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444932172	25920679	Allele G is associated with decreased response to metformin in healthy individuals as compared to allele C.	1.75
1184986623	1183682143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682143	23263737	Genotype GG is not associated with increased clearance of lamotrigine as compared to genotypes GT + TT.	-0.75
1184986623	1184754437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754437	24820767	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.	2.0
1184986623	1447683061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447683061	26790665	Genotypes GG + GT are associated with decreased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype TT.	2.0
1184986623	1449560356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449560356	29791014	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.	-1.0
1184986623	1447980777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980777	22047493	UGT1A4 *2 + *3a are associated with decreased clearance of lamotrigine as compared to UGT1A4 *1a.	This annotation is not used for clinical annotation scoring. In vitro assay
1444708021	1444707987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707987	25938071	HLA-B *46:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	2.25
1444708021	1451640720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451640720	34350628	HLA-B *46:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
1184755459	1184755450	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755450	8530011	CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.	0.125
1184986643	1184754523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754523	23807564	Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA.	1.5
1184988834	1184988562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988562	25266681	Allele G is associated with decreased likelihood of Asthma when exposed to hmg coa reductase inhibitors in people with Asthma as compared to allele C.	1.25
1184988834	1184988575	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184988575	25266681	Allele C is associated with increased expression of HLA-G in lymphoblastoid cell lines as compared to allele G.	0.0
1184988834	1184988590	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184988590	25266681	Genotype GG is associated with increased expression of HLA-G when exposed to simvastatin in lymphoblastoid cell lines.	0.0
1445594176	1444703337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703337	25624441	Genotype CC is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	2.5
1445594176	981239079	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981239079	22846425	Genotype CT is associated with decreased activity of TPMT when assayed with purine analogues as compared to genotype TT.	0.0
1445594176	981239095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239095	22846425	Allele C is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	3.0
1445594176	1184407291	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184407291	18605963	Genotype CT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype TT.	0.0
1445594176	1447682783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682783	26503813	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.25
1445594176	1447682798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682798	26503813	Genotype CT is not associated with event-free survival when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	-1.75
1445594176	1448268979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268979	27564568	Allele C is associated with exposure to mercaptopurine in children with Leukemia as compared to allele T.	0.0
1445594176	1449311061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311061	29683944	Genotype TT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	-0.25
1445594556	1444703591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703591	25695618	Allele A is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.	0.0
1445601678	1444703611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703611	25695618	Allele C is associated with decreased response to hydrochlorothiazide in people with Essential hypertension as compared to allele G.	0.0
1449003811	1448993902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993902	28750087	Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele del.	3.0
1449003817	1448993840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993840	28750087	Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.	3.0
1449003823	1448994060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994060	28182634	Genotype AG is associated with increased risk of Alcoholism when exposed to ethanol as compared to genotype GG.	3.0
1449003829	1448995092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995092	28358842	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.	2.0
1449003839	1448995530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995530	28358908	Genotype AA is associated with increased response to methadone as compared to genotypes AG + GG.	2.25
1449003845	1448995536	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995536	28358908	Genotype CC is associated with increased response to methadone as compared to genotypes AA + AC.	2.25
1449003851	1448996035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448996035	21931540	HLA-C *02:02:01 + *04:01:01:01 + *05:01:01:01 + *06:02:01:01 + *15:02:01 + *17:01:01:01 is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to HLA-C *01:02:01 + *03:02 + *07:01:01 + *08:01 + *12:02:01 + *14:02:01 + *16:01:01.	0.0
1449003869	1448995913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995913	28107378	Allele T is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.	2.5
1444703243	981859179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859179	21747585	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	2.75
1444703243	981954805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954805	18812236	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	-1.75
1444703243	981954817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954817	18812236	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	-1.75
1444703243	981954839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954839	18812236	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	-1.75
1444703243	769146001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769146001	20417680	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	-1.5
1444666130	1184748707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748707	9179433	HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.	3.5
1444666130	1184748766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748766	15007363	HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.	3.5
1444666130	1185001852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001852	19392989	HLA-DPB1 *03:01:01 is associated with increased risk of Asthma when treated with aspirin.	4.0
1444706709	1184416003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184416003	20504258	HLA-C *01:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.	3.25
1444706709	1444706661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706661	25918017	HLA-C *01:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	3.75
1444706709	1450397888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397888	30242287	HLA-C *01:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	1.0
1444666137	1184748718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748718	9179433	HLA-DPB1 *04:01:01:01 is associated with decreased risk of aspirin-induced asthma.	2.5
1444666145	1185001029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001029	10200020	HLA-DRB1 *11:01:01 is associated with increased risk of anaphylactoid reaction when treated with Antiinflammatory agents, non-steroids.	3.0
1444666342	1185235759	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235759	24619498	Genotype AA is associated with increased clearance of docetaxel in men with Prostatic Neoplasms as compared to genotypes AG + GG.	1.0
1444666376	1296598578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598578	25143324	Genotype CC is associated with increased response to benazepril or imidapril in people with Hypertension as compared to genotypes CT + TT.	2.5
1444666557	1333193034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193034	25348619	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	1.75
1444666557	1448101354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101354	27193993	Genotype AA is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.	-0.5
1444666564	1333193041	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193041	25348619	Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	1.25
1444666564	1448101336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101336	27193993	Genotypes AC + CC are not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.	-0.5
1444666571	1448101330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101330	27193993	Genotype TT is not associated with concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.	-0.5
1444666571	1333193048	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193048	25348619	Genotypes CC + CT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype TT.	2.25
1444667537	1185003191	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003191	25372592	Allele G is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.	0.0
1444667549	1185003204	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003204	25372592	Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.	0.0
1444667566	1185003226	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003226	25372592	Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele T.	3.0
1444702822	1444702812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702812	25846690	Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.	2.5
1444703408	1444667518	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667518	25485598	Allele T is associated with decreased creatinine clearance when treated with tenofovir in people with HIV Infections as compared to genotype CC.	0.25
1444703422	1183681016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681016	24128935	Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.	2.5
1444703521	1009360953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1009360953	20824505	Genotype GG is associated with increased risk of Peptic Ulcer Hemorrhage when treated with aspirin as compared to genotypes GT + TT.	2.75
1444703529	1184469093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469093	24751813	Genotype CT is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype TT.	0.0
1444703537	1184469080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469080	24751813	Genotype TT is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype CT.	0.0
1444703544	982031696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031696	23778325	Allele A is associated with increased risk of Adenoma when treated with celecoxib in people with Colorectal Neoplasms as compared to allele G.	2.5
1444703552	1184173773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173773	24681964	Allele G is associated with increased risk of Anemia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.	3.0
1444703560	1183863853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863853	24583629	Allele C is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	0.0
1444703560	1449558039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449558039	29743634	Allele C is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.	-1.0
1444703401	1444696287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696287	25710658	Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.25
1444703401	1448602501	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602501	27618250	Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.25
1444665904	1444665867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444665867	24766668	CYP2D6 poor metabolizers is associated with decreased clearance of vortioxetine in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0
1444665904	1451888600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451888600	35703273	CYP2D6 *4/*4 + *4/*10 is associated with increased concentrations of vortioxetine as compared to CYP2D6 *1/*1.	2.75
1184748865	1184748734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748734	25084201	Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	0.0
1184748874	1184748726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748726	25084201	Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.	0.0
1184748879	1184748821	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748821	25084201	Genotype GG is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	2.0
1184748884	1184748858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748858	25084201	Genotypes CT + TT is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	0.0
1184748889	1184748761	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748761	25084201	Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	0.0
1184997142	1184988788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988788	22258364	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with lamotrigine in women with Epilepsy.	0.25
1184997142	1184988910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988910	19668019	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.	4.0
1184997142	1444935718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935718	25495410	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine.	0.0
1184997195	1184466872	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466872	21342230	HLA-B *59:01:01:01 is associated with risk of Stevens-Johnson Syndrome when treated with acetazolamide.	0.25
1444608396	1184510370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510370	23816762	Genotype CC is associated with decreased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT.	3.0
1444667175	1185023149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185023149	24367646	Genotype CC is associated with increased risk of Gastrointestinal Hemorrhage when treated with aspirin as compared to genotypes CT + TT.	0.0
1444667499	1185003198	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003198	25372592	Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.	0.0
1444667512	1185003143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003143	25372592	Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.	3.0
1444700536	827827116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827116	21164499	Allele G is associated with decreased blood pressure (BP) reduction when treated with hydrochlorothiazide in people with Hypertension as compared to genotype CC.	3.25
1446896596	1446896579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896579	25408262	Genotypes AA + AG is associated with increased concentrations of erlotinib in healthy individuals as compared to genotype GG.	1.0
1444700391	981482256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482256	20886544	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.0
1444700391	981862083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862083	19132693	Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.	2.5
1444700391	1450928739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450928739	29621993	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-2.0
1444608384	1184510363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510363	23505228	Genotype CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	3.5
1444608384	1447679904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679904	26167726	Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC.	2.25
1444608384	1450371570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371570	30457672	Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	2.25
1444665995	981954577	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954577	23400009	CYP2C9 *44 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954584	23400009	CYP2C9 *54 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954590	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954590	23400009	CYP2C9 *40 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954596	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954596	23400009	CYP2C9 *42 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954602	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954602	23400009	CYP2C9 *43 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954608	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954608	23400009	CYP2C9 *45 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954614	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954614	23400009	CYP2C9 *52 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954620	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954620	23400009	CYP2C9 *36 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954626	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954626	23400009	CYP2C9 *39 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954632	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954632	23400009	CYP2C9 *46 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954638	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954638	23400009	CYP2C9 *55 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954644	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954644	23400009	CYP2C9 *38 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954650	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954650	23400009	CYP2C9 *53 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954656	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954656	23400009	CYP2C9 *47 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954662	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954662	23400009	CYP2C9 *48 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954668	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954668	23400009	CYP2C9 *37 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954674	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954674	23400009	CYP2C9 *50 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954680	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954680	23400009	CYP2C9 *2 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954686	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954686	23400009	CYP2C9 *13 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	981954692	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981954692	23400009	CYP2C9 *3 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.	0.0
1444665995	1445117488	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1445117488	25994031	CYP2C9 *59 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan and tolbutamide as compared to CYP2C9 *1.	0.0
1444665995	1447680126	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447680126	26255664	CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.	0.0
1444665995	1447680150	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447680150	26255664	CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.	0.0
1444665995	1448615951	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448615951	20814155	CYP2C9 *3 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.	0.0
1444665995	1448615959	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448615959	20814155	CYP2C9 *13 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.	0.0
1444665995	1451234364	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234364	32531309	CYP2C9 *2 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1444665995	1451234360	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234360	32531309	CYP2C9 *62 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1444665995	1451234420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234420	32531309	CYP2C9 *3 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1444665995	1184510805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510805	23959274	CYP2C9 *1/*3 + *1/*8 are associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1444700667	1184513848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513848	22717018	Genotypes AC + CC is associated with increased risk of adverse cognitive effects when treated with escitalopram in people with Anxiety Disorders as compared to genotype AA.	2.5
1444700675	1184513810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184513810	22717018	Genotypes CT + TT is associated with increased risk of adverse cognitive effects when treated with escitalopram in people with Anxiety Disorders as compared to genotype CC.	2.5
1184756841	1184756770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756770	21393610	HLA-C *03:02 is associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	3.25
1184756979	1184756830	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756830	11470994	CYP2D6 *29 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or debrisoquine in COS-1 cells as compared to CYP2D6 *1.	0.0
1184756979	1184756847	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756847	11470994	CYP2D6 *29 is not associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in yeast cells as compared to CYP2D6 *1.	-0.0
1184756979	1184756863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756863	11470994	CYP2D6 *29/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*29.	1.0
1184756979	1184756875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756875	11470994	CYP2D6 *17/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*17.	1.0
1184756979	1184756941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756941	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1184756979	1184756952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756952	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	0.125
1184756979	1184756965	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756965	11823760	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *29/*29.	0.25
1184764194	1184746848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746848	21801394	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C.	0.0
1184764194	1184746853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746853	21801394	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C.	0.0
1184764199	1184746803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746803	21801394	Allele G is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele A.	0.0
1184764204	1184746741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746741	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	0.0
1184764204	1184746786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746786	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.	0.0
1184997007	1184407587	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407587	19694795	HLA-B *15:18:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	0.0
1184997013	1184468176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468176	22818943	HLA-B *15:19 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.0
1184997019	1184468183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468183	22818943	HLA-B *15:27:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.25
1444703032	1183684305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684305	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with mianserin in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1444703032	1183624260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183624260	14652703	CYP2D6 *1xN + *2xN are associated with decreased response to citalopram, mianserin, mirtazapine, nortriptyline, paroxetine or venlafaxine in people with Mood Disorders.	2.0
1444703032	1444703011	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703011	9408809	CYP2D6 *1/*10 + *5/*10 are associated with increased concentrations of mianserin in people with Depression as compared to CYP2D6 *1/*1.	1.5
1184997201	1184407594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407594	19694795	HLA-B *59:01:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	0.0
1444700660	1183699182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699182	24225399	Allele C is associated with increased risk of Neutropenia when treated with gemcitabine as compared to allele A.	2.5
1444703063	1043817944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043817944	23799451	Genotype AG is associated with agitation and dysphoria when treated with venlafaxine in patient with depression.	0.25
1444703115	827807924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807924	20679960	Allele A is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.	2.75
1444703207	827784097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827784097	21192345	Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.	2.25
1444703215	827825885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825885	22293537	Allele C is associated with increased risk of Leukopenia when treated with gemcitabine in people with Neoplasms as compared to allele A.	0.0
1444704321	981352439	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981352439	18565259	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele T.	1.5
1444704321	982047110	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047110	22129793	Genotype TT is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.	-1.25
1444704321	1444704286	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704286	25850964	Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.	3.75
1444704321	1447959074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959074	25537528	Genotypes GG + GT are associated with decreased response to adalimumab, etanercept, infliximab or ustekinumab in people with Psoriasis as compared to genotype TT.	1.75
1444704328	1444704274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704274	25850964	Allele C is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	2.75
1444704328	1444704297	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704297	25850964	Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	2.75
1444704335	1444704305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444704305	25850964	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	0.0
1444704763	981865068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865068	19388002	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	0.0
1444704775	981502794	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502794	20084518	Allele C is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele T.	1.5
1444704861	981238105	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981238105	22405131	Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele C.	0.0
1444704861	981238130	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981238130	22405131	Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele C.	0.0
1444704861	981238133	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981238133	22405131	Allele C is associated with increased expression of IL17A when treated with estradiol as compared to allele G.	0.0
1444704861	981238136	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981238136	22405131	Allele C is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.	0.0
1444704861	981238139	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981238139	22405131	Allele C is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.	0.0
1444704869	981479914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981479914	21740768	Genotype CC is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine in men.	2.75
1444704881	769170934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170934	14583680	Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.	2.0
1450826374	769169604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169604	15961980	Genotype AA is associated with increased area under the visual analog scale-time curve during the induced state when exposed to lorazepam as compared to genotype CC.	1.0
1450826374	769169595	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169595	15961980	Genotype AA is associated with decreased clearance of lorazepam.	0.0
1444703223	1183863858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863858	24583629	Allele G is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	0.0
1444703223	1449558004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449558004	29743634	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.0
1184997207	1184349250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349250	9109770	HLA-B *59:01:01:01 is associated with Stevens-Johnson Syndrome when treated with methazolamide in people with Glaucoma.	0.25
1184997207	1184415386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184415386	20504258	HLA-B *59:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.	3.25
1184997207	1444706649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444706649	25918017	HLA-B *59:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.	3.75
1184997207	1444709192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444709192	25970075	HLA-B *59:01:01:01 is associated with Epidermal Necrolysis, Toxic when treated with methazolamide in people with Glaucoma.	0.25
1184997207	1448530438	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530438	26458485	HLA-B *59:01:01:01 is associated with Epidermal Necrolysis, Toxic when treated with methazolamide in women with Glaucoma.	0.25
1184997207	1450397876	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397876	30242287	HLA-B *59:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.	1.0
1184997120	1184988832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988832	23025739	HLA-B *56:02 is associated with drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	0.25
1184997120	1447948922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948922	26928377	HLA-B *56:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	2.5
1184997120	1450823542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823542	31206740	HLA-B *56:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	0.25
1184754547	1184746545	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746545	11477075	SLCO1B1 *12 is associated with decreased uptake of conjugated estrogens as compared to SLCO1B1 *1.	0.0
1184754547	1184746552	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746552	11477075	SLCO1B1 *13 is associated with decreased uptake of conjugated estrogens as compared to SLCO1B1 *1.	0.0
1184753824	1184746618	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746618	16513443	SLCO1B1 *15 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.	0.0
1184753824	1184746597	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746597	16513443	SLCO1B1 *5 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.	0.0
1184753824	1184746609	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746609	16513443	SLCO1B1 *9 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.	0.0
1184753824	1184746628	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184746628	16513443	SLCO1B1 *14 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.	0.0
1184753824	1451533240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451533240	16513443	SLCO1B1 *15/*15 + *1/*15 + *15/*37 + *14/*37 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased concentrations of atrasentan as compared to SLCO1B1 *1/*1 + *37/*37 + *1/*37 (assigned as normal metabolizer phenotype) .	1.0
1184997136	1184468239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468239	23830818	HLA-B *58:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.	-1.75
1184997136	1184469120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469120	24399721	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	2.5
1184997136	1451641000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451641000	34350628	HLA-B *58:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
1446899836	1446897245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897245	26194361	Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.	3.0
1444607318	1183699510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699510	23609392	Genotype GG is associated with decreased 9-hydroxy-risperidone levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.	1.75
1444607318	1183699519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699519	23609392	Genotype GG is associated with decreased active moiety levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.	2.25
1444607318	1183699525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699525	23609392	Genotype AA is not associated with clearance of risperidone in people with Psychotic Disorders as compared to genotype GG.	-0.125
1444607325	1183699684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699684	23204795	Genotype CT is associated with increased dose of bevacizumab in people with Macular Degeneration as compared to genotype TT.	1.75
1444607427	1183703802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703802	23559402	Genotype CCT/CCT is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.	1.25
1444607427	1183703807	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703807	23559402	Genotype CCT/CCT is associated with decreased area under the curve when exposed to olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.	1.25
1444607459	1183703820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703820	23559402	Genotype GG is associated with decreased area under the curve from baseline to the last measured concentration when exposed to olanzapine in healthy individuals as compared to genotypes AA + AG.	0.75
1444607565	1184135927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184135927	23503455	CYP2D6 *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .	1.5
1444607565	1184135944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184135944	23503455	CYP2D6 *1/*4 + *4/*41 + *5/*41 + *6/*41 (assigned as heterozygous normal metabolizer phenotype) are not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizers phenotype) .	-0.125
1444607565	1184136002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136002	23503455	CYP2D6 *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizers phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*4 + *4/*41 + *5/*41 + *6/*41 (assigned as heterozygous normal metabolizer phenotype) .	1.0
1444607796	1184165220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184165220	23266789	Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	3.0
1444607803	981940113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981940113	18086475	Genotype AA is associated with increased social and clinical needs when treated with olanzapine in people with Psychotic Disorders as compared to allele G.	2.0
1444607803	655385595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655385595	17038883	Allele A is associated with positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype when treated with olanzapine.	1.5
1444607827	981758521	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758521	23267855	Genotype CC is associated with increased response to metformin when exposed to metformin in healthy individuals as compared to genotypes CT + TT.	2.25
1444607827	981758528	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981758528	23267855	Genotype CC is associated with increased response to metformin when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.	2.5
1444607827	1043818148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818148	23873119	Allele C is not associated with CLrenal nor the secretory clearance (CLsec) of metformin when exposed to metformin in healthy individuals as compared to allele T.	-0.5
1444607827	1448998619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448998619	28834135	Allele C is not associated with response to metformin in women with Polycystic Ovary Syndrome as compared to allele T.	-0.25
1444607986	1184167044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184167044	24128861	CYP2B6 *1/*6 + *6/*6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	3.25
1444607986	1184167069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184167069	24128861	CYP2B6 *1/*6 + *6/*6 is associated with decreased risk of Drug Toxicity when treated with cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	2.75
1444607986	1184167098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184167098	24128861	CYP2B6 *1/*6 + *6/*6 is not associated with response to fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	-1.75
1444607986	1184167118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184167118	24128861	CYP2B6 *1/*6 + *6/*6 is not associated with risk of Drug Toxicity when treated with fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.	-1.75
1444608027	981861603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981861603	19236730	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotypes CC + CT.	3.0
1444608027	1184167140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184167140	22965830	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.75
1444608182	1184168981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168981	24647007	Allele T is associated with increased severity of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	3.0
1444608182	1184168997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168997	24647007	Allele T is not associated with severity of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-3.0
1444608182	1184169001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169001	24647007	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	3.0
1444608189	1184168973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168973	24647007	Allele C is not associated with risk of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	-2.0
1444608189	1184168985	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168985	24647007	Allele C is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	3.0
1444608189	1184169005	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169005	24647007	Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.	3.0
1444608189	1448568409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568409	27995989	Genotype CC is not associated with risk of Drug Toxicity when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.	-1.5
1444608201	1184168977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168977	24647007	Allele T is not associated with risk of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	-2.0
1444608201	1184168989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168989	24647007	Allele T is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	3.0
1444608201	1184169009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169009	24647007	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.	3.0
1444608224	1184168941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168941	24647007	Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	3.5
1444608224	1184168950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168950	24647007	Allele A is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	3.5
1444608224	1184168958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168958	24647007	Allele A is not associated with severity of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	-2.0
1444608231	1184169017	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169017	23880023	Genotype GG is associated with increased risk of Psychotic Disorders when exposed to methamphetamine in men with methamphetamine dependence as compared to genotypes AA + AG.	2.25
1444608284	1184169737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169737	24407380	Genotypes AA + AG is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype GG.	2.25
1444608291	1184169710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169710	24407380	Genotypes CC + CT is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype TT.	2.0
1444667222	1185002465	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002465	25372392	Allele A is associated with increased response to capecitabine or fluorouracil in people with Neoplasm Metastasis as compared to allele G.	0.0
1444667432	1185003211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003211	25372592	Allele A is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.	3.0
1444667585	1185003244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003244	25372592	Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele T.	3.0
1444667592	1185003217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003217	25372592	Allele G is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.	3.0
1444702771	1444698532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698532	24230997	Genotypes CT + TT is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to genotype CC.	3.0
1444843493	1444843476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843476	26075078	Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.	3.0
1451760600	1451685240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451685240	33731884	Genotype CC is associated with decreased ability to concentrate when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-2.5
1451760600	1451760524	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451760524	33731884	Genotypes CC + TT are associated with decreased likelihood of Tremor or Diarrhea when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotype CT.	3.5
1451760600	1451683860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451683860	33731884	Genotype CC is associated with decreased likelihood of Dizziness when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CT + TT.	This annotation is not used for clinical annotation scoring. Other VAs from this paper already on this CA
1446899176	1446767165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446767165	26257249	Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.	3.0
1446899176	1448267368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267368	27740732	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.	2.25
1446899708	1446895707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895707	26169577	Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C.	0.0
1446899722	1446895877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895877	26169577	Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele T.	0.0
1446899722	1448569459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448569459	28084903	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele T.	-2.0
1446899729	1446895906	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895906	26169577	Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele G.	2.0
1446899729	1448569470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448569470	28084903	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele G.	-2.0
1446899736	1446895923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895923	26169577	Allele C is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele T.	2.5
1446899736	1448569481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448569481	28084903	Allele C is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele T.	-2.0
1446899749	1184746917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184746917	25051018	CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.	2.0
1446899749	1184746928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184746928	25051018	CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.	2.25
1446899749	1184754878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184754878	24598718	CYP3A4 *1/*22 is associated with increased bioavailability of simvastatin as compared to CYP3A4 *1/*1.	0.0
1446899749	1446896996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896996	26164721	CYP3A4 *1/*22 is associated with increased concentrations of simvastatin in people with Hypercholesterolemia as compared to CYP3A4 *1/*1.	2.5
1446899749	1448624746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624746	28482130	CYP3A4 *22 is not associated with response to simvastatin as compared to CYP3A4 *1.	-2.0
1446899843	1446897207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897207	26194361	Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.	3.0
1446899860	1446897238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897238	26194361	Genotype CC is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CT + TT.	3.0
1446899866	1446897254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897254	26194361	Genotypes CC + CT are associated with increased response to carboplatin and taxanes in women with as compared to genotype TT.	2.5
1446899883	1446897227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897227	26194361	Genotype GG is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AA + AG.	3.5
1446899890	1446897198	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897198	26194361	Genotype CC is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AA + AC.	3.5
1446899905	1446897125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446897125	26194361	Genotype AA is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AG + GG.	3.0
1446903240	1446903123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446903123	25344452	Allele A is associated with increased risk of Hypertension when treated with sunitinib in people with Neoplasms as compared to allele G.	2.75
1446903310	1446903250	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903250	25665511	Genotypes CC + CT is associated with increased response to fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	3.25
1185000522	1184747414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747414	20504240	Allele A is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.	-1.5
1185000522	1184747531	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747531	21288825	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.	-1.5
1185000522	1184997529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184997529	17148966	Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.	2.0
1185000522	1184997536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184997536	17148966	Allele G is not associated with risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele A.	-1.5
1185000522	1184997688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184997688	25151207	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.	-0.25
1185000522	1445297339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297339	25622064	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.	-0.75
1185000522	1447984433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447984433	26857335	Allele A is not associated with likelihood of treatment failure when treated with atazanavir in people with HIV Infections as compared to allele G.	-1.75
1185000522	1448260868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260868	26174719	Genotypes AA + AG is associated with dose of atazanavir in people with HIV Infections.	2.25
1185000522	1448617122	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448617122	17324111	Allele G is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.	-0.125
1185000522	1448617170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448617170	1655344	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.	-0.5
1185000522	1448617179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617179	1655344	Allele G is not associated with likelihood of Hyperbilirubinemia when treated with atazanavir in people with as compared to allele A.	-1.0
1185000522	1448617197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617197	16355344	Allele G is not associated with severity of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele A.	-1.25
1185000522	1448617211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448617211	16355344	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.	-0.75
1185000522	1448821824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821824	28718515	Genotypes AA + AG are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.	-0.75
1444607789	1183623391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623391	20075642	Genotypes AC + CC are not associated with increased risk of discontinuation syndrome due to paroxetine in people with Depressive Disorder, Major as compared to genotype AA.	-1.25
1444607789	1183701692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701692	16534507	Genotype AA is associated with increased risk of Nausea when treated with paroxetine in people with Mental Disorders as compared to genotypes AC + CC.	1.75
1444607789	1183701697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701697	16534507	Genotype AA is not associated with differences in paroxetine daily dose and plasma concentrations when treated with paroxetine in people with Mental Disorders as compared to genotypes AC + CC.	-0.75
1444608040	981861633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981861633	19236730	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype CC.	3.0
1444608040	1184167131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184167131	22965830	Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.	-1.75
1444608040	1449311473	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311473	29748862	Genotype TT is not associated with response to escitalopram in people with Depressive Disorder as compared to genotypes CC + CT.	-1.75
1446899715	1446895723	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895723	26169577	Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C.	1.25
1446899715	1448569448	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448569448	28084903	Allele A is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension and Pulmonary Disease, Chronic Obstructive as compared to allele C.	-2.0
1446898992	1446898364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898364	23920449	Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.	1.25
1446898992	1446898393	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898393	22566560	Allele A is associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	1.125
1446898992	1446898411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898411	22566560	Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.	2.0
1446898992	1446898605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898605	23799528	Allele A is not associated with risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.	-1.0
1446898992	1449001922	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449001922	27217270	Genotype AA is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to genotypes AC + CC.	1.5
1184987378	1184985742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184985742	25148458	Allele T is associated with increased risk of Fractures, Bone when exposed to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	0.0
1184987397	1184985736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184985736	25148458	Allele T is associated with increased risk of Fractures, Bone when exposed to anastrozole and exemestane in women with Breast Neoplasms as compared to allele C.	0.0
1184987471	1184755508	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755508	25096645	Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C.	1.5
1184987488	1184755483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755483	25096645	Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C.	1.5
1184987503	1184755371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755371	25096645	Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG.	1.5
1185002351	1185002324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002324	23691226	Genotypes AA + AG is associated with increased dose of acenocoumarol as compared to genotype GG.	3.0
1185002357	1185002340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002340	23691226	Genotypes AA + AC is associated with increased dose of acenocoumarol as compared to genotype CC.	3.0
1185002363	1185002313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002313	23691226	Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC.	3.0
1185002369	1185002333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002333	23691226	Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.	3.0
1184996903	PA166176623	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166176623		Annotation of CPIC Guideline for oxcarbazepine and HLA-B	100
1184996903	PA166265201	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265201		Annotation of DPWG Guideline for oxcarbazepine and HLA-B	100
1184996903	PA166105213	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166105213		Annotation of FDA Label for oxcarbazepine and HLA-B	100
1184996903	981859082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859082	20235791	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine in Epilepsy.	2.75
1184996903	1184469071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184469071	24496695	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	2.5
1184996903	1184988799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988799	18785891	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in men with Seizures.	0.25
1184996903	1184988858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988858	22429379	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	0.25
1184764228	1184746894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746894	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	0.0
1184764228	1184746899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746899	21801394	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.	0.0
1185000534	749069601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/749069601	20921307	Genotype TT is associated with increased metabolism of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	1.0
1185000534	1447947668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947668	26892777	Genotype CT (assigned as deficiency phenotype) is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + TT.	1.25
1185000534	1448260859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260859	26174719	Genotype TT is associated with dose of atazanavir in people with HIV Infections.	2.25
1185000534	1448617361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448617361	18831695	Genotype TT is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	2.5
1184764213	1184746726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746726	21801394	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G.	0.0
1184764213	1184746735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184746735	21801394	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G.	0.0
1184764213	1449157517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449157517	29193002	Genotypes AA + AG are not associated with risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype GG.	-2.5
1451760701	1451685290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451685290	33143542	Genotype AA is associated with decreased concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.	This annotation is not used for clinical annotation scoring. The do specify the rs number of the allele, but then they only state results by *1F allele and I cannot see it specified that they are using the PharmVar definition of *1F. Since there has been some confusion in the literature about which variant at the location is *1F. PharmVar states CYP1A2*1F allele is defined as having -163A, so I have represented *1F/*1F here as AA.
1451760701	1451685223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451685223	33143542	Genotype AA is associated with increased concentrations of clozapine in people with Schizophrenia as compared to genotypes AC + CC.	This annotation is not used for clinical annotation scoring. The do specify the rs number of the allele, but then they only state results by *1F allele and I cannot see it specified that they are using the PharmVar definition of *1F. Since there has been some confusion in the literature about which variant at the location is *1F. PharmVar states CYP1A2*1F allele is defined as having -163A, so I have represented *1F/*1F here as AA.
1451760701	1451720320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451720320	35259926	Genotype AA is associated with decreased dose-adjusted trough concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.	1.0
1451760701	1451760610	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451760610	33731885	Genotypes AA + AC are associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype CC.	1.75
1451760701	769218883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769218883	19593168	Genotype AA is not associated with metabolism of clozapine.	-0.75
1451760701	1451125720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451125720	31616047	CYP1A2 *1F is not associated with concentrations of clozapine in people with Schizophrenia as compared to CYP1A2 *1A.	-0.75
1444666212	1185002829	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002829	23362284	HLA-DQB1 *05:01:01:01 is associated with decreased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	3.0
1444666212	1185002903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002903	23362284	HLA-DQB1 *05:01:01:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1444666674	1296667078	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667078	24980784	Genotypes AG + GG is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	3.0
1444666681	1296667099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667099	24980784	Genotypes GG + GT is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	3.0
1444666688	1296667070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667070	24980784	Genotypes CC + CG is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.0
1444666695	1296667085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667085	24980784	Genotypes AA + AC is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	3.0
1444666886	1296599109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599109	24446315	Genotypes AA + AG is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.25
1444666886	1296599264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599264	24446315	Genotypes AA + AG is associated with decreased overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.75
1444694602	769180581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180581	21289623	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.	1.75
1444694602	1448573389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573389	28135009	Genotypes AG + GG is not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	-1.25
1444694616	1184470478	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470478	24625991	Genotype AG is associated with increased risk of Hypokalemia when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.	1.5
1444703076	981789712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981789712	23111422	Genotypes AA + AG are associated with decreased etravirine clearance when treated with etravirine in people with HIV Infections as compared to genotype GG.	2.0
1444704105	1183701963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701963	24322002	Genotypes AC + CC is associated with increased sensitive to antilymphocyte serum when treated with antithymocyte globulin in people with Kidney Transplantation as compared to genotype AA.	1.25
1444704118	827785905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785905	21037509	Genotype CC is associated with the most benefit from statin treatment in reducing the risk of myocardial infarction when treated with hmg coa reductase inhibitors as compared to genotype GG.	2.5
1444933020	1444933003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444933003	26141406	Genotypes GT + TT are associated with decreased dose of propofol as compared to genotype GG.	2.0
1445400703	1444702987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702987	22383676	Genotype AA is associated with increased response to Pertussis vaccines in children as compared to genotypes AG + GG.	1.75
1444666198	1184468253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468253	23830818	HLA-DRB1 *03:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.	1.75
1445402201	1444696628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444696628	25647612	Genotype CT is associated with increased Drug Toxicity when treated with haloperidol in people with Psychotic Disorders as compared to genotype CC.	1.75
1444694609	1183491718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491718	23900887	Genotype GG is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444694609	1183491722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183491722	23900887	Genotype GG is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444694609	1183697966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183697966	23149441	Allele A is not associated with acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.5
1444694609	1184470460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470460	24625991	Genotype AG is associated with increased risk of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.	1.5
1444694609	1444693904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444693904	22786571	Genotypes AA + AG is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-1.0
1444694609	1449165845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165845	28945481	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.25
1444694609	1449748717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449748717	29689130	Genotypes AA + AG is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-1.75
1444704097	1448107570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107570	21946898	Allele A is associated with increased response to simvastatin in people with Chronic Disease as compared to genotype GG.	1.75
1444704097	1448624746	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624746	28482130	CYP3A4 *22 is not associated with response to simvastatin as compared to CYP3A4 *1.	-2.0
1185235008	769163304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163304	20860463	Genotype AG is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to allele A.	-0.5
1185235008	1185234929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234929	25303294	Allele G is associated with concentrations of efavirenz in people with HIV Infections as compared to allele A.	1.75
1185235008	1447680733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680733	26779253	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	-1.0
1185235008	1448994422	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994422	28886044	Genotype GG is associated with increased concentrations of efavirenz in children with HIV Infections.	1.5
1444608132	1184168580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168580	23953100	Genotype CC is associated with increased anti-VEGF injections when treated with bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.	1.75
1444608132	1184168589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168589	23953100	Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.	3.25
1444608139	1184168621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168621	23521149	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.	3.25
1444608139	1184168659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168659	23521149	HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.	2.0
1444608175	1184168946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168946	24647007	Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	3.5
1444608175	1184168954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168954	24647007	Allele A is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	3.5
1444608175	1184168962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168962	24647007	Allele A is not associated with severity of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.	-2.0
1444666091	1184510873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510873	23963147	UGT1A1 *60 is associated with decreased response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	2.5
1444666091	1184510880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510880	23963147	UGT1A1 *60 is associated with decreased overall survival when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.	1.5
1444666855	1296599320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296599320	24589909	Genotypes AA + AG is associated with increased electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotype GG.	2.25
1444667305	1185002489	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002489	25372392	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.	0.0
1444667322	1185002444	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002444	25372392	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.	0.0
1444702664	981417500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981417500	23007924	Allele A is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.	-1.0
1444702664	1444702631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702631	25834819	Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	3.25
1445401406	1184511510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511510	24013576	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	-1.25
1445401406	1446765323	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446765323	26244574	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	3.25
1445401406	1444936647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936647	25778465	Genotype GG is associated with increased risk of Exanthema and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.	1.0
1445401406	1446765330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446765330	26244574	Genotypes AA + AG is associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell.	2.25
1445402226	827825187	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825187	22188361	Genotype CT is not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-1.5
1445402226	637880151	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880151	17409936	Allele C is not associated with survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	-1.5
1445402226	1444936069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936069	25592234	Genotypes CT + TT is associated with decreased event-free survival and overall survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC.	3.25
1446897342	1444694050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694050	25615449	Genotype TT is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.	2.75
1446897485	769250751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250751	20125120	Genotype AC is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms.	1.75
1446897485	1444842390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842390	25955730	Genotype CC is associated with increased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AC.	1.25
1446899695	1446767227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446767227	26030142	Allele A is associated with increased likelihood of increased creatine kinase level when exposed to vancomycin as compared to allele C.	0.0
1446903540	1446897318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897318	25918834	Allele T is associated with decreased response to adrenergics, inhalants in children with Asthma as compared to allele C.	0.0
1446903556	1446903336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903336	26407342	Allele T is associated with decreased clearance of nicotine as compared to allele C.	1.25
1446903556	1449161382	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449161382	29232328	Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.	0.0
1446903563	1446903395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903395	26407342	Allele A is associated with decreased clearance of nicotine as compared to allele G.	1.25
1446903570	1446903387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903387	26407342	Allele T is associated with decreased clearance of nicotine as compared to allele C.	0.0
1446903577	1446903431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903431	26306225	Allele A is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele C.	2.75
1446904604	1446899495	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446899495	26033044	Genotype GG is associated with response to carboplatin, lonafarnib and paclitaxel in women with Ovarian Neoplasms.	3.0
1446908543	1445402071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445402071	25774163	Genotype GG is associated with decreased response to varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	3.0
1446908568	981502180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502180	20725741	Genotype AA is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to genotypes AG + GG.	2.75
1445401915	827824114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824114	22188362	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	-1.5
1445401915	769257715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257715	16753003	Allele A is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele G.	-1.0
1445401915	613978577	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978577	15805193	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	-1.0
1445401915	1444935495	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935495	25495409	Genotype GG is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotype AG.	2.5
1445401915	1447678304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678304	26555147	Genotype AG is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	1.5
1445401915	1447678328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678328	26555147	Genotype AG is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	-1.5
1445401915	1448266671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266671	26421491	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	-0.5
1446904693	1446901003	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901003	26403473	Genotype GT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.	0.25
1446903527	1444695526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444695526	25665007	Allele A is associated with increased risk of Ototoxicity when exposed to cisplatin in children with Brain Neoplasms as compared to allele G.	2.5
1446903527	1451128101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128101	31666714	Allele A is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele G.	-1.75
1446903527	1447948911	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948911	26928270	Genotype AG is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to genotype GG.	2.0
1446903527	1448624818	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624818	28445188	Genotypes AA + AG is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to genotype GG.	2.0
1184749208	1184749138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184749138	25084203	Allele A is associated with decreased likelihood of event-free survival when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	2.75
1184756443	1184756116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756116	8946471	CYP2D6 *5/*18 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184756443	1184756131	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756131	8946471	CYP2D6 *18 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol in yeast cells as compared to CYP2D6 *1.	0.0
1184756443	1184756194	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756194	18784265	CYP2D6 *18 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184756443	1184756346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756346	10471060	CYP2D6 *18/*21 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine in healthy individuals.	0.125
1184756443	1184756472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756472	15618746	CYP2D6 *2/*44 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.	0.125
1184756443	1184756523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756523	15618746	CYP2D6 *1/*21 + *10/*21 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*2.	0.125
1184756890	1184756431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756431	21545408	HLA-DQB1 *05:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	2.5
1184756894	1184756369	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756369	21545408	HLA-DRB1 *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0.0
1184756898	1184756396	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756396	21545408	HLA-DRB1 *13:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0.0
1184757151	1184757143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184757143	12811367	CYP2D6 *40/*42 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.	0.125
1184757151	1184986040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184986040	17392730	CYP2D6 *4xN/*56 is associated with decreased metabolism of dextromethorphan.	0.125
1184757151	1184986056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184986056	12152006	CYP2D6 *3/*4xN (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.	0.125
1184757151	1446897132	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897132	16415111	CYP2D6 *4/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.	0.125
1184757151	1446897141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897141	16415111	CYP2D6 *4xN/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.	0.125
1184987055	1184986941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986941	24116192	Genotype AA is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to genotypes AC + CC.	1.5
1184987062	1184986951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184986951	24116192	Allele G is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.	1.5
1184987556	1184755495	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755495	25096645	Allele A is associated with increased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele G.	1.5
1184987573	1184755489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755489	25096645	Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG.	2.0
1184989651	1184989609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989609	25217962	Allele C is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele A.	4.0
1184989663	1184989629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989629	25217962	HLA-DRB1 *07:01:01:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.	0.0
1184989676	1184989640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989640	25217962	HLA-DQA1 *02:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.	0.0
1446897495	1444842369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842369	25955730	Genotype TT is associated with decreased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.	1.25
1446897495	1447813751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813751	26100253	Allele T is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C.	-2.5
1446897495	1448427025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427025	27139155	Genotype TT is associated with decreased overall survival when treated with bevacizumab in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1446908580	1446907494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907494	26352872	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1446908587	1446907551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907551	26352872	Allele A is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	2.5
1446908594	1446907535	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907535	26352872	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1446908603	1446908075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908075	25278896	Genotypes CC + CT is associated with increased risk of Coronary Disease when treated with chlorthalidone.	0.0
1446908603	1446908101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908101	25278896	Genotypes CC + CT is associated with increased risk of Coronary Disease when treated with lisinopril.	0.0
1446908615	1446908111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908111	25278896	Genotypes CC + CT is associated with decreased risk of Coronary Disease when treated with chlorthalidone.	0.0
1446908615	1446908117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908117	25278896	Genotypes CC + CT is associated with increased risk of Coronary Disease when treated with lisinopril.	0.0
1446908622	1446907521	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907521	26352872	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1446908672	1446907605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907605	26398624	Allele G is associated with increased risk of Urticaria when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones as compared to genotype AA.	3.0
1446908679	1446907649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907649	26398624	Allele C is associated with increased risk of Angioedema and Urticaria when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives and Pyrazolones as compared to genotype TT.	2.5
1446908686	1446907632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446907632	26398624	Allele G is associated with increased risk of Angioedema when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives and Pyrazolones as compared to genotype AA.	2.5
1444842040	1183693308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183693308	22527345	CYP2C19 *1 is not associated with risk of Death due to carisoprodol.	-1.75
1444842040	1444827984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444827984	16021435	CYP2C19 *1/*2 (assigned as intermediate metabolizers phenotype) is associated with increased concentrations of carisoprodol in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1451506746	1451505840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451505840	34231218	Allele T is associated with increased risk of adverse cardiovascular events when treated with Beta Blocking Agents in people with Hypertension as compared to allele C.	1.5
1444668292	1184466663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466663	24853734	Allele C is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele T.	1.75
1444668292	1184466659	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466659	24853734	Allele C is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.	2.75
1444668298	1184407335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407335	24853734	Allele G is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele A.	1.25
1444668298	1184407330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407330	24853734	Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.	2.75
1444668298	1449165223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165223	29352482	Allele A is not associated with exposure to metformin as compared to allele G.	-1.0
1444668306	1184466652	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466652	24853734	Allele T is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	2.75
1444673002	982045433	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045433	20877298	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.	1.75
1444673002	978627411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978627411	17460608	Allele C is associated with increased 24-h excretion of chloride and potassium when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele G.	2.25
1444673123	1184173879	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173879	23963056	Genotype AG is associated with increased likelihood of extrapyramidal symptoms when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG.	2.0
1184755711	1184755389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755389	7845481	CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184755428	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184755428	9089660	CYP2D6 *7 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol.	0.0
1184755711	1184755702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755702	8563771	CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184755725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755725	8655150	CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184757252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184757252	17460029	CYP2D6 *41/*62 is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184757284	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184757284	17460029	CYP2D6 *62 is associated with decreased catalytic activity of CYP2D6 when assayed with propafenone in COS-1 or insect cells.	0.0
1184755711	1184764277	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184764277	9241659	CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184764284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184764284	9241659	CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184764290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184764290	9241659	CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184764296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184764296	9241659	CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184764302	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184764302	17001296	CYP2D6 *4/*59 is associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184755711	1184764309	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184764309	17001296	CYP2D6 *59 is associated with decreased expression of CYP2D6 in Huh7 hepatoma cells as compared to CYP2D6 *1.	0.0
1184755711	1184764323	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184764323	17001296	CYP2D6 *59 is associated with decreased catalytic activity of CYP2D6 when assayed with propafenone in Huh7 hepatoma cells as compared to CYP2D6 *1.	0.0
1184755711	1184986212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184986212	9511177	CYP2D6 *5/*7 + *5/*8 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.	0.125
1184987911	1184755585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755585	25224784	Genotype AA is associated with decreased metabolism of itopride in healthy individuals as compared to genotype GG.	1.5
1184987918	1184755593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755593	25224784	Genotype GG is associated with decreased metabolism of itopride in healthy individuals as compared to genotype AA.	1.5
1444667292	1185002413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002413	25372392	Allele T is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele C.	0.0
1444673130	1183680813	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680813	23996099	Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.	2.25
1444673197	1184512103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184512103	24061601	Genotype GG is associated with decreased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG.	2.25
1444673209	1184512158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512158	24061601	Genotype GG is associated with decreased response to docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG.	1.5
1444673209	1444934910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934910	25111199	Genotype AA is associated with decreased progression-free survival when treated with cyclophosphamide and docetaxel in people with Prostatic Neoplasms as compared to genotypes AG + GG.	2.0
1444680145	1183689066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689066	24192117	Genotype CC is not associated with clearance of busulfan in children with Transplantation as compared to genotype TT.	-0.75
1444680145	1184514267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184514267	24165757	Genotype CC is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to genotypes CT + TT.	1.5
1444700452	982032470	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032470	23736108	Genotypes AG + GG are associated with increased FEV1 decrease after aspirin challenge when exposed to aspirin in people with Asthma as compared to genotype AA.	3.0
1444700466	982032427	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032427	23736108	Genotypes CC + CG are associated with increased FEV1 decrease after aspirin challenge when exposed to aspirin in people with Asthma as compared to genotype GG.	3.0
1444700550	827807849	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807849	21063236	Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 4.8 mg/week as compared to allele C.	2.5
1444700558	827807860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807860	21063236	Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 2.2 mg/week as compared to allele C.	2.5
1444700566	769261522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261522	21540762	Allele C is associated with increased risk of developing nicotine dependence or heavy smoking when exposed to nicotine as compared to allele T.	1.5
1444700574	769261536	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261536	21540762	Allele T is associated with increased risk of developing nicotine dependence or heavy smoking when exposed to nicotine as compared to allele C.	1.5
1444700581	1183699628	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699628	24300566	Allele G is associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.	1.75
1444700903	827829188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827829188	20538124	Genotype TT is associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AT.	3.25
1444700916	1444608310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444608310	24602049	Genotypes CC + CT is associated with decreased risk of Hemorrhage when treated with warfarin as compared to genotype TT.	2.5
1444700950	1444672881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444672881	25054431	Allele G is associated with increased risk of pneumonitis when treated with radiotherapy as compared to allele T.	3.5
1444700958	981239208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239208	22843789	Allele A is associated with increased risk of sensory peripheral neuropathy when treated with paclitaxel in women Breast Neoplasms as compared to allele G.	3.0
1444700970	1444672851	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444672851	25054431	Allele T is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele A.	3.0
1444700983	982047266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047266	22543981	Genotype TT is associated with increased risk of emergency department utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes GG + GT.	1.5
1444700991	981344072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344072	22151084	Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG.	2.25
1444700991	1449002763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002763	29036176	Allele G is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.	-1.5
1444672993	982046893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046893	21359536	Genotype AA is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	-2.25
1444672993	827814000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814000	21806386	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.5
1444672993	1183491664	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491664	23900887	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444672993	1183491669	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491669	23900887	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444672993	1183684117	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684117	23107770	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.	-1.0
1444672993	1183693336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693336	22660440	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	-1.75
1444672993	1183697415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697415	22183771	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	-2.5
1444672993	1183697971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697971	23149441	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1444672993	1183959854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183959854	19376366	Genotype AG is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.0
1444672993	1184468815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468815	21047202	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.25
1444672993	1184470908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470908	24528196	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	1.5
1444672993	1448423969	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423969	26450467	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele G.	-0.125
1444672993	1448573355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573355	28135009	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	-0.75
1444672993	1449165830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165830	28945481	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.25
1444672993	1449171411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171411	27966227	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.	-0.125
1444672993	1185012341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012341	25310192	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.	-1.25
1444672993	1185023192	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023192	24383873	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-0.125
1444672993	1445164614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164614	26176181	Genotype GG is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.	2.0
1444672993	1445164635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445164635	26176181	Genotype GG is associated with decreased concentrations of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.	2.0
1444672993	1447520853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520853	26543771	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1444672993	1447946367	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946367	26705892	Genotype AG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.75
1444672993	1447946591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946591	26705892	Genotype AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-1.75
1451506740	1451506720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451506720	34231218	Allele T is associated with decreased response to Beta Blocking Agents in people with Hypertension as compared to allele C.	1.5
1184749403	1184748435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748435	18781850	SLCO1B1 *14 is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	3.5
1444668477	1296599203	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296599203	25348609	Genotypes CT + TT is associated with increased response to insulin recombinant and zinc acetate in healthy individuals as compared to genotype CC.	2.75
1444673032	1185002099	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002099	21505298	Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.	2.5
1444673039	1185002114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002114	21505298	Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.	2.5
1444673046	981501287	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501287	21652606	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	2.0
1444673046	1450928241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928241	28696411	Allele T is not associated with response to risperidone in people with Schizophrenia as compared to allele C.	-1.75
1444673053	981501278	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501278	21652606	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	3.0
1444673060	982047038	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047038	22129793	Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.	2.75
1444700775	827639418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827639418	21562465	Allele A is associated with decreased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele G.	2.25
1185003571	827825713	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825713	21109570	Genotype AA is associated with increased progression free survival when treated with trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.	1.5
1185003571	827825723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827825723	21109570	Genotype AA is associated with increased response to cyclophosphamide, doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.	1.5
1185003571	1185003550	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185003550	18347005	Genotype AA is associated with increased response to trastuzumab in people with Breast Neoplasms as compared to genotypes AG + GG.	0.0
1185003571	1185003557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003557	18347005	Genotype AA is associated with increased progression-free survival when treated with trastuzumab in women Breast Neoplasms as compared to genotype GG.	1.75
1184996860	PA166182810	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182810		Annotation of DPWG Guideline for flucloxacillin and HLA-B	100
1184996860	1184407571	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407571	19483685	HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.	3.0
1184996860	1184407578	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407578	19483685	HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.	2.75
1444699308	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444699308	1444699562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699562	25515069	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	1.5
1444699308	1444699568	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699568	19682603	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	0.25
1444699308	1448256024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256024	27397648	Allele T is associated with risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.	0.25
1444699308	1444699253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699253	14681830	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or streptomycin as compared to allele C.	0.0
1444699308	1444699296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699296	17698299	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1444699308	1444699302	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699302	20100600	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials in children as compared to allele C.	This annotation is not used for clinical annotation scoring. Subjects previously reported in PMID 17698299
1444699308	1444699290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699290	17698030	Allele T is associated with Ototoxicity when treated with aminoglycoside antibacterials or gentamicin as compared to allele C.	0.25
1444699308	1451438436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438436	21205314	Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1444699743	PA166229081	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166229081		Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1	100
1444699743	1444699671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699671	11313749	Allele C is associated with Ototoxicity when treated with aminoglycoside antibacterials as compared to allele T.	0.25
1444699743	1444699735	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699735	25515069	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele T.	1.5
1444699743	1451438430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451438430	21205314	Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials, gentamicin, kanamycin or streptomycin.	0.25
1184749271	1184749064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184749064	25084203	Allele A is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	3.0
1184753976	1184516457	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516457	25001882	CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.	0.0
1184753976	1184516565	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184516565	25001882	CYP2C19 *10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.	0.0
1185002307	1185002301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002301	21635147	Allele A is associated with increased dose of warfarin as compared to allele G.	2.0
1444672968	1444672922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444672922	25188725	GSTT1 null/null is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to GSTT1 non-null/non-null + non-null/null.	2.0
1444700860	1183629353	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629353	24018773	Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.	3.0
1444700860	1183629413	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183629413	24018773	Allele A is associated with increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.	3.0
1444702764	1444687090	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444687090	23057546	Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CC + CT.	2.5
1444876859	1444843860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843860	23944300	Genotype CC is associated with increased response to deleobuvir and faldaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1445401325	1444936434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444936434	25712183	Genotypes CT + TT is associated with increased response to adalimumab in people with Crohn Disease as compared to genotype CC.	2.75
1445401377	1445297413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297413	25730298	Genotype AA is associated with increased dose of phenylephrine in women as compared to genotype GG.	1.75
1445401377	1448263056	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263056	26771271	Genotype AA is associated with decreased dose of ephedrine or phenylephrine in people with Hypotension as compared to genotype GG.	0.0
1445401389	1444936566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936566	25740917	Genotypes AA + AG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype GG.	2.5
1445401399	1444936574	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444936574	25740917	Genotypes AG + GG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype AA.	2.5
1445401824	1444935257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935257	25495407	Genotypes CG + GG is associated with increased risk of Anemia when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.	2.0
1444702725	981502529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502529	22840423	Genotype TT is associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	2.75
1444702725	981755370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981755370	22840423	Genotype CT is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	-1.75
1444702725	827920021	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827920021	22594510	Genotype CC is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype TT.	-1.5
1444702725	1183491546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491546	23337555	Genotype CC is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	-2.5
1444702725	1183682034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682034	23559864	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	-1.5
1444702725	1183699659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699659	23204795	Genotype CT is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotype TT.	-1.25
1444702725	1184165232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184165232	24070809	Allele T is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele C.	-1.75
1444702725	1184166132	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184166132	23584701	Genotype CC is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes CT + TT.	-1.25
1444702725	1184510377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510377	23842101	Allele C is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele T.	-1.75
1444702725	1446902514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902514	26411831	Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.	2.0
1444702725	1448100703	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100703	26439641	Genotype CC is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes CT + TT.	1.0
1445401817	1444935266	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935266	25495407	Genotypes CT + TT is associated with increased risk of Anemia when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.	2.0
1445401817	1448263648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263648	27574448	Genotype CC is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CT + TT.	-1.25
1445401817	1448263821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263821	27574448	Genotype CC is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CT + TT.	-1.25
1445401831	1444935324	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935324	25495407	Genotype TT is associated with increased risk of Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to genotypes GG + GT.	2.25
1445401831	1448263677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263677	27574448	Genotype TT is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes GG + GT.	-1.5
1445401831	1448263798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263798	27574448	Genotype TT is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes GG + GT.	-1.5
1139506787	1183689160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689160	23371292	CYP2A6 poor metabolizer genotype is associated with increased ratio of cotinine formation to removal when exposed to nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1183689165	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689165	23371292	CYP2A6 poor metabolizer genotype is associated with decreased ratio of plasma cotinine to urinary TNE when exposed to nicotine in smokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1183703333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703333	24448396	CYP2A6 poor metabolizer genotype is associated with decreased metabolism of nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.	1.0
1139506787	1451663080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451663080	15592323	Genotypes CT + TT are associated with decreased metabolism of nicotine as compared to genotype CC.	0.0
1139506787	1451667320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451667320	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1139506787	1451672860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672860	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1139506787	981201935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981201935	12445030	CYP2A6 *4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	827698978	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698978	15900015	CYP2A6 *1/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.0
1139506787	1447982613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447982613	27035242	CYP2A6 *4/*17 + *9/*26 are associated with decreased metabolism of nicotine.	0.125
1139506787	1450809796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809796	15861035	CYP2A6 *2 + *4 + *9 + *12 are associated with decreased clearance of cotinine and nicotine in healthy individuals as compared to CYP2A6 *1.	2.25
1139506787	1450824161	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824161	27599351	CYP2A6 *1/*2 + *1/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	0.0
1139506787	827824861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824861	18360915	CYP2A6 *20 + *26 + *24+ *9 + *27 + *17 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	2.5
1139506787	981344956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344956	22569203	CYP2A6 *4 + *10 + *9 is associated with decreased plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT) when exposed to nicotine in healthy individuals as compared to CYP2A6 *1.	2.75
1139506787	827824877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824877	18360915	CYP2A6 *28 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	1.5
1139506787	1451409603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451409603	31959879	CYP2A6 *1/*12 is associated with decreased concentrations of 3-hydroxycotinine as compared to CYP2A6 *1/*1.	1.25
1139506787	1451662800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451662800	10448083	CYP2A6 *4/*4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	1451662880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451662880	11237731	CYP2A6 *7 is associated with decreased metabolism of coumarin or nicotine as compared to CYP2A6 *1.	0.0
1139506787	827827654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827654	15993850	CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1.	This annotation is not used for clinical annotation scoring. In vitro study
1139506787	1451664820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451664820	17112802	CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12 are associated with decreased clearance of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	1.75
1139506787	1451664980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451664980	17220563	CYP2A6 *1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	1.5
1139506787	1451665040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665040	17220563	CYP2A6 *4/*7 + *4/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	This annotation is not used for clinical annotation scoring. VA 1451664980 is from the same paper and has been attached to the same clinical annotations.
1139506787	1451665780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665780	19279561	CYP2A6 *1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*9 + *1/*12.	This annotation is not used for clinical annotation scoring. Score covered by other VA on this paper.
1139506787	1451666180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666180	19365400	CYP2A6 *1/*35 + *9/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	2.75
1139506787	1451666225	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666225	19365400	CYP2A6 *35/*35 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	0.0
1139506787	1451666260	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666260	19365400	CYP2A6 *17 + *35 are associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.	0.0
1139506787	1451666264	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666264	19365400	CYP2A6 *24 is not associated with catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.	-0.0
1139506787	827699021	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699021	15900015	CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.	0.0
1139506787	981201993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981201993	11779172	CYP2A6 *4/*4 + *4/*7 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	827827639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827639	15993850	CYP2A6 *1/*20 + *17/*20 are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	0.0
1139506787	827699412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827699412	12844137	CYP2A6 *4/*9 + *9/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 + *1/*4 + *1/*9.	2.5
1139506787	1451822580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451822580	16952495	CYP2A6 *2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	827827796	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827796	17267622	CYP2A6 *1x2 is associated with increased metabolism of nicotine as compared to CYP2A6 *1.	0.0
1139506787	1451663040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451663040	15265511	CYP2A6 *4/*4 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1 + *1/*46 + *1/*4.	0.125
1139506787	1451665280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665280	19279561	CYP2A6 *1/*46 + *46/*46 are associated with increased metabolism of nicotine as compared to CYP2A6 *1/*1.	This annotation is not used for clinical annotation scoring. Score covered by other VAs from paper
1139506787	1451675720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451675720	21597399	CYP2A6 *1 + *46 + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4.	2.5
1139506787	1451675840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451675840	21597399	CYP2A6 *1 + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *46.	This annotation is not used for clinical annotation scoring. Score for this paper comes from another VA.
1139506787	1451665300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665300	19279561	CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 (assigned as intermediate and low activity phenotype) are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 +*1/*46 + *46/*46 (assigned as normal metabolizer phenotype) .	2.5
1139506787	827705098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827705098	17522595	CYP2A6 *1/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.	1.5
1139506787	1448601760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601760	28181923	CYP2A6 *46/*46 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1.	2.0
1139506787	827705096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827705096	17522595	CYP2A6 *46/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.	1.5
1445400186	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400186	1184511797	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511797	1354642	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele G.	0.0
1445400186	1444697813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697813	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1444697969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697969	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1445400662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400662	25989378	Genotypes AG + CG are associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400186	1445400809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445400809	12124989	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447672542	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672542	18564801	Allele C is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400186	1447674350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674350	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400186	1447948045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948045	19346234	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447960710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960710	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400186	1447987329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987329	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400186	1449275206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275206	21804810	Allele C is associated with increased risk of Malignant Hyperthermia when exposed to sevoflurane as compared to allele G.	0.25
1451678240	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451678240	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451678240	1451228540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451228540	29950617	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.	3.0
1451678240	1451356526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451356526	20347093	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.	-0.25
1451678240	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451678240	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678240	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451678240	1448821127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821127	28812116	Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.	3.25
1451678240	1183689623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689623	23708174	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.	-2.0
1451678600	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678600	982048103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048103	17289397	CYP2C9 *3 is not associated with likelihood of myopathy when treated with fluvastatin, rosuvastatin or simvastatin as compared to CYP2C9 *1.	-0.25
1451678600	1451678500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451678500	24024895	CYP2C9 *2 + *3 are associated with increased likelihood of adverse events when treated with fluvastatin in people with Kidney Transplantation as compared to CYP2C9 *1/*1.	2.25
1451678600	982048096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982048096	17289397	CYP2C9 *2 is not associated with likelihood of myopathy when treated with fluvastatin, rosuvastatin or simvastatin as compared to CYP2C9 *1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1451678620	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678620	1450823491	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823491	30989645	Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C.	This annotation is not used for clinical annotation scoring. this is in LD with rs4149056 which is already included in scoring.
1451678620	827827170	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827827170	17015053	Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.	-0.125
1451678620	1450823509	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823509	30989645	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.	2.0
1451678620	1451226441	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226441	30528195	SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.	-0.125
1451678620	1451451102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451451102	18408565	SLCO1B1 *15/*15 is not associated with increased concentrations of fluvastatin in healthy individuals as compared to SLCO1B1 *1/*1.	-0.125
1184755382	1184755073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755073	15743917	HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
1445401186	1445296452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296452	25156213	Genotypes AG + GG is associated with increased concentrations of cotinine in children as compared to genotype AA.	2.0
1445401193	1445296571	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296571	25223561	Genotype GG is associated with increased response to alendronate in women with Bone Diseases as compared to genotypes AA + AG.	3.25
1446846513	1446834941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446834941	26237429	Allele A is associated with increased risk of cardiotoxicity when treated with anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1446900938	1446900812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900812	26335211	Genotype CC is associated with decreased event-free survival and overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	3.25
1446900938	1446900825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900825	26335211	Genotype TT is associated with increased risk of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.25
1446901291	1446901188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901188	26387812	Genotype TT is associated with increased likelihood of Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AT.	1.75
1446901311	1446901228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901228	26387812	Genotype TT is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.	0.0
1446901311	1446901245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901245	26387812	Genotype TT is associated with increased risk of Leukopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.	2.25
1185000213	1184515558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515558	21677300	Allele T is not associated with allograft clinical outcome when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.5
1185000213	1184515832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515832	21851254	Genotypes CT + TT are associated with increased blood pressure when exposed to tacrolimus in people with Kidney Transplantation as compared to genotype CC.	1.25
1185000213	1184515840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515840	23146466	Allele T is not associated with blood pressure when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.25
1185000213	1184470490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470490	24625991	CYP3A5 *1/*1 + *1/*3 is not associated with blood pressure when treated with tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.0
1445400222	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400222	1447673616	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673616	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele G.	0.0
1445400222	1447674780	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674780	9497245	Genotype GT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1445400222	1445296846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296846	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400222	1445297377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297377	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400222	1447674004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674004	10484775	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447674304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674304	10051009	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447675311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675311	17710899	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400222	1447675326	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675326	9389851	Genotype GT is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to genotype GG.	0.0
1445400222	1447948052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948052	19346234	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400222	1447952500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952500	16163667	Genotype GT is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400222	1447960973	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960973	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400232	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400232	1447644914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447644914	15731587	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1444697843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697843	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1445297273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297273	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	0.0
1445400232	1447674408	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674408	11525881	Genotype AG is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to genotype GG.	0.25
1445400232	1447674416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674416	11525881	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400232	1447675461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675461	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400232	1447952518	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952518	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400232	1447952711	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952711	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1445400232	1447960739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960739	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400232	1447987517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987517	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400247	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400247	1445296980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445296980	20681998	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400247	1445297386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297386	24433488	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.	1.5
1445400247	1447521378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521378	25611019	Allele T is associated with Malignant Hyperthermia as compared to allele C.	0.0
1445400247	1447673898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673898	10484775	Allele T is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine as compared to allele C.	0.0
1445400247	1447673930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673930	12411788	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to isoflurane as compared to genotype CC.	0.25
1445400247	1447674392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674392	10612851	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445400247	1447952543	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952543	16163667	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1445400247	1447960997	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960997	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1445400247	1449275158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275158	29608462	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1451681540	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1451681540	1446896983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896983	26164721	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.	2.5
1451681540	1451249860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451249860	17108811	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.	1.5
1451681540	1184754854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184754854	24598718	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.	0.0
1451681540	1447983120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983120	25446771	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	0.5
1451681540	1451352480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352480	26774055	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	1.5
1451681540	1451352500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352500	25673568	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.	0.125
1451681540	1446907580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907580	26367500	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.	2.0
1451681540	1448612369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612369	28350522	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.	1.0
1451681540	1449556752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449556752	29469964	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.	1.5
1184996891	1184407486	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407486	18007983	HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene.	3.25
1184996897	1184468155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468155	22818943	HLA-B *13:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.25
1185000260	1184471749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471749	24438215	CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Toxic liver disease when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.	1.25
1185000350	1184997580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184997580	25151207	Allele T is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.	1.75
1185000362	1184997603	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184997603	25151207	Allele G is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.	2.25
1185000369	1184997612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184997612	25151207	Allele G is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.	1.75
1444673379	1184512515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512515	24123600	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	2.0
1444673386	1184512524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512524	24123600	Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	2.0
1444673412	1184512528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512528	24123600	Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.	2.0
1444700808	827815537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815537	22134350	Allele A is associated with decreased likelihood of Nausea when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele C.	3.0
1444700867	1444697697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697697	25713999	Genotype TT is associated with increased risk of Anemia when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.	3.0
1444700874	1184469118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469118	24809448	Genotypes CT + TT are associated with increased response to levodopa in people with Cocaine-Related Disorders as compared to genotype CC.	2.25
1444702778	1444698740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698740	24495780	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	3.0
1444702784	1444698707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698707	24495780	Genotypes CC + CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.	2.75
1444702784	1447681648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681648	26788534	Allele T is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele C.	1.375
1444702792	1444698694	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698694	24495780	Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	2.75
1444702792	1447681639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681639	26788534	Allele G is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele A.	1.375
1444703171	1183699283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699283	24253594	Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele C.	2.0
1444703258	1183848058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183848058	22796099	Allele C is associated with early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele T.	0.0
1444703430	1444667492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667492	25485598	Genotype CT is associated with decreased creatinine clearance when treated with tenofovir in people with HIV Infections as compared to genotype CC.	2.0
1444703438	1444667525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444667525	25485598	Genotype CT is associated with decreased creatinine clearance when treated with tenofovir in people with HIV Infections as compared to genotype CC.	2.0
1444703446	1184469058	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469058	24751813	Genotype GG is associated with increased response to haloperidol in people with Schizophrenia as compared to genotype AG.	0.0
1444703453	1184469067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469067	24751813	Genotype AG is associated with increased response to olanzapine, quetiapine, risperidone or ziprasidone in people with Schizophrenia as compared to genotype GG.	0.0
1444703487	1043818425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043818425	17496729	Allele A is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to allele T.	1.5
1444703495	1021399730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1021399730	18727619	Genotypes CC + CT are associated with increased risk of aspirin intolerance when exposed to aspirin in people with Asthma as compared to genotype TT.	2.25
1444704089	827785764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827785764	21934636	Allele T is associated with increased risk of Edema when treated with thiazolidinediones in people with Diabetes Mellitus, Type 2 as compared to allele C.	3.25
1444705174	981862265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862265	19065121	Allele A is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele G.	0.0
1445401804	1444935352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935352	25495407	Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.	2.0
1445401838	1444935440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935440	25495407	Genotype CC is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AC.	2.75
1445401847	1444935474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935474	25495407	Genotypes AA + AC is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.	2.0
1445401853	1444935333	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935333	25495407	Genotype AA is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AG + GG.	1.75
1445401880	1183703731	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703731	24384557	Allele C is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele T.	-0.5
1445401880	1448266716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266716	26421491	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.	-0.5
1445401880	1448266816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266816	26421491	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	1.5
1445401880	1444935535	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935535	25495409	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	2.0
1445401880	1444935560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935560	25495409	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.0
1445401880	981501747	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501747	23252947	CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1445401952	1444935833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444935833	25521355	Genotypes CT + TT is associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype CC.	2.5
1445402033	769152964	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769152964	20938465	Genotype GG is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	1.75
1445402033	1444687104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444687104	25567217	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	-1.75
1445402033	1445297074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297074	25558979	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.	1.25
1445402085	1444699502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444699502	25560469	Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CG.	2.0
1446898009	1444843016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843016	25991051	Genotypes CT + TT are associated with decreased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype CC.	2.25
1446898016	1444842903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444842903	25991051	Genotypes AA + AG are associated with increased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype GG.	0.0
1444703480	1183863845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183863845	24583629	Allele G is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	0.0
1444703480	1449557981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557981	29743634	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	-1.0
1446897666	1184511530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184511530	24013576	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.	-1.25
1446897666	1446706605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446706605	26244574	Genotype AA is associated with increased risk of Leukopenia and Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	2.75
1446897666	1448431935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448431935	19667267	Genotypes AG + GG is associated with decreased likelihood of Leukopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.	3.0
1446897666	1448432443	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448432443	20683446	Genotypes AG + GG is associated with decreased likelihood of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.	2.0
1445400206	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1445400206	1444697865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697865	15448513	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1444698012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698012	23558838	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1445297038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297038	20681998	Allele A is associated with increased risk of Malignant Hyperthermia in people with increased creatine kinase level as compared to allele G.	0.25
1445400206	1445297392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297392	24433488	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.	1.5
1445400206	1447634061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447634061	17081152	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1447672469	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672469	12059893	Genotype AG is associated with Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447673950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673950	10484775	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to methoxyflurane as compared to allele G.	0.0
1445400206	1447674319	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674319	10051009	Allele A is associated with increased risk of Malignant Hyperthermia and multi-core congenital myopathy as compared to allele G.	0.0
1445400206	1447674385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447674385	11575529	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447675923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675923	21455645	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447946199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447946199	25960145	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447948719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948719	12709367	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447952549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952549	16163667	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.25
1445400206	1447952717	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952717	26951757	Allele A is associated with increased risk of Malignant Hyperthermia when exposed to volatile anesthetics as compared to allele G.	0.0
1445400206	1447960670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960670	19648156	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.0
1445400206	1447961289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961289	19191333	Genotype AG is associated with increased risk of Malignant Hyperthermia as compared to genotype GG.	0.0
1445400206	1447987594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987594	16917943	Allele A is associated with increased risk of Malignant Hyperthermia as compared to allele G.	0.25
1445400206	1449160148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449160148	27382027	Allele A is associated with Malignant Hyperthermia as compared to allele G.	0.25
1451677518	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451677518	1451465284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465284	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.	3.5
1451678188	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451678188	1448601968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601968	27967318	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.	2.0
1451678188	1444713578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713578	26020121	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1444703273	1451760997	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451760997	33850298	Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.	2.5
1444703273	1444703265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703265	25801567	Genotypes AC + CC is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.	2.0
1451761240	1451125982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125982	31619748	Allele A is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele G.	-1.75
1451761240	1451760942	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451760942	33850298	Genotypes AG + GG are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.	2.0
1451677736	PA166262221	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262221		Annotation of CPIC Guideline for atorvastatin and SLCO1B1	100
1451677736	1451151642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451151642	32453264	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.	-1.5
1451677736	1451163185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163185	32128760	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.	3.0
1451677736	1451226140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451226140	30595243	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.	-1.5
1451677736	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1451677736	1451390498	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390498	26376374	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-0.875
1451677736	1451390500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390500	30569848	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.5
1451677736	1451390640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390640	27296832	Genotypes CC + CT are not associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to genotype TT.	-1.75
1451677736	1451465304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451465304	34114646	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-2.0
1451677736	1451479880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479880	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	1.375
1451677736	1451480162	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480162	33150478	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.	-1.0
1451677736	1451352267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451352267	25992810	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.	-2.0
1451677736	827810986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810986	21928084	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	-1.5
1451677736	769164520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164520	21243006	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.	-0.25
1451677736	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451677736	1183699594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699594	24263182	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.	3.25
1451677736	1447689782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447689782	26086347	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.	2.5
1451677736	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451677736	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1451677736	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451677736	1451905600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905600	35034348	SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.	2.5
1445401303	1444934979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934979	25410890	Genotypes AG + GG is associated with decreased systolic blood pressure when treated with losartan in people with Essential hypertension as compared to genotype AA.	2.75
1445401296	1444934970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444934970	25410890	Genotypes AG + GG is associated with decreased systolic blood pressure when treated with losartan in people with Essential hypertension as compared to genotype AA.	2.75
1451761248	1451760984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451760984	33850298	Genotypes AC + CC are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.	2.0
1447990846	1444698203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698203	25781442	Genotype TT is associated with decreased risk of Colorectal Neoplasms when exposed to Antiinflammatory agents, non-steroids and aspirin as compared to genotypes AA + AT.	2.0
1447990846	1449169613	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449169613	29425227	Allele T is not associated with risk of Colorectal Neoplasms in people not taking aspirin as compared to allele A.	-1.0
1448100067	769169630	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169630	17602083	Genotype GG is associated with increased response to interferons in people with Carcinoma, Renal Cell as compared to genotypes CC + CG.	2.75
1448100194	1447983254	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983254	27091189	Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.	0.0
1448602108	1448602052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602052	28178031	Genotype CC is associated with increased exposure to cotinine in people with Tobacco Use Disorder as compared to genotypes AA + AC.	1.5
1448602108	1448602071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448602071	28178031	Genotype CC is associated with decreased clearance of cotinine in people with Tobacco Use Disorder as compared to genotypes AA + AC.	1.5
1448613237	1448613179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613179	28112181	Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	2.25
1448613363	1448613321	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613321	26962983	Genotype TT is associated with low on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to genotypes CC + CT.	3.25
1451678626	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451678626	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678626	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451678460	PA166262281	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262281		Annotation of CPIC Guideline for pravastatin and SLCO1B1	100
1451678460	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451678460	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451678460	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
1451678460	1451341160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451341160	19833260	SLCO1B1 *5 is not associated with increased risk of Drug Toxicity when treated with pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.	-1.5
1451678112	PA166262241	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262241		Annotation of CPIC Guideline for lovastatin and SLCO1B1	100
1451678112	1448601968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448601968	27967318	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.	2.0
1451678112	1444713578	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444713578	26020121	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.	1.5
1451678210	PA166262261	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262261		Annotation of CPIC Guideline for pitavastatin and SLCO1B1	100
1451678210	1451674520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674520	23556337	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.	1.0
1451678210	1451674400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451674400	17460607	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.	1.5
1448427005	1448426989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448426989	27089937	Genotype AA is associated with increased risk of Diarrhea and Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	3.25
1448427005	1447948459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948459	25554506	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	-0.25
1448633833	1448633821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633821	28389387	CYP2B6 *6/*6 is associated with decreased risk of drug-induced liver injury when treated with ethambutol, isoniazid, pyrazinamide and rifampin in men with Tuberculosis as compared to CYP2B6 *1/*1.	2.25
1448634522	1448634256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634256	28589365	Allele T is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	2.5
1448258741	1448258721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448258721	27533851	Genotypes CT + TT are associated with increased likelihood of Thrombocytopenia when treated with sorafenib as compared to genotype CC.	2.5
1448423682	1448423474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448423474	26194362	Genotype AG is associated with increased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype GG.	3.0
1448423689	1448423491	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448423491	26194362	Genotypes AG + GG is associated with decreased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	2.5
1448423696	1448423504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448423504	26194362	Genotype AA is associated with decreased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.	2.5
1448423703	1448423485	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448423485	26194362	Genotype GG is associated with increased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AA + AG.	2.5
1448428937	1448428823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428823	27798726	Allele T is associated with increased dose of allopurinol or febuxostat in people with Gout as compared to allele C.	1.75
1448428944	1448428814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428814	27798726	Allele G is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele A.	2.25
1448522754	1448522650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522650	27670765	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.	3.0
1448522760	1448522676	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522676	27670765	Genotypes AG + GG are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	3.5
1448525745	1296598677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296598677	22211527	HLA-A *11:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	0.25
1448525745	1448525667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525667	27888155	HLA-A *11:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.0
1448525750	1448525656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525656	27888155	HLA-B *38:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.	3.75
1448525763	1448525698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525698	27888155	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	3.25
1448525768	1444935593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935593	25495410	HLA-C *08:01 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.	3.5
1448525768	981859091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859091	20235791	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	2.5
1448526098	1448526058	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448526058	27958380	Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	2.75
1448530595	1448530372	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530372	27747372	Genotypes GT + TT are associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	2.5
1448600720	1448598925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448598925	28171547	Genotypes CC + CT is associated with increased response to ivacaftor in children with Cystic Fibrosis as compared to genotype TT.	2.5
1448427833	1448427775	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448427775	27241063	Genotype AA is associated with increased response to granisetron in people with Nausea and Vomiting as compared to genotypes AG + GG.	2.0
1448427833	1449170236	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170236	29177570	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.	-1.5
1448532002	1448531994	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531994	27400856	Allele T is associated with increased risk of Neutropenia when treated with clozapine in people with Schizophrenia as compared to allele C.	0.0
1448532196	1448532160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448532160	27893182	Genotypes AA + AG is associated with increased exposure to rivaroxaban in healthy individuals as compared to genotype GG.	0.0
1448532202	1448531977	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531977	27893182	Genotype CC is associated with decreased exposure to Dabigatran in healthy individuals as compared to genotypes AA + AC.	0.0
1448532211	1448532176	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448532176	27893182	Genotype CC is associated with decreased exposure to rivaroxaban in healthy individuals as compared to genotypes AA + AC.	0.0
1449565416	1449565399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565399	26658169	Genotype GT is associated with increased risk of Drug Toxicity due to phenytoin in children.	0.25
1449565422	1449565410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565410	26658169	Genotype AG is associated with increased risk of Drug Toxicity due to phenytoin in children.	0.25
1449575674	1449575519	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575519	29769267	Allele del is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.	0.0
1449575645	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1449575645	1449575556	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575556	29769267	Allele T is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele G.	0.0
1448525458	1448525418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525418	27779245	Genotype GG is associated with increased risk of gastrointestinal toxicity when treated with levodopa in people with Parkinson Disease as compared to genotypes G/del + del/del.	2.0
1448615589	1448614816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614816	28391407	Allele A is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele G.	3.0
1448615589	1448614825	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614825	28391407	Allele G is not associated with likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele A.	-1.5
1448617146	1184747390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747390	20504240	Genotype AT is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.	2.5
1448615575	981344455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344455	22990067	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.75
1448615575	981478621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478621	23150151	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.	-2.0
1448615575	981802753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981802753	23056288	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	-0.5
1448615575	981843559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843559	22624833	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	-2.0
1448615575	982037849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037849	21831410	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	-1.5
1448615575	1043766070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043766070	20650435	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.	-2.0
1448615575	1183705612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705612	24535487	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.	-1.5
1448615575	1184168867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168867	23726091	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-1.75
1448615575	1184470351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470351	22045970	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.	-2.25
1448615575	1184472517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472517	22285300	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	-1.75
1448615575	1444607054	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607054	25542807	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1448615575	1444607066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444607066	25542807	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	2.75
1448615575	1444702924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444702924	25850030	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.	2.25
1448615575	1448119339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119339	27380588	Genotype AG is associated with increased platelet reactivity when treated with clopidogrel as compared to genotypes AA + GG.	2.5
1448615575	1448258646	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448258646	25060201	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	-0.25
1448615575	1448615253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448615253	28378058	Allele A is not associated with platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to allele G.	-0.5
1448615575	1448633764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633764	28135763	Allele A is not associated with response to clopidogrel as compared to allele G.	-1.75
1448615575	1448994492	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994492	28358842	Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.	2.0
1448615575	1449187765	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449187765	29397568	Allele A is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	-1.5
1448525452	1448525426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525426	27779245	Genotype TT is associated with increased risk of gastrointestinal toxicity when treated with levodopa in people with Parkinson Disease as compared to genotypes CC + CT.	2.0
1448525452	1450935096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935096	30794329	Genotypes CT + TT are associated with increased likelihood of Hallucinations due to levodopa in people with Parkinson Disease as compared to genotype CC.	3.0
1448613032	1448613020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613020	28331852	Genotype AA is associated with increased exposure to sulindac in healthy individuals as compared to genotype GG.	1.0
1448613038	1448613027	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613027	28331852	Genotype GG is associated with increased exposure to sulindac in healthy individuals as compared to genotype AA.	1.0
1448616855	1448616190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616190	28347776	Genotypes CT + TT are associated with increased likelihood of Hyperbilirubinemia when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	2.75
1451510621	1451510520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451510520	34043814	Genotypes AA + AG are associated with decreased risk of Thromboembolism when treated with rivaroxaban as compared to genotype GG.	3.0
1451510641	1451510561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451510561	34043814	Genotypes CT + TT are associated with decreased risk of Hemorrhage when treated with apixaban as compared to genotype CC.	2.75
1448605577	1448605559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448605559	28323125	HLA-B *35:05:01 is associated with increased risk of drug-induced liver injury when treated with minocycline in people with.	3.5
1448613011	1448613000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613000	28332719	Genotype CC is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CT + TT.	2.0
1448615153	1448615091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448615091	27747906	Genotype AA is associated with increased Recurrence free survival when treated with anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.	2.0
1448634786	1448634771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634771	28351962	Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to genotype AA.	3.5
1450374895	1450374888	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374888	26810137	Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	3.5
1448602934	1448602927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602927	26911666	Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.0
1448612776	1448612748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612748	28222112	Allele G is associated with increased response to Antihypertensives in people with Hypertension as compared to allele T.	0.0
1449166396	1183620980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183620980	15976989	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.	2.25
1449166396	1449166382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166382	29377228	Genotypes AA + AG are associated with increased concentrations of omeprazole in infants with Gastroesophageal Reflux as compared to genotype GG.	1.75
1448428030	981755178	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755178	19390945	Genotypes AG + GG are not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.	-1.5
1448428030	981843841	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981843841	18221820	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	-1.5
1448428030	1448428015	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428015	25869015	Genotype GG is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.	1.75
1448635217	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1448635217	PA166184613	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166184613		Annotation of DPWG Guideline for mercaptopurine and NUDT15	100
1448635217	1447945037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945037	26878724	NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .	1.625
1448635217	1448576430	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576430	28146264	NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1448635217	1448624581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624581	28445187	NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.25
1448635217	1448624596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624596	28445187	NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	2.0
1448635217	1448635204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635204	28659275	NUDT15 *1/*2 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.	0.25
1448635217	1449750346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750346	29967377	NUDT15 *1/*3 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 + *1/*5 + *1/*6 + *1/*2.	0.0
1448635217	1449750363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750363	29967377	NUDT15 *3/*3 + *3/*5 is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*1.	0.0
1451510840	1451510773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451510773	33768542	Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.	1.25
1448604251	1451401904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451401904	33454797	Allele A is not associated with concentrations of methadone as compared to allele C.	-1.0
1448604251	1448104442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104442	27284701	Genotype AC is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + CC.	This annotation is not used for clinical annotation scoring. Association only found as part of diplotype analysis, not at the individual variant level.
1448604251	1447520720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520720	25456329	Genotype CC is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AC + CT.	1.0
1448624874	1450112816	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450112816	30487649	Genotypes AG + GG are associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	0.0
1448624874	1448624837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624837	27981573	Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	0.0
1448624874	1450117776	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450117776	30487649	Allele G is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele A.	0.0
1447949171	1447949113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949113	26927288	HLA-B *15:13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	3.75
1448267381	1448267343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267343	27740732	Genotypes AA + AG is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype GG.	2.25
1448267389	1448267332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267332	27740732	Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AA + AC.	2.25
1448267397	1448267319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267319	27740732	Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.	2.25
1448617231	1448617223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617223	27995340	Allele A is associated with increased risk of Death when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to allele G.	2.5
1448635185	1448635132	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635132	28659275	Allele del is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele GGAGTC.	0.25
1448635612	1448635477	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635477	28689274	GSTM1 null is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV as compared to GSTM1 non-null.	2.5
1448635612	1448635546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635546	28689274	GSTM1 null is not associated with likelihood of Toxic liver disease when treated with nevirapine in women with HIV as compared to GSTM1 non-null.	-1.5
1449190330	1449190265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190265	19298317	Genotype CC is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to genotypes CT + TT.	2.75
1449190330	1451123400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451123400	31510971	Allele C is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele T.	-1.0
1449190339	1449190258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190258	19298317	Genotypes CT + TT is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to genotype CC.	2.25
1449190339	1451122941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451122941	31510971	Allele C is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele T.	-0.5
1448635585	982047684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047684	23774940	Allele T is associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele G.	0.0
1448635585	827848806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827848806	21824325	Allele T is not associated with increased risk of toxicity when treated with nevirapine in people with HIV Infections as compared to allele G.	-1.25
1448635585	1185002120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002120	21505298	Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.	0.0
1448635585	1448635492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635492	28689274	Allele T is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele G.	0.0
1448635585	1448635562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448635562	28689274	Allele T is not associated with likelihood of Toxic liver disease when treated with nevirapine in women with HIV Infections as compared to allele G.	-1.5
1448635585	1449155771	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155771	28819312	Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and dress syndrome when treated with nevirapine in people with HIV Infections as compared to allele G.	0.0
1448632697	1448632687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448632687	28090653	Genotypes CG + GG are associated with increased risk of Toxic liver disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.5
1448632697	1449154606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449154606	28744905	Genotypes CG + GG are associated with increased risk of Toxic liver disease when treated with asparaginase, cyclophosphamide, daunorubicin, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.5
1451510921	1451510886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451510886	33768542	HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.	1.25
1447981289	827923267	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923267	22676193	Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG.	3.25
1447982825	1447948883	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447948883	26906009	Allele A is associated with decreased expression of NT5C1A in HEK 293 cells.	0.0
1447982825	1447948887	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447948887	26906009	Allele A is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele G.	0.0
1447983050	1447982893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982893	25732572	Allele T is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	3.25
1447986967	1447986948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447986948	26946962	Genotypes GT + TT is associated with increased likelihood of Hyperglycemia when treated with atenolol in people with Essential hypertension as compared to genotype GG.	2.5
1447986986	1183684634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684634	22981363	Allele T is associated with increased metabolism of sulfinpyrazone as compared to allele C.	1.5
1447952921	1447680404	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680404	26774523	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CG + GG.	1.5
1447953109	1447519640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519640	26536870	Genotype AA is associated with decreased bone density when treated with exemestane and letrozole in women with Breast Neoplasms as compared to genotypes AG + GG.	2.5
1447953109	1447519863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519863	26536870	Genotype AA is associated with decreased bone density when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.	2.5
1447953130	1447645086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447645086	26607661	Genotypes CC + CT are associated with increased likelihood of Cough when treated with enalapril in people with Essential hypertension as compared to genotype TT.	3.25
1447953250	1447680268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680268	26757307	Genotypes AC + CT is associated with increased response to modafinil in people with Narcolepsy as compared to genotype CC.	2.0
1447960436	1043859264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859264	17541557	Genotype CC is associated with decreased dose of catecholamines in people with Coronary Artery Disease as compared to genotypes CG + GG.	1.5
1447960509	827921552	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827921552	20124171	Genotype AA is associated with increased risk of recurrence of breast cancer when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.	3.25
1447960509	1183682011	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682011	24019753	Genotype AG is not associated with risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.	-0.0
1447960745	827849253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849253	21810746	Allele T is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele C.	3.25
1447960775	827849270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849270	21810746	Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C.	3.25
1447961115	981848290	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848290	23508266	Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
1447961122	981848315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848315	23508266	Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
1447962603	1183703328	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703328	24448396	Genotypes CT + TT is associated with increased metabolism of nicotine in CYP2A6 normal, but not reduced, metabolizers as compared to genotype CC.	1.5
1447962649	827677387	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827677387	12181437	Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	0.0
1447962843	982046419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046419	16321621	Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.	1.75
1447962843	982047285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047285	19891551	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.	2.25
1447964136	981344890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344890	22506592	Genotype CC is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CT + TT.	0.0
1447964136	981352373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352373	22012226	Genotype TT is not associated with increased likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis as compared to genotypes CC + CT.	-1.5
1447964136	981417460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417460	20819434	Genotype TT is associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CC + CT.	2.0
1447964136	981475570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475570	19761367	Allele C is not associated with likelihood of Hepatitis, Toxic when treated with isoniazid in people with Tuberculosis as compared to allele T.	-1.5
1447964136	981476373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476373	22335459	Genotype CC is not associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CT + TT.	-1.75
1447964136	981476519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476519	12668988	Genotype CC is associated with increased likelihood of Hepatitis, Toxic when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CT + TT.	3.25
1447964136	981477658	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477658	21753138	Allele C is not associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis as compared to allele T.	-1.5
1447964136	981939621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981939621	19891553	Allele T is not associated with risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
1447964136	1183702624	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702624	23875638	Genotype CC is not associated with risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
1447964136	1183702646	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702646	23394127	Genotype CC is not associated with risk of hepatotoxicity when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	-1.5
1447964136	1450932101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932101	30458875	Genotypes CT + TT are associated with decreased risk of Toxic liver disease due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype CC.	0.75
1447964136	1447944619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944619	24465778	Genotype CT is not associated with risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype CC.	-2.0
1447964136	1448994974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994974	28799976	Genotypes CT + TT are associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype CC.	3.25
1447964136	1449002691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002691	29036176	Allele T is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C.	-1.5
1447964136	981417440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417440	20860460	CYP2E1 *1A/*5A is not associated with Hepatitis, Toxic when treated with Drugs For Treatment Of Tuberculosis.	-1.25
1447964136	981476514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476514	16677176	CYP2E1 *5B is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis.	-1.5
1447964136	1447944368	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944368	24637014	CYP2E1 *1A/*5B is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to CYP2E1 *1A/*1A.	2.75
1447963096	982023118	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982023118	23677058	Allele C is associated with increased clearance of busulfan as compared to allele A.	0.0
1447964236	1450376849	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376849	22486528	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	0.25
1447964236	1447964201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964201	25989180	Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	0.0
1447964236	1450180321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450180321	29230023	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.	-1.0
1447964236	1450376612	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376612	28871191	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1447964236	1450376824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376824	22851411	Allele G is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	2.75
1447964236	1450376870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376870	25229170	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1447964236	1450376929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376929	20157310	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.0
1447987005	1183634180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634180	24080498	Genotypes AA + AG are not associated with plasma concentration of efavirenz in people with HIV Infections as compared to genotype GG.	-1.25
1447987005	1184473325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473325	23172109	Allele G is associated with decreased metabolism of efavirenz in people with HIV Infections.	2.0
1447987005	1184473329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473329	23172109	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	2.0
1447987005	1184512556	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512556	23173844	Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype AG.	-0.125
1447987030	1184512504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512504	23173844	Genotype GG is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	1.0
1447987045	981501880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501880	23252947	Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C.	1.0
1447987052	981501862	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501862	23252947	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	1.75
1447987059	981501851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501851	23252947	Allele G is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	1.25
1447987066	981501889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501889	23252947	Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	1.5
1447987073	1447984289	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984289	26132489	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	1.5
1447987073	1449161350	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449161350	29232328	Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.	0.0
1447987101	981501734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501734	23252947	Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	1.25
1447987113	1447984307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984307	26132489	Allele T is associated with increased response to bupropion and Drugs used in nicotine dependence in people with Tobacco Use Disorder as compared to allele C.	1.75
1448102470	981477583	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477583	19749757	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	2.0
1448102470	1444705514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705514	21346780	Genotypes CC + CT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.	3.5
1448427398	1448427012	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427012	27139155	Genotype TT is associated with decreased overall survival when treated with bevacizumab in women with Breast Neoplasms as compared to genotypes GG + GT.	3.0
1448427405	1448427025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427025	27139155	Genotype TT is associated with decreased overall survival when treated with bevacizumab in women with Breast Neoplasms as compared to genotypes CC + CT.	2.5
1448522766	1448522661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522661	27670765	Genotypes AG + GG are associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.	3.0
1448522772	1448522700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522700	27670765	Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	2.5
1448522778	1448522689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522689	27670765	Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.	2.0
1448522784	1448522639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522639	27670765	Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes CT + TT.	2.5
1450373755	1450373732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373732	30889042	Allele A is associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to allele G.	2.75
1450373761	1450373696	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373696	30889042	Genotype AA is associated with increased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	2.75
1447987094	981501792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501792	23252947	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.	1.0
1447987094	827824080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827824080	22188362	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	-1.5
1447987094	769257718	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257718	16753003	Allele G is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.	-1.0
1447987094	1448266704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266704	26421491	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	-0.5
1447963234	981706710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981706710	23340505	Allele A is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to allele C.	2.5
1447963234	769164849	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164849	21150907	Allele A is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.	3.0
1447986998	1183623881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183623881	17228018	Genotypes AA + AG are associated with increased risk of severe hearing impairment when treated with cisplatin in men with Testicular Neoplasms as compared to genotype GG.	-2.5
1447986998	1183624561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624561	23065688	Genotypes AG + GG are associated with increased risk of Ototoxicity when treated with cisplatin in children with Medulloblastoma as compared to genotype AA.	2.25
1447986998	1451128202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128202	31666714	Allele G is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele A.	-1.75
1447986998	1448616296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616296	28448657	Allele G is associated with increased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.	2.5
1451510926	1451510891	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451510891	33768542	HLA-DRB1 *07:01:01:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.	0.0
1448099568	1448099557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448099557	26663398	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.	2.5
1448099745	981940080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981940080	18086475	Genotype GG is not associated with increased likelihood of side effects when exposed to antipsychotics in people with Psychotic Disorders as compared to allele del.	-1.5
1448099745	981940087	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981940087	18086475	Genotype GG is associated with increased likelihood of side effects when exposed to antipsychotics as compared to allele del.	1.5
1448099745	982025839	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982025839	18579277	Allele G is not associated with increased risk of Hyperprolactinemia when treated with risperidone in people with Schizophrenia as compared to allele del.	-1.5
1448099745	827807969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807969	20664489	Allele del is associated with increased risk of Weight gain when treated with antipsychotics in people with Schizophrenia as compared to allele G.	1.75
1448099745	827813179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813179	21749219	Allele del is associated with decreased likelihood of sexual dysfunction when treated with antipsychotics in men with Schizophrenia as compared to allele G.	2.75
1448102463	981477615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477615	19749757	Allele A is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	2.0
1448102463	1444705526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705526	21346780	Genotypes AA + AG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.5
1448102490	1444705057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705057	22328925	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AA + AC.	3.0
1448102490	1444876471	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444876471	25287681	Allele C is associated with increased expression of IFNL3 as compared to allele A.	0.0
1448102490	1445206674	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445206674	26186989	Genotypes AC + CC are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	2.0
1448124590	1448123888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448123888	27402191	Genotype AC is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.	2.0
1448124604	1448124596	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124596	27402191	Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.	2.5
1448125853	1448125834	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448125834	27426203	Genotype CC is associated with increased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.	2.0
1448265174	1448265114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265114	25869013	Genotypes AT + TT is associated with increased risk of Hypersensitivity when treated with Antibiotics in people with Infection as compared to genotype AA.	4.0
1448602385	1448602371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602371	27670767	Allele G is associated with decreased risk of Diabetes Mellitus when exposed to atenolol or verapamil in people with Hypertension as compared to allele A.	0.0
1448603291	1448603181	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603181	25558980	Genotypes GT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.	3.0
1449576307	1449576280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576280	29097388	Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C.	0.0
1449576551	1449576503	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576503	28940478	Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.	2.0
1449576557	1449576511	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576511	28940478	UGT1A3 *2 is associated with decreased concentrations of montelukast in healthy individuals as compared to UGT1A3 *1/*1.	2.0
1449576566	1449576525	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576525	28940478	Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.	2.0
1449715913	1449715874	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449715874	17192767	Genotype AA is associated with increased likelihood of Respiratory Insufficiency due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.	2.0
1449715919	1449715893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449715893	17192767	Genotype AA is associated with increased likelihood of Respiratory Insufficiency due to fentanyl in people with Pain, Postoperative.	0.0
1449715928	1449715882	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449715882	17192767	Genotype AA is associated with increased likelihood of Respiratory Insufficiency due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.	0.0
1449716035	1449715954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715954	30106255	Allele A is associated with increased response to fentanyl in people with Pain, Postoperative as compared to allele C.	2.75
1449747892	1449163533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163533	29318894	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.	3.0
1449747892	1449747838	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747838	29454235	Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	1.75
1449747954	1449747898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449747898	29539600	CYP3A5 *3/*3 is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	2.0
1449751564	1449750851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750851	30325732	Genotypes CC + CT are associated with increased response to phenazepam in men with Alcohol-Related Disorders as compared to genotype TT.	2.75
1450815160	1450815079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815079	23241943	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1449576572	1449576530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576530	28940478	CYP2C8 *3 is associated with decreased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.	2.0
1449576572	1449576542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576542	28940478	CYP2C8 *4 is associated with increased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.	1.5
1451825200	1451819144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451819144	35710811	Genotype AA is associated with increased likelihood of Erythema when treated with naloxone and oxycodone in people with Pain as compared to genotypes AG + GG.	2.0
1451825220	1451819200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451819200	35710811	Genotype AA is associated with increased likelihood of Vomiting when treated with naloxone and oxycodone in people with Pain as compared to genotypes AG + GG.	3.0
1451825226	1451819240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451819240	35710811	Genotype GG is associated with increased likelihood of Erythema when treated with naloxone and oxycodone in people with Pain as compared to genotypes AA + AG.	2.5
1447954390	1447952261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952261	18722008	Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele C.	2.0
1447954390	1447952771	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952771	20622033	Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele C.	2.0
1447954397	1447952179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952179	21233271	Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	2.0
1447954397	1447952247	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952247	18722008	Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	2.0
1447954397	1447952362	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952362	24836205	Allele A is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	-1.5
1447954397	1447952765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952765	20622033	Allele A is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.	2.0
1447949632	827690011	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827690011	15282200	Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T.	2.5
1447954525	1447954445	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447954445	27005817	Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to genotype AA.	3.0
1447959694	1447959685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959685	27001119	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.	2.5
1447959700	1447959649	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959649	27001119	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.	2.5
1447959717	1447959603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959603	27001119	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.	2.5
1447959724	1447959667	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959667	27001119	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.	2.5
1447960623	1043880431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880431	10594793	Genotypes AC + CC are associated with increased response to losartan in healthy individuals as compared to genotype AA.	1.75
1447960874	769248365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769248365	15122075	Genotype AA is associated with decreased metabolism of tipifarnib as compared to genotypes AG + GG.	1.0
1447962620	769164622	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164622	9860300	Genotype TT is associated with increased spine Bone Mineral Density when treated with conjugated estrogens and medroxyprogesterone as compared to genotype CC.	2.5
1447962768	982046350	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046350	16238680	Genotypes AA + AG are associated with change in HDL-cholesterol when treated with atorvastatin or simvastatin in people with Hypercholesterolemia.	2.25
1447962768	982046413	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046413	19904013	Genotype GG is not associated with increased change in lipid parameters when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	-0.0
1447962855	982046465	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046465	16321621	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.	2.0
1447962874	827695410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827695410	16267764	Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.	2.75
1447962874	1444698605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698605	25752914	CYP2C19 *1/*2 is associated with increased concentrations of nelfinavir in people with Pancreatic Neoplasms as compared to CYP2C19 *1/*1.	1.0
1447962874	1444698677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444698677	25752914	CYP2C19 *1/*2 is associated with decreased metabolism of nelfinavir in people with as compared to CYP2C19 *1/*1.	1.0
1447962927	1447962899	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447962899	17235330	CYP2B6 *27 is associated with decreased expression of CYP2B6 as compared to CYP2B6 *1.	0.0
1447962927	1447962916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447962916	17235330	CYP2B6 *28 is associated with increased exposure to efavirenz in people with HIV as compared to CYP2B6 *1.	0.0
1447963219	981739388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981739388	23353631	Genotypes CC + CG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.25
1447963846	769171457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171457	19247266	Genotype GG is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CC + CG.	2.5
1447963991	769257748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257748	17125969	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.	-1.75
1447963991	769171338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171338	19450124	Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.	2.5
1447963991	769171334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171334	19450124	Allele G is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.	2.75
1447964250	1447964243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964243	25989180	Genotypes CT + TT are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	0.0
1447987080	981501809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501809	23252947	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.	1.0
1448102306	981865142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865142	19448608	Genotype AA is associated with decreased likelihood of Event-Free Survival when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes AG + GG.	2.0
1448102306	1449164377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449164377	28485375	Genotypes AG + GG is associated with increased overall survival when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype AA.	2.0
1448103875	981861777	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861777	19386276	Genotype CC is associated with increased likelihood of Psychotic Disorders due to methamphetamine in men as compared to genotypes CT + TT.	2.25
1448109754	827805742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805742	21900104	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1448109754	1448109338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109338	23441093	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.5
1448257149	1448257121	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257121	27488389	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.75
1448109591	827805788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805788	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1448109591	1448108826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108826	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.0
1447964041	981936634	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981936634	22506592	Genotype TT is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype CC.	3.0
1451511220	1451511160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511160	24908438	Genotype GG is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	1.0
1448101278	981482222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482222	20886544	Allele G is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele C.	1.5
1448101285	1446900225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900225	25798582	Allele G is not associated with risk of drug-induced liver injury when treated with ethambutol, isoniazid, pyrazinamide, rifampin and streptomycin in people with Tuberculosis as compared to allele A.	-1.75
1448101285	1448101155	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448101155	27281183	Genotype AA is associated with increased likelihood of drug-induced liver injury when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AG + GG.	3.25
1448101285	1449002705	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002705	29036176	Allele G is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.	-1.5
1448101408	1447984232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984232	27043265	Genotype CC is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	2.25
1448101408	1448101296	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101296	27193993	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	1.5
1448101408	1448613540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613540	28346059	Genotype CC is associated with decreased risk of Iron Overload when treated with deferasirox in children with Thalassemia as compared to genotypes CT + TT.	2.0
1448101436	1447984241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984241	27043265	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	1.75
1448101436	1448101303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448101303	27193993	Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.	1.5
1448101436	1448613522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613522	28346059	Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.	1.0
1447962661	827677417	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827677417	12181437	Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	0.0
1447962737	982045571	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045571	16103896	Genotype TT is associated with increased response to lovastatin as compared to genotype CT.	2.75
1447963042	769250889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250889	18926547	Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.	2.5
1447963042	613979290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613979290	18855532	Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	2.0
1447963570	1447963466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447963466	26959717	HLA-DRB1 *16:01:01 is associated with increased risk of drug-induced liver injury when treated with flupirtine.	2.5
1447979493	1447979385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979385	24510746	Genotype GG is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CG.	2.0
1447979493	1447979397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979397	24510746	Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CG.	2.5
1447979500	1447979405	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979405	24510746	Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.	3.0
1447979500	1447979415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979415	24510746	Genotype CC is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.	2.5
1447979507	1447964636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964636	27058899	Genotype TT is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.	3.25
1447979507	1447964654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964654	27058899	Genotype TT is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.	2.5
1447979514	1447964663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964663	27058899	Genotype GG is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.	3.25
1447979514	1447964675	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447964675	27058899	Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.	2.25
1447980904	981934278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934278	22162992	Genotype AA is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.	2.0
1447980911	827922492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827922492	22162992	Genotype TT is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.	2.0
1448100326	1447987289	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987289	25935875	Genotype TT is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.	0.0
1448100712	1183684077	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684077	22398969	Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.	2.5
1448101238	981482210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482210	20887379	Allele C is associated with increased likelihood of neuropathy when treated with stavudine in people with HIV Infections as compared to allele T.	2.25
1448101271	981482230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482230	20886544	Allele A is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele T.	2.0
1448102497	1444705107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705107	22328925	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AT + TT.	3.0
1448102543	1444706639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706639	24073221	Allele T is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic.	-1.5
1448102543	1444707745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707745	21145801	Genotypes GT + TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	2.0
1448102666	981502856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502856	20447721	Genotypes AA + AC are associated with decreased risk of Disease Progression when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.5
1448122847	1448122772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448122772	27356304	CYP2C19 *1/*1 is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	2.0
1448122847	1448122820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448122820	27356304	CYP2C19 *1/*2 + *1/*3 are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *2/*2 + *2/*3.	2.0
1448125544	1448125529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125529	25816720	Genotype CT is associated with decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.	2.75
1447963662	981352447	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352447	17148776	Genotype GT is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Lung Neoplasms as compared to genotype GG.	2.5
1447963662	827784406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827784406	21332310	Genotype GG is not associated with increased likelihood of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	-1.25
1447963662	827824152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824152	20035425	Allele T is not associated with increased risk of Drug Toxicity when treated with gefitinib as compared to allele G.	-1.25
1447963662	1447948452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948452	25554506	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	-0.25
1447987235	1447979316	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447979316	26903268	Allele G is associated with decreased concentrations of serotonin in people with Depressive Disorder as compared to allele A.	1.25
1447987235	1447979364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447979364	26903268	Allele G is not associated with response to citalopram and escitalopram in people with Depressive Disorder as compared to allele A.	-1.75
1451516314	1043818258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818258	20376629	CYP2C9 *3 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	1.5
1451516314	1043818268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818268	20376629	CYP2C9 *2 is not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	-1.5
1451516314	1444707589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707589	24224579	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	2.5
1451516314	1444707660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707660	23423913	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	-1.5
1451516314	1444707861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707861	18629445	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	0.0
1451516314	1444708196	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444708196	21110013	CYP2C9 *1/*2 + *2/*2 + *2/*3 + *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	-1.25
1451516314	1448255703	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255703	26984978	CYP2C9 *2 + *3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	-1.25
1451516314	1449747475	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747475	30207196	CYP2C9 *2 + *3 is associated with decreased dose of phenprocoumon in children as compared to CYP2C9 *1.	1.5
1451516314	1451516060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451516060	20833980	CYP2C9 *2 + *3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.	-1.25
1451516314	981934332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934332	15128048	CYP2C9 *2 + *3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	-2.0
1451516314	1444707881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707881	16847664	CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are not associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.	-1.5
1451516314	1043737399	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737399	15536456	CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	2.75
1451516314	1043818092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818092	20020283	CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.	2.5
1447961108	981848305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848305	23508266	Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
1447963860	769171392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171392	19247266	Genotype CC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CT + TT.	2.5
1447964142	1447964109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964109	27035618	Genotypes CTT/del + del/del are associated with increased response to cysteamine in people with Cystic Fibrosis as compared to genotype CTT/CTT.	2.25
1447964278	1447964271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964271	25989180	Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.5
1447964324	981478221	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478221	20602614	Allele C is associated with increased risk of intolerance of aspirin in people with Asthma as compared to allele G.	2.25
1447983184	1447948893	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447948893	26906009	Allele T is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele C.	0.0
1448098793	1447676983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676983	26590194	Allele C is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	0.0
1448102432	1444705532	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705532	21346780	Genotypes CG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
1448102432	1444705538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705538	21346780	Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.	3.0
1448102477	981477606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477606	19749757	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	2.0
1448102477	1444705084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705084	22328925	Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CG + GG.	3.0
1448112196	1448112188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112188	27098059	Genotypes GG + GT are associated with increased concentrations of tamoxifen-n-glucuronide in women with Breast Neoplasms as compared to genotype TT.	2.0
1448112196	1447980797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980797	22047493	UGT1A4 *2 + *3a are not associated with decreased clearance of tamoxifen as compared to UGT1A4 *1a.	-0.25
1183679785	827849313	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849313	21810746	Allele G is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele A.	3.25
1447964187	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1447964187	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1447964187	1447964156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964156	25698453	Allele A is associated with response to ivacaftor in Cystic Fibrosis as compared to allele G.	0.25
1447964187	1447984881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984881	26324139	Genotype AG is associated with response to ivacaftor in women with Cystic Fibrosis.	0.25
1447964187	1447984897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984897	26070913	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	1.75
1447964187	1447986312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447986312	26070913	Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.	1.75
1447964187	1449191039	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191039	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447964187	1449192603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192603	28419121	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1451516322	1444707906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707906	15742978	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451516322	982046660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046660	21110013	CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon as compared to CYP2C9 *1.	1.75
1451516322	1027521661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1027521661	15128047	CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1.	1.5
1449296314	1449296299	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296299	29317847	Allele A is associated with decreased metabolism of folic acid.	0.125
1451809140	981859096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859096	17509004	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.	2.75
1451809140	981859101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859101	17509004	HLA-B *15:02:01 is not associated with increased risk of maculopapular exanthema when treated with antiepileptics or carbamazepine in Epilepsy.	-1.25
1451809140	1446902379	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902379	25647819	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.	3.25
1451809140	1451507720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451507720	34488672	HLA-B *15:02:01 is associated with increased risk of Maculopapular Exanthema when treated with antiepileptics in people with Epilepsy.	2.5
1451809140	1451783980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451783980	34175889	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with antiepileptics.	4.0
1447946212	1447521024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521024	26554440	Genotypes AA + AG is associated with increased systolic blood pressure when exposed to regadenoson as compared to genotype GG.	2.25
1447946212	1447521058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521058	26554440	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with regadenoson as compared to genotype GG.	2.25
1447946219	1447675109	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675109	25778468	Genotype AG is associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.	2.25
1447946226	1447675096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675096	25778468	Allele T is associated with increased severity of mucositis when treated with methotrexate in people with Osteosarcoma as compared to allele C.	2.25
1447946233	1447675063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675063	25778468	Genotype CC is associated with increased risk of Neoplasm Metastasis when treated with methotrexate in people with Osteosarcoma as compared to genotype AC.	2.25
1447960468	981794008	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794008	20665488	Genotype AC is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + CC.	2.0
1447960468	1183960654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960654	21642870	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	-1.5
1447960554	982048062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048062	17885551	Genotypes AA + GG are associated with increased response to ramipril in people with Hypertension as compared to genotype AG.	2.25
1447960566	982048078	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048078	17885551	Genotypes CC + TT are associated with increased response to ramipril in people with Hypertension as compared to genotype CT.	2.75
1447960649	1043858597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858597	8952600	Genotype AA is associated with decreased response to perindopril in people with Hypertension as compared to genotypes AC + CC.	1.5
1447960850	769246433	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769246433	19841321	Allele G are associated with increased overall survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.	1.5
1447961178	981345612	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345612	22486600	Genotype CC is associated with increased severity of Drug Toxicity when exposed to cetuximab, irinotecan, leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotype AC.	2.25
1447961337	981750299	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981750299	19747927	Allele A is associated with Psychotic Disorders when exposed to methamphetamine in people with Substance-Related Disorders as compared to allele G.	3.0
1447962751	982046355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046355	16238680	Genotypes CC + CT are associated with change in HDL-cholesterol when treated with atorvastatin or simvastatin in people with Hypercholesterolemia.	2.25
1447962751	982046361	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046361	18430057	Genotype CC is associated with increased response to simvastatin in people with Coronary Disease as compared to genotype TT.	2.0
1447962751	982046402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046402	19904013	Genotype CC is not associated with increased change in lipid parameters when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.	-0.0
1447963255	981417734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417734	23007406	Genotypes CC + CT are associated with increased risk of relapse when treated with asparaginase, dexamethasone or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	0.0
1447981070	827919981	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919981	22594510	Genotype GG is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype AA.	2.5
1447981158	827923229	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923229	22676193	Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG.	3.25
1447981207	827923235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923235	22676193	Genotype AA is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AT + TT.	3.25
1447981222	827923238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923238	22676193	Genotype TT is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CT.	3.25
1447981250	827923241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923241	22676193	Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	3.25
1447981259	827923244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923244	22676193	Genotype AA is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	3.25
1448423795	1448423731	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423731	26282453	Allele C is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	3.0
1448426938	1448426917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426917	27020477	HLA-DRB1 *04:01:01 is associated with increased response to interferon beta-1a in people with Multiple Sclerosis.	2.75
1448426944	1448426926	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426926	27020477	HLA-B *15:01:01:01 is associated with decreased response to interferon beta-1a in people with Multiple Sclerosis.	2.75
1447981089	827919998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919998	22594510	Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	2.5
1447981089	1183491593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491593	23337555	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	-2.0
1447981089	1183682052	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682052	23559864	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.	-1.5
1447981089	1184510410	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510410	23842101	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.	-1.75
1451511240	1451511164	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511164	24908438	Genotypes CT + TT are associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	0.0
1451511240	1451547383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451547383	27987364	Genotype TT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	1.25
1451511240	1451615343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615343	33501733	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.0
1448109812	827805812	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805812	21900104	Allele G is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.	0.0
1448109812	1448108873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108873	23441093	Allele G is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.	-1.0
1447982582	1444703466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703466	25676789	Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.	0.0
1447982582	1447982552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447982552	26810134	Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.	3.0
1447982582	1450375524	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375524	30924126	Allele T is associated with decreased response to allopurinol as compared to allele G.	2.5
1447981268	827923247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923247	22676193	Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AA + AG.	3.25
1447986938	981844200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981844200	23327575	CYP3A5 *1/*3 is associated with increased metabolism of midazolam in people with Neoplasms as compared to CYP3A5 *3/*3.	2.0
1447986938	1184165572	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184165572	24214410	CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of midazolam in people with Gastrointestinal Neoplasms as compared to CYP3A5 *3/*3.	0.125
1447986938	1447979521	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447979521	25979262	CYP3A5 *1/*1 is associated with increased metabolism of midazolam in fetal liver microsomes as compared to CYP3A5 *3/*3.	0.0
1447986938	1449005313	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005313	28986606	CYP3A5 *3 is not associated with metabolism of midazolam in healthy individuals as compared to CYP3A5 *1.	-0.125
1447987087	981501801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501801	23252947	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.	1.0
1447987264	1447987245	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987245	27143689	Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel in men with Prostatic Neoplasms as compared to allele C.	0.0
1448099430	1447676969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676969	26590194	Allele G is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	0.0
1448099454	1444843306	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843306	25872459	Genotype AG is associated with decreased metabolism of sulfasalazine in healthy individuals.	0.125
1448100187	1447983338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983338	27091189	Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.	0.0
1448103832	981862115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862115	19132693	Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A.	2.5
1448103839	981862125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862125	19132693	Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A.	2.5
1448103846	769171551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171551	19219602	Genotype AA is associated with increased progression-free survival and overall survival when treated with capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.	2.75
1448103882	981501169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501169	19968402	Genotype AA is associated with decreased stop reaction time when treated with amphetamine in healthy individuals as compared to genotypes AG + GG.	1.75
1448103889	981502804	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502804	20084518	Allele G is associated with risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	1.5
1448103910	769173189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769173189	20220551	Genotype TT is associated with decreased risk of withdrawal effects when treated with methadone in people with Heroin Dependence as compared to genotypes CC + CT.	2.25
1448103942	982022345	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022345	20485328	Allele G is associated with decreased likelihood of Alcoholism due to ethanol as compared to allele A.	2.5
1448103942	982022355	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022355	20485328	Allele G is not associated with likelihood of Alcoholism due to ethanol as compared to allele A.	-2.0
1448103949	982022325	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022325	20485328	Allele T is associated with decreased likelihood of Alcoholism due to ethanol as compared to allele C.	2.5
1448103949	982022335	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022335	20485328	Allele T is not associated with likelihood of Alcoholism due to ethanol as compared to allele C.	-2.0
1448103956	982022310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022310	20485328	Allele G is associated with increased likelihood of Cocaine-Related Disorders due to cocaine as compared to allele C.	2.0
1448103956	982022318	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022318	20485328	Allele G is not associated with likelihood of Cocaine-Related Disorders due to cocaine as compared to allele C.	-1.0
1448103963	981502270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502270	20523342	Genotypes GT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	1.5
1448103973	981502261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502261	20523342	Genotypes AC + CC are associated with decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.	1.5
1448104005	981502125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981502125	20580759	Allele A is associated with increased response to clozapine in people with Schizophrenia as compared to allele T.	3.0
1448104022	981482057	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482057	21094359	Genotypes CT + TT are associated with decreased plasma level of high-sensitivity C-reactive protein when treated with rosuvastatin in people with Coronary Disease as compared to genotype CC.	2.75
1448104029	981482079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482079	21094359	Genotypes CC + CT are associated with decreased plasma level of high-sensitivity C-reactive protein when treated with rosuvastatin in people with Coronary Disease as compared to genotype TT.	2.75
1448104036	769164853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164853	21150907	Allele C is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele T.	3.0
1448112147	1448112136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448112136	27234217	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.	1.5
1448256864	1448256760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256760	27498158	Genotype GG is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	3.5
1448256872	1448256774	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256774	27498158	Genotypes GT + TT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.5
1448256881	1448256793	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256793	27498158	Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1448256881	1448256834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256834	27498158	Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.5
1447963011	769170560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170560	18685564	Allele A is associated with increased risk of Neutropenia when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	3.0
1447963011	1447680940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680940	26237184	Genotype CC is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AC.	-2.75
1447963011	1447682366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682366	26405151	Genotype CC is not associated with risk of Myelosuppression when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.	-1.25
1447963011	1449749288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449749288	28418010	Allele A is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.25
1448109578	1448109361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109361	23441093	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-2.0
1448109578	827805824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805824	21900104	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1448109598	827805803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805803	21900104	Allele G is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele T.	0.0
1448109598	1448108966	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448108966	23441093	Allele G is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele T.	-1.0
1448109605	827805873	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805873	21900104	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1448109605	1448109288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109288	23441093	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.5
1448109802	827805725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805725	21900104	Allele G is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele T.	0.0
1448109802	1448109152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109152	23441093	Allele G is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele T.	-1.25
1451511344	1451511320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451511320	24927955	Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	1.5
1447982688	1447982652	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447982652	27111237	Allele A is associated with decreased affinity to exemestane in human liver cytosol as compared to allele G.	0.0
1447982723	1447982629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447982629	26331942	Genotype TT is associated with increased response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CC + CT.	1.75
1447982732	1444707079	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707079	25919112	Genotype GG is associated with increased response to corticosteroids in people with Asthma as compared to genotypes GT + TT.	2.0
1447952936	1447951874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951874	25649181	Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G.	3.0
1447953072	1447944264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944264	26189437	Allele C is associated with increased discontinuation of capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele G.	3.0
1447953116	1447813766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813766	25563748	Genotype GG is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes AA + AG.	1.75
1447953123	1447678000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678000	26729200	Genotypes CC + CG are associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to genotype GG.	2.75
1447953162	1447681659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681659	26788534	Allele A is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele T.	1.375
1447953171	1447677992	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677992	26729200	Genotypes AG + GG are associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to genotype AA.	2.25
1447953178	1447677984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677984	26729200	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype GG.	2.25
1447953192	1447679358	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447679358	25642918	Genotype CG is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CC + GG.	2.75
1447953212	1447677963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447677963	26729200	Genotypes GG + GT are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype TT.	2.25
1447953263	1447682328	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682328	26792136	Genotype CG is associated with decreased severity of Sleep Disorders when treated with methadone in men with Opioid-Related Disorders as compared to genotype CC.	0.0
1447953270	1447682320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682320	26792136	Genotype AA is associated with decreased severity of Sleep Disorders when treated with methadone in men with Opioid-Related Disorders as compared to genotypes AG + GG.	0.0
1447953277	1447519869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519869	26536870	Genotype AA is associated with decreased bone density when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.	2.5
1447953311	1447949461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949461	26905411	Genotype GG is associated with increased response to risperidone in people with as compared to genotypes AA + AG.	0.0
1447953328	1447520580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520580	26521987	Genotype AA is associated with increased response to cyclophosphamide, dexamethasone and thalidomide in people with Multiple Myeloma as compared to genotypes AG + GG.	2.0
1447953328	1447520596	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520596	26521987	Genotype AA is associated with increased risk of Neutropenia when treated with lenalidomide in people with Multiple Myeloma as compared to genotypes AG + GG.	2.0
1447953340	1447520587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520587	26521987	Genotype AA is associated with increased response to thalidomide in people with Multiple Myeloma as compared to genotypes AC + CC.	2.0
1447953340	1447520604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520604	26521987	Genotype AA is associated with increased risk of Neutropenia when treated with lenalidomide in people with Multiple Myeloma as compared to genotypes AC + CC.	1.5
1447953347	1447949447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949447	26905411	Genotype CC is associated with increased response to risperidone in people with as compared to genotypes CG + GG.	1.75
1447959508	1447959457	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959457	27019981	Genotype GG is associated with increased risk of Toxic liver disease when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.	3.0
1447959731	1447959629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959629	27001119	Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.	2.5
1447959738	1447959676	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959676	27001119	Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.	2.5
1447960211	982046476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046476	22761669	Genotype GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	0.0
1447961194	981478670	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478670	22471906	Genotypes CT + TT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype CC.	1.75
1447962703	982045604	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045604	16103896	Genotype AG is associated with increased response to fluvastatin as compared to genotype AA.	2.75
1447963070	982026055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026055	23692359	Allele T is associated with increased BMI when exposed to nicotine in tobacco users as compared to allele C.	0.0
1447964331	769164820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164820	20860465	Genotype TT is associated with better survival outcome when treated with fluorouracil in people with Stomach Neoplasms as compared to genotype GG.	3.0
1447982739	1447958955	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958955	26310775	Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.	0.0
1447982674	1447982661	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447982661	27111237	Allele T is associated with decreased affinity to exemestane in human liver cytosol as compared to allele C.	0.0
1447982754	1447958909	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958909	26310775	Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.	0.0
1447982761	1447958868	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958868	26310775	Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.	0.0
1447983170	1447520814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520814	26524290	Allele C is associated with increased response to topiramate as compared to genotype AA.	0.0
1447983177	982029098	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982029098	9435198	Allele G is associated with decreased metabolism of mephenytoin as compared to allele A.	0.5
1447986872	1444930282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930282	26010901	Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G.	3.0
1447986872	1447814223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814223	26833182	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	0.0
1447986902	1447814214	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814214	26833182	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele C.	0.0
1447986910	1447814229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814229	26833182	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	0.0
1447986925	1447814206	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814206	26833182	Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.	0.0
1448103860	981864962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981864962	19303909	Genotypes CT + TT are associated with increased likelihood of increased pulse rate due to opioids in people with withdrawal from opioid addiction as compared to genotype CC.	1.5
1448103928	981502716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502716	20222094	Genotype CC is associated with increased risk of Toxic liver disease when treated with flucloxacillin.	3.5
1448104043	981488655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981488655	21095016	Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.	1.75
1448104050	981488647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981488647	21095016	Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele G.	1.75
1447991854	1447991775	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991775	16551910	CYP2D6 *1/*1xN is associated with increased likelihood of Vomiting when treated with dolasetron in people with Postoperative Nausea and Vomiting.	1.5
1447991854	1447991787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991787	16551910	CYP2D6 *3 + *4 + *5 + *6 are not associated with likelihood of Vomiting when treated with dolasetron in people with Postoperative Nausea and Vomiting.	-0.25
1447991854	1447991815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991815	16551910	CYP2D6 *1 + *2 + *35 are not associated with risk of Vomiting when treated with dolasetron in people with Postoperative Nausea and Vomiting.	-1.5
1447991854	1447991835	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991835	16551910	CYP2D6 *9 + *10 + *41 are not associated with likelihood of Vomiting when treated with dolasetron in people with Postoperative Nausea and Vomiting.	-0.25
1447983144	1447945718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945718	26727275	Genotypes AA + AC is associated with decreased bone density when treated with valproic acid in people with Epilepsy as compared to genotype CC.	1.5
1447983151	1184747888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747888	25171760	Allele A is associated with increased risk of Stroke when treated with chlorthalidone in people with Hypertension.	0.0
1447983163	1446907744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446907744	26426212	Allele T is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotype CC.	2.75
982045465	981755899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755899	22616655	Genotype AA is associated with increased mean AUC (area under curve) prothrombin time when exposed to warfarin in men as compared to genotype GG.	1.5
1447946114	1447521111	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447521111	26556041	Allele A is associated with increased response to imiquimod in people with Carcinoma, Basal Cell as compared to allele T.	2.5
1447946169	1446906141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446906141	25515945	Genotype AG is associated with increased concentrations of voriconazole in people with Mycoses as compared to genotype GG.	2.0
1447960484	1183690860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690860	22706620	Genotypes CC + CT are associated with increased response to enalapril in people with Hypertension as compared to genotype TT.	2.0
1447960502	981785661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785661	18538445	Genotype GG is associated with decreased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.	1.75
1447960582	1183690169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183690169	22763757	Genotype CC is associated with increased risk of bone marrow toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.	2.5
1447960656	1144135755	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1144135755	15743363	Genotype AA is associated with increased response to losartan in people with Liver Cirrhosis as compared to genotypes AC + CC.	2.0
1447960663	982047936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047936	11849656	Genotype GG is associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotypes AA + AG.	2.0
1447960716	827847677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827847677	22082652	Genotype CC is associated with increased likelihood of lower nevirapine plasma concentrations when treated with nevirapine in people with HIV Infections as compared to genotypes CT + TT.	2.0
1447960731	827849293	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849293	21810746	Allele C is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele T.	3.25
1447962710	982045510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045510	16103896	Genotypes CC + CT are associated with increased response to fluvastatin as compared to genotype TT.	2.75
1447962710	982045517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045517	16103896	Genotype CT is associated with increased response to simvastatin as compared to genotype TT.	2.75
1447962723	982045523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045523	16103896	Genotype TT is not associated with response to pravastatin as compared to genotypes CC + CT.	-1.75
1447962723	982046080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046080	16115483	Genotypes CT + TT are associated with increased response to pravastatin in people with Hypercholesterolemia as compared to genotype CC.	2.0
1447963247	981479989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981479989	23166513	Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G.	3.0
1447979532	827698754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698754	21521021	Genotypes AG + GG are associated with increased metabolism of tegafur as compared to genotype AA.	0.125
1447979532	827698762	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827698762	21521021	Genotypes AG + GG are associated with increased expression of CYP2A6 in human liver samples.	0.0
1447979541	827698736	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698736	21521021	Genotypes AA + AG are associated with increased metabolism of tegafur as compared to genotype GG.	1.0
1447979541	827698744	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827698744	21521021	Genotypes AA + AG are associated with increased expression of CYP2A6 in human liver samples.	0.0
1447979548	827698774	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827698774	21521021	Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.	0.0
1447979548	827698783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698783	21521021	Genotypes AC + CC are associated with decreased metabolism of tegafur as compared to genotype AA.	0.125
1447981410	981237807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237807	22838950	Genotypes GT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	1.75
1447981430	981237819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237819	22838950	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CG + GG.	1.75
1447981440	981237767	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237767	22838950	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	3.25
1447981457	981237777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237777	22838950	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	2.75
1447981465	981237795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237795	22838950	Genotypes AG + GG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	0.0
1447981474	981237788	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237788	22838950	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	1.75
1447983137	1184747903	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747903	25171760	Allele C is associated with decreased risk of Stroke when treated with amlodipine in people with Hypertension.	0.0
1447987124	769180491	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769180491	21386754	Genotype AA is associated with decreased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype GG.	0.0
1447987124	1447984377	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447984377	25753936	Allele A is associated with increased likelihood of Muscular Diseases and Myalgia unspecified when exposed to atorvastatin or simvastatin in people with Cardiovascular Diseases as compared to allele G.	2.5
1447987124	1448613079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613079	27839692	Allele A is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele G.	-2.0
1448123001	1448122968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448122968	27338075	Genotypes AA + AG are associated with increased response to losartan in people with Hypertension as compared to genotype GG.	1.75
1448123060	1448123026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123026	27377818	CYP2C9 *1/*3 + *1/*13 are associated with decreased clearance of zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1448123060	1448123039	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123039	27377818	CYP2C9 *1/*3 + *1/*13 are associated with increased exposure to zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1448124426	1448124260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124260	27399166	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AA + AG.	2.75
1448265017	1448265008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265008	25534433	Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.5
1448266396	1448266389	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266389	26129906	Genotype AG is associated with decreased clearance of risperidone in people with as compared to genotype GG.	2.0
1448266413	1448266403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266403	26129906	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression or Substance-Related Disorders as compared to genotypes CT + TT.	2.0
1448266429	1448266420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266420	26129906	Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to genotypes CT + TT.	1.5
1451662923	1451663084	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451663084	15592323	Allele T is associated with decreased metabolism of coumarin as compared to allele C.	0.0
1451662923	827827685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827685	12325023	CYP2A6 *12 is associated with decreased metabolism of coumarin as compared to CYP2A6 *1.	0.125
1451662923	1184813326	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184813326	16679388	CYP2A6 *9/*9 (assigned as poor metabolizers phenotype) is associated with decreased enzyme activity of CYP2D6 when assayed with coumarin in liver cells.	0.0
1451662923	1448110357	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448110357	27339126	CYP2A6 *1/*4 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.	0.0
1451662923	1448110367	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448110367	27339126	CYP2A6 *1/*9 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.	0.0
1451662923	1451662880	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451662880	11237731	CYP2A6 *7 is associated with decreased metabolism of coumarin or nicotine as compared to CYP2A6 *1.	0.0
1451662923	827827654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827827654	15993850	CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1.	This annotation is not used for clinical annotation scoring. In vitro study
1451662923	1451664980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451664980	17220563	CYP2A6 *1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	1.5
1451662923	1451665040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451665040	17220563	CYP2A6 *4/*7 + *4/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.	This annotation is not used for clinical annotation scoring. VA 1451664980 is from the same paper and has been attached to the same clinical annotations.
1451662923	827699021	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699021	15900015	CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.	0.0
1451662923	1448104199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104199	11278503	CYP2A6 *6 is associated with decreased metabolism of coumarin as compared to CYP2A6 *1.	This annotation is not used for clinical annotation scoring. In vitro study
1451662923	981202028	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981202028	11779172	CYP2A6 *4/*4 + *4/*10 are associated with decreased metabolism of coumarin as compared to CYP2A6 *1/*1.	1.5
1451662923	827699426	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699426	12844137	CYP2A6 *4/*9 + *9/*9 are associated with decreased enzyme activity of CYP2A6 when assayed with coumarin.	0.0
1451662923	827699384	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699384	14583682	CYP2A6 *4/*9 is associated with decreased enzyme activity of CYP2A6 when assayed with coumarin.	0.0
1447960204	1043859244	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043859244	16027735	Genotype GG is associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes CC + CG.	2.5
1447963598	1447963506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447963506	26959717	HLA-DQB1 *05:02:01 is associated with increased risk of drug-induced liver injury when treated with flupirtine.	2.5
1447980691	827815712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815712	21902501	Allele C is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele T.	2.5
1447980691	827815792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815792	21902501	Allele C is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele T.	2.0
1447983909	1447979910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447979910	25953735	CYP2D6 *4 + *5 are associated with increased exposure to tolperisone in healthy individuals as compared to CYP2D6 *1.	1.5
1447983940	1447980873	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980873	26762380	Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC.	1.5
1447983949	1447814198	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447814198	26833182	Allele G is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele A.	0.0
1448531661	1448435399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448435399	27845419	Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1448567797	1448567704	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448567704	23974086	Genotype CC are not associated with clearance of sirolimus in human liver microsomes as compared to genotypes CT + TT.	-0.0
1448567797	1448567743	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567743	23974086	Genotypes CT + TT are associated with decreased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotype CC.	1.5
1450930440	1450827231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827231	28692418	Genotype GG is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes AA + AG.	2.25
1450931410	1450931199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931199	29667742	Allele C is associated with increased risk of Alcoholism due to ethanol as compared to allele T.	0.0
1447960257	981478172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478172	18050121	Allele T is not associated with increased response to photodynamic therapy in people with Macular Degeneration as compared to allele C.	-1.25
1447960257	981478561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478561	18292785	Genotype TT is associated with decreased response to photodynamic therapy in people with Macular Degeneration as compared to genotypes CC + CT.	1.5
1447960257	1447680594	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680594	26780119	Genotype TT is not associated with response to photodynamic therapy in people with Macular Degeneration as compared to genotype CC.	-1.5
1448567803	1448567692	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448567692	23974086	CYP3A4 *1/*22 + *22/*22 are associated with decreased clearance of sirolimus in human liver microsomes as compared to CYP3A4 *1/*1.	0.0
1448567803	1448567714	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567714	23974086	CYP3A4 *1/*22 + *22/*22 are not associated with metabolism of sirolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-1.0
1447963078	981482246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482246	20886544	Allele A is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.0
1447963078	981754819	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981754819	19706762	Allele A is associated with decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	3.5
1447963078	982026035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026035	23692359	Allele G is associated with increased plasma level of nicotine in tobacco users as compared to allele A.	2.25
1447963078	1450813176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813176	22046326	Allele A is not associated with risk of Tobacco Use Disorder due to nicotine as compared to allele G.	-2.0
1447963078	1450813521	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813521	22046326	Allele A is not associated with severity of Tobacco Use Disorder due to nicotine as compared to allele G.	-2.0
1447963078	1444930252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444930252	26010901	Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.	-1.5
1447963078	1451120340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120340	31402126	Genotype GG is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AA + AG.	2.5
1447963078	1451135780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135780	31796940	Allele A is not associated with likelihood of cessation of nicotine in people with Tobacco Use Disorder as compared to allele G.	-1.5
1451810680	1451799880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451799880	34302046	Allele G is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	0.0
1448098376	1448098367	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448098367	25944848	Genotypes CC + CT are associated with decreased metabolism of antiepileptics in people with Bipolar Disorder and Psychotic Disorders as compared to genotype TT.	0.0
1448099118	1183704875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704875	24420746	Genotype AC is associated with increased clearance of rifampin in healthy individuals as compared to genotype CC.	0.125
1448102644	981502840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502840	20447721	Genotypes AC + CC are associated with decreased likelihood of Drug Toxicity when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.5
1448107270	1448107222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448107222	25813999	Allele T is associated with increased Ocular Hypertension when treated with triamcinolone in people with Retinal Diseases as compared to allele C.	1.25
1448107277	1448107249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448107249	25813999	Allele G is associated with increased Ocular Hypertension when treated with triamcinolone in people with Retinal Diseases as compared to allele C.	2.25
1448263285	1448263072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263072	26771271	Genotype AA is associated with increased severity of Hypotension when treated with fentanyl, propofol, remifentanil or sevoflurane as compared to genotype CC.	3.0
1447963604	982028438	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982028438	16740595	Allele A is associated with increased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele G.	2.5
1447963644	982025734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982025734	17092969	Genotype GT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes GG + TT.	0.25
1447963688	769170550	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769170550	17290447	Genotype AA is associated with decreased risk of Substance-Related Disorders when exposed to cannabinoids as compared to genotypes AC + CC.	2.75
1447963713	982015286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015286	17541984	Allele G is associated with increased likelihood of obesity when treated with olanzapine in people with Schizophrenia as compared to allele A.	1.5
1447990902	1446900395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446900395	26002049	Genotypes AA + AC are associated with increased response to enalapril in people with Hypertension as compared to genotype CC.	2.75
1448097768	1183960611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960611	21642870	Genotype AA is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	3.0
1448097775	1183960616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960616	21642870	Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.	3.0
1448098213	1448097971	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097971	24193570	Genotype AA is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AG + GG.	2.5
1448605477	1448605339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448605339	26644205	Genotype AA is associated with increased risk of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Transplantation as compared to genotypes AG + GG.	3.75
1448605477	1448605357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448605357	26644205	Genotypes AA + AG are associated with increased concentrations of glucose in people with Transplantation as compared to genotype GG.	2.0
1448613108	1448613098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613098	27839692	HLA-DRB1 *04:06:01 is associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to HLA-DRB1 *01:01:01.	3.5
1447963979	981859171	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981859171	21747585	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	-1.75
1447963979	981954797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981954797	18812236	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	-1.75
1447963979	827804237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827804237	21391884	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-0.5
1447963979	769257608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769257608	16386926	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.	-1.5
1447963979	769257749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769257749	17125969	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.	-1.75
1447963979	769145998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769145998	20417680	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	-1.5
1447963979	769171341	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171341	19450124	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.	2.25
1447987204	1447987173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987173	27139004	Allele C is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele G.	3.25
1447979749	PA166152939	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166152939		Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	100
1447979749	1449192069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192069	29126871	Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	1.0
1447979749	1449192108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192108	28606620	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.5
1447979749	1449192508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192508	27898234	Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	3.0
1447979749	1449192520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192520	27898234	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	-1.5
1447979749	1449192588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192588	25981758	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1449192632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192632	27805836	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.75
1447979749	1449192645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192645	27805836	Genotype del/del is not associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	-1.25
1447979749	1449192689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192689	29327948	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.75
1447979749	1449192749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192749	29451946	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.	2.5
1447979749	1449191920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191920	28325531	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.25
1447979749	1449192352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192352	27334259	Allele del is associated with response to ivacaftor / lumacaftor.	0.25
1447979749	1446903870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903870	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.0
1447979749	1446903951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903951	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1446903975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903975	24973281	Genotype CTT/del is not associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	-0.375
1447979749	1448107229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107229	27298017	Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	2.5
1447980699	827815721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815721	21902501	Allele A is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele G.	2.5
1447980699	827815801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815801	21902501	Allele A is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G.	2.0
1447980706	827815744	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815744	21902501	Allele A is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele G.	2.5
1447980713	827815753	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815753	21902501	Allele G is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele A.	2.5
1447980713	827815821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815821	21902501	Allele A is associated with decreased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G.	2.0
1447980724	827816704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816704	21961650	Genotype TT is associated with increased response to lithium in people with Bipolar Disorder as compared to genotype CC.	2.5
1447980740	827816621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816621	21961650	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG.	3.0
1447980753	827816744	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816744	21961650	Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CT + TT.	2.5
1447980767	827819994	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827819994	22026923	Genotype AA is associated with decreased dose of somatropin recombinant in people with growth hormone deficiency as compared to genotype CC.	2.0
1447980857	1447980818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980818	22047493	UGT1A4 *3a is associated with increased clearance of testosterone as compared to UGT1A4 *1a.	1.5
1447980875	827823698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823698	22111602	Genotypes AA + AG are associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotype GG.	1.5
1447980897	1447980773	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980773	27007499	Genotypes AA + AG are associated with response to curcumin and ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	0.0
1447990296	1444694774	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444694774	24699530	Allele C is associated with decreased expression of TRAF1 in HapMap LCLs as compared to allele G.	0.0
1447990296	1444694778	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444694778	24699530	Allele C is associated with increased expression of MIRLET7I in HapMap LCLs as compared to allele G.	0.0
1447990296	1444694783	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444694783	24699530	Allele C is associated with increased sensitivity to endoxifen HapMal LCLs as compared to allele G.	0.0
1447991104	1447991084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447991084	24717838	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of brivaracetam in healthy individuals as compared to CYP2C19 *1/*1.	0.125
1448112052	1448112033	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448112033	27324805	Genotype CC is associated with increased risk of agitation when treated with citalopram in children with Anxiety Disorders or Depressive Disorder, Major as compared to genotypes CG + GG.	1.75
1448256890	1448256813	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256813	27498158	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	0.0
1448256898	1448256820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256820	27498158	Genotypes CG + GG are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	0.0
1448276370	1448276358	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276358	27780742	Genotype CC is associated with decreased response to rituximab in people with Vasculitis as compared to genotypes CT + TT.	2.5
1448428918	1448428843	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428843	27798726	Allele T is associated with decreased dose of allopurinol or febuxostat in people with Gout as compared to allele C.	2.25
1447980849	1451414900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451414900	32483200	UGT1A4 *1b is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to UGT1A4 *1a.	1.25
1447980849	1447980777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980777	22047493	UGT1A4 *2 + *3a are associated with decreased clearance of lamotrigine as compared to UGT1A4 *1a.	This annotation is not used for clinical annotation scoring. In vitro assay
1447963821	769170846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170846	19207029	Genotype CG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	2.0
1447963829	769170844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170844	19207029	Genotype GG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes GT + TT.	2.0
1447964002	769171364	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171364	19622037	Genotype CG is associated with increased Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	1.25
1447964164	982046398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046398	19904013	Genotype GG is associated with decreased oxidative stress when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	1.0
1447989777	982010177	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010177	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype CC.	1.75
1447989796	982010181	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010181	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype TT.	1.25
1447989803	827813655	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813655	21487324	Genotypes AG + GG are associated with decreased likelihood of survival when treated with fluorouracil in people with Pancreatic Neoplasms as compared to genotype AA.	2.5
1448101213	981483837	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483837	20854418	Genotype AG is associated with increased response to nicotine in people with daily smoking as compared to genotype GG.	1.25
1448258734	1448258707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448258707	27533851	Genotypes AG + GG are associated with decreased likelihood of Diarrhea when treated with sorafenib as compared to genotype AA.	3.0
1448259025	1448258953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448258953	20630084	Allele T is associated with increased risk of Hypertension when treated with sorafenib as compared to genotype AA.	2.5
1448259025	1448258961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448258961	20630084	Allele T is associated with increased risk of hand-foot syndrome when treated with sorafenib as compared to genotype AA.	2.5
1448260752	1448260710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260710	27527109	HLA-B *51:01:01 is associated with increased risk of Drug Toxicity when treated with clindamycin.	3.75
1447989732	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989732	1449575578	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575578	29769267	Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.	0.0
1447989732	1448125041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125041	24648345	Allele A is not associated with activity of DPYD when assayed with fluorouracil as compared to allele C.	-0.0
1447989732	1449575614	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449575614	29769267	Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.	0.0
1447989739	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989739	1450960027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450960027	9865912	Genotype AC is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Breast Neoplasms as compared to genotype CC.	0.25
1447989739	1447945441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945441	26846104	Genotype CC is not associated with Drug Toxicity when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.	-1.5
1447953199	1447681351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681351	25710119	Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.	1.5
1447953354	1447675704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447675704	25748439	Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	2.75
1447960352	1183634055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634055	21636554	Genotype AG is associated with decreased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	2.75
1447963674	982015306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015306	17233643	Allele A is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele G.	0.0
1447963798	827864092	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864092	19119263	Genotype CT is not associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype CC.	-1.5
1447963798	827864109	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864109	19119263	Genotype CT is associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype CC.	2.0
1448262537	1448262522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262522	27213804	Genotypes CT + TT is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	3.0
1447979561	827698727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698727	21521021	CYP2A6 *4 is associated with decreased metabolism of tegafur.	1.0
1447979561	827824614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824614	19921195	CYP2A6 *1 is associated with increased plasma fluorouracil when treated with tegafur in people with Neoplasms.	1.5
1447979561	1183703449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703449	19052543	CYP2A6 *1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9 is associated with increased area under the plasma concentration-time curve of tegafur in people with Neoplasms as compared to CYP2A6 *1/*1.	1.0
1447979561	1451216480	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451216480	12042667	CYP2A6 *11 is associated with decreased catalytic activity of CYP2A6 when assayed with tegafur as compared to CYP2A6 *1.	0.0
1447979561	827699021	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699021	15900015	CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.	0.0
1447979561	827699058	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827699058	15900015	CYP2A6 *18 is associated with decreased catalytic activity of CYP2A6 when assayed with coumarin or tegafur as compared to CYP2A6 *1.	0.0
1447979561	827698683	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698683	21326246	CYP2A6 *1/*1 is associated with increased metabolism of tegafur in people with biliary tract neoplasms as compared to CYP2A6 *1/*10 + *1/*4 + *1/*7 + *1/*9 + *4/*9 + *7/*10 + *7/*9 + *9/*9.	0.125
1447979561	827700537	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827700537	18380793	CYP2A6 *4/*4 + *4/*7 + *7/*7 are associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1/*1.	2.25
1447979561	827700554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827700554	18380793	CYP2A6 *4/*9 + *7/*9 + *9/*9 are not associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1/*1.	-0.75
1447979561	827700577	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827700577	18212800	CYP2A6 *1/*4 + *4/*4 + *4/*7 + *4/*9 are associated with decreased metabolism of tegafur in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2A6 *1/*1 + *1/*7 + *1/*9 + *7/*7 + *7/*9.	1.0
1447979561	827698809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698809	21521021	CYP2A6 *46 is associated with increased metabolism of tegafur.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from the same paper.
1447979561	827698827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827698827	12042667	CYP2A6 *4 is associated with decreased metabolism of tegafur in people with Stomach Neoplasms.	0.125
1447979561	1451216440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451216440	12042667	CYP2A6 *11/*4 is associated with decreased metabolism of tegafur in people with Stomach Neoplasms as compared to CYP2A6 *1/*1.	0.125
1447989784	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989784	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1447989784	827823468	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823468	19530960	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	2.0
1447989784	1448119085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448119085	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
1447989784	1448120697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448120697	19473056	Genotype CT is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	-1.5
1447989784	1448122949	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448122949	20803296	Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele C.	2.0
1447989784	1448124454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124454	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1447989784	1448255378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255378	26603945	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1447989784	1448262687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262687	24923815	Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1447989784	1450373074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373074	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
1447989671	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989671	1450957700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957700	10071185	Allele del is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to allele G.	0.125
1447989671	1450960647	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960647	9439663	Genotypes G/del + del/del are associated with decreased activity of DPYD as compared to genotype GG.	0.0
1447989671	1448124998	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448124998	24648345	Allele del is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1447989678	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989678	1450958000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450958000	10071185	Genotype del/del is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype ATGA/ATGA.	0.125
1447989678	1448125015	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448125015	24648345	Allele del is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele ATGA.	0.0
1447989706	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989706	1450957760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957760	10071185	Allele A is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to allele G.	0.125
1447989706	1450960680	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960680	9439663	Allele A is associated with decreased activity of DPYD as compared to allele G.	0.0
1447989706	1450960685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960685	9439663	Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.	0.0
1447989706	1444699974	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444699974	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.	0.0
1447989723	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1447989723	1450957900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450957900	10071185	Genotype AA is associated with decreased Purine-Pyrimidine Metabolism, Inborn Errors as compared to genotype CC.	0.125
1447989723	1444700075	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444700075	24648345	Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.	0.0
1451829900	1451821080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451821080	35697190	Genotype GG is associated with decreased concentrations of buprenorphine in people with Opioid-Related Disorders as compared to genotypes AA + AG.	2.0
1451832220	1451821000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451821000	35697190	Genotype CC is associated with decreased concentrations of buprenorphine in people with Opioid-Related Disorders as compared to genotype CT.	This annotation is not used for clinical annotation scoring. rs7439366 was not in Hardy-Weinberg equilibrium.
1447960245	981785693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785693	18538445	Genotype CC is associated with decreased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	1.75
1447960245	981785702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981785702	18538445	Genotype CC is associated with decreased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	2.25
1447960245	981794132	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794132	20665488	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.	-1.5
1447963227	981706681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981706681	23340505	Allele A is associated with increased risk of Death due to cocaine in people with Cocaine-Related Disorders as compared to allele C.	3.0
1447963227	769164857	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164857	21150907	Genotype AA is not associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to genotype CC.	-1.5
1447963227	769164845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164845	21150907	Allele A is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.	3.0
1447963432	769169358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169358	14643574	Genotype GG is associated with decreased risk of Stroke when treated with Ace Inhibitors, Plain in people with Hypertension as compared to genotypes AA + AG.	2.5
1447964123	981240102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240102	19891553	Allele A is associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	2.5
1447964123	981240145	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981240145	19891553	Allele A is associated with decreased transcription of NAT2 (as determined in luciferase reporter assays) as compared to allele T.	0.0
1447964123	981240151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981240151	19891553	Genotype AT is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype TT.	2.25
1447964264	1447964257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964257	25989180	Genotypes CC + CG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	2.5
1448256091	1448256063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256063	27452984	Genotypes CT + TT is associated with decreased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1448256091	1448256083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256083	27452984	Genotypes CT + TT is associated with decreased likelihood of dose reduction when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.75
1448266177	1448266141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266141	27714501	Genotype GG is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.	3.0
1448266177	1448266158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266158	26632884	Genotype GG is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.	2.5
1448266177	1448266167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266167	22992578	Genotype GG is not associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes CC + CG.	-1.5
1448423763	1448423725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423725	26282453	Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	3.0
1448423788	1448423713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423713	26282453	Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.	3.0
1448424039	1448424016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448424016	26927285	Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G.	1.375
1448431545	1448431519	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431519	26223945	Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	2.5
1448431545	1448624188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624188	28550460	Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.	-1.5
1448431545	1449559870	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449559870	29737521	Allele T is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele C.	0.0
1447953029	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1447953029	1447673606	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447673606	9334205	Allele T is associated with increased sensitivity to caffeine or halothane as compared to allele C.	0.0
1447953029	1447674751	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447674751	9497245	Genotype CT is associated with sensitivity to caffeine or halothane in muscle.	0.0
1447953029	1446900671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900671	25658027	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447953029	1447948695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948695	16244001	Genotype CT is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine and volatile anesthetics as compared to genotype CC.	0.0
1447953029	1447952837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952837	9138151	Genotype CT is associated with increased risk of Malignant Hyperthermia as compared to genotype CC.	0.25
1447953029	1447960961	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447960961	25989378	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447953029	1447987348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987348	16917943	Allele T is associated with increased risk of Malignant Hyperthermia as compared to allele C.	0.25
1447990050	1185234819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234819	12668920	Genotype CC is not associated with increased response to rivastigmine in people with Lewy Body Disease as compared to genotype TT.	-0.25
1447990050	1185234844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234844	12668920	Genotype CT is associated with increased response to rivastigmine in people with Lewy Body Disease as compared to genotype TT.	1.5
1447990050	1185234906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234906	25376930	Genotypes CT + TT is associated with decreased response to rivastigmine in people with Alzheimer Disease as compared to genotype CC.	3.0
1447990050	1185234957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234957	25376930	Genotypes CT + TT is associated with decreased response to memantine and rivastigmine in people with Alzheimer Disease as compared to genotype CC.	2.0
1447990050	1185235073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235073	18780301	Genotype TT is not associated with response to rivastigmine in people with Alzheimer Disease as compared to genotypes CC + CT.	-1.25
1447990050	1185235569	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235569	17047484	Genotype CC is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CT + TT.	1.5
1448097405	1448097395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448097395	27110128	Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.	2.25
1448097600	1185000982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000982	17058217	Genotype CC is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.	3.5
1448099125	1183704865	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704865	24420746	Genotype GG is associated with decreased clearance of rifampin in healthy individuals as compared to genotypes AA + AG.	0.125
1448256689	1448256681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448256681	27500523	Allele C is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele T.	0.0
1448266663	1448266657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266657	27587472	Allele T is associated with increased response to hmg coa reductase inhibitors as compared to allele C.	0.0
1448266838	1448266710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266710	26421491	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	-0.5
1448266838	1448266807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266807	26421491	Genotype AA is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	1.5
1448526040	1451679300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451679300	34910759	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.	-2.0
1448526040	1448526016	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448526016	27958381	Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	3.5
1447963063	1183509048	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183509048	23936393	Genotype CT is associated with increased expression of FKBP5 when exposed to gemcitabine as compared to genotype CC.	0.0
1447963063	1183516888	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183516888	23936393	Genotype CT is associated with increased expression of NR3C1 when exposed to gemcitabine as compared to genotype CC.	0.0
1447964091	982046527	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046527	19802823	Genotypes CC + CT are associated with decreased risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1447980968	1447980951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447980951	26977146	Genotypes AA + AG are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	1.25
1447983057	1447982869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982869	25732572	Allele C is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.75
1447983064	1447982881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982881	25732572	Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.75
1447983818	981238217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981238217	22909202	Genotype GG is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.	2.5
1448098947	981501842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501842	23252947	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.	1.0
1448262901	1448262853	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262853	27632229	Genotypes CT + TT are associated with decreased international normalized ratio variability (inr-var) when treated with warfarin as compared to genotype CC.	2.5
1448262908	1448262863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262863	27632229	Allele G is associated with increased international normalized ratio variability (inr-var) when treated with warfarin as compared to allele C.	3.0
1447960179	982047262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047262	22543981	Genotype GG is associated with increased risk of emergency department and hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AA + AG.	1.5
1447960218	1183685485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183685485	19033450	Genotype AA is associated with decreased metabolism of voriconazole in healthy individuals as compared to genotype GG.	1.0
1447960225	1043858918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858918	19444285	Genotypes AA + AG are associated with increased response to nifedipine in people with Hypertension as compared to genotype GG.	2.75
1447960387	1183633726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633726	21636554	Genotypes AG + GG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	3.5
1447960403	1183634035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634035	21636554	Genotypes AG + GG are associated with increased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.75
1447960599	1043858602	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858602	8952600	Genotype AA is associated with increased response to nitrendipine in people with Hypertension as compared to genotypes AC + CC.	2.0
1447960795	827849329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849329	21810746	Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C.	3.25
1447960803	827849339	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827849339	21810746	Allele G is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele T.	3.25
1447961322	981861862	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861862	19482054	Allele C is associated with increased likelihood of Psychotic Disorders due to methamphetamine as compared to allele T.	2.75
1448432217	1448432137	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448432137	27503580	Genotypes AA + AG is associated with decreased progression-free survival when treated with bevacizumab in people with Colorectal Neoplasms as compared to genotype GG.	3.0
1449191564	1449191184	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191184	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191574	1449191154	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191154	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191643	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191643	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191643	1449191133	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191133	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191649	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191649	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191649	1449191103	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191103	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191664	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191664	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191664	1449191073	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191073	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191682	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191682	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191682	1449191108	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191108	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191682	1449192081	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192081	29279204	Allele T is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
1447961371	769180270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769180270	20859243	Allele T is associated with decreased metabolism of catecholamines and metformin as compared to allele C.	1.5
1447961389	1184168890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168890	24733007	Genotypes CT + TT is associated with decreased likelihood of abstinance when treated with nicotine in smokers as compared to genotype CC.	3.5
1447961389	1184168898	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168898	24733007	Genotypes CT + TT is associated with decreased likelihood of abstinance when treated with nicotine in smokers as compared to genotype CC.	2.5
1447963004	827923097	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923097	18576903	Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.	1.0
1447963049	1043761183	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043761183	19023160	Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome.	1.25
1447963442	769169620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169620	15073101	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.	2.5
1449191708	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191708	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191708	1449190985	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449190985	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191722	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191722	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191722	1449191029	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191029	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447963458	981477503	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477503	15604153	Genotype CG is associated with increased response to corticosteroids in children with Asthma as compared to genotype CC.	2.5
1447963681	982015311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015311	17233643	Allele C is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele A.	1.5
1447964010	1184471413	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471413	19659438	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	1.5
1447964025	981344347	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344347	19686464	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.	0.25
1447964025	981934278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981934278	22162992	Genotype AA is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.	2.0
1447964025	1449002661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002661	29036176	Allele A is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele G.	-1.5
1449191734	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191734	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191734	1449191049	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191049	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447982712	1447958994	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958994	26310775	Allele A is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele G.	0.0
1449191670	1449191024	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191024	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191676	1449191226	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191226	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191698	1449191058	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191058	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191752	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191752	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191752	1449191098	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191098	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191716	1449191194	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191194	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191728	1449191142	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191142	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1447990192	1185235045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235045	18780301	Genotype TT is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CC + CT.	1.75
1447990224	981785580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981785580	18538445	Genotype CC is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	-1.25
1447990224	1183960639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960639	21642870	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	-1.5
1447990224	1184175245	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175245	20226083	Genotype AC is associated with increased response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	1.75
1447990224	1184175360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175360	18483375	Genotype AC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.	1.75
1448101220	981483844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483844	20854418	Allele C is associated with increased response to nicotine in people with daily smoking as compared to allele A.	1.25
1448101220	613977142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/613977142	19290018	Allele C is not associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	-1.0
1448101260	981482265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482265	20886544	Allele C is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.	2.0
1448103818	981865025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865025	19076153	Genotypes GG + GT are associated with increased risk of Death when treated with amlodipine, Dihydropyridine derivatives or nifedipine in people with Hypertension as compared to genotype TT.	0.0
1448256718	1448256493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256493	22736425	Genotype CC is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.	2.25
1448256734	1448256709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448256709	27010727	Genotypes AG + GG are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype AA.	0.0
1448264356	1448264230	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264230	27666425	HLA-DRB1 *04:03:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.5
1448422839	1448422782	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422782	27160286	Genotypes AG + GG are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.	2.5
1448422846	1448422795	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422795	27160286	Genotype GG are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.	2.5
1448109612	827805860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805860	21900104	Allele C is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.	0.0
1448109612	1448109054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109054	23441093	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.	-1.25
1447949639	827690019	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827690019	15282200	Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T.	3.0
1451810960	1451787287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451787287	34175889	CYP2C9 *3 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin.	0.0
1447963182	982017500	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982017500	23649425	Allele A is associated with decreased transport of cefotaxime as compared to allele T.	0.0
1447963182	982017795	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982017795	23649425	Genotype AT is associated with decreased clearance of cefotaxime in healthy individuals as compared to genotype TT.	1.5
1447963701	827690120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827690120	17434921	Genotype CT is associated with increased risk of Endometrial Neoplasms when treated with tamoxifen in people with Breast Neoplasms as compared to genotype TT.	2.0
1447983217	1447983204	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447983204	27114598	Allele T is associated with increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	3.0
1448262915	1448262871	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262871	27632229	Allele C is associated with increased international normalized ratio variability (inr-var) when treated with warfarin as compared to allele T.	2.0
1448423436	1448423402	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423402	25963335	Genotype AA is associated with decreased response to zileuton in people with Asthma as compared to genotypes AG + GG.	2.5
1448427972	1448427727	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427727	27378793	Allele G is associated with increased risk of suicide when treated with antidepressants in people with Depressive Disorder as compared to allele T.	2.75
1448428108	1448428045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428045	27272046	Genotype CT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype TT.	3.0
1448428117	1448428058	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428058	27272046	Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT.	3.0
1448428124	1448428070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428070	27272046	Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype GG.	3.0
1448428151	1448428082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448428082	27272046	Genotypes AG + GG are associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype AA.	3.0
1448428239	1448428115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428115	27353638	CYP2C9 *1/*2 + *1/*3 are associated with decreased dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.	2.5
1448428239	1448428159	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448428159	27353638	CYP2C9 *1/*2 + *1/*3 are not associated with concentrations of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.	-1.0
1448531639	1448435413	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448435413	27845419	Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1448531652	1448432548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448432548	27845419	Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.	1.75
1448531802	1448435420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448435420	27845419	Genotypes CT + TT are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.	1.75
1447960443	982047250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982047250	22543981	Genotype GG is associated with decreased risk of emergency department utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes CC + CG.	1.0
1451666140	1451665860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451665860	19279561	CYP2A6 *1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with increased likelihood of cessation of nicotine as compared to CYP2A6 *1/*1 + *1/*46 + *46/*46 + *1/*9 + *1/*12.	0.0
1447952004	1447951958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951958	22331829	Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC.	0.0
1447959745	1447959640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959640	27001119	Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.	2.5
1447959752	1447959658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959658	27001119	Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.	2.5
1447962730	982045682	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045682	16103896	Genotypes CG + GG are associated with increased response to pravastatin as compared to genotype CC.	2.75
1448097455	1448097420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448097420	27116457	Genotype AA is associated with decreased exposure to irinotecan in people with Colonic Neoplasms as compared to genotypes AG + GG.	2.5
1448098299	1448097926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097926	24193570	Genotype AG is associated with increased severity of Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.	1.5
1448102324	981865177	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981865177	19455410	Allele C is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	2.5
1448102337	981865171	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981865171	19455410	Allele T is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.	2.5
1448102346	827808581	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808581	22100668	Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.	3.25
1448102407	827815370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815370	21491142	Genotypes CC + CT are associated with increased risk of Neurobehavioral Manifestations when exposed to methamphetamine in men with HIV Infections as compared to genotype TT.	1.75
1448102422	1448102319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448102319	27262302	Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.	3.5
1448265266	1448263922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263922	27564082	Genotype CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.	1.75
1448265280	1184168650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184168650	23521149	Genotype GG is not associated with response to ustekinumab in people with Psoriasis as compared to genotype TT.	-1.25
1448265280	1448263941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263941	27564082	Genotype GG is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT.	0.0
1448104059	981481784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481784	20863575	Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.	-1.75
1448104059	827809082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827809082	21127421	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	2.5
1448104059	1450180222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450180222	29230023	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	1.5
1448104059	1450376330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376330	15322419	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	2.0
1448104059	1450376338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376338	19858760	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.25
1448104059	1450376345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376345	23083021	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	-1.5
1448104059	1450376393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376393	20929549	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	-1.5
1448104059	1450376415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376415	22591463	Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	2.25
1448104059	1450376462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376462	29374517	Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	0.0
1448104059	1450376478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376478	29374517	Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	0.0
1448104059	1450376514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376514	23609393	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1448104059	1450376581	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450376581	28871191	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	-1.5
1448102439	981477593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477593	19749757	Allele G is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele A.	2.0
1448102439	1444705070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705070	22328925	Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AG + GG.	3.0
1448102439	1444705502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705502	21346780	Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	3.5
1448102439	1444843596	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843596	23281610	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AG.	3.0
1451834440	1450821004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821004	24950410	Genotype AA is associated with decreased risk of Opioid-Related Disorders due to tramadol as compared to genotypes AG + GG.	3.0
1448423855	1448423843	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423843	27812499	Allele C is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele T.	1.5
1448423855	1449191159	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191159	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1448531857	1448531842	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531842	27937053	Genotype TT is associated with increased response to ticagrelor in healthy individuals as compared to genotype GT.	2.0
1448531862	1448531830	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531830	27937053	Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotypes AG + GG.	1.5
1448531862	1448531836	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531836	27937053	Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotype GG.	1.5
1448531868	1448531852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448531852	27937053	Genotypes GT + TT is associated with decreased response to ticagrelor in healthy individuals as compared to genotype GG.	1.5
1448616179	1448616140	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616140	28406961	TPMT *3A is associated with increased sensitivity to cisplatin in HEI-OC1 cells as compared to TPMT *1.	0.0
1448616179	1448616150	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616150	28406961	TPMT *3A is associated with increased sensitivity to cisplatin in UB/OC1 cells as compared to TPMT *1.	0.0
1448616179	1448616161	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448616161	28406961	TPMT *3A is associated with increased expression of TLR4 when treated with cisplatin in HEI-OC1 cells as compared to TPMT *1.	0.0
1448616865	1448616725	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616725	28347776	Genotype AG is associated with increased likelihood of Hyperbilirubinemia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	2.75
1447953291	1447676042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676042	26222310	Genotype CT is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CC.	2.25
1447953304	608178498	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608178498	18484082	Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.	2.5
1447953304	1447681340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447681340	25710119	Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.	2.0
1447960327	1183633925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633925	21636554	Genotype AG is associated with increased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	3.5
1447960335	981785684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981785684	18538445	Genotype CC is associated with decreased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.25
1447960371	1183633732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633732	21636554	Genotypes CC + CT are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	3.0
1447960379	1183633706	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183633706	21636554	Genotype AT is associated with decreased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	3.0
1447964346	769164824	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164824	20860465	Genotype AA is associated with better survival outcome when treated with fluorouracil in people with Stomach Neoplasms as compared to genotype GG.	3.0
1447984146	981419964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981419964	22909202	Genotype CC is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.	2.5
1447990143	1447947794	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947794	21842338	Genotype AC is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype AA.	1.5
1447990143	1447947806	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947806	21842338	Genotype AC is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype AA.	1.5
1447990143	1447947817	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947817	21842338	Genotype AC is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype AA.	2.0
1447990143	1447947867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947867	16094537	Genotype AC is associated with increased concentrations of irbesartan in people with Essential hypertension as compared to genotype AA.	3.0
1447990143	1447947879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947879	16094537	Genotype AC is not associated with response to irbesartan in people with Essential hypertension as compared to genotype AA.	-2.0
1447990283	1184233708	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233708	24614921	Allele T is associated with increased risk of Drug Toxicity when treated with cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.5
1448097681	1184472289	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184472289	20861217	Allele C is associated with increased catalytic activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2 as compared to allele A.	0.0
1448097711	1183960529	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960529	21642870	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	2.5
1448097718	1183960601	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960601	21642870	Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung.	3.0
1448100861	981239066	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239066	22846425	Allele T is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	2.0
1448100861	981239161	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/981239161	22846425	Allele C is associated with increased activity of TPMT when assayed with purine analogues erythrocytes as compared to allele T.	0.0
1448100874	981755606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755606	19644963	Allele T is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele A.	2.5
1448100887	981478035	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478035	19684603	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	1.0
1448102273	1447989821	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447989821	27023460	CYP2D6 *1/*10 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.	0.0
1448102273	1447989829	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447989829	27023460	CYP2D6 *10/*10 is not associated with inhibition of CYP2D6 when exposed to berberine and coptisine.	-0.0
1448102273	1447989858	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989858	27023460	CYP2D6 *1/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1448102273	1447989908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447989908	27023460	CYP2D6 *10/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1448102273	1447989932	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447989932	27023460	CYP2D6 *1/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.	0.0
1448616900	1448616780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616780	28347776	Genotypes AG + GG are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.	2.75
1450932374	981785397	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785397	23407049	Allele T is not associated with grade 3-4 overall toxicity, febrile neutropenia or hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms.	-1.5
1450932374	827783261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827783261	22045187	Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT.	2.75
1450932374	827811371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811371	18245544	Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT.	2.25
1450932374	827824702	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824702	17700593	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes GT + TT.	1.75
1450932374	769176381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176381	20819423	Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	2.25
1450932374	1183681944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681944	23736036	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
1450932374	1183681970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681970	23736036	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Neoplasms.	3.0
1450932374	1184471982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471982	24167597	Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes GT + TT.	-1.75
1450932374	1448431761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448431761	27864592	Genotype GG is not associated with Drug Toxicity or event-free survival when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes GT + TT.	-1.5
1450932374	1448431856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448431856	27864592	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes GT + TT.	2.5
1450932374	1448522579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448522579	27557140	Genotypes GT + TT is not associated with risk of Drug Toxicity when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotype GG.	-1.25
1450932374	1449161934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161934	27738344	Allele G is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer as compared to allele T.	-1.5
1450932374	1449165566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165566	26967565	Allele G is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-1.75
1448423861	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1448423861	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1448423861	1448423827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448423827	27812499	Allele A is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele G.	1.5
1448423861	1449191118	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191118	23891399	Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1448423861	1449191353	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191353	23891399	Allele C is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	-0.0
1448423861	1449192347	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192347	27334259	Allele G is not associated with response to ivacaftor or lumacaftor in people with Cystic Fibrosis.	-0.25
1448104189	1183702890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702890	16338275	CYP2B6 *6/*6 is associated with increased (S)-methadone plasma levels when treated with methadone as compared to CYP2B6 *1/*1 + *1/*6.	2.0
1448104189	1183702923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702923	17329992	CYP2B6 *6/*6 is associated with increased trough ( R , S )-methadone plasma concentrations when treated with methadone as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .	1.5
1448104189	1447944325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944325	26389554	CYP2B6 *1/*6 + *6/*6 is associated with decreased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1448104189	1447944355	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447944355	26389554	CYP2B6 *1/*4 + *4/*6 is associated with increased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.	1.25
1448104189	1448104418	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104418	27286724	CYP2B6 *6 is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1.	2.0
1448104189	1449266547	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266547	17178267	CYP2B6 *6/*6 is associated with increased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*6.	2.0
1448104189	1451156500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156500	17502774	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.	1.0
1448104189	1451156540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156540	17502774	CYP2B6 *6/*6 is not associated with concentrations of (R)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.	-0.125
1448104189	1451161580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161580	21589866	CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.	0.0
1448104189	1451226268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226268	28723731	CYP2B6 *6/*6 is associated with increased concentrations of methadone as compared to CYP2B6 *1/*1.	2.25
1448104189	1451226300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226300	28723731	CYP2B6 *1/*6 is not associated with concentrations of methadone as compared to CYP2B6 *1/*1.	-0.75
1448104189	1451353463	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451353463	32302325	CYP2B6 *1/*6 + *1/*18 + *6/*6 + *6/*18 are associated with decreased metabolism of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*5 + *1/*7.	1.25
1451868500	1451843527	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451843527	25049040	Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele C.	4.0
1447953102	1447951867	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951867	25649181	Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G.	3.0
1447960191	981345407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981345407	12563174	Genotype GG is associated with increased response to terbutaline in healthy individuals as compared to genotypes CC + CG.	0.5
1447961166	981475158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475158	19201048	Genotype CC is associated with increased response rate (RR) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes CT + TT.	2.25
1447961166	981475166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475166	19201048	Genotype CC is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes CT + TT.	2.25
1447961329	769174083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769174083	20673984	Allele G is associated with increased response to salbutamol in people with Asthma as compared to allele A.	2.5
1447961329	769174165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769174165	20673984	Allele G is not associated with increased response to salbutamol in people with Asthma as compared to allele A.	-1.75
1447961329	769174162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769174162	20673984	Allele G is associated with increased response to salbutamol in people with Asthma as compared to allele A.	0.0
1447964292	1447964285	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447964285	25989180	Genotypes CC + CT are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	2.5
1447983071	1447982856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982856	25732572	Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease or Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	3.25
1447983078	1447982930	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447982930	25732572	Allele A is associated with increased risk of Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	3.25
1448100229	769152906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769152906	18261733	Genotype TT is associated with increased response to pravastatin in people with Vascular Diseases as compared to genotype CC.	0.0
1448102633	981502832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502832	20447721	Genotype CC is associated with increased likelihood of Drug Toxicity when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1448125537	1447979475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447979475	24510746	Genotype AA is associated with decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.	2.0
1448125537	1448125506	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125506	25816720	Genotype AA is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.	3.0
1448125537	1448125515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125515	25816720	Genotype AA is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.	3.0
1448125537	1448126009	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126009	25182707	Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AG.	-2.25
1448262922	1448262881	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262881	27632229	Allele G is associated with decreased time in therapeutic range when treated with warfarin as compared to allele C.	3.0
1448525395	1448525354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448525354	27670766	Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.	3.0
1448615167	1448615054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448615054	27747906	Genotype GG is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.	2.5
1448109558	827805798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805798	21900104	Allele C is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele T.	0.0
1448109558	1448109322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109322	23441093	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele T.	-1.25
1448109783	827805715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805715	21900104	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1448109783	1448109331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109331	23441093	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-1.75
1451666355	1451666267	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666267	19365400	Allele C is associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to allele G.	0.0
1451815200	1451812400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451812400	35705023	Genotype CC is associated with decreased severity of Dyspepsia when treated with ketoprofen in people with Pain, Postoperative as compared to genotype CT.	1.75
1451868400	1451843520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451843520	25049040	Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.	3.5
1447961129	981848295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848295	23508266	Allele G is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele A.	0.0
1447961136	981848279	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848279	23508266	Allele G is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele A.	0.0
1447961144	981848285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848285	23508266	Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
1448100630	769172931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769172931	18687376	Genotype GG is associated with decreased response to methadone in people with Substance-Related Disorders.	0.0
1448100630	1444695435	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695435	25556837	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	-1.25
1447961151	981848300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848300	23508266	Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.	0.0
1447961158	981848310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981848310	23508266	Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T.	0.0
1447962744	982045615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045615	16103896	Genotype CC is associated with increased response to lovastatin as compared to genotype CT.	2.75
1447963611	981477805	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477805	16822847	Genotype GG is associated with increased likelihood of Disease Free Survival when treated with cyclophosphamide, fluorouracil and methotrexate in women with Breast Neoplasms as compared to genotypes AA + AG.	1.75
1447981346	978639692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639692	22838948	Allele A is associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	1.25
1447987211	1447987188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987188	27139004	Allele G is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to allele A.	3.25
1447987227	1447979349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447979349	26903268	Allele A is associated with increased response to citalopram and escitalopram in people with Depressive Disorder as compared to allele C.	2.5
1447990925	1445401362	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445401362	26222057	Allele G is associated with increased progression-free survival when treated with bevacizumab, capecitabine, cetuximab and oxaliplatin in people with Colorectal Neoplasms as compared to allele A.	2.25
1448097805	1184755616	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755616	25163792	Allele del is associated with decreased metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	1.5
1448097837	1184988967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184988967	24312228	Genotype TT is associated with Cocaine-Related Disorders when exposed to cocaine in as compared to genotypes CC + CT.	2.0
1448100644	827813541	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813541	22174377	Genotype CT is associated with decreased Baseline Bone Mineral Density in women as compared to genotype CC.	0.0
1448100644	827813551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813551	22174377	Genotype CT is associated with increased severity of change in Lumbar Bone Mineral Density when treated with tamoxifen as compared to genotype CC.	1.0
1448100644	827813560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813560	22174377	Genotype CT is associated with increased severity of change in Hip Bone Mineral Density when treated with tamoxifen as compared to genotype CC.	0.0
1448100644	827813600	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827813600	22174377	Allele T is associated with increased half-life of NCOA1.	0.0
1448100644	827813611	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827813611	22174377	Allele T is associated with decreased activity of NCOA1 when exposed to tamoxifen.	0.0
1448100661	827815388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815388	22180457	Allele C is associated with decreased recurrence-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele T.	3.75
1448100687	981238263	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981238263	22373943	Genotypes CC + CT are associated with decreased likelihood of smoking cessation when treated with bupropion as compared to genotype TT.	3.25
1448100687	981238271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981238271	22373943	Genotypes CC + CT are associated with increased risk of Recurrence when treated with bupropion in people with Tobacco Use Disorder as compared to genotype TT.	2.5
1448100695	981238278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981238278	22373943	Genotypes CC + CT are not associated with risk of Recurrence when treated with nicotine as compared to genotype TT.	-2.0
1448100695	981481919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481919	21430647	Genotypes CT + TT are associated with increased severity of craving due to nicotine in people with Tobacco Use Disorder.	1.75
1448100695	981481927	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481927	21430647	Genotypes CT + TT are associated with increased severity of craving due to nicotine in people with Tobacco Use Disorder.	1.75
1448100751	981238979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981238979	22440088	Genotypes CT + TT are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.	2.5
1448100751	981239001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239001	22440088	Genotypes CT + TT are not associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.	-1.5
1448100777	981505272	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981505272	22484315	Allele C is associated with increased clearance of midazolam as compared to allele T.	1.25
1448100777	978639296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639296	22484315	Allele C is associated with increased jejunal CYP3A4 protein levels as compared to allele T.	1.0
1448100777	978639316	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639316	22484315	Allele T is associated with decreased CYP3A4 hydroxylation of midazolam as compared to allele C.	1.0
1448100777	978639425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639425	22484315	Allele T is associated with decreased CYP3A4 mRNA duodenal expression levels as compared to allele C.	1.0
1448100786	981505339	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981505339	22484315	Allele T is associated with increased clearance of midazolam as compared to allele C.	1.25
1448100786	978639442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639442	22484315	Allele T is associated with increased jejunal CYP3A4 protein levels as compared to allele C.	1.0
1448100786	978639454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639454	22484315	Genotype CC is associated with increased duodenal CYP3A4 mRNA expression levels as compared to genotypes CT + TT.	1.0
1448100804	981565062	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981565062	22484315	Genotypes CT + TT are associated with increased clearance of midazolam as compared to genotype CC.	1.25
1448100804	1448100793	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448100793	22484315	Allele T is associated with increased steady-state level of CYP3A4 protein as compared to allele C.	0.0
1451646580	1451646560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451646560	34476566	Genotype TT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	3.0
1451868520	1451843560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451843560	25049040	Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.	4.0
1451868540	1451862762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451862762	25049040	Allele T is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.	3.5
1448265557	1448265539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265539	27671213	Allele G is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele A.	0.0
1448265565	1448265461	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265461	27671213	Allele C is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele T.	0.0
1448265573	1448265402	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265402	27671213	Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.	0.0
1448265573	1450372202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372202	30720667	Genotypes AA + AG is associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype GG.	2.25
1448265581	1448265489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265489	27671213	Allele G is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele A.	0.0
1448265598	1448265385	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265385	27671213	Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.	0.0
1448427559	769182608	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769182608	19593168	Genotype AA is associated with increased plasma concentrations of clozapine as compared to genotype GG.	1.25
1448427559	1448427414	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427414	27168101	Genotype AA is associated with increased risk of Agranulocytosis and Neutropenia when treated with clozapine as compared to genotypes AG + GG.	3.25
1448427566	1448427432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427432	27168101	GSTM1 null/null is associated with decreased risk of Neutropenia when treated with clozapine as compared to GSTM1 non-null/non-null + non-null/null.	2.75
1448427588	1448427423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427423	27168101	GSTT1 null/null is associated with increased risk of Neutropenia when treated with clozapine as compared to GSTT1 non-null/non-null + non-null/null.	2.75
1448532190	1448532144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448532144	27893182	Genotypes AA + AG is associated with increased exposure to Dabigatran in healthy individuals as compared to genotype GG.	0.0
1448613357	1448613309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613309	26962983	Allele T is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele C.	2.25
1448616690	1448616662	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616662	28444425	HLA-C *06:02:01:01 is associated with increased response to methotrexate in people with Psoriasis.	3.0
1448635176	1448635118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448635118	28659275	Allele C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.25
1445401427	1445297920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297920	26071337	Genotype TT is associated with increased risk of Anemia when treated with peginterferon alfa-2b, protease inhibitors and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.	2.5
1447953284	1447675725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447675725	25748439	Genotypes AG + GG are associated with decreased response to cisplatin in people with Osteosarcoma as compared to genotype AA.	2.25
1447962613	1183685326	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685326	24122840	Allele C is associated with increased glucose elevation when treated with atenolol in people with Hypertension as compared to allele T.	2.0
1447962862	982048064	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/982048064	17047488	Genotype CG is associated with increased expression of ABCC2 mRNA in human liver samples as compared to genotype CC.	0.0
1447962862	982048069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982048069	17047488	Genotype CG is associated with increased clearance of pravastatin in healthy individuals as compared to genotype CC.	1.0
1447963853	769171399	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171399	19247266	Genotypes AA + AC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotype CC.	2.5
1447979272	827783469	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783469	21174621	Genotype TT is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotype CC.	2.0
1447979279	827793164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827793164	21449675	Genotype AA is associated with decreased risk of intolerance when treated with aspirin in people with Asthma as compared to genotype TT.	1.75
1447979279	827793177	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827793177	21449675	Genotype AA is associated with decreased expression of TBXAS1 in PBMCs.	0.0
1447979279	827793205	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827793205	21449675	Genotype AA is associated with decreased steady-state level of TBX2 in plasma.	0.0
1447980677	827816247	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816247	21902500	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT.	3.25
1447981282	827923262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923262	22676193	Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	3.25
1447981372	978639911	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639911	22838949	Genotype CC is associated with increased elimination clearance of dFdU when treated with gemcitabine in people with Neoplasms as compared to genotype CT.	1.0
1447981385	978639890	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978639890	22838949	Genotype AA is associated with increased clearance of gemcitabine in people with Neoplasms as compared to genotype GG.	1.0
1447990324	1184466644	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184466644	24853734	Allele G is associated with decreased severity of Hyperglycemia when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.	2.25
1447990324	1444668331	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668331	24853734	Allele G is associated with decreased clearance of metformin in healthy individuals as compared to allele C.	1.25
1447990324	1449165218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165218	29352482	Allele C is not associated with exposure to metformin as compared to allele G.	-1.0
1448097693	1444698780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698780	25782327	Genotype CC is not associated with severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotypes CT + TT.	-1.25
1448097693	1446901632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446901632	25655103	Allele C is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	3.0
1448097693	1446901707	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446901707	24401318	Allele C is associated with decreased enzyme activity of DPYD when assayed with fluorouracil in peripheral blood mononuclear cells as compared to allele T.	0.0
1448097693	1448097800	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448097800	24401318	Genotype CC is associated with increased expression of MIR27A in lymphoblastoid cell lines as compared to genotype TT.	0.0
1448097693	1448255218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255218	26804235	Genotypes CC + CT is associated with increased risk of Drug Toxicity when treated with Pyrimidine analogues in people with Neoplasms as compared to genotype TT.	1.75
1450821121	1450821075	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821075	25064769	Genotype GG is associated with decreased response to amiloride or spironolactone in people with Hypertension as compared to genotypes AA + AG.	2.25
1447987018	769163162	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163162	20860463	Genotype GG is not associated with plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	-0.5
1447987018	769163138	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163138	19779319	Genotypes AG + GG are not associated with altered plasma concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	-0.75
1447987018	1183634172	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634172	24080498	Genotypes AG + GG are not associated with plasma concentration of efavirenz in people with HIV Infections as compared to genotype AA.	-1.25
1447987018	1184467530	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467530	24729586	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	2.25
1447987018	1184473345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473345	23172109	Allele G is not associated with metabolism of efavirenz in people with HIV Infections as compared to allele A.	-2.0
1447987018	1447680442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680442	26774523	Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	-1.0
1448109565	1448109074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109074	23441093	Allele T is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.	-1.25
1448109565	827805777	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805777	21900104	Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.	0.0
1447981275	827923250	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923250	22676193	Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	3.25
1448102294	981865152	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981865152	19448608	Genotypes AA + AG are associated with increased likelihood of Event-Free Survival when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype GG.	2.5
1448102294	1449576864	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576864	29938344	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	-1.5
1448102368	827892726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892726	21723677	Genotypes AA + AG are associated with increased Heroin Dependence due to heroin as compared to genotype GG.	2.0
1448259308	1448259284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259284	27546373	Genotype CC is associated with decreased response to raloxifene in women Menopause and Schizophrenia as compared to genotypes CT + TT.	1.75
1448531674	1448432559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448432559	27845419	Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.	1.25
1448568152	1448568141	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568141	28115488	Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.	0.0
1448109707	827805867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827805867	21900104	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.	0.0
1448109707	1448109037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109037	23441093	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.	-1.25
1448263578	1451415258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415258	32483200	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.	-0.75
1448263578	1448263457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263457	27610747	Genotypes AA + AG is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	2.0
1448102550	1444706633	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706633	24073221	Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.	3.0
1448102550	1448602901	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602901	26911666	Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.0
1447960458	1183621181	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621181	16633140	Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotypes CC + CT.	2.0
1447990940	1447979333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447979333	26903268	Allele T is associated with decreased concentrations of serotonin in people with Depressive Disorder as compared to allele C.	0.0
1448616678	1448616510	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448616510	28444425	Allele G is associated with decreased response to methotrexate in people with Psoriasis as compared to allele T.	2.5
1449144364	1449144268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449144268	29121268	Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.	0.0
1451666660	PA166262321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262321		Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1	100
1451666660	1451228555	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228555	29950617	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	2.5
1451666660	1448612852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612852	28322941	Genotype GT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	0.25
1451666660	1451352522	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352522	25673568	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	0.125
1451666660	1451358668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451358668	27557342	Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.	1.75
1451666660	655388369	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388369	16784736	Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes GT + TT.	1.5
1451666660	655388373	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388373	19474787	Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.	2.0
1451666660	1183631249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183631249	23930675	Genotype TT is associated with increased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype GG.	2.25
1451666660	1184169604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169604	23876492	Allele T is associated with increased plasma concentrations of rosuvastatin as compared to allele G.	1.5
1451666660	1444693893	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693893	25630984	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.	0.0
1451666660	1451124102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124102	31857620	Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.	1.5
1451666660	1451141440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141440	32361904	Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.	2.25
1448100955	1448100784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100784	27261537	Genotype GG is associated with increased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotypes AA + AG.	1.25
1448101044	769163289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163289	20592726	Allele T is associated with increased risk of when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	1.75
1447960411	982046699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046699	21110013	Genotype CC is associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	1.75
1447960633	1183491853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491853	10594793	Genotype AA is associated with increased response to angiotensin II in healthy individuals as compared to genotypes AC + CC.	1.75
1447961057	981237722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237722	22838950	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	3.0
1447961057	1183960626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960626	21642870	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	-1.5
1447961057	978639917	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978639917	22838949	Genotype CC is associated with decreased formation clearance of dFdCTP when treated with gemcitabine in people with Neoplasms as compared to genotype TT.	1.0
1447962674	827677344	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/827677344	12181437	Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.	0.0
1447981296	827923271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827923271	22676193	Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	3.5
1447981313	1447981305	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447981305	27052877	Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.	1.75
1447982768	1447675216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675216	26641474	Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1447982768	1447675226	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447675226	26641474	Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.	0.0
1447990044	1447947908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947908	12359989	Genotype CT is associated with increased response to irbesartan in people with Hypertension as compared to genotype CC.	1.5
1448100437	1447988337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447988337	27096233	Genotypes CT + TT are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype CC.	2.25
1448100444	1447990611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447990611	27190009	Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.	0.0
1448100451	981477831	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477831	18615156	Allele G is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.	2.75
1448100464	1447990584	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447990584	27190009	Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.	2.5
1448100471	1447990618	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447990618	26158282	Allele C is associated with decreased trough concentration of telaprevir in people with Hepatitis C as compared to allele T.	2.0
1448100508	1448099032	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099032	27160388	Genotype AA is associated with decreased response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	2.0
1448100514	1448099774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099774	25622599	Allele T is associated with increased response to bisoprolol in men with Hypertension as compared to allele C.	0.0
1448100552	1448099986	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099986	26307985	Genotype CT is associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.	0.25
1448100552	1449163102	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449163102	29318894	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.	-1.5
1448100552	1449748273	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748273	29603629	Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	2.0
1448100567	981755988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755988	22765258	Genotype CC is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype TT.	-0.5
1448100567	1184755669	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755669	25163792	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.	-0.125
1448100567	1448099974	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099974	26307985	Genotype CT is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes CC + TT.	1.25
1448100942	1448100925	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100925	27261537	Genotypes CT + TT are associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype CC.	0.0
1448101059	981501304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501304	20597903	Allele G is associated with increased likelihood of Asthma when treated with aspirin in people with Asthma as compared to allele A.	2.5
1448101073	981500745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500745	20649757	Allele T is associated with increased likelihood of GI intolerance when treated with mycophenolate mofetil in children with Organ Transplantation as compared to allele C.	2.25
1448101086	981483940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483940	20680652	Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.	1.75
1448101086	981483959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981483959	20680652	Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.	1.75
1448101102	981500808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981500808	20688905	Genotype GG is associated with decreased risk of Prostatic Neoplasms when exposed to aspirin as compared to genotypes GT + TT.	2.5
1448100501	1448098929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448098929	26213157	Genotype AA is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.	2.0
1448100501	1448263500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263500	27610747	Genotypes AA + AG is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	-1.0
1448100501	1448263553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263553	27610747	Allele A is not associated with response to lamotrigine in people with Epilepsy as compared to allele G.	-1.5
1448101114	981500768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500768	20724655	Genotype AA is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes AG + GG.	2.5
1448101149	981502141	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502141	20725741	Allele A is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to allele G.	2.75
1448101163	981502153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502153	20725741	Genotype GG is associated with increased Tobacco Use Disorder when treated with Opium alkaloids and derivatives in people with Pain as compared to genotypes AA + AG.	2.25
1448101175	981502246	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502246	20736995	Allele T is associated with increased severity of Tobacco Use Disorder due to nicotine in smokers as compared to allele C.	1.75
1448101202	981481458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981481458	20812847	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.	2.0
1448101252	981482273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981482273	20886544	Allele G is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.	2.0
1448102446	981477611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981477611	19749757	Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.	2.0
1448102446	1444705477	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705477	21346780	Genotype CT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
1448104353	769250871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250871	20125120	Genotype CG is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + GG.	1.75
1448266599	1448266553	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266553	26453102	Genotype TT is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.	2.75
1448266609	1448266567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266567	26453102	Genotype CC is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	2.25
1450826553	1450826517	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826517	28376280	Allele del is associated with increased response to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.	2.0
1448100487	1451415220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415220	32483200	Allele T is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.	-0.75
1448100487	1448098923	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448098923	26213157	Genotypes GT + TT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.	2.0
1448100487	1448263482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448263482	27610747	Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.	1.5
1448100487	1449560343	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449560343	29791014	Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.	2.0
1448100487	1449560381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449560381	29791014	Allele G is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.	-1.0
1448100494	1451415252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415252	32483200	Allele C is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele T.	-0.75
1448100494	1448098912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448098912	26213157	Genotypes CC + CT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.	2.0
1448101182	981502254	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502254	20736995	Allele A is associated with increased severity of Tobacco Use Disorder due to nicotine in smokers as compared to allele G.	1.75
1448101182	981755656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755656	19755656	Genotype GG is associated with increased abstinence due to nicotine in smokers as compared to genotypes AA + AG.	2.5
1448101182	655387319	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655387319	18593715	Genotype GG is associated with increased likelihood of smoking cessation as compared to genotypes AA + AG.	2.25
1448101182	1449155888	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155888	29196725	Allele A is not associated with Tobacco Use Disorder when exposed to nicotine as compared to allele G.	-1.75
1448101182	1449155973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449155973	29196725	Allele A is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele G.	-1.75
1449164133	1449164032	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164032	29298995	Genotype GG is associated with increased dose of warfarin as compared to genotypes CC + CG.	3.0
1449164149	1449164037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164037	29298995	Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.	3.0
1449164155	1449164026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164026	29298995	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
1448525559	1448525471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525471	27779248	Genotype TT is associated with increased risk of Hepatic Veno-Occlusive Disease when treated with busulfan and cyclophosphamide in children with hemopoietic stem cell transplant as compared to genotypes GG + GT.	3.0
1448612662	1448612637	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612637	27900402	Genotype CC is associated with increased response to oxcarbazepine in people with Seizures as compared to genotypes CT + TT.	2.0
1448612682	1448612673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612673	28373444	Genotypes CG + GG is associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to genotype CC.	2.0
1448613243	1448613188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613188	28112181	Genotypes AG + GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype AA.	2.25
1448613243	1448613196	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448613196	28112181	Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	1.75
1448614963	1448614774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448614774	28409297	Genotypes T/del + TT are associated with decreased clearance of rocuronium in healthy individuals as compared to genotype del/del.	2.0
1448615614	1448614900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448614900	28391406	Genotypes AA + AG are associated with decreased likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotype GG.	1.5
1448617757	1448617460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448617460	22394315	Allele C is associated with decreased clearance of atazanavir in healthy individuals as compared to allele T.	0.375
1448633935	1448633915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448633915	28620303	Allele G is associated with decreased dose of warfarin as compared to allele A.	2.25
1448634752	1448100012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100012	26307985	Genotype AG is associated with increased concentrations of mycophenolic acid in people with lung transplantation as compared to genotype GG.	0.0
1448634752	981755995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981755995	22765258	Genotype GG is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype AA.	-0.5
1448634752	1184755664	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755664	25163792	Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele A.	-0.125
1448634752	1448634570	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634570	28624888	Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G.	2.25
1448634752	1448634582	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634582	28624888	Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G.	2.25
1449164121	1184511624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511624	25026456	Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.	2.0
1449164121	1449164090	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164090	29298995	Allele G is not associated with dose of warfarin as compared to allele T.	-2.0
1449164127	1184511628	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511628	25026456	Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.	2.0
1449164127	1449164097	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164097	29298995	Allele G is not associated with dose of warfarin as compared to allele T.	-2.0
1450374089	1450936394	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936394	30908574	Genotype CC is associated with increased response to acetaminophen in healthy individuals as compared to genotypes CT + TT.	1.75
1447960238	982046656	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046656	21110013	Genotype CC is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT.	1.75
1447960238	1043858513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858513	21057703	Genotype CC is associated with increased likelihood of being overanticoagulated due to phenprocoumon as compared to genotypes CT + TT.	1.75
1447960238	1447679595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447679595	21057703	Genotype CC is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype TT.	1.75
1447960930	1447960889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447960889	16123753	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del.	3.0
1447960937	1447960897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447960897	16123753	Genotypes G/del + del/del is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.	3.25
1447963057	1183532556	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183532556	23944767	Allele G is associated with increased baseline adiponectin and with greater adiponectin decline when treated with efavirenz, lopinavir, Nucleoside and nucleotide reverse transcriptase inhibitors or ritonavir in people with HIV Infections as compared to allele A.	2.0
1447990235	1447947823	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947823	21842338	Genotype CT is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype TT.	2.0
1447990235	1447947832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947832	21842338	Genotype CT is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype TT.	1.5
1447990235	1447947839	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947839	21842338	Genotype CT is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype TT.	1.0
1447990245	1447521568	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447521568	22415532	Allele C is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.	0.0
1447990245	1447521558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521558	22415532	Allele C is associated with Malignant Hyperthermia as compared to allele G.	0.25
1448097556	1185000944	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000944	17058217	Genotype GG is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.	3.5
1448097574	1185000959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000959	17058217	Genotype GG is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.	3.5
1448097587	1185000974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000974	17058217	Genotype AA is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.	3.5
1448100201	982015607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015607	18092181	Allele T is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele C.	2.5
1448100313	1451415080	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451415080	32483200	Genotype AG is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype AA.	-0.75
1448100313	1183682139	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183682139	23263737	Genotype AA is not associated with increased clearance of lamotrigine as compared to genotypes AG + GG.	-0.75
1448100313	1447983631	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983631	27096250	Genotype GG is associated with increased clearance of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.	1.25
1448100208	982015594	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015594	18092181	Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele G.	3.0
1448100215	981502605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502605	20373477	Allele C is not associated with likelihood of weight gain when treated with antipsychotics in people with Schizophrenia as compared to allele A.	-1.5
1448100215	982009676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009676	18195716	Allele C is associated with increased severity of weight gain when treated with antipsychotics in people with Schizophrenia as compared to allele A.	1.5
1448100222	1447983363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983363	27115882	Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT.	2.75
1448100242	769152908	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769152908	18261733	Genotype GG is associated with increased response to pravastatin in people with Vascular Diseases as compared to genotype AA.	0.0
1448100249	982017925	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982017925	18285546	Genotypes AA + AG are associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.75
1448100257	982022211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022211	18458677	Genotype CC is associated with decreased risk of Depression when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CG + GG.	2.25
1448100265	1184168809	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168809	18458677	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with decreased risk of Depression when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).	0.0
1448100296	1183701285	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701285	18574025	Allele C is associated with dose of warfarin.	2.5
1448100296	1184482805	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482805	23941071	Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.	2.75
1448100306	981502554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981502554	20393862	Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.	2.5
1448100306	1448267559	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448267559	18593894	Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.	0.0
1448100334	1447987342	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987342	25935875	Genotype CC is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.	0.0
1448100340	1447987295	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987295	25935875	Allele G is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele A.	0.0
1448100347	1447987282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987282	25935875	Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C.	0.0
1448100354	1447987275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987275	25935875	Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T.	0.0
1448100361	1184407280	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184407280	18605963	Genotype AT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype AA.	0.0
1448100361	1184467382	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467382	24624911	Allele A is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.	2.25
1451666740	PA166262341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166262341		Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1	100
1451666740	1450823480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823480	30989645	Allele G is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele A.	2.0
1451666740	982037414	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037414	12891229	Allele T is not associated with response to fluvastatin in healthy individuals as compared to allele C.	-0.125
1451666740	982037405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037405	12891229	Genotype CC is not associated with response to fluvastatin in healthy individuals as compared to genotype AA.	-0.125
1451666740	982037396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037396	12891229	Genotypes CT + TT are not associated with metabolism of fluvastatin in healthy individuals as compared to genotype CC.	-0.125
1451666740	982037386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037386	12891229	Genotype CC is associated with decreased metabolism of fluvastatin in healthy individuals as compared to genotype AA.	1.5
1451666740	1450823485	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823485	30989645	CYP2C9 *3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451666740	1451666680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666680	22941809	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451666740	1451666701	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451666701	19663817	CYP2C9 *1/*3 is associated with decreased metabolism of fluvastatin as compared to CYP2C9 *1/*1.	0.0
1451666740	1451666721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451666721	32373204	CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451666740	1450823501	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823501	30989645	CYP2C9 *2 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.	This annotation is not used for clinical annotation scoring. duplicate scoring with another VA.
1451773100	1451773040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451773040	34616002	Genotype GG is associated with increased Shortened QT interval of digoxin as compared to genotypes GT + TT.	1.5
1448123834	1448123760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448123760	27396837	Genotype AA is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AG + GG.	1.5
1448264343	1448264240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264240	27666425	HLA-B *15:01:01:01 is associated with decreased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	3.0
1449146785	1449144475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449144475	28791697	Genotypes AA + AG are associated with decreased risk of gastrointestinal toxicity, Hematologic Diseases and Leukopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	3.5
1449146785	1449144490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449144490	28791697	Genotypes AA + AG are not associated with risk of Anemia, Neutropenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	-2.0
1449146832	1449146792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449146792	28992563	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.	3.25
1449146840	1449001814	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449001814	28992563	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	3.25
1449147022	1449146999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449146999	29107709	Genotypes CT + TT are associated with increased likelihood of Recurrence when treated with sofosbuvir, velpatasvir and voxilaprevir in people with Hepatitis C, Chronic as compared to genotype CC.	2.5
1451702280	1447813595	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447813595	26817948	Genotype CT is associated with decreased catalytic activity of CES1 when treated with sacubitril as compared to genotype CC.	0.0
1449147609	1449147520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147520	26407542	Genotype TT is associated with increased response to buprenorphine in people with Ischemia and Pain as compared to genotype CC.	2.25
1449147609	1449147567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449147567	26407542	Genotype CT is not associated with response to buprenorphine in people with Ischemia and Pain.	-1.25
1447990578	1184755622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184755622	25163792	Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.	1.5
1447990578	1448100023	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448100023	26307985	Genotype AA is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes AG + GG.	0.0
1448099059	1447676926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676926	26590194	Allele A is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.0
1448099065	1183688944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688944	24192120	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype AA.	2.25
1448099080	1183688854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183688854	24192120	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype CC.	2.25
1448099093	1447676991	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676991	26590194	Allele A is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	0.0
1448099100	1184174513	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174513	24329191	Genotypes AA + AG is associated with increased total cholesterol when treated with hmg coa reductase inhibitors in people with Schizophrenia as compared to genotype GG.	1.0
1448104372	1448104351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448104351	27296832	Allele C is associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to allele T.	3.25
1448257263	1448257237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257237	27488176	Allele G is associated with decreased dose of warfarin as compared to allele A.	0.0
1448257270	1448257253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448257253	27488176	Allele G is associated with increased dose of warfarin as compared to allele T.	0.0
1448257290	1448257282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257282	27488176	Allele T is associated with decreased time in therapeutic range when treated with warfarin as compared to allele G.	0.0
1448259317	1448259252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259252	27546373	Genotype CC is associated with increased response to raloxifene in women with Menopause and Schizophrenia as compared to genotype CG.	1.75
1448260762	1448260730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448260730	27527109	HLA-B *15:27:01 is associated with increased risk of Drug Toxicity when treated with clindamycin.	2.75
1448264186	1448264149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264149	27561198	Genotype GG is associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.	2.5
1448519686	1448489015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448489015	27549341	CYP3A4 *1/*22 is associated with increased concentrations of exemestane in women with Breast Neoplasms as compared to CYP3A4 *1/*1.	2.0
1448615137	1448615035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448615035	27747906	Genotype AA is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AG + GG.	2.0
1448615147	1448614987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448614987	27747906	Genotype AA is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.	1.5
1448124242	769169225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169225	16405973	Allele G is not associated with increased likelihood of Myocardial Infarction in people with Coronary Artery Disease as compared to allele A.	-1.0
1448124242	1448124144	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124144	26870959	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele G.	2.75
1448124216	1448124169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124169	26870959	Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele C.	2.25
1183532576	1450973560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450973560	10736278	Allele C is associated with increased risk of mortality after myocardial infarction, however this can be eliminated when treated with simvastatin as compared to allele T.	2.5
1447982779	1446445115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446445115	26287941	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.	0.0
1447982788	1447958810	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958810	26310775	Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.	0.0
1447982797	1447675205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447675205	26641474	Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.	2.5
1447982797	1447679627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447679627	26267044	Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.	2.5
1447982804	1447958822	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958822	26310775	Allele G is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele A.	0.0
1447982811	1447958815	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958815	26310775	Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.	0.0
1447982818	1447948899	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447948899	26906009	Allele G is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele A.	0.0
1447982832	1447963626	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447963626	26967570	Genotype GG is associated with decreased response to dimethyl fumarate in people with Psoriasis as compared to genotypes AA + AG.	2.75
1447982843	1447982795	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447982795	27071970	Allele A is associated with increased expression of LDLR mRNA as compared to allele G.	0.0
1448103935	981501160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501160	20305679	Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to allele G.	1.75
1448264329	1448264210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448264210	27666425	HLA-B *40:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.	4.0
1448265605	1448265475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265475	27671213	Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.	0.0
1448636111	1448636103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636103	28703131	Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	3.0
1450933001	1450932983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932983	30651574	Genotype AA is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.	2.0
1450933052	1450933031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933031	30653751	Genotypes GG + GT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotype TT.	2.0
1450933104	1450933095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450933095	30696812	Genotype CT is associated with increased risk of Alcoholism due to ethanol in people with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	1.75
1450933110	1450933071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450933071	30696812	Genotype AG is associated with increased risk of Tobacco Use Disorder due to nicotine in people with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + GG.	2.0
1450934055	1450933220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450933220	30713339	Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.	3.75
1450934203	1450934116	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934116	30611854	Allele A is associated with decreased inhibition of SCN4A with mexiletine as compared to allele G.	0.0
1450934656	1450934443	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934443	30723321	Allele C is associated with increased response to migalastat in people with Fabry Disease.	0.0
1043880143	769171544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171544	14660992	Allele A is associated with decreased risk of cardiovascular events when treated with hmg coa reductase inhibitors in people with Coronary Artery Disease as compared to allele G.	2.5
1451702428	1451702360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451702360	35169303	HLA-B *07:02:01 is associated with increased risk of Respiratory Insufficiency when treated with sulfamethoxazole / trimethoprim.	2.75
1447946124	1444668751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444668751	18713756	Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG.	2.25
1447947019	1447946985	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946985	26882121	Genotypes CT + TT is associated with increased concentrations of tacrolimus in healthy individuals as compared to genotype CC.	1.0
1447947019	1448995005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995005	28777242	Genotypes CT + TT are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1447947019	1448995012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995012	28777242	Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.5
1447947019	1449749382	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449749382	29733390	Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.	-0.75
1447960269	1183634027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634027	21636554	Genotype CT is associated with decreased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.75
1447960309	1183689654	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689654	22960943	Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG.	1.5
1447964180	1448106683	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448106683	20048079	Genotype AG is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole.	0.0
1447990932	1446900848	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446900848	26335211	Genotype GT is associated with increased risk of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	1.75
1448100089	981240157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240157	17606663	Allele T is associated with increased likelihood of Substance-Related Disorders due to methamphetamine as compared to allele A.	2.25
1448100089	981240192	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240192	17606663	Allele T is associated with increased likelihood of Recurrence due to methamphetamine in people with Substance-Related Disorders as compared to allele A.	1.75
1448100103	1447983346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983346	27091189	Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele C.	0.0
1448100110	981419361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419361	18021981	Allele A is associated with increased likelihood of Gingival Overgrowth when treated with cyclosporine in people with Kidney Transplantation as compared to allele G.	2.25
1448100117	1447983283	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983283	27091189	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	0.0
1448100132	1447983239	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983239	27091189	Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.	0.0
1448100139	1447983318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983318	27091189	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	0.0
1448100146	1447983326	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983326	27091189	Allele G is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.	0.0
1448100158	1447983268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983268	27091189	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	0.0
1448100165	1447983310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983310	27091189	Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.	0.0
1448100173	1447983276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983276	27091189	Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.	0.0
1448100180	1447983231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983231	27091189	Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele C.	0.0
1448100521	1448099742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099742	25622599	Allele T is associated with increased response to losartan in men with Hypertension as compared to allele C.	0.0
1448258925	1448258877	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448258877	23237922	Genotype CC is associated with increased risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CT.	1.75
1451702465	1451702424	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451702424	35169303	HLA-C *07:02:01:01 is associated with increased risk of Respiratory Insufficiency when treated with sulfamethoxazole / trimethoprim.	2.75
1447960948	827812715	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812715	21806385	Genotype CC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.	2.5
1447960948	827812721	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812721	21806385	Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA.	2.5
1447961028	981861762	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981861762	11595069	Allele T is not associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.	-1.25
1447961028	981862030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981862030	16677176	Allele T is not associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis.	-1.5
1447961028	981952671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981952671	21856096	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.	2.25
1447961028	982046582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046582	18421452	Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1447961028	1183702615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702615	23875638	Genotype CC is associated with decreased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1447961028	1183702620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702620	23875638	Genotype TT is associated with increased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.	3.0
1447961028	1449002627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002627	29036176	Allele T is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C.	-1.5
1447961028	981344330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981344330	19686464	Genotype CT is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women with Tuberculosis.	0.25
1447961028	1447944559	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447944559	24465778	Genotype CT is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype CC.	0.0
1447961074	981237802	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981237802	22838950	Genotypes CT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.	2.5
1447961344	981417070	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417070	16385453	Allele C is associated with increased risk of Alcoholism due to ethanol as compared to allele A.	1.5
1448099908	1448099841	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099841	26307969	Genotypes AA + AC are associated with decreased response to photodynamic therapy in people with Choroidal Neovascularization as compared to genotype CC.	2.75
1448532313	1448532296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532296	28100007	Genotype TT is associated with increased likelihood of Recurrence when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.	3.5
1449156809	1449156802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156802	29210332	Allele G is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.	3.0
1449156815	1449156795	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156795	29210332	Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.	3.0
1449156815	1451146045	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451146045	32232669	Allele G is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele A.	-2.0
1447948727	1447947989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447947989	23207012	CYP2D6 *10/*10 is associated with increased risk of Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*114 + *2/*2 + *2/*10.	2.5
1447948727	1447948127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948127	26323212	CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*14 + *2/*5 + *2/*10.	1.75
1447948727	1447948195	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948195	23664723	CYP2D6 *1/*10 + *2/*10 + *1/*5 + *5/*10 + *10/*10 is not associated with risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung.	-1.75
1447948727	1447948278	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948278	25554506	CYP2D6 *1/*5 + *1/*10 + *5/*10 + *10/*10 is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1.	-0.25
1447948727	1447948494	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447948494	21502555	CYP2D6 *1/*10 + *1/*5 + *10/*10 is associated with Toxic liver disease when treated with gefitinib in people with Adenocarcinoma.	0.25
1447990855	1444704480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704480	25823661	Allele G is associated with increased risk of Death when treated with antineoplastic agents in women with Breast Neoplasms as compared to allele A.	1.75
1448098232	1448097958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097958	24193570	Genotype GG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AG.	2.5
1448098287	1448097937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097937	24193570	Genotype CC is associated with decreased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.	2.0
1448098293	1448097947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097947	24193570	Genotype TT is associated with increased severity of Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AT.	2.5
1448098304	1448097875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097875	24193570	Genotype AA is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AG.	2.0
1448098315	1448097890	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097890	24193570	Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.	2.0
1448098320	1448097900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097900	24193570	Genotypes CC + TT are associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.	2.5
1448098325	1448097998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097998	24193570	Genotype AG is associated with increased severity of Anemia and Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.	2.0
1448098354	1448097982	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448097982	24193570	Genotype AG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.	1.5
1448099112	1447676833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676833	26590194	Allele T is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	0.0
1448099135	1447676940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676940	26590194	Allele G is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	0.0
1448099156	1448098054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098054	24193570	Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.	2.0
1448099162	1448098063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098063	24193570	Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.	1.5
1448099178	1448098074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098074	24193570	Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.	1.5
1448099320	1448098038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098038	24193570	Genotype AG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.	1.5
1448276473	1448276427	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276427	27271184	Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.	2.25
1448099149	1184467504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467504	24624916	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.	2.5
1448099149	1451406461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406461	33812699	Genotypes AC + CT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.	-1.5
1448099149	1451406470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406470	33812699	Genotypes AA + AT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.	This annotation is not used for clinical annotation scoring. Unable to display all options of a triallelic variant in one VA. This VA should be considered part of VA 1451406461 and does not contribute to a CA score to avoid double counting of the finding from this paper.
1447954378	1447952104	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952104	21233271	Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	2.0
1447954378	1447952408	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952408	24836205	Allele T is not associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	-1.5
1447954378	1447952428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952428	18722008	Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.	2.0
1447954378	1447952758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447952758	20622033	Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.	2.0
1183491175	1448107552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107552	20207952	Allele C is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele T.	2.5
1444843613	982031608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982031608	21390311	Genotype AA is not associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AG + GG.	-1.75
1444843613	769248374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769248374	19749757	Allele A is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.	0.0
1444843613	1184136370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136370	24308755	Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.	3.25
1444843613	1444705508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705508	21346780	Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.	3.5
1444843613	1444705811	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444705811	21987611	Genotype AA is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	2.25
1444843613	1444706383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706383	21112657	Genotype AA is not associated with response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	-1.75
1444843613	1444843603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843603	25769643	Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.	1.0
1448099168	1448098046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098046	24193570	Genotype GT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.	1.5
1448099784	827812178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827812178	21635146	Allele G is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.	2.0
1448099828	1448099807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099807	27173875	Genotypes CT + TT are associated with decreased response to alemtuzumab, chlorambucil, cyclophosphamide, fludarabine, prednisone, rituximab or vincristine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype CC.	2.25
1448568208	637880031	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/637880031	16788380	Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G.	-0.25
1448568208	1448568197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568197	28031227	Genotypes AA + AG are associated with decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to genotype GG.	1.75
1448624484	1448624269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624269	29100455	Allele C is associated with increased likelihood of Leukopenia and Neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.	2.5
1448624484	1448624283	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624283	29100455	Allele C is not associated with likelihood of Leukopenia and Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to allele T.	-2.0
1451673180	1451672680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672680	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele G.	0.0
1448632491	1448632466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448632466	23444229	Genotype GG is associated with increased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	2.0
1451673200	1451672684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672684	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451703980	1444929357	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929357	26086150	HLA-C *06:02:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	2.5
1451703980	1444929367	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929367	26086150	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	2.5
1451703980	1451348845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348845	32452529	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	3.0
1451703980	1451348900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348900	32452529	HLA-C *07:27:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	2.5
1447949088	1447949071	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949071	26387494	Genotype GG is associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotypes AA + AG.	2.5
1448098975	1183624629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183624629	23274376	Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms.	2.25
1448099022	1183690897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690897	24192117	Genotype AA is associated with increased clearance of busulfan in children with Transplantation as compared to genotypes AG + GG.	1.75
1448103867	981861789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981861789	19345712	Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.	1.75
1448126020	1448125954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125954	25182707	Genotype TT is associated with increased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AT.	2.25
1448126020	1448125992	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125992	25182707	Genotype TT is associated with increased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AT.	2.75
1448522748	1448522617	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448522617	27670765	Genotypes CC + CT are associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype TT.	2.0
1448532363	1448532347	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448532347	27357737	Genotype TT is associated with increased sustained virological response (svr) when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.	2.5
1449156167	1448998275	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998275	28819312	HLA-B *35:10 is associated with dress syndrome, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1449156175	1184407551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407551	19104471	HLA-C *04:01:01:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.	-1.75
1449156175	1184482759	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184482759	24911354	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.25
1449156175	1185001907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001907	19845952	HLA-C *04:01:01:01 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV.	0.0
1449156175	1185002071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002071	21505298	HLA-C *04:01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.	3.5
1449156175	1185002228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002228	21902584	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1449156175	1185002808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002808	23362284	HLA-C *04:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	3.5
1449156175	1185002850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185002850	23362284	HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.	2.5
1449156175	1444697789	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697789	25714001	HLA-C *04:01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.	1.0
1449156175	1448925862	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448925862	28819312	HLA-C *04:01:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	3.5
1449156051	1448926055	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448926055	28819312	HLA-B *67:01:01 is associated with dress syndrome, Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.	0.0
1451704000	1444929346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444929346	26086150	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.	3.0
1451704000	1451348840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348840	32452529	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	3.0
1451704000	1451348850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348850	32452529	HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfamethoxazole / trimethoprim.	3.0
1451704000	1451348861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451348861	32452529	HLA-B *38:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.	2.5
1448112486	1448112479	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112479	27339827	Allele A is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to allele G.	2.75
1448112493	1448112462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112462	27339827	Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	1.75
1451704080	982022148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022148	22850190	Allele A is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.	-1.5
1451704080	982022926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022926	11191886	NAT2 *5A + *5B + *6A + *6B + *7A + *7B + *14A + *14B (assigned as slow acetylator phenotype) are associated with increased risk of severe cutaneous adverse reactions when treated with sulfamethoxazole / trimethoprim in people with Acquired Immunodeficiency Syndrome.	2.5
1451704080	982022910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022910	8689813	NAT2 *4 is not associated with likelihood of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with HIV Infections.	-0.25
1451704080	982022061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022061	12580987	NAT2 *5A + *5B + *5C + *5F + *6A + *6E + *7A + *7B (assigned as slow acetylator phenotype) are not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with HIV Infections.	-0.25
1451704080	982022082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022082	12043950	NAT2 *4 + *12A + *12B + *12C + *13A (assigned as rapid acetylator phenotype) are not associated with likelihood of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with HIV Infections as compared to NAT2 slow acetylator.	-0.25
1451704080	982022054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022054	9923584	NAT2 *4 is associated with decreased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia as compared to NAT2 *5A + *5B + *6B + *7A.	2.0
1447991729	769171479	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171479	10683861	Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.	2.75
1448426887	1448426866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426866	27809336	CYP1A1 *2A is associated with increased clearance of granisetron as compared to CYP1A1 *1/*1.	1.0
1451674140	1451672700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672700	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele A.	0.0
1451674148	1451672704	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672704	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451704120	982022157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022157	22850190	Allele A is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.	-1.5
1451704120	982022046	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022046	9923584	Allele A is associated with increased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia.	2.0
1450932250	1450932194	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932194	30458875	Genotypes AA + AG are associated with decreased risk of Maculopapular Exanthema due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype GG.	1.0
1448603625	1184471182	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471182	24465960	Genotype CT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.	-2.0
1448603625	1448603549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448603549	28246425	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype CT.	1.25
982043234	1451608120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451608120	23116553	Genotype GG is associated with increased response to docetaxel and doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.	3.0
1185012209	1183702102	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702102	24336023	HLA-A *24:02:01:01 is associated with decreased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	1.625
1185012209	1184467978	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467978	21917426	HLA-A *24:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.25
1185012209	1184468281	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184468281	22348435	HLA-A *24:02:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	3.25
1185012209	1448525709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448525709	27888155	HLA-A *24:02:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	3.75
1185012209	1451640380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451640380	34350628	HLA-A *24:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	-1.5
982029200	655387163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387163	14534525	Allele T is associated with increased metabolism of repaglinide in healthy individuals as compared to allele C.	1.5
982042110	982041059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982041059	23817222	Genotype CC is associated with decreased time to tumor recurrence (TTR) when treated with fluorouracil in people with Colonic Neoplasms as compared to genotypes AA + AC.	2.0
1043873018	637880320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880320	19924111	Genotype GG is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to genotypes AA + AG.	2.25
1043880392	981785747	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785747	23376925	Allele C is associated with decreased CYP2C9 promoter activity as compared to allele T.	1.0
1043880392	982038282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038282	20653674	Allele C is associated with decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to allele T.	2.75
1183615090	769169612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169612	11408373	Allele C is associated with decreased clearance of losartan.	0.0
1183615090	982028496	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028496	22735459	CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1183615090	982028504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982028504	22735459	CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1183615090	1043880889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880889	15197523	CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	1.25
1183615090	1043880897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043880897	15197523	CYP2C9 *1/*2 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	-0.75
1183615090	1133417241	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1133417241	15289788	CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183615090	1134049001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1134049001	15289788	CYP2C9 *1/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183615090	1134736215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1134736215	15289788	CYP2C9 *1/*8 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.	-0.375
1183615090	1445117488	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1445117488	25994031	CYP2C9 *59 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan and tolbutamide as compared to CYP2C9 *1.	0.0
1183615090	1451234364	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234364	32531309	CYP2C9 *2 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1183615090	1451234360	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234360	32531309	CYP2C9 *62 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1183615090	1451234420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234420	32531309	CYP2C9 *3 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1183618204	827696145	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827696145	21562485	Allele A is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals.	1.5
1183631792	981344263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344263	22907730	Allele T is associated with decreased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.	0.0
1183693485	981501459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501459	20107430	Genotype CC is associated with decreased likelihood of weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype CT.	0.25
1183693485	827828539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828539	20631561	Allele T is not associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.	-1.25
1183693485	1446898493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898493	23799528	Allele C is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.	2.0
1184512433	1184512419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512419	25079360	Allele G is associated with decreased dose of warfarin as compared to allele A.	3.0
1184512433	1184512426	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512426	25079360	Allele G is associated with decreased dose of warfarin as compared to allele A.	2.75
1185000451	981481958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981481958	23033116	CYP3A5 *1/*3 + *1/*1 are associated with increased oral clearance (CL) of atazanavir when treated with atazanavir in people with HIV as compared to CYP3A5 *3/*3.	1.5
1185000451	1184998561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998561	19710077	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.	1.0
1185012258	1185003048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185003048	23874514	HLA-B *18:01:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.	0.0
1445400672	1444702155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702155	17699831	Genotype GG is associated with decreased response to Pertussis vaccines in children as compared to genotype AG.	2.5
1446898324	1446765735	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765735	26153084	Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.	2.0
1446898324	1446765748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765748	26153084	Genotype AA is not associated with response to bupropion and varenicline in people with Tobacco Use Disorder as compared to genotypes AG + GG.	-1.75
1446899639	1444704671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444704671	25823661	Allele A is associated with increased risk of Death when treated with anthracyclines and related substances in women with Breast Neoplasms as compared to allele G.	1.75
1448112600	1448112528	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112528	27150640	Genotype GG is associated with increased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	2.25
1448112607	1448112545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112545	27150640	Genotypes AA + AC are associated with decreased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotype CC.	2.25
1448112614	1448112449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112449	27150640	Genotype TT is associated with increased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT.	2.25
1448567993	1448567928	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448567928	22094953	Genotype CC are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotypes CT + TT.	1.25
1449576983	1449576962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576962	29027195	Allele A is associated with decreased response to abiraterone and prednisolone in people with Prostatic Neoplasms as compared to allele G.	2.25
1449576983	1449576969	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576969	29027195	Genotype AA is associated with decreased progression-free survival when treated with abiraterone and prednisolone in people with Prostatic Neoplasms as compared to genotype GG.	2.75
1451704127	982022148	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022148	22850190	Allele A is not associated with increased risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection.	-1.5
1451704127	982022036	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982022036	9923584	Allele A is associated with increased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia.	1.5
1448616381	1448616280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616280	28448657	Allele T is associated with decreased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.	3.5
1448616381	1451128216	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451128216	31666714	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.	-1.75
1449140069	1449139965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449139965	28676933	Genotypes AG + GG is associated with decreased likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to genotype AA.	2.0
1449140069	1449140022	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449140022	28676933	Genotype GG is associated with increased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.	1.0
1449140085	1449140043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449140043	28676933	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.	1.0
1450815120	1450814996	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814996	23241943	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele A.	0.0
1450823713	1450823671	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823671	26320194	Genotype CC is associated with increased severity of Psychomotor Agitation due to aripiprazole in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.	1.5
1446897383	1444702613	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702613	25793413	Genotype AA is associated with decreased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	3.0
1446897383	1449154515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154515	26191232	Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	2.75
1450931979	1450931972	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931972	30381583	Genotype TT is associated with increased response to fentanyl in women with Pain, Postoperative as compared to genotypes CC + CT.	2.5
982030836	1451155200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451155200	25869015	Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotypes AG + GG.	2.0
982030836	1451155287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451155287	20530282	Genotype AA is associated with increased risk of Neutropenia and Vomiting when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes AG + GG.	3.0
982030836	981785803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785803	17510208	Genotype AA is associated with increased Neutropenia when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.	2.75
982030836	981785904	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785904	17510208	Genotype AA is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.	3.25
982030836	981792403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981792403	19450125	Genotype AA is not associated with Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	-1.25
982030836	982023184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982023184	23386248	Allele A is not associated with risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms.	-1.5
982030836	827552106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827552106	15007088	Allele A is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele G.	1.25
982030836	1448531604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448531604	27845419	Genotypes AA + AG are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype GG.	2.25
982030854	981859123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981859123	22935916	Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	2.0
982030854	982015818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982015818	22935916	Allele C is associated with decreased response to risperidone in people with Schizophrenia.	2.0
982030854	1450928312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928312	28696411	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	-1.75
1183491446	769148499	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769148499	18222355	Genotypes AG + GG are associated with increased benefit when treated with atorvastatin in people with Acute coronary syndrome as compared to genotype AA.	2.5
1183491446	1449748074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748074	30304062	Genotype GG is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.	-2.0
1183491446	981482129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981482129	20886236	Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.	3.5
1447990271	1184212596	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184212596	24498053	Allele C is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele T.	2.5
1448255939	1448255931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255931	22736425	Genotype GG is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotype AG.	2.25
1447990913	1445401341	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445401341	26222057	Allele G is associated with decreased progression-free survival when treated with bevacizumab, capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to allele A.	2.25
1448097822	1444698212	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444698212	25781442	Genotype AA is associated with decreased likelihood of Colorectal Neoplasms when exposed to Antiinflammatory agents, non-steroids and aspirin.	2.0
1448098339	1448098020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098020	24193570	Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CC.	1.5
1444706164	982045579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045579	16103896	Genotypes GT + TT are associated with increased response to lovastatin as compared to genotype GG.	2.75
1444706201	827815118	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827815118	21709081	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.	0.0
1444842113	1185001714	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185001714	17339877	HLA-C *14:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.	3.25
1444842126	1444841865	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444841865	24107802	UGT1A1 *28 + *37 + *6 (assigned as reduced metabolisers phenotype) are associated with increased risk of Hyperbilirubinemia when treated with pazopanib in people with Carcinoma, Renal Cell as compared to UGT1A1 normal metabolizer.	2.75
1444842126	1444841889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444841889	20389299	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with pazopanib in people with Carcinoma, Renal Cell as compared to UGT1A1 *28/*1 + *1/*1.	0.0
1447813727	1447813652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447813652	26806518	Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.	1.5
1447943591	1447676729	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676729	26664259	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.	1.75
1447949305	1447949177	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949177	25673014	Genotype GG is not associated with glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	-1.25
1447949305	1447949228	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949228	25673014	Genotypes AA + AG is associated with decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.75
1447952819	1447947763	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947763	26307125	Genotype GG is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotype TT.	2.5
1447952825	1447945779	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945779	26876050	Genotypes AA + AG are associated with increased response to clozapine in people with Schizophrenia as compared to genotype GG.	0.0
1447952831	1447947702	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947702	26307125	Genotype AA is associated with increased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.	2.0
1447964542	769262745	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769262745	21142915	Genotype AA is associated with decreased risk of hand-foot syndrome and Neutropenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype GG.	2.25
1447979295	827811937	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811937	21510767	Allele G is associated with increased likelihood of Obesity when treated with antipsychotics in women as compared to allele A.	0.75
1447979295	827811963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811963	21510767	Allele G is associated with decreased likelihood of Obesity when treated with antipsychotics in men as compared to allele A.	0.0
1448098344	1448098028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448098028	24193570	Genotype GG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.	1.5
1448099574	1448099557	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448099557	26663398	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.	2.5
1448100125	1447983260	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983260	27091189	Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.	0.0
1448100235	1447983378	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447983378	27115882	Allele T is associated with increased response to adalimumab in people with Crohn Disease as compared to allele C.	0.0
1448100826	981239234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239234	22843789	Allele T is associated with increased risk of sensory peripheral neuropathy when treated with paclitaxel in women Breast Neoplasms as compared to allele C.	0.0
1448100826	1446904916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446904916	26133776	Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms or Ovarian Neoplasms as compared to genotypes CC + CT.	3.0
1448100826	1446904959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446904959	26133777	Genotype TT is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes CC + CT.	-3.5
1448100826	1447678946	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447678946	26763541	Genotypes CT + TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel as compared to genotype CC.	2.5
1448104015	769146060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769146060	21121773	Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.	2.5
1448104015	1448424049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448424049	26951882	Genotype AA is associated with decreased response to antiepileptics in women with Epilepsy as compared to genotypes AC + CC.	2.5
1448259106	1448259091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448259091	27546928	Genotype AA is associated with decreased severity of Kidney Failure when treated with captopril in people with Alzheimer Disease as compared to genotypes AT + TT.	2.0
1448276321	1448276223	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276223	27558924	Allele A is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele G.	3.75
1448615319	1448615235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448615235	28378058	Allele A is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Disease as compared to allele G.	1.0
1448616890	1448616773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616773	28347776	Genotype TT is associated with increased likelihood of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotypes CC + CT.	2.75
1444706245	981420020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420020	18650507	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.	0.0
1444706245	1183689623	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689623	23708174	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.	-2.0
1446899702	1446895686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446895686	26169577	Allele T is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C.	0.0
1446899702	1448569429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448569429	28084903	Allele T is not associated with Cough when treated with Ace Inhibitors, Plain in people with Asthma, Diabetes Mellitus, Heart Failure, Hypertension or Pulmonary Disease, Chronic Obstructive as compared to allele C.	-2.0
1444672986	982037259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037259	17431185	Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	3.5
1444672986	982037327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037327	17431185	Genotypes CG + GG are not associated with response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.	-2.0
1444672986	982037980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037980	19057464	Genotypes CC + CG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG.	3.5
1444672986	982044699	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044699	19056598	Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia.	3.0
1447961082	1447235135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447235135	22734028	Allele T is associated with increased progression-free survival when treated with cetuximab, fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms.	2.5
1447961082	1447519218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519218	20978259	Allele T is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms.	1.625
1447961082	1447519232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519232	22537608	Allele T is not associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms.	-1.5
1447961082	1447519243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519243	23090619	Allele A is associated with increased overall survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms.	1.5
1447961082	1447519253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519253	26371285	Allele T is not associated with increased response to cetuximab in people with Colorectal Neoplasms.	-0.25
1447961082	1447519260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519260	23071293	Allele T is not associated with increased overall survival when treated with cetuximab and irinotecan in people with Colorectal Neoplasms.	-0.25
1447961082	1447961091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961091	26812186	Allele T is not associated with increased overall survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms.	-0.75
1447961082	1447961269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447961269	26623049	Allele T is associated with increased progression-free survival when treated with cetuximab in people with Colorectal Neoplasms.	0.25
1447990255	982034082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034082	17764537	Genotypes CG + GG are associated with decreased dose of warfarin when treated with warfarin as compared to genotype CC.	1.5
1447990255	769168957	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769168957	20694283	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
1447990255	1183704700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704700	24019055	Genotype CG is associated with decreased dose of warfarin as compared to genotype CC.	2.5
1447990255	1184472412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472412	20128861	Allele C is not associated with dose of warfarin as compared to allele G.	-1.5
1447990255	1184511588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511588	25042728	Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.	2.0
1447990255	1444695597	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695597	25681132	Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.	1.5
1447990255	1449190777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190777	29432897	Allele G is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-1.75
1447990255	1449250615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449250615	28049362	Allele G is not associated with dose of warfarin as compared to allele C.	-1.75
1447990255	1450370798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450370798	30821933	Allele G is not associated with decreased dose of warfarin as compared to allele C.	-1.25
1444842106	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1444842106	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
1444842106	1183702544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702544	12698304	CYP2C9 *1/*3 is associated with increased AUC, higher half-life and lower flurbiprofen clearance when treated with flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1444842106	1183702553	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702553	12698304	CYP2C9 *1/*2 is associated with increased AUC and longer longer flurbiprofen elimination half-life when treated with flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1444842106	1444828093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828093	25712887	CYP2C9 *1/*3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1444842106	1444828107	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444828107	25712887	CYP2C9 *1/*1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*3.	1.5
1447681932	PA166104995	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104995		Annotation of DPWG Guideline for metoprolol and CYP2D6	100
1447681932	1183685331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685331	23665868	CYP2D6 poor metabolizer is associated with increased peak plasma metoprolol concentration (CMax/dose), increased area under the concentration-time curve (AUC/dose), increased elimination half-life, and decreased apparent oral clearance (CL/F) when treated with metoprolol as compared to CYP2D6 ultra-metabolizer phenotype.	0.5625
1447681932	1447676621	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676621	26461463	CYP2D6 normal metabolizers are associated with increased clearance of metoprolol in women with Pregnancy as compared to CYP2D6 intermediate metabolizers.	0.5
1447681932	1450944125	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944125	10223777	Allele A is not associated with increased concentrations of metoprolol in healthy individuals as compared to allele G.	-0.125
1447681932	769181593	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769181593	19037197	Allele T is associated with increased plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. when treated with metoprolol as compared to allele C.	2.25
1447681932	751923645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/751923645	19037197	Genotype del/del is associated with increased plasma concentrations of metoprolol when treated with metoprolol.	1.25
1447681932	1450944140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944140	10223777	Allele A is associated with increased concentrations of metoprolol in healthy individuals as compared to allele G.	1.0
1447681932	1043858995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858995	15467211	CYP2D6 *10 is associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	0.5
1447681932	1043859002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859002	15467211	CYP2D6 *2 is not associated with decreased clearance of metoprolol as compared to CYP2D6 *1.	-0.125
1447681932	1043859140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859140	15592325	CYP2D6 *2 is not associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	-2.0
1447681932	1043859395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859395	18834373	CYP2D6 *10 is associated with decreased metabolism of metoprolol in healthy individuals as compared to CYP2D6 *1.	1.0
1447681932	1184000492	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184000492	24193112	CYP2D6 *1/*4 + *4/*4 are associated with increased plasma metoprolol concentrations when treated with metoprolol as compared to CYP2D6 *1/*1.	2.5
1447681932	1184756327	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756327	10471072	CYP2D6 *4/*20 (assigned as poor metabolizers phenotype) is associated with decreased enzyme activity of CYP2D6 when assayed with metoprolol.	0.0
1447681932	1184756685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756685	15726636	CYP2D6 *4/*31 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of metoprolol in healthy individuals.	0.125
1447681932	1184756692	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756692	15726636	CYP2D6 *31 is associated with decreased enzyme activity of CYP2D6 when assayed with debrisoquine, dextromethorphan or metoprolol in yeast cells.	0.0
1447681932	1184756902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756902	11823760	CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	2.0
1447681932	1184756913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756913	11823760	CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.	2.0
1447681932	1184756941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756941	11823760	CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.	1.0
1447681932	1184986272	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184986272	11692084	CYP2D6 *35 is not associated with increased enzyme activity of CYP2D6 when assayed with debrisoquine, dextromethorphan or metoprolol in yeast cells as compared to CYP2D6 *1.	-0.0
1447681932	1043859051	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859051	15592325	CYP2D6 *4 + *3 + *5 + *6 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	2.0
1447681932	1043859096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043859096	15592325	CYP2D6 *9 + *29 + *45 + *46 + *17 + *10 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.	2.0
1448265356	1448265319	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265319	26223287	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is associated with increased risk of Weight gain when treated with valproic acid in women with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	0.75
1448265356	1448265331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448265331	26223287	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with increased risk of Weight gain when treated with valproic acid in men with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	-0.625
1448265356	1444608497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444608497	25372290	CYP2C19 *2 + *3 are not associated with clearance of valproic acid in people with Epilepsy as compared to CYP2C19 *1.	-1.0
1447990789	1444667615	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1444667615	25330300	Allele G is associated with decreased sensitivity to methotrexate in peripheral blood mononuclear cells as compared to allele A.	0.0
1451674160	1451672720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672720	34476898	Allele C is associated with decreased metabolism of nicotine as compared to allele T.	0.0
1451674200	1451672760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672760	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674220	1451672764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672764	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele G.	0.0
1448634065	1448634042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634042	28560854	Genotype TT is associated with nephrotoxicity when treated with cisplatin as compared to genotype CC.	0.25
1448634071	1448634049	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634049	28560854	Genotype TT is associated with nephrotoxicity when treated with cisplatin as compared to genotype CC.	0.25
1448634742	1448634590	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634590	28624888	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.	1.25
1448634742	1448634598	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448634598	28624888	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.	1.75
1451674180	1451672740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672740	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674240	1451672768	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672768	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele T.	0.0
1451674260	1451672772	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672772	34476898	Allele G is associated with decreased metabolism of nicotine as compared to allele C.	0.0
982031723	982026168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982026168	23670235	Genotypes CC + CT are associated with increased glucuronidation metabolic ratios when treated with ABT-751 in people with Neoplasms as compared to genotype TT.	1.0
1183606758	982035751	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035751	16610939	Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.	2.25
1183606758	1450812390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812390	19205682	Genotype TT is not associated with response to nimodipine in healthy individuals as compared to genotype GT.	-0.25
1183606758	982035593	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035593	16610939	Genotype TT is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes GG + GT.	2.5
1183606758	982035781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035781	16610939	Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.	2.25
1448616882	1448616817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616817	28347776	Genotypes CC + CG are associated with increased likelihood of Asthenia when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype GG.	3.25
1448616922	1448616739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616739	28347776	Genotype TT is associated with increased likelihood of Nausea and Vomiting when treated with capecitabine in people with as compared to genotypes CC + CT.	2.75
1448616922	1448616759	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448616759	28347776	Genotypes CT + TT are associated with decreased likelihood of Asthenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.	2.75
1450943780	1450943742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450943742	31350855	Genotypes A/del + del/del are associated with decreased response to Beta Blocking Agents in people with Hypertension as compared to genotype AA.	2.75
1444694588	982046809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046809	21359536	Genotype GG is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	2.25
1444694588	1000539639	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1000539639	23894093	Genotype GG is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.	-0.125
1444694588	827813819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813819	21770725	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.75
1444694588	827830265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830265	12966368	Allele G is not associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.	-1.25
1444694588	769170882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170882	14747421	Genotype GG is associated with increased dose of tacrolimus in people with Transplantation as compared to genotypes AA + AG.	1.25
1444694588	769170937	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170937	14583680	Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.5
1444694588	769172715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769172715	15521904	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-0.75
1444694588	1183491684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491684	23900887	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444694588	1183491688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491688	23900887	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-1.25
1444694588	1183492294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183492294	23375287	Genotypes AG + GG are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	1.0
1444694588	1183684058	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684058	21903774	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	-1.0
1444694588	1183684112	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684112	23107770	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.	-1.0
1444694588	1183684270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684270	24120259	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.	-0.125
1444694588	1183684288	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684288	23733010	Allele A is not associated with bioavailability of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.25
1444694588	1183693332	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183693332	22660440	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	-1.75
1444694588	1183697411	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697411	22183771	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	-2.5
1444694588	1183697956	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697956	21094796	Genotype GG is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	-0.75
1444694588	1183697961	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697961	23149441	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1444694588	1183958243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183958243	18429967	Allele G is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.	-1.0
1444694588	1183960183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960183	20383212	Allele A is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele G.	-0.25
1444694588	1183960187	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183960187	20383212	Allele A is not associated with clearance of tacrolimus in children with hemopoietic stem cell transplant as compared to allele G.	-0.25
1444694588	1184468799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468799	21047202	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.25
1444694588	1184470275	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470275	24625991	Allele A is not associated with likelihood of achieving target concentrations of tacrolimus in children with Kidney Transplantation as compared to allele G.	-0.125
1444694588	1184470904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470904	24528196	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	1.5
1444694588	1184470927	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470927	24526611	Genotypes AG + GG is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype AA.	1.0
1444694588	1184471270	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471270	24444408	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1444694588	1185012360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185012360	25310192	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.	-1.25
1444694588	1185023205	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185023205	24383873	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-0.125
1444694588	1444693914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444693914	22786571	Genotypes AA + AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-0.75
1444694588	1450944360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944360	16797284	Genotype AA is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.	2.75
1444694588	1450944400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450944400	16797284	Genotype GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	1.75
1444694588	1445125617	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445125617	26184414	Allele G is not associated with concentrations of tacrolimus as compared to allele A.	-0.75
1444694588	1445297476	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297476	25817604	Genotype AA is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid as compared to genotype GG.	1.75
1444694588	1445297512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445297512	25817604	Genotype AA is not associated with dose of tacrolimus in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	-1.25
1444694588	1447520701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520701	26227094	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.	-0.75
1444694588	1447520846	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520846	26543771	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.	-1.0
1444694588	1447674287	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674287	26622455	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	-0.75
1444694588	1447946341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946341	26705892	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype AG.	1.75
1444694588	1447946579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447946579	26705892	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.	1.75
1444694588	1447949199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447949199	25673014	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	-0.75
1444694588	1448099963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448099963	26307985	Genotypes AA + AG are associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.	1.0
1444694588	1448285628	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448285628	26990259	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.	-0.75
1444694588	1448308434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448308434	27503662	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	-0.75
1444694588	1448573188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573188	28094348	Genotype GG is not associated with metabolism of tacrolimus in children with Kidney Transplantation as compared to genotypes AA + AG.	-0.125
1444694588	1448573364	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573364	28135009	Genotypes AG + GG are not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.	-0.75
1444694588	1448612336	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448612336	28324194	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes AA + AG.	-1.25
1444694588	1448641151	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448641151	28342282	Genotype GG is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to genotypes AA + AG.	-0.125
1444694588	1448820632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448820632	28736028	Genotype GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	-0.125
1444694588	1449170406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449170406	27138785	Genotype AA is not associated with dose of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.	-0.25
1444694588	1449171233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171233	29162334	Genotype AG is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	-0.125
1444694588	1449171405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171405	27966227	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.	-0.125
1444694588	1449732693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449732693	28833329	Genotype GG is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.	1.0
1448640301	1450950800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450950800	20530282	Genotype CT is not associated with response to FOLFIRI, FOLFOX, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	-2.0
1448640301	1450951310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450951310	25381393	Genotype CT is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	-2.0
1448640301	1447945405	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945405	26846104	Genotype CC is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	2.0
1448640301	1447945434	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945434	26846104	Genotype CC is not associated with event-free survival when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.	-1.5
655385129	699639387	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699639387	18559695	Genotype AA is associated with decreased HMGCRv_1 expression and an increase in the expression of the full-length transcript as compared to genotypes AG + GG.	0.0
655385409	981239992	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981239992	12844134	Genotype AA is associated with increased response to metoprolol in people with Hypertension as compared to genotype AG.	1.5
655385409	981476533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981476533	16815314	Genotype AA is associated with increased response to metoprolol in people with Essential hypertension as compared to genotype AG.	1.75
655385409	827816346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816346	22192668	Genotypes AG + GG are not associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype AA.	-1.75
655385409	613979010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613979010	15861037	Allele A is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.	-1.5
1043872988	769166446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769166446	17549067	Genotype GG is associated with decreased progression free survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.	2.5
1183605989	982036156	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036156	16610939	Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.	1.75
1183605989	982036189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036189	16610939	Allele C is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to allele T.	-1.25
1183605989	982035533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035533	16610939	Allele C is associated with increased response to calcium channel blockers in people with Hypertension as compared to allele T.	2.0
1183606395	982035812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035812	16610939	Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.	1.75
1183606395	982035861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035861	16610939	Genotype CC is not associated with response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotype CG.	-1.25
1183606395	982035563	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982035563	16610939	Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes CC + CG.	2.5
1183700517	981476048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476048	22341855	Genotype CC is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes CT + TT.	2.25
1183700517	1449002721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002721	29036176	Allele T is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C.	-1.5
1444704963	827700164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827700164	20520601	Genotype TT is associated with increased Anxiety Disorders when exposed to caffeine as compared to genotypes CC + CT.	0.0
1448125499	1448125490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448125490	25965825	Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.	2.5
1449003940	1448996269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996269	27157822	Allele del is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A.	0.0
1449157000	1449156987	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156987	29222992	Allele A is associated with increased insomnia due to methadone in people with Opioid-Related Disorders as compared to allele G.	2.75
1449157284	1449157237	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157237	23612435	Genotype CC is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.	2.0
1449157284	1449157244	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449157244	23612435	Allele C is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele T.	-1.75
1449162591	1449162314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162314	26332828	Allele G is associated with decreased risk of cognitive dysfunction when treated with fentanyl in people with Neoplasms as compared to allele A.	3.25
1449164443	1449164359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164359	29369421	Genotype CC is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Myeloproliferative Disorders as compared to genotypes CT + TT.	2.75
1449167245	1449166044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166044	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449191952	1449191933	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449191933	28325531	Genotype del/del is associated with increased likelihood of adverse events when treated with ivacaftor / lumacaftor in people with Cystic Fibrosis.	0.0
1449192683	1449192671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192671	28930490	Allele A is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.	1.5
1449269278	1184483916	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483916	23104259	Allele T is not associated with increased risk of all, major and minor hemorrhage as well as over anticoagulation when treated with warfarin as compared to allele C.	-1.75
1449269278	1184510096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510096	22417713	Genotype TT is associated with decreased likelihood of INR >3 (over-anticoagulation) when treated with warfarin as compared to genotypes CC + CT.	0.0
1449269278	1447952681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447952681	26877068	Genotype TT is associated with decreased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	0.0
1449269278	1444708189	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708189	24911077	Genotypes CT + TT are associated with decreased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to genotype CC.	2.25
1449269278	1447223100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223100	23104259	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.75
1449269278	1449254297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449254297	28049362	Allele T is not associated with Blood Coagulation Disorders when treated with warfarin as compared to allele C.	-1.75
1449271075	1449270815	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270815	29593529	Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
981201946	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201946	1447945626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945626	26099996	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.	-1.75
981201946	827892923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892923	14635116	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
981201946	1450953025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953025	26603945	Allele T is not associated with risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele C.	-1.0
981201946	1450954000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954000	18299612	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
981201946	1450954540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954540	19473056	Genotype CT is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	-1.5
981201946	1450954660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954660	19530960	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
981201946	1450959905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450959905	15591715	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
981201946	1448124239	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124239	23736036	Genotype CT is associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.0
981201946	1448126269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126269	26794347	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele C.	-1.75
981201946	1448262697	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262697	24923815	Allele T is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201946	1449161763	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161763	28427087	Genotype CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CT + TT.	-2.0
981201946	1449162040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162040	29065426	Genotypes CT + TT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	-2.0
981201946	1449732020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732020	30114658	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.5
1450810975	1450810926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810926	16732015	Genotypes CT + TT are associated with decreased Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.	3.0
981201962	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
981201962	1447987416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447987416	22490566	Genotypes CC + CT are not associated with Drug Toxicity when treated with capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.	-1.75
981201962	1447945633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945633	26099996	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.75
981201962	769169854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169854	17848752	Genotype CC is associated with increased likelihood of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	1.75
981201962	827892939	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892939	14635116	Genotype CT is not associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	-1.5
981201962	769169871	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/769169871	17848752	Genotype CC is associated with decreased clearance of fluorouracil as compared to genotype TT.	0.0
981201962	769169847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169847	17848752	Genotype CC is associated with increased likelihood of Nausea and Vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	2.25
981201962	1450952700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952700	11156223	Allele C is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to allele T.	0.25
981201962	1450954520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954520	19473056	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.	-1.5
981201962	1450954700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954700	19530960	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.	-1.5
981201962	1450954820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954820	23942539	Allele C is not associated with Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele T.	-0.25
981201962	1450954900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954900	18299612	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil.	-1.75
981201962	1448126219	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126219	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms or Colorectal Neoplasms as compared to allele T.	-1.75
981201962	1448262704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262704	24923815	Allele C is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.75
981201962	1449162048	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162048	29065426	Genotypes CC + CT is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype TT.	-2.0
981201962	1449732013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732013	30114658	Genotypes CC + CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.	-2.0
1450928601	1450928591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928591	28820077	Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.	1.75
1445401793	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1445401793	1450952420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450952420	10803677	Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1445401793	982009850	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009850	23588312	Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype CC.	1.25
1445401793	1450953041	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450953041	16115930	Genotype CT is not associated with decreased catalytic activity of DPYD as compared to genotype CC.	-0.0
1445401793	1450955300	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955300	26265035	Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.	0.0
1445401793	1450951685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450951685	26804652	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
1445401793	1447987720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447987720	23328581	Genotype TT is not associated with activity of DPYD when assayed with fluorouracil as compared to genotype CC.	-0.0
1450936735	1450936730	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936730	31002879	Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes CC + TT.	0.0
827843617	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
827843617	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
827843617	769176388	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176388	20819423	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1450950682	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950682	19104657	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.0
827843617	981352322	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352322	15017333	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	0.0
827843617	981352338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352338	18443386	Genotype CT is associated with Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms.	1.75
827843617	981352346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352346	19858398	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	-2.0
827843617	981390716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981390716	19473056	Genotype CT is associated with increased likelihood of mucositis when treated with fluorouracil in women with Neoplasms as compared to genotype CC.	3.0
827843617	981394390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981394390	19473056	Genotype CT is associated with increased likelihood of Thrombocytopenia when treated with fluorouracil in women with Neoplasms as compared to genotype CC.	2.25
827843617	982006233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006233	23603345	Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
827843617	982010242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982010242	23585145	Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
827843617	827810976	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810976	20809970	Genotype CT is associated with risk of Drug Toxicity when treated with fluorouracil in people with Gastrointestinal Neoplasms.	0.25
827843617	827814910	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827814910	11555601	Genotypes CT + TT is associated with Death and Myelosuppression when treated with fluorouracil in people with Drug Toxicity as compared to genotype CC.	0.25
827843617	827823452	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823452	19530960	Genotype CT is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-1.5
827843617	827824695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824695	17700593	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.	2.25
827843617	827825029	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825029	17335544	Genotype CT is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.	0.0
827843617	827825042	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825042	17165084	Genotype CT is associated with Death when treated with fluorouracil in people with Pancreatic Neoplasms.	0.25
827843617	827892654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892654	17064846	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.75
827843617	827892773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892773	17121937	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	2.75
827843617	769171393	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171393	18299612	Genotype CT is associated with increased risk of Drug Toxicity, Leukopenia and mucositis when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.75
827843617	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
827843617	1184471962	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471962	24167597	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	3.25
827843617	1184473549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473549	24817302	Genotypes CT + TT is associated with increased severity of Myelosuppression when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473554	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473554	24817302	Genotypes CT + TT is associated with increased severity of hand-foot syndrome when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473558	24817302	Genotypes CT + TT is associated with increased severity of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	1.75
827843617	1184473562	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473562	24817302	Genotypes CT + TT is not associated with severity of mucositis when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.25
827843617	1184473566	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473566	24817302	Genotypes CT + TT is not associated with severity of gastrointestinal toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.25
827843617	1450945020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450945020	9472650	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in men with Colorectal Neoplasms as compared to genotype CC.	0.25
827843617	1450949820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450949820	30898145	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Pancreatic Neoplasms as compared to genotype CC.	0.25
827843617	1450950640	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450950640	11953843	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	0.25
827843617	1450951027	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951027	23481061	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Head and Neck Neoplasms as compared to allele C.	-0.25
827843617	1450951200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951200	24700034	Allele T is associated with increased risk of Drug Toxicity when treated with fluorouracil in women with Pancreatic Neoplasms as compared to allele C.	0.25
827843617	1450951260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951260	9470816	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in women with Breast Neoplasms as compared to genotype CC.	0.25
827843617	1450951303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951303	25381393	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	4.0
827843617	1450951481	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951481	29134491	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	2.0
827843617	1450951510	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951510	8698850	Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in men with Neoplasms.	0.25
827843617	1450951600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951600	27738344	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer.	0.25
827843617	1450951660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450951660	30775324	Allele T is associated with increased risk of Death when treated with fluorouracil in men with Carcinoma, Squamous Cell.	0.25
827843617	1450952760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952760	11156223	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms, Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms or Stomach Neoplasms as compared to genotype CC.	0.25
827843617	1450952800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952800	11350878	Genotype TT is associated with increased risk of Drug Toxicity and Death when treated with fluorouracil in women with Rectal Neoplasms.	0.25
827843617	1450952860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952860	12360106	Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	3.0
827843617	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
827843617	1450953460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953460	16361556	Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450953940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953940	18299612	Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil.	3.5
827843617	1450954786	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450954786	20385995	Genotype CT is associated with increased likelihood of Neutropenia when treated with fluorouracil, FOLFIRI or FOLFOX in people with Colorectal Neoplasms as compared to genotype CC.	0.0
827843617	1450955720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450955720	20803296	Genotype CT is associated with decreased activity of DPYD.	0.0
827843617	1450955734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450955734	20803296	Genotype CT is associated with increased Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450956264	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450956264	23736036	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
827843617	1450960760	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450960760	9439663	Allele T is associated with decreased activity of DPYD as compared to allele C.	0.0
827843617	1447945371	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945371	26846104	Genotype CT is associated with increased Infection and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.	2.0
827843617	1447945531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945531	26099996	Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.	4.0
827843617	1447959056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959056	24923815	Allele T is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	-3.75
827843617	1447988372	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988372	12209976	Genotypes CT + TT is associated with risk of Neutropenia when treated with fluorouracil in people with Neoplasms.	0.25
827843617	1447988460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988460	19795123	Allele T is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	0.25
827843617	1448124202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124202	23736036	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
827843617	1448126243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126243	26794347	Allele T is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms and Colorectal Neoplasms as compared to allele C.	-1.75
827843617	1449162076	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449162076	29065426	Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.	0.0
827843617	1449165558	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165558	26967565	Genotype CT is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	-1.75
827843617	1449731693	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449731693	30114658	Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.	4.0
827843617	1449732176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449732176	29998006	Genotype CT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms.	0.25
827843617	1450371900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371900	30723313	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	3.5
827843617	1450373052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373052	30485432	Genotype CT is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.	0.25
1450944540	1450944460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450944460	20030680	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with cyclosporine in people with hematopoietic stem cell transplantation as compared to genotypes AA + AG.	0.25
1450945347	1450945340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450945340	31932420	Genotypes AA + AC are associated with increased resistance to glucocorticoids in people with Asthma as compared to genotype CC.	3.25
1451674300	1451672880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672880	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674308	1451672884	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672884	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele G.	0.0
1451526333	PA166105005	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105005		Annotation of CPIC Guideline for simvastatin and SLCO1B1	100
1451526333	PA166182844	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182844		Annotation of DPWG Guideline for simvastatin and SLCO1B1	100
1451526333	1451231960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451231960	29242847	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.	2.25
1451526333	1448821136	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448821136	28812116	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.	-1.75
1451526333	655386692	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386692	18650507	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.	3.5
1451526333	1450397924	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450397924	30250148	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.	1.75
1451526333	1451390520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451390520	26376374	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.75
1451526333	1451463080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451463080	34114646	Genotype CC is associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	3.5
1451526333	1451479840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451479840	33608664	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.5
1451526333	1451480140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451480140	33150478	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.	1.75
1451526333	981420028	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420028	18650507	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.	0.0
1451526333	769164512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769164512	21243006	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.	1.75
1451526333	1183689645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183689645	23942138	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.	3.25
1451526333	1183699306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699306	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	2.5
1451526333	1183699611	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699611	24263182	Genotype CC is not associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	-1.75
1451526333	1183699615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183699615	24263182	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.	0.0
1451526333	1448613086	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448613086	27839692	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.	-2.0
1451526333	1449576945	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449576945	28940218	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.	2.5
1451526333	1184989268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184989268	19833260	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.	2.25
637880087	637880083	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/637880083	19625999	Genotype AC is associated with decreased risk of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotype CC.	0.0
637880087	827816530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816530	21902499	Genotype CC is not associated with increased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AC.	-1.25
637880087	1448633980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448633980	28640195	Genotype AC is associated with increased severity of nephrotoxicity due to cisplatin in people with Neoplasms as compared to genotype CC.	2.25
1450812229	1450812146	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812146	18518925	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	0.0
1450812229	1450822370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822370	22500942	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.0
1450812229	1450827139	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827139	28692418	Allele T is not associated with risk of Heroin Dependence due to heroin as compared to allele C.	-2.5
1450813775	1450812534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812534	19764934	Genotype GG is associated with increased severity of Alcoholism due to ethanol as compared to genotypes G/del + del/del.	2.25
1450815148	1450815067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815067	23241943	Allele A is associated with increased response to quetiapine in people with Schizophrenia as compared to allele G.	0.0
1450820507	1444694036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694036	25615449	Genotype TT is not associated with dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.	-1.75
1450820507	1450820493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450820493	23940630	Genotypes CC + CT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype TT.	2.25
1450959466	1450958825	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958825	19036622	Allele A is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.	0.0
1450959472	1450958862	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958862	19036622	Allele G is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele A.	0.0
1451674315	1451672960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672960	34476898	Allele G is associated with decreased metabolism of nicotine as compared to allele A.	0.0
613978931	1447678164	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678164	26555147	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	2.0
613978931	1447678392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678392	26314341	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	0.0
613978931	981500472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500472	22292851	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
613978931	982023304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023304	22591328	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
613978931	827823984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823984	22188362	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	2.5
613978931	827823998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823998	22188362	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.5
613978931	613978592	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978592	15805193	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	2.75
1183630664	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1183630664	PA166104939	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104939		Annotation of DPWG Guideline for fluorouracil and DPYD	100
1183630664	1447959040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959040	24923815	Allele C is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Article designed about c.11295923C>G as additional risk variant and not to detect association with toxicity and c.1679T>G In the conclusion the authors state: "....c.11295923C>G DPYD variant as a predictive marker of earlyonset FP toxicity in a realworld clinical setting. We estimate that fewer than 50 patients need to be screened prior to therapy for this variant and for c.1905+1G>A, c.1679T>G and c.2846A>T in order to prevent one case of severe FP toxicity."
1183630664	1444607122	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607122	25381393	Genotype AC is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population (only 4 patients with the AC genotype). No significant increase in risk of experiencing grade 3 or higher adverse events, either 5-fluorouracil-related adverse events or overall adverse events.
1183630664	1447945597	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945597	26099996	Genotype AC is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population Only two patients carried the varian and both had toxicities.
1183630664	1447991202	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447991202	19530960	Genotype AC is not associated with Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	This annotation is not used for clinical annotation scoring. Lack of a statistically significant association was likely due to the low frequency of the allele in the population. Only 1 heterozygote variant carrier, which experienced grade 0-2 toxicity
1183630664	1450372235	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372235	30858516	Genotypes AC + CC is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	This annotation is not used for clinical annotation scoring. c.1679T>G was present in 2 of the cases group, but were absent in the controls group. 2 patients developed Grade >=3 toxicity. Non-significance likely due to sample size.
1183630664	1448126314	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448126314	26794347	Allele C is not associated with severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele A.	This annotation is not used for clinical annotation scoring. "Although our data set was relatively large and the power was good enough to detect AE variants with relatively large effects, the power may have been too low to detect variants with low allele frequency (including DPYD*2A and I560S) and/or smaller effect sizes."
1183630664	827892788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827892788	17121937	Genotype AC is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.	2.75
1183630664	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1183630664	1446440411	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446440411	26265035	Genotype AC is associated with increased risk of Death when treated with fluorouracil in women with Intestinal Neoplasms.	0.25
1183630664	1447988419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447988419	19795123	Allele C is associated with risk of Neutropenia when treated with fluorouracil in people with Neoplasms.	0.25
1183630664	1448124253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448124253	23736036	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.	2.75
1183630664	1449161870	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161870	28427087	Genotype AA is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes AC + CC.	-2.0
1183630664	1450373067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450373067	30485432	Genotype AC is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype AA.	0.25
1043859155	PA166105007	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105007		Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6	100
1043859155	PA166104964	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104964		Annotation of DPWG Guideline for clomipramine and CYP2D6	100
1043859155	1183683963	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683963	1451721	CYP2D6 poor metabolizer is associated with decreased metabolism of clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.	0.0625
1043859155	1183683968	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683968	3582462	CYP2D6 poor metabolizer is associated with increased plasma concentrations of clomipramine and desmethylclomipramine when treated with clomipramine.	0.0625
1043859155	1183684300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684300	1527229	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	0.5
1043859155	1184470662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470662	2741190	CYP2D6 poor metabolizers are associated with increased plasma concentrations of clomipramine and desmethylclomipramine when treated with clomipramine.	0.0625
1043859155	982030030	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982030030	11763000	CYP2D6 *10/*10 is not associated with difference in the metabolic ratio of desmethyl clomipramine (DC)/hydroxy desmethyl clomipramine (HDC) when treated with clomipramine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-0.75
1043859155	1183616635	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616635	8181196	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616668	10460069	CYP2D6 *4/*4 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1183616898	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616898	8181196	CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616907	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616907	8181196	CYP2D6 *3/*4 (assigned as poor metabolizers phenotype) is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2D6 *1 (assigned as normal metabolizers phenotype) .	1.5
1043859155	1183616915	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616915	10460069	CYP2D6 *3/*4 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1183616923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183616923	10460069	CYP2D6 *4/*5 is associated with increased clomipramine and desmethyl clomipramine plasma concentration when treated with clomipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1.	0.0
1043859155	1446901329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901329	8093319	CYP2D6 *2/*1xN is associated with decreased concentrations of clomipramine in people with Agoraphobia.	0.125
1043859155	1446901449	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901449	16871470	CYP2D6 *4/*6 is associated with increased concentrations of clomipramine in people with Depressive Disorder, Major.	0.125
1043859155	1446901471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446901471	9562213	CYP2D6 *1/*1xN is associated with decreased concentrations of clomipramine in people with Depression.	0.125
1043859155	1446903175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903175	20531370	CYP2D6 *3 + *4 + *5 + *6 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2D6 *1/*1.	-1.0
1043859155	1450368707	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450368707	29894392	CYP2D6 *4/*5 is associated with decreased metabolism of clomipramine.	0.0
1043859155	1448631815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448631815	28470111	CYP2D6 *4/*41 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.	0.0
1447814391	1447676752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676752	26729753	Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA.	0.0
1448266008	1448265990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448265990	27707539	Genotype AA is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.	1.0
1448266008	1448266001	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448266001	27707539	Allele A is associated with increased activity of CFTR when treated with ivacaftor as compared to allele G.	0.0
1448266986	1448266896	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266896	27590272	Genotypes AA + AC are associated with increased severity of Toxic liver disease when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.75
1448266986	1448266907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266907	27590272	Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.25
1448531101	1448530854	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530854	27450232	Allele G is associated with decreased risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	2.25
1448573523	1448573308	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573308	28117133	CYP2C19 ultra-metabolizer genotype is associated with increased metabolism of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to CYP2C19 intermediate metabolizer genotype.	0.375
1450963020	1296667150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1296667150	25069034	Genotypes CT + TT is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.0
1450963060	1448256843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256843	27498158	Genotypes CC + CT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.5
1451674360	1451672964	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672964	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674380	1451672968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672968	34476898	Allele A is associated with decreased metabolism of nicotine as compared to allele C.	0.0
655384666	827843584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827843584	15809899	Genotypes CC + CT are associated with increased non-HDL cholesterol when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C.	2.25
1184757183	1183678427	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678427	9415713	CYP2D6 *17 is associated with decreased activity of CYP2D6 when assayed with bufuralol or codeine as compared to CYP2D6 *1.	0.0
1184757183	1183678504	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678504	17470523	CYP2D6 *10 is associated with decreased clearance of bufuralol as compared to CYP2D6 *1.	0.0
1184757183	1183678521	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678521	17470523	CYP2D6 *17 is associated with decreased clearance of bufuralol as compared to CYP2D6 *1.	0.0
1184757183	1184755428	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184755428	9089660	CYP2D6 *7 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol.	0.0
1184757183	1184756131	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756131	8946471	CYP2D6 *18 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol in yeast cells as compared to CYP2D6 *1.	0.0
1184757183	1184756168	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756168	18784265	CYP2D6 *10 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756185	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756185	18784265	CYP2D6 *114 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756194	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756194	18784265	CYP2D6 *18 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756204	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756204	18784265	CYP2D6 *36 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756212	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756212	18784265	CYP2D6 *47 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756220	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756220	18784265	CYP2D6 *49 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756228	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756228	18784265	CYP2D6 *50 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756236	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756236	18784265	CYP2D6 *51 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756244	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756244	18784265	CYP2D6 *54 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756252	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756252	18784265	CYP2D6 *55 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756260	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756260	18784265	CYP2D6 *57 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756830	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756830	11470994	CYP2D6 *29 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or debrisoquine in COS-1 cells as compared to CYP2D6 *1.	0.0
1184757183	1184756847	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184756847	11470994	CYP2D6 *29 is not associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in yeast cells as compared to CYP2D6 *1.	-0.0
1184757183	1184757130	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184757130	12152006	CYP2D6 *29 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-1 cells as compared to CYP2D6 *2.	0.0
1184757183	1184763836	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184763836	19158312	CYP2D6 *49 is associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in E. coli membrane as compared to CYP2D6 *1.	0.0
1184757183	1184763858	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184763858	19158312	CYP2D6 *72 is associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in E. coli membrane as compared to CYP2D6 *1.	0.0
1184757183	1184763865	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184763865	19158312	CYP2D6 *10/*49 is associated with decreased enzyme activity of CYP2D6 when assayed with dextromethorphan in liver microsomes as compared to CYP2D6 *1/*1.	0.0
1184757183	1296599977	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1296599977	25469868	CYP2D6 *89 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in 293 FT cells as compared to CYP2D6 *1.	0.0
1184757183	1296599992	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1296599992	25469868	CYP2D6 *92 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in 293 FT cells as compared to CYP2D6 *1.	0.0
1184757183	1296600006	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1296600006	25469868	CYP2D6 *93 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in 293 FT cells as compared to CYP2D6 *1.	0.0
1184757183	1296600018	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1296600018	25469868	CYP2D6 *96 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in 293 FT cells as compared to CYP2D6 *1.	0.0
1184757183	1446896390	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446896390	18784265	CYP2D6 *27 is not associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	-0.0
1184757183	1446896400	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446896400	18784265	CYP2D6 *39 is not associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	-0.0
1184757183	1446896410	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446896410	18784265	CYP2D6 *53 is associated with increased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1446896420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446896420	18784265	CYP2D6 *48 is not associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	-0.0
1184757183	1446896444	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446896444	18784265	CYP2D6 *14 is associated with decreased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1446897814	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446897814	26310775	CYP2D6 *92 + *96 are associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol in insect microsomes as compared to CYP2D6 *1.	0.0
1184757183	1446897826	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446897826	26310775	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of bufuralol in insect microsomes as compared to CYP2D6 *1.	0.0
1184757183	1446898923	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446898923	11950793	CYP2D6 *17 is associated with decreased clearance of bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.	0.0
1184757183	1446898988	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1446898988	11950793	CYP2D6 *17 is associated with decreased clearance of bufuralol, debrisoquine or dextromethorphan in microsomes from baculovirus-transfected cells as compared to CYP2D6 *1.	0.0
1184757183	1447958757	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447958757	25469868	CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or dextromethorphan in 293 FT cells as compared to CYP2D6 *1.	0.0
1184757183	1447959361	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959361	24647041	CYP2D6 *12 + *114 + *36 + *47 + *51 + *57 + *62 are associated with decreased activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1184757183	1447959384	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447959384	24647041	CYP2D6 *7 + *10 + *37 + *40 + *54 + *64 + *71 + *75 are associated with decreased activity of CYP2D6 when assayed with bufuralol or dextromethorphan in COS-7 microsomes as compared to CYP2D6 *1.	0.0
1184757183	1447984275	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447984275	27043475	CYP2D6 *114 is associated with decreased activity of CYP2D6.	0.0
1184757183	1447991350	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447991350	7935325	CYP2D6 *36 is associated with decreased catalytic activity of CYP2D6 when exposed to bufuralol in COS-1 cells as compared to CYP2D6 *1.	0.0
1184757183	1447991358	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1447991358	7935325	CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when exposed to bufuralol in COS-1 cells as compared to CYP2D6 *1.	0.0
1184757183	1450042169	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450042169	17470523	CYP2D6 *10 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.	0.0
1184757183	1450042188	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450042188	17470523	CYP2D6 *17 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.	0.0
1447521683	1450974120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450974120	21923605	Genotype CC is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CT + TT.	1.75
1448999856	1448532490	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448532490	28087463	CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 when assayed with tolterodine.	0.0
1448999856	1448532500	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448532500	28087463	CYP2D6 *10 + *93 + *94 + *95 are associated with decreased clearance of tolterodine as compared to CYP2D6 *1.	0.0
1448999856	1448532449	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448532449	28087463	CYP2D6 *2 + *87 + *88 + *89 + *90 + *91 + *97 + *98 are not associated with decreased catalytic activity of CYP2C19 when assayed with tolterodine as compared to CYP2D6 *1.	-0.0
1450975180	1450974101	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450974101	21923605	Genotype TT is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CC + CT.	1.75
655384733	1451340144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340144	31869433	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	1.0
655384733	1451589762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589762	31114289	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.25
655384733	981483987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483987	20653676	Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.	2.5
655384733	981500585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981500585	21127708	Allele T is associated with increased dose of warfarin in people with Myocardial Infarction as compared to allele C.	0.0
655384733	982034243	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034243	16270629	Allele T is associated with increased dose of warfarin as compared to allele C.	0.0
655384733	827567329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567329	15883587	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
655384733	655388073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388073	16676068	Allele T is associated with increased dose of warfarin.	2.5
655384733	1183697222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697222	22349464	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655384733	1183697701	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697701	23990957	Genotypes CT + TT is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to genotype CC.	2.25
655384733	1183704904	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704904	24019055	Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.	3.0
655384733	1184472447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472447	20128861	Allele T is associated with increased dose of warfarin as compared to allele C.	2.5
655384733	1184483453	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483453	23208322	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
655384733	1184756163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756163	25126975	Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	3.5
655384733	1185002294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185002294	21635147	Allele T is associated with increased dose of warfarin as compared to allele C.	2.0
655384733	1444694676	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694676	25594941	Genotype CC is not associated with dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	-1.5
655384733	1444694686	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694686	25594941	Genotype CC is associated with decreased concentrations of warfarin in people with heart valve replacement as compared to genotypes CT + TT.	2.5
655384733	1450979280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450979280	25084205	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.0
655384733	1448276167	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276167	21326313	Genotype TT is associated with increased dose of warfarin as compared to genotype CC.	3.0
655384733	1447519684	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519684	18466099	Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.	2.75
655384733	769277903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277903	15358623	Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.	2.0
655384733	827649690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827649690	16611750	Allele T is associated with increased dose of warfarin as compared to allele C.	1.75
655384733	769277912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769277912	17049586	Genotype CT is associated with increased dose of warfarin as compared to genotype CC.	2.25
1183704228	981238818	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981238818	22920394	Allele A is associated with dose of acenocoumarol in people with a stable maintenance dose.	0.0
1183704228	981934126	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981934126	16815313	Genotype GG is associated with increased dose of acenocoumarol as compared to genotypes AA + AG.	1.5
1183704228	1043737589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737589	16201835	Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.	1.75
1183704228	1043818101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818101	20020283	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	3.0
1183704228	655388351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388351	19270263	Genotype AA is associated with decreased dose requirement of acenocoumarol as compared to genotypes AG + GG.	2.0
1183704228	1450979500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450979500	18781852	Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.	0.0
1183704228	1450415284	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450415284	30983536	Genotype AA is associated with decreased dose of acenocoumarol.	0.25
1183704228	1444706973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444706973	19225451	Genotypes AA + AG are associated with decreased dose of acenocoumarol as compared to genotype GG.	3.0
1183704228	1444707128	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707128	17596133	Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.	2.25
655387652	655388504	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388504	16513877	Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT.	-2.25
655387652	655387624	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387624	17105675	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	1.0
655387652	1450928193	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928193	28696411	Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T.	-1.75
655387652	655387634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387634	18855532	Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT.	2.0
1447673005	1444697569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697569	25769357	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.	3.0
1447673005	1447223035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223035	18690342	Genotype TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	1.5
1447673005	1447223093	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223093	23104259	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.75
1447673005	1447519274	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519274	23602689	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	2.5
1447673005	1447519425	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519425	25244877	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.5
1447673005	1447520024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520024	26445138	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	2.0
1447673005	1447520306	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520306	19794411	Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	3.25
1447673005	1447521449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521449	22990331	Allele T is not associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	-1.5
1447673005	1447521736	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521736	23279643	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin in children as compared to genotypes CC + CT.	0.0
1447673005	1447586730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586730	21318593	Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	3.5
1447673005	1447680569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680569	26739746	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.	0.0
1447673005	982046164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046164	19874474	Allele T is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.	1.75
1447673005	978616277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/978616277	22571356	Genotypes CT + TT are associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to genotype CC.	3.5
1447673005	1183701243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701243	18574025	Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin.	3.5
1447673005	1184483167	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483167	23932037	Genotypes CT + TT is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to genotype CC.	1.5
1447673005	1448602391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602391	28033245	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	2.0
1447673005	1449192296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192296	28049362	Allele T is associated with increased Blood Coagulation Disorders when treated with warfarin as compared to allele C.	2.75
655385024	1451340084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451340084	31869433	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	1.0
655385024	1451589745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451589745	31114289	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	2.25
655385024	982038164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982038164	20203262	Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.	2.0
655385024	982044349	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044349	16611750	Allele G is associated with increased dose of warfarin as compared to allele A.	2.25
655385024	827567321	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827567321	15883587	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385024	1183701268	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701268	18574025	Allele A is associated with dose of warfarin.	2.5
655385024	1183704894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183704894	24019055	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385024	1184472436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472436	20128861	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
655385024	1450980680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450980680	18322281	Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.	2.75
655385024	1450980780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450980780	18322281	Genotypes AA + AG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype GG.	3.75
655385024	1448106998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448106998	18030307	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.25
655385024	1448276172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276172	21326313	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.	3.0
655385024	1447519671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519671	18466099	Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.	3.25
655385024	1447519944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519944	19752777	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.75
655385024	613977249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613977249	16270629	Allele A is associated with decreased dose of warfarin.	2.5
655386075	981477959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477959	16331627	Genotype GG is associated with increased likelihood of Complete Remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	1.75
655386075	981477974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477974	16331627	Genotype GG is associated with increased likelihood of 3-year Event Free Survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.	1.75
655386075	769152970	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769152970	20938465	Genotype GG is not associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype AA.	-1.25
655386075	1445297082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297082	25558979	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.	1.5
655386075	1446897938	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897938	25567217	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.	-1.75
1183684172	655388061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388061	16331627	Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.	2.0
1183684172	655388064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655388064	16331627	Genotype CC is associated with increased likelihood of 3 year event free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.	2.0
1183684172	769152967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769152967	20938465	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.	1.75
1183684172	1445297092	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445297092	25558979	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.	1.25
1183684172	1446897929	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446897929	25567217	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.	-1.75
1183703296	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1183703296	1183703229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703229	16182270	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1183703296	1183703238	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703238	15764711	CYP2C9 *1/*3 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703250	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703250	15764711	CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703257	15764711	CYP2C9 *1/*13 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1183703296	1183703264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183703264	15764711	CYP2C9 *1/*13 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092460	PA166192341	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192341		Annotation of CPIC Guideline for tenoxicam and CYP2C9	100
1451092460	1183702710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702710	18992346	CYP2C9 *3 is associated with increased AUC and half-life time (t1/2) when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1 + *2.	1.5
1451092460	1183702721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702721	15229460	CYP2C9 *1/*3 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092460	1183702730	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702730	15229460	CYP2C9 *1/*2 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451092541	PA166192321	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192321		Annotation of CPIC Guideline for piroxicam and CYP2C9	100
1451092541	1183702677	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702677	16198655	CYP2C9 *1/*2 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092541	1183702686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702686	16198655	CYP2C9 *1/*3 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092541	1451092520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092520	17112811	CYP2C9 *1/*3 + *3/*3 are associated with decreased metabolism of piroxicam in healthy individuals as compared to CYP2C9 *1/*1.	0.5
1451092677	PA166192301	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166192301		Annotation of CPIC Guideline for meloxicam and CYP2C9	100
1451092677	PA166182753	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166182753		Annotation of FDA Label for meloxicam and CYP2C9	100
1451092677	1183702049	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183702049	24322170	CYP2C9 *3/*3 is associated with decreased clearance of meloxicam in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3.	1.0
1451092677	1451092564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092564	26774055	CYP2C9 *1/*3 + *2/*2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092677	1451092600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092600	24615047	CYP2C9 *1/*3 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451092677	1451092660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092660	29024493	CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092677	1451092671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451092671	21395648	CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.	1.5
1451092720	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1451092720	981862003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862003	12152005	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	2.0
1451092720	981862010	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862010	12152005	CYP2C9 *2 is not associated with clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	-0.125
1451092720	981862045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862045	15289789	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	2.5
1451092720	981862303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981862303	15289789	CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.	0.0
1451092720	1183702755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702755	18694831	CYP2C9 *1/*3 is associated with decreased racemic, S-ibuprofen and R-ibuprofen metabolism, with increase of AUC(0-infinity) and reduction of clearance when exposed to ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451092720	1447682551	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682551	26122864	CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092720	1447682561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682561	26122864	CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	2.0
1451092720	1450935257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935257	19480553	CYP2C9 *3 + *2 are associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.	0.125
1451674409	1451672980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451672980	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674424	1451673000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451673000	34476898	Allele T is associated with decreased metabolism of nicotine as compared to allele C.	0.0
1451674418	1451673020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451673020	34476898	Allele G is associated with decreased metabolism of nicotine as compared to allele A.	0.0
1447959515	1447959492	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447959492	26109805	Genotype GG is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype AA.	1.75
1447672658	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
1447672658	982033589	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033589	10961881	Allele T is not associated with likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy when treated with warfarin as compared to allele C.	-2.0
1447672658	982033570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033570	10961881	Allele C is not associated with likelihood of severe over-anticoagulation or stability of anticoagulation during long-term therapy when treated with warfarin as compared to allele A.	-2.0
1447672658	1447519958	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519958	19752777	Allele C is associated with risk of over-anticoagulation when treated with warfarin as compared to allele A.	2.75
1447672658	982046133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046133	19874474	CYP2C9 *2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	982046140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046140	19874474	CYP2C9 *3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	1183700149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700149	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Hemorrhage and over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672658	1184483140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483140	23932037	CYP2C9 *2 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.	1.5
1447672658	1184483159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483159	23932037	CYP2C9 *3 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
1447672658	1184483894	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483894	23104259	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	2.75
1447672658	1184510190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184510190	22075505	CYP2C9 *1/*3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.75
1447672658	1444607544	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607544	25246753	CYP2C9 *1/*3 is associated with increased risk of over-anticoagulation when treated with warfarin in people with Thyrotoxicosis as compared to CYP2C9 *1/*1.	0.25
1447672658	1444697555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697555	25769357	CYP2C9 *2/*3 + *3/*3 + *2/*2 are associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation.	3.0
1447672658	1444707455	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707455	12634980	CYP2C9 *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1444708161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444708161	24911077	CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	2.75
1447672658	1447223022	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223022	18690342	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
1447672658	1447223110	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223110	22571356	CYP2C9 *2 is not associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672658	1447223124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223124	22571356	CYP2C9 *3 is not associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672658	1447519168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519168	19297219	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672658	1447519284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519284	23602689	CYP2C9 *1/*2 + *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672658	1447519432	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519432	25244877	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447519788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519788	18466099	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1447520234	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520234	17226852	CYP2C9 *1/*2 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.	1.5
1447672658	1447520315	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520315	19794411	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.25
1447672658	1447521386	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521386	17989110	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672658	1447521410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521410	20354686	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.25
1447672658	1447521435	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521435	22990331	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447521456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521456	15001971	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672658	1447521716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521716	23279643	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin in children as compared to CYP2C9 *1/*1.	0.0
1447672658	1447572186	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447572186	19074728	CYP2C9 *2 + *3 are not associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672658	1447680579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680579	26739746	CYP2C9 *3/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672658	1447586719	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447586719	21318593	CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.5
1447672658	1183701124	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701124	18574025	CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with warfarin.	3.5
1447672658	1447521153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521153	17324110	CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.75
1447672988	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
1447672988	PA166182842	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182842		Annotation of DPWG Guideline for warfarin and CYP2C9	100
1447672988	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
1447672988	1449190810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190810	29432897	Allele T is not associated with likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	-2.25
1447672988	1183700629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700629	10509530	Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to genotypes AA + AC.	2.5
1447672988	1451113584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451113584	31186542	Allele C is not associated with risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.	-1.5
1447672988	1449190803	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190803	29432897	Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele A.	3.25
1447672988	982044429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044429	17653141	CYP2C9 *3 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044454	17653141	CYP2C9 *2 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044460	17653141	CYP2C9 *5 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044466	17653141	CYP2C9 *6 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044472	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044472	17653141	CYP2C9 *11 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	982044636	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044636	18756910	CYP2C9 *3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	2.0
1447672988	1183685004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685004	24503627	CYP2C9 *3 is not associated with risk of Hemorrhage when treated with warfarin.	-2.0
1447672988	1183685010	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685010	24503627	CYP2C9 *3 is not associated with risk of major bleeding when treated with warfarin.	-2.0
1447672988	1183700149	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700149	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Hemorrhage and over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672988	1183700618	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700618	10509530	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to CYP2C9 *1/*1 + *1/*3.	2.5
1447672988	1183701135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701135	18574025	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin.	0.0
1447672988	1183704584	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704584	24503627	CYP2C9 *2 + *3 is not associated with Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	-2.0
1447672988	1183704604	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183704604	24503627	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1.	0.0
1447672988	1184472914	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184472914	24474498	CYP2C9 *1/*3 is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1/*1.	1.75
1447672988	1184473641	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473641	25001883	CYP2C9 *2 is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1.	-1.25
1447672988	1184473649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473649	25001883	CYP2C9 *3 is not associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1.	-1.25
1447672988	1184483171	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483171	23932037	CYP2C9 *2 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	1.25
1447672988	1184483179	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483179	23932037	CYP2C9 *3 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	1.5
1447672988	1184483255	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483255	23774101	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.0
1447672988	1184483817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483817	23104259	CYP2C9 *3 is associated with increased risk of all and minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.	3.25
1447672988	1184483861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483861	23104259	CYP2C9 *3 is not associated with increased risk of major hemorrhage when treated with warfarin as compared to CYP2C9 *1.	-1.75
1447672988	1444607206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607206	25521356	CYP2C9 *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1444607233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444607233	25521356	CYP2C9 *1/*2 + *2/*2 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1444608341	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444608341	24602049	CYP2C9 *1/*3 + *3/*3 is not associated with increased risk of Hemorrhage when treated with warfarin.	-1.5
1447672988	1444697514	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444697514	25769357	CYP2C9 *3/*3 + *3/*2 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation.	3.5
1447672988	1444703983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444703983	25858232	CYP2C9 *2 + *3 is associated with increased risk of Hemorrhage when treated with warfarin in people with Alcoholism as compared to CYP2C9 *1.	0.0
1447672988	1447024601	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447024601	14676821	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672988	1447148295	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447148295	17955230	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1447223001	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223001	18690342	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
1447672988	1447223135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447223135	22571356	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1447519142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519142	19297219	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1447519308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519308	23602689	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1447519366	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519366	21148049	CYP2C9 *2 + *3 are not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.	-1.5
1447672988	1447519410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519410	25244877	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672988	1447519466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519466	15714076	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.875
1447672988	1447519480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519480	23348161	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
1447672988	1447519505	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519505	18570163	CYP2C9 *1/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	0.0
1447672988	1447680520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680520	26777610	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	3.0
1447672988	1448257304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448257304	27488176	CYP2C9 *2 + *3 are not associated with risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	-2.0
1447672988	1448262972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448262972	27581200	CYP2C9 *1/*2 + *1/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1447672988	1448602404	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602404	28033245	CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1447672988	1448602417	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602417	28033245	CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.	3.0
1447672988	1449005238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449005238	28689179	CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.	3.0
1446907373	1446906210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446906210	26426352	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .	2.0
1447813861	1447947627	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447947627	26892777	CYP3A5 deficiency is not associated with concentrations of atazanavir in people with HIV as compared to CYP3A5 non-deficient.	-0.375
1447813861	1184998461	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184998461	19710077	CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.	2.0
1448426877	1448426850	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448426850	27809336	CYP3A5 *3/*3 is associated with decreased clearance of granisetron as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1449003986	1449003038	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003038	21209234	CYP3A5 *3/*3 is associated with increased dose of oxycodone in people with Neoplasms as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1449003986	1451135000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451135000	31773688	CYP3A5 *3 is not associated with dose of oxycodone in people with Pain, Postoperative as compared to CYP3A5 *1.	-0.25
1449005135	1449004108	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004108	29043387	CYP3A5 *1/*1 + *1/*3 are associated with increased likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	0.0
1449005135	1449004120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449004120	29043387	CYP3A5 *1/*1 + *1/*3 are not associated with likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-1.75
1449165704	982023222	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982023222	23354298	Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.	1.5
1449165704	827813960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813960	21806386	Allele C is not associated with clearance of cyclosporine in people with Kidney Transplantation as compared to allele T.	-1.5
1449165704	1183698750	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183698750	23557867	Genotype CC is not associated with metabolism of cyclosporine in people with Kidney Transplantation as compared to genotypes CT + TT.	-0.75
1449165704	1184470327	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470327	24658827	Allele C is not associated with metabolism of cyclosporine in people with Kidney Transplantation as compared to allele T.	-0.75
1449165704	1448997381	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997381	28952408	Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CT + TT.	2.0
1449165704	1184470953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184470953	24522145	CYP3A5 *1/*1 + *1/*3 is not associated with clearance of cyclosporine or everolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	-0.75
1449165704	1184483059	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483059	24691060	CYP3A5 *1 is not associated with trough concentration of cyclosporine in people with Kidney Transplantation as compared to CYP3A5 *3.	-1.25
1449165704	1444843695	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843695	25976223	CYP3A5 *1/*3 is associated with decreased concentrations of cyclosporine in men as compared to CYP3A5 *3/*3.	1.5
1449165704	1444843717	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444843717	25976223	CYP3A5 *1/*1 is associated with decreased concentrations of cyclosporine in women as compared to CYP3A5 *3/*3.	1.0
1449165704	1449004146	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449004146	29043387	CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	2.75
1449165704	1449165650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165650	29135906	CYP3A5 *3/*3 is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1449165704	1449183240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449183240	29441922	CYP3A5 *1 is not associated with metabolism of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.	-0.75
1449309910	1449275137	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449275137	29637588	CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in children with Nephrotic Syndrome as compared to CYP3A5 *1/*1.	1.5
1449716378	1449716271	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716271	22277678	CYP3A5 *3/*3 is associated with increased risk of adverse events due to fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	2.25
1449716378	1450931788	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931788	30281924	CYP3A5 *3 is not associated with likelihood of adverse events due to fentanyl in healthy individuals as compared to CYP3A5 *1.	-0.25
1450812401	1450812359	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812359	19205682	CYP3A5 *3/*3 is associated with increased exposure to nimodipine in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.	2.5
1450812594	1450812582	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812582	20133509	CYP3A5 *3/*3 is associated with increased exposure to dextropropoxyphene in healthy individuals as compared to CYP3A5 *1/*3.	1.0
1450371828	1450371727	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371727	30192390	CYP3A5 poor metabolizers and intermediate metabolizers are not associated with response to efavirenz or maraviroc in people with HIV as compared to CYP3A5 normal metabolizers.	-1.0
1450371828	1450371753	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371753	30192390	CYP3A5 poor metabolizers are associated with decreased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.	1.0
1450371828	1450371766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371766	30192390	CYP3A5 intermediate metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.	-0.375
1450371828	1450371773	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371773	30192390	CYP3A5 poor metabolizers are not associated with concentrations of maraviroc in people with HIV as compared to CYP3A5 intermediate metabolizers.	-0.75
1450371828	1450371799	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371799	30192390	CYP3A5 poor metabolizers are associated with increased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.	0.875
1450371828	1450371807	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450371807	30192390	CYP3A5 intermediate metabolizers are associated with increased concentrations of maraviroc in people with HIV as compared to CYP3A5 normal metabolizer.	1.0
1449713943	1449713910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713910	27236640	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	1.0
1449713943	1449716224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716224	22277678	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1449713943	1449716437	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716437	24365989	CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1449713943	1449716462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716462	24365989	CYP3A5 *3/*3 is associated with decreased clearance of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.	1.75
1449713943	1450931669	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931669	30281924	CYP3A5 *3/*3 is not associated with exposure to fentanyl in healthy individuals as compared to CYP3A5 *1/*3.	-0.125
1449713943	1451678262	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451678262	34877660	CYP3A5 *1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased clearance of fentanyl in children as compared to CYP3A5 *1/*1 (assigned as normal metabolizer genotype phenotype) .	1.75
1448423466	1448423446	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448423446	26179145	CYP3A5 *1/*3 is associated with increased risk of Leukopenia or Neutropenia when treated with carboplatin and paclitaxel in women with Ovarian Neoplasms as compared to CYP3A5 *3/*3.	2.25
1451100007	1451100046	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451100046	30237584	Allele G is associated with decreased response to Antihypertensives in people with Hypertension as compared to allele A.	0.0
1451100053	1451099900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451099900	30237584	Allele A is associated with decreased response to Antihypertensives in people with Hypertension as compared to allele G.	0.0
1451100080	1451100040	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451100040	30237584	Allele T is associated with decreased response to Antihypertensives in people with Hypertension as compared to allele C.	0.0
1451100120	1451099067	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451099067	30371861	CYP2D6 *9 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.	1.5
1451100120	1451099074	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451099074	30371861	CYP2D6 *29 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.	1.5
1451103240	1451102844	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451102844	30992538	Genotypes GT + TT are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.	2.5
1451100100	1451440560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451440560	30371861	Allele C is associated with decreased clearance of fentanyl in people with Burns as compared to allele T.	1.5
1451103560	1451103539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451103539	31004399	Genotypes CC + CT are associated with increased severity of Alcoholism due to ethanol in men as compared to genotype TT.	2.75
1449188311	1451350842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451350842	30085428	Allele A is associated with increased risk of Alcoholism due to ethanol in men as compared to allele G.	-2.25
1449188311	1450809995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450809995	16476706	Allele G is not associated with risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	-2.0
1449188311	769171508	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171508	15525999	Allele G is associated with risk of Alcoholism when exposed to ethanol.	2.0
1449188311	1450810431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810431	16679777	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-1.5
1449188311	1450811217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811217	15902904	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-1.75
1449188311	1450812547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812547	19860800	Allele G is associated with increased risk of Alcoholism due to ethanol in children as compared to allele A.	3.0
1449188311	1450814869	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814869	23136901	Genotypes AG + GG are associated with increased risk of Alcoholism due to ethanol in children as compared to genotype AA.	2.5
1449188311	1450820261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820261	23729673	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-2.0
1449188311	1450820547	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820547	24035285	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-2.0
1449188311	1450822091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822091	26042510	Genotypes AG + GG are associated with increased risk of Alcoholism due to ethanol in men as compared to genotype AA.	2.75
1449188311	1450822698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822698	23254216	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-1.5
1449188311	1450823732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823732	26392368	Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.	0.0
1449188311	1449161426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161426	16387451	Allele G is not associated with increased risk of Alcoholism, Cocaine-Related Disorders, Opioid-Related Disorders or Tobacco Use Disorder when exposed to cocaine, ethanol, nicotine or opioids as compared to allele A.	-1.0
1449188311	1450824111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450824111	27447243	Allele G is not associated with risk of Alcoholism due to ethanol as compared to allele A.	-1.5
1449188311	1450931911	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450931911	30322771	Genotypes AG + GG are not associated with risk of Alcoholism due to ethanol as compared to genotype AA.	-1.5
1449188311	1451103420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451103420	31004399	Allele G is not associated with risk of Alcoholism due to ethanol in men as compared to allele A.	-2.0
1449188311	1449166440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449166440	9399694	Allele G is not associated with risk of Alcoholism with ethanol as compared to allele A.	-1.75
1449188311	1449188297	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188297	22071118	Allele G is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele A.	1.5
1449188311	1449188304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449188304	22071118	Allele G is not associated with risk of Alcoholism when exposed to ethanol as compared to allele A.	-1.0
1449188311	1449275217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275217	19891732	Allele G is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele A.	2.0
1449188311	1450371975	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450371975	29497164	Allele G is not associated with likelihood of Alcoholism due to ethanol as compared to allele A.	-2.0
1449188311	1450372065	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450372065	29070014	Allele G is not associated with risk of Alcoholism when exposed to ethanol as compared to allele A.	-1.5
1449188311	1450807082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807082	10490697	Genotype AA is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AG + GG.	-2.5
1449188311	1450807370	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807370	11424981	Allele G is not associated with risk of Alcoholism as compared to allele A.	-2.0
1449188311	1450807673	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807673	11522434	Allele G is not associated with risk of Alcoholism when exposed to ethanol as compared to allele A.	-2.0
1449188311	1450808784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808784	15252283	Genotypes AG + GG are not associated with risk of Alcoholism due to ethanol as compared to genotype AA.	-1.75
1450811261	1451149748	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149748	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1450811261	1450811224	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811224	15902904	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	3.25
1450811261	1451110060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451110060	31090166	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	2.5
1451110071	1451110000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451110000	31090166	Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.	2.5
1451110320	1451110300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451110300	31099054	Genotype GG is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	0.0
1184989990	1183849063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183849063	15812265	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	1.75
1184989990	1183849716	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183849716	23288236	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C is associated with decreased HAM-D score changes in fluvoxamine-treated patients compared to paroxetine-treated patients when treated with fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531T/L allele-rs25531C + L allele-rs25531T/L allele-rs25531T.	1.75
1184989990	1183944189	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944189	15274037	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine or paroxetine in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	2.0
1184989990	1183959936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183959936	16874005	SLC6A4 HTTLPR long form (L allele) is associated with increased improvement based on HAM-D score percentage reduction when treated with fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	2.25
1184989990	1183959975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959975	16874005	SLC6A4 HTTLPR long form (L allele) is not associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	-0.375
1184989990	1184472274	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472274	9857976	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	1.75
1184989990	1184472345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472345	11543734	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).	1.75
1184989990	1184509840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509840	11817517	SLC6A4 HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major.	-2.25
1184989990	1184511110	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511110	12082589	SLC6A4 HTTLPR long form (L allele) is not associated with response to fluvoxamine in people with Obsessive-Compulsive Disorder as compared to SLC6A4 HTTLPR short form (S allele).	-1.25
1184989990	1183959953	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183959953	16874005	SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).	This annotation is not used for clinical annotation scoring. since only associated if not drugs are pooled together for analysis
1444704359	827808161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827808161	20051929	Genotype CC is associated with increased median plasma lopinavir Cmin and C2-6 when treated with lopinavir as compared to genotypes CT + TT.	2.75
1444704359	1451114623	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451114623	20078617	Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT.	1.25
1444704359	1451114889	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451114889	21743379	Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT.	1.0
1444704359	1451115303	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451115303	23503447	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	1.5
1444704359	1451116340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451116340	32022294	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	2.5
1444704359	1447986096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447986096	27142945	Allele C is not associated with concentrations of lopinavir in people with HIV Infections.	-0.75
1444704359	1448821812	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448821812	28718515	Genotypes CC + CT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype TT.	-0.75
1451116100	1451115880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451115880	23503447	Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T.	1.0
1450812488	1450812458	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812458	19683391	Genotype GG is associated with decreased Nausea and Vomiting due to opioids in people with Pain as compared to genotypes AA + AG.	0.75
1450812488	1450812476	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812476	19683391	Allele G is associated with decreased adverse events due to opioids in people with Pain as compared to allele A.	0.125
1450812488	1450823193	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823193	25794200	Genotypes AG + GG are associated with decreased likelihood of Vomiting due to opioids as compared to genotype AA.	1.5
1450812488	1450823199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823199	25794200	Genotypes AG + GG are not associated with likelihood of Nausea due to opioids as compared to genotype AA.	-1.0
1450812488	1450823205	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823205	25794200	Genotypes AG + GG are associated with decreased likelihood of Postoperative Nausea and Vomiting due to opioids in people with Pain, Postoperative as compared to genotype AA.	1.5
1450812488	1451118407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118407	31337162	Genotypes AG + GG are associated with decreased likelihood of Nausea due to opioids in people with Pain or Pain, Postoperative as compared to genotype AA.	1.25
1450812488	1451118415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118415	31337162	Genotypes AG + GG are not associated with likelihood of Vomiting due to opioids in people with Pain or Pain, Postoperative as compared to genotype AA.	-1.0
1450812488	1451134210	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134210	31745220	Genotypes AG + GG are associated with increased likelihood of Erectile Dysfunction, Sexual Dysfunctions, Psychological or Vomiting due to opioids in men with Pain as compared to genotype AA.	-3.0
1451117640	1451117460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117460	31327267	Allele G is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele T.	3.0
1451117646	1451117264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117264	31327267	Allele C is associated with increased response to candesartan in people with Hypertension as compared to allele T.	3.0
1451118241	1451117340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117340	31327267	Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele A.	3.0
1451118277	1451117350	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117350	31327267	Allele C is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1451118320	1451117360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117360	31327267	Allele T is associated with decreased response to candesartan in people with Hypertension as compared to allele C.	3.0
1451118326	1451117356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117356	31327267	Allele A is associated with decreased response to atenolol in people with Hypertension as compared to allele C.	3.0
1451118332	1451117386	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117386	31327267	Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T.	3.0
1451118338	1451117391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117391	31327267	Allele A is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1451118340	1451117401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117401	31327267	Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1451119080	1451118989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118989	31371054	Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele C.	0.0
1451119086	1451119020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451119020	31371054	Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele A.	0.0
981238341	PA166104949	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104949		Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1	100
981238341	PA166182842	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182842		Annotation of DPWG Guideline for warfarin and CYP2C9	100
981238341	PA166104776	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104776		Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1	100
981238341	1449164047	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449164047	29298995	CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers.	1.5
981238341	1451221905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451221905	32559398	Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.	2.5
981238341	982033292	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033292	10073515	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982033561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033561	10961881	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
981238341	982036689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036689	18542936	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	982036901	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036901	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982037879	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037879	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	982038144	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982038144	11966680	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	827602050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827602050	18305455	Allele T is associated with decreased dose of warfarin as compared to allele C.	3.0
981238341	827641894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641894	19300499	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	827657784	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827657784	17111199	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.	2.5
981238341	827814765	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814765	21148049	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.	-1.5
981238341	827823816	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823816	21110192	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	608431758	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431758	19794411	Allele T is associated with decreased dose of warfarin.	2.75
981238341	655387565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387565	19228618	Allele T is associated with decreased dose of warfarin.	0.0
981238341	827864546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864546	21228733	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1183699325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699325	17387222	Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C.	2.25
981238341	1183701883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701883	8004131	Allele T is associated with decreased metabolism of warfarin as compared to allele C.	0.125
981238341	1448109670	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109670	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
981238341	1448112390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112390	26010205	Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.	2.5
981238341	1449192282	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192282	28049362	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.	3.25
981238341	1449262882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449262882	29568565	Allele T is associated with dose of warfarin in people with Cardiovascular Diseases as compared to allele C.	0.5
981238341	1449269199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269199	28973620	Allele T is associated with dose of warfarin as compared to allele C.	0.0
981238341	981785769	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785769	23376925	Allele A is associated with decreased S-warfarin clearance when treated with warfarin as compared to allele G.	1.5
981238341	981785989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981785989	23376925	Allele A is associated with decreased median weekly warfarin dose requirements when treated with warfarin as compared to allele G.	2.0
981238341	827787814	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787814	21635147	Allele A is associated with warfarin variability when treated with warfarin as compared to allele G.	2.0
981238341	608431781	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431781	20072124	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.0
981238341	827864548	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864548	21228733	Allele A is associated with decreased dose of warfarin as compared to allele G.	2.5
981238341	608431785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431785	20072124	Allele del is associated with decreased dose of warfarin.	2.5
981238341	1448109688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109688	27121899	Allele A is associated with dose of warfarin as compared to allele del.	0.0
981238341	1449005482	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005482	28685643	Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A.	0.25
981238341	982036973	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036973	19387626	Allele T is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982043421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043421	15970795	Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.	2.0
981238341	608431789	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431789	20072124	Allele T is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1448109696	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109696	27121899	Allele C is associated with dose of warfarin as compared to allele T.	0.0
981238341	982032955	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982032955	18535201	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982033206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982033206	9630825	Genotype AC is associated with decreased in vivo metabolism of (S)-warfarin but not (R)-warfarin when treated with warfarin as compared to genotype AA.	1.75
981238341	982033269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033269	10073515	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982033533	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982033533	10961881	Allele C is associated with decreased dose of warfarin as compared to allele A.	3.0
981238341	982035694	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982035694	18030307	Genotype AC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.	2.5
981238341	982036698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036698	18542936	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	982036874	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036874	19387626	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	982037860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037860	20072124	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	827602228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827602228	18305455	Allele C is associated with decreased dose of warfarin as compared to allele A.	3.0
981238341	827641903	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827641903	19300499	Allele C is associated with decreased dose of warfarin as compared to allele A.	0.0
981238341	827658659	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827658659	17111199	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	827661941	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827661941	16432637	Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.	3.0
981238341	827814740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827814740	21148049	Allele C is associated with decreased dose of warfarin as compared to allele A.	1.5
981238341	827823825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827823825	21110192	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	827845798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827845798	22248286	Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.	2.75
981238341	655388494	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655388494	11127854	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	608431732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431732	19794411	Allele C is associated with decreased dose of warfarin.	2.75
981238341	655387562	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/655387562	19228618	Allele C is associated with decreased dose of warfarin.	0.0
981238341	769182559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769182559	21383771	Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC.	2.5
981238341	827864562	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864562	21228733	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.5
981238341	1183699129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699129	19177029	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.75
981238341	1183699320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699320	17387222	Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A.	2.25
981238341	1183700614	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700614	10509530	Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.	2.5
981238341	1184169096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169096	24728385	Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC.	3.0
981238341	1184482810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482810	23941071	Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC.	2.75
981238341	1184511620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511620	25026456	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1184756158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184756158	25126975	Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.	3.5
981238341	1444694693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444694693	25594941	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	2.5
981238341	1446765922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765922	26257249	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1447519932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519932	19752777	Allele C is associated with decreased dose of warfarin as compared to allele A.	2.75
981238341	1448109677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109677	27121899	Allele A is associated with dose of warfarin as compared to allele C.	0.0
981238341	1448112396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448112396	26010205	Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.	2.5
981238341	1448431507	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431507	26223945	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	2.5
981238341	1448615546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448615546	28429387	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.	3.0
981238341	1448624168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448624168	28550460	Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.	2.5
981238341	1449005162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005162	29054760	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1449005213	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005213	28262345	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	2.5
981238341	1449190935	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449190935	29432897	Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A.	2.75
981238341	1449192290	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192290	28049362	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.	3.25
981238341	1449258301	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449258301	27617219	Allele C is associated with decreased dose of warfarin as compared to allele A.	1.75
981238341	1449269204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449269204	28973620	Allele C is associated with dose of warfarin as compared to allele A.	0.0
981238341	982034970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982034970	21228733	Genotype CT is associated with decreased dose of warfarin as compared to genotype TT.	2.5
981238341	982036710	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036710	18542936	Allele C is associated with decreased dose of warfarin as compared to allele T.	2.5
981238341	982036958	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036958	19387626	Allele C is associated with decreased dose of warfarin as compared to allele T.	0.0
981238341	982036951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036951	19387626	Allele G is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	982036966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982036966	19387626	Allele G is associated with decreased dose of warfarin as compared to allele C.	0.0
981238341	608431793	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/608431793	20072124	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	827864554	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864554	21228733	Allele G is associated with decreased dose of warfarin as compared to allele C.	2.5
981238341	1448109681	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109681	27121899	Allele C is associated with dose of warfarin as compared to allele G.	0.0
981238341	1449005488	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449005488	28685643	Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C.	0.25
981238341	827919407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919407	22378156	CYP2C9 *8 is associated with decreased in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein when treated with warfarin as compared to CYP2C9 *1/*1.	1.0
981238341	827783868	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783868	21174619	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827925130	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827925130	22528326	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1.	2.5
981238341	978614428	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614428	22676192	CYP2C9 *2 is associated with dose of warfarin.	0.0
981238341	978614420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614420	22676192	CYP2C9 *8 is associated with dose of warfarin.	0.0
981238341	978614436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/978614436	22676192	CYP2C9 *3 is associated with dose of warfarin.	0.0
981238341	981344709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344709	12496751	CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	1.25
981238341	981344716	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981344716	12496751	CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	1.25
981238341	981345061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981345061	12496751	CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	0.75
981238341	981345093	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981345093	12496751	CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.	0.75
981238341	981483998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981483998	20653676	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1.	2.5
981238341	827783863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783863	21174619	CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827783312	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783312	22040439	CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	0.25
981238341	827807419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827807419	18322281	CYP2C9 *1/*1 is associated with increased dose of warfarin.	2.75
981238341	827783860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827783860	21174619	CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.	2.75
981238341	827863693	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863693	21692828	CYP2C9 *3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	0.0
981238341	827863698	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863698	21692828	CYP2C9 *2 is associated with decreased clearance of warfarin as compared to CYP2C9 *1.	0.0
981238341	827919392	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919392	22378156	CYP2C9 *8 is associated with decreased unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	827919897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919897	22594507	CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.	3.0
981238341	827919924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919924	22594507	CYP2C9 *3 is associated with decreased dose of warfarin.	3.0
981238341	827919905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919905	22594507	CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin.	-2.0
981238341	827919910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827919910	22594507	CYP2C9 *2 is associated with decreased dose of warfarin.	3.0
981238341	981505317	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505317	21185752	CYP2C9 *2 is associated with lower warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	981505330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981505330	21185752	CYP2C9 *3 is associated with decreased warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	981754835	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981754835	23061746	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3.	2.5
981238341	981858924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981858924	23183958	CYP2C9 *1/*2 + *1/*3 is not associated with dose of warfarin in children as compared to CYP2C9 *1/*1.	-0.25
981238341	982037353	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982037353	19745563	CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982037661	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982037661	17391071	CYP2C9 *1/*3 + *1/*4 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982040707	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982040707	19135231	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043050	17510308	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043064	17510308	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043409	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043409	15590403	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982043415	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043415	15590403	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982043530	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043530	17049586	CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	982043569	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043569	16493479	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043575	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043575	16493479	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.25
981238341	982043654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043654	17456829	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	3.0
981238341	982043785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043785	12621390	CYP2C9 *1/*3 is associated with decreased unbound oral clearance for S-warfarin when treated with warfarin as compared to CYP2C9 *1/*1.	1.25
981238341	982043863	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043863	14656880	CYP2C9 *3 is associated with decreased warfarin dose (40% lower) when treated with warfarin as compared to CYP2C9 *1.	0.25
981238341	982043913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043913	15883587	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	982043919	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982043919	15883587	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	982043928	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043928	15947090	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982043935	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982043935	15947090	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982044336	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044336	16611750	CYP2C9 *3 is associated with decreased warfarin dose after adjustment for VKORC1*1173 when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982044343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044343	16611750	CYP2C9 *2 is not associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	-1.25
981238341	982044381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044381	16890578	CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982044620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044620	18756910	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.5
981238341	982044655	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982044655	18836275	CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	982045728	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045728	19077919	CYP2C9 *1/*3 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	982045852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045852	19297219	CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982045885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045885	19297219	CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.	2.75
981238341	982046133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046133	19874474	CYP2C9 *2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982046140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046140	19874474	CYP2C9 *3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.	1.75
981238341	982047396	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047396	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*3.	2.5
981238341	982047403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047403	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*2.	0.0
981238341	982047409	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047409	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*2.	2.5
981238341	982047415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047415	22010099	CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *2/*3.	2.5
981238341	982047968	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982047968	22130800	CYP2C9 *2 + *3 are associated with dose of warfarin in children as compared to CYP2C9 *1.	0.0
981238341	1183697100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697100	22349464	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.25
981238341	1183697679	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183697679	23990957	CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.	2.75
981238341	1183699114	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699114	19177029	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1183699285	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699285	17387222	CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	2.25
981238341	1183699310	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183699310	17387222	CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.	2.25
981238341	1183700066	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700066	19031075	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700096	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700096	19031075	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700106	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700106	19031075	CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700115	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700115	19031075	CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700123	19031075	CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183700166	11926893	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700587	10509530	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in men as compared to CYP2C9 *1/*1.	2.5
981238341	1183700648	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700648	15001971	CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700669	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700669	15001971	CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700730	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700730	20375999	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.0
981238341	1183700748	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700748	20375999	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.0
981238341	1183700775	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700775	17851566	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183700824	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700824	17851566	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.	1.5
981238341	1183700910	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700910	19663669	CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	1.0
981238341	1183701108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701108	18574025	CYP2C9 *2 is associated with decreased dose of warfarin.	2.5
981238341	1183701116	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701116	18574025	CYP2C9 *3 is associated with decreased dose of warfarin.	2.5
981238341	1183701135	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183701135	18574025	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin.	0.0
981238341	1183701311	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701311	17989110	CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.0
981238341	1183701320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701320	17989110	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.0
981238341	1183701419	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701419	19802360	CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	3.25
981238341	1183701501	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701501	20421126	CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1.	2.5
981238341	1183701514	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701514	20421126	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.	2.5
981238341	1183701549	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701549	16160068	CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	0.25
981238341	1183701565	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701565	16160068	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	0.25
981238341	1183701573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701573	15094935	CYP2C9 *1/*3 is associated with decreased dose of warfarin.	0.25
981238341	1183701586	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183701586	15094935	CYP2C9 *6/*6 is associated with decreased dose of warfarin.	0.25
981238341	1184471902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184471902	22892446	CYP2C9 *1/*3 is associated with decreased Unbound oral clearance for S-warfarin when treated with warfarin in children as compared to CYP2C9 *1/*1.	0.125
981238341	1184472455	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472455	20128861	CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin.	1.5
981238341	1184472857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472857	24474498	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	1.75
981238341	1184472866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184472866	24474498	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	0.0
981238341	1184473587	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473587	25001883	CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1.	2.25
981238341	1184482762	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184482762	23949431	CYP2C9 *3/*3 + *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184483457	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483457	23208322	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1184483798	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184483798	23104259	CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184509852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184509852	22854539	CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.0
981238341	1184510026	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510026	22549502	CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1184510108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510108	22274142	CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1184510172	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510172	22075505	CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.25
981238341	1184510232	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510232	21782804	CYP2C9 *3/*13 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	0.25
981238341	1184510263	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510263	21590310	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1184510278	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510278	21590310	CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.	2.5
981238341	1184510322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510322	21320153	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1184511561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511561	25042728	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.0
981238341	1184511945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511945	24029542	CYP2C9 *1/*1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as poor metabolizers and intermediate metabolizers phenotype) .	1.5
981238341	1184654356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654356	24330000	CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654374	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654374	24330000	CYP2C9 *2/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	0.0
981238341	1184654383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654383	24330000	CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654392	24330000	CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184654401	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184654401	24330000	CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.	1.5
981238341	1184748897	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184748897	25084205	CYP2C9 *3 is associated with decreased dose of warfarin.	2.0
981238341	1185235722	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235722	24601977	CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.	2.25
981238341	1444695840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695840	25712185	CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.	1.75
981238341	1445296737	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296737	26024874	CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1447519652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447519652	18466099	CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1447682605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682605	26745506	CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.75
981238341	1448267984	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448267984	21981797	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.	2.5
981238341	1448268043	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448268043	22534826	CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.	2.75
981238341	1448269030	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448269030	21326313	CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3.	3.0
981238341	1448573256	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448573256	28135054	CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.5
981238341	1183689399	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689399	22990331	CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.0
981238341	1451120160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451120160	31395958	CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.	2.75
981238341	1451130680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451130680	31653973	CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1.	2.5
981238341	1451516060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451516060	20833980	CYP2C9 *2 + *3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.	-1.25
981238341	982045974	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982045974	19582440	CYP2C9 *1/*3 + *3/*3 are associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to CYP2C9 *1/*1.	2.5
1451120960	1451120880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120880	31462767	Allele T is associated with increased risk of Alcoholism, Heroin Dependence or methamphetamine dependence due to ethanol, heroin or methamphetamine as compared to allele G.	2.5
1451120980	1451120880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120880	31462767	Allele T is associated with increased risk of Alcoholism, Heroin Dependence or methamphetamine dependence due to ethanol, heroin or methamphetamine as compared to allele G.	2.5
1451123020	1451122920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451122920	31510971	Allele A is associated with increased risk of Opioid-Related Disorders due to opioids as compared to allele G.	0.75
1451123321	1451123300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451123300	31549442	CYP2B6 *6/*6 is associated with decreased metabolism of artemether in healthy individuals as compared to CYP2B6 *1/*1.	1.0
1451125512	1451125161	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125161	31616045	Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.5
1451125518	1451125157	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125157	31616045	Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451125520	1451125168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125168	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125526	1451125150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125150	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125532	1451125207	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125207	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125538	1451125240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125240	31616045	Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
1451125544	1451125184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125184	31616045	Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
981203689	827828625	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828625	19400747	Genotype CC is associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to genotypes CT + TT.	2.5
981203689	827828787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828787	17083032	Genotype CC is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to genotypes CT + TT.	-0.25
981203689	1451125840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125840	31619748	Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.	2.25
981203689	1447673691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673691	26535588	Genotypes CT + TT are not associated with glomerular disease when exposed to tenofovir in people with HIV Infections as compared to genotype CC.	-2.0
981203689	1447682940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682940	26807589	Allele T is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele C.	-1.75
1451125564	1451125247	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125247	31616045	Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.5
1451125570	1451125268	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125268	31616045	Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.5
1451125580	1451125261	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125261	31616045	Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451125600	1451125275	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125275	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125620	1451125282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125282	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125640	1451125289	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125289	31616045	Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451125646	1451125296	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125296	31616045	Allele A is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451125660	1451125303	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125303	31616045	Allele A is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele del.	2.5
1451125666	1451125334	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125334	31616045	Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	2.5
1451125672	1451125341	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125341	31616045	Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125680	1451125320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125320	31616045	Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
1451125687	1451125327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125327	31616045	Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	2.5
1451125693	1451125348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125348	31616045	Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451544841	1451544786	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451544786	25406899	Allele C is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele G.	This annotation is not used for clinical annotation scoring. Study combines ADRB1, ADRB2 and ADRA2C genotypes for analysis - individual effect of each variant is unclear.
1451544841	1451840020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451840020	19628119	Genotype CC is not associated with risk of Death when treated with Beta Blocking Agents in people with Heart Failure as compared to genotypes CG + GG.	-1.75
1451544841	1451843594	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451843594	25638254	Genotype GG is associated with decreased response to Beta Blocking Agents in people with Heart Failure as compared to genotypes CC + CG.	0.0
1451544841	613979015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613979015	15861037	Allele C is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.	-1.5
1451544860	1451544780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451544780	25406899	Allele del is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele GGGGCGGGGCCG.	This annotation is not used for clinical annotation scoring. Study combines ADRB1, ADRB2 and ADRA2C genotypes for analysis - individual effect of each variant is unclear.
1451544860	1451861680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451861680	22703928	Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is associated with increased risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes GGGGCGGGGCCG/del + del/del.	3.0
1451544860	1451861722	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451861722	22703928	Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is not associated with risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes GGGGCGGGGCCG/del + del/del.	This annotation is not used for clinical annotation scoring. The variant was not in Hardy-Weinberg equilibrium (p=0.0334).
1451544880	613978995	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/613978995	15861037	Allele A is not associated with response to Beta Blocking Agents in people with Heart Failure as compared to allele G.	-1.5
1451544880	1451544792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451544792	25406899	Allele A is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele G.	This annotation is not used for clinical annotation scoring. Study combines ADRB1, ADRB2 and ADRA2C genotypes for analysis - individual effect of each variant is unclear.
1451544880	1451842220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451842220	22703928	Genotype GG is associated with decreased risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes AA + AG.	2.5
1451544880	1451842820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451842820	22703928	Allele G is not associated with risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome.	-2.0
1451544880	1451869184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451869184	30374408	Genotype AA is not associated with risk of heart transplantation or Death when treated with Beta Blocking Agents in people with Heart Failure as compared to genotypes AG + GG.	-2.0
1451544980	1451544909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451544909	26239289	Allele A is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele G.	2.5
1451547422	1451547391	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451547391	27987364	Genotype TT is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	2.25
1451137080	PA166219301	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166219301		Annotation of CPIC Guideline for dexlansoprazole and CYP2C19	100
1451137080	1451137042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137042	22455762	CYP2C19 poor metabolizer is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 normal metabolizer.	0.0625
1451137080	1451136960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451136960	29018343	CYP2C19 *2/*2 is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1451137080	1451136980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451136980	29018343	CYP2C19 *1/*2 + *1/*3 are associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.	1.0
1451135569	1183702561	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702561	18548238	CYP2C8 *1/*3 + *3/*3 is associated with increased diclofenac/5-hydroxydiclofenac urinary concentration ratio when exposed to diclofenac in healthy individuals as compared to CYP2C8 *1/*1.	1.5
1451135569	1183702572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183702572	18548238	CYP2C8 *1/*4 + *4/*4 is associated with increased diclofenac/5-hydroxydiclofenac urinary concentration ratio when exposed to diclofenac in healthy individuals as compared to CYP2C8 *1/*1.	1.5
1451135569	1449156587	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449156587	29203276	CYP2C8 *4 is associated with decreased metabolism of diclofenac acyl glucuronide as compared to CYP2C8 *1.	0.0
1451135569	1450401716	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450401716	29203276	CYP2C8 *4 is associated with decreased catalytic activity of CYP2C8 when assayed with diclofenac as compared to CYP2C8 *1.	0.0
1451548374	1451548340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451548340	29306656	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	1.5
1451548374	1451615134	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451615134	33501733	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.	-1.0
1451139061	1451139000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451139000	25241292	CYP2C19 *2 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C19 *1/*1.	2.25
1451139070	1451139042	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451139042	25241292	NAT2 *5D + *6B + *7A + *14A (assigned as slow acetylator phenotype) are associated with decreased metabolism of dipyrone in healthy individuals.	2.25
1451139660	1451138220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138220	1396201	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.75
1451139660	1451139502	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451139502	7408395	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.1875
1451139660	1451140180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451140180	445966	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	1.0
1451139660	1451138770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138770	21781652	NAT2 slow acetylator is associated with increased concentrations of hydralazine in healthy individuals as compared to NAT2 rapid acetylator.	0.0625
1451139660	1451140400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451140400	7284051	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in men with Hypertension as compared to NAT2 rapid acetylator.	0.75
1451139660	1451139946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451139946	7438695	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.5
1451139660	1451140220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451140220	5026380	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.75
1451139660	1451139280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451139280	7471604	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	1.0
1451139660	1451140360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451140360	7259927	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.0625
1451139660	1451138866	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138866	21781652	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.	0.0
1451139660	1451138920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138920	17183730	NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.	0.0625
1451139660	1451138603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138603	17761710	NAT2 slow acetylator is not associated with decreased metabolism of hydralazine in people with Neoplasms as compared to NAT2 rapid acetylator.	-0.0625
1451139660	1451141600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141600	7298112	NAT2 slow acetylator is associated with increased concentrations of hydralazine in men with Hypertension as compared to NAT2 rapid acetylator.	0.0625
1451139660	1451141940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141940	1136859	NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 intermediate and rapid acetylators.	0.0625
1451139660	1451135223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451135223	31257615	NAT2 *4/*5 + *4/*6 + *4/*7 (assigned as rapid acetylator phenotype) are associated with increased metabolism of hydralazine in women with Hypertension as compared to NAT2 *5/*5 + *5/*6 + *5/*7 + *6/*6 (assigned as slow acetylator phenotype) .	1.0
1451139660	1451135506	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451135506	29018032	NAT2 *4/*5 + *4/*6 are associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *5/*5 + *5/*6 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) .	0.0
1451139660	1451135500	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451135500	29018032	NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *4/*5 + *4/*6 (assigned as intermediate acetylator phenotype) .	0.0
1451139660	1451136500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451136500	24702251	NAT2 *5D/*5D + *5D/*6B + *5D/*7A (assigned as slow acetylator phenotype) are associated with decreased metabolism of hydralazine in healthy individuals as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .	0.125
1451140140	1444707430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707430	12876643	CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with acenocoumarol and indomethacin as compared to CYP2C9 *1/*1.	0.25
1451140140	1447521084	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447521084	26544900	CYP2C9 *3 is associated with increased risk of Gastrointestinal Hemorrhage when treated with aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, naproxen or piroxicam as compared to CYP2C9 *2 + *1/*1.	0.0
1451139160	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
1451139160	981478337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981478337	19280158	CYP2C9 *1/*3 is not associated with clearance of naproxen in men with no disease as compared to CYP2C9 *1/*1.	-0.125
1451139160	1451139140	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451139140	17686967	CYP2C9 *2 + *3 are associated with decreased metabolism of naproxen as compared to CYP2C9 *1/*1.	0.0
1451905680	1451905307	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905307	35710824	HLA-DRB1 *04:02:01 is associated with increased likelihood of Agranulocytosis when treated with clozapine in people with Schizophrenia.	1.25
1451143820	1451142984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451142984	21781652	NAT2 slow acetylator is associated with increased likelihood of adverse events when treated with hydralazine in healthy individuals as compared to NAT2 rapid acetylator.	0.125
1451143820	1451143710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451143710	6432120	NAT2 slow acetylator is associated with increased likelihood of drug-induced lupus erythematosus due to hydralazine when treated with hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.0
1451143820	1451135320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135320	28932614	NAT2 intermediate acetylator is associated with increased likelihood of drug-induced lupus erythematosus due to hydralazine and pneumonitis when treated with hydralazine in women Hypertension.	0.125
1451143820	1451142000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451142000	318493	NAT2 slow acetylator is associated with increased likelihood of adverse events when treated with hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.	0.75
1451143820	1184174628	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174628	24444407	NAT2 *5D/*14A + *5D/*5D + *5D/*6B + *5D/*7A + *6B/*14A + *6B/*6B + *7A/*6B (assigned as slow acetylator phenotype) is associated with increased likelihood of adverse effects when treated with hydralazine in people with resistant hypertension.	0.0
1451952760	1451947231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947231	35484400	Allele A is not associated with risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to allele G.	-1.5
1451952760	1451947260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947260	35484400	Allele A is associated with increased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.	3.0
1451954480	1451945420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451945420	35484400	Allele A is not associated with risk of Drug Toxicity when treated with regorafenib in people with Colorectal Neoplasms as compared to allele T.	-1.5
1451954480	1451954440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451954440	35484400	Allele A is associated with increased risk of Drug Toxicity when treated with regorafenib in people with Neoplasms as compared to allele T.	2.25
1451952780	1451945644	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451945644	35484400	Allele A is associated with increased risk of Drug Toxicity when treated with sorafenib in people with Neoplasms as compared to allele T.	3.5
1451952700	1451945560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451945560	35484400	Allele T is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	3.0
1451952700	1451945720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451945720	35484400	Allele T is not associated with risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	-1.5
1451954520	1451947100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947100	35484400	Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.	3.0
1451954540	1451947020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947020	35484400	Allele C is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.	3.0
1451152706	1451152645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152645	7654478	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of ethylmorphine in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	This annotation is not used for clinical annotation scoring.
1451152706	1451152700	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451152700	7756104	CYP2D6 *4/*4 is associated with decreased enzyme activity of CYP2D6 when assayed with ethylmorphine as compared to CYP2D6 *1/*1 + *1/*4.	0.0
1451954560	1451947080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947080	35484400	Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	3.0
1451158880	1451158560	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451158560	19786980	Genotype TCCTC/TCCTC is associated with decreased risk of Anemia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.	3.0
1451158880	1451158580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451158580	19786980	Genotype TCCTC/TCCTC is associated with decreased risk of Thrombocytopenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.	2.5
1451158880	1451158600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451158600	19786980	Genotype TCCTC/TCCTC is associated with decreased risk of Neurotoxicity Syndromes when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.	0.0
1451158880	1451158740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451158740	22188361	Genotype TCCTC/TCCTC is not associated with increased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.	-1.25
1451158887	1451158820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451158820	23559402	Genotype TCCTC/TCCTC is associated with decreased concentrations of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.	1.25
1451158887	1451158825	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451158825	23559402	Genotype TCCTC/TCCTC is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.	1.25
1451159780	1451159740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159740	19088262	Genotype del/del is not associated with increased response to methotrexate in people with Arthritis, Rheumatoid.	-0.5
1451159780	1451159760	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159760	16906016	Genotype del/del is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del.	3.0
1451162662	1451162640	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451162640	22565219	UGT1A1 *28/*28 is associated with decreased metabolism of clozapine in human liver microsomes as compared to UGT1A1 *1/*1 + *1/*28.	0.0
1451162986	1451162880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451162880	19371317	UGT1A1 *28/*28 is associated with increased bone mineral density when treated with raloxifene in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.	1.75
1451163060	1451162800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451162800	19371317	UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.	1.5
1451163060	1184483310	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483310	23682072	UGT1A1 *28 is associated with decreased formation of raloxifene 6-glucuronide in human liver microsomes as compared to UGT1A1 *1.	0.0
1451163060	1184483321	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1184483321	23682072	UGT1A1 *1/*28 + *28/*28 is not associated with decreased formation of raloxifene-4-glucuronide in human liver microsomes as compared to UGT1A1 *1/*1.	-0.0
1451165201	1451165180	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451165180	14647407	UGT1A1 *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with tranilast in people with Myocardial Ischemia as compared to UGT1A1 *1/*1 + *1/*28.	3.0
1451165381	1446908381	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446908381	24898899	UGT1A1 *6/*6 + *6/*28 is associated with increased risk of Hyperbilirubinemia when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*6 + *1/*28 + *27/*28.	2.5
1451165381	1451165360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451165360	17611564	UGT1A1 *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*28.	2.75
1451204520	1451204460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204460	27533851	UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with sorafenib as compared to UGT1A1 *1/*1.	2.5
1451204520	1451204540	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204540	19672597	UGT1A1 *1/*28 is associated with increased risk of Hyperbilirubinemia when treated with sorafenib in people with Carcinoma, Hepatocellular.	0.25
1451206982	PA166104951	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104951		Annotation of DPWG Guideline for irinotecan and UGT1A1	100
1451206982	PA166104831	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104831		Annotation of FDA Label for irinotecan and UGT1A1	100
1451206982	1447945228	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447945228	26862009	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with decreased dose of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*28 + *1/*6.	2.75
1451206982	1448261674	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261674	20038727	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451206982	1448261782	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261782	21654688	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451206982	1448261806	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261806	26739304	UGT1A1 *28/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	0.25
1451206982	1448281118	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448281118	27507617	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	0.25
1451206982	1451206740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206740	18594531	UGT1A1 *1/*28 + *28/*28 are not associated with dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451206982	1451207688	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207688	18300238	UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451206982	1451209847	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451209847	16636344	UGT1A1 *1/*28 is not associated with dose of irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451206982	1451214640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451214640	28493308	UGT1A1 *28 is associated with decreased dose of irinotecan in people with Adenocarcinoma and Gastrointestinal Neoplasms as compared to UGT1A1 *1.	0.25
1451206982	1451294486	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451294486	33203301	UGT1A1 *1/*28 is associated with decreased dose of irinotecan in women with Colorectal Neoplasms.	0.25
1451954568	1451946358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946358	35484400	Allele G is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.	2.5
1451954620	1451946718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946718	35484400	Allele C is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.	3.0
1451954626	1451946700	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946700	35484400	Allele C is associated with decreased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.	3.0
1451954640	1451946761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946761	35484400	Allele A is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	3.0
1451212480	1451211320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211320	27061230	Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT.	2.5
1451212500	1451211400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211400	27061230	Genotype AA is associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotypes AG + GG.	3.0
1451212540	1451212190	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451212190	32433338	Allele A is associated with increased likelihood of Recurrence when treated with tafenoquine in people with Malaria, Vivax as compared to allele G.	0.0
1451212440	1451209365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451209365	16849011	UGT1A1 *28 is associated with increased metabolism of carvedilol in people with Angina Pectoris as compared to UGT1A1 *1.	1.0
1451212440	1451212360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451212360	20643254	UGT1A1 *28/*28 is not associated with dose of carvedilol or metoprolol in people with Heart Failure as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.	-1.25
1451163884	PA166128738	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166128738		Annotation of CPIC Guideline for atazanavir and UGT1A1	100
1451163884	1183863801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863801	24557078	Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele C.	0.0
1451163884	1183863806	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183863806	24557078	Genotype TT is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to genotype CC.	0.0
1451163884	1445296945	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296945	26180834	Genotype TT is associated with increased discontinuation of atazanavir in people with HIV Infections as compared to genotypes CC + CT.	3.25
1451163884	1449154881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154881	29117017	Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.	3.0
1451163884	1449154902	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154902	29117017	Genotype CT is not associated with increased discontinuation of atazanavir as compared to genotype CC.	-1.75
1451163884	1184747361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747361	20504240	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV.	3.0
1451163884	1184747406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747406	20504240	UGT1A1 *6 is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV.	-1.5
1451163884	1184747517	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747517	24516079	UGT1A1 *28 is associated with Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV.	1.5
1451163884	1184747549	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184747549	21317582	UGT1A1 *28/*28 + *1/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV as compared to UGT1A1 *1/*1.	1.75
1451163884	1184998649	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998649	19710077	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in healthy individuals.	1.0
1451163884	1184998662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998662	19710077	UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in healthy individuals.	1.0
1451163884	1184999159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184999159	23548653	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV.	0.0
1451163884	1184999665	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184999665	21348813	UGT1A1 *28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV as compared to UGT1A1 *1.	1.5
1451163884	1185000885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1185000885	17058217	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV.	3.5
1451163884	1451163820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163820	16170755	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir or indinavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28.	2.25
1451163884	1451163920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163920	23148286	UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.	3.5
1451163884	1451163981	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451163981	23148286	UGT1A1 *28/*28 is associated with increased likelihood of Jaundice when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 +*1/*36 + *36/*36.	3.5
1451163884	1451164100	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164100	22661571	UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.	2.75
1451163884	1451164185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164185	17148966	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.	3.0
1451163884	1451164300	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451164300	22179231	UGT1A1 *1/*28 is associated with increased Hyperbilirubinemia and Jaundice when treated with atazanavir in men with Acquired Immunodeficiency Syndrome.	0.25
1451163884	1451165241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451165241	25622064	UGT1A1 *1/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to UGT1A1 *1/*1.	1.75
1451163884	1451213520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213520	23782005	UGT1A1 *1/*36 + *28/*36 + *36/*37 + *1/*1 are associated with decreased severity of Hyperbilirubinemia when treated with atazanavir / ritonavir, lamivudine and zidovudine in women with HIV Infections and Pregnancy as compared to UGT1A1 *1/*28 + *1/*37 + *28/*28 + *28/*37.	2.0
1451954600	1451946346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946346	35484400	Allele A is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.	3.0
1450823852	1450823832	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823832	26449981	Genotypes AA + AG is associated with increased craving of nicotine in children as compared to genotype GG.	2.5
1450823858	1450823843	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823843	26449981	Genotype GG is associated with increased severity of craving when exposed to nicotine in children as compared to genotypes AA + AG.	3.0
1451151340	769245653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245653	20638924	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele C.	2.0
1451151340	827828096	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828096	22188361	Genotype GG is not associated with increased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + CG.	-2.0
1451151340	655386329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386329	19786980	Genotype GG is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CC + CG.	2.5
1451151340	1448263741	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263741	27574448	Genotype CC is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CG + GG.	-1.5
1451151340	1448263781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448263781	27574448	Genotype CC is not associated with risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CG + GG.	-1.5
1451151340	1449718196	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718196	29507678	Genotype GG is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CG.	3.25
1451151380	827810856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810856	19052714	Genotypes CG + GG are associated with decreased one year progression free survival when treated with cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype GG.	2.5
1451151380	827828127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827828127	22188361	Genotypes CG + GG are not associated with decreased risk of progression-free survival or overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.	-2.0
1451151380	1451150880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451150880	29731921	Genotype CG is associated with increased overall survival when treated with cisplatin and radiotherapy in women with Uterine Cervical Neoplasms as compared to genotypes CC + GG.	2.0
1451151380	1449752734	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752734	29925895	Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.	2.5
1451215020	981747419	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981747419	19299905	Genotypes AA + AG are associated with increased severity of Diarrhea when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.	2.5
1451215020	981794265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794265	18221820	Genotype AA is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.5
1451215020	981794523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981794523	16636344	Genotype AA is not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	-1.25
1451215020	1448617817	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617817	28367249	Allele A is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to allele G.	2.0
1451215020	1448617936	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617936	28502040	Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG.	3.5
1451215020	1447959787	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447959787	26125934	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with cisplatin and irinotecan in women with Ovarian Neoplasms as compared to UGT1A1 *1/*1.	3.25
1451215020	1448422688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422688	26857783	UGT1A1 *6 + *28 are not associated with risk of Diarrhea when treated with irinotecan in people with Neoplasms.	-1.5
1451215020	1448422767	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422767	27160286	UGT1A1 *6 + *28 are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms.	3.0
1451215020	1451204620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204620	20335017	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451206340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206340	15280927	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451206467	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206467	16456808	UGT1A1 *1/*28 + *28/*28 are associated with increased risk of Diarrhea when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.75
1451215020	1451206751	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206751	18594531	UGT1A1 *1/*28 + *28/*28 are not associated with Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451215020	1451207680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207680	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451215020	1451208420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208420	17577039	UGT1A1 *28/*28 is not associated with increased risk of Diarrhea or Neutropenia when treated with irinotecan in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	-1.25
1451215020	1451208821	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208821	17185998	UGT1A1 *1/*28 + *28/*28 are not associated with Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451215020	1451208880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208880	16951398	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	2.25
1451215020	1451209203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209203	11990381	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	0.375
1451215020	1451209840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209840	16636344	UGT1A1 *1/*28 is not associated with Diarrhea when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451215020	1451210040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210040	23529007	UGT1A1 *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.75
1451215020	1451210050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210050	23529007	UGT1A1 *1/*28 is not associated with risk of Diarrhea when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.0
1451215020	1451212320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451212320	15297419	UGT1A1 *28 is not associated with increased likelihood of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.25
1451215020	1451213400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213400	28367249	UGT1A1 *1/*1 + *1/*28 is associated with decreased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.	1.75
1451215020	1451213590	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213590	19450125	UGT1A1 *28/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.25
1451215020	1451213621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213621	24815493	UGT1A1 *1/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451215020	1451213837	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213837	18221820	UGT1A1 *1/*28 is not associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.5
1451215020	1451214007	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214007	25285015	UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Diarrhea when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	3.0
1451215020	1451214200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214200	28502040	UGT1A1 *1/*1 + *1/*28 is associated with decreased severity of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.	1.25
1451215020	1451214800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214800	29504153	UGT1A1 *28/*28 + *28/*37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.25
1451215020	1447945258	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945258	26862009	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28.	0.0
1451549101	1451255063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451255063	32344632	Genotype TTA/TTA is associated with increased likelihood of gastrointestinal toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TTA/TTAAAGTTA + TTAAAGTTA/TTAAAGTTA.	2.5
1451549101	1450821752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450821752	30222710	Genotype TTAAAGTTA/TTAAAGTTA is not associated with increased likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TTA/TTA + TTA/TTAAAGTTA.	-1.5
1451549101	1451548960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451548960	30684021	Genotypes TTA/TTA + TTA/TTAAAGTTA are associated with increased risk of Neutropenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TTAAAGTTA/TTAAAGTTA.	2.25
1451954607	1451946500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946500	35484400	Allele C is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.	2.5
1450929222	1450826585	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826585	28388599	Genotype AA is associated with decreased dose of fentanyl in children as compared to genotypes AG + GG.	1.75
1450929222	1449296415	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296415	27883323	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.	2.25
1450929222	1449714007	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449714007	23557865	Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.	-1.5
1450929222	1183681975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681975	19514130	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	3.25
1451114600	827811361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811361	19384296	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms.	-1.5
1451114600	769176378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769176378	20819423	Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.	2.25
1451114600	769169688	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169688	16818689	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Adenocarcinoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.75
1451114600	1448267291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448267291	27752409	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased Cardiomyopathies when treated with FOLFOX in people with.	0.25
1451114600	1448267833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448267833	27774364	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased Drug Toxicity when treated with fluorouracil in women with Rectal Neoplasms.	0.25
1451114600	827823429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827823429	20714149	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased likelihood of Hyperammonemia when treated with FOLFOX in people with Pancreatic Neoplasms and Stomach Neoplasms.	0.25
1451114600	1183681932	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183681932	23736036	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.75
1451114600	769245656	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769245656	20638924	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.0
1451114600	769169085	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169085	11913730	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased severity of side effects when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.0
1451114600	1449161776	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161776	28427087	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	-2.0
1451114600	1449161948	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161948	27738344	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with gastroesophageal cancer as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.5
1451114600	1449165595	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449165595	26967565	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.75
1451114600	1449716926	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449716926	30013790	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with risk of Drug Toxicity when treated with fluorouracil in women with Rectal Neoplasms.	0.25
1451114600	1449718056	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449718056	29507678	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	3.25
1451114960	827811344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811344	19384296	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with survival when treated with fluorouracil in people with Colorectal Neoplasms.	-1.5
1451114960	827813351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813351	21919605	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.	-3.5
1451114960	769261466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261466	20385995	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype 33.	2.75
1451114960	1184468622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468622	20165956	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype 33.	1.75
1451114960	1184469575	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469575	20932673	Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Rectal Neoplasms.	-1.0
1451114960	769169069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169069	14522928	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.0
1451114960	769169217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169217	15918040	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to fluorouracil in people with as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	0.0
1451114960	769165179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769165179	21167658	Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	-1.75
1451114960	827813447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813447	20665215	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.25
1451114960	1184886844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886844	25232828	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	1.5
1451114960	827825053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825053	16249645	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased survival when treated with cisplatin and fluorouracil in people with Stomach Neoplasms.	0.25
1451114960	769169082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169082	11913730	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	1.5
1451114960	1449155868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155868	28972045	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with cisplatin, epirubicin and fluorouracil in people with Esophageal Neoplasms or Stomach Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.5
1451243628	1444705902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705902	24919870	Genotypes CT + TT is associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to genotype CC.	3.0
1451243628	1447519358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447519358	21148049	Allele T is not associated with increased risk of Hemorrhage when treated with acenocoumarol or warfarin as compared to allele C.	-1.5
1451243628	982006653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006653	23113310	Genotype TT is not associated with increased risk of hemorrhage when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes CC + CT.	-1.25
1451243628	982044609	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982044609	18950464	Genotype TT is not associated with risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.	-1.25
1451243628	1448602391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448602391	28033245	Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.	2.0
1451243628	1449190889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190889	29432897	Allele T is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.	2.75
1451243628	1449269120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449269120	29577257	Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to genotype CC.	3.5
1451244448	699638684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/699638684	18332269	Genotype AA is associated with increased reduction of LDL cholesterol when treated with simvastatin.	2.5
1184133833	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1184133833	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1184133833	PA166105117	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166105117		Annotation of FDA Label for efavirenz and CYP2B6	100
1184133833	1184473249	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473249	23399569	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	981478651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478651	22471906	Genotype GG is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1183491434	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491434	23254426	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1447680752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680752	26779253	Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1183491467	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491467	23254426	Genotype AG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4.
1184133833	1184473253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473253	23399569	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997136	26107645	Genotypes AG + GG are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997456	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997456	20841522	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448997270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997270	22481606	Genotypes AG + GG are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype AA.	This annotation is not used for clinical annotation scoring. The association between 785A>G SNP and decreased CYP2B6 function (increased EFV concentration) is likely due to linkage disequilibrium of this SNP with a decreased function SNP 516G>T, forming the *6 haplotype. When 785A>G and 516G>T were individually tested and found associations of each SNP with efavirenz exposure, the finding is likely to be due to *6 not *4
1184133833	1448665077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448665077	28816644	Allele G is not associated with increased concentrations of efavirenz in children with HIV Infections as compared to allele A.	-0.75
1184133833	1184988315	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988315	20952418	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.5
1184133833	827824895	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827824895	21659470	Allele G is associated with decreased metabolism of bupropion and efavirenz.	0.0
1184133833	1184349357	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184349357	20625352	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	-0.5
1184133833	1184473257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473257	23399569	Genotype GG is not associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AG.	-0.75
1184133833	1451112320	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451112320	21821736	Allele G is associated with increased metabolism of efavirenz as compared to allele A.	0.0
1184133833	981480742	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981480742	22927450	Genotypes CC + CT are associated with increased exposure of efavirenz in women with HIV Infections as compared to genotype TT.	2.5
1184133833	982046519	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982046519	23080225	Allele C is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele T.	2.5
1184133833	827807683	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807683	18281305	Allele C is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele T.	2.5
1184133833	769162986	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769162986	20860463	Genotype CT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	1.5
1184133833	769163091	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163091	19779319	Genotype CT is not associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	-0.75
1184133833	769163497	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769163497	19371316	Genotype CT is not associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	-0.75
1184133833	769170863	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170863	16495778	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	0.125
1184133833	1183634164	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634164	24080498	Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.	2.25
1184133833	1184467538	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467538	24729586	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	1.75
1184133833	1184471365	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471365	19659438	Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) .	1.5
1184133833	1184473165	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473165	24316028	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	1.25
1184133833	1446905210	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446905210	25611810	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	2.0
1184133833	1447680778	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447680778	26779253	Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	2.0
1184133833	1448636182	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448636182	28692529	Genotypes CC + CT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	0.0
1184133833	1448665545	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448665545	28816644	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	1.25
1184133833	1448994431	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994431	28886044	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.	-0.25
1184133833	1448997158	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997158	25889207	Genotypes CC + CT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1184133833	1448997264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997264	22481606	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	1.75
1184133833	827787878	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827787878	21814190	CYP2B6 *1 is associated with decreased plasma concentration of efavirenz when treated with efavirenz in people with HIV.	2.0
1184133833	981417238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417238	15194512	CYP2B6 *6/*6 is associated with increased plasma concentration when treated with efavirenz in people with HIV.	2.0
1184133833	981419341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981419341	17559344	CYP2B6 *6 is associated with decreased metabolism of efavirenz in human liver microsomes as compared to CYP2B6 *1.	1.25
1184133833	982032006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032006	23778320	CYP2B6 *6/*6 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	982032013	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032013	23778320	CYP2B6 *18/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	982032019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982032019	23778320	CYP2B6 *1/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1183491475	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491475	23254426	CYP2B6 *1/*1 is associated with increased clearance of efavirenz in people with HIV.	1.5
1184133833	1183616504	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183616504	23254426	CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in people with HIV.	2.0
1184133833	1183764170	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183764170	24497997	CYP2B6 *1/*1 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.	1.75
1184133833	1183771932	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183771932	24497997	CYP2B6 *1/*6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.	0.0
1184133833	1183944291	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183944291	24497997	CYP2B6 *6 is associated with metabolism of efavirenz in people with HIV.	1.75
1184133833	1184165591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184165591	24142869	CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.	1.5
1184133833	1184473220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473220	23399569	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1184510497	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184510497	23846872	CYP2B6 *1/*1 + *1/*6 is not associated with clearance of efavirenz in healthy individuals as compared to CYP2B6 *6/*6.	-0.125
1184133833	1447962916	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447962916	17235330	CYP2B6 *28 is associated with increased exposure to efavirenz in people with HIV as compared to CYP2B6 *1.	0.0
1184133833	1447984366	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447984366	27045425	CYP2B6 *6 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 *1.	0.0
1184133833	1448993987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448993987	26655325	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448994001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994001	26655325	CYP2B6 *18 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1448994017	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448994017	21896912	CYP2B6 *1/*6 + *6/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.0
1184133833	1448995403	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995403	28622951	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.0
1184133833	1448995845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995845	27333947	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.	1.25
1184133833	1448995859	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995859	20881953	CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448995871	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995871	19916993	CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.	1.0
1184133833	1448995983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995983	17235330	CYP2B6 *6/*6 + *1/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1184133833	1448996001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448996001	17235330	CYP2B6 *1/*4 are associated with decreased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.5
1184133833	1448997246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997246	23734829	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.0
1184133833	1448997763	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997763	16495778	CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.	1.25
1184133833	1449156732	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449156732	23640958	CYP2B6 *6 + *38 are associated with decreased clearance of efavirenz as compared to CYP2B6 *1/*1.	0.0
1184133833	1451112380	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451112380	21821736	CYP2B6 *6 is associated with decreased metabolism of efavirenz as compared to CYP2B6 *1.	0.0
1184133833	1448997750	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448997750	16495778	CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.	1.75
1184133833	1184988354	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988354	20952418	CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1184133833	1184988346	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988346	20952418	CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1184133833	1184988338	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184988338	20952418	CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV Infections.	1.0
1451208740	981794068	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981794068	18221820	Genotype AA is associated with increased concentrations of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.5
1451208740	981747792	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981747792	17627617	Genotype AA is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to genotype GG.	2.5
1451208740	981843914	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981843914	16636344	Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.25
1451208740	1184747085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747085	15179405	UGT1A1 *6/*60 + *6/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	0.75
1451208740	1184747113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747113	15179405	UGT1A1 *6/*6 + *1/*6 is associated with decreased metabolism of SN-38 in people with Neoplasms.	1.25
1451208740	1184747123	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184747123	15179405	UGT1A1 *28/*28 + *1/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451208740	1185235188	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235188	24958824	UGT1A1 *1/*28 + *28/*28 is associated with increased concentrations of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451208740	1185235470	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185235470	25427841	UGT1A1 *6 + *28 is associated with increased concentrations of SN-38 in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451208740	1451205300	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205300	20562211	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.5
1451208740	1451208680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208680	17577039	UGT1A1 *28/*28 is associated with increased concentrations of SN-38 in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	0.0
1451208740	1451208780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208780	17185998	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451208740	1451208840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208840	16951398	UGT1A1 *1/*28 + *28/*28 are associated with decreased clearance of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451208740	1451208948	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208948	15007088	UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.25
1451208740	1451209187	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451209187	11990381	UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451208740	1451211800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451211800	18797458	UGT1A1 *1/*28 + *28/*28 are not associated with metabolism of SN-38 in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-0.125
1451208740	1451213120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451213120	27116457	UGT1A1 *28 is associated with increased concentrations of SN-38 in people with Colonic Neoplasms as compared to UGT1A1 *1.	2.0
1451236700	PA166191841	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166191841		Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9	100
1451236700	PA166104843	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104843		Annotation of FDA Label for celecoxib and CYP2C9	100
1451236700	827826389	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826389	11337938	Allele T is associated with decreased metabolism of celecoxib.	0.0
1451236700	827826410	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826410	11337938	Allele T is not associated with increased AUC of celecoxib when treated with celecoxib.	-0.125
1451236700	827826458	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826458	16401468	Genotype CT is associated with higher plasma concentrations of celecoxib when exposed to celecoxib in healthy individuals as compared to genotype CC.	1.5
1451236700	1183690922	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690922	12893985	Allele T is not associated with clearance of celecoxib in healthy individuals as compared to allele C.	-0.125
1451236700	827826380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826380	11337938	Allele C is associated with decreased metabolism of celecoxib.	0.0
1451236700	827826398	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827826398	11337938	Allele C is associated with increased AUC of celecoxib when treated with celecoxib as compared to allele A.	0.125
1451236700	1183690913	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690913	16153401	Genotype CC is associated with decreased metabolism of celecoxib in children as compared to genotype AA.	0.5
1451236700	1183690931	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183690931	12893985	Genotype CC is associated with decreased clearance of celecoxib in healthy individuals as compared to genotype AA.	1.0
1451236700	1183680709	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680709	23996211	CYP2C9 *1/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451236700	1183680725	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680725	23996211	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1451236700	1183680733	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680733	23996211	CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*3.	1.0
1451236700	1183680745	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680745	23996211	CYP2C9 *1/*2 is associated with increased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	-1.0
1451236700	1448431851	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448431851	27864660	CYP2C9 *1/*3 + *1/*13 + *3/*3 are associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.75
1451236700	1449171322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171322	26360837	CYP2C9 *1/*3 is associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.	1.25
1451237940	PA166104940	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104940		Annotation of DPWG Guideline for phenprocoumon and VKORC1	100
1451237940	827864542	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827864542	20833980	Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.	1.75
1451237940	1444707634	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707634	24224579	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.5
1451237940	1444707652	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707652	23423913	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.	2.5
1451237940	1444707757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707757	23299853	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.5
1451237940	1444707853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707853	18629445	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	0.0
1451237940	982046650	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046650	21110013	Genotype CC is associated with increased dose of phenprocoumon as compared to genotypes CT + TT.	2.25
1451237940	1043818234	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818234	20376629	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT.	1.5
1451237940	1043858478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043858478	21057703	Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.	1.75
1451237940	1448255689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448255689	26984978	Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.	2.25
1451237940	1448259259	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448259259	21636598	Allele T is associated with dose of acenocoumarol or phenprocoumon.	0.0
1451242500	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1451242500	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1451242500	1448107499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107499	26196596	Genotype GG is associated with increased dose of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	0.0
1451242500	1184511673	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184511673	20441246	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.	0.25
1451242500	1184987905	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184987905	24956253	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.	0.0
1451242500	1448261257	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448261257	17918089	CYP2B6 *1/*26 + *6/*6 + *6/*26 is associated with decreased dose of efavirenz in people with HIV.	0.25
1451243676	1444707678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707678	23423913	Genotype TT is associated with increased likelihood of Hemorrhage when treated with phenprocoumon as compared to genotype CC.	0.0
1451243676	1444707784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444707784	23016521	Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with phenprocoumon as compared to genotype CC.	3.0
1451243676	1447679579	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447679579	21057703	Genotype TT is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CT.	2.25
1451243676	1447680482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447680482	23016521	Genotype TT are associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CC.	3.0
1451244040	1043737589	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043737589	16201835	Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.	1.75
1451244040	1043818101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1043818101	20020283	Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.	3.0
1451244040	1449747466	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449747466	30207196	Allele A is associated with decreased dose of phenprocoumon in children as compared to allele G.	2.0
1451244040	1444707640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444707640	24224579	Genotypes AA + AG are associated with decreased dose of phenprocoumon as compared to genotype GG.	2.5
1451245360	769170794	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769170794	19827168	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	1.75
1451245360	981239954	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981239954	15677700	Genotypes CC + CT are associated with increased severity of Arthritis, Rheumatoid when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.	1.5
1451245360	827863341	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827863341	22450926	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.75
1451245360	655386407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386407	15457444	Genotype TT is associated with decreased disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	3.0
1451245360	769171231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171231	18322994	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.	2.75
1451245360	769171199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769171199	17325736	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	2.0
1451245360	769171198	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769171198	17325736	Genotype TT is associated with increased likelihood of remission when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
1451245360	1451110120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451110120	31099054	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	-1.5
1451245360	1447674478	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447674478	26616421	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.	2.5
1451245360	1448576460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576460	27992285	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.	1.375
1451250540	1447673749	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447673749	15737014	Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.	0.25
1451250540	981417766	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417766	18596266	Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.	2.5
1451250540	981475217	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475217	18992959	Genotype CT is associated with increased resistance when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype CC.	0.25
1451250540	981475231	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475231	16912157	Allele T is associated with decreased response rate (RR) when treated with gefitinib in non-small-cell lung cancer patients as compared to allele C.	1.5
1451250540	981475241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475241	18093943	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475253	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475253	17085664	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475265	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475265	17020982	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in non-small cell lung cancer as compared to allele C.	0.25
1451250540	981475276	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475276	18981003	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.25
1451250540	981475286	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475286	20129249	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475298	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475298	19381876	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475309	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475309	19589612	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475337	21430269	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.	0.25
1451250540	981475352	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475352	22215752	Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.	1.75
1451250540	981475378	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475378	21248300	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.0
1451250540	981475801	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981475801	21921847	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.	0.25
1451250540	981477537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477537	16258541	Allele T is associated with increased acquired resistance to EGFR inhibitor when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.	0.25
1451251080	827830235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827830235	12966368	Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.	1.25
1451251080	1183683991	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683991	21903774	Genotype GG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.	3.0
1451251080	827815666	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827815666	21902502	Genotype AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	1.5
1451251080	1184989819	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184989819	25322286	Genotypes AA + AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.	0.0
1451251080	982046215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982046215	23837477	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in children with Transplantation as compared to CYP3A4 *1/*1.	2.75
1451251080	1184471333	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184471333	24444408	CYP3A4 *1/*22 is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	-1.5
1451251080	1185234468	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1185234468	25287072	CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	2.75
1451251080	1449173523	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173523	29469606	CYP3A4 *1/*20 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.	0.0
1451237200	PA166104945	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104945		Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT	100
1451237200	PA166104952	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104952		Annotation of DPWG Guideline for mercaptopurine and TPMT	100
1451237200	1184348827	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348827	1960624	TPMT poor metabolizer phenotype is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1451237200	1444705000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444705000	25347948	TPMT intermediate metabolizer phenotype is associated with increased likelihood of treatment modification when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT normal metabolizer phenotype.	0.875
1451237200	1444703337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444703337	25624441	Genotype CC is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.	2.5
1451237200	1447682783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682783	26503813	Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.25
1451237200	1449311061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311061	29683944	Genotype TT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.	-0.25
1451237200	1449311070	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311070	29683944	Genotype GG is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CG.	-0.25
1451237200	981501231	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981501231	23029095	TPMT *1/*1 is associated with increased dose of mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*3A.	0.0
1451237200	1184134029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134029	20175817	TPMT *2 + *3A + *3B + *3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	0.0
1451237200	1184134089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134089	16202677	TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.5
1451237200	1184134384	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134384	17164697	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	0.0
1451237200	1184169832	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184169832	18987660	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.75
1451237200	1184282060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184282060	20153897	TPMT *1/*3C + *1/*2 + *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.25
1451237200	1184348438	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348438	12142782	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184348458	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184348458	12142782	TPMT *1/*3C is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184467037	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467037	9510461	TPMT *3A/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184467044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184467044	9510461	TPMT *3A/*3A is associated with decreased dose of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237200	1184518608	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184518608	21319286	TPMT *1/*3A + *1/*3C + *3A/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1451237200	1184521242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184521242	18467186	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.25
1451237200	1333193294	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1333193294	25441457	TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	-3.5
1451237200	1448256071	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256071	27452984	TPMT *1/*3A is associated with increased likelihood of dose reduction when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	3.25
1451237200	1448260658	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448260658	27577869	TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1451237200	1448576445	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448576445	28146264	TPMT *1/*2 + *1/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.0
1451237200	1449750276	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449750276	29720126	TPMT *1/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	0.0
1451237200	1356539101	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1356539101	25441457	TPMT *1/*3C is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1451237200	1353450854	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1353450854	25441457	TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	This annotation is not used for clinical annotation scoring. CA already has a scoring VA from this paper
1451237326	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1451237326	1184516561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184516561	15570193	TPMT low activity phenotype is associated with decreased dose of azathioprine as compared to TPMT high activity phenotype.	1.125
1451237326	1451237363	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451237363	30987408	Genotype CT is associated with decreased dose of azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.	2.5
1451237326	1184134029	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134029	20175817	TPMT *2 + *3A + *3B + *3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	0.0
1451237326	1184134089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184134089	16202677	TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.5
1451237326	1184174025	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174025	12477776	TPMT *3A/*3A is associated with decreased dose of azathioprine in people with Crohn Disease as compared to TPMT *1/*1.	0.25
1451237326	1184174034	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184174034	12477776	TPMT *3A/*3C is associated with decreased dose of azathioprine in people with Crohn Disease as compared to TPMT *1/*1.	0.25
1451237326	1184175334	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184175334	15349717	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine in people with Transplantation as compared to TPMT *1/*1.	2.25
1451237326	1184521242	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184521242	18467186	TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.25
1451237326	1184548150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184548150	21819368	TPMT *1/*3C is not associated with dose of azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	-1.0
1451237326	1451237580	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451237580	26072396	TPMT *1/*2 + *1/*3A + *1/*3C + *3A/*3A is associated with decreased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	0.0
1451237240	PA166104933	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104933		Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT	100
1451237240	1184174063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174063	20136357	TPMT poor metabolizer phenotype is associated with increased risk of myelotoxicity when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1451237240	1184174068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174068	20136357	TPMT intermediate metabolizer phenotype is associated with increased risk of mild leukopenia when treated with azathioprine, mercaptopurine or purine analogues as compared to TPMT normal metabolizer phenotype.	0.0625
1451237240	1184233739	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233739	20308917	TPMT intermediate metabolizer phenotype is associated with decreased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT poor metabolizer phenotype.	1.0
1451237240	1184349913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349913	18616518	TPMT intermediate metabolizer genotype is associated with increased likelihood of adverse effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.5
1451237240	1184407184	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407184	16543290	TPMT intermediate metabolizers is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1451237240	1184414133	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184414133	12269967	TPMT intermediate metabolizer phenotype is associated with increased likelihood of intolerable side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT normal metabolizer phenotype.	1.5
1451237240	1448266607	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448266607	26674571	TPMT poor metabolizers are associated with increased likelihood of Leukopenia and Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.	1.375
1451237240	1451237464	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451237464	31024313	Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.	-1.5
1451237240	1449750678	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449750678	29867468	Genotype CT is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic and Sjogren's Syndrome as compared to genotype TT.	-1.25
1451237240	1184134111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134111	16202677	TPMT *1/*2 + *1/*3A is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184134311	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184134311	10376773	TPMT *1/*3A is associated with hepatic toxicity when treated with azathioprine, mercaptopurine or purine analogues in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.25
1451237240	1184136197	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184136197	15792824	TPMT *1/*3A + *1/*3C is associated with increased likelihood of haematological toxicity or hepatotoxicity when treated with azathioprine in people with neurological problems as compared to TPMT *1/*1.	2.0
1451237240	1184173900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184173900	9841604	TPMT *1/*3A is associated with increased risk of low leukocyte counts when treated with azathioprine in people with Rheumatic Diseases as compared to TPMT *1/*1.	1.25
1451237240	1184174715	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174715	12172211	TPMT *3A/*3A is associated with increased severity of myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases.	0.25
1451237240	1184175442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184175442	16611274	TPMT *1/*3A + *1/*3C is not associated with likelihood of Leukopenia, malaise and Pancreatitis when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184233233	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233233	16044099	TPMT *1/*2 + *1/*3A + *1/*3C is associated with increased likelihood of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation as compared to TPMT *1/*1.	2.0
1451237240	1184233329	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233329	16044099	TPMT *3A/*3C is associated with severity of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation.	1.5
1451237240	1184233545	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233545	19695401	TPMT *1/*3C is associated with increased likelihood of myelosuppression when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	3.0
1451237240	1184233570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233570	19682195	TPMT *1/*3C is not associated with increased likelihood of severe adverse reactions when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.5
1451237240	1184233729	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233729	20308917	TPMT *1/*3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	2.75
1451237240	1184233750	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233750	16396707	TPMT *1/*3C + *1/*6 is not associated with likelihood of adverse events when treated with azathioprine in people with Lupus Erythematosus, Systemic as compared to TPMT *1/*1.	-1.25
1451237240	1184233780	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233780	17241387	TPMT *3C/*3C is associated with increased risk of severe myelosuppression when treated with azathioprine in people with Hepatitis, Autoimmune as compared to TPMT *1/*1.	0.25
1451237240	1184233799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184233799	18827410	TPMT *1/*3C is not associated with myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184272572	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184272572	19048245	TPMT *1/*3C is not associated with risk of hematotoxicity or hepatotoxicity when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	-0.25
1451237240	1184348490	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348490	17176368	TPMT *1/*3C is associated with increased likelihood of haematopoietic toxicity when treated with azathioprine in people with Kidney Transplantation.	2.5
1451237240	1184348908	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184348908	21712851	TPMT *3A/*3A is associated with severe myelosuppression when treated with azathioprine in people with Kidney Transplantation.	0.25
1451237240	1184349269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349269	10798786	TPMT *1/*3A + *1/*3C is associated with decreased leukocytes and neutrophils when treated with azathioprine in people with heart transplantation as compared to TPMT *1/*1.	1.5
1451237240	1184349305	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349305	15476481	TPMT *1/*3A + *1/*3B + *1/*3C is associated with decreased hematological indices when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.	1.5
1451237240	1184349431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184349431	20593505	TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	1.75
1451237240	1184407209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184407209	17439508	TPMT *1/*3A + *1/*3C is not associated with increased likelihood of myelosuppression or any other side effect when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.5
1451237240	1184467185	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467185	16431304	TPMT *1/*3A + *1/*3C + *3A/*3A is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	3.25
1451237240	1447682889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447682889	26735160	TPMT *1/*3C is associated with Leukopenia when treated with azathioprine in children with Crohn Disease.	0.0
1451237240	1447983088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447983088	27082580	TPMT *1/*3C is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	0.0
1451237240	1448261284	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448261284	27604507	TPMT *1/*3C is not associated with risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to TPMT *1/*1.	-1.75
1451237240	1448268166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268166	18662289	TPMT *3A + *3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.	2.5
1451237240	1448268960	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448268960	22535280	TPMT *3A + *3B + *3C is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	3.0
1451237240	1449161615	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161615	29210335	TPMT *6 is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.5
1451237240	1449161632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161632	29210335	TPMT *3C is not associated with Drug Toxicity when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1.	-2.5
1451237240	1184174686	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174686	12172211	TPMT *1/*3A + *3A/*3A is not associated with risk of Gastrointestinal side effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.	-1.25
1451237240	1184133979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184133979	20175817	TPMT *2 + *3A + *3B + *3C is not associated with likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1.	-1.25
1451237240	1184174663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184174663	14560161	TPMT *3A/*3A is associated with increased severity of bone marrow suppression when treated with azathioprine in people with Colitis, Ulcerative.	0.25
1451237240	1451905428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451905428	34582038	TPMT *1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of discontinuation and Myelosuppression when treated with azathioprine in people with Inflammation as compared to TPMT *1/*1 (assigned as normal metabolizer phenotype) .	3.5
1450929125	981750833	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/981750833	19628476	Allele A is associated with increased dose of nicotine as compared to allele G.	2.5
1450929125	769169430	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169430	18385739	Allele A is associated with increased number of cigarettes smoked per day in people with Tobacco Use Disorder as compared to allele G.	0.0
1450929131	982006957	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982006957	19429911	Allele A is associated with increased likelihood of smoking when exposed to nicotine in women smokers who are pregnant as compared to allele G.	2.0
1451954660	1451946580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946580	35484400	Allele A is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.	3.0
1451954660	1451946600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946600	35484400	Allele A is not associated with risk of Diarrhea when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to allele G.	-1.5
1451954683	1451947113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947113	35484400	Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.	2.5
1450811960	1450811896	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811896	18433502	Allele A is associated with increased response to ethanol as compared to allele G.	3.25
1450930542	1450930500	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450930500	29650764	Allele C is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele T.	2.25
1449645543	1449645334	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645334	29705271	Allele T is associated with increased sulfation of tapentadol as compared to allele C.	0.0
1449645555	1449645216	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645216	29705271	Allele T is associated with decreased sulfation of acetaminophen as compared to allele G.	0.0
1449645561	1449645344	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645344	29705271	Allele T is associated with decreased sulfation of morphine as compared to allele G.	0.0
1449645567	1449645348	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645348	29705271	Allele T is associated with decreased sulfation of tapentadol as compared to allele G.	0.0
1449645573	1449645352	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645352	29705271	Allele T is associated with decreased sulfation of o-desmethyltramadol as compared to allele G.	0.0
1449733531	1449733463	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449733463	30273369	Allele A is associated with decreased risk of Peripheral Nervous System Diseases due to stavudine in people with HIV Infections as compared to allele G.	2.75
1450811948	1450811690	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811690	18433502	Allele A is associated with increased response to ethanol as compared to allele C.	3.25
1450812260	1450812130	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812130	18518925	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.	3.5
1450812260	1450820238	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450820238	22500942	Allele A is not associated with risk of Heroin Dependence due to heroin as compared to allele G.	-2.5
1451952740	1451946864	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946864	35484400	Allele T is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.	3.0
1451952740	1451946880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451946880	35484400	Allele T is not associated with risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to allele C.	-1.5
1451954700	1451947304	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947304	35484400	Allele C is associated with decreased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.	3.0
1451954720	1451947273	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451947273	35484400	Allele T is associated with decreased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.	3.0
1449003966	981476064	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981476064	22341855	Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotype GG.	2.25
1449003966	1449002712	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449002712	29036176	Allele A is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele G.	-1.5
1449167106	1449165982	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165982	29382897	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167120	1449165990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165990	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167147	1449165997	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449165997	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167178	1449166003	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166003	29382897	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167200	1449166009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166009	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167211	1449166015	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166015	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167228	1449166032	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166032	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167256	1449166050	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166050	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167267	1449166057	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166057	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167278	1449166063	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166063	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449168649	1449168289	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168289	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168656	1449168185	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168185	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168663	1449168173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168173	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449715840	1449715638	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449715638	23144877	Allele T is associated with increased likelihood of Vomiting due to fentanyl in women with Pain, Postoperative as compared to allele A.	2.0
1450810399	1450810193	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810193	16476706	Allele G is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele A.	0.0
1450930833	1450930705	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450930705	29666375	Allele G is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele C.	3.0
1449167469	1449166269	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166269	29382897	Allele A is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167480	1449166275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166275	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167495	1449166319	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166319	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167512	1449166325	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166325	29382897	Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167529	1449166331	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166331	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167546	1449166337	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166337	29382897	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167557	1449166345	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166345	29382897	Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449167584	1449166371	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449166371	29382897	Allele T is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	0.0
1449168093	1449167803	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167803	29407288	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168330	1449167809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167809	29407288	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168337	1449167785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167785	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168343	1449167797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167797	29407288	Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168350	1449167815	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167815	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168357	1449167764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167764	29407288	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168454	1449168131	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168131	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168461	1449168143	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168143	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1450812253	1450812114	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812114	18518925	Allele T is associated with decreased risk of Heroin Dependence due to heroin as compared to allele C.	0.0
1450812253	1444935998	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444935998	25521358	Genotype CC is associated with increased risk of Heroin Dependence when exposed to heroin as compared to genotypes CT + TT.	0.0
1449171009	1451440360	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451440360	29450233	Genotype CT is associated with increased dose of buprenorphine in people with Opioid-Related Disorders.	0.25
1449171009	1451440400	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451440400	31676110	Genotypes CC + CT is associated with increased risk of Substance Withdrawal Syndrome when treated with buprenorphine in people with Opioid-Related Disorders as compared to genotype TT.	2.0
1449168468	1449168137	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168137	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168475	1449167881	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167881	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168482	1449167912	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167912	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168489	1449167888	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167888	29407288	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168496	1449167906	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167906	29407288	Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168503	1449167900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167900	29407288	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168510	1449167894	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167894	29407288	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168517	1449168149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168149	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168524	1449168155	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168155	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168531	1449168233	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168233	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168538	1449168240	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168240	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168545	1449168246	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168246	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168552	1449168252	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168252	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168559	1449168191	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168191	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168565	1449168199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168199	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168572	1449168211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168211	29407288	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	0.0
1449168579	1449168217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168217	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168586	1449168258	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168258	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168593	1449168223	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168223	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168600	1449168264	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168264	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168607	1449168271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168271	29407288	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168614	1449168277	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449168277	29407288	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	0.0
1449168691	1449167918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167918	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168698	1449167930	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167930	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	0.0
1449168705	1449167924	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167924	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168712	1449167936	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167936	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449168719	1449167942	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449167942	29407288	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	0.0
1449566334	1449565950	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449565950	28476759	HLA-A *24:02:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	2.25
1450808778	1450808755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808755	15203796	Genotypes AA + AG are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype GG.	2.0
1449296086	1449713987	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713987	23557865	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	-1.5
1449296086	1449716420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716420	21128989	CYP3A4 *18 is not associated with dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1.	-1.25
1449296086	1449715317	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715317	23313934	CYP3A4 *18/*18 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	1.75
1449296086	1449715329	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715329	23313934	CYP3A4 *18 is not associated with dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1.	-1.25
1449296086	1450823962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823962	19784640	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1449716539	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716539	21223952	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1450823212	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823212	25794200	CYP3A4 *36 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.	1.375
1449296086	1449716742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716742	29601950	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1449296086	1449296077	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449296077	21535061	CYP3A4 *36 is associated with decreased dose of fentanyl in women with Pain, Postoperative.	1.75
1449296086	1449716632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716632	21513075	CYP3A4 *36/*36 is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1450814192	1450814181	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814181	22457278	Genotype GG is associated with decreased response to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotypes AA + AG.	1.75
1450814424	1450814400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814400	31058543	Genotype GT is associated with increased response to l-methylfolate in children with Depressive Disorder, Major.	0.25
1450814424	1450814412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814412	27035272	Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.	2.5
1450814430	1450814388	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814388	27520898	Genotype AG is associated with increased response to l-methylfolate in men with Bipolar Disorder, Depression and Obsessive-Compulsive Disorder.	0.25
1450814430	1450814406	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814406	27035272	Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.	2.5
1450814563	1450814539	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814539	22882391	Allele G is associated with increased severity of Cocaine-Related Disorders due to cocaine as compared to allele C.	2.0
1450815114	1450814990	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450814990	23241943	Allele T is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele C.	0.0
1450815136	1450815045	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815045	23241943	Allele T is associated with increased response to quetiapine in people with Schizophrenia as compared to allele C.	0.0
1450928823	1450928764	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928764	29621993	Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.	2.25
1450929143	1183705482	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183705482	24535486	Genotypes AA + AG are associated with decreased lung function when exposed to nicotine in people with Tobacco Use Disorder as compared to genotype GG.	2.5
1450929810	1449003085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003085	21209234	Genotype GG is not associated with dose of oxycodone in people with Neoplasms as compared to genotypes AA + AG.	-1.25
1450929810	1183681975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681975	19514130	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	3.25
1450934868	1450821451	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821451	25472448	Allele T is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele C.	-1.75
1450934868	1450934857	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934857	30762755	Genotypes CT + TT are associated with increased dose of fentanyl in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.	2.0
1449161121	1449161094	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161094	28750137	Allele C is associated with increased risk of Drug Hypersensitivity due to Antiinflammatory agents, non-steroids as compared to allele T.	3.0
1449715590	1451147960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147960	32401749	Allele T is not associated with response to fentanyl in women with Pain, Postoperative as compared to allele C.	-1.75
1449715590	1449715433	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715433	28256933	Genotype TT is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.	2.75
1449748202	1449748084	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748084	30304062	Genotype GG is associated with decreased response to rosuvastatin in people with Hypercholesterolemia as compared to genotype AA.	1.5
1449748202	1449748095	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449748095	30304062	Genotype GG is associated with decreased response to atorvastatin, rosuvastatin or simvastatin in people with Hypercholesterolemia as compared to genotype AA.	0.0
1450376319	1450376232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376232	29288229	Allele G is associated with increased risk of Maculopapular Exanthema due to phenytoin as compared to allele T.	3.0
1450809657	1450809598	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809598	12893983	Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT.	3.5
1450810375	1450810080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810080	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1450810375	1451103441	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451103441	31004399	Allele G is not associated with risk of Alcoholism due to ethanol in men as compared to allele A.	-2.0
1450811942	1450811671	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811671	18433502	Allele T is associated with increased response to ethanol as compared to allele C.	3.25
1450812204	1450812123	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812123	18518925	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.	0.0
1450812241	1450812098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812098	18518925	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	0.0
1450812241	1450823024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823024	25744370	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.5
1450812241	1450827121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827121	28692418	Allele C is not associated with risk of Heroin Dependence due to heroin as compared to allele T.	-2.0
1450812247	1450812107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812107	18518925	Allele C is associated with decreased risk of Heroin Dependence due to heroin as compared to allele T.	0.0
1450813875	1450813804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450813804	22048466	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AA + AG.	2.75
1450933023	1450932822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932822	30651574	Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.	2.0
1450935050	1450935020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935020	30776417	HLA-A *32:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to vancomycin.	2.75
1450935050	1451149040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149040	32439433	HLA-A *32:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to vancomycin.	0.25
1450806640	1449271320	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449271320	12960749	Allele T is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele C.	-1.5
1450806640	1450806531	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806531	9689128	Allele T is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to allele C.	0.0
1450806626	1451355480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451355480	32492095	Allele G is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele A.	1.75
1450806626	1451402351	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451402351	33589790	Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AG + GG.	2.5
1450806626	1450809995	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450809995	16476706	Allele G is not associated with risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	-2.0
1450806626	1184755224	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755224	24086514	Allele G is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.	-0.75
1450806626	1450811428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811428	17416470	Allele G is not associated with risk of Heroin Dependence or Opioid-Related Disorders due to heroin or opioids as compared to allele A.	-2.0
1450806626	1450823726	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823726	26392368	Allele G is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele A.	0.0
1450806626	1449161426	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161426	16387451	Allele G is not associated with increased risk of Alcoholism, Cocaine-Related Disorders, Opioid-Related Disorders or Tobacco Use Disorder when exposed to cocaine, ethanol, nicotine or opioids as compared to allele A.	-1.0
1450806626	1451137681	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451137681	31853823	Genotype AA is associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes AG + GG.	-2.25
1450806626	1449192963	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192963	23226031	Allele G is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele A.	-1.0
1450806626	1449271327	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449271327	12960749	Allele G is not associated with risk of Opioid-Related Disorders due to opioids as compared to allele A.	-1.5
1450806626	1450806512	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806512	9689128	Allele G is not associated with likelihood of Opioid-Related Disorders due to opioids as compared to allele A.	-1.5
1450806626	1450806520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450806520	9689128	Allele G is associated with decreased likelihood of Opioid-Related Disorders due to opioids as compared to allele A.	2.25
1450935200	1451436960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451436960	30799432	Allele T is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to allele C.	0.0
1450935200	1451437000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451437000	29043387	Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.	This annotation is not used for clinical annotation scoring. Significance is for combination of CYP3A4 and CYP3A5 genotypes.
1450811641	827816288	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816288	21902500	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	-1.75
1450811641	1450811579	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811579	18424454	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	2.25
1450811641	1449192852	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192852	17178268	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	-1.5
1450811641	1451643611	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451643611	34380995	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.	-1.25
1449188689	1449188368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188368	23223006	Allele A is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.	1.75
1449188695	1449188376	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188376	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	2.25
1449188749	1449188436	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188436	23223006	Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	2.25
1449188755	1449188442	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449188442	23223006	Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.	1.75
1449190104	1449190069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190069	29546524	Genotype AG is associated with increased severity of Nausea when treated with antineoplastic agents in people with Neoplasms as compared to genotypes AA + GG.	1.75
1449190397	1449190361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190361	23454283	Allele T is associated with decreased likelihood of Cocaine-Related Disorders or Heroin Dependence due to cocaine or heroin as compared to allele G.	3.0
1449190422	1451105241	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451105241	31025317	Allele A is not associated with risk of Heroin Dependence due to heroin as compared to allele C.	-2.0
1449190422	1449190403	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190403	24359476	Allele A is associated with increased risk of Opioid-Related Disorders due to opioids as compared to allele C.	3.0
1449190422	1449296061	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449296061	19373123	Allele A is associated with increased likelihood of Heroin Dependence due to heroin as compared to allele C.	2.5
1449271003	1449270704	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270704	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271039	1449270764	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270764	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1450808106	1450808090	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450808090	11933204	Genotype AG is associated with increased dose of heroin in people with Heroin Dependence as compared to genotype GG.	2.0
1450813540	1450813456	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813456	22046326	Genotype CT is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype CC.	2.5
1450934191	1450934104	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450934104	30611854	Allele C is associated with decreased inhibition of SCN4A with mexiletine as compared to allele A.	0.0
1449275238	982034008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982034008	23651028	Genotypes AA + AG are associated with decreased likelihood of addiction due to heroin as compared to genotype GG.	0.75
1449275238	1450810875	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810875	16682632	Genotype AG is associated with increased risk of Heroin Dependence due to heroin as compared to genotype AA.	2.0
1449275238	1450811428	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811428	17416470	Allele G is not associated with risk of Heroin Dependence or Opioid-Related Disorders due to heroin or opioids as compared to allele A.	-2.0
1449275238	1450812160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812160	18518925	Allele G is not associated with risk of Heroin Dependence due to heroin.	-2.0
1449275238	1450812921	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812921	21277709	Allele G is not associated with risk of Heroin Dependence due to heroin as compared to allele A.	-2.0
1449275238	1450827115	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450827115	28692418	Allele G is not associated with risk of Heroin Dependence due to heroin as compared to allele A.	-2.0
1449275238	1449190380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190380	23454283	Allele G is not associated with likelihood of Cocaine-Related Disorders or Heroin Dependence due to cocaine or heroin as compared to allele A.	-2.0
1449275238	1449275225	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275225	19891732	Allele G is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele A.	2.5
1449275238	1450807242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807242	11338173	Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.	2.25
1449275238	1450807489	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807489	11424981	Allele G is not associated with risk of Heroin Dependence as compared to allele A.	-2.0
1449275238	1450808068	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808068	11933204	Allele G is not associated with risk of Heroin Dependence when exposed to heroin as compared to allele A.	-1.5
1449275238	1450808236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808236	12657887	Genotypes AG + GG are associated with decreased risk of Heroin Dependence when exposed to heroin as compared to genotype AA.	2.0
1450809583	1448110390	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1448110390	27339126	CYP2C9 *1/*3 is associated with decreased clearance of tolbutamide as compared to CYP2C9 *1/*1.	0.0
1450809583	1450809160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809160	11875364	CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.	1.0
1450809583	1450809558	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450809558	11875364	CYP2C9 *1/*2 + *2/*2 are not associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.	-0.125
1450809583	1451234364	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234364	32531309	CYP2C9 *2 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1450809583	1451234360	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234360	32531309	CYP2C9 *62 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1450809583	1451234420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451234420	32531309	CYP2C9 *3 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.	0.0
1450813547	1450813116	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813116	22046326	Genotypes AT + TT are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype AA.	This annotation is not used for clinical annotation scoring. Already have a scoring VA from this paper on the CA
1450813547	1450813348	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813348	22046326	CYP2A6 *1/*1x2 is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to CYP2A6 *1/*1.	3.0
1450811035	1450811006	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450811006	16842817	Allele T is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.	0.0
1450811035	1450811001	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450811001	16842817	Allele C is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.	0.0
1450811044	1450811016	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450811016	16842817	Allele T is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.	0.0
1450811044	1450811011	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450811011	16842817	Allele C is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.	0.0
1450811267	1450811236	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811236	15902904	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	3.25
1450811267	1447520941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520941	25514903	Allele C is not associated with Alcoholism when exposed to ethanol as compared to allele T.	-0.75
1450811267	1447520967	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447520967	25514903	Allele T is not associated with severity of Alcoholism when exposed to ethanol in people with Alcoholism as compared to allele C.	-0.5
1450811267	1449192808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449192808	29588096	Allele T is not associated with risk of Alcoholism due to ethanol as compared to allele C.	-2.0
1450811379	1446765775	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446765775	26153084	CYP2B6 *6 is not associated with response to bupropion in people with Tobacco Use Disorder.	-1.5
1450811379	1450811368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811368	17223085	CYP2B6 *1/*6 + *6/*6 are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1.	2.75
1450811954	1450811875	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811875	18433502	Allele T is associated with increased response to ethanol as compared to allele C.	3.25
1450811966	1450811713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811713	18433502	Allele T is associated with increased response to ethanol as compared to allele G.	3.25
1450811978	1450811856	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811856	18433502	Allele G is associated with increased response to ethanol as compared to allele C.	3.25
1450811984	1450811918	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811918	18433502	Allele T is associated with increased response to ethanol as compared to allele C.	3.25
1450815104	1450815085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815085	23241943	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1450815154	1450815073	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815073	23241943	Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1450815172	1450815024	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815024	23241943	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.	0.0
1450826899	827847849	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827847849	19605407	Genotypes AG + GG are associated with increased dose of alfentanil in people with Pain as compared to genotype AA.	2.75
1450826919	1446902603	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446902603	25752520	Genotype AA is associated with decreased dose of codeine in women as compared to genotype AG.	2.25
1450826949	1183703081	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703081	18403122	Genotypes AG + GG is associated with higher responsiveness to opioids and required less analgesic drugs in laboring women when treated with fentanyl in women as compared to genotype AA.	2.5
1450826949	1183703088	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703088	19783098	Genotypes AG + GG is associated with less pain control in Japanese patients undergoing painful orofacial cosmetic surgery when treated with fentanyl as compared to genotype AA.	2.25
1450826949	1449713797	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713797	23592691	Allele G is not associated with response to fentanyl in women with Pain as compared to allele A.	-1.5
1450826949	1449715215	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715215	23302985	Allele G is not associated with response to fentanyl in women with as compared to allele A.	-1.25
1450826949	1449716072	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716072	23909491	Genotypes AG + GG are associated with increased response to fentanyl in women with Pain as compared to genotype AA.	1.25
1450826949	1449716512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716512	20171873	Genotypes AG + GG are not associated with response to fentanyl in women with Pain as compared to genotype AA.	-1.5
1450929037	1450929002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450929002	30031856	Genotypes CT + TT are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype CC.	2.5
1450929137	982031845	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982031845	23249876	Allele A is associated with decreased chance of achieving 6 month abstinence in the placebo group as compared to allele G.	3.0
1450933011	1450932804	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932804	30651574	Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.	2.5
1450935856	1450935713	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450935713	30745309	Allele G is associated with decreased clearance of mephenytoin as compared to allele A.	0.125
1450936159	1450936050	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936050	30822619	Allele T is associated with increased sulfation of desmethylnaproxen as compared to allele C.	0.0
1450936211	1450936010	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936010	30822619	Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.	0.0
1450936236	1450935992	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935992	30822619	Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.	0.0
1450936248	1450936060	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936060	30822619	Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.	0.0
1450936266	1450936065	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936065	30822619	Allele C is associated with decreased sulfation of desmethylnaproxen as compared to allele A.	0.0
1450936278	1450936119	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936119	30822619	Allele T is associated with decreased sulfation of tapentadol as compared to allele A.	0.0
1450936290	1450935987	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935987	30822619	Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.	0.0
1450936320	1450936089	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936089	30822619	Allele G is associated with decreased sulfation of desmethylnaproxen as compared to allele T.	0.0
1450936577	1450936493	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936493	30840592	Genotype AG is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.	2.5
1450936592	1450936529	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936529	30840592	Genotypes CC + CG are associated with decreased risk of Anemia due to cisplatin in people with Mesothelioma as compared to genotype GG.	2.0
1450826957	1451407420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451407420	31806881	Genotype AG is not associated with increased response to morphine in healthy individuals as compared to genotype AA.	-2.0
1450826957	827807525	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807525	17898703	Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.	2.5
1450826957	1184753740	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184753740	25155931	Genotypes AG + GG is associated with increased severity of Pain requiring treatment with morphine in infants as compared to genotype AA.	0.0
1450826957	1450826813	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450826813	28591085	Genotypes AG + GG are not associated with response to morphine in women with Pain, Postoperative as compared to genotype AA.	-1.25
1450826957	1445296785	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296785	25266679	Genotypes AG + GG is associated with decreased response to morphine in children as compared to genotype AA.	1.75
1450929798	827816224	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827816224	21902500	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	3.25
1450929798	1444695451	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444695451	25556837	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	-1.25
1450929798	1450811573	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811573	18424454	Genotype AA is not associated with dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.	-1.25
1450929798	1449192844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192844	17178268	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.	-1.5
1450929798	1451161780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161780	21589866	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.	-1.5
1450929798	1451643605	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451643605	34380995	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.	-1.25
1450929792	1183681975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183681975	19514130	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.	3.25
1450929792	1451645407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645407	34461232	Allele G is not associated with dose of methadone in people with Neoplasms and Pain as compared to allele A.	-0.25
1450826969	1451134687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134687	31773688	Genotypes AG + GG are not associated with dose of oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA.	-1.25
1450826969	1449000085	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449000085	25239082	Genotype GG is associated with increased dose of oxycodone in women with Pain, Postoperative as compared to genotypes AA + AG.	3.0
1450826969	1449003091	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003091	21209234	Genotype AA is not associated with dose of oxycodone in people with Neoplasms as compared to genotypes AG + GG.	-1.25
1449003759	1448994043	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994043	28750087	Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele T.	2.5
1449003777	1448993919	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993919	28750087	Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.	3.0
1449003799	1448994037	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994037	28750087	Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.	2.5
1449003805	1448994019	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994019	28750087	Allele del is associated with decreased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele G.	3.0
1449270985	1449270773	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270773	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449270991	1449270732	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270732	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449270997	1449270625	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270625	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271009	1449270674	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270674	29593529	Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.	0.0
1449271015	1449270667	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270667	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449271021	1449270657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449270657	29593529	Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.	0.0
1449271288	1449271251	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271251	29333880	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	2.5
1450375065	1450374643	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450374643	30914949	Genotypes GT + TT are associated with increased risk of Leukopenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype GG.	3.0
1450807362	1450807338	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807338	11338173	Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	2.25
1450822690	1450822676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822676	22795689	Allele T is associated with decreased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.	3.5
1450822710	1450814337	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450814337	22562052	SLCO1B1 *15 is associated with increased risk of drug-induced liver injury due to rifampin.	3.5
1450823123	1450822861	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822861	25744370	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.5
1450823150	1450823044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823044	25744370	Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.	3.5
1450932256	981417330	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981417330	20941486	Genotypes CT + TT are associated with decreased likelihood of Maculopapular Exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype CC.	2.5
1450932256	1450932187	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450932187	30458875	Genotypes CT + TT are associated with decreased risk of Maculopapular Exanthema due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis.	1.0
1450936183	1450936033	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936033	30822619	Allele G is associated with increased sulfation of desmethylnaproxen as compared to allele A.	0.0
1450936224	1450936055	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936055	30822619	Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.	0.0
1450936230	1450936100	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936100	30822619	Allele T is associated with decreased sulfation of tapentadol as compared to allele C.	0.0
1450936254	1450935997	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450935997	30822619	Allele C is associated with decreased sulfation of acetaminophen as compared to allele A.	0.0
1449310414	1183617941	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617941	12920424	CYP2D6 *1/*2xN is associated with increased risk of Drug Toxicity when treated with codeine, hydrocodone or oxycodone in healthy individuals as compared to CYP2D6 *1/*1.	0.0
1449565774	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
1449565774	1449565504	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565504	27163851	CYP2C9 *19 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565522	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565522	27163851	CYP2C9 *27 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565567	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565567	27163851	CYP2C9 *36 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565603	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565603	27163851	CYP2C9 *40 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565612	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565612	27163851	CYP2C9 *41 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565667	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565667	27163851	CYP2C9 *47 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565685	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565685	27163851	CYP2C9 *49 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565706	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565706	27163851	CYP2C9 *51 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565724	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565724	27163851	CYP2C9 *53 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565733	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565733	27163851	CYP2C9 *54 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449565774	1449565751	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449565751	27163851	CYP2C9 *56 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	0.0
1449645356	1449639548	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449639548	29705271	Allele C is associated with decreased sulfation of acetaminophen as compared to allele T.	0.0
1449645398	1449645242	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645242	29705271	Allele T is associated with decreased sulfation of tapentadol as compared to allele C.	0.0
1449645404	1449645247	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645247	29705271	Allele T is associated with decreased sulfation of o-desmethyltramadol as compared to allele C.	0.0
1449645414	1449638033	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449638033	29705271	Allele C is associated with decreased sulfation of acetaminophen as compared to allele A.	0.0
1449645420	1449645255	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645255	29705271	Allele C is associated with decreased sulfation of tapentadol as compared to allele A.	0.0
1449645426	1449645259	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645259	29705271	Allele C is associated with decreased sulfation of o-desmethyltramadol as compared to allele A.	0.0
1449645549	1449645338	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449645338	29705271	Allele T is associated with increased sulfation of o-desmethyltramadol as compared to allele C.	0.0
1449752831	1449752784	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752784	29233746	HLA-A *24:02:01:01 is associated with increased risk of Drug Hypersensitivity due to dapsone.	0.0
1449752836	1449752755	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752755	29233746	HLA-DRB1 *16:02:01 is associated with increased risk of Drug Hypersensitivity due to dapsone.	0.0
1449752836	1449752798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449752798	29233746	HLA-DRB1 *15:01:01:01 is associated with increased risk of Drug Hypersensitivity due to dapsone.	0.0
1450810363	1450810107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450810107	16476706	Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.	3.25
1450811346	1450811055	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811055	16960700	Genotypes AG + GG are associated with decreased response to nicotine in women with Tobacco Use Disorder as compared to genotype AA.	1.5
1450812210	1450811999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450811999	18518925	Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	0.0
1450812210	1450823098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823098	25744370	Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.	3.5
1450812223	1450812139	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812139	18518925	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	0.0
1450812223	1450822391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450822391	22500942	Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.	3.0
1450824225	1450973900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450973900	28212683	Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Alzheimer Disease as compared to genotypes CT + TT.	3.0
1450824473	1450824235	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450824235	28273335	Genotypes CC + CT are associated with decreased response to ethanol as compared to genotype TT.	2.25
1450826931	1449716754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716754	29601950	Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG.	2.0
1450826931	1183703072	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183703072	21150856	Genotype GG is associated with higher fentanyl dose requirement to achieve adequate pain relief in Chinese women undergoing gynecologic surgery when treated with fentanyl as compared to genotypes AA + AG.	2.5
1450826931	1451159083	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451159083	19514130	Genotype G is not associated with dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to genotype A.	-1.75
1450826931	1449713783	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713783	21174568	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotype AA.	2.0
1450826931	1449713980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713980	23557865	Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.	-1.5
1450826931	1449715307	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449715307	23313934	Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele A.	-1.25
1450826931	1449716064	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716064	23909491	Genotypes AG + GG are associated with decreased dose of fentanyl in women with Pain as compared to genotype AA.	1.125
1450826931	1449716606	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716606	20003118	Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG.	2.0
1450826931	1449716657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716657	23599738	Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele A.	-1.5
1450826975	1451352200	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352200	31755291	Genotype AG is associated with increased dose of sufentanil in people with Pain, Postoperative as compared to genotype AA.	2.25
1450826975	1450931989	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931989	30455395	Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA.	2.0
1450826975	1451134687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134687	31773688	Genotypes AG + GG are not associated with dose of oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA.	-1.25
1450826975	1449171287	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449171287	22153130	Allele G is associated with decreased dose of sufentanil in women with Pain as compared to allele A.	-1.75
1449266588	1448104379	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448104379	27286724	Genotype AA is associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.	1.5
1449266588	1448109809	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448109809	27284701	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.	1.5
1449266588	1449266512	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266512	17178267	Allele A is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele G.	1.5
1449266588	1449271546	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271546	18460585	Genotype AG is associated with decreased concentrations of methadone.	0.125
1449266588	1449271576	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271576	18460585	Genotype AG is associated with increased concentrations of (S)-EDDP.	0.125
1449266588	1451156420	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156420	17502774	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.	-0.125
1449266588	1451161820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161820	21589866	Allele G is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to allele A.	-1.0
1449266588	1451401880	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451401880	33454797	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.	1.5
1449266582	1449266505	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266505	17178267	Genotype CT is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes CC + TT.	1.5
1450931850	1450931660	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931660	30281924	CYP3A4 *1/*22 is associated with increased exposure to fentanyl in healthy individuals as compared to CYP3A4 *1/*1.	2.0
1450931850	1451147640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147640	32331352	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	0.0
1450931850	1449716584	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449716584	26088794	CYP3A4 *36/*36 is associated with decreased metabolism of fentanyl in human liver microsomes as compared to CYP3A4 *1/*1 + *1/*36.	0.0
1450931850	1449716526	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449716526	21223952	CYP3A4 *36/*36 is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1450931850	1451678271	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451678271	34877660	CYP3A4 *36 is not associated with clearance of fentanyl in children as compared to CYP3A4 *1 (assigned as normal metabolizer genotype phenotype) .	-1.25
1449311670	1449311615	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449311615	29755652	Genotype GG is associated with increased response to propofol and remifentanil in children as compared to genotypes AA + AG.	2.0
1450815098	1450815036	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815036	23241943	Allele C is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele A.	0.0
1450931960	1450931954	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931954	30324302	Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG.	2.75
1450934500	1450934425	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934425	30723321	Allele C is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934662	1450934350	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934350	30723321	Allele C is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450936314	1450936016	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450936016	30822619	Allele G is associated with decreased sulfation of acetaminophen as compared to allele T.	0.0
1450936557	1450936543	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936543	30840592	Genotype CC is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.	2.5
1450936586	1450936522	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450936522	30840592	Genotypes CC + CG are associated with increased risk of Alopecia due to cisplatin in people with Mesothelioma as compared to genotype GG.	2.0
1449003875	1448995971	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448995971	28107378	Allele C is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.	2.5
1449003881	1448996481	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448996481	28921760	Allele C is associated with decreased metabolism of nicotine as compared to allele T.	0.0
1449003918	1448996256	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996256	27157822	Allele del is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele TTTT.	0.0
1449003926	1448996262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996262	27157822	Allele C is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele T.	0.0
1449003946	1448996285	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996285	27157822	HLA-B *08:01:01 is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations.	0.0
1449003951	1448996277	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448996277	27157822	HLA-B *27:05:02 is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations.	0.0
1449191764	1449191000	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191000	23891399	Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191874	1449191808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191808	25266159	Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.	2.0
1449192420	1449192330	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192330	27334259	Allele A is associated with response to ivacaftor / lumacaftor.	0.25
1449192431	1449192323	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192323	27334259	Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.	0.25
1449192570	1449191321	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191321	23891399	Allele A is not associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	-0.0
1449192570	1449192561	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449192561	24902474	Allele A is associated with activity of CFTR when treated with ivacaftor in BHK cells.	0.0
1450809956	1450809934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450809934	16402083	Allele C is associated with decreased risk of methamphetamine dependence due to methamphetamine as compared to allele G.	2.25
1450811519	1450375324	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375324	30906561	CYP2B6 *6 is associated with decreased metabolism of nicotine as compared to CYP2B6 *1.	0.125
1450811519	1450811499	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450811499	18004205	CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.	2.0
1450812410	1450812380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812380	19205682	Genotype CC is associated with increased response to nimodipine in healthy individuals as compared to genotype CT.	1.5
1450815130	1450815009	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450815009	23241943	Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.	0.0
1450826981	1446898218	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446898218	21837673	Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG.	2.25
1450826963	1451206853	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206853	24747667	Allele G is not associated with concentrations of codeine or morphine as compared to allele A.	-0.75
1450826963	1449162966	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162966	24703092	Allele G is associated with increased concentrations of morphine in women with Pain, Postoperative as compared to allele A.	0.25
1450826963	1449173387	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449173387	29474345	Allele G is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele A.	-1.25
1449717812	1445296178	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445296178	24673480	CYP2D6 normal metabolizer genotype is not associated with dose of carvedilol in people with Heart Failure.	-0.625
1449717812	982045201	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045201	20643254	CYP2D6 *3/*10 + *4/*4 is associated with increased dose of carvedilol in people with Heart Failure.	1.75
1449717812	982045318	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/982045318	20643254	CYP2D6 *4/*5 + *4/*6 is associated with increased dose of carvedilol in people with Heart Failure.	1.75
1449717812	1449717757	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449717757	28181117	CYP2D6 *4 is associated with increased dose of carvedilol in people with Heart Failure.	0.0
1449191758	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191758	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191758	1449191005	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191005	23891399	Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449191770	PA166114461	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166114461		Annotation of CPIC Guideline for ivacaftor and CFTR	100
1449191770	PA166104890	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104890		Annotation of FDA Label for ivacaftor and CFTR	100
1449191770	1449191012	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1449191012	23891399	Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.	0.0
1449266594	1449266520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266520	17178267	Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T.	1.5
1450808823	1450812523	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812523	19764934	Genotype AA is associated with increased severity of Alcoholism due to ethanol as compared to genotypes AG + GG.	3.25
1450808823	1450812893	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450812893	21039637	Genotypes AG + GG is associated with increased severity of Alcoholism due to ethanol as compared to genotype AA.	1.75
1450808823	1451103500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451103500	31004399	Allele G is not associated with severity of Alcoholism due to ethanol in men as compared to allele A.	-1.75
1450808823	1450808792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808792	15252283	Allele G is associated with increased severity of Alcoholism due to ethanol as compared to allele A.	2.25
1450808823	1450808802	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450808802	15252283	Allele G is not associated with severity of Alcoholism due to ethanol as compared to allele A.	-1.75
1450934668	1450934356	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934356	30723321	Allele G is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450934711	1450934392	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450934392	30723321	Allele T is associated with increased response to migalastat in people with Fabry Disease.	0.0
1450935171	1450935153	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935153	30796320	Genotype AA is associated with increased risk of suicidal ideation due to tianeptine in people with Depressive Disorder, Major as compared to genotypes AG + GG.	2.75
1450959380	1450958840	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958840	19036622	Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.	0.0
1450959386	1450958720	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958720	19036622	Allele G is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele A.	0.0
1450959460	1450958845	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958845	19036622	Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.	0.0
1450959480	1450958853	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958853	19036622	Allele G is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele A.	0.0
1450959486	1450958940	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958940	19036622	Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.	0.0
1450959492	1450958944	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958944	19036622	Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.	0.0
1450959498	1450958985	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958985	19036622	Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.	0.0
1450959500	1450959000	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450959000	19036622	Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.	0.0
1450959506	1450959004	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450959004	19036622	Allele A is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele G.	0.0
1450959524	1450958994	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958994	19036622	Allele A is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele G.	0.0
1450959530	1450959221	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450959221	19036622	Allele C is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.	0.0
1450959540	1450959200	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450959200	19036622	Allele C is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.	0.0
1450959560	1450958820	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1450958820	19036622	Allele A is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.	0.0
1451101225	1451101168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451101168	30971809	Allele T is associated with decreased metabolism of tramadol as compared to allele G.	1.5
1451101231	1451101160	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451101160	30971809	Allele A is associated with decreased metabolism of tramadol as compared to allele T.	1.5
1451101242	1451101180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451101180	30971809	Allele A is associated with decreased metabolism of tramadol as compared to allele G.	1.5
1451101248	1451101175	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451101175	30971809	Allele C is associated with decreased metabolism of tramadol as compared to allele G.	1.5
1451101280	1451101220	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451101220	30971809	Allele T is associated with decreased metabolism of tramadol as compared to allele C.	1.5
1451101400	1450936689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936689	31002879	Genotype CC is associated with decreased concentrations of ethanol in healthy individuals as compared to genotypes AA + AC.	1.5
1451101400	1450936723	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936723	31002879	Genotype CC is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes AA + AC.	0.0
1451101406	1450936677	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936677	31002879	Genotype AG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype GG.	2.0
1451101406	1450936718	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450936718	31002879	Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG.	2.0
1451103260	1451103000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451103000	30992538	Genotypes GT + TT are associated with increased risk of chronic lung allograft dysfunction when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.	2.0
1451103280	1451102867	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451102867	30992538	Genotypes AG + GG are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.	3.0
1451103320	1451102885	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451102885	30992538	Genotypes GT + TT are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.	2.5
1451103340	1451102856	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451102856	30992538	Genotypes AG + GG are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.	2.5
1451103360	1451102993	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451102993	30992538	Genotypes AG + GG are associated with increased risk of chronic lung allograft dysfunction when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.	0.0
1451105061	1451104645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451104645	31014225	Allele A is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele G.	2.5
1451105080	1451104640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451104640	31014225	Allele G is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele A.	2.0
1451105180	1451105105	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451105105	31022310	Genotype TT is associated with decreased exposure to letermovir as compared to genotypes CC + CT.	2.25
1451105200	1451105100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451105100	31022310	Genotypes CC + CT are associated with increased exposure to letermovir as compared to genotype TT.	2.25
1451105206	1451105113	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451105113	31022310	Genotypes AA + AG are associated with increased exposure to letermovir as compared to genotype GG.	1.75
1451105228	1451105215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451105215	31025317	Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.	3.5
1450826987	1450812440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812440	19683391	Allele G is not associated with dose of opioids in people with Pain as compared to allele A.	-0.5
1450826987	1450812447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450812447	19683391	Genotype GG is associated with increased dose of opioids in people with Pain as compared to genotypes AA + AG.	0.75
1450826987	1450821136	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450821136	25102313	Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.	1.5
1450826987	1450823183	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450823183	25794200	Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.	1.5
1450826987	1451118400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118400	31337162	Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA.	1.75
1450826987	1448818810	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448818810	28745577	Genotypes AG + GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.	0.0
1450826987	1449002543	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449002543	28379874	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotype GG.	1.5
1450826987	1449713808	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713808	23803057	Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.	2.5
1450826987	1449714623	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449714623	21398039	Allele G is not associated with dose of opioids in people with Pain as compared to allele A.	-2.0
1451106200	1451106148	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451106148	31033190	Genotypes CC + CT are associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to genotype TT.	0.0
1451106206	1451106140	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451106140	31033190	Allele A is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.	0.0
1451106265	1451106280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451106280	31043678	Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.	2.25
1451106460	1451106420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451106420	31059723	Allele G is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele A.	3.5
1451106705	1451106680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451106680	31087723	Genotype GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotypes GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/del + del/del.	2.5
1451107342	1451107100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451107100	31090079	Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.	1.75
1451107360	1451106720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451106720	31090079	Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.	1.75
1451112120	1451112060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451112060	31134657	CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.	2.0
1451114072	1451113480	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451113480	31186542	Allele G is associated with increased risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.	3.0
1451114080	1451113520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451113520	31186542	Allele G is associated with increased risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.	3.0
1451116049	1451116000	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451116000	23503447	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.	1.25
1451116107	1447986089	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447986089	27142945	Allele A is not associated with concentrations of lopinavir in people with HIV Infections.	-0.75
1451116107	1451116120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451116120	24950369	CYP3A4 *22/*22 is associated with decreased clearance of lopinavir in people with HIV Infections as compared to CYP3A4 *1/*1 + *1/*22.	2.25
1451117560	1451117379	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117379	31327267	Allele T is associated with increased response to metoprolol in people with Hypertension as compared to allele C.	3.0
1451117580	1451117412	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117412	31327267	Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1451117590	1451117373	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117373	31327267	Allele T is associated with increased response to atenolol in people with Hypertension as compared to allele C.	3.0
1451117620	1451117480	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117480	31327267	Allele T is associated with increased response to candesartan in people with Hypertension as compared to allele C.	3.0
1451118364	1451117367	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117367	31327267	Allele A is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele G.	3.0
1451118370	1451117407	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451117407	31327267	Allele A is associated with decreased response to candesartan in people with Hypertension as compared to allele G.	3.0
1451118760	1451118680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118680	31346154	Genotype GG is associated with increased dose of remifentanil as compared to genotype AA.	2.25
1451118760	1451118687	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118687	31346154	Genotype AG is not associated with dose of remifentanil as compared to genotypes AA + GG.	-1.75
1451118766	1451118692	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118692	31346154	Genotype AG is not associated with response to remifentanil as compared to genotypes AA + GG.	-1.75
1451118766	1451118697	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451118697	31346154	Genotype GG is associated with decreased response to remifentanil as compared to genotype AA.	3.25
1451118940	1451118820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118820	31362332	Allele T is associated with increased severity of Overdose due to opioids as compared to allele C.	1.5
1451118946	1451118846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118846	31362332	Allele G is associated with increased severity of Overdose due to opioids as compared to allele C.	1.25
1451118960	1451118880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451118880	31362332	Allele A is associated with increased severity of Overdose due to opioids as compared to allele C.	1.25
1451120280	1451120240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120240	31401974	Genotype AA is associated with increased risk of Psychotic Disorders due to phenobarbital and phenytoin in men with Epilepsy.	0.25
1451120359	1451120361	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120361	31402126	Genotype CC is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AA + AC.	2.5
1451120421	1451120340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120340	31402126	Genotype GG is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AA + AG.	2.5
1451120427	1451120346	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120346	31402126	Genotype AA is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AG + GG.	2.0
1451120561	1451120506	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451120506	31423876	Allele A is associated with increased response to Beta blocking agents, selective in people with Hypertension as compared to allele G.	1.5
1451120702	1451120660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120660	31447353	Genotype AA is associated with decreased severity of Weight gain due to antipsychotics as compared to genotypes AG + GG.	0.0
1451120760	1451120691	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120691	31447353	Genotype GG is associated with decreased severity of Weight gain due to antipsychotics as compared to genotypes AA + AG.	0.0
1451120986	1451120880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120880	31462767	Allele T is associated with increased risk of Alcoholism, Heroin Dependence or methamphetamine dependence due to ethanol, heroin or methamphetamine as compared to allele G.	2.5
1451121780	1451121020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451121020	31493434	Genotypes AA + AG are associated with decreased response to oxycodone as compared to genotype GG.	2.0
1451121805	1451121060	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451121060	31493434	Genotype CT is associated with decreased response to oxycodone as compared to genotype TT.	2.0
1451123485	1451123460	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451123460	31557306	Genotypes AG + GG are associated with increased response to budesonide in children with Asthma as compared to genotype AA.	0.0
1451124240	1450813724	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813724	19764934	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with severity of Alcoholism due to ethanol as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele).	-1.75
1451124240	1451124080	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451124080	31595439	SLC6A4 HTTLPR short form (S allele) is associated with increased risk of Alcoholism due to ethanol as compared to SLC6A4 HTTLPR long form (L allele).	3.75
1451124260	1451124160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451124160	31595439	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	3.25
1451124280	1451124107	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451124107	31595439	Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele T.	2.75
1451124300	1451124220	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451124220	31595439	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	3.25
1450807831	1451116582	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451116582	31246565	Genotype AG is associated with increased risk of Substance-Related Disorders due to 3,4-methylenedioxymethamphetamine, cocaine, ethanol or opioids as compared to genotype AA.	2.5
1450807831	1451400363	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451400363	33402148	Genotypes AG + GG are associated with increased risk of Substance-Related Disorders in men as compared to genotype AA.	3.0
1450807831	1450823720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450823720	26392368	Allele G is associated with decreased risk of Substance-Related Disorders due to cannabinoids, cocaine, ethanol, nicotine or opioids as compared to allele A.	-1.5
1450807831	1450377358	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450377358	29881439	Allele G is not associated with risk of Substance-Related Disorders as compared to allele A.	-2.0
1450807831	1450807687	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450807687	11840318	Genotype AA is associated with increased severity of Substance-Related Disorders as compared to genotypes AG + GG.	-3.5
1451120724	1451120684	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451120684	31447353	Genotype TT is associated with decreased severity of Weight gain due to antipsychotics as compared to genotypes GG + GT.	0.0
1451124486	1451124400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124400	31607718	Genotypes CT + TT are associated with decreased response to morphine in people with Neoplasms and Pain as compared to genotype CC.	2.0
1451124500	1451124440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124440	31607718	Genotypes CT + TT are associated with decreased concentrations of morphine in people with Neoplasms and Pain as compared to genotype CC.	1.5
1451124500	1449162960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162960	24703092	Allele T is associated with increased concentrations of morphine or morphine-3-glucuronide in women with Pain, Postoperative as compared to allele C.	0.25
1451124500	1450320917	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450320917	12185559	Allele T is not associated with concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in people with Neoplasms as compared to allele C.	-0.75
1451124808	1451124591	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124591	31611591	Genotypes CC + TT are associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Liver Neoplasms as compared to genotype CT.	2.0
1451124852	1451124803	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124803	31611591	Genotype GG is associated with increased response to cisplatin and fluorouracil in people with Liver Neoplasms as compared to genotypes GT + TT.	1.75
1451124880	1451124822	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124822	31611591	Genotype GG is associated with increased response to sorafenib in people with Hepatitis C and Liver Neoplasms as compared to genotypes GT + TT.	1.5
1451125500	1451125200	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125200	31616045	Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	2.5
1451125506	1451125140	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125140	31616045	Allele C is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	2.5
1451126020	1451125880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125880	31619748	Genotypes CT + TT are associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype CC.	2.75
1451126040	1451125900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125900	31619748	Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.	2.25
1451126064	1451125907	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451125907	31619748	Genotype GG is associated with decreased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes AA + AG.	3.25
1451126200	1451126120	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451126120	31624332	Genotype CT is associated with decreased response to temozolomide in people with Glioma as compared to genotype CC.	1.75
1451126312	1451126280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451126280	31624333	Genotypes AA + AG are associated with increased response to creatine in people with Amyotrophic Lateral Sclerosis as compared to genotype GG.	2.0
1449163324	1451124322	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451124322	31607718	Allele C is not associated with dose of morphine in people with Neoplasms and Pain as compared to allele T.	-1.5
1449163324	1449162934	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162934	24703092	Genotype CC is associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT.	2.0
1449163324	1449244383	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449244383	16580900	Genotypes CC + CT are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype TT.	-1.25
1449163324	1449244619	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449244619	24703092	Genotype CT is not associated with dose of morphine in women with Pain, Postoperative as compared to genotype TT.	-0.5
1451127140	1451127020	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451127020	31406237	Genotype CC is associated with increased severity of sedation due to desloratadine in people with Urticaria as compared to genotypes CT + TT.	3.0
1451129800	1451129785	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451129785	31634677	Genotype TT is associated with increased risk of Alcoholism due to ethanol in people with Bipolar Disorder as compared to genotypes CC + CT.	2.5
1451129880	1451129840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451129840	31636356	Genotypes CG + GG are associated with decreased response to lurasidone in people with Schizophrenia as compared to genotype CC.	2.25
1451129880	1451129862	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451129862	31636356	Genotypes CG + GG are not associated with response to lurasidone in people with Schizophrenia as compared to genotype CC.	-1.5
1451130528	1451129902	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451129902	31648372	Genotypes AG + GG are associated with decreased risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype AA.	2.5
1451129680	827695614	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827695614	16267764	Genotypes CT + TT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype CC.	-1.75
1451129680	827807710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827807710	18281305	Genotype CC is not associated with plasma concentration of efavirenz or nevirapine in people with HIV Infections as compared to genotype CT.	-1.25
1451129680	1183491471	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183491471	23254426	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotype CT.	-1.0
1451129680	1184473261	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184473261	23399569	Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	-0.75
1451129680	1184512390	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184512390	16433869	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	-1.0
1451129680	1451127150	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451127150	31628422	Genotypes CT + TT are associated with decreased exposure to efavirenz in healthy individuals as compared to genotype CC.	1.0
1451130640	1451130600	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451130600	31649263	Genotype TT is associated with increased response to interferon beta-1a in people with Multiple Sclerosis as compared to genotypes CC + CT.	2.25
1451131729	1451130923	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451130923	31664190	Genotype CC is associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	2.5
1451131735	1451130947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451130947	31664190	Genotype CC is associated with decreased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.5
1451131750	1451130940	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451130940	31664190	Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.5
1451131761	1451130980	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451130980	31664190	Genotype CC is associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	2.5
1451131767	1451131600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131600	31664190	Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.0
1451131781	1451131629	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131629	31664190	Genotypes AA + AT are associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.0
1451131787	1451131500	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131500	31664190	Genotype AA is associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	2.0
1451131820	1451131520	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131520	31664190	Genotypes CC + CT are associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.	2.0
1451131840	1451131660	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131660	31664190	Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.5
1451131846	1451131695	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131695	31664190	Genotype CC is associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CG + GG.	2.0
1451131852	1451131710	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131710	31664190	Genotypes CT + TT are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.0
1451131858	1451131721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131721	31664190	Genotypes CT + TT are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	2.0
1451131860	1451131680	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451131680	31664190	Genotypes AG + GG are associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.	2.0
1451132040	1451131960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451131960	31482508	CYP2C19 *1/*2 + *2/*17 are associated with increased exposure to progesterone in women as compared to CYP2C19 *1/*1.	1.0
1451134300	1451134203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134203	31745220	Genotype CT is associated with increased likelihood of Dizziness due to opioids in people with Pain as compared to genotypes CC + TT.	2.0
1451134540	1451134269	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134269	31745220	Genotype CC is associated with increased likelihood of Sexual Dysfunctions, Psychological due to opioids in women with Pain as compared to genotypes CT + TT.	2.0
1451135380	1450932012	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932012	30455395	Genotypes AA + AC are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.	2.0
1451135380	1451352281	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451352281	31755291	Allele C is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele A.	-1.25
1451133765	1451133560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451133560	31738228	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.	2.5
1451135140	1451134740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134740	31773688	CYP3A4 *36/*36 is associated with increased response to sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	1.5
1451135188	1451134983	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134983	31773688	CYP3A5 *1/*3 + *3/*3 are associated with increased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A5 *1/*1.	1.5
1451135197	1450931998	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450931998	30455395	Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA.	2.0
1451135400	1450932005	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450932005	30455395	Genotypes AA + AG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype GG.	2.0
1451135574	1451135563	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451135563	31792237	Allele C is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to allele T.	0.0
1451136460	1451136420	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451136420	31837295	Allele T is associated with decreased activity of CES1 when assayed with heroin as compared to allele C.	0.0
1451137805	1451137662	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451137662	31853823	Genotypes AA + AG are associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotype GG.	3.25
1451137828	1451137720	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451137720	31853823	Genotype CC is associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CT + TT.	3.25
1451138160	1451137970	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137970	31866536	Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele A.	3.0
1451138166	1451137980	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137980	31866536	Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele C.	3.0
1451138182	1451137985	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137985	31866536	Genotype CT is not associated with dose of methadone in people with Heroin Dependence as compared to genotype CC.	-2.5
1451138182	1451138001	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138001	31866536	Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	3.0
1451138494	1451138265	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138265	31907389	Genotype GG is associated with increased dose of methadone as compared to genotypes GT + TT.	2.75
1451138544	1451138275	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138275	31907389	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.	2.25
1451138560	1451138270	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138270	31907389	Genotype GG is associated with increased concentrations of methadone as compared to genotypes GT + TT.	2.25
1451138860	1451138607	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138607	31940240	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	2.5
1451138880	1451138662	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138662	31940240	Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.	2.5
1451138886	1451138668	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451138668	31940240	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.	2.5
1451139960	1451139342	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139342	31953506	Allele T is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.	0.0
1451141140	1451139362	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139362	31953506	Allele T is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.	0.0
1451141146	1451139380	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139380	31953506	Allele T is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele C.	0.0
1451141152	1451139390	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139390	31953506	Allele C is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.	0.0
1451141160	1451139416	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139416	31953506	Allele T is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele C.	0.0
1451141166	1451139440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139440	31953506	Allele A is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.	0.0
1451141166	1451139406	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139406	31953506	Allele A is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.	0.0
1451141180	1451139449	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451139449	31953506	Allele G is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele T.	0.0
1451550960	1450373508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450373508	27649267	Genotypes CC + CT are associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT.	2.5
1451138140	1451137960	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451137960	31866536	Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele C.	3.0
1451135160	1451134900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451134900	31773688	CYP3A4 *36/*36 is associated with increased likelihood of Respiratory Insufficiency due to sufentanil in people with Pain, Postoperative as compared to CYP3A4 *1/*1 + *1/*36.	2.0
1451144760	1451144700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451144700	32112986	Genotype AG is associated with increased concentrations of alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.	2.0
1451145100	1451144826	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451144826	32152934	Genotype CC is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to genotypes CT + TT.	0.0
1451145106	1451144820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451144820	32152934	Genotype GG is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to genotypes AA + AG.	0.0
1451146140	1451145889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451145889	32232669	Genotypes AA + AG is associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.	3.0
1451146160	1451145900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451145900	32232669	Genotypes CT + TT are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype CC.	3.0
1451146222	1451146199	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451146199	32256718	Genotypes CG + GG are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.	2.75
1451146241	1451146204	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451146204	32256718	Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.	2.75
1451146260	1451146211	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451146211	32256718	Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.	2.75
1451147643	1451147625	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147625	32331352	CYP3A4 *3 + *20 + *22 are associated with increased clearance of fesoterodine in healthy individuals as compared to CYP3A4 *1.	0.0
1451147700	1451147640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147640	32331352	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	0.0
1451148025	1451148002	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451148002	32407152	Genotypes CC + CT are associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotype TT.	2.5
1451148520	1451148460	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451148460	31041874	Genotype AG is associated with increased likelihood of Hyperalgesia due to opioids in people with Pain as compared to genotypes AA + GG.	2.5
1451147720	PA166265421	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166265421		Annotation of DPWG Guideline for quetiapine and CYP3A4	100
1451147720	1451147640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451147640	32331352	CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.	0.0
1451147720	1451648462	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451648462	24525658	CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.	2.0
1451144780	1451725340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451725340	32112986	CYP3A4 low activity is associated with increased response to alprazolam in men with Alcoholism and Anxiety Disorders as compared to CYP3A4 high activity.	-1.25
1451144780	1451144740	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451144740	32112986	Genotype AG is associated with decreased response to alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.	2.5
1451141882	PA166228121	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228121		Annotation of CPIC Guideline for hydrocodone and CYP2D6	100
1451141882	1183683979	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183683979	7693389	CYP2D6 normal metabolizer phenotype is associated with increased metabolism of hydrocodone as compared to CYP2D6 poor metabolizer phenotype.	0.0625
1451141882	1445117515	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1445117515	24269714	CYP2D6 poor metabolizer is associated with decreased metabolism of hydrocodone as compared to CYP2D6 ultrarapid metabolizer phenotype.	0.0
1451141882	1447948869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447948869	25621429	CYP2D6 poor metabolizers are associated with decreased metabolism of hydrocodone in healthy individuals as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	1.0
1451141882	1449189944	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449189944	20837591	CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.	0.125
1451141882	1451141840	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141840	31969823	CYP2D6 *5/*17 is associated with decreased concentrations of hydromorphone in women.	0.125
1451141882	1451155490	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451155490	14998425	CYP2D6 *4/*4 is associated with decreased concentrations of hydromorphone in human liver microsome as compared to CYP2D6 *1/*1 + *1/*4.	0.0
1451148780	1451148752	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148752	32423989	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele A.	0.0
1451148820	1451148752	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148752	32423989	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele A.	0.0
1451148840	1451148752	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148752	32423989	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele A.	0.0
1451148920	1451148748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148748	32423989	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	0.0
1451149000	1451148962	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451148962	32432768	Genotype CC is associated with decreased dose of morphine in people with Lung Neoplasms and Pain as compared to genotypes AA + AC.	2.5
1451149980	1451149600	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149600	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451149986	1451149621	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149621	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451149992	1451149627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149627	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451149998	1451149633	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149633	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451150020	1451149645	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149645	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150040	1451149651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149651	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150046	1451149657	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149657	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150060	1451149663	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149663	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150080	1451149669	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149669	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150086	1451149781	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149781	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451150092	1451149800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149800	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151460	1451149840	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149840	32451486	Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151466	1451149846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149846	32451486	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451151472	1451149852	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149852	32451486	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151478	1451149858	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149858	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451151484	1451149868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149868	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451151490	1451149900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149900	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151496	1451149920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149920	32451486	Allele C is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151500	1451149880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149880	32451486	Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451151512	1451149947	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149947	32451486	Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.	1.5
1451151522	1451149953	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149953	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151540	1451149959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149959	32451486	Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151560	1451149965	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451149965	32451486	Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.	1.5
1451151857	1450928304	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450928304	28696411	Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.	-1.75
1451151857	1451151829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451151829	32462699	Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.	2.0
1451151920	1451151848	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451151848	32462699	Genotypes AG + GG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype AA.	1.75
1451151920	1451151860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451151860	32462699	Genotypes AA + AG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype GG.	1.75
1451151920	1183689306	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183689306	19000940	Allele G is not associated with response to olanzapine in people with Schizophrenia as compared to allele A.	-1.5
1451152801	1451152760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451152760	9352573	CYP2D6 *3/*3 + *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	2.5
1451152821	1451152760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451152760	9352573	CYP2D6 *3/*3 + *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	2.5
1451152965	1451152920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451152920	9431830	CYP2D6 *4/*4 is associated with decreased metabolism of dihydrocodeine as compared to CYP2D6 *1/*1 + *1/*4.	This annotation is not used for clinical annotation scoring.
1451153940	1450374173	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374173	30907440	CYP2D6 poor and ultrarapid metabolizers are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.	-0.625
1451153940	1451153800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153800	11270921	CYP2D6 *1/*1xN is associated with increased dose of methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .	0.0
1451153940	1451161472	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161472	21589866	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.	2.0
1451155125	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451155125	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451155125	1183618106	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618106	18713907	CYP2D6 *1xN is associated with Respiratory Insufficiency when treated with tramadol as compared to CYP2D6 *1/*1.	0.25
1451155125	1183618150	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618150	21691803	CYP2D6 *1/*1xN is associated with increased risk of severe cardiotoxicity (refractory cardiac arrest) when treated with tramadol as compared to CYP2D6 *1/*1.	0.25
1451155125	1444694442	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444694442	25647677	CYP2D6 *2/*2xN is associated with increased risk of Respiratory Insufficiency when treated with tramadol.	0.25
1451152827	1451152760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451152760	9352573	CYP2D6 *3/*3 + *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	2.5
1451153920	1449266559	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266559	17178267	CYP2D6 ultrarapid metabolizer genotype is associated with decreased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.75
1451153920	1449266567	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449266567	17178267	CYP2D6 poor metabolizer genotype is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	-0.5
1451153920	1450374142	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374142	30907440	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (R)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.	-0.375
1451153920	1450374166	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374166	30907440	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.	-0.375
1451153920	1451158020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451158020	19133059	CYP2D6 poor metabolizer phenotype is not associated with trough concentration of methadone as compared to CYP2D6 normal metabolizer phenotype.	-0.375
1451153920	1451153720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153720	11270921	CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .	2.0
1451153920	1451153742	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153742	11270921	CYP2D6 *3/*4 + *4/*4 + *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .	2.0
1451153920	1451156440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156440	17502774	CYP2D6 *3/*4 + *4/*4 are not associated with concentrations of methadone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.	-0.125
1451153920	1451228801	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451228801	28723731	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*5 are not associated with concentrations of methadone as compared to CYP2D6 *1/*1.	-0.75
1451153920	1451161540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161540	21589866	CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.	This annotation is not used for clinical annotation scoring. UMs had significantly higher doses of methadone compared to other phenotype groups
1451153963	1449271217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449271217	29333880	CYP2D6 poor metabolizers and intermediate metabolizers is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer.	-1.0
1451153963	1450374180	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450374180	30907440	CYP2D6 poor and ultrarapid metabolizers are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.	-0.375
1451153963	1451156302	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156302	17234366	CYP2D6 ultrarapid metabolizer genotype is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer and poor metabolizers genotypes.	1.25
1451153963	1451156320	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156320	17234366	CYP2D6 poor metabolizer genotype is not associated with response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer genotype.	-0.75
1451153963	1451153754	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153754	11270921	CYP2D6 *1/*1xN is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .	0.0
1451153963	1451161371	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161371	21589866	CYP2D6 *1/*2xN + *2/*2xN are associated with increased response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 *1/*1.	2.0
1451155020	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451155020	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451155020	1183617989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617989	8988065	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.	1.5
1451155020	1183684640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684640	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.75
1451155020	1183684653	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684653	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of nausea when treated with tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.125
1451155020	1183684657	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684657	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.	0.75
1451155020	1183684661	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183684661	18204346	CYP2D6 normal metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.	0.75
1451155020	1446896368	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446896368	20488759	CYP2D6 ultrarapid metabolizer genotype is associated with increased metabolism of tramadol.	1.0
1451155020	1449154915	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449154915	27082504	CYP2D6 deficiency is associated with decreased exposure to o-desmethyl-tramadol in infants with Pain.	0.0
1451155020	1449162774	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162774	24709712	CYP2D6 poor metabolizer genotype is not associated with exposure to o-desmethyl-tramadol or tramadol as compared to CYP2D6 normal metabolizer genotype.	-0.0625
1451155020	1449752869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752869	29555325	CYP2D6 ultrarapid metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 normal metabolizer.	0.875
1451155020	1449752878	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449752878	29555325	CYP2D6 poor metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain and Osteoarthritis as compared to CYP2D6 normal metabolizer.	0.875
1451155020	1451134163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134163	31744222	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of tramadol in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1451155020	1451134168	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134168	31744222	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in healthy individuals as compared to CYP2D6 normal metabolizers.	0.0625
1451155020	1451153020	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451153020	9476037	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.875
1451155020	1451155560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155560	15906019	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.	0.0625
1451155020	1451155820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155820	17175164	CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.	0.5
1451155020	1451207900	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207900	24968714	CYP2D6 poor metabolizer is associated with increased exposure to tramadol as compared to CYP2D6 intermediate metabolizer and normal metabolizer.	0.0625
1451155020	1451230620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230620	30051214	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	0.875
1451155020	1451230640	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451230640	30051214	CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of n-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	0.875
1451155020	1183617999	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617999	12893130	CYP2D6 *4 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618008	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618008	12893130	CYP2D6 *3 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618016	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618016	12893130	CYP2D6 *6 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.	0.125
1451155020	1183618024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618024	16368820	CYP2D6 *4/*4 is associated with decreased tramadol metabolism and response when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1451155020	1183678578	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678578	17470523	CYP2D6 *10 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.	0.0
1451155020	1183678588	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1183678588	17470523	CYP2D6 *17 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.	0.0
1451155020	1183680395	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183680395	14624403	CYP2D6 *4/*4 is associated with decreased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.5
1451155020	1451154280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451154280	12191703	CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.	1.0
1451155020	1451155780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155780	16763825	CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1451156620	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451156620	17667796	CYP2D6 *1/*1xN is associated with decreased concentrations of tramadol in healthy individuals as compared to CYP2D6 *1/*2 + *2/*4.	0.125
1451155020	1451157780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157780	18317231	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.	1.75
1451155020	1451157820	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157820	18317231	CYP2D6 *1/*1xN is associated with increased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.	1.75
1451155020	1451157920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451157920	18520597	CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .	1.25
1451155020	1451207940	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207940	25560051	CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41 (assigned as normal metabolizer phenotype) .	0.125
1451155020	1451208380	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208380	26926096	CYP2D6 *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.	0.0
1451155020	1451229440	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229440	29196917	CYP2D6 *10/*10 is associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1 + *2.	1.5
1451155020	1451229484	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229484	29524157	CYP2D6 *5/*5 + *10/*10 are associated with decreased concentrations of n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1 + *2.	0.125
1451155020	1451229680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451229680	29992026	CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with decreased exposure to n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*9 + *1/*35 + *1/*41 + *2/*5 + *2/*35 + *2/*41 + *4/*35 + *4/*41 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	0.125
1451155020	1451552540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552540	32538291	CYP2D6 *1/*4 + *1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer genotype phenotype) .	1.5
1451155020	1451565700	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451565700	33131142	CYP2D6 *1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.	1.75
1451155020	1183618125	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618125	20456744	CYP2D6 *10/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1183618134	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618134	20456744	CYP2D6 *2/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	1.0
1451155020	1183618142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618142	20456744	CYP2D6 *2/*2 is not associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.	-0.125
1451148762	1451148752	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451148752	32423989	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele A.	0.0
1451154980	PA166228101	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166228101		Annotation of CPIC Guideline for tramadol and CYP2D6	100
1451154980	PA166104959	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104959		Annotation of DPWG Guideline for tramadol and CYP2D6	100
1451154980	1183617989	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617989	8988065	CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.	1.5
1451154980	1183684648	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183684648	18204346	CYP2D6 ultra-metabolizer genotype is associated with increased pain threshold and pain tolerance when treated with tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.	0.125
1451154980	1450376063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376063	30784356	CYP2D6 poor and ultrarapid metabolizers is associated with increased likelihood of discontinuation when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.625
1451154980	1450376074	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450376074	30784356	CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.	1.25
1451154980	1451155685	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451155685	16129989	CYP2D6 poor metabolizer phenotype is associated with increased response to tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	1.0
1451154980	1451205845	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451205845	22428763	CYP2D6 poor metabolizer is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.	0.0
1451154980	1451406280	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451406280	33812699	CYP2D6 ultrarapid metabolizer genotype is associated with increased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	0.0
1451154980	1451645100	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451645100	34423496	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.	1.5
1451154980	1183617913	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617913	16631290	CYP2D6 *4/*6 is associated with intolerance to oxycodone and tramadol ( significant side effects as well as no pain relief) when treated with oxycodone and tramadol.	0.25
1451154980	1183618035	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618035	17361124	CYP2D6 *3/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618044	17361124	CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618052	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618052	17361124	CYP2D6 *4/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.	2.5
1451154980	1183618060	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618060	14499440	CYP2D6 *4/*4 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618069	14499440	CYP2D6 *3/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618082	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618082	14499440	CYP2D6 *5/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618090	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618090	14499440	CYP2D6 *4/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1183618098	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183618098	14499440	CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.	2.75
1451154980	1446898050	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446898050	25948472	CYP2D6 *10/*10 is associated with increased severity of Pain when treated with tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.	2.5
1451154980	1451141860	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451141860	31969823	CYP2D6 *5/*17 is associated with decreased response to hydrocodone or tramadol in women.	0.25
1451154980	1451638720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451638720	34246203	CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.	2.0
1451905420	1451905400	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451905400	34656068	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	2.5
1451184626	1451184620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451184620	29610167	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to oxcarbazepine in children with Epilepsy.	0.25
1451207020	1449162993	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449162993	24703092	Allele A is not associated with concentrations of morphine in women with Pain, Postoperative as compared to allele G.	-0.25
1451207020	1451206861	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451206861	24747667	Genotypes AG + GG are associated with decreased concentrations of morphine as compared to genotype AA.	1.25
1451207862	1451207780	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451207780	32564268	CYP3A5 *1/*1 is associated with decreased exposure to Dabigatran in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.	1.5
1451208240	1451208192	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451208192	25825958	CYP2D6 *10/*10 is associated with increased dose of fentanyl in people with Gastrointestinal Neoplasms and Pain, Postoperative as compared to CYP2D6 *1/*1.	2.0
1451208340	1451208260	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208260	25989235	CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .	1.75
1451217440	1448631931	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448631931	28453395	Genotype TT is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a in people with Hepatitis B as compared to genotypes CC + CT.	3.0
1451217440	1450810253	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450810253	31201901	Allele C is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele T.	-1.75
1451217440	1449713162	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449713162	30016335	Genotype CC is not associated with response to peginterferon alfa-2a in people with Hepatitis B, Chronic as compared to genotypes CT + TT.	-0.25
1451217520	1449190317	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449190317	29534310	Genotype CC is associated with increased sustained virological response (svr) when treated with ribavirin and sofosbuvir in people with Hepatitis C, Chronic and Liver Cirrhosis as compared to genotypes CT + TT.	2.5
1451217560	1447951883	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447951883	26334898	Genotype CC is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1451223500	1451222570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222570	28320034	Genotypes AG + GG are not associated with severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AA.	-0.25
1451223500	982009331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009331	23632726	Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1451223520	982009331	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982009331	23632726	Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.	1.25
1451223540	1451222587	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222587	28320034	Genotype AA is associated with increased severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AG.	1.5
1451223580	1451222211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222211	27983768	Allele A is associated with increased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele C.	0.0
1451223586	1451222211	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222211	27983768	Allele A is associated with increased severity of Neonatal Abstinence Syndrome due to buprenorphine or methadone in women as compared to allele C.	0.0
1451223592	1451222563	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451222563	28320034	Genotype GG is associated with increased severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype GT.	1.5
1451161878	1451161493	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451161493	21589866	CYP2B6 *6/*6 is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1.	0.0
1451161878	1451226244	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451226244	28723731	CYP2B6 *6 is not associated with dose of methadone as compared to CYP2B6 *1.	-1.25
1451253260	PA166104968	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104968		Annotation of DPWG Guideline for venlafaxine and CYP2D6	100
1451253260	1184169551	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169551	23545896	CYP2D6 normal metabolizers is associated with increased risk of side effects when treated with venlafaxine in people with Obsessive-Compulsive Disorder.	0.0
1451253260	1043858956	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1043858956	23799451	Genotype AG is associated with agitation and dysphoria when treated with venlafaxine in patient with depression.	0.25
1451253260	982029474	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029474	16642541	Genotypes CT + TT are not associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.	-0.25
1451253260	982015063	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015063	19822698	CYP2D6 *4/*4 is associated with tachycardia and agitation when treated with venlafaxine.	0.25
1451253260	982029483	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982029483	10780263	CYP2D6 *4/*4 is associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major.	0.25
1451253260	1183619024	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183619024	17008819	CYP2D6 *4/*4 is associated with side effects when treated with venlafaxine.	0.25
1451253260	1184169374	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169374	23545896	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	-1.5
1451253260	1450934262	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450934262	31799914	CYP2D6 *1/*4 is associated with increased cardiotoxicity, Edema, Nausea and Vomiting when treated with venlafaxine in men with Alcohol-Related Disorders.	0.25
1451253260	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451253260	982015073	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/982015073	16958828	CYP2D6 *5/*4 + *6/*6 + *6/*4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	2.0
1451217540	981352209	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352209	22438096	Genotype CC is associated with increased sustained virological response (svr) when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.75
1451217540	981352215	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981352215	22438096	Genotype CC is not associated with increased sustained virological response (svr) when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	-1.75
1451163460	1449576398	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449576398	27417511	CYP2A6 *17 is not associated with clearance of metronidazole in infants as compared to CYP2A6 *1.	-0.125
1451163460	1451162952	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451162952	30706508	CYP2A6 *1/*2 + *1/*9 + *1/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of metronidazole in healthy individuals as compared to CYP2A6 *1/*1 (assigned as normal metabolizers phenotype) .	1.5
1451265448	PA166104999	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104999		Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6	100
1451265448	PA166104972	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104972		Annotation of DPWG Guideline for imipramine and CYP2D6	100
1451265448	1183683984	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183683984	2741190	CYP2D6 poor metabolizers is associated with side effects when treated with imipramine.	0.125
1451265448	1183617418	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183617418	18070221	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	3.5
1451265448	1184467243	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467243	8941025	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	1.75
1451257280	1448276391	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448276391	27271184	CYP2C8 *3 is associated with decreased Weight gain when treated with rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	2.25
1451257280	1450935033	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935033	23426382	CYP2C8 *3 is associated with decreased risk of Edema when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.	0.0
1451266120	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266120	827810959	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810959	21410976	Genotype AT is associated with risk of Diarrhea when treated with tegafur in people with Rectal Neoplasms.	0.25
1451266120	1183630516	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630516	23930673	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451266120	1448255407	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255407	26603945	Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	1.75
1451266065	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266065	827810951	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827810951	21410976	Genotype CT is associated with risk of Neutropenia when treated with tegafur in people with Rectal Neoplasms.	0.25
1451266065	1183630475	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183630475	23930673	Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.	2.0
1451266065	1450952880	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450952880	26603945	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.	1.75
1451266020	PA166104944	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104944		Annotation of DPWG Guideline for tegafur and DPYD	100
1451266020	1450953032	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953032	26603945	Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.	2.0
1451266020	1448109214	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448109214	21410976	Genotype AC is associated with risk of Diarrhea when treated with tegafur in people with Rectal Neoplasms.	0.25
1451257700	1449270277	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449270277	29589488	Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA.	0.5
1451257700	1449557869	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449557869	29743634	Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	1.75
1451257700	1448266186	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448266186	27676277	Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	2.5
1451263060	1451263006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451263006	30357299	Allele C is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele T.	1.625
1183680656	1183680651	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183680651	24113216	Genotypes CT + TT are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.	2.25
1183680656	1184483206	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483206	24921414	Allele T is not associated with new-onset diabetes mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.	-1.5
1183680656	1449183025	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449183025	29399716	Genotypes CC + CT is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype TT.	-1.25
1451257285	1448276377	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448276377	27271184	CYP2C8 *3 is associated with decreased response to rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.	2.75
1451257285	1450935044	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450935044	23426382	CYP2C8 *3 is associated with decreased mean absolute difference in HbA1c when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.	2.0
1451257285	1451604160	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451604160	17178266	CYP2C8 *3 is not associated with glucose lowering when treated with rosiglitazone in healthy individuals as compared to CYP2C8 *1.	-0.25
1451285000	655386860	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/655386860	19020788	Allele C is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans.	2.75
1451256440	981477934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477934	17702092	Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.	-1.5
1451256440	981478537	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981478537	22967772	Allele C is not associated with Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele T.	-1.5
1451256440	769261698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261698	21121776	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	1.0
1451256440	608431026	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431026	19636338	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Depressive Disorder or Schizophrenia as compared to allele C.	1.75
1451256440	608431038	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431038	15666332	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.	2.0
1451256440	608431041	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/608431041	19434072	Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.	2.0
1451256440	1448997846	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997846	25152019	Allele C is associated with increased severity of Weight gain when treated with olanzapine in people with schizoaffective disorder and Schizophrenia as compared to allele T.	0.0
1451256440	1448998639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998639	18718676	Allele T is not associated with increased Weight gain when treated with olanzapine or risperidone in women with Schizophrenia as compared to allele C.	-1.5
1451256440	1448998799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998799	17016522	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	0.0
1451256440	1448998884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998884	20504252	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	2.0
1451256440	1449000436	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449000436	19193342	Allele T is not associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.	-1.5
1451256448	981477934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477934	17702092	Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.	-1.5
1451256448	981501343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981501343	21186965	Allele T is associated with decreased likelihood of Weight gain when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.	2.0
1451256448	769261698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261698	21121776	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	1.0
1451256448	1183621168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183621168	16633140	Genotypes CT + TT is associated with decreased severity of Weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.	2.0
1451256448	1448998639	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998639	18718676	Allele T is not associated with increased Weight gain when treated with olanzapine or risperidone in women with Schizophrenia as compared to allele C.	-1.5
1451256448	1448998799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998799	17016522	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	0.0
1451256448	1448998884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998884	20504252	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	2.0
1451256448	1447945120	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447945120	26880915	Genotypes CC + CT are associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT.	0.0
1451256466	981477934	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981477934	17702092	Allele T is not associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele C.	-1.5
1451256466	769261698	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261698	21121776	Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.	1.0
1451256466	1448998718	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998718	15635667	Allele T is associated with decreased risk of Weight gain when treated with clozapine in people with Schizophrenia.	1.5
1451256466	1448998799	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998799	17016522	Allele T is associated with decreased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.	0.0
1451256466	1448998884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448998884	20504252	Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.	2.0
1451274840	1451273890	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451273890	31490856	Genotypes CC + CT are associated with increased response to esomeprazole in children with eosinophilic esophagitis as compared to genotype TT.	2.25
1451282140	1444702623	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1444702623	25793413	Genotype AA is associated with increased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to genotypes AC + CC.	2.75
1451282140	1447987564	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447987564	26191232	Genotypes AA + AC are associated with increased response to tamoxifen in women with Breast Neoplasms as compared to genotype CC.	2.25
1451286280	769250129	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769250129	15707415	Genotypes CT + TT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype CC.	1.75
1451286280	1447520826	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447520826	26543771	CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.	2.5
1451204660	PA166104951	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166104951		Annotation of DPWG Guideline for irinotecan and UGT1A1	100
1451204660	PA166104831	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104831		Annotation of FDA Label for irinotecan and UGT1A1	100
1451204660	1184483423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483423	24308720	UGT1A1 *28 is not associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	-1.0
1451204660	1184483429	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483429	24308720	UGT1A1 *6 + *28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.	1.0
1451204660	1184483709	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184483709	24519753	UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28 + *1/*1.	1.25
1451204660	1448422676	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422676	26857783	UGT1A1 *6 + *28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.	2.5
1451204660	1448422855	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448422855	27385990	UGT1A1 *1/*28 + *6/*28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	1.0
1451204660	1448427979	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427979	25869015	UGT1A1 *28 is not associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1.	-1.25
1451204660	1448519703	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448519703	20530282	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.5
1451204660	1451204842	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451204842	20562211	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	2.0
1451204660	1451205308	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205308	17728214	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	1.625
1451204660	1451205360	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205360	19390945	UGT1A1 *1/*28 + *28/*28 are not associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451205440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205440	17510208	UGT1A1 *28/*28 is associated with increased likelihood of Anemia, Leukopenia, Neutropenia or Thrombocytopenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 *1/*1.	0.0
1451204660	1451205620	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451205620	17510208	UGT1A1 *28/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451204660	1451206354	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206354	15280927	UGT1A1 *1/*28 + *28/*28 are not associated with Anemia, mucositis, Nausea, Neutropenia or Thrombocytopenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451206444	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206444	16456808	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451206820	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451206820	18594531	UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	3.0
1451204660	1451207040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207040	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451204660	1451207282	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451207282	18300238	UGT1A1 *1/*28 + *28/*28 are associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.5
1451204660	1451208420	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208420	17577039	UGT1A1 *28/*28 is not associated with increased risk of Diarrhea or Neutropenia when treated with irinotecan in children with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	-1.25
1451204660	1451208752	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208752	17185998	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451208889	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451208889	16951398	UGT1A1 *1/*28 + *28/*28 are not associated with Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-0.25
1451204660	1451209004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209004	15007088	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.	2.75
1451204660	1451209203	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209203	11990381	UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	0.375
1451204660	1451209760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209760	16636344	UGT1A1 *1/*28 is not associated with Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451209900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209900	23529007	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451204660	1451209909	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451209909	23529007	UGT1A1 *1/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.75
1451204660	1451210000	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210000	23529007	UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	2.0
1451204660	1451210158	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451210158	26229432	UGT1A1 *28/*28 + *6/*6 + *1/*6 + *1/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 *1/*1.	2.0
1451204660	1451211761	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211761	26830078	UGT1A1 *28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	2.0
1451204660	1451211808	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211808	18797458	UGT1A1 *1/*28 + *28/*28 are associated with increased Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	1.5
1451204660	1451211900	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211900	23386248	UGT1A1 *28 is not associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451204660	1451212280	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451212280	15297419	UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.	2.75
1451204660	1451213421	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213421	28367249	UGT1A1 *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1.	-1.0
1451204660	1451213580	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213580	19450125	UGT1A1 *28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms.	-1.25
1451204660	1451213606	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213606	24815493	UGT1A1 *1/*28 is not associated with increased likelihood of Anemia, Leukopenia, Neutropenia, Thrombocytopenia or Vomiting when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.	-1.25
1451204660	1451213905	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451213905	18221820	UGT1A1 *1/*28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to UGT1A1 *1/*1.	-1.5
1451204660	1451214002	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214002	25285015	UGT1A1 *28 is not associated with increased risk of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.	-1.5
1451204660	1451214143	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214143	28502040	UGT1A1 *1/*28 + *28/*28 is not associated with increased severity of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.	-0.5
1451204660	1451214800	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451214800	29504153	UGT1A1 *28/*28 + *28/*37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.	3.25
1451243980	PA166182603	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182603		Annotation of CPIC Guideline for efavirenz and CYP2B6	100
1451243980	PA166182846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166182846		Annotation of DPWG Guideline for efavirenz and CYP2B6	100
1451243980	1451289240	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451289240	25889207	Allele C is not associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele T.	-1.5
1451243980	1183634232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183634232	24080498	Genotypes CC + CT are not associated with risk of Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to genotype TT.	-1.75
1451243980	1184473287	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184473287	24517233	Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections.	2.0
1451243980	1448636199	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448636199	28692529	Genotype CC is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype TT.	2.0
1451243980	1448993810	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993810	26715213	Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.	3.5
1451243980	827707534	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827707534	21862974	CYP2B6 *6/*6 is associated with increased risk of drug-induced liver injury when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.5
1451243980	1184168515	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184168515	23734829	CYP2B6 *1 is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV as compared to CYP2B6 *6.	-1.5
1451243980	1448993721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993721	22808112	CYP2B6 *6 is associated with increased risk of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.25
1451243980	1448993746	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448993746	27333947	CYP2B6 *6/*6 is associated with increased risk of Long QT Syndrome when exposed to efavirenz in healthy individuals as compared to CYP2B6 *1/*1.	1.75
1451243980	1448994067	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448994067	17686225	CYP2B6 *2/*2 is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	0.25
1451243980	1449156721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156721	23640958	CYP2B6 *6 + *38 are associated with increased risk of Neurotoxicity Syndromes when treated with efavirenz as compared to CYP2B6 *1/*1.	0.0
1451243980	1449156770	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449156770	24359841	CYP2B6 *6/*6 is associated with increased likelihood of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.	2.0
1451551426	1183700726	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183700726	18347182	Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.	1.75
1451551460	827816972	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827816972	22026922	Genotypes AG + GG are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.	0.0
1450813831	1450813768	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450813768	30806694	Allele del is associated with increased risk of Myelosuppression when treated with azathioprine, mercaptopurine or thioguanine in people with Inflammatory Bowel Diseases as compared to allele GGAGTC.	4.0
1451135100	1451121680	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451121680	31493434	Allele G is not associated with response to oxycodone as compared to allele A.	-0.25
1451135100	1451134629	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451134629	31773688	Genotypes AG + GG are associated with decreased response to oxycodone in people with Pain, Postoperative as compared to genotype AA.	1.5
1451289660	PA166122686	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166122686		Annotation of CPIC Guideline for fluorouracil and DPYD	100
1451289660	1450953760	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450953760	17417073	Genotype AG is associated with increased likelihood of Drug Toxicity and Neutropenia when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.	0.0
1451551520	1451551149	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551149	32173978	Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele C.	3.0
1451551520	827813117	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827813117	19620936	Allele A is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C.	-2.75
1451551520	1448568298	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448568298	27995989	Genotype CC are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AC.	-1.5
1451551528	1451551163	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551163	32173978	Genotypes AG + GG are associated with increased response to cisplatin in women with Ovarian Neoplasms as compared to genotype AA.	0.0
1451551846	1451551766	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551766	32295690	Genotypes CC + CT are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.	2.5
1451551817	1451551777	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551777	32295690	Genotypes AA + AG are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	2.5
1451551883	1451551800	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451551800	32295690	Genotypes AC + CC are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	2.5
1451552587	1451552561	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552561	32538291	Genotype TT is associated with increased exposure to tramadol in healthy individuals as compared to genotypes GG + GT.	1.0
1451553326	1451465044	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465044	21387541	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.0
1451553326	1451552752	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451552752	32612964	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	0.0
1451553595	1449003004	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003004	28525903	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.	-1.75
1451553595	1451553526	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451553526	32695297	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.25
1451553595	1451553540	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451553540	32695297	Genotypes AA + AG are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.75
1451553580	1296598882	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1296598882	25303299	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.5
1451553580	1449003393	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449003393	28525903	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	-1.25
1451553580	1451465061	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451465061	21387541	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.	-1.0
1451553580	1451553370	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451553370	32695297	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.	1.75
1451553580	1451614946	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451614946	33501733	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	-1.0
1451566760	1451566720	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451566720	33236485	Genotypes AA + AG are associated with increased response to bupropion and naltrexone in people with Obesity as compared to genotype GG.	1.5
1451567040	1451566980	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451566980	33393779	CYP3A4 *6 + *17 + *20 + *21 + *26 + *30 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.	0.0
1451567040	1451647340	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451647340	34480108	CYP3A4 *22 is associated with decreased metabolism of oxycodone as compared to CYP3A4 *1.	2.5
1451567040	1451566922	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451566922	33393779	CYP3A4 *2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.	0.0
